<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Treatment | mesothelioma</title>
    <link>/mesothelioma/syntax_summary/treatment/</link>
      <atom:link href="/mesothelioma/syntax_summary/treatment/index.xml" rel="self" type="application/rss+xml" />
    <description>Treatment</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>BioHub - UFPE</copyright><lastBuildDate>Sun, 09 Sep 2018 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/mesothelioma/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png</url>
      <title>Treatment</title>
      <link>/mesothelioma/syntax_summary/treatment/</link>
    </image>
    
    <item>
      <title>Treatment Sentence Context</title>
      <link>/mesothelioma/syntax_summary/treatment/info/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/syntax_summary/treatment/info/</guid>
      <description> 

&lt;script src=&#34;/mesothelioma/mesotheliomarmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 1.&lt;/strong&gt; Analysis of context sentence of 2625 absracts clustered as Treatment
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Title
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Gene Context Sentence
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
ePubDate
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10022219&#34; target=&#34;_blank&#34;&gt;Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of diffuse malignant pleural mesothelioma (DMPM) remains grim. […] Neither surgery, radiotherapy nor chemotherapy can be considered as a standard therapy. […] Total treatment duration was thus 25 weeks. […] Four patients received IFN maintenance therapy, one for 3 months and three for 6 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10048474&#34; target=&#34;_blank&#34;&gt;The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no standard therapy for malignant pleural mesothelioma (MPM), but recent reports have shown that extensive surgery combined with chemo- and radiotherapy prolongs the survival of selected patients with early stage disease. […] This emphasises the need for accurate staging procedures at diagnosis and reliable imaging methods to assess response to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10078630&#34; target=&#34;_blank&#34;&gt;Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura–a single-institution experience with 189 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival was 5 months from the start of RT and only 17% of patients were alive at 1 year after treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10096972&#34; target=&#34;_blank&#34;&gt;Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study was planned to investigate the feasibility, safety, and pharmacokinetics of a multimodality therapy including an operation, pleural space perfusion (60 minutes) with cisplatin (100 mg/m2), hyperthermia (41. 5 degrees C), and postoperative radiotherapy (55 Gy to chest wall incisions). […] No lung damage was demonstrated after treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1010182&#34; target=&#34;_blank&#34;&gt;[Primary pericardial mesothelioma: report of a case (author’s transl)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The clinical, anatomic, pathologic aspects, as well as treatment of primary pericardial mesothelioma are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1977-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10194545&#34; target=&#34;_blank&#34;&gt;Impressive remission in a patient with locally advanced malignant pleural mesothelioma treated with gemcitabine.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results of treatment of malignant pleural mesothelioma are quite unsatisfactory regardless of the substance or schedule employed. […] At week 36 after beginning of treatment, the CT scan exhibited a substantial partial remission with a reduction of tumor volume of over 50%. […] The adverse effects of the therapy were very moderate with a hematotoxicity not exceeding WHO grade I and a mild ‘flu-like syndrome’ during the first three cycles which responded quite well to steroids. […] The compliance of the patient was excellent and his general condition improved significantly under therapy. […] Gemcitabine seems to be an active drug for the treatment of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10223568&#34; target=&#34;_blank&#34;&gt;Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is associated with a poor prognosis because of its resistance to treatment. […] Treatment was well tolerated and the major toxicity was hematologic: anemia in 30% of cases, neutropenia in 24%, and 2 probable cases of mitomycin-induced pneumonitis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-05-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10327696&#34; target=&#34;_blank&#34;&gt;[Pleural mesotheliomas. Current knowledge].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three groups are classified under the term mesothelioma: 1) benign pleural mesothelioma for which complete surgical treatment is curative with a good prognosis; 2) localized malignant mesothelioma which is a fibrosarcoma, best treated by wide en-bloc resection; 3) diffuse malignant mesothelioma which is mainly of epithelial type. […] Rigorous combinations of multimodality therapy are needed to improve local control and survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10347962&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment reflected varying approaches.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10357408&#34; target=&#34;_blank&#34;&gt;Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to assess the efficacy and toxicity of a combination of cisplatin and irinotecan (CPT-11) in the treatment of patients with malignant pleural mesothelioma and to characterize the pharmacokinetic profiles of CPT-11 and its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38). […] The course of treatment was repeated every 28 days. […] The median survival time after chemotherapy was 28.3 weeks, and the median time to treatment failure was 22.1 weeks. […] Toxicity was well tolerated, and there were no treatment-related deaths. […] These results warrant further clinical evaluation of this combination chemotherapy for the treatment of malignant pleural mesothelioma in a confirmatory Phase II trial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-06-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10365266&#34; target=&#34;_blank&#34;&gt;Indications for pneumonectomy. Extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection is considered a mainstay for the treatment of malignant pleural mesothelioma (MPM), but the indications for extrapleural pneumonectomy in this disease remain controversial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10375105&#34; target=&#34;_blank&#34;&gt;A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The European Organization for Research and Treatment of Cancer-Lung Cancer Cooperative Group has performed several sequential Phase II trials of new agents for the treatment of mesothelioma over the last 10 years. […] Therapy continued for up to ten cycles unless disease progression or excessive toxicity mandated discontinuation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10399472&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma. A case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery, radio- and chemo-therapy must be administered with articulate strategy and with realistic objective of palliation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10403693&#34; target=&#34;_blank&#34;&gt;Ifosfamide in malignant mesothelioma: a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Response to treatment was evaluated in accordance with WHO criteria. […] The median age of patients was 59 years (range 39-68), 18 patients (69%) had a history of asbestos exposure and the median of treatment cycles was four (range 1-10). […] The toxicity of the treatment was considerable. […] Eleven patients (42%) went off the study due to the toxicity of the treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10407698&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
If radiotherapy is necessary in preventing the malignant seeding after pleural procedures in patients, the lack of comparative studies did not show the superiority of a given treatment against another. […] A new international staging of the disease, however, allows physicians to discriminate several groups of patients for such comparative studies–in particular, for testing the efficacy of intrapleural therapy, e.g., cytokines–for early-stage MPM and multimodal management, i.e., extrapleural pneumonectomy, radiotherapy, and chemotherapy for more advanced diseases, has led to prolonged survival in carefully selected patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10414144&#34; target=&#34;_blank&#34;&gt;[Therapy of malignant pleural mesothelioma–a permanent dilemma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Adjuvant first generation photodynamic therapy is not superior to operation only. […] There is no standard therapy, and no advantage to poly- versus monochemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10421502&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a problematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because of disappointing treatment results, malignant pleural mesothelioma has remained an area of active research and development. […] A clinicopathologic review is performed in light of several problematic issues involving diagnosis, staging, natural history, and treatment. […] Multimodality treatment with surgery followed by adjuvant local and systemic therapy remains the most optimal therapy. […] Many controversial issues still exist in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10437690&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pre-treatment CT findings of 70 patients at our institution, and the subsequent findings of the 35 patients who had follow-up CT, have been reviewed by three observers by consensus. 16 patients had surgical resections. […] The most common pre-treatment findings were pleural thickening (94%) and pleural effusions (76%). […] CT plays an important role in the diagnosis, assessment, and evaluation of treatment response of this tumour, although it has some limitations in specific areas in evaluating patients for surgical resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10439104&#34; target=&#34;_blank&#34;&gt;How should we treat malignant pleural mesothelioma (MPM)?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore in my opinion the first operative step must be followed by a second therapeutic step as immune- or gene therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10442339&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleural space.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant pleural mesothelioma is resistant to standard modes of therapy and, if untreated, results in death 4 to 12 months from the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10453867&#34; target=&#34;_blank&#34;&gt;Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with histopathologically confirmed DMPM were evaluated for treatment with chemoimmunotherapy. […] Forty-three patients with DMPM received chemoimmunotherapy until the end of the survey; 19 patients were given supportive therapy alone after refusing chemoimmunotherapy. […] The median survival time was 11.5 months for the 43 patients who received chemoimmunotherapy and 7.0 months for the 19 patients who received supportive therapy alone. […] The difference in survival times between the chemoimmunotherapy and supportive therapy groups was not significant. […] The toxicities associated with the treatment schedule of this study were, for the most part, tolerable. […] The drug combination used in this study is moderately effective and well tolerated in patients with DMPM, especially in those who responded to the treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10453882&#34; target=&#34;_blank&#34;&gt;Advances in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review will discuss the roles of chemotherapy, radiotherapy, surgery, and combined modality approaches in the treatment of pleural mesothelioma, as well as scientific advances made in the past decade that have led to the development of experimental techniques, such as photodynamic therapy, immunotherapy, and gene therapy, that are currently undergoing human clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10459435&#34; target=&#34;_blank&#34;&gt;Late results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of resistant mycobacteria or the complications of tuberculosis frequently require pneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10468296&#34; target=&#34;_blank&#34;&gt;High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At the end of MTX treatment the IFNs were continued as maintenance therapy until disease progression. […] Treatment was stopped in one patient who developed grade IV neurological toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10483823&#34; target=&#34;_blank&#34;&gt;Subcutaneous seeding after ultrasound-guided placement of intrapleural catheter. An unusual complication of the intracavitary palliative treatment of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intrapleural catheters are useful in the palliative treatment of malignant effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10566617&#34; target=&#34;_blank&#34;&gt;Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Athymic nude mice (n = 65) were injected intrapleurally with human MPM cells (CRL-2081), equally divided into three groups (IL-8 Ab, control Ab, untreated), and received IP injection of IL-8 Ab, control Ab, or no treatment, respectively, every 48 h up to 15 days. […] We demonstrate that antibody treatment against IL-8 decreased human MPM progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10585061&#34; target=&#34;_blank&#34;&gt;Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Among patients having EPP or P/D, 142 received adjuvant therapy. […] By multivariate analysis, stage, histology, gender, adjuvant therapy, but not the type of surgical resection, were significant. […] Locally advanced T and N status, and nonepithelial histology, identify poor prognosis patients who should be considered for novel treatment regimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10587144&#34; target=&#34;_blank&#34;&gt;Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MR imaging is superior to CT in revealing solitary foci of chest wall invasion and endothoracic fascia involvement and in showing diaphragmatic muscle invasion; however, this advantage does not affect surgical treatment. […] For cost reasons, CT should be considered the standard diagnostic study before therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10596313&#34; target=&#34;_blank&#34;&gt;Palliative treatment of malignant pleural effusions by video-assisted thoracoscopic surgery.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prompt clinical evaluation followed by aggressive treatment often results in successful palliation. […] Video-assisted Thoracic Surgery (VATS) today can be employed in the diagnosis and treatment of idiopatic and known MPE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10596319&#34; target=&#34;_blank&#34;&gt;Video-assisted thoracoscopic pleurodesis for malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A retrospective study was made of an initial series of 75 patients undergoing lifetime follow-up who received TP in our department for the treatment of malignant pleural effusions (MPE). […] Videothoracoscopic pleurodesis (talc poudrage) as a simple and efficient procedure seems to be the best alternative treatment regimen for the management of MPE in a group of selected patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10601613&#34; target=&#34;_blank&#34;&gt;Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We determined the toxicity and pharmacokinetics of high-dose intrapleural cisplatin (CDDP) as a treatment of malignant pleural effusions (MPE). […] Further studies are needed to determine the value of high-dose intrapleural CDDP for the treatment of MPE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10604731&#34; target=&#34;_blank&#34;&gt;Pleuro-pulmonary tumours detected by clinical and chest X-ray analyses in rats transplanted with mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New strategies for cancer therapy must be developed, especially in severe neoplasms such as malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10619506&#34; target=&#34;_blank&#34;&gt;Pleuropneumonectomy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is predominantly a local/regional disease that results in a survival time that ranges from 4 to 12 months without treatment. […] Single-modality therapy using surgery, chemotherapy, or radiotherapy alone is largely ineffective. […] The objective of the study was presentation of the use of pleuropneumonectomy in a multimodality treatment setting and the results. […] One hundred eighty-three patients who underwent multimodality therapy. […] Of all the single-modality treatment approaches, pleuropneumonectomy has been associated most consistently with long-term disease-free survival and has provided the greatest amount of tumor cytoreduction. […] Multimodality therapy, including chemotherapy, radiotherapy, and extrapleural pneumonectomy, was used to treat patients. […] Outcomes were presented for 183 patients with MPM who underwent multimodality therapy. […] With the development of multimodality therapy, pleuropneumonectomy followed by sequential chemotherapy and radiotherapy has demonstrated a significant survival benefit, especially for patients who have epithelial tumor histology, tumor-free resection margins, and tumor-free extrapleural node status.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10619507&#34; target=&#34;_blank&#34;&gt;Emerging translational therapies for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Translational mechanisms for treatment of the disease are emerging from newly learned characteristics of the tumor on a molecular, cellular, and extracellular basis. […] This review describes the rationale and status of these newer treatment ideas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10626792&#34; target=&#34;_blank&#34;&gt;Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These effects were not observed after similar treatment of mesothelioma or lung cancer cells containing no SV40 DNA sequences. […] Collectively, these data suggest that SV40 oncoproteins contribute to the malignant phenotype of pleural mesotheliomas and indicate that interventions designed to abrogate their expression may be efficacious in the treatment of individuals with these neoplasms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10631693&#34; target=&#34;_blank&#34;&gt;Contemporary management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For patients with stage I tumors of epithelial type and good performance status, pleuropneumonectomy combined with chemotherapy and radiotherapy provides the best chance of prolonged survival, but further investigation is required to determine the optimum combination of adjuvant therapy. […] Debulking pleurectomy/decortication combined with adjuvant therapy is a worthwhile alternative for patients with more advanced disease, impaired performance status or tumors of less favorable histology (sarcomatous or biphasic). […] More clinical trials are urgently required to identify better adjuvant therapy for tumors containing sarcomatous elements. […] On currently available evidence, neither radiotherapy nor chemotherapy offer worthwhile prolonged disease control when used in isolation, although both have an important role as part of multimodality therapy. […] Research into immunotherapy and gene therapy suggests that these newer approaches may have a place if tumor volume is small. […] Consensus in mesothelioma management currently remains elusive but it seems clear that the way forward will involve striving for much earlier diagnosis, the use of multimodality therapy and collaboration between centers with special expertise in mesothelioma treatment to organize multicenter trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10673205&#34; target=&#34;_blank&#34;&gt;Talc induces apoptosis in human malignant mesothelioma cells in vitro.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleurodesis with talc is an accepted method for the treatment of symptomatic pleural effusions secondary to mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10678010&#34; target=&#34;_blank&#34;&gt;[VATS in malignant pleural effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Postoperative complications included transient fever and slight asthma in 2 cases, and the symptoms were relieved obviously after some simple therapy to symptom.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10699694&#34; target=&#34;_blank&#34;&gt;Long term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin’s disease treated with 90yttrium-silicate.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As primary treatment and to relieve symptoms of dyspnea secondary to pleural effusion a thoracic drain was installed, followed by intracavitary radiation therapy with 90yttrium-silicate. […] Minor complaints of fever and a dry cough as a side-effect of this treatment were effectively treated with prednisone during 2 weeks. […] Considering the few therapeutic options the use of 90yttrium-silicate intrapleural installation could be propagated as a safe and effective antitumour treatment for a selected group of patients with malignant PM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10703192&#34; target=&#34;_blank&#34;&gt;[The incidence of malignant mesothelioma (1977-1996) and asbestos exposure in the population of an area neighboring Lake Iseo, northern Italy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the study was: identification of malignant mesotheliomas occurring between 1977 and 1996 among the residents of 11 villages, which constituted the recruitment area of the work-force; estimation of the incidence of malignant pleural mesothelioma; collection of working histories of all cases to evaluate previous exposure to asbestos and radiation therapy. 21 cases of mesothelioma were detected (20 pleural, 1 peritoneal; 9 among males), and 20 were supported by histopathologic diagnosis. […] No cases had been exposed to radiation therapy, whereas all cases had been occupationally exposed to asbestos.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10732455&#34; target=&#34;_blank&#34;&gt;Monitoring of impending myocardial damage after pleuropneumonectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma using biochemical markers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In five patients who were treated for malignant pleural mesothelioma (MPM) with pleuropneumonectomy and intraoperative photodynamic therapy (IPDT), impending myocardial damage was monitored using ECG, the classical biochemical markers (creatine kinase [CK], total activity; CKMB, mass; and myoglobin), and the new cardiac markers troponin I (cTnI) and troponin T (cTnT).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10737384&#34; target=&#34;_blank&#34;&gt;Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MnSOD immunoreactivity was assessed semiquantitatively with and without microwave pretreatment. […] Fifteen of the 35 malignant mesotheliomas showed moderate or strong MnSOD expression without and 23 with microwave pretreatment, the corresponding figures for metastatic adenocarcinoma of the pleura being 1 and 2 out of 21 (P = 0.002 and P &amp;lt; 0.001, respectively by Fisher’s exact test).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10741777&#34; target=&#34;_blank&#34;&gt;Mesothelioma: new concepts in diagnosis and management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an uncommon, but no longer rare, cancer that is frequently difficult to diagnose and poorly responsive to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-04-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10759883&#34; target=&#34;_blank&#34;&gt;Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This can be achieved by other simpler and cheaper treatment, thus we see no justification for further studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-05-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10761473&#34; target=&#34;_blank&#34;&gt;[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient was evaluated at the University Hospital Lübeck for Phase II experimental therapy with whole-body hyperthermia (WBH). […] The pretreatment evaluation revealed normal cardiorespiratory function and a normal contrast-enhanced CT of the brain. […] The WBH-radiant heat device (RHD) used for therapy was Aquatherm provided by the Cancer Research Institute (CRI, New York, USA). […] Radiant heat whole body hyperthermia, in conjunction with a defined anticancer treatment and pharmacological approach to sedation, was a safe and effective palliative treatment in this patient.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10763038&#34; target=&#34;_blank&#34;&gt;Current Therapy for Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A uniformly accepted staging system would allow comparison of treatment approaches from various institutions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10773558&#34; target=&#34;_blank&#34;&gt;18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The increasing incidence of malignant pleural mesothelioma has led to the development of new treatment strategies, which still need to be fully validated. […] There is, therefore, a need for new diagnostic techniques that can lead to a definite diagnosis and a satisfactory evaluation of the response to treatment. […] PET was also performed before and after treatment in patients who underwent chemotherapy to evaluate the accuracy of this technique in the assessment of the response. […] These preliminary results demonstrate that 18-FDG PET may have a great potential, both in the differential diagnosis of pleural diseases and in the evaluation of the response to treatment. […] At present, however, histological thoracoscopic diagnosis remains mandatory before planning treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10783675&#34; target=&#34;_blank&#34;&gt;The diagnostic yield of pleural fluid cytology in malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate diagnosis of the cause of the pleural effusion in such a patient is essential as the treatment and prognosis may vary.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10786419&#34; target=&#34;_blank&#34;&gt;Malignant pleural diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In cases of malignant effusion which are not sensitive to chemotherapy, pleurodesis is the treatment of choice for palliation of symptoms, and talc is the most effective agent.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10812006&#34; target=&#34;_blank&#34;&gt;Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MM is unresponsive to present treatment regimens and new protocols are desperately needed. […] The localised nature, the potential accessibility, and the relative lack of distant metastases make MM a particularly attractive candidate for somatic gene therapy. […] A common target for cancer gene therapy is the tumour suppressor protein p53. p53 does not seem to be mutated or deleted in MM, but it can be inactivated by binding to other proteins, like mdm2 and SV40 large T antigen. […] These results indicate that p53-gene therapy should be strongly exploited for clinical trials in MM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10859770&#34; target=&#34;_blank&#34;&gt;[Primary biphasic synovial sarcoma of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because the efficacy of chemotherapy and/or radiotherapy is poor, surgery remains the basis of treatment, whenever possible.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10884665&#34; target=&#34;_blank&#34;&gt;Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to evaluate the utility of positron emission tomography with F18-fluorodeoxyglucose in the preoperative evaluation and staging of malignant mesothelioma in patients who were candidates for aggressive combined modality therapy. […] Identification of occult extrathoracic metastases by positron emission tomography was the basis for excluding two patients from surgical therapy. […] Positron emission tomography can identify malignant pleural mesothelioma and appears to be a useful noninvasive staging modality for patients being considered for aggressive combined modality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10912631&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma: a critical review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma remains a uniformly fatal disease and best supportive care continues to be the standard treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10925221&#34; target=&#34;_blank&#34;&gt;The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Talc pleurodesis remains our primary treatment option but in those patient shown to have the ‘trapped lung syndrome’, in whom pleurodesis would fail, we have been using a pleuroperitoneal shunt.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10969653&#34; target=&#34;_blank&#34;&gt;Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although numerous treatments have been employed, including chemotherapy, radiation therapy, surgical resection, and combinations of the above, no satisfactory treatment yet exists, and affected patients will die of this disease, usually within 12 months. […] Cell-based “suicide gene” therapy utilizing the “bystander effect” with the gene-modified ovarian cancer cell line PA1-STK is feasible in human pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11013806&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura, pericardium and peritoneum. 1: Etiology, pathogenesis, pathology].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery may gain a more important role in the therapy of malignant tumors of serosal membranes not only in palliative, but also in potential curative approaches if the diagnosis can be made at earlier tumor stages.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11013807&#34; target=&#34;_blank&#34;&gt;[Mesothelioma of the pleura and peritoneum. Diagnostic and therapeutic sequelae].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most of these patients survive less than 12 months irrespective of the treatment modality.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11099320&#34; target=&#34;_blank&#34;&gt;Phase II study of vinorelbine in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The new guidelines to evaluate the response to treatment in solid tumors were used. […] There were seven partial responses (24% [95% confidence interval, 10% to 44%]), 16 patients had stable disease (55%), and six patients had disease progression on therapy (21%). […] Quality-of-life analyses showed a benefit for vinorelbine therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11124644&#34; target=&#34;_blank&#34;&gt;Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Management of malignant pleural mesothelioma (MPM) has been an important clinical issue regardless of the treatment modality employed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11127555&#34; target=&#34;_blank&#34;&gt;[Surgical treatment for malignant pleural mesothelioma in eight cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;ol start=&#34;3&#34; style=&#34;list-style-type: decimal&#34;&gt;
&lt;li&gt;Because recurrent pattern for localized type was diffuse type, diagnosis and surgical treatment in early stage was essential for long time survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11130573&#34; target=&#34;_blank&#34;&gt;Well-differentiated papillary mesothelioma involving the peritoneal and pleural cavities: successful treatment by local and systemic administration of carboplatin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It usually shows an indolent course and no standard treatment is available.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11130574&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for sarcomas report of two cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
EPP may be considered for salvage treatment in selected patients with intrathoracic sarcomas not amenable to other effective therapies to achieve mid- to long-term disease control, even in the case of advanced spread.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11139313&#34; target=&#34;_blank&#34;&gt;p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is highly aggressive and largely unresponsive to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11149649&#34; target=&#34;_blank&#34;&gt;Huge malignant localized fibrous tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The best treatment of this disease is radical surgical resection. […] In consideration of the apparent local radicality we did not perform any adjuvant treatment. […] Six months after the operation a wide local recurrence was evident and a systemic treatment with Ifosfamide and Adriamicina is still in progress.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11156085&#34; target=&#34;_blank&#34;&gt;Efficacy of repeated adenoviral suicide gene therapy in a localized murine tumor model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Gene therapy using adenovirus to deliver herpes simplex virus thymidine kinase (Ad.HSVtk) followed by the administration of the prodrug ganciclovir has been an effective anticancer therapy in models of localized tumor (including malignant mesothelioma) and is currently being evaluated in clinical trials. […] Repeat Ad.HSVtk is a feasible approach and may be a useful strategy in human cancer gene therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11162868&#34; target=&#34;_blank&#34;&gt;A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Further treatment was administered if no radiological disease progression was demonstrated. […] Three patients failed to complete one cycle of treatment because of toxicity and one died of disease before response evaluation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11165411&#34; target=&#34;_blank&#34;&gt;Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In order to assess the palliative and therapeutic activity of IL-2 in unresectable pleural malignant mesothelioma with pleural effusion, we performed a phase II study on 31 consecutive patients (M/F 16/15; median age 61 years, range 40-84; PS ECOG 0 n=7; ECOG 1 n=15; ECOG 2 n=9; stage IA n=13; IB n=9; II n=7; IV=2) who received first-line therapy with intrapleural repeated instillation of 9000000 I.U. […] Toxicity (WHO criteria) with intrapleural IL-2 consisted of grade 3 fever in 6/31 (19%) patients and of cardiac toxicity (failure) grade 3 in one patient (3%); toxicity during subcutaneous treatment was mild to moderate, mainly a flu-like syndrome.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11167110&#34; target=&#34;_blank&#34;&gt;Solitary fibrous tumour of the pleura: surgical treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection of benign solitary fibrous tumours is usually curative, but local recurrences can occur years after seemingly adequate surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11174727&#34; target=&#34;_blank&#34;&gt;The alpha folate receptor is highly activated in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This finding may help explain the observations that antifolate drugs have activity in the treatment of mesothelioma. […] It also encourages further study of folate receptor-related treatment strategies in this malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11190547&#34; target=&#34;_blank&#34;&gt;[Treatment of malignant pleural effusion by pleurodesis with talc].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aims of this study were to report on our experience with the use of pleurodesis with talc in the treatment of patients affected by malignant pleural effusions and to analyse the results in the short and mean term.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11224994&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early referral to a tertiary center experienced in the treatment of MPM may be important for several reasons: (1) decreased risk of tumor spread along multiple thoracenesis/biopsy tracts, (2) the availability of specialized pathologic assays for definitive diagnosis, (3) the availability of critical staging modalities (aggressive mediastinoscopy +/- thoracoscopy, MRI scans performed according to specific mesothelioma protocols, and perhaps PET scans), (4) surgical experience with pleurectomy/decortication and/or extrapleural pneumonectomy, that may decrease morbidity and mortality, and (5) the availability of novel adjuvant protocols. […] Single-modality therapy is unlikely to result in long-term survival. […] Hyperthermia, photodynamic therapy, intracavitary therapy, and gene therapy are all relatively new techniques under active investigation that should be supported by enrollment in on-going protocols. […] Predictably, many of these techniques provide greater benefit when used in the setting of adjuvant protocols or minimal residual disease, emphasizing the importance of multimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11228529&#34; target=&#34;_blank&#34;&gt;A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One of the primary limitations of adenoviral (Ad) -mediated gene therapy is the generation of anti-Ad inflammatory responses that can induce clinical toxicity and impair gene transfer efficacy. […] The effects of immunosuppression on these inflammatory responses, transgene expression, and toxicity have not yet been systematically examined in humans undergoing Ad-based gene therapy trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11243900&#34; target=&#34;_blank&#34;&gt;SV40 and the pathogenesis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current therapy is ineffective in slowing the course of the disease, and median survival from the time of diagnosis is rarely greater than 1 year.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11249674&#34; target=&#34;_blank&#34;&gt;Immunotherapy-based treatment strategies for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current treatment modalities include surgery, chemotherapy and radiation therapy, although in some clinical trials none of these modalities have proven to be superior to no treatment at all.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11251277&#34; target=&#34;_blank&#34;&gt;Trimodality management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From September 1998 to August 2000, 32 consecutive patients with histological diagnosis of MPM underwent trimodality therapy, including surgery followed by adjuvant chemotherapy and radiation therapy. […] (1) Trimodality therapy is feasible in selected patients with MPM and has an acceptable operative mortality rate.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11257775&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma. A treatment option in selected cases?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no standard treatment for diffuse malignant pleural mesothelioma. […] To evaluate the role of extrapleural pneumonectomy in the treatment for the disease, cases that underwent surgery in a single institution are reported with descriptions of the stages based on the system from the International Mesothelioma Interest Group. […] There was no treatment-related death. […] Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma was concluded to be a treatment option in stage Ib cases with epithelial histology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11283936&#34; target=&#34;_blank&#34;&gt;Expression and prognostic significance of catalase in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Furthermore, to investigate the effect of catalase inhibition in the drug resistance of these cells in vitro, the authors exposed mesothelioma cells with the highest catalase level to epirubicin with and without aminotriazole pretreatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11305067&#34; target=&#34;_blank&#34;&gt;Superior vena cava obstruction: is stenting necessary?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No therapy is currently available for patients with recurrent vascular obstruction of the superior vena cava (SVC) caused by tumor regrowth after chemotherapy or radiation therapy. […] Intravascular stenting is a new option for the treatment of vena cava syndrome.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-09-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11319288&#34; target=&#34;_blank&#34;&gt;Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At present there is no standardized treatment of this neoplasia. […] The treatment consisted of mitoxantrone 10 mg/m2 intravenous (IV) or intrapleural (IPL), methotrexate 35 mg/m2 IV, and mitomycin 7 mg/m2 IV on day 1 and repeated every 3 weeks, with mitomycin in alternate cycles (MMM regimen). […] One complete response (4.5%) (42 months of duration) and 6 partial responses (27.3%) (5, 5, 7, 9, 14, and 19 months of duration) were achieved; the overall response rate (ORR) was 31.8% (95% CI, 12.4-51.3%); 7 patients were stable under this treatment (31.8%). […] This treatment produced a considerable clinical benefit, with improvement of dyspnea (68.4%) and pain (33.3%); 15 of 19 patients (78.9%) with pleural effusion at the time of diagnosis showed an important reduction in pleural fluid during chemotherapy. […] From the data presented here, this regimen can be considered active in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11338024&#34; target=&#34;_blank&#34;&gt;Treatment of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Traditionally, strategies for the treatment of MPM have included supportive care, surgery, radiotherapy, and chemotherapy. […] Single-modality therapy using traditional approaches (surgery, radiotherapy, chemotherapy) alone has failed to improve patient survival significantly. […] Innovative therapies such as the use of photodynamic, targeted cytokines and gene therapy are currently being investigated for management of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11358044&#34; target=&#34;_blank&#34;&gt;Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Synovial sarcoma of the pleural cavity is exceptionally rare and may be confused, both clinically and histologically, with malignant mesothelioma, with subsequent inappropriate therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11386383&#34; target=&#34;_blank&#34;&gt;Percutaneous balloon pericardiotomy for patients with malignant pericardial effusion including three malignant pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These results suggest that percutaneous balloon pericardiotomy may be used in the treatment of patients with malignant pericardial effusion as an alternative to surgical pericardial window creation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11398882&#34; target=&#34;_blank&#34;&gt;Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There were no objective or symptomatic responses though nine patients (64%) had stable disease on therapy. […] The median overall survival by intention-to-treat analysis was 6.1 months from the time of first treatment. […] The median duration of stable disease from time of first treatment for patients not progressing on therapy was 5.1 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-11-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11423790&#34; target=&#34;_blank&#34;&gt;[Treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study all patients observed between January 1993 and October 1997 with malignant pleural mesothelioma (MPM) have been analyzed in order to describe the impact of treatment modality on survival. […] Four treatment modalities were identified: 1) Surgery (subtotal pleurectomy) = 20 patients; 2) Chemotherapy = 19 patients; 3) Surgery+Chemo-therapy = 8 patients; 4) Supportive care = 9 patients. […] Using univariate analysis, 8 prognostic factors were studied (age, sex, asbestos exposure, side, histotype, performance status, stage, treatment). […] Among these, only the stage and the performance status had shown a prognostic value on survival (p&amp;lt;0.05), while the treatment modality had not significantly influenced the prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11474931&#34; target=&#34;_blank&#34;&gt;Wedge-shaped applicator for additional light delivery and dosimetry in the diaphragmal sinus during photodynamic therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In situ light dosimetry during photodynamic therapy (PDT) of malignant pleural mesothelioma (MPM) after tumour resection facilitates the delivery of a controlled light distribution to the inner thoracic surface.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11494349&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma from neighborhood exposure to anthophyllite asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pleural mesothelioma was an epithelial type with tubulopapillary structures and was treated with an extrapleural pneumonectomy followed by radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11505321&#34; target=&#34;_blank&#34;&gt;A case of repetitive intrapleural cancer chemotherapy using INFUSE-A-PORT for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
INFUSE-A-PORT may be useful for repetitive intrapleural chemotherapy in outpatient treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11507034&#34; target=&#34;_blank&#34;&gt;p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our results suggest that human mesotheliomas with wild-type p53 yet lacking p14(ARF) are potential candidates for ONYX-015 therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-09-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11510098&#34; target=&#34;_blank&#34;&gt;[A case of desmoplastic malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient was treated with combined chemo-radiotherapy, but the response to this treatment was unclear.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11517828&#34; target=&#34;_blank&#34;&gt;[Unusual case of mesothelioma of the tunica vaginalis associated with prostatic adenocarcinoma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival, without surgical treatment is 23 months. […] Surgery was followed by radiation therapy. […] Since chemotherapy and radiation therapy had poor results, a rapid surgical treatment, by radical orchiectomy, is important.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11536437&#34; target=&#34;_blank&#34;&gt;Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No pretreatment of samples was necessary for the HBME-1-stained slides; microwave antigen retrieval was performed on all slides stained for calretinin.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11571736&#34; target=&#34;_blank&#34;&gt;Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Regardless of the modality of therapy used, malignant pleural mesothelioma is a highly treatment-resistant and invariably fatal disease. […] A multivariate analysis confirmed the independent predictive power of histologic subtype, and an elevated concentration of hyaluronan in the pleural fluid also indicated longer survival in older patients and in patients receiving therapy other than supportive. […] The prognostic value of histologic subtype and the concentration of hyaluronan in pleural effusions should be considered when designing and evaluating treatment trials for patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11581615&#34; target=&#34;_blank&#34;&gt;A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Stage III disease has a high risk of early distant relapse and should be considered for trials of systemic therapy added to this regimen of resection and radiation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11591556&#34; target=&#34;_blank&#34;&gt;Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To determine the optimal administered dose of meta-tetrahydroxyphenylchlorin (mTHPC) for intraoperative photodynamic therapy (IPDT) in resected malignant pleural mesothelioma (MPM). […] The primary objective of this combination treatment was to improve local tumor control. […] Three patients died in the perioperative period, and one death was directly related to photodynamic therapy. […] Local tumor control, 9 months after treatment, was achieved in 13 of the 26 patients treated with IPDT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11601750&#34; target=&#34;_blank&#34;&gt;Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to investigate the effects of various pretreatment clinical and laboratory characteristics on the survival of patients with diffuse malignant pleural mesothelioma (DMPM). […] Fifty-nine were treated with chemoimmunotherapy while 41 who had refused chemoimmunotherapy received supportive therapy alone. […] The following pretreatment characteristics were evaluated in both univariate and multivariate Cox regression analyses: age, gender, Karnofsky performance score (KPS), histology asbestos exposure, presence of chest pain, dyspnoea, weight loss, symptom duration, smoking history, disease location, platelet count, haemoglobin, white blood cell (WBC) count, serum lactate dehydrogenase (LDH) and extent of disease (stage).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-11-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11676187&#34; target=&#34;_blank&#34;&gt;[Incidence of malignant mesothelioma (1980-1999) and asbestos exposure in 190 cases diagnosed among residents of the province of Brescia].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ten cases of MM were diagnosed in subjects under 45 years old (5.2%) with only one case occupationally exposed. 2 cases were exposed to radiation therapy (1%) and 2 cases to thoracic trauma (1%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11679187&#34; target=&#34;_blank&#34;&gt;Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ninety-one patients received a treatment (38 palliative pleurectomy and no further therapy, 16 palliative pleurectomy followed by chemotherapy, 37 chemotherapy alone), while 30 were referred to supportive care only. […] Patients receiving any therapy survived longer than patients treated with supportive care only (P=0.0004). […] Treatment modality had an independent prognostic value (P=0.00005), with a survival advantage for patients receiving surgery and adjuvant chemotherapy. […] Multivariate analysis confirmed the independent prognostic value of PS (P=0.001; HR=2.48) and treatment modality (P=0.003; HR=1.38). […] The prognostic role of PS (P=0.02) and treatment modality (P=0.01) was confirmed in the subset of patients with epithelial histology. […] On the contrary, therapy had no impact on survival in patients with sarcomatoid MPM (P=0.74). […] Despite the predicted bias of a retrospective non-randomized evaluation of treatment-related factors, patients with good PS and epithelial histology seemed to have a survival benefit from surgery or multimodality therapy, as opposite to patients with poor PS or non-epithelial histotype. […] However, these results must be confirmed in a larger prospective trial with uniform treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11712816&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma following chemotherapy for breast cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To our knowledge, this is the f rst reported case of malignant pleural mesothelioma following treatment with chemotherapy alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11713768&#34; target=&#34;_blank&#34;&gt;Technology evaluation: gene therapy (mesothelioma), NCI.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The National Cancer Institute is sponsoring a phase I clinical trial by the University of Pennsylvania involving administration of recombinant adenovirus containing the HSV-tk gene and subsequent tumor kill by ganciclovir, for the gene therapy of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-01-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11717014&#34; target=&#34;_blank&#34;&gt;Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment aims were pleural drainage, lung re-expansion, pleurodesis and pleural debulking for symptom control.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11721205&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Up today, no treatment has been demonstrated as effective in influencing disease-related survival and the median prognosis ranges between 9 and 17 months after the diagnosis. […] The epithelial subtype of the disease seems to have a better prognosis when early diagnosed and treated with intrapleural immunotherapy or multimodality therapy. […] For the early-stage disease (stage I) a therapeutic approach seems to be neoadjuvant intrapleural treatment using cytokines. […] For more advanced disease (stages II and III) resectability should be discussed with the thoracic surgeons and a multimodality treatment combining surgery, radiotherapy and chemotherapy should be proposed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11745800&#34; target=&#34;_blank&#34;&gt;Survival after conservative (palliative) management of pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Aggressive multimodality treatment protocols are reportedly associated with improved survival, but the apparent survival benefits may simply reflect patient selection and the variable natural history of this malignancy. […] Before embarking on our own protocol of experimental treatment for mesothelioma, we sought to identify important prognostic factors and document the survival of patients treated conservatively (with palliative intent only) in our region. […] Since curative intent treatment had not been given, we assumed that measured survival would largely reflect the natural history of the malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11757221&#34; target=&#34;_blank&#34;&gt;[Two cases of malignant mesothelioma of the pleura within one family].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because of various degree of disease advancement, various methods of treatment were used. […] One brother was treated with radical surgery followed by radiotherapy; the other brother with more advanced disease underwent palliative treatment using chemotherapy. […] Currently, he undergoes symptomatic treatment. […] The cases above have been presented because the familial occurrence of this neoplasm is extremely rare and to show the possibility of radical surgical treatment of this type of neoplasm which has poor prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11826504&#34; target=&#34;_blank&#34;&gt;[Results of phase II clinical trial of cycloplatam in refractory solid tumors].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Having passed phase I trials, it was approved for treatment of pleural mesothelioma, ovarian carcinoma and multiple myeloma. […] They include treatment of solid tumors with cycloplatam alone in urinary bladder tumors, cervical carcinoma and malignant pleurites of various etiology as well as in combination with other cytostatics (carcinoma of the prostate, pleural mesothelioma and urinary bladder tumors).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-02-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11828289&#34; target=&#34;_blank&#34;&gt;Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pretreatment with cisplatin resulted in a reduction of 50% inhibitory concentration from infinity to 4.17 +/- 0.14 ng/mL and 10.23 +/- 1.58 ng/mL, respectively. […] Exposure of these cells to lymphokine-activated killer cells or lymphokine-activated killer cell-conditioned medium followed by a 24-hour treatment with cisplatin resulted in a significant reduction in 50% inhibitory concentration of soluble Fas ligand and pronounced induction of apoptosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11834661&#34; target=&#34;_blank&#34;&gt;Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No established curative treatment is available for pleural thymoma metastases and malignant pleural mesothelioma (MPM). […] We investigated the feasibility and safety of this multimodality treatment in the thoracic cavity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11836664&#34; target=&#34;_blank&#34;&gt;The pathogenesis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The expression of the SV40 large tumor antigen in mesothelioma cells, and not in nearby stromal cells, and the capacity of antisense T-antigen treatment to arrest mesothelioma cell growth in vitro suggest that SV40 contributes to tumor development.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11836666&#34; target=&#34;_blank&#34;&gt;The role of imaging in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These imaging modalities help triage patients to the most appropriate diagnostic and treatment options. […] Following patients after therapy usually relies on chest radiographs, although CT can more accurately describe response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11836667&#34; target=&#34;_blank&#34;&gt;Prognostic factors in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For malignant mesothelioma, the prognostic scoring systems of the Cancer and Leukemia Group B (CALGB) and European Organization for Research and Treatment of Cancer (EORTC) are the most useful of those currently available.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11836668&#34; target=&#34;_blank&#34;&gt;Multimodality treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant pleural mesothelioma (DMPM) is a challenging disease in all of its aspects, from presentation and diagnosis to staging and treatment. […] Single-modality therapy was the initial approach to this disease. […] Randomized controlled studies comparing various strategies are lacking and, thus, the debate continues regarding the effectiveness of different treatment approaches.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11836672&#34; target=&#34;_blank&#34;&gt;The emerging role of antifolates in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The second trial is being conducted by the European Organization for the Research and Treatment of Cancer (EORTC) and compares cisplatin with or without raltitrexed with planned accrual of 240 patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11836674&#34; target=&#34;_blank&#34;&gt;Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The incidence of the disease is rising rapidly in many countries, and there is no generally accepted standard treatment for patients with unresectable disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11847028&#34; target=&#34;_blank&#34;&gt;[Current insights in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although there is still no unanimously recognized therapy for MPM, long survival has been observed for some patients treated with associated therapies (surgery + radiotherapy + chemotherapy). […] This article tries to summarize current insights concerning epidemiology, diagnosis and treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11862420&#34; target=&#34;_blank&#34;&gt;SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive cancer, with survival of less than one year following diagnosis and treatment with current protocols.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11862475&#34; target=&#34;_blank&#34;&gt;Hyperthermia and mafosfamide in a human-derived malignant pleural mesothelioma cell line.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no standard therapy for this highly aggressive disease and the development of new therapeutic strategies is imperative. […] After therapy, cells were prepared for light and electron microscopy. […] We suggest that the effect of substances such as ifosfamide and cyclophosfamide which are in clinical use, might be enhanced by the combination of local or regional hyperthermia in order to improve the therapeutical index of these substances in the treatment of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11875694&#34; target=&#34;_blank&#34;&gt;Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immuno-haematological parameters were analyzed pre-treatment and 1 month after completion of treatment. […] Haemato-immunological parameters, measured in seven patients pre and post-therapy, revealed that response rate correlated with a decrease in platelet count and there was an increase in activation of natural killer cells and a decrease in the percentage of IL-4 producing T cells in all tested patients post-treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11888966&#34; target=&#34;_blank&#34;&gt;Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No treatment-related mortality, renal dysfunction, bone marrow suppression, or infection occurred. […] In the future, prospective randomized studies will be necessary to compare the efficacy of therapy for MPE using the implantable access system with that of pleurodesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11905410&#34; target=&#34;_blank&#34;&gt;Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Both groups were compared in terms of age, presentation, treatment, survival, tumor architecture, mitotic rate, necrosis, nuclear grade, and immunohistochemical profile. […] Patients in the two groups were similar in terms of age at diagnosis (median ages, 50.7 years and 49.9 years), presentation, initial tumor burden, and treatment. […] Slightly less than 50% of patients in both groups received some form of chemotherapy or radiation therapy after undergoing tumor-reductive surgery or biopsy. […] However, because there do not appear to be morphologic features that reliably identify favorable tumors versus unfavorable tumors, aggressive therapy for all women with diffuse peritoneal mesotheliomas may be warranted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11923140&#34; target=&#34;_blank&#34;&gt;Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The forced overexpression of PTEN may prove useful clinically in this treatment-resistant neoplasm.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-06-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11933739&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma. Present data and perspectives for treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The interest of prophylactic parietal radiation following invasive thoracic treatment has been demonstrated. […] Mean survival of patients having undergone surgery is of 10 to 17 months with rates between 10 and 30% at 2 years ASSOCIATED THERAPY: For the first time, despite high morbidity rates, associated therapy has led to prolonged survival, whereas isolated therapy has not. […] In the treatment of malignant pleural mesothelioma, genetic, anti-proliferative and immune therapy, that attempt to use the immune system of the patient to obtain an anti-tumour cytotoxic reaction, appear promising.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11937311&#34; target=&#34;_blank&#34;&gt;A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy continued up to 10 cycles unless disease progression or excessive toxicity mandated discontinuation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11961432&#34; target=&#34;_blank&#34;&gt;A case of malignant pleural mesothelioma with unexpectedly long survival without active treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We present the case of a patient with MPM who survived for more than 10 years without active treatment after the disease had been diagnosed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11989592&#34; target=&#34;_blank&#34;&gt;Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of inoperable malignant pleural mesothelioma is a challenge for the oncologist. […] We herein report the results of a pilot study about the treatment of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11996472&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a phase II trial with docetaxel.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current cytotoxic therapy has been of limited benefit to patients with malignant pleural mesothelioma. […] Docetaxel, an effective taxane in the treatment of advanced breast cancer and non-small-cell lung cancer, was administered intravenously at a dose of 100 mg/m2 every 3 weeks to 30 chemotherapy naive patients with malignant pleural mesothelioma in a prospective multi-institutional phase II clinical trial. […] Three patients died within 2 weeks post-first cycle of therapy, although only one patient’s death was directly attributed to the investigational drug, whilst in the majority of the patients, manageable and treatable toxicities were encountered. […] In this phase II clinical trial, docetaxel proved to be mildly effective in the treatment of patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12017884&#34; target=&#34;_blank&#34;&gt;[Surgery and hyperthermic pleural perfusion–a new approach for malignancies with pleural involvement].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The preferred treatment of these tumors is not clear. […] To evaluate whether regional therapy that includes resection, local chemotherapy and hyperthermia is feasible, safe and effective for tumors with pleural spread. […] Twenty-five patients received previous treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12023790&#34; target=&#34;_blank&#34;&gt;Pemetrexed for diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of diffuse malignant pleural mesothelioma (MPM) is currently less than satisfactory. […] The response to chemotherapeutic agents is poor, and to date there is no standard cytotoxic treatment. […] There is also no evidence that any chemotherapy regimen given as a part of multimodality treatment, including radiotherapy and surgery, can improve survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-06-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12044240&#34; target=&#34;_blank&#34;&gt;Current therapy for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review briefly summarizes the results of previous systemic (chemotherapy) and local (surgery and radiotherapy) treatment attempted to date for malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12044246&#34; target=&#34;_blank&#34;&gt;Current surgical management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Single-modality therapy has failed to improve median survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12057100&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multiple trials of traditional cancer therapies for malignant pleural mesothelioma (including surgery, radiation therapy, and chemotherapy) have not convincingly demonstrated that any one treatment is superior to supportive care alone. […] Photodynamic therapy (PDT), a local treatment modality, is being evaluated as an adjuvant therapy to surgical resection. […] The treatment effect of PDT is superficial, mostly because of the limited depth of light absorption in tissues. […] Therefore, it is theoretically an ideal treatment for tissue surfaces and body cavities after surgical debulking procedures. […] Several studies have evaluated the efficacy of PDT in the treatment of mesothelioma. […] Additional studies are necessary to determine the role of PDT in the treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12057102&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This paper summarizes the author’s thoughts about the use of cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy (CS-IPHC) for treatment of peritoneal malignant mesothelioma. […] It is well known that chemotherapy for mesothelioma is largely unsatisfactory, and measurement of treatment responses can be difficult. […] The author’s approach relies on surgery to achieve the following: 1) accurate staging; 2) tumor debulking, as possible, and treatment of mechanical obstruction as well as prevention of impending obstruction by resection or bypass; and 3) preparation for the use of intra-operative hyperthermic chemotherapy perfusion. […] This approach has been associated with rapid clinical symptom improvement, as well as a reliable and durable resolution of ascites with a single therapy. […] The inability to provide effective systemic therapy to maintain or consolidate these gains is problematic.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12057155&#34; target=&#34;_blank&#34;&gt;Pericardial mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection remains the main treatment modality. […] Newer therapeutic approaches for malignant pleural mesothelioma are likely to influence the treatment of pericardial mesothelioma in the future.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12057157&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because most patients die of respiratory failure from extensive disease progression in the thorax, treatment usually includes attempts at local control. […] Although there have been several single-institution reports of combined-modality therapy with extrapleural pneumonectomy, postoperative radiation, and chemotherapy in which prolonged survival has been observed, most patients with malignant pleural mesothelioma have locally advanced disease, advanced age, or comorbid medical illnesses that preclude aggressive surgery. […] Therefore, the use of a systemic anticancer agent is the only treatment option for most patients with malignant pleural mesothelioma. […] The impressive 48% response rate reported for the combination of gemcitabine with cisplatin in a single phase II study has made this regimen the new standard of care for off-protocol treatment of this disease, although this trial still requires validation. […] Early trials of angiogenesis inhibitors, gene therapy, and vaccines offer additional avenues for treatment. […] As we begin to incorporate these active new drugs with each other and in adjuvant and neoadjuvant treatment regimens, there is reason to believe that superior results for patients with malignant pleural mesothelioma can be achieved in the near future.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12060628&#34; target=&#34;_blank&#34;&gt;Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is a fatal tumor of increasing incidence, which is resistant to current therapy. […] Furthermore, COX-2 expression contributed in multivariate analysis to both European Organization for Research and Treatment of Cancer (P = 0.001) and Cancer and Leukemia Group B (P = 0.003) prognostic scoring systems. […] COX-2 is a potential therapeutic target in MM, and trials are required of COX-2 inhibitors alone or in combination with existing treatment modalities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12065358&#34; target=&#34;_blank&#34;&gt;Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
If the patient’s disease progressed after AM Phi treatment, an additional treatment was left to the choice of the investigator. […] After completion of the AM Phi cellular therapy, 10 patients were treated with chemotherapy as their diseases progressed. […] One patient, who could not be evaluated by thoracoscopy because of pleural symphysis, is still alive without any clinical or radiologic sign of disease 69 months after treatment. […] No major adverse effects were observed during the infusion of either AM Phi or gamma-IFN, and there was no interruption of treatment because of toxicity. […] However, symphysis was observed in 7 of 14 patients who received the complete treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-08-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12096506&#34; target=&#34;_blank&#34;&gt;[A case of desmoplastic malignant mesothelioma with elevated serum CYFRA 21-1].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Though she received antituberculosis therapy, the pleural thickening progressed and the serum CYFRA 21-1 level was elevated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12111493&#34; target=&#34;_blank&#34;&gt;CT-guided percutaneous selective cordotomy for treatment of intractable pain in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the treatment of intractable pain, CT-guided cordotomy is a perfect method in selected cases with malignancy. […] This is the most effective and suitable treatment modality for local pain due to malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12122570&#34; target=&#34;_blank&#34;&gt;Tumorigenicity of cellulose fibers injected into the rat peritoneal cavity.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There were 50 rats per treatment group except for the 10(8) and 10(9) fibers crocidolite groups which were reduced to 26 rats because of the expectation of high tumor incidence in these groups. […] However, 9 (18%) of the 10(9) cellulose group had malignant tumors that, in contrast to the usual pattern of mesothelioma development following treatment with mineral fibers in rats, showed no obvious involvement of mesothelial tissues, were not associated with blood-stained ascites fluid, and were thus classified as sarcomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12142203&#34; target=&#34;_blank&#34;&gt;The management of malignant pleural mesothelioma; single centre experience in 10 years.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an asbestos-related disease of the pleura with a survival time without treatment ranging from 4 to 12 months. […] The objective of this study is to review our experience in selection of MPM patients for various modalities of treatment. […] Majority (191 patients, 61%) of them received no specific treatment. […] The average survival was 8.9 months for those treated by palliative care only. […] Further trials are needed to improve on the adjuvant treatment regimes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12164558&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma of the pleural space and its management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Difficulties in diagnosis, staging, and treatment set this disease apartfrom other malignancies. […] The variable clinical presentation and problems in establishing a definite histopathologic diagnosis result in significant delays in treatment. […] The disease’s natural history involves aggressive local growth, invasion of vital mediastinal structures, and death within 4 to 12 months without treatment. […] Single-modality therapy of any kind has failed to substantially alter this natural history.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12177114&#34; target=&#34;_blank&#34;&gt;Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A total of 163 courses of treatment were administered (median, six; range, one to 10).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12189542&#34; target=&#34;_blank&#34;&gt;A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here we confirm these findings in a multicentre setting, and assess the effect of this treatment on quality of life and pulmonary function. […] The median time to disease progression was 6.4 months, median survival from start of treatment 11.2 months, and median survival from diagnosis 17.3 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12194801&#34; target=&#34;_blank&#34;&gt;Malignant gonadal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The principle reasons for this are difficulty in making a preoperative diagnosis and advanced stage at the time of treatment. […] Adjuvant therapy in the form of chemotherapy, immunotherapy, or radiotherapy has negligible benefit.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12196927&#34; target=&#34;_blank&#34;&gt;Overexpression of gamma-glutamylcysteine synthetase in human malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma is a fatal tumor resistant to all treatment modalities for reasons that are still unresolved. […] Treatment of cultured mesothelioma cells with buthionine sulfoximine (BSO), to inhibit gamma GCS, significantly potentiated cisplatin-induced cytotoxicity mainly by nonapoptotic mechanism when assessed by counting the living cells, TUNEL (terminal deoxytransferase-mediated dUTP nick-end labeling) assay, and caspase-3 cleavage.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12209878&#34; target=&#34;_blank&#34;&gt;Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Combined treatment with Trastuzumab (10 microg/ml) and CDDP (1 microg/ml) showed synergism.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12215551&#34; target=&#34;_blank&#34;&gt;Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
(18)F-FDG identified extrathoracic metastases in 5 patients, excluding them from surgical therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12229245&#34; target=&#34;_blank&#34;&gt;[Prognosis, staging and therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
So far there is no effective standard therapy. […] Neither chemotherapy, radiotherapy nor photodynamic therapy can prevent local relapse which occurs in the majority of patients. […] The effectiveness of primary radiation therapy remains controversial. […] It remains unclear whether radiation therapy may palliate tumor associated symptoms. […] Research of the biological behavior of mesothelioma resulted in first phase I gene therapy trials. […] The results of the few promising approaches tested in phase II and III trials with sufficient patient numbers have to be awaited until we have learned whether and in which stage of the disease patients may benefit from therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12234991&#34; target=&#34;_blank&#34;&gt;Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Furthermore, treatment with ZD1839 led to a significant dose-dependent reduction of colony formation (41-89% at 10 microM) when MPM cells were grown in soft agarose.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1224688&#34; target=&#34;_blank&#34;&gt;[Etiology and clinical diagnosis of diffuse pleural mesothelioma (author’s transl)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A therapeutical treatment is not known till now.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12400973&#34; target=&#34;_blank&#34;&gt;Survival after pleural malignant mesothelioma: a population-based study in Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Either there was no change in treatment efficacy or the effect was limited to small subgroups and could not be noticed when the analysis included larger categories.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12405438&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in a child: long-term survival with ICE-WAC chemotherapy regimen.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Presently, treatment of this disease continues to be frustrating and prognosis remains poor. […] She did not receive any further therapy and remains disease-free three years after the first remission.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-11-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12408739&#34; target=&#34;_blank&#34;&gt;Potential of interferon-alpha in solid tumours: part 2.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In superficial bladder cancer, intravesical rIFNalpha has a promising role as second-line therapy in patients resistant or intolerant to intravesical bacille Calmette-Guérin (BCG). […] In neuroendocrine tumours, including carcinoid tumour, low-dosage (&amp;lt;/=3 MU) or intermediate-dosage (5 to 10 MU) rIFNalpha is indicated as second-line treatment, either with octreotide or alone in patients resistant to somatostatin analogues. […] Similarly, intraperitoneal IFNalpha may have a role in the treatment of minimal residual disease in ovarian cancer. […] IFNalpha may have a role as a radiosensitising agent for the treatment of cervical cancer; however, this requires confirmation in randomised trials. […] On the basis of current evidence, the routine use of rIFNalpha is not recommended in the therapy of head and neck squamous cell cancers, upper gastrointestinal tract, colorectal and lung cancers, or mesothelioma. […] Studies of IFNalpha-stimulated gene expression, which are now feasible, should help to identify molecular predictors of response and allow us to target therapy more selectively to patients with solid tumours responsive to IFNalpha.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12447185&#34; target=&#34;_blank&#34;&gt;Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We performed a retrospective review of the efficacy and morbidity of radical pleurectomy/decortication and intraoperative radiotherapy followed by external beam radiation therapy with or without chemotherapy for diffuse malignant pleural mesothelioma. […] External beam radiation therapy was generally started 1 to 2 months after resection and delivered by means of 3-dimensional conformal radiation therapy or with inverse treatment planning intensity-modulated radiation therapy. […] Radical pleurectomy/decortication with aggressive radiotherapy with or without chemotherapy might offer an alternative treatment option to those who cannot tolerate extrapleural pneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-01-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12472131&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: options for management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As with other tumors, early diagnosis-while the disease is still in stage I, or even at an in situ stage-must be the goal so that therapy can be maximized, particularly if immunotherapy or gene therapy is to be used. […] Patients with pure epithelial mesothelioma have a better prognosis and respond better to trimodality therapy. […] The place of immunotherapy and gene therapy as adjunctive treatments also remains to be defined. […] For example, it may be possible to reduce tumor bulk and perhaps downstage the disease with immunotherapy before radical surgery, if treatment is started early enough. […] Gene therapy may have a role either preoperatively or in destroying the microscopic disease that remains after radical surgery. […] These and other combinations of treatment need to be tested in well-designed clinical trials, probably on a multicenter basis (to enroll a sufficient number of patients). […] Finding the means to improve treatment for sarcomatous and mixed histology mesothelioma remains a challenge. […] At present, radical surgery does not seem worthwhile for these patients when combined with currently employed chemotherapy and radiotherapy; however, chemotherapy combinations used for treating other sarcomas need to be evaluated as adjunctive therapy before radical surgery is abandoned altogether as a mode of treatment. […] Despite its increasing frequency, mesothelioma is still a relatively rare tumor, so treatment should be concentrated in relatively few supraregional centers to maximize expertise and allow innovative treatment combinations to be implemented with the greatest chance of success. […] The nihilistic approach of simply waiting until the mesothelioma epidemic eventually begins to decline spontaneously in 20 or 30 years is untenable in view of the hundreds of thousands of deaths that will result if no effective treatment is found.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-12-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12479365&#34; target=&#34;_blank&#34;&gt;Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, we investigated the expression of survivin, a member of the inhibitors of apoptosis protein gene family, in mesothelioma and an antisense oligonucleotide-based gene therapy for mesothelioma using survivin as a target. […] Down-regulation of survivin by a targeted antisense oligonucleotide appears to be an effective gene therapy approach to the treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12516073&#34; target=&#34;_blank&#34;&gt;Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Experimental assessment of photodynamic therapy (PDT) for malignant pleural mesothelioma using a polyethylene glycol conjugate of meta-tetrahydroxyphenylchlorin (PEG-mTHPC). (a) PDT was tested on H-meso-1 xenografts (652 nm laser light; fluence 10 J/cm(2); 0.93, 9.3, or 27.8 mg/kg of PEG-mTHPC; drug-light intervals 3-8 days). (b) Intraoperative PDT with similar treatment conditions was performed in the chest cavity of minipigs (n = 18) following extrapleural pneumonectomy (EPP) using an optical integrating balloon device combined with in situ light dosimetry. (a) PDT using PEG-mTHPC resulted in larger extent of tumor necrosis than in untreated tumors (P &amp;lt; or = 0.01) without causing damage to normal tissue. (b) Intraoperative PDT following EPP was well tolerated in 17 of 18 animals. […] PEG-mTHPC mediated PDT showed selective destruction of mesothelioma xenografts without causing damage to intrathoracic organs in pigs at similar treatment conditions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-05-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12525529&#34; target=&#34;_blank&#34;&gt;Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this open-label phase II study was to evaluate the activity of raltitrexed (Tomudex; AstraZeneca, Cergy, France) and oxaliplatin combination therapy in patients with diffuse malignant pleural mesothelioma. […] In chemotherapy-naive patients, median survival was 31 weeks (95% CI, 23 to 40 weeks) from the start of treatment and 49 weeks (95% CI, 40 to 52 weeks) from diagnosis of mesothelioma. […] In pretreated patients, median survival was 44 weeks (95% CI, 24 to 40 weeks) from the start of treatment and 226 weeks (95% CI, 63 to 292 weeks) from the diagnosis of mesothelioma. […] The most common adverse events were asthenia, nausea/vomiting, and paraesthesia, and no treatment-related deaths were reported.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12527624&#34; target=&#34;_blank&#34;&gt;Interferons and their application in the diseases of the lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
IFN-gamma is emerging as an important cytokine for use in the treatment of patients with infectious diseases, including multidrug-resistant pulmonary TB. […] A better understanding of IFN biology, indications, side effect profiles, and toxicity management will aid in optimizing its use in the treatment of patients. […] The purpose of this article is, therefore, to review the current clinical use of IFNs in the treatment of patients with respiratory diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12544259&#34; target=&#34;_blank&#34;&gt;Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy (HITHOC) is studied in a phase I study in the treatment of malignant pleural mesothelioma and pleural thymoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12560629&#34; target=&#34;_blank&#34;&gt;[Diagnosis and treatment of pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Adjuvant therapy (chemotherapy or radiotherapy) was given to 10 pts. […] The best results of treatment were achieved after combined treatment: surgery, after chemotherapy and radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12565988&#34; target=&#34;_blank&#34;&gt;The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We investigated the activity and toxicity of raltitrexed (Tomudex) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II European Organization for Research and Treatment of Cancer (EORTC) study. […] We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-04-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12571809&#34; target=&#34;_blank&#34;&gt;Emerging insights into the biology and therapy of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognostic scoring systems of the Cancer and Leukemia Group B and the European Organization for Research and Treatment of Cancer are the most useful of those currently available. […] Most patients with mesothelioma are not candidates for surgical or radiotherapy treatment, and cytotoxic agents are the only options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-03-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12573747&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New insight into the extent of the target volume for the postoperative irradiation of malignant pleural mesothelioma as determined during surgery has indicated that standard conformal radiotherapy (IMRT) is not sufficient for curative treatment. […] After extrapleural pneumonectomy, 7 patients underwent simulation, treatment planning, and treatment with IMRT to the involved hemithorax and adjacent abdomen. […] IMRT for treatment of malignant mesothelioma after extrapleural pneumonectomy results in more potentially curative doses to large, complex target volumes with acceptable doses to normal tissues.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12573764&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) causes symptoms and death mainly due to local progression, even after combined modality treatment. […] Intensity-modulated radiation therapy (IMRT) has the potential to overcome these geometric/dosimetric constraints. […] Treatment was delivered by intensity-modulated 6-MV photon beams using dynamic multileaf collimation. […] Treatment of the extensive operative area after an EPP is feasible using IMRT. […] In light of patients’ tolerance to post-EPP IMRT, it may be feasible to incorporate systemic therapy, including novel biologic therapies into the treatment regimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12576380&#34; target=&#34;_blank&#34;&gt;Surgical treatment of malignant pleural mesothelioma: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite many years of clinical research, there is still no effective therapy for malignant pleural mesothelioma (MPM). […] Therefore, focus on local treatment seems rational. […] Surgical resection has been considered the mainstay of treatment by some.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12579319&#34; target=&#34;_blank&#34;&gt;The usefulness of 99mTc-tetrofosmin SPECT in the detection of intrathoracic malignant lesions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The semiquantitative analysis added useful information in differentiating malignant from benign lesions and in monitoring the response to chemo-therapy. […] TF SPECT appears a highly accurate diagnostic method in the detection of intrathoracic malignant lesions, in lungs and pleura, as well as in NSCLC mediastinal lymph node staging and in monitoring treatment effectiveness, playing a complementary role to CT in selected cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1257933&#34; target=&#34;_blank&#34;&gt;Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An analysis is made of the results of pleuropneumonectomy for diffuse malignant pleural mesothelioma in 29 patients and a comparison is made with the results of non-surgical treatment in a further 17 patients. […] Means of reducing operative mortality are discussed and alternative methods of treatment described.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-06-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12601277&#34; target=&#34;_blank&#34;&gt;The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Improvements in the detection of regional and distant metastases are needed to identify patients most likely to benefit from aggressive combined modality treatment regimes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12601278&#34; target=&#34;_blank&#34;&gt;The role of surgery in diagnosis and treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the increasing incidence of the disease together with reports of long-term survivors has resulted in a more aggressive surgical approach toward therapy. […] Radical surgery, with the aim of macroscopic clearance of the tumor, may not be of prognostic benefit alone but, as part of a multimodality treatment regime, may result in long-term survivors. […] Adjuvant treatments with chemotherapy and radiotherapy appear to prolong survival, whereas photodynamic therapy may be detrimental. […] Selection criteria for radical treatment need to be refined and a radical multimodality protocol must be subjected to a randomized, controlled evaluation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1260651&#34; target=&#34;_blank&#34;&gt;Chemotherapy of malignant diffuse mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conclude that adriamycin or COMF treatment may offer worthwhile remissions in mesothelioma and that malignant diffuse mesothelioma is more responsive to chemotherapy than previously realized.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12609573&#34; target=&#34;_blank&#34;&gt;Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median survival time from the start of treatment for all patients was 76.6 weeks (95% CI 65.4-87.8 weeks). […] Major treatment toxicities included grade 3/4 neutropenia and thrombocytopenia in 74 and 33% of treatment cycles, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12610498&#34; target=&#34;_blank&#34;&gt;Chemotherapy for malignant pleural mesothelioma: past results and recent developments.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While response rates exceeding 30% have barely been achieved with established cytotoxic drugs in MPM therapy, novel chemotherapeutic agents and their combinations appear more promising.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12620914&#34; target=&#34;_blank&#34;&gt;Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, this treatment is accompanied by considerable morbidity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12633032&#34; target=&#34;_blank&#34;&gt;[Pleuro-pneumonectomy, RT and CT for pleural mesothelioma. Prospective study].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Though associated with substantially prolonged survival, the favourable results of Sugarbaker’s trimodality treatment for malignant pleural mesothelioma are controversial and have yet to be extensively reproduced. […] The aim was to evaluate the prospective medium-term (3-year) reproducibility of the results of trimodality treatment in a significant group of patients staged using the international IMIG classification. […] This series confirms the reproducibility of trimodality treatment for malignant pleural mesothelioma. […] The treatment is associated with prolonged survival in the case of early-stage tumours and has an acceptable complication rate.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1263545&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma. Report of 19 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy proved to be palliative at best. […] Neither radiation therapy nor chemotherapy had a significant effect on survival time or palliation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12645723&#34; target=&#34;_blank&#34;&gt;A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) is a light-based cancer treatment that, in the correct setting, can be delivered intraoperatively as an adjuvant therapy. […] A total of 26 patients completed treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12697881&#34; target=&#34;_blank&#34;&gt;Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This phase II clinical study evaluated the efficacy of pemetrexed for the treatment of malignant pleural mesothelioma (MPM). […] Forty-three patients received vitamin supplementation for all courses of therapy, and 21 patients did not. […] Vitamin-supplemented patients completed more cycles of therapy than nonsupplemented patients (median, six v two cycles, respectively). […] Patients supplemented with folic acid and vitamin B12 tolerated treatment better (less toxicity and more cycles of treatment) and had a 5-month greater median overall survival than nonsupplemented patients. […] These results indicate that patients with MPM could benefit from single-agent pemetrexed treatment combined with vitamin supplementation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12720495&#34; target=&#34;_blank&#34;&gt;Pemetrexed and its emerging role in the treatment of thoracic malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Similar trends were also initially observed with pemetrexed as well, but investigators later showed that these toxicities could be minimised with folic acid and vitamin B(12) supplementation included in the treatment regimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12722691&#34; target=&#34;_blank&#34;&gt;[Gemcitabine improved QOL and survival in a case of diffuse malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant pleural mesothelioma is a disease with poor prognosis, and no standard therapy for inoperable cases has been established. […] Recently, some reports revealed that gemcitabine (GEM), which has been demonstrated to be effective for the treatment of non-small cell lung carcinoma, was effective in cases of diffuse malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12767092&#34; target=&#34;_blank&#34;&gt;Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The gemcitabine/carboplatin combination is a valid option in the treatment of MPM due to its acceptable toxicity profile, the good response rate, and the clinical benefit to patients. […] Minor adjustments in schedule (3-week cycles instead of 4-week cycles) would permit a more optimal treatment administration.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12781077&#34; target=&#34;_blank&#34;&gt;Advances in the management of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Finding effective chemotherapeutic treatment for malignant mesothelioma is a challenge. […] There is no standard treatment because this tumor is relatively resistant to therapy. […] Several treatment modalities have been studied, including chemotherapy, radiotherapy, surgery, and immunotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12789123&#34; target=&#34;_blank&#34;&gt;Menstruation in an unusual place: a case of thoracic endometriosis in Kampala, Uganda.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
She did well on surgical excision and hormonal therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12795087&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM is a challenging disease in all aspects, including diagnosis, staging and treatment. […] Multimodal treatment including surgery has shown significant benefit in highly selected patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12800189&#34; target=&#34;_blank&#34;&gt;Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Preferential downregulation of either Bcl-xL alone or of Bcl-xL and Bcl-2 simultaneously was achieved by treatment with antisense oligonucleotides 4259 and 4625, respectively, whereas the expression of other apoptosis-relevant genes remained unaffected. […] Treatment with oligonucleotides 4259 or 4625 lowered the apoptosis threshold in ZL34 mesothelioma cells, as indicated by an increase in cell death accompanied by increased caspase-3-like activity, a decrease of the mitochondrial transmembrane potential and the cleavage of procaspase-7 and ICAD. […] In addition to the direct induction of apoptosis, antisense treatment sensitized ZL34 cells to the cytostatic effect of cisplatin and gemcitabine, with the combination of 4625 and cisplatin being the most effective. […] Our results demonstrate that Bcl-2 and Bcl-xL antisense treatment facilitates apoptosis in mesothelioma cells and suggest the use of Bcl-2/Bcl-xL bispecific antisense treatment in combination with cisplatin or gemcitabine for therapy of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1281957&#34; target=&#34;_blank&#34;&gt;Diagnostic criteria for human diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pathologists are required to provide a reliable diagnosis of the tumor for clinicians who are responsible for the treatment of affected patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12822605&#34; target=&#34;_blank&#34;&gt;The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with localized malignant pleural mesothelioma (MPM) can be considered for surgical resection with or without additional treatment. […] Cervical mediastinoscopy is a valuable diagnostic procedure for patients with MPM who are considered candidates for surgical-based therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12833842&#34; target=&#34;_blank&#34;&gt;[A case of benign asbestos pleural effusion suspected on thoracoscopic examination under local anesthesia].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In September 2001, bilateral pleural effusions were revealed on chest radiography, and continued to progress despite treatment for heart failure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1283538&#34; target=&#34;_blank&#34;&gt;[Conservative, palliative therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No effective conventional therapy for malignant pleural mesothelioma has yet been described. […] Additional surgical treatment has not prolonged the life expectancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12839939&#34; target=&#34;_blank&#34;&gt;Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These studies suggest that inhibition of fra-1 signaling pathways may be a strategy for therapy of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-08-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12843860&#34; target=&#34;_blank&#34;&gt;[Cutaneous metastasis of pleural mesothelioma: two cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No specific treatment was proposed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12845210&#34; target=&#34;_blank&#34;&gt;Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with oxaliplatin plus raltitrexed has demonstrated an encouraging therapeutic index in patients with advanced colorectal cancer and malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12845968&#34; target=&#34;_blank&#34;&gt;Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Some positive results have been observed after interleukin-2 treatment, especially in melanoma, and pulmonary metastasis of renal carcinoma. […] A database search was performed to trace studies describing interleukin-2 tumor treatment in non-melanoma and non-renal cells malignancies, published between 1.1.1999 and 30.01.2001. […] The literature review suggests that the optimal way of application of interleukin-2 in metastatic colorectal carcinoma is the local use in a low dose, with intervals between applications, for 4-6 months, after some pretreatment. […] In hematological malignancies interleukin-2 treatment was followed by remission or increase in immune defense depending on the histological type. […] The maintenance treatment with low doses of interleukin-2 in responders to previous chemotherapy is promising. […] Cycles with longer duration (4-6 months) have a better effect also for patients with response to former treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12847573&#34; target=&#34;_blank&#34;&gt;Mesothelioma: Drug treatment and other interventions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma was reported to be a tumor of the pleura for which there is no satisfactory treatment. […] Due to the dismal prognosis for patients with this malignant disease, a new mode of treatment is desperately needed. […] Current drugs and other interventional modalities which include surgery, chemotherapy and radiation therapy are discussed below. […] However, in some patients none of these modalities are superior to absence of treatment. […] Discussed within this article are single agent and combined chemomodality therapy studies, target ligands, radiation-sensitizing and antiviral agents, multimodality and gene therapy, and chemoresistance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-10-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12852202&#34; target=&#34;_blank&#34;&gt;[The in vitro release of hydroxyl radicals from dust containing fluoro-edenite fibers identified in the volcanic rocks of Biancavilla (eastern Sicily)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with 1,3-dimethyl-2-thiourea (DMTU), a hydroxyl radical scavenger, or deferoxamine (DFX), an iron chelator, was performed to confirm hydroxyl radical production and study the role of iron. […] Treatment of the dusts with DMTU or DFX significantly reduced hydroxyl radical production by both samples.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12853097&#34; target=&#34;_blank&#34;&gt;Surgical experience of 15 solitary benign fibrous tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors review the literature, and report on 15 cases of localized benign fibrous tumors of the pleura surgically treated over a period of 15 years to further knowledge of this pathology, its therapy and prognosis. […] The whole group of 15 patients underwent surgical approach well tolerated the surgical treatment with perfect recovery of post-operative respiratory function. […] We consider surgery as the treatment of choice in this pathology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-03-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12860938&#34; target=&#34;_blank&#34;&gt;Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone. […] A total of 456 patients were assigned: 226 received pemetrexed and cisplatin, 222 received cisplatin alone, and eight never received therapy. […] Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cisplatin alone in patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12872353&#34; target=&#34;_blank&#34;&gt;High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The current study was conducted to assess the activity and toxicity of high-dose ifosfamide and mesna with recombinant human granulocyte-colony-stimulating factor (rhG-CSF), given in an outpatient setting, in the treatment of patients with unresectable malignant mesothelioma. […] There was one treatment-related death, the result of infection, pulmonary edema, and renal failure. […] This regimen demonstrated a low overall objective response rate with substantial toxicity, and in the opinion of the authors does not warrant further investigation in the treatment of patients with unresectable malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-01-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12873676&#34; target=&#34;_blank&#34;&gt;Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of malignant pleural mesothelioma remains a therapeutic challenge, with median survival rates of about 12 months and local failure rates of up to 80%. […] Between 1990 and 2001, 35 patients with malignant pleural mesothelioma were treated with EPP followed by hemithoracic radiation therapy (median dose: 54 Gy, range: 45-54 Gy) at Memorial Sloan-Kettering Cancer Center. […] The radiation therapy target volume was the entire hemithorax, including the pleural folds and the thoracotomy and chest tube incision sites. […] Radiation therapy was well tolerated, and toxicity data are described. […] Extrapleural pneumonectomy followed by high-dose hemithoracic radiation therapy is a feasible treatment regimen that is well tolerated for patients with malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1288739&#34; target=&#34;_blank&#34;&gt;Interferon-alpha and -gamma in combination with chemotherapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This tumor has proved to be exceptionally resistant to treatment, although a variety of multi-modality therapies have been tried. […] To further investigate the lack of response to cisplatin treatment, we examined the binding of cisplatin to the mesothelioma cell DNA.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12892825&#34; target=&#34;_blank&#34;&gt;Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to examine the antiproliferative potentialities of a pool of new generation compounds (Paclitaxel, Docetaxel, Gemcitabine, Topotecan, SN-38) together with fenretinide, a synthetic derivative of retinoic acid, in comparison with the current first choice treatment cisplatin molecule, on a pool of human malignant pleural mesothelioma cell lines derived from either bioptic and pleural effusions samples.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12912960&#34; target=&#34;_blank&#34;&gt;Gene expression profiling of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several challenging clinical problems include poor understanding of the pathophysiology, inaccurate diagnosis from tissue samples, and unsuccessful treatment strategies. […] Additional genes that could be important in our understanding of the pathogenesis of mesothelioma, aiding in diagnosis, or improving targets for therapy were also identified.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12929277&#34; target=&#34;_blank&#34;&gt;Diffuse malignant pleural mesothelioma: Part I. An overview of diagnosis, staging, and treatment options.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article reviews the risk factors, incidence, signs, symptoms, diagnosis, staging, treatment options, and follow-up care of diffuse malignant pleural mesothelioma (DMPM). […] Extrapleural pneumonectomy combined with multimodal treatments provides a potentially curative approach, and newer efforts in multimodality therapy are promising.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12929752&#34; target=&#34;_blank&#34;&gt;Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients treated on a Phase-I clinical trial of photodynamic therapy (PDT) developed a systemic capillary leak syndrome that constituted the dose-limiting toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-04-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12965317&#34; target=&#34;_blank&#34;&gt;Treatment of mesothelioma in Bloemfontein, South Africa.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A trend towards improved survival in patients undergoing pleuro pneumonectomy and receiving radiation as adjuvant therapy was observed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1297232&#34; target=&#34;_blank&#34;&gt;Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conclude that MMC plus VDS is an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1316255&#34; target=&#34;_blank&#34;&gt;Issues in the management of chest malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Opinions can vary as to the best method of treatment for specific types of chest malignancies. […] If the pulmonologist is to make the primary treatment decision regarding a complicated chest malignancy, he or she must be aware of both the surgical and nonsurgical treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1322613&#34; target=&#34;_blank&#34;&gt;[Spontaneous pneumothorax. Graduated concept of surgical therapy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The clinical course of 83 patients suffering from spontaneous pneumothorax lead to a modified surgical therapy according to the development of the underlying disease. […] The indication for non operative therapy, thoracic tube drainage, thoracic endoscopic methods and treatment by thoracotomy are defined and change of treatment from non-invasive procedures described in detail.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1325339&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medical or surgical treatment or both did not change the outcome of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-10-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1344148&#34; target=&#34;_blank&#34;&gt;[Malignant peritoneal mesothelioma: its evolution and outlook].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report a case and show the most recent concepts about histology, pathology, diagnosis and medical-surgical therapy of these diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1384016&#34; target=&#34;_blank&#34;&gt;Mesothelial and related neoplasms in children and adolescents: a clinicopathologic and immunohistochemical analysis of eight cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At last follow-up, three patients were dead of tumor, three were alive and well, and two had been recently diagnosed and were undergoing treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1386470&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy for thoracic malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) is an experimental form of cancer therapy which employs photoactivation of a sensitizing chemical by light of a given wavelength via the production of toxic oxygen species. […] The treatment has been used for the treatment of endobronchial obstruction by primary and metastatic tumors. […] Most recently, trials are being performed to evaluate this therapy as a surgical adjunct in the treatment of pleural malignancies such as mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1419863&#34; target=&#34;_blank&#34;&gt;Survival of asbestos insulation workers with mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No effective therapy is yet available.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1423183&#34; target=&#34;_blank&#34;&gt;A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a highly treatment-resistant neoplasm. […] This study represents an attempt to define an effective form of systemic therapy. […] Patients were either previously untreated with chemotherapy or had at most one prior systemic treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-12-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1429086&#34; target=&#34;_blank&#34;&gt;Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radical surgical removal of the tumor is generally not possible, and most treatment regimens involve combined chemotherapy and radiotherapy, as well as debulking surgery. […] We have prospectively evaluated five locally-aggressive multi-modality treatment programs, using different hemithorax irradiation schedules and chemotherapy regimens. […] The treatment programs, which can consecutively, were: I, 20 Gy (10 x 2 Gy) to the hemithorax + CYVADIC (cyclophosphamide 500 mg/m2 d 1, vincristine 1 mg/m2 d 1 and 5, adriamycin 40 mg/m2 d 1 and dacarbazine 200 mg/m2 d 1 and 5, several cycles before and after irradiation); II, 55 Gy (25 x 2.2 Gy) to the hemithorax + 15 Gy (6 x 2.5 Gy) to the tumor + CYVADIC (2 cycles before, 1 cycle during, and 2 cycles after irradiation); III, Mitoxantrone (14 mg/m2 q 28 d, &amp;lt; or = 6 cycles) followed by 70 Gy (56 x 1.25 Gy, twice a day); IV, 4-Epirubicin (110-130 mg/m2 q 28 d, &amp;lt; or = 6 cycles) followed by 35 Gy (28 x 1.25 Gy twice a day) to the hemithorax + 36 Gy (9 x 4 Gy every 2 days) to the tumor; V, Etoposide (150 mg/m2 1, 3, 5 q 28 d) followed by 38.5 Gy (11 x 3.5 Gy) to the hemithorax. […] None of the combined treatment programs prevented local invasive growth or the spread of mesothelioma outside the hemithorax. […] We conclude that data relating to therapeutic responses and treatment programs in malignant mesothelioma should be better correlated internationally, if the problems associated with the evaluation of treatment and the management of patients with mesothelioma are to be improved.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1434257&#34; target=&#34;_blank&#34;&gt;[A case of malignant localized visceral pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical treatment was performed, and diagnosed that its origin was visceral pleura. […] We recommend that firstly the surgical treatment should be carried out for malignant mesothelioma, which needs extended resection for preventing its recurrence.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14509952&#34; target=&#34;_blank&#34;&gt;Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In a feasibility study, we evaluated if inversely planned stereotactic intensity-modulated radiation therapy (IMRT) could be applied in the treatment of MPM. […] Due to craniocaudal extension of the tumor, it was necessary to develop a special software attached to the inverse planning program KonRad, which can connect two inverse treatment plans and consider the applied dose of the first treatment plan in the area of the matchline of the second treatment plan. […] Except for one patient, in whom radiotherapy was canceled due to abdominal metastasis, treatment could be completed in all patients and was well tolerated. […] Pure treatment time ranged between 10 and 21 min. […] The presented possibilities of stereotactic IMRT in the treatment of MPM will justify the evaluation of IMRT in early-stage pleural mesothelioma combined with chemotherapy in a study protocol, in order to improve the outcome of these patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-10-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1451080&#34; target=&#34;_blank&#34;&gt;New strategies are needed in diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival after the appearance of symptoms, the diagnosis, and the treatment were 13, 10, and 8 months, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-01-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14516539&#34; target=&#34;_blank&#34;&gt;Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings suggest that PET is useful in the evaluation of a variety of rare tumors both for initial preoperative staging and post-therapy assessment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14596692&#34; target=&#34;_blank&#34;&gt;Chemotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients are candidates for chemotherapy at some point in their treatment, but no standard regimen has been established.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-11-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14603551&#34; target=&#34;_blank&#34;&gt;Diffuse malignant pleural mesothelioma: Part II. Symptom management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with diffuse malignant pleural mesothelioma (DMPM) experience multiple symptoms from their disease and treatment, which can affect all aspects of their lives.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14605068&#34; target=&#34;_blank&#34;&gt;Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
TN contributed independently to the European Organisation for Research and Treatment of Cancer (EORTC) [p = 0.03] and to the Cancer and Leukemia Group B (CALGB) [p = 0.03] prognostic groups in respective multivariate Cox analyses.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1462582&#34; target=&#34;_blank&#34;&gt;[Diagnostic difficulties in pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results of treatment were not satisfactory.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14630441&#34; target=&#34;_blank&#34;&gt;Mesothelin-family proteins and diagnosis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14635508&#34; target=&#34;_blank&#34;&gt;Localized benign pleural mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Complete surgical resection is the preferred treatment for both types and usually curative with the benign mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14644341&#34; target=&#34;_blank&#34;&gt;Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This approach, known as molecular epidemiology has a great potential in the study of MM, contributing to the understanding of susceptibility factors, to the evaluation of cancer risk in people occupationally or environmentally exposed to carcinogens, and to the enhancement of diagnosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14658085&#34; target=&#34;_blank&#34;&gt;[“Disappearance” of retroperitoneal vessels - a case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although free retroperitoneal air is a rare condition, it is crucial for the examiner to be aware of the characteristic sonographic findings in order to initiate appropriate therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-03-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14659025&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: surgical roles and novel therapies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results of protocols at selected centers that offer gene therapy, photodynamic therapy, hyperthermic chemotherapeutic perfusion, and intrapleural chemokines will be discussed, as well as newer preclinical approaches that base targeted therapies on novel molecular findings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14725755&#34; target=&#34;_blank&#34;&gt;Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A total of 91 cycles of treatment were administered to 20 patients with a median of 4 cycles per patient.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-01-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14730040&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Each imaging modality has its advantages and limitations, but their combined use is crucial in determining the most appropriate treatment options for patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14732480&#34; target=&#34;_blank&#34;&gt;Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive serosal tumor, strongly associated with former exposure to asbestos fibers and for which there is currently no effective treatment available. […] These molecular markers should improve the accuracy of mesothelioma diagnosis, prognosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14751636&#34; target=&#34;_blank&#34;&gt;Solitary cerebellar metastasis of malignant pleural mesothelioma: case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Postoperatively, the patient received a combined chemotherapy regimen of Adriamycin and Cisplatin and underwent whole brain radiation therapy. […] We also review past cases of intracranial metastasis of this malignancy, its histologic subtypes, outcome, and recent treatment modalities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14760119&#34; target=&#34;_blank&#34;&gt;Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Response according to these criteria predicted for superior survival (15.1 versus 8.9 months; P = 0.03) and forced vital capacity (FVC) increase during treatment (P &amp;lt;0.0001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14760156&#34; target=&#34;_blank&#34;&gt;BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no generally accepted standard treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1480298&#34; target=&#34;_blank&#34;&gt;[Localized pleural mesotheliomas. Clinicopathological considerations on a case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural mesotheliomas are rare, and their diagnosis and treatment not clear. […] This showed that differential diagnosis with pulmonary carcinoma is very difficult, even in cases of parietal mesothelioma; however local treatment may be performed even in malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14871960&#34; target=&#34;_blank&#34;&gt;Gene expression profiles predict survival and progression of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Gene expression analyses from 21 MPM patients having cytoreductions and identical postoperative adjuvant therapy were performed using the U95 Affymetrix gene chip.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1487409&#34; target=&#34;_blank&#34;&gt;An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
More than 50% of the patients had at least one episode of severe or life threatening toxicity and 2 patients had lethal toxicity (1 renal and 1 pulmonary oedema attributed to treatment), and an additional 4 patients died while on study (2 of cardiac and 2 of cerebral vascular disease not considered directly related to treatment). […] The median time to treatment failure for all eligible patients was 2.5 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14987796&#34; target=&#34;_blank&#34;&gt;Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our approach allowed a comprehensive in situ examination of mesothelioma and provided an accurate way to find new marker genes that may be useful for diagnosis and treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14991330&#34; target=&#34;_blank&#34;&gt;Factors influencing long-term survival in mesothelioma patients–results of the German mesothelioma register.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Significant deviations in survival time dependent on therapy applied could not be proved.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15005252&#34; target=&#34;_blank&#34;&gt;Squamous cell carcinoma of the lung producing granulocyte colony-stimulating factor and resembling a malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
He underwent both chemotherapy and radiation therapy, but these therapies were ineffective and thereafter the developed radiation pneumonitis and carcinomatous pleuritis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15006637&#34; target=&#34;_blank&#34;&gt;Behaviour of the new asbestos amphibole fluor-edenite in different lung cell systems.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The sequence of the damage is hypothesised to be as follows: at increasing fluoro-edenite concentrations, and/or treatment times, the increase in reactive oxygen species (ROS) production could trigger significant DNA damage in cell cultures, concomitantly with drop in cell metabolism and increase in lactic dehydrogenase release.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15014036&#34; target=&#34;_blank&#34;&gt;Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In contrast, sequential DP/FLA treatment mediated marked growth inhibition and apoptosis in these cell lines. […] The proapoptotic effects of DP/FLA treatment coincided with inhibition of DP-mediated induction of p21 by FLA. […] Overexpression of p21 by adenoviral gene transfer techniques rendered MPM cells refractory to the cytotoxic effects of this treatment regimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1502425&#34; target=&#34;_blank&#34;&gt;[The locoregional treatment of neoplastic ascites with interferon-beta].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The locoregional therapy with beta interferon is proposed in palliative management of malignant ascites.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15026591&#34; target=&#34;_blank&#34;&gt;Patterns of lymphadenopathy in thoracic malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the role of radiologic imaging extends beyond initial staging and the guidance of interventions to include posttreatment assessment and the detection of recurrent disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15039138&#34; target=&#34;_blank&#34;&gt;Ultrastructural and chromosomal studies on manganese superoxide dismutase in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma represents an aggressive tumor type with high resistance to all treatment modalities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15069782&#34; target=&#34;_blank&#34;&gt;[A case of splenic hemorrhage in the course of malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Under this combined therapy, sudden anemia and hypotension appeared due to splenic hemorrhage, which suggested splenic metastasis of the malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-06-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15070823&#34; target=&#34;_blank&#34;&gt;Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an uncommon tumor largely confined to the thoracic cavity, which is resistant to conventional therapies, therefore prompting an intensive search for effective treatment alternatives. […] Our results show that both apoptotic preparations were equivalent regarding the responsiveness of DCs to combined treatment with tumor necrosis factor-alpha and poly(inosinic-cytidylic) acid, as determined by similar increased expression of costimulatory molecules and interleukin-12 production. […] These findings therefore carry the potential of offering an alternative, promising approach for the therapy of patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15079127&#34; target=&#34;_blank&#34;&gt;[Possibilities of diagnosis and treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Objective of our work was to evaluate: incidence, ethiology, diagnostic and treatment methods of malignant pleural mesothelioma. […] Mean survival time after combined treatment was 12+/-2 months. […] After conservative treatment alone - 6.0+/-2 months. […] In combined treatment group 22 patients (17.6%) had recurrence of disease during 3 years. […] In conservative treatment group no one survived 3 years. […] Combined surgical treatment of malignant pleural mesothelioma is still the most effective. […] Mean survival time after combined treatment is 12.0+/-2 months, after conservative - 6.0+/-2 months, and recurrence of the disease during 3 years - 17.6% and 100% respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15084390&#34; target=&#34;_blank&#34;&gt;Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cycles were repeated every 21 days with restaging performed every two cycles and therapy continuing for up to six cycles. […] One patient withdrew from the study prior to receiving therapy and is removed from further analysis. […] Eligibility criteria included no prior treatment, PS 0-1 by CALGB criteria and histologically documented mesothelioma. gender; male 19 (73%), female seven; median age 70 (range 40-81); histology: epithelial 15 (58%), mixed eight (31%), unclassified three; site of origin pleura, 25 (96%); weight loss in previous six months of more than 10% in seven (27%), symptoms longer than six months in five (19%). […] One patient died of treatment related toxicity during cycle one.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15086967&#34; target=&#34;_blank&#34;&gt;Integration of multimodality approaches in the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
More than half a century after the first descriptions of mesothelioma as a pathologic entity, satisfactory treatment is still elusive. […] Some use palliative treatment as the primary means of therapy even now. […] On the other hand, a cadre of individuals have studied how surgery, chemotherapy, and radiation therapy affect the disease. […] In addition, intriguing discoveries in immunology and gene profiling and therapy promise hope for further improvement.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15098157&#34; target=&#34;_blank&#34;&gt;[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We performed a phase-II-study combining 41.8 degrees C whole body hyperthermia with ICE chemotherapy, i. e., ifosfamide (5 g/m (2) on day 1), carboplatin (300 mg/m (2) on day 1) and etoposide (150 mg/m (2) on days 2 and 3), administered every 4 weeks, to assess the treatment benefit for patients with malignant pleural mesothelioma. […] A positive score means a therapy benefit and vice versa. […] Major treatment toxicities included grade 3/4 neutropenia and thrombocytopenia and affection of the GI tract, like mucositis, nausea and vomiting. […] MBS is a suitable tool to evaluate the treatment benefit especially in non-standard therapy approaches.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15117426&#34; target=&#34;_blank&#34;&gt;Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Antifolate agents have recently shown promising data in the treatment of this malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15117427&#34; target=&#34;_blank&#34;&gt;Novel combinations using pemetrexed in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article summarizes the data regarding pemetrexed in the treatment of malignant mesothelioma and the potential novel combinations involving the drug that may be used in the future for the treatment of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15128453&#34; target=&#34;_blank&#34;&gt;Multimodal treatment for resectable epithelial type malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy with perioperative adjuvant treatment is safe and effective procedure for epithelial type malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15133442&#34; target=&#34;_blank&#34;&gt;[Surgery for malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current surgical treatment involves in a multimodality regimen with radiation and multiple-drug chemotherapy. […] Schematically: for stage Ia (early stage disease), the therapeutic approach is generally neo-adjuvant intrapleural treatment using cytikines followed by surgical pleurectomy; for more advanced disease (stage Ib, II and III), a multimodal treatment combining extra-pleural pneumonectomy, radiotherapy and multiple-drug chemotherapy, including in all cases cisplatin, is proposed. […] Recently, results using this multiple modality approach have been favorable especially for patients with epithelial histology, negative resection margins and no metastases to extrapleural lymph nodes; for stage IV (unresectable tumor), palliative treatment is indicated. […] Early results have been encouraging and the use of recent drugs should allow more optimal treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15141012&#34; target=&#34;_blank&#34;&gt;Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Western blot analysis of BCL-2 family proteins was performed following single agent and combined treatment. […] Similar approaches using a combination of molecular and conventional treatment may have clinical utility for this tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15143397&#34; target=&#34;_blank&#34;&gt;[Gene therapy in malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is not any accepted treatment of malignant mesothelioma. […] Nowadays four main forms of therapy and the combination of these forms are put in the practise for the treatment of malignant mesothelioma. […] These are surgical therapy, chemotherapy protocols, radiotherapy protocols and recently immunologic therapy which is based on direct antiproliferative effect of interferon. […] Gene therapy has been studying experimentally for recent years. […] The main principles of the gene therapy is sensitizing to antiviral drugs by infecting and changing the gene structure of the malign cells. […] In malignant mesothelioma, there is no standard treatment protocol and the main cause of death is local spread of tumor and the pathological effects of its mass rather than metastasis and the diagnosis and treatment results are evaluated from the same localization (pleural space). […] According of these factors, gene therapy could be an appropriate treatment for malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15161435&#34; target=&#34;_blank&#34;&gt;Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is the first FDA-approved drug for the treatment of MPM. […] The combination of cisplatin plus pemetrexed is now the standard of care for the treatment of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15186594&#34; target=&#34;_blank&#34;&gt;Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent studies show that new therapeutic approaches can lead to an improvement in life quality and to a prolonged survival; therefore, proper evaluation of MPM before, as well as after, therapy, is needed. […] Five (5) patients were studied for staging, while 10 patients were studied after therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15188066&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma–a diagnostic challenge].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment is palliative in most cases because of the extension of the disease at the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15199394&#34; target=&#34;_blank&#34;&gt;A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A single 9-MeV electron treatment, following invasive thoracic procedures in patients with malignant pleural mesothelioma, was examined. […] A single 10-Gy treatment with 9-MeV electrons appears ineffective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15208818&#34; target=&#34;_blank&#34;&gt;Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM treatment includes surgery, radiotherapy, and chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1523703&#34; target=&#34;_blank&#34;&gt;Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytokines have recently appeared to be effective in the palliative therapy of neoplastic effusions. […] This preliminary study showed that low dose IL-2 given intracavitarily is an effective and well-tolerated therapy in patients with neoplastic effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-10-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15254610&#34; target=&#34;_blank&#34;&gt;Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Their clinical and radiological features, as well as the therapy, were retrospectively evaluated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15255294&#34; target=&#34;_blank&#34;&gt;Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A large-scale phase II study of the efficacy of this combination therapy is required.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15260038&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: radiotherapy for the prevention of seeding nodules].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radiotherapy for the prevention of skin nodules appearing at the sites of aspiration, needle biopsies, chest drains or surgical incisions is the only treatment currently recommended for malignant mesothelioma. 59 patients suffering from this condition were identified from the database of the Nantes Regional Cancer Centre. 33 received prophylactic irradiation, 25 did not and 1 was excluded. […] The delay in initiating radiotherapy ranged from 10 to 123 days and several different treatment regimes were used. […] The poor results compared with the reference series may be explained by a longer follow-up (mean 12 months), less thorough treatment of all puncture sites and a very long delay before treatment (mean 37 days).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261433&#34; target=&#34;_blank&#34;&gt;Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the UK mortality from malignant mesothelioma (MM) is likely to more than double over the next 20 years and despite advances in surgery, chemotherapy and radiation treatment the overall prognosis for patients remains poor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261435&#34; target=&#34;_blank&#34;&gt;Staging and response to therapy of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients response to therapy can be measured using the response evaluation criteria in solid tumors (RECIST) criteria involving multiple measurements of a single diameter of tumour thickness.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261437&#34; target=&#34;_blank&#34;&gt;The use of magnetic resonance imaging in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Magnetic resonance imaging (MRI) is not routinely used in investigations for patients with suspected malignant pleural mesothelioma but it can be a useful tool in some instances–particularly predicting malignancy in patients with asbestos exposure; differentiating between metastatic pleural disease and malignant pleural mesothelioma (MPM); assessing patients for radical surgery and post treatment evaluation of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261438&#34; target=&#34;_blank&#34;&gt;Positron emission tomography in the diagnosis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The increasing incidence of malignant pleural mesothelioma has led to the development of new treatment strategies and a need for new diagnostic techniques to identify the extent of the disease at an early stage and to evaluate treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261440&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma–British surgical strategies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With the incidence of mesothelioma in the United Kingdom (UK) expected to attain epidemic proportions over the next 20 years, prospective randomised evaluation of the role of surgery in the treatment of mesothelioma is required so that appropriate resource planning can be made. […] Possible prospective trials to evaluate the role of radical surgery are proposed together with the principles which must be conceded in the approach to radical surgery, patient selection, resectability, operability, treatment modalities, debulking surgery, chemotherapy and radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261442&#34; target=&#34;_blank&#34;&gt;Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The considerations which have determined the policy of radiotherapy planning and treatment delivery for patients with mesothelioma in The Netherlands are given. […] As well as general considerations such as patient selection, target volume and critical organ delineation, a dose-fractionation scheme, constraints relating to normal tissue, treatment planning, the type of external beam equipment, treatment verification and radiation toxicity and scoring are all taken into account.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261443&#34; target=&#34;_blank&#34;&gt;Chemotherapy for malignant pleural mesothelioma: past results and recent developments.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While response rates exceeding 30% have barely been achieved with established cytotoxic drugs in MPM therapy, novel chemotherapeutic agents and their combinations appear somewhat more promising.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261444&#34; target=&#34;_blank&#34;&gt;The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, vitamin supplementation reduced treatment associated toxicities with no apparent affect on activity. […] This review summarizes preclinical and clinical data to define the future role of Alimta in the treatment of patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261446&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma. Medical oncology: standards, new trends, trials–the French experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical trials investigating new trends in the treatment of stage I and II malignant mesothelioma have shown both intra-pleural immunotherapy and systemic chemo-immunotherapy to be efficacious. […] Intra-pleural gamma-interferon (gamma-IFN) therapy was associated with tolerable toxicity and an overall response (ORR) rate of 19%, while treatment with intra-pleural recombinant interleukin-2 (IL-2) was more toxic, but yielded an ORR of 47% in phase I trial and 55% in a phase II study. […] Treatment with cisplatin, alpha-IFN and mitomycin C was associated with moderate toxicity and an ORR of 21% and a median survival of 12 months. […] The most encouraging results obtained from trials investigating systemic chemotherapy were following treatment with cisplatin, 5-fluorouracil, mitomycin C and etoposide, where an ORR of 38% and an overall median survival rate of 16 months were achieved.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15270656&#34; target=&#34;_blank&#34;&gt;Pemetrexed: a novel antifolate agent enters clinical practice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The US Food and Drug Administration recently approved pemetrexed, in combination with cisplatin, for the first-line treatment of advanced malignant pleural mesothelioma. […] Moreover, pemetrexed was recently shown to be as efficacious as docetaxel (Taxotere, Aventis) in the second-line treatment of non-small cell lung cancer, and its toxicity profile was preferable. […] Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15274072&#34; target=&#34;_blank&#34;&gt;Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemotherapy-naive patients with unresectable malignant pleural mesothelioma who were participating in two clinical trials of pemetrexed (ALIMTA; Eli Lilly, Indianapolis, IN) completed the scale twice before the start of therapy and once weekly during the trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15276492&#34; target=&#34;_blank&#34;&gt;Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an uncommon but highly fatal neoplasm for which only limited treatment is available.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15290457&#34; target=&#34;_blank&#34;&gt;Thoracic actinomycosis with mainly pleural involvement.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because the recurrence of pulmonary actinomycosis was also suspected after surgical treatment, penicillin G was administered intravenously and afterward amoxicillin was administered intraorally.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15291392&#34; target=&#34;_blank&#34;&gt;[Survival analysis of malignant mesothelioma treated in Brescia, northern Italy, 1982-2000].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To study the survival for malignant mesothelioma on general population cases over the 1982-2000 period and to evaluate the effectiveness of the new therapeutic protocols (intrapleural immunotherapy and mulitmodality therapy) to improve the prognosis on the group of selected hospital patients treated from 1996 to 2000. […] Observed survival (%) at one, three, five-year and median survival by gender, site and residence on the general population cases treated with conventional therapy and on selected hospital patients group treated with intrapleural immunotherapy and mulimodality therapy. […] From 1996 the number of cases treated with new therapic protocols is steadily increasing, patients without therapy (or only talcaggio) passed from 87% in the period between 1982-1995 to 43% in the period 1996-2000. […] These results are similar to those of previous studies conducted to identify prognostic factors for mesothelioma survival; they don’t permit confirmation of the efficacy of the recent therapy on the population base cases and only allow one to suppose them in the cases of the non resident population. […] The efficacy of the recent therapy has to be further investigated with regard to the stage of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15319247&#34; target=&#34;_blank&#34;&gt;The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With the rising incidence of malignant mesothelioma (MM), it is important to optimise treatment to control symptoms, maintain quality of life and, if possible, prolong life. […] Between October 1986 and May 2002 all patients with inoperable pleural mesothelioma were considered for treatment with MVP (mitomycin C 8 mg/m2 every 6 weeks, vinblastine 6 mg/m2 every 3 weeks and cisplatin 50 mg/m2 every 3 weeks) chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15337794&#34; target=&#34;_blank&#34;&gt;Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate neoadjuvant chemotherapy with cisplatin and gemcitabine followed by extrapleural pneumonectomy with or without radiation therapy in patients with potentially resectable malignant pleural mesothelioma (MPM). […] According to the European Organization for Research and Treatment of Cancer prognostic score, two patients were in the good prognosis group, and 17 patients were in the poor prognosis group. […] Two patients remain alive and free of disease 41 and 38 months after initiation of therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15343490&#34; target=&#34;_blank&#34;&gt;[Pleuromesothelioma – psychology and pathogenesis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Investigations into the anatomical pathology are of crucial importance for the diagnosis and therapy of pleural tumours.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15355924&#34; target=&#34;_blank&#34;&gt;Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Transforming growth factor (TGF)-beta blockade has been proposed as an anticancer therapy; however, understanding which tumor patients might benefit most from such therapy is crucial. […] An ideal target of such inhibitory therapy might be malignant mesothelioma (MM), a highly lethal, treatment-resistant malignancy of mesothelial cells of the pleura and peritoneum that produces large amounts of TGF-beta.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15451229&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma: little evidence, still time to do trials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although EPP as part of trimodality therapy (preoperative chemotherapy and postoperative radiation) is thought to be the best that can be offered and is regarded as the standard of care for selected patients given the morbidity associated with it, evidence for benefit is needed to justify its wider use. […] is to find evidence of effectiveness to avoid futile and distressing treatment when possible.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15458619&#34; target=&#34;_blank&#34;&gt;[Localized fibrous tumors of the pleura: clinical and surgical evaluation].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of choice was complete resection of the tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-11-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15469478&#34; target=&#34;_blank&#34;&gt;The pathology associated with therapeutic procedures in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All six malignant pleural mesotheliomas receiving chemotherapy appeared refractory to treatment in that chemotherapy did not appear to have any significant effect on the tumour morphology, cytonuclear pleomorphism, mitotic activity, extent of necrosis or immunophenotype.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15470919&#34; target=&#34;_blank&#34;&gt;Methodology for lognormal modelling of malignant pleural mesothelioma survival time distributions: a study of 5580 case histories from Europe and USA.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The methodology describes the computation of reference baseline probabilities, 5-200 weeks, which can be used in clinical trials to assess results of future promising treatment methods.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15474666&#34; target=&#34;_blank&#34;&gt;Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although great efforts have been made to improve conventional therapy for diffuse malignant pleural mesothelioma, the median survival time of the patients after appearance of clinical symptoms remains poor. […] In this context locoregional gene therapy using the recombinant adeno-associated virus 2 (rAAV-2) may be a new approach. […] Using the rAAV-2-based suicide system, a nearly complete eradication of transduced and GCV-treated mesothelioma cells was observed. rAAV-2-based suicide gene therapy may be a new approach for locoregional treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15477632&#34; target=&#34;_blank&#34;&gt;FDA drug approval summaries: pemetrexed (Alimta).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On February 4, 2004, pemetrexed was approved by the FDA in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. […] Patients must receive oral folic acid and vitamin B(12) injections prior to the start of therapy and continue these during therapy to reduce severe toxicities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-01-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15486399&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, traditional treatment modalities–surgery, radiotherapy, and chemotherapy–have evolved slowly, and few gains in therapeutic efficacy have occurred. […] Recently, however, continuing research efforts have led to novel treatment strategies that are changing the way clinicians view a disease that has traditionally been managed with almost universal therapeutic nihilism.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15510595&#34; target=&#34;_blank&#34;&gt;A cytokeratin- and calretinin-negative staining sarcomatoid malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma is a very aggressive cancer with limited treatment, and a median survival of about 1 year.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-11-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15510811&#34; target=&#34;_blank&#34;&gt;[Extrapleural pneumonectomy for thoracic malignancies].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy has been used by thoracic surgeons in the treatment of malignant pleural mesothelioma as well as other pleural diseases, such as tuberculous empyema. […] Recently, this operative procedure has been also sporadically applied for the treatment of carcinomatous pleuritis of lung cancer and/or invasive thymoma in some institutions. […] All patients with malignant pleural mesothelioma except 1, who lately underwent this treatment, died of disease from 15 to 27 months after surgery. […] Nevertheless, the ultimate value of this surgical treatment should be ascertained in a prospective study with a large number of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15510812&#34; target=&#34;_blank&#34;&gt;[Extrapleural pneumonectomy for malignant pleural mesothelioma and primary lung cancer].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In those, we experienced a case of malignant mesothelioma with excellent reduction by induction therapy of cisplatin+docetaxel hydrate, who underwent the extrapleural pneumonectomy continuously. […] We mentioned more over about the role of extrapleural pneumonectomy for primary lung cancer with pleural dissemination, and intrapleural perfusion hyperthermo-therapy for malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15510813&#34; target=&#34;_blank&#34;&gt;[Extrapleural pneumonectomy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy with adjuvant therapy could be effective treatment for malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15510814&#34; target=&#34;_blank&#34;&gt;[Extrapleural pneumonectomy for malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Standard treatment for malignant pleural mesothelioma (MPM) has not been proved yet. […] However, it has been recognized that extrapleural pneumonectomy (EPP) is a treatment of choice for epithelial MPM when combined with adjuvant therapies though EPP may frequently cause fetal complications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15510816&#34; target=&#34;_blank&#34;&gt;[Multimodality therapy for diffuse malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite the rising incidence of diffuse malignant pleural mesothelioma (MPM), there is still no standard treatment for this disease, and the prognosis for patients remains poor. […] Recently, long-term survival has been reported when multimodality therapy is used, combining extrapleural pneumonectomy with perioperative chemotherapy and/or radiotherapy in highly selected patients. […] We report a case of a patient who presented with MPM, accompanied by a large malignant pleural effusion and pneumothorax, who was successfully treated with combination therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15511473&#34; target=&#34;_blank&#34;&gt;Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival after tri-modality therapy with extrapleural pneumonectomy (EPP) and postoperative chemoradiotherapy is longer for patients with epithelial MPM versus mixed or sarcomatoid subtypes, leading some to decline aggressive therapy for patients with nonepithelial histology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15519879&#34; target=&#34;_blank&#34;&gt;Cerebral metastases in malignant mesothelioma: case report and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is one of a handful of case reports in the literature in which histological confirmation has been obtained ante-mortem and where surgical treatment of the intracranial mesothelioma was undertaken.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15559050&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: overview of the North American and European experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM is an uncommon disease with limited treatment options. […] Early diagnosis, a standardized staging system, early referral to centers experienced in MPM, and efforts to develop collaborative multicenter trials are essential to improving treatment for patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15559057&#34; target=&#34;_blank&#34;&gt;Preoperative assessment and therapeutic options for patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prompt medical evaluation and aggressive treatment can lead to prolonged survival or successful palliation of symptoms for patients with malignant pleural mesothelioma, but the window for implementing treatment is short. […] Heightened clinical suspicion and proper patient selection through accurate staging and pathologic identification are paramount to defining and delivering therapy for this rare, lethal cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15559059&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Kaiser has reported using novel therapies, such as cytokines and suicide gene therapy, to target mesothelioma. […] Pass et al , Moskal et al , Schouwink et al , and Friedberg et al have applied photodynamic therapy to the hemithorax after surgical resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15559064&#34; target=&#34;_blank&#34;&gt;Patterns of failure following surgical resection for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients present with more advanced disease, however, and the optimum local and systemic treatment for these patients has not been defined. […] Evaluation of treatment efficacy based on observed patterns of failure may suffer from treatment selection biases. […] Consequently, it is difficult to discern the potential impact of a given adjuvant therapy. […] Efforts to decrease the chance of local recurrence after P/D have included the use of intrapleural and intravenous chemotherapy, brachytherapy, and external beam radiation therapy. […] None of these adjuvant treatment trials was randomized, and when compared with historical controls, none of the treatments used suggested a consistent outcome benefit. […] From a review of available data, patients with mesothelioma who have undergone P/D (with or without intrapleural chemotherapy) who are evaluated at the Dana Farber Cancer Institute and Brigham and Women’s Hospital are offered therapy with systemic chemotherapy alone. […] After P/D, radiation is used only for palliative treatment. […] Advances in local therapy also may decrease the rate of abdominal recurrences. […] The lowest rate of local recurrence (13%), with a 4% local-only recurrence rate, was seen in the study by Rusch et al, who used 54 Gy hemithorax radiation as adjuvant therapy. […] Baldini et al reported a 50% local recurrence rate, with a 13% local-only rate, after trimodality therapy. […] In the study by Rusch et al, distant failures predominate, and the patients are appropriate candidates for systemic chemotherapy, which could be administered either as neoadjuvant or adjuvant therapy. […] Kestenholz et al currently are performing a phase II clinical trial of neoadjuvant cisplatin and gemcitabine administered for three cycles followed by EPP and adjuvant radiation therapy. […] Alternatively, patients who have undergone EPP could be treated with adjuvant chemotherapy in addition to adjuvant radiation therapy. […] Further clinical studies are needed for all patients with mesothelioma to define the optimum surgery and duration and types of adjuvant therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15568123&#34; target=&#34;_blank&#34;&gt;Fibrinolysis of loculated pleural effusion in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection is not feasible in most cases of malignant mesothelioma and palliation of symptoms remains the mainstay of treatment. […] When a pleural effusion is loculated, the standard treatment methods of intercostal tube drainage and pleurodesis may not be helpful.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15571462&#34; target=&#34;_blank&#34;&gt;Current chemotherapeutic treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Until recently, there has been no effective treatment which can improve symptoms and prolong survival. […] This article reviews recent developments in the treatment of mesothelioma, particularly advances in drug therapy and the use of the current most active drug combination: pemetrexed and cisplatin. […] This combination has become the standard of care in mesothelioma treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15625372&#34; target=&#34;_blank&#34;&gt;Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The European Organisation for Research and Treatment of Cancer (EORTC) prognostic model was reported to predict survival in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15639727&#34; target=&#34;_blank&#34;&gt;Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options are limited, although recently published data have offered cause for optimism. […] Treatment continued up to six cycles. […] Progression-free survival from first treatment was 4.7 months, and overall survival was 8.8 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15642204&#34; target=&#34;_blank&#34;&gt;[Long-term prognostic analysis of patients with malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multivariate analysis showed that clinical classification (P=0.038), and mode of treatment (P=0.005) were independent prognostic factors of MPM. […] Mode of treatment, and clinical classification are independent prognostic factors for patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15654178&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery, radiotherapy, and chemotherapy have each been used in the treatment of mesothelioma, but generally with little impact on survival. […] New directions in therapy include aggressive multimodality programs for potentially resectable patients and targeted therapies, including antifolates, antiangiogenesis agents, and drugs directed at epidermal growth factor receptor for the majority of patients presenting with unresectable disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15655933&#34; target=&#34;_blank&#34;&gt;Pemetrexed in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Historically, antifolates such as methotrexate have been the most active drugs in the treatment of mesothelioma. […] Newer antifolates have recently demonstrated higher efficacy than older regimens in the treatment of this rare disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15677623&#34; target=&#34;_blank&#34;&gt;Chemotherapy options and new advances in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early attempts at treatment and palliation with single agents such as doxorubicin met with low response rates and little clinical benefit. […] Single-agent therapy with vinorelbine may provide useful palliation with low toxicity. […] Targeted agents developed through increased understanding of the biology of the disease, used alone or as part of multimodal therapy, may provide major clinical gains in the next few years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15691252&#34; target=&#34;_blank&#34;&gt;Metastatic renal cell carcinoma presenting as multiple pleural tumours.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pleural lesions dramatically decreased in size following right radical nephrectomy and subsequent interferon-alpha treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1569770&#34; target=&#34;_blank&#34;&gt;Iodized talc pleurodesis for the treatment of pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thirty-four patients underwent this treatment (three bilaterally) between October 1, 1989, and March 31, 1991. […] These observations indicate that intrapleural instillation of a slurry of iodized talc is a safe, adequate, and effective treatment for control of neoplastic or benign pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15709163&#34; target=&#34;_blank&#34;&gt;Pemetrexed in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Food and Drug Administration (FDA) of a New Drug Application for the treatment of malignant pleural mesothelioma (MPM). […] Pemetrexed in combination with cisplatin was approved by the FDA on February 4, 2004 for the treatment of patients with MPM whose disease is either unresectable or who are otherwise not candidates for curative surgery. […] Patients must receive oral folic acid and vitamin B(12) injections before the start and during therapy to reduce severe toxicities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15724224&#34; target=&#34;_blank&#34;&gt;[Second-line treatment of malignant pleural mesothelioma with Pemetrexed (Alimta) – a case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After a first line therapy with Gemcitabine/Oxaliplatin, partial remission was assessed. 15 months later a distinct progress was detected. […] After a second line therapy with Pemetrexed a sound partial response could be determined radiologically and clinically. […] This case history is supposed to exemplify that patients with malignant pleural mesothelioma should not only be considered for a first line therapy, but that a second line therapy may also be offered to a certain group of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15724226&#34; target=&#34;_blank&#34;&gt;[Management of malignant pleural effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Alternative local and systemic treatment options are discussed in detail. […] A special emphasis is put on the epidemiology, diagnosis, treatment, and prognosis of malignant effusions in patients with lung and breast carcinomas, and with lymphomas. […] Finally, open questions are listed which need future research, which will hopefully improve the treatment and prognosis of malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15737904&#34; target=&#34;_blank&#34;&gt;A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To report results of a phase II trial of high-dose-rate intra-operative radiation therapy (HDR-IORT) for malignant pleural mesothelioma (MPM). […] Postoperative external beam radiation therapy (EBRT) was given 3-5 weeks later.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15754636&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma–case with effusion in both pleural cavities].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At the beginning of hospital stay antituberculosis therapy was applied but was unsuccessful. […] Patient died after 3 months of observations and attempt at treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15755635&#34; target=&#34;_blank&#34;&gt;Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The tumour is generally resistant to conventional treatment and there is urgent need for novel preventative and therapeutic measures to combat this growing public threat.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15755794&#34; target=&#34;_blank&#34;&gt;Pemetrexed therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a promising new drug for the treatment of solid malignancies, most notably MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15756029&#34; target=&#34;_blank&#34;&gt;Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Growth of MPM cells was substantially not affected by treatment with different FTIs (SCH66336, BMS-214662, R115777, RPR-115135, and Manumycin).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15771030&#34; target=&#34;_blank&#34;&gt;Pleurectomy/decortication plus chemotherapy: outcomes of 40 cases of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment was relatively well tolerated and quality of life satisfactory. […] Low morbidity and mortality and good quality of life after treatment make pleurectomy/decortication with intracavitary and systemic chemotherapy not only a radical approach in early stages, but also a good palliative treatment in advanced malignant pleural mesothelioma, especially in patients who are unsuitable for extrapleural pneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15780570&#34; target=&#34;_blank&#34;&gt;Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is increasing in incidence and no current therapy significantly prolongs survival. […] Post-operative radiotherapy was administered to port sites, but no other adjuvant therapy was given.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15788680&#34; target=&#34;_blank&#34;&gt;Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Eligible patients had unresectable pleural or peritoneal mesothelioma, measurable disease, no prior therapy, and performance status 0-1 by Cancer and Leukemia Group B criteria. […] Therapy was continued until disease progression or unacceptable toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1581074&#34; target=&#34;_blank&#34;&gt;Characterization of a tumor necrosis factor-alpha inhibitor activity in cancer patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the feasibility of tumor necrosis factor-alpha (TNF-alpha) treatment of lung cancer patients, we chose the malignant cells contained in their pleural effusions as a first convenient target. […] This study suggests that tumors may evade TNF cytotoxic action by modulating systemic levels of TNF and implies a reassessment of TNF therapy in cancer patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15816607&#34; target=&#34;_blank&#34;&gt;Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It seems possible that fludarabine, an immunosuppressive chemotherapy, accelerated the occurrence and progression of malignant mesothelioma during the therapy for his B-PLL.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15818532&#34; target=&#34;_blank&#34;&gt;Pemetrexed (Alimta) in small cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In limited stage (LS)-SCLC, combined-modality therapy represents the standard of care. […] Therapy should be approached curatively in fit patients with a good performance status because 5-year survival rates approach 26% in aggressively treated patients. […] In contrast, cure is not possible in extensive stage (ES)-SCLC with median 2-year survival rates with current therapy remaining at less than 10%. […] Also, preliminary data indicates that full doses of carboplatin/pemetrexed can be administered with thoracic radiation therapy, supporting a future clinical trial initiative in LS-SCLC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15824080&#34; target=&#34;_blank&#34;&gt;Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Kaplan-Meier survival estimates were compared by treatment groups, and by PSC and non-PSC subgroups. […] The percentage of patients receiving PSC was imbalanced between the treatment arms. […] A multiple regression analysis performed in this trial showed that PSC had a statistically significant correlation with prolonged survival (P &amp;lt;0.01), adjusting for baseline prognostic factors and treatment intervention. […] The pemetrexed plus cisplatin treatment group had a statistically significant survival advantage even though fewer patients from that arm of the trial received PSC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15829316&#34; target=&#34;_blank&#34;&gt;Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No randomized controlled trials comparing pleurectomy (PL) with extrapleural pneumonectomy (EPP) or comparing surgery with an alternative treatment were identified. […] Future studies of the role of surgery in the treatment of mesothelioma should include evaluations of quality of life.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15829331&#34; target=&#34;_blank&#34;&gt;Thalidomide in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to describe the experience with the anti-angiogenic agent thalidomide in the treatment of patients with a malignant pleural mesothelioma (MPM). […] Twenty of them (50%) had received prior treatment. […] The percentage of patients seen with prolonged disease stabilization upon thalidomide treatment warrants phase III studies in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15835625&#34; target=&#34;_blank&#34;&gt;[Development in the treatment of malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For many years there has been a search for an effective treatment of malignant pleural mesothelioma. […] Surgery is of limited applicability and is reserved for special cases, in which it is combined with radiation therapy. […] New drugs, including the new antifolates, are being used much more often in the treatment of malignant pleural mesothelioma in combination with a platinum derivative. […] The current studies focus on the use of chemotherapy and biological agents as part of a more complex treatment schedule.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15849999&#34; target=&#34;_blank&#34;&gt;Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two patients (8%) could not be evaluated for response (no therapy performed). […] This multi-center phase II clinical trial showed that epirubicin plus gemcitabine, as a first-line treatment in malignant pleural mesothelioma, has promising activity with a good tolerability profile and symptom palliation. […] The role of interleukin-2 in maintenance therapy for malignant pleural mesothelioma is encouraging and requires further study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15867774&#34; target=&#34;_blank&#34;&gt;The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is notoriously refractory to aggressive multimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15877521&#34; target=&#34;_blank&#34;&gt;Pemetrexed-cisplatin combination in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite the desperate struggle for improvement in the therapy of malignant pleural mesothelioma in previous decades, no standard therapy could be established. […] These data led to the approval of the drug by the US Food and Drug Administration and recently by the European Medicines Evaluation Agency for this combination in malignant pleural mesothelioma, and consequently founded the first standard of treatment in this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1588364&#34; target=&#34;_blank&#34;&gt;Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intrapleural cisplatin-based chemotherapy has been used in the treatment of patients with malignant pleural mesothelioma and malignant pleural effusions, but the pharmacokinetics of this form of chemotherapy have not been previously evaluated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15893012&#34; target=&#34;_blank&#34;&gt;Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three patients died of treatment-related toxicities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15893013&#34; target=&#34;_blank&#34;&gt;Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Within a single-institution phase II trial, we investigated the antitumor activity of the Raltitrexed-Oxaliplatin combination as second-line therapy for malignant pleural mesothelioma (MPM). […] The best response observed was disease stabilization in 4 patients only (28.57%), while the other 10 patients (71.42%) progressed despite treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15900580&#34; target=&#34;_blank&#34;&gt;Wnt2 as a new therapeutic target in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma of the pleura (MPM) is a highly aggressive neoplasm with a poor prognosis and limited treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15902599&#34; target=&#34;_blank&#34;&gt;[Therapeutic options in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In most patients, the treatment remains palliative with symptom relief and a moderate survival gain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15908659&#34; target=&#34;_blank&#34;&gt;Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopic evaluation with pleural biopsies was performed before therapy and then after every two cycles. […] After at least two cycles, post-treatment pleural biopsy analysis was negative in 14 patients for a pathologic response rate of 42% (95% CI, 25% to 61%). […] There were three treatment-related deaths secondary to peritonitis, cellulitis at the thoracoscopy site, and empyema. […] Intrapleural L-NDDP therapy in this patient population is feasible with significant but manageable toxicity. […] The optimal role of intrapleural L-NDDP therapy currently remains to be determined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1591306&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Local treatments such as surgery or radiation therapy are technically difficult because of the extent of disease. […] Ongoing trials confirm that DMM is resistant to standard forms of therapy, but mesothelial cells are susceptible to immune effector cells and cytokines in in vitro and in vivo models. […] Thus, recombinant interferon-alpha, -beta, and -gamma have been used for both local and systemic treatment, as has interleukin-2 with and without autologous lymphokine-activated killer cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-07-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15914055&#34; target=&#34;_blank&#34;&gt;Palliative intracavitary carboplatin therapy in a cat with suspected pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Further treatment was declined and the cat was euthanased 120 days after initial presentation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-12-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15916831&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy as an adjunct to surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, effective tumor control requires new loco-regional treatment modalities, eventually in combination with neoadjuvant chemotherapy. […] Intraoperative photodynamic therapy (PDT) of the chest cavity has been proposed as an attractive treatment concept for MPM since a selective treatment of the tumor bed following resection has the potential to improve local tumor control. […] Experimental work on MPM has shown that tumor selectivity of PDT depend on treatment conditions and can be improved by structural modification and improved targeting of the sensitizers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15928495&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the authors’ opinion, the major developments in the management of malignant effusions during the past year are the development of safer pleurodesis agents and the promise of better combination chemotherapy agents for the treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15942579&#34; target=&#34;_blank&#34;&gt;Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Integrated computed tomography-positron emission tomography increases the accuracy of malignant pleural mesothelioma staging and is important in determining the appropriate therapy in patients being considered for extrapleural pneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15946584&#34; target=&#34;_blank&#34;&gt;New therapeutic options for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, novel cytotoxic agents such as pemetrexed have shown promise in the treatment of malignant pleural mesothelioma, and in early trials new small-molecule agents targeted to the specific biochemical properties of this tumor have shown promise.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950790&#34; target=&#34;_blank&#34;&gt;Clinical trials in malignant pleural mesothelioma in Australasia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two current and three proposed trials in mesothelioma in this region are discussed, covering the diverse clinical scenarios of diagnosis and staging, health-related quality of life, maintenance therapy, prediction of response and combined modality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950791&#34; target=&#34;_blank&#34;&gt;Overview on ongoing or planned clinical trials in Europe.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most widespread study treatment in Europe is an ‘Extended Access Program (EAP)’ evaluating pemetrexed alone or combined with cisplatin or carboplatin with about 1500 enrolled patients. […] Important national trials are ongoing: in the UK the addressed questions were the role of radical surgery (MARS Trial), the role of chemotherapy (MS-01 trial) and the role of VATS on active treatment of pleural effusion. […] In Switzerland the SAKK group phase III study explores in a comparative way the value of hemithoracic radiotherapy after primary treatment with cisplatin/pemetrexed followed by surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950794&#34; target=&#34;_blank&#34;&gt;Epidemic of mesothelioma in Egypt.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The use of EGFR inhibitors may have a role in the treatment of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950796&#34; target=&#34;_blank&#34;&gt;The role of PET in the surgical management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current imaging modalities fail to define precisely the extent of disease in MPM and are inaccurate in selecting patients for treatment. […] These findings suggest that FDG-PET can be used to stratify patients for treatment and clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950799&#34; target=&#34;_blank&#34;&gt;CT, RECIST, and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The unique growth pattern of malignant pleural mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950801&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: staging systems.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Restaging of mesothelioma after induction therapy is even more complicated and still controversial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950802&#34; target=&#34;_blank&#34;&gt;Molecular prognostic markers in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent advances in both surgical and medical therapy have improved survival, but the treatments remain toxic and selection of appropriate patients for these therapies is difficult. […] Alterations in cell cycle control proteins such as p16, p21, and p27 also offer information on prognosis and represent potential targets for therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950805&#34; target=&#34;_blank&#34;&gt;Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Induction therapy was: gemcitabine (1250 mg/m2 days 1, 8) and cisplatin (75 mg/m2 day 8)x2-4 cycles. […] Patients underwent EPP 3-5 weeks after induction therapy, then 54 Gy RT 4-6 weeks postop. […] This experience supports additional studies of induction and multimodality therapy, especially with regimens such as cisplatin and pemetrexed which may be better tolerated and more effective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950806&#34; target=&#34;_blank&#34;&gt;Treatment planning system evaluation for mesothelioma IMRT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
IMRT improved radiation dose distributions to the complex operative bed, and preliminary results suggested improved local control compared with conventional treatment planning. […] IMRT was initially developed on the Corvus treatment planning system. […] Other treatment planning systems are also IMRT-capable. […] Treatment plans from several systems were compared to determine the feasibility of using IMRT in a multi-institution trial. […] Treatment plans were generated on Corvus, Eclipse, and Pinnacle for a right-sided MPM after EPP using 6 MV X-rays. […] The treatment time and delivery efficiency were estimated. […] Treatment plans could be calculated by all three planning systems without system failure. […] IMRT plans can be calculated for MPM targets by at least three commonly available treatment planning systems.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950807&#34; target=&#34;_blank&#34;&gt;Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the palliative treatment of malignant mesothelioma of the pleura: the Heidelberg experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intensity modulated radiation therapy (IMRT) is a new promising treatment technique, which allows a more conformal application of the dose to the tumor volume, as compared to conventional radio-oncological approaches, while protecting the surrounding normal tissue more accurately. […] This manuscript presents the final results of IMRT in the treatment of unresectable pleural mesothelioma in Heidelberg.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15951053&#34; target=&#34;_blank&#34;&gt;Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Side effects of the medication were mild and included edema, nausea, constipation and diarrhea.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15955137&#34; target=&#34;_blank&#34;&gt;Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality treatment programs that combine surgical cytoreduction with novel forms of radiation therapy and more effective chemotherapy combinations may offer significant increases in survival for certain subgroups of mesothelioma patients. […] Experimental treatments such as immunotherapy and gene therapy present a window of hope for all mesothelioma patients, and in the future, may be combined with ‘standard therapy’ in multimodality protocols.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15958625&#34; target=&#34;_blank&#34;&gt;Validation of genomics-based prognostic tests in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm with limited pretreatment prognostication strategies. […] We also used a subset of these tumors associated with widely divergent patient survival (n = 23) as a training set to identify new treatment-specific candidate prognostic molecular markers and gene ratio-based prognostic tests. […] Newly discovered treatment-specific prognostic genes and gene ratio-based prognostic tests were highly accurate and statistically significant when examined in an independent group of 52 tumors from patients undergoing similar treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15962527&#34; target=&#34;_blank&#34;&gt;Pemetrexed disodium.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In February 2004, pemetrexed disodium (Alimta; Eli Lilly), an anticancer drug that targets folate-dependent reactions that are essential for cell proliferation, became the first drug to be approved by the US FDA for the treatment of the rare cancer malignant pleural mesothelioma. […] Its accelerated approval for the second-line treatment of non-small-cell lung cancer followed in August 2004.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15988688&#34; target=&#34;_blank&#34;&gt;New agents in the management of advanced mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite unquestionable improvement in the diagnostic methods at our disposal and the availability of new treatment strategies, the prognosis of MPM patients remains dramatically poor (12 to 18 months’ median survival from diagnosis), although exceptional cases of long-survivors are reported in all literature series. […] The current review will cover the dramatic improvements in the treatment of this rare disease that have been recently achieved, as well as the promise that new, molecular-targeted therapies, such as bortezomid, mTOR ( m ammalian t arget o f r apamycin) inhibitors, and Met inhibitors, seem to offer for the next few years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16006571&#34; target=&#34;_blank&#34;&gt;Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We investigated the use of triplet combination chemotherapy with cisplatin (CDDP), gemcitabine (GEM) and vinorelbine (VNR) for the treatment of Japanese patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16021506&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The myxoid material stained positive for Alcian blue, and the staining diminished after treatment with hyaluronidase in 12 of 12 cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16029815&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To compare treatment plans for multileaf collimators (MLCs) with different leaf widths and different finite pencil beam (FPB) sizes, to determine the planning quality and delivery efficiency of segmented MLC (SMLC) delivery of intensity-modulated radiation therapy (IMRT) for malignant pleural mesothelioma (MPM). […] Computerized tomography images of 10 right-side MPM patients were used for this planning study on a CORVUS treatment-planning system (NOMOS Corporation, Sewickley, PA) for a Varian Millennium 120-MLC (Varian Medical Systems, Palo Alto, CA).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16035560&#34; target=&#34;_blank&#34;&gt;CT in differential diagnosis of benign and malignant pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT plays a valuable role in assessment of patients with a wide variety of diseases of the pleura, and pulmonologists should be aware of the significance of different CT findings for the differential diagnosis of benign and malignant pleural diseases. 155 patients with pleural disease who had undergone CT scans of the lungs and thorax before treatment were enrolled.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16054774&#34; target=&#34;_blank&#34;&gt;Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate pleurectomy/decortication (P/D) and adjuvant radiotherapy (RT) in the treatment of malignant pleural mesothelioma (MPM). […] Two patients (1.6%) died from Grade 5 toxicity within 1 month of treatment. […] Pleurectomy/decortication with adjuvant radiotherapy is not an effective treatment option for patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16054941&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is an aggressive, treatment-resistant tumour, which is increasing in frequency throughout the world. […] Gene therapy and immunotherapy are used on an experimental basis only.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16060178&#34; target=&#34;_blank&#34;&gt;[The role of surgery in the treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of surgery in the treatment of diffuse pleural malignant mesothelioma is controversial. […] External radiation or intraoperative implantation of radioisotopes, chemotherapy and intrapleural treatment with various different agents are also considered as adjuvant therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16086544&#34; target=&#34;_blank&#34;&gt;PET in lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate tumor staging is essential for choosing the appropriate treatment strategy in patients with lung cancer. […] A very high accuracy of FDG-PET in distinguishing recurrent disease from benign treatment effects has been shown. […] Patients should be evaluated after a minimum of 2 months after completion of therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16098243&#34; target=&#34;_blank&#34;&gt;Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To date, few large studies have been reported of patients with peritoneal mesothelioma, and treatment of this disease has been largely extrapolated from the treatment of pleural disease. […] From June 12, 2002 to February 18, 2004, 1056 patients with malignant mesothelioma were enrolled and received &amp;gt; or = 1 dose of treatment at 462 sites in the United States.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16101199&#34; target=&#34;_blank&#34;&gt;Mesothelioma: treatment and survival of a patient population and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 2/28 patients with pleural mesothelioma the tumor was excised and in 7 with intraperitoneal disease, surgical therapy was palliative and there was survival prolongation. […] Malignant mesothelioma of the pleura and intraperitoneum is a slow-growing disease which is indicated by the long survival, despite the failure of chemotherapy, radiation therapy and surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16111784&#34; target=&#34;_blank&#34;&gt;Radiation recall dermatitis with pemetrexed.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radiation therapy is frequently administered to the thoracic orifices and no data are available about the interactions between radiotherapy and pemetrexed. […] We report the first case of radiation recall dermatitis occurring after pemetrexed chemotherapy in a patient with MPM previously treated with radiation therapy to the thoracoscopy and drainage orifices. […] The patient received chemotherapy with pemetrexed and cisplatin 19 days after completion of chest wall radiation therapy delivering 21 gray in 3 days. […] The toxicity grade of this lesion was evaluated at 2 according to the Acute Radiation Morbidity Scoring Criteria proposed by the Radiation Therapy Oncology Group.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16118627&#34; target=&#34;_blank&#34;&gt;Immunocytochemical detection of XIAP in body cavity effusions and washes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Elevated expression of XIAP could be an underpinning of relapse and/or resistance to apoptosis-inducing cancer therapy. […] The degree of XIAP staining of tumor cells may be a means of identifying the most therapy-resistant cases (ie, those with strong XIAP expression), and allow additional triaging to XIAP-blocking drugs presently being developed and clinically tested.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16130821&#34; target=&#34;_blank&#34;&gt;The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study investigated the benefit of single therapy with cyclophosphamide or hyperthermia or the combination of both on cells of a human pleural mesothelioma cell line, xenotransplanted subcutaneously in the paw of mice. […] The greatest benefit was achieved using combined thermochemotherapy consisting of cyclophosphamide plus hyperthermia: 50% of this group had partial remissions, and 67% responded to this therapy. […] This study shows promising results in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16143373&#34; target=&#34;_blank&#34;&gt;The evolution of cancer research and drug discovery at Lilly Research Laboratories.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review highlights the discovery and development of chemotherapy at Eli Lilly &amp;amp; Company over the past 30 years from the Vinca alkaloids-vincristine, vinblastine, and vindesine-to targeted therapy. […] Gemcitabine, a pyrimidine nucleoside that has a profound effect on DNA synthesis, has been approved for the treatment of pancreatic, non-small cell lung, bladder, and most recently, breast, and ovarian cancer. […] Pemetrexed, given in combination with cisplatin, has been recently approved for the treatment of malignant pleural mesothelioma and as second-line treatment for non-small cell lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1616870&#34; target=&#34;_blank&#34;&gt;High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT scan was performed before and after treatment and used for response evaluation. […] Median survival from start of treatment for all patients was 11 months, for 42 patients with the epithelial type 12 months, and for 20 patients with sarcomatous or mixed types only 5 months. […] Toxicity was acceptable, with only five patients (8%) terminating therapy due to toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16174857&#34; target=&#34;_blank&#34;&gt;Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Testicular cancer survivors are at statistically significantly increased risk of solid tumors for at least 35 years after treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16192580&#34; target=&#34;_blank&#34;&gt;Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conducted a phase III trial to determine whether first-line treatment with raltitrexed, a thymidine synthase inhibitor, and cisplatin results in superior outcome compared with cisplatin alone in patients with malignant pleural mesothelioma (MPM). […] Health related quality of life (HRQOL) was measured using the European Organisation for Research and Treatment of Cancer QLQ-C30 and Lung Module (QLQ-LC13).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-11-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16219479&#34; target=&#34;_blank&#34;&gt;[Recent progress in treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As compared to 1999, standart treatment adds chemotherapy with cisplatin and pemetrexed to local radiotherapy for prevention of local seeding after invasive diagnostic procedures. […] Multimodality therapy with extrapleural pneumonectomy and radiation therapy (+/-chemotherapy) can be of benefit in subgroups of patients but it cannot be recommended in a routine approach. […] As compared to bronchial carcinoma, inclusion of patients in clinical trials (using intensity-modulated radiation therapy) is the only way to somewhat improve results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-12-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16227449&#34; target=&#34;_blank&#34;&gt;Physical and chemical stability of pemetrexed solutions in plastic syringes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a multitargeted antifolate antineoplastic agent that is indicated for single-agent use in advanced or metastatic non-small-cell lung cancer and in combination with cisplatin for the treatment of malignant pleural mesothelioma not treatable by surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16243818&#34; target=&#34;_blank&#34;&gt;Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This report focuses on the 21 patients receiving “high-dose” therapy, defined by an intrapleural dose of vector (&amp;gt; or =1.6 x 10(13) viral particles), where transgene-encoded tk protein was reliably identified on immunohistochemical staining. […] Posttreatment antibody responses against the tumors were consistently seen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16245295&#34; target=&#34;_blank&#34;&gt;Intraoperative photodynamic therapy of the chest cavity in malignant pleural mesothelioma bearing rats.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Experimental assessment of anticancer effect, normal tissue damage, and toxicity of intrathoracic mTHPC-mediated photodynamic therapy (PDT) combined to surgery in malignant pleural mesothelioma (MPM) bearing rats.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16253024&#34; target=&#34;_blank&#34;&gt;Review and update of uncommon primary pleural tumors: a practical approach to diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Correct diagnosis is important because of different prognosis and treatment implications for the various neoplasms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16266800&#34; target=&#34;_blank&#34;&gt;Needle-track metastases and prophylactic radiotherapy for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Further treatment was administered to an adjacent field in both.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16268920&#34; target=&#34;_blank&#34;&gt;Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since 1982, we have performed thoracoscopic talc poudrage (TTP) as a primary therapy in mesothelioma patients presenting with pleural effusion. […] TTP remains a safe, low-morbidity, inexpensive primary palliative treatment option for malignant pleural mesothelioma and a valid control arm option for therapeutic trials. […] TTP is ideal for patients who wish to avoid thoracotomy, long hospital stays and morbidity from multimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16268922&#34; target=&#34;_blank&#34;&gt;Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment consisted of chemotherapy or radiation therapy in four patients, but with little clinical effect.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16285225&#34; target=&#34;_blank&#34;&gt;Update on malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multicystic mesotheliomas and well-differentiated papillary mesotheliomas are associated with long survival in the absence of treatment and should be excluded from clinical trials intended for the usual rapidly lethal histologic variants of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-12-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16291410&#34; target=&#34;_blank&#34;&gt;Pemetrexed: a multitargeted antifolate.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The US Food and Drug Administration approved pemetrexed in February 2004 for the treatment of malignant pleural mesothelioma (MPM) in combination with cisplatin in patients with unresectable disease or for whom curative surgery is not an option. […] Pemetrexed is the first agent approved for the treatment of MPM. […] In August 2004, pemetrexed was approved as a second-line, single-agent treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). […] The goals of this article were to summarize the pharmacology, pharmacokinetics, efficacy, and safety of pemetrexed, and to review its current and potential roles in therapy for MPM, NSCLC, and other oncologic conditions. […] A single, multicenter, randomized Phase III trial compared the efficacy of pemetrexed in combination with cisplatin versus cisplatin alone in the treatment of MPM. […] Efficacy for the treatment of MPM in combination with cisplatin has been demonstrated, and approval as a second-line agent in NSCLC was based on response rate as a surrogate end point for survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16291426&#34; target=&#34;_blank&#34;&gt;Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small-cell lung cancer (NSCLC) and treatment of malignant pleural mesothelioma. […] It is currently in clinical development for the first-line treatment of NSCLC. […] With its innovative mode of action, proven efficacy, favorable toxicity profile and convenient administration, pemetrexed represents a new therapeutic option for the treatment of advanced NSCLC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16291429&#34; target=&#34;_blank&#34;&gt;Standard therapy for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Almost all of the established cytotoxic agents have now been examined both as single-agents and in combination chemotherapy regimens as treatment approaches for malignant pleural mesothelioma (MPM). […] This doublet-based chemotherapy regimen is now the standard therapy for the first-line treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16291430&#34; target=&#34;_blank&#34;&gt;Seeking new options for the treatment of small-cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With an excellent antitumor activity, favorable tolerability profile, ease of administration and convenient schedule in NSCLC patients, pemetrexed is currently being investigated in a phase II trial for the first-line treatment of ES SCLC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16291431&#34; target=&#34;_blank&#34;&gt;Perspective on the development of new agents in thoracic cancers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The development of several targeted agents that play a critical role in the growth and survival of carcinomas has paved the way for a new era in the treatment of patients with thoracic malignancies. […] The novel antimetabolite pemetrexed has emerged as a key agent in the treatment of advanced malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16294031&#34; target=&#34;_blank&#34;&gt;Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Combination therapy with NV1066 and cisplatin showed strong synergism in epithelioid (H-2452, H-Meso), sarcomatoid (H-2373, H-28), and biphasic (JMN, Meso-9, MSTO-211H) MPM cell lines, and an additive effect in others. […] In VAMT cells combination therapy enhanced viral replication 4 to 11-fold (p &amp;lt; 0.01) and cell kill 2 to 3-fold (p &amp;lt; 0.01). […] This provides a cellular basis for combination therapy with cisplatin and NV1066 to treat MPM and achieve synergistic efficacy, while minimizing dosage and toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16299245&#34; target=&#34;_blank&#34;&gt;Inhibition of the met receptor in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Taken together, these findings suggest that inhibition of the Met receptor may be an effective therapeutic strategy for patients with MPM and provides a mechanism, the presence of a HGF/Met autocrine loop, by which to select patients for PHA-665752 treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16316830&#34; target=&#34;_blank&#34;&gt;[Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These data should improve the accuracy of mesothelioma diagnosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16317014&#34; target=&#34;_blank&#34;&gt;A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this prospective randomised trial we assess the use of early versus delayed cytotoxic therapy. […] A total of 43 patients were recruited, of which 21 were randomised to the early treatment group and 22 to the delayed treatment group. […] Quality of life was in general better maintained for early treatment and the health resources use was similar in both arms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16325120&#34; target=&#34;_blank&#34;&gt;Molecular biology of malignant mesothelioma: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It also details some of the signal transduction pathways that seem to be important in MM with the potential for novel targeted therapeutics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16325125&#34; target=&#34;_blank&#34;&gt;Multimodality treatments in the management of malignant pleural mesothelioma: an update.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The therapy for this aggressive local malignancy is currently inadequate. […] The first order of therapy in MPM is currently, as it has been for decades, to control effectively the tumor’s locoregional spread and then deal with controlling the distant disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16325126&#34; target=&#34;_blank&#34;&gt;Radiotherapy for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Single-modality therapy with radiation plays a role for palliation. […] Locoregional tumor recurrence can be dramatically reduced with combinations of extrapleural pneumonectomy and radiation therapy. […] However, the preponderance of death from distant metastases makes the development of better systemic therapy essential. […] Better therapy also must be developed for patients who are not candidates for extrapleural pneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16325129&#34; target=&#34;_blank&#34;&gt;Gene therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Gene therapy for mesothelioma is currently in its adolescence. […] The expansion of knowledge regarding molecular aspects of mesothelioma carcinogenesis has facilitated the development of promising gene therapy modalities that target specific oncoproteins and mutant tumor suppressor genes. […] Although implementation of any of these gene therapy approaches as part of standard medical care for patients who have mesothelioma remains years in the future, the field is finally progressing toward more definitive phase II/III efficacy studies. […] Unfortunately, the marginal benefits garnered from standard anticancer treatments in mesothelioma argue strongly for continued participation in clinical studies of various experimental approaches, particularly gene therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16326244&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient was diagnosed with MPM, and a surgical therapy option was considered because of the aggressive nature of the lesion and her advanced age.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16332304&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: early diagnosis and multimodality management].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Universally acknowledged therapeutic approaches still don’t exist at the moment, because of its refractory behaviour to all standard therapies; treatment protocols inclusive of either surgery, radiotherapy or chemotherapy have been largely employed, but usually with little impact on survival. […] Other approaches, i.e. palliative, proved to be useful in the treatment of two major symptoms, namely dyspnea and thoracic pain. […] In this work the Authors are reporting their experience with malignant pleural mesothelioma, stressing the role of videothoracoscopy in the early diagnosis, weighing the radical cancer resection option and the effectiveness of multimodal treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16343925&#34; target=&#34;_blank&#34;&gt;Multimodality approach in management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The survival rate without treatment ranges from 4 to 12 months. […] Response to chemotherapy and radiation is poor, and surgery is the most effective therapy. […] Single-modality therapy has not been effective in changing the natural history of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16354315&#34; target=&#34;_blank&#34;&gt;Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection is definitive therapy; however, patients with tumors with histologic atypia require close postoperative observation because of the frequency of locoregional recurrence.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16360237&#34; target=&#34;_blank&#34;&gt;Pemetrexed-associated urticarial vasculitis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The United States Food and Drug Administration has approved pemetrexed for the treatment of patients with malignant pleural mesothelioma and previously treated patients with locally advanced or metastatic non-small cell lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-06-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16397249&#34; target=&#34;_blank&#34;&gt;Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ultimately, c-Met would be an important target for therapy against MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16401712&#34; target=&#34;_blank&#34;&gt;Lung Cancer Highlights from ASCO 2005.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of surgery in the multimodality treatment of stage III NSCLC was further defined by the North American Intergroup 0139 trial and the European Organization for the Research and Treatment of Cancer Lung Cancer group 08941 trial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1643319&#34; target=&#34;_blank&#34;&gt;Chemotherapy for intrathoracic cancer in dogs and cats.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although reports describing anticancer chemotherapy use in dogs and cats for tumors of the thoracic cavity largely have been anecdotal, as advances are made in the chemotherapeutic management of comparable tumors in human cancer patients and as veterinarians become familiar with these compounds, use of antineoplastics as an adjunct to, or in place of, local treatment modalities should increase.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16434257&#34; target=&#34;_blank&#34;&gt;Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings support further evaluation of DNMT knockdown strategies for cancer therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16437396&#34; target=&#34;_blank&#34;&gt;Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In more advanced disease stages, a multimodality treatment, including various combinations of chemotherapy, external radiotherapy and surgery, may provide some favourable results though the prognosis remains poor. […] In this regard, an accurate pre-treatment staging plays an important role in offering patients a more appropriate therapeutic planning. […] On the basis of PET/CT findings, treatment planning was changed in 5 patients (33.3% of cases). […] Our data show that (18)F-FDG PET/CT fusion imaging can play a relevant role in the staging and treatment planning of MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16440159&#34; target=&#34;_blank&#34;&gt;Intrapleural hypotonic cisplatin treatment for malignant pleural mesothelioma: in vitro experiments and clinical application.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We studied the inhibitory effects of hypotonic cisplatin on the growth of malignant pleural mesothelioma (MPM) cell lines in vitro, and assessed the effectiveness of intraoperative intrapleural hypotonic cisplatin treatment combined with extrapleural pneumonectomy for patients with this tumor. […] In the clinical study, five patients with MPM underwent intraoperative intrapleural hypotonic cisplatin treatment combined with extrapleural pneumonectomy. […] The hypotonic cisplatin treatment inhibited cell growth at a significantly greater rate than the isotonic cisplatin treatment. […] Hypotonic cisplatin treatment is effective against MPM, and should be investigated further.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16446322&#34; target=&#34;_blank&#34;&gt;Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article compares the impact on HRQOL of first-line treatment with cisplatin versus raltitrexed and cisplatin. […] HRQOL was assessed with the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire C30 (EORTC QLQ-C30) and EORTC Lung Cancer Module (QLQ-LC13) tools. […] Assessments were conducted at baseline, immediately before every treatment cycle, at the end of treatment, and every six weeks for 12 months. […] The global HRQOL scale was comparable at baseline on both treatment arms (P = .848); at no point was any significant difference apparent on this end point. […] However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16457433&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite unquestionable improvement in the diagnostic methods at our disposal and the availability of new treatment strategies, the prognosis of MMe patients remains dramatically poor. […] For all the above reasons, translational research is the key to success; indeed, ever increasing knowledge of the molecular mechanisms underlying MMe pathogenesis could lead (and is actually leading) to new, hopefully more active, treatment options. […] To foster discussion among investigators working in this field, and to exchange different viewpoints concerning the newest advances in MMe pathogenesis and treatment, the VII International Mesothelioma Interest Group (IMIG) meeting was held in Brescia (Italy) between 24 and 26 June 2004 in cooperation with the Italian Group for the Study and Therapy of MMe (GIMe).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16459635&#34; target=&#34;_blank&#34;&gt;Computed tomographic characterization of malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New approaches to treatment using cytoreductive surgery and intraperitoneal chemotherapy suggest that long-term survival is possible in selected patients. […] Early recognition of this disease process with an orderly surgical approach will begin to optimize treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16472713&#34; target=&#34;_blank&#34;&gt;Clinical experience with pemetrexed in breast cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A randomized phase II study comparing pemetrexed 600 and 900 mg/m(2) with vitamin supplementation as first-line treatment for metastatic breast cancer is ongoing.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16475242&#34; target=&#34;_blank&#34;&gt;Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive cancer that is refractory to current treatment modalities. […] Oncolytic herpes simplex viruses (HSV) used for gene therapy are genetically engineered, replication-competent viruses that selectively target tumor cells while sparing normal host tissue. […] The localized nature, the potential accessibility and the relative lack of distant metastasis make MPM a particularly suitable disease for oncolytic viral therapy. […] The infectivity, selective replication, vector spread and cytotoxic ability of three oncolytic HSV: G207, NV1020 and NV1066, were tested against eleven pathological types of MPM cell lines including those that are resistant to radiation therapy, gemcitabine or cisplatin. […] Furthermore, NV1066 was able to reduce the tumor burden and prolong survival even when treatment was at an advanced stage of the disease. […] These findings support the continued investigation of oncolytic HSV as potential therapy for patients with therapy-resistant MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-07-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16495068&#34; target=&#34;_blank&#34;&gt;Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Univariate analysis was performed to identify prognostic factors [sex, age, side of operation, weight loss, smoking, chemotherapy, EORTC-score (European Organization for Research and Treatment of Cancer-classification) and duration of operation].
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-06-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/165155&#34; target=&#34;_blank&#34;&gt;BCG therapy of pleural and peritoneal growth of transplanted rat tumours.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As little as 10 mug moist weight of organisms was effective, and treatment could be given several days before or after tumour challenge. […] With two other transplanted tumours, a chemically induced mammary carcinoma and a spontaneous sarcoma, both of which lack significant immunogenicity, BCG treatment of pleural and peritoneal growths was less successful and more variable. […] Nevertheless, these studies indicate the potential of this type of treatment of thoracic and peritoneal tumour deposits for possible clinical application in the treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1975-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16515926&#34; target=&#34;_blank&#34;&gt;Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In each group 5 subgroups of 4 animals were defined according to the harvesting time of blood and tissue samples (2, 4, 24, and 72 hours and 1 week) after local therapy. […] Platinum concentrations in tissue were significantly higher in the gel group (group 1) than in the solution group (group 2) at 1, 3, and 7 days after therapy (1510, 1224, and 1069 pg/mg for group 1 vs 598, 382, and 287 pg/mg for group 2; P = .007, P = .005, and P = .0002, respectively).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16516163&#34; target=&#34;_blank&#34;&gt;Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New therapies toward inhibition of the Wnt pathway through WIF-1 might be promising for the future treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16542214&#34; target=&#34;_blank&#34;&gt;Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with cisplatin, but not gemcitabine, significantly inhibited the production of pleural effusions, but it was not effective for thoracic tumors, consistent with chemotherapy refractory characteristics of MPM in patients. […] Our patient-like orthotopic model using EHMES-10 cells overexpressing VEGF and its receptor may be useful for examining the molecular pathogenesis of MPM and may contribute to the development of novel treatment strategies for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16542747&#34; target=&#34;_blank&#34;&gt;Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment produced a good symptom control, with an improvement during chemotherapy in dyspnea and pain in 52.9 and 48.3% of patients, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-09-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16549838&#34; target=&#34;_blank&#34;&gt;Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Forty-eight patients (47.0%; 95% CI, 37.1% to 57.2%) had stable disease after treatment. […] Compliance to treatment was excellent, with a relative dose-intensity of 97% for pemetrexed and 98% for carboplatin. […] Treatment with pemetrexed and carboplatin was active and well tolerated in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16556051&#34; target=&#34;_blank&#34;&gt;Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Phase III studies with pemetrexed have established a clinical role for this drug as a single agent in the second-line treatment of non-small cell lung cancer and in combination with cisplatin for the frontline treatment of unresectable malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1658318&#34; target=&#34;_blank&#34;&gt;Intracavitary cisplatin chemotherapy experience with six dogs.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Resolution of effusion occurred after one treatment in two dogs and after two treatments in one dog. […] In three dogs with carcinomatosis of unknown origin, complete responses was seen in two dogs after one treatment for 255 and greater than 807 days, respectively. […] Toxicity was minimal, and this method of therapy should be further explored in dogs with similar malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16612848&#34; target=&#34;_blank&#34;&gt;[Thoracoscopic pleurodesis in malignant pleural effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopic talc pleurodesis is a safe, economical and effective treatment for malignant pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16616827&#34; target=&#34;_blank&#34;&gt;Systemic chemotherapy in the management of malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All original research and review papers related to the role of systemic chemotherapy in the treatment of malignant mesothelioma, published from 1966 through February 2005, were identified through a MEDLINE search of the literature using the following search terms: “mesothelioma”, “peritoneal”, “chemotherapy”, “antifolates”, “cancer therapy”. […] This search was supplemented by a manual search of the Proceedings of the Annual Meetings of the American Association for Cancer Research, American Society of Clinical Oncology, and the American Association for Cancer Research (AACR)-European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI) Symposium on New Anticancer Drugs. […] Pemetrexed in combination with cisplatin is the first treatment regimen that demonstrates a survival improvement in patients with unresectable malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16619474&#34; target=&#34;_blank&#34;&gt;Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment-induced cytotoxicity was evaluated by MTT or Annexin V assays. […] The selective MEK or PI3K kinase inhibitors are equally effective in down-regulating the expression of pro-metastasis phenotypes, suggesting that MEK or PI3K are appropriate targets for the development of molecular therapeutics for malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16625107&#34; target=&#34;_blank&#34;&gt;Monitoring of lung motion in patients with malignant pleural mesothelioma using two-dimensional and three-dimensional dynamic magnetic resonance imaging: comparison with spirometry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, dMRI is proposed for use as a further measure of therapy response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16637794&#34; target=&#34;_blank&#34;&gt;Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a newly approved antifolate agent for the treatment of malignant pleural mesothelioma (MPM) and metastatic non-small cell lung cancer (NSCLC).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16683083&#34; target=&#34;_blank&#34;&gt;Imaging before and after multimodal treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT, PET and CT-PET are indicated for diagnosis and, above all, for staging of MPM, in the selection of patients who might benefit from surgery after neoadjuvant therapy and also in identifying small recurrences and/or remote metastases. […] Each imaging modality has its advantages and limitations, but their combined use is crucial in determining the most appropriate treatment options for patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16683892&#34; target=&#34;_blank&#34;&gt;Synchronous pulmonary carcinoma and pleural diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patients underwent surgery for treatment of adenocarcinoma that was diagnosed preoperatively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16698098&#34; target=&#34;_blank&#34;&gt;A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study showed that IMRT or IMRT+e is a viable treatment modality for MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16704740&#34; target=&#34;_blank&#34;&gt;Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, an in vivo model can represent an important tool for assessing the efficacy of novel approaches in the treatment of MPM.Presently, human MPM cells have been grown orthotopically in mice upon transplantation of tumor masses or tumor cell suspensions following surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16714696&#34; target=&#34;_blank&#34;&gt;Management of malignant mesothelioma by decortication and adjunct phototherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median survival increased from 250 to 440 days in the combined treatment group.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16716822&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There have been few randomized controlled trials regarding treatment options, although these have increased in recent years, and results are eagerly awaited.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16720706&#34; target=&#34;_blank&#34;&gt;Physical and chemical stability of pemetrexed in infusion solutions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a multitargeted, antifolate, antineoplastic agent that is indicated for single-agent use in locally advanced or metastatic non-small-cell lung cancer after prior chemotherapy and in combination with cisplatin for the treatment of malignant pleural mesothelioma not treatable by surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1672261&#34; target=&#34;_blank&#34;&gt;Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Response evaluation was based on the following: (1) CT scan performed 2 weeks after treatment ended, and (2) repeat thoracoscopic examination with histopathologic verification in nine patients who had demonstrated a stabilization or a regression of the disease on CT scan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16770231&#34; target=&#34;_blank&#34;&gt;Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy is the surgical treatment of choice in 10% to 15% of patients who present with resectable disease and is reported to prolong survival. […] Accurate staging is important to distinguish patients who are resectable from those requiring palliative therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16778277&#34; target=&#34;_blank&#34;&gt;Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
DCE-MRI was performed before treatment (n = 19) and after the third cycle (n = 12) and sixth cycle (n = 7) of chemotherapy. […] DCE-MRI can be used in patients with MPM to assess tumor microvascular properties and to demonstrate tumor heterogeneity for therapy monitoring. […] High pretherapeutic values of kep within the tumor correlated with a poor overall response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16785733&#34; target=&#34;_blank&#34;&gt;Preclinical comparison of mTHPC and verteporfin for intracavitary photodynamic therapy of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Efficacy and tumour selectivity of photodynamic therapy with two clinically approved sensitizers (mTHPC, verteporfin) were assessed for focal intracavitary photodynamic therapy (PDT) in rodents with malignant pleural mesothelioma (MPM) at recommended drug-light conditions and at escalating sensitizer dosages.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16795078&#34; target=&#34;_blank&#34;&gt;Cellular and molecular parameters of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These mechanistic approaches offer new hope for early detection and treatment of these devastating tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16820238&#34; target=&#34;_blank&#34;&gt;The role of radiation therapy in malignant pleural mesothelioma: a systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radiation therapy may offer patients presenting with malignant pleural mesothelioma (MPM) symptom palliation and improvements in quality of life. […] This systematic review will address the role of radiation therapy in the management of MPM. […] Three small randomized controlled trials compared prophylactic external beam radiation therapy to no radiation therapy for patients with thoracic tracts caused by drainage tubes or diagnostic procedures. […] Future studies including radiotherapy for the treatment of such patients should include formal measures of quality of life and symptom control.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16822897&#34; target=&#34;_blank&#34;&gt;Physical instability of frozen pemetrexed solutions in PVC bags.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a multitargeted antifolate antineoplastic agent indicated for single-agent use in advanced or metastatic non-small-cell lung cancer and in combination with cisplatin for the treatment of malignant pleural mesothelioma not treatable by surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16828196&#34; target=&#34;_blank&#34;&gt;Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There was no treatment related death.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16855840&#34; target=&#34;_blank&#34;&gt;Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The CSF penetration of pemetrexed was less than 2% (range 0.33-1.58%), suggesting that it should be used in conjunction with other CNS preventive strategies when used in the treatment of malignancies with a predilection for CNS or leptomeningeal metastases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16856023&#34; target=&#34;_blank&#34;&gt;Radiotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Very few patients are suitable for any potentially curative treatment and the effectiveness of radical therapy with surgery, radiotherapy and/or chemotherapy in curing patients or prolonging survival is uncertain. […] The role of radiotherapy is controversial although it has been used as part of multimodal therapy. […] As radiotherapy has never been compared to chemotherapy or surgery or to best supportive care (as part of combination therapy) in a prospective, randomised trial, no data exist supporting one or the other treatment as a better option for patients with malignant pleural mesothelioma. […] There is a need for multicentre controlled randomised trials assessing the role of radiotherapy in the radical treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-10-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16867217&#34; target=&#34;_blank&#34;&gt;p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We did not detect SV40 L-Tag mRNA in either MPM cell lines or primary cultures, and treatment of p14(ARF)-deficient cells with cisplatin (CDDP) increased both total and phosphorylated p53 and enhanced p53 DNA-binding activity. […] Significantly, p53-induced apoptosis was activated by CDDP in p14(ARF)-deficient cells, and treatment with p53-specific siRNA rendered them more CDDP-resistant. p53 was also activated by: 1) inhibition of MDM2 (using nutlin-3); 2) transient overexpression of p14(ARF); and 3) targeting of survivin using antisense oligonucleotides.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1689538&#34; target=&#34;_blank&#34;&gt;The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment did not significantly affect survival, although there was an indication that patients having radical surgery did better (median survival 17 months) than those who did not (median survival 9 months) (p = 0.13). […] Fifteen patients were given radiotherapy with radical intent but only 12 completed treatment (50 Gy).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16925806&#34; target=&#34;_blank&#34;&gt;Tumor suppressor gene alterations in patients with malignant mesothelioma due to environmental asbestos exposure in Turkey.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We believe that this study will provide important support for other research into molecular-genetic variations, both on this subject and other malignancies, and may also constitute a base for early diagnosis and gene therapy research in the future.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16928523&#34; target=&#34;_blank&#34;&gt;Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Phosphorylation of mitogen-activated protein kinase and Akt, downstream IGF pathway mediators, were also shown to be repressed by drug treatment. […] Further evaluation of NVP-AEW541, and other selective IGF-1R inhibitors, may play an important role in multimodal treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16989994&#34; target=&#34;_blank&#34;&gt;Biology and management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery and radiotherapy have a limited role in highly selected patients and systemic therapy is the only potential treatment option for the majority of patients. […] An improvement of the knowledge of major molecular pathways involved in malignant mesothelioma is needed in order to define proper targets for the systemic treatment of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16996165&#34; target=&#34;_blank&#34;&gt;Pemetrexed-induced edema of the eyelid.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a novel antimetabolite that targets multiple enzymes in the folate pathway, and has exhibited clear antitumor activities in the treatment of malignant pleural mesothelioma and non-small cell lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17000285&#34; target=&#34;_blank&#34;&gt;Positron emission tomography predicts survival in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings suggest that fluorodeoxyglucose positron emission tomography can be used to stratify patients for treatment and clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17008700&#34; target=&#34;_blank&#34;&gt;Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is growing evidence that therapy-induced changes in tumor [(18)F]fluorodeoxyglucose (FDG) uptake as measured by positron emission tomography (PET) may predict response and patient outcome early in the course of treatment. […] Patients were evaluated by FDG-PET and CT at baseline and after two cycles of therapy. […] The use of MR evaluated by FDG-PET in the assessment of treatment efficacy in MPM appears promising.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-10-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17020984&#34; target=&#34;_blank&#34;&gt;Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The DNA methylation paradox, manifested as derepression of cancer-testis antigens, and silencing of tumor suppressors during malignant transformation, provides the rationale for the utilization of chromatin remodeling agents for cancer therapy. […] Thirty-five patients with cancers refractory to standard therapy received continuous 72-hour DAC infusions using a phase I dose-escalation schema. […] Each full course of therapy consisted of two identical 35-day cycles. […] Thirty-five patients were evaluable for toxicities; 25 were evaluable for treatment response. […] Posttreatment antibodies to NY-ESO-1 were detected in three patients exhibiting NY-ESO-1 induction in their tumor tissues. […] Complex, heterogeneous gene expression profiles were observed in pretreatment and posttreatment tissues. […] These findings support further evaluation of DNA-demethylating agents alone or in combination with other regimens targeting induced gene products for the treatment of these neoplasms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1703129&#34; target=&#34;_blank&#34;&gt;Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All 5 patients were males with known crocidolite asbestos exposure, who had received no treatment for their disease and in whom the diagnosis was confirmed by cytology, histology and electron microscopy (EM). […] The establishment of these 5 cultured human MM cell lines now provides an opportunity for comparative study of several aspects of the biology of MM in vitro as well as screening new treatment modalities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17033611&#34; target=&#34;_blank&#34;&gt;5-year prospective results of trimodality treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Even though followed by a prolonged survival in highly selected patients, the promising results of Sugarbaker’s trimodality treatment for malignant pleural mesothelioma (MPM) are debated and not yet uniformly replicated. […] The purpose of this study is to evaluate prospectively the reproducibility of the trimodality treatment results in a patient population with mesothelioma staged by the IMIG classification. […] Most of the disease recurrences are loco-regional and the current insufficiency of intraoperative or postsurgical radicality needs improvement, along with earlier diagnosis, more accurate staging, and preoperative induction for the multimodality treatment of pleural mesothelioma to become an established curative option. […] This series confirms the reproducibility of the trimodality treatment for MPM,which is associated with prolonged survival for early-stage tumors at the cost of a not prohibitive treatment-related mortality rate.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17038662&#34; target=&#34;_blank&#34;&gt;Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Lung cancers, malignant mesotheliomas (MM), and fibrosis are devastating diseases with limited treatment strategies, in part due to poorly-effective drug delivery to affected areas of lung. […] In the treatment of lung and pleural diseases, APMS-TEG may be useful tools to deliver chemotherapeutic drugs or molecular constructs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17044195&#34; target=&#34;_blank&#34;&gt;Spindle cell tumors of the pleura: differential diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is crucial to arrive at a correct diagnosis since many of these neoplasms show different prognoses and require varying treatment modalities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17044196&#34; target=&#34;_blank&#34;&gt;The pathogenesis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover, these data provide a rationale for the observation that only a fraction of heavily exposed asbestos workers developed mesothelioma, and novel targets for prevention and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17056195&#34; target=&#34;_blank&#34;&gt;Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma (MPM) from a viewpoint of dose distribution analysis using Simulation Environment for Radiotherapy Applications (SERA), a currently available BNCT treatment planning system. […] The BNCT treatment plans were constructed for 3 patients with MPM using the SERA system, with 2 opposed anterior-posterior beams. […] From a viewpoint of the dose-distribution analysis, BNCT has the possibility to be a promising treatment for MPM patients who are inoperable because of age and other medical illnesses.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17059852&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a new standard of care.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A rise in the incidence of this fatal disease, which, in the past has been considered to be relatively refractory to therapy, is predicted over the next decade. […] The realisation that patients can benefit from systemic chemotherapy and more aggressive multimodal approaches, including extrapleural pneumonectomy (EPP), in earlier stages of disease now provides the opportunity to offer more effective treatment for this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17067119&#34; target=&#34;_blank&#34;&gt;Can pemetrexed help in malignant mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Conventional treatment options have not improved this poor outlook. […] It is against this background that pemetrexed (pronounced pe-me-treks-ed) (Alimta - Lilly) has recently become available for use with cisplatin for the treatment of patients with unresectable malignant pleural mesothelioma who have not previously been treated with chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17075562&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a comprehensive review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Effects on underlying structures limit application of radiation therapy, but some systemic agents are beginning to enhance survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17075563&#34; target=&#34;_blank&#34;&gt;Solitary fibrous tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The initial evaluation and diagnosis, tumor classification, surgical treatment, results of therapy, and long-term prognosis are reviewed, based on a selective review of the literature from MEDLINE beginning 1980. […] Complete en bloc surgical resection is the preferred treatment of benign and malignant varieties of the tumor. […] Adjuvant therapy remains controversial in SFTP.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17078889&#34; target=&#34;_blank&#34;&gt;Mesothelioma with non-pleural malignancy: a red herring or just an uncommon pairing?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report four cases of female patients with MPM referred for palliation of symptoms thought to be due to previous non-pleural malignancy.With emerging novel treatments for MPM, this article discusses four unusual cases of MPM occurring in the setting of other malignancy, highlights the importance of considering a primary diagnosis of MPM even in patients with other malignancy, and reinforces the benefits of video-assisted surgical biopsy which allows simultaneous diagnosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17079218&#34; target=&#34;_blank&#34;&gt;Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prognosis for patients with malignant pleural mesothelioma (MPM) remains poor and such patients require intensive treatment. […] The treatment regimen comprised of weekly thermo-radiotherapy with intra-thoracic chemotherapy 2-5 times at initiation of treatment. […] Pleural fluid decreased in all patients after therapy, while all patients displayed improved performance status and could be discharged from hospital. […] All patients underwent the complete course of treatment and only one of 11 patients developed grade 4 thrombocytopenia. […] This approach appears effective and more acceptable for patients with MPM with pleural effusion than other multi-modality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-12-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17080237&#34; target=&#34;_blank&#34;&gt;Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Such stress response is beneficial for oncolytic viral therapy. […] We hypothesized that a combination of RT and NV1066, an oncolytic herpes virus, might exert an additive or synergistic effect in the treatment of MPM. […] RT can be combined with oncolytic herpes simplex virus therapy in the treatment of malignant pleural mesothelioma to achieve synergistic efficacy while minimizing dosage and toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17087333&#34; target=&#34;_blank&#34;&gt;[Autopsy case of sarcomatoid malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For the selection of the best treatment strategy for mesothelioma especially in the early stage, we should be aware of this difficulty.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17092602&#34; target=&#34;_blank&#34;&gt;Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Eligible patients had a histologic or cytologic diagnosis of malignant mesothelioma that was not amenable to curative treatment with surgery. […] Study treatment consisted of pemetrexed 500mg/m(2) in combination with cisplatin 75mg/m(2) once every 21 days.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17114082&#34; target=&#34;_blank&#34;&gt;PET: other thoracic malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PET findings may be used to assess therapy response and evaluate for esophageal tumor recurrence after treatment. […] Similarly, PET may be used to assess the extent of disease in patients with malignant pleural mesothelioma, thereby facilitating optimal therapy approaches.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17137779&#34; target=&#34;_blank&#34;&gt;Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New therapeutic strategies such as gene or cell therapy are still on clinical trial. […] Therefore, an optimal treatment of MPM is not clearly defined yet, despite the introduction of recent drugs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17145837&#34; target=&#34;_blank&#34;&gt;In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an increasing health burden on many societies worldwide and, being generally resistant to conventional treatment, has a poor prognosis with a median survival of &amp;lt;1 year.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17146783&#34; target=&#34;_blank&#34;&gt;Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options remain limited and the outcome in recurrent disease is poor. […] IPM appeared to have a reasonable response rate with an acceptable toxicity profile in the first- and second-line treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17174436&#34; target=&#34;_blank&#34;&gt;A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Especially, of epithelial cell type stages 1 and 2 should receive multimodal treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17181984&#34; target=&#34;_blank&#34;&gt;Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the clinical effectiveness and cost-effectiveness of pemetrexed disodium in combination with cisplatin for the treatment of unresectable pleural mesothelioma in chemotherapy-naive patients. […] During the trial, increased reporting of severe toxicity in the pemetrexed arm led to a change in the protocol to add folic acid and vitamin B12 supplementation to therapy. […] For fully supplemented patients (n = 331) the hazard ratio for median survival in favour of pemetrexed plus cisplatin was also comparable (0.75), but of borderline significance between treatment arms (p = 0.051). […] The new therapy examined in this document demonstrates an extension of life expectancy and palliation, as measured by time to progression of disease and other end-points. […] However, the absolute benefit obtained is small, and it needs to be weighed against the benefits of effective palliative care services.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17188885&#34; target=&#34;_blank&#34;&gt;A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From therapeutic nihilism to extremely aggressive management, there is a wide range of possibilities in the treatment of malignant pleural mesothelioma (MPM). […] Unfortunately, there is little evidence as regards the best treatment to offer to the MPM patients. […] In 1999, we started a phase II study based on the multimodality treatment of stage II-III MPM, the results of which have been analysed and reported. […] From 1999 to 2004, 49 patients with IMIG stage II-III MPM underwent a multimodality treatment including: intrapleural pre-operative interleukin 2 (IL-2, 18x10(6) UI/day per 3 days), pleurectomy/decortication, intrapleural post-operative epidoxorubicin (25mg/m2 per 3 days), IL-2 (18x10(6) UI/day per 3 days), adjuvant radiotherapy (30Gy), systemic chemotherapy (cisplatin 80 mg/m2 day 1, gemcitabine 1250 mg/m2 day 1 and 8 up to 6 courses) and long-term sub-cutaneous IL-2 (3x10(6) UI/day 3 days per week). […] The multimodality treatment we adopted for stage II-III MPM was feasible, well tolerated by most of the patients and produced a favourable outcome. […] New targeted therapies are awaited for further improvements in the treatment of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17198794&#34; target=&#34;_blank&#34;&gt;Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Adjuvant hemithoracic radiation therapy, however, significantly decreased the risk of locoregional recurrence. […] Adjuvant hemithoracic radiation therapy but not N2 disease affects the risk of locoregional recurrence.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17203752&#34; target=&#34;_blank&#34;&gt;Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive treatment-resistant tumor with a median survival from diagnosis of 12 months. […] Objective responses were assessed by CT-scan 30 and 60 days after the end of treatment in all 27 enrolled patients. […] Our data show that TSP is a relatively effective second-line treatment in patients with progressive disease after systemic chemotherapy, with a low rate of major complications and treatment-related toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1720658&#34; target=&#34;_blank&#34;&gt;The role of palliative radiotherapy in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment was well tolerated, with nausea and vomiting in only 1 patient.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17237002&#34; target=&#34;_blank&#34;&gt;[Immunotherapy and malignant mesothelioma: clinical perspectives].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical trials investigating new trends in the treatment of stage I and II malignant mesothelioma have shown both immunotherapy and systemic chemo-immunotherapy to be efficacious. […] Thus, immunotherapy of cancer is undoubtedly a highly promising but also very challenging approach in the treatment of a disease that has slipped through the defence lines of the immune system.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17249533&#34; target=&#34;_blank&#34;&gt;[Survey of surgical treatment of malignant pleural mesothelioma in Japan].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Postoperative adjuvant therapy was performed in 56 cases. […] According to Cox regression analysis, prognostic factors for survival included postoperative adjuvant therapy (p=0.003) and complete resection (p=0.037) significantly, and International Mesothelioma Interest Group (IMIG) stage (p=0.051) and performance status (p=0.086) with a marginal significance, indicating that complete surgical resection of the tumor and perioperative adjuvant therapy could be effective treatment for MPM in Japan. […] Thus, the development of multimodality therapy including surgical treatment for this disease may be required to improve surgical results of MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17249535&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma carries a poor prognosis, for which no standard therapy has been established. […] In addition to 2 of these 3 patients, 2 underwent extrapleural pneumonectomy (EPP) without adjuvant treatment. […] Remaining 1 received palliative treatment only.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17249536&#34; target=&#34;_blank&#34;&gt;[Diffuse malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment included intrapleural chemotherapy in 4 patients, extrapleural pneumonectomy in 3, pleural drainage in 2, and best supportive care in 2.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17249538&#34; target=&#34;_blank&#34;&gt;[Extrapleural pneumonectomy with wide resection of the chest wall, diaphragm, and pericardium for malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy is performed as surgical therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17253564&#34; target=&#34;_blank&#34;&gt;Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is the first and only chemotherapy agent that has been granted a marketing approval for use in combination with cisplatin for the treatment of chemo-naïve patients with unresectable MPM. […] To examine evidence on the clinical effectiveness of pemetrexed disodium used in combination with cisplatin for the treatment of unresectable malignant pleural mesothelioma in chemotherapy naïve patients compared with other cytotoxic agents used alone or in combination, or supportive care. […] Randomised Controlled Trials (RCTs) where the use of pemetrexed disodium in combination with cisplatin is compared with other cytotoxic agents, or supportive care for the treatment of malignant pleural mesothelioma (or non-RCTs, in the absence of RCT data ). […] One RCT involving 448 patients and comparing pemetrexed plus cisplatin versus cisplatin alone for the treatment of unresectable malignant mesothelioma was included in the review. […] Further studies including patients with poor performance status are needed in order to generalise the treatment findings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17270034&#34; target=&#34;_blank&#34;&gt;Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our results with array comparative genomic hybridization analysis provide new insights into the genetic background of MPM, and also give some clues to develop a new molecular target therapy for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17279584&#34; target=&#34;_blank&#34;&gt;Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a challenging disease with regard to diagnosis and treatment; early and accurate diagnosis would lead to appropriate therapeutic strategies, including extrapleural pneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17283842&#34; target=&#34;_blank&#34;&gt;[Malignant peritoneal mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The symptomatology is insidious and poses difficult problems in diagnosis and treatment. […] It was performed surgical ablation of the tumor, splenectomy with favorable postoperative evolution, the patient being now under chemotherapy treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17294804&#34; target=&#34;_blank&#34;&gt;Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings suggest that the restored expression of MYO18B may be a useful therapeutic strategy for the treatment of locally advanced MPM in humans.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17311837&#34; target=&#34;_blank&#34;&gt;Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study provides a rationale for a novel translational approach to the treatment of mesothelioma which relies on enhancement of tumour chemosensitivity by inhibition of Akt.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17332368&#34; target=&#34;_blank&#34;&gt;A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
SM16 penetrated tumor cells in vivo, suppressing tumor phosphorylated Smad2/3 levels for at least 3 h following treatment of tumor-bearing mice with a single i.p. bolus of 20 mg/kg SM16. […] Treatment of mice bearing large tumors with 5 mg/kg/d SM16 after debulking surgery reduced the extent of tumor recurrence from 80% to &amp;lt;20% (P &amp;lt; 0.05). […] These data suggest that ALK5 inhibitors, such as SM16, offer significant potential for the treatment of malignant mesothelioma and possibly other cancers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17333344&#34; target=&#34;_blank&#34;&gt;Molecular basis of antifolate resistance.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, the novel antifolates raltitrexed and pemetrexed that target thymidylate synthase (TS) and glycineamide ribonucleotide transformylase (GARTF) were introduced for the treatment of colorectal cancer and malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17337201&#34; target=&#34;_blank&#34;&gt;Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There were no significant differences in the proportion of patients undergoing some adjuvant therapy in each group (p=0.2).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17339766&#34; target=&#34;_blank&#34;&gt;Palliative intravenous cisplatin treatment for concurrent peritoneal and pleural mesothelioma in a dog.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intravenous administration of cisplatin was chosen as the treatment. […] During treatment, the dog’s overall body condition improved and the clinical signs were relieved without significant side effects.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17349242&#34; target=&#34;_blank&#34;&gt;[Immunohistochemistry and surgical approaches in solitary fibrous tumor of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nowadays, videothoracoscopy (VTC) allows adequate access for the surgical treatment of these tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17350855&#34; target=&#34;_blank&#34;&gt;Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Local recurrence remains a major problem in the treatment of malignant pleural mesothelioma. […] In a second experiment, this new recurrence model was evaluated for the effect of intrapleural therapy with different agents: 4 ml of cisplatin-solution (100mg(2)/kg BW), cisplatin combined with the fibrin-based sealant Vivostat, 4 ml taurolidine 2%, repeated injection of 1 microg of the chemokine CCL-19 at the tumour site and 4 ml povidone-iodine in a dilution 1:10.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17352172&#34; target=&#34;_blank&#34;&gt;[Clinico-pathological prognostic factors in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis of malignant pleural mesothelioma is poor, but selected patients might benefit from multimodality treatment. […] Twenty-three patients received treatment, while 31 were referred to supportive care only. […] The European Organization for Research and Treatment of Cancer (EORTC) score showed a significant correlation with survival (P = 0.0146).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17355218&#34; target=&#34;_blank&#34;&gt;Emerging drugs for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, relief of symptoms and improvement of quality of life parameters are the short-term goals of therapy. […] At present, the regimen of cisplatin/pemetrexed is the medical treatment of choice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17359904&#34; target=&#34;_blank&#34;&gt;The role of radiotherapy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radiation therapy for the treatment of malignant pleural mesothelioma has historically been limited by its efficacy. […] However, the increasing incidence of this tumour and the emergence of new technologies present a number of opportunities and challenges for this treatment modality. […] However, the optimum dose and timing of treatment are not clear. […] There is no role for radical radiotherapy alone, but the role of radiotherapy as part of multimodality therapy is discussed. […] There have been studies of intensity-modulated radiotherapy as part of multimodality therapy and this technique needs to be evaluated further.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17375514&#34; target=&#34;_blank&#34;&gt;Asbestos-related lung disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of patients with asbestos exposure and lung cancer is identical to that of any patient with lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17383050&#34; target=&#34;_blank&#34;&gt;Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Taurolidine but not PVP-I treatment resulted in p53 activation in 2/3 MPM cell lines and a decrease in the protein levels of survivin, Bcl-2 and Mcl-1. […] Targeting of Bcl-xL with siRNA sensitized MPM cells to taurolidine and taurolidine treatment sensitized MPM cells to cisplatin-induced apoptosis. […] Both agents are promising candidates for use in local treatment within multimodality concepts for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17385835&#34; target=&#34;_blank&#34;&gt;Retroperitoneal malignant schwannoma and peritoneal malignant mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite combined-modality treatment the disease progressed and the patient was operated on for third time 2.5 years after the first operation with partial tumor resection. […] Singlemodality therapy of these tumors has shown poor results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17394948&#34; target=&#34;_blank&#34;&gt;Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multinucleated cells were counted using flow cytometry, and cell survival after treatment was determined using clonogenic assay. […] This treatment resulted in increased formation of multinucleated cells after irradiation but did not increase levels of cleaved caspase 3.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-06-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17403553&#34; target=&#34;_blank&#34;&gt;Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Trimodality therapy seems to be the best treatment for malignant pleural mesothelioma (MPM). […] Trimodality therapy results have led us to test induction chemotherapy followed by EPP and adjuvant radiotherapy in stages I-III of MPM. […] EPP was performed 3-5 weeks after induction therapy, while post-operative RT was given 4-6 weeks after operation. […] Our results are similar to those of other studies using a heavier modality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17409804&#34; target=&#34;_blank&#34;&gt;Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After a protocol amendment, patients were supplemented with vitamin B12 and folic acid at the time of starting therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17409823&#34; target=&#34;_blank&#34;&gt;Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the toxicity and effectiveness of pemetrexed maintenance therapy (PMT) in patients with malignant pleural mesothelioma (MPM). […] Eligible were patients with histologically proven advanced MPM, WHO PS 0-2 and adequate hematological, renal and hepatic function in whom during 6 courses of pemetrexed containing induction therapy no disease progression was observed. […] Of the 27 patients who received induction therapy, 13 were treated with PMT. […] During PMT 23% of the patients with stable disease after induction therapy achieved a partial response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17409872&#34; target=&#34;_blank&#34;&gt;Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy (EPP) and adjuvant high-dose radiation therapy (RT) are associated with a median survival of 3 years in early-stage malignant pleural mesothelioma (MPM) but of less than 1 year in locally advanced disease. […] Induction therapy was four cycles of gemcitabine and cisplatin. […] Pretreatment disease stage was III in 13 patients and IV in six patients. […] Response to induction therapy was complete in zero patients, partial in five patients, stable disease in six patients, and progression of disease in eight patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17409909&#34; target=&#34;_blank&#34;&gt;Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The data from this EAP study suggest that patients with previously treated MPM can benefit from treatment with pemetrexed alone or in combination with cisplatin. […] The treatment is associated with acceptable toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17409924&#34; target=&#34;_blank&#34;&gt;The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overall response rate (24% versus 14%, p = 0.056) was greater in the combination treatment arm, but this difference was not statistically significant. […] Such treatment should be administered with supplementation of vitamin B12 and folic acid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17409940&#34; target=&#34;_blank&#34;&gt;Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma is a highly malignant neoplasm with no effective treatment. […] Conditionally replicative adenoviruses (CRAds) represent a promising new modality for the treatment of cancer in general.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17410031&#34; target=&#34;_blank&#34;&gt;Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is active as first-line treatment of malignant pleural mesothelioma. […] The objective was to evaluate its activity as second-line treatment. […] Treatment was pemetrexed alone or pemetrexed combined with carboplatin. […] Thirty-nine patients were included: 28 Danish patients received pemetrexed (three patients received pemetrexed as third-line treatment), whereas 11 Norwegian patients received pemetrexed plus carboplatin. […] The median number of treatment courses was six (range, 1-23). […] Pemetrexed was generally well tolerated with noteworthy activity in malignant pleural mesothelioma after previous platinum-based treatment and may be considered for second-line treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17410047&#34; target=&#34;_blank&#34;&gt;Four-modality therapy in malignant pleural mesothelioma: a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment approaches in malignant pleural mesothelioma (MPM) patients range from mere palliation to aggressive anticancer therapy, and there is currently no consensus on the optimal therapeutic strategy. […] In 1999, we began a phase II study to investigate four-modality treatment of advanced stage MPM. […] From 1999 to 2004, 49 patients with International Mesothelioma Interest Group stage II-III MPM underwent four-modality treatment with intrapleural preoperative interleukin-2 (18 x 10(6) UI/day for 3 days), pleurectomy/decortication, intrapleural postoperative epidoxorubicin (25 mg/m2 for 3 days), interleukin-2 (18 x 10(6) UI/day for 3 days), adjuvant radiotherapy (30 Gy), systemic chemotherapy (cisplatin 80 mg/m2 day 1, gemcitabine 1250 mg/m2 days 1 and 8 for up to six courses) and long-term subcutaneous interleukin-2 (3 x 10(6) UI/day on 3 days per week). […] The four-modality treatment that we adopted for advanced-stage MPM was feasible, well tolerated by most of the patients, and produced a favorable median survival. […] This treatment approach warrants further investigation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17415849&#34; target=&#34;_blank&#34;&gt;Diagnostic procedures of pleural malignant mesothelioma: our experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The accurate diagnosis of MM is mandatory for appropriate treatment decision (surgical or nonsurgical).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17419436&#34; target=&#34;_blank&#34;&gt;[A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In spite of chemotherapy and radiation therapy for the abdominal wall tumor, the tumor rapidly progressed and the patient died three months after admission.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17426232&#34; target=&#34;_blank&#34;&gt;Catheter-tract metastases associated with chronic indwelling pleural catheters.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Indwelling pleural catheters are increasingly being used for ambulatory treatment of malignant pleural effusion, particularly for patients unsuitable for pleurodesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17431335&#34; target=&#34;_blank&#34;&gt;[Treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As for the treatment of this disease,extrapleural pneumonectomy or pleurectomy/decortication are available for those patients who can be surgically operated on. […] However, since a complete cure rate is low when only surgical treatment is performed, generally a multimodality treatment is performed wherein chemotherapy and/or radiotherapy are combined. […] For chemotherapy, a large-scale randomized phase III study demonstrated that a treatment using two agents: pemetrexed, which is a new multitargeted antifolate, and cisplatin is effective. […] As other treatment methods, chemohyperthermia, treatments using various kinds of cytokines and angiogenesis inhibitors, genetic treatment and photodynamic therapy have been attempted. […] The current treatment results for this disease are very poor, and there has been a strong demand for establishing an effective treatment method.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17475364&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma following thoracic radiotherapy for lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although some of these malignancies may be related to common environmental exposures, a significant number are considered to be therapy-related. […] We report the case of a 66-year-old woman with no prior asbestos exposure who developed pleural mesothelioma 17 years after pneumonectomy and adjuvant radiation therapy for non-small cell lung cancer. […] Opacification of the lung field from prior therapy made determination of the diagnosis more challenging. […] Secondary malignancies such as mesothelioma should be considered in patients who develop unexplained symptoms even long after treatment of a primary tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17492119&#34; target=&#34;_blank&#34;&gt;Computer-assisted diagnosis for early stage pleural mesothelioma: towards automated detection and quantitative assessment of pleural thickening from thoracic CT images.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For its early stage, pleurectomy with perioperative treatment can reduce morbidity and mortality.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17504993&#34; target=&#34;_blank&#34;&gt;Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too late for a curative treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17513310&#34; target=&#34;_blank&#34;&gt;A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of the present study is to verify the treatment effects of boron neutron capture therapy (BNCT) in ectopic tumors implanted in the thoracic cavity mimicking malignant pleural mesothelioma (MPM). […] Mice were sorted into four groups: group I for non-treatment; group II for neutron irradiation; group III for gamma-ray irradiation; and group IV for BNCT irradiation. […] BNCT is a potentially promising treatment for malignant tumors spreading in the thoracic cavity such as MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17519817&#34; target=&#34;_blank&#34;&gt;[Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a chemotherapeutic drug with good tolerance, used as first line treatment for malignant pleural mesothelioma in association with cisplatin, and alone as second line treatment in resistant or relapsing non-small cell lung cancer (NSCLC). […] Treatment with steroids and gammaglobulins led to local resolution and improvement in his general condition.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17521217&#34; target=&#34;_blank&#34;&gt;Management options for malignant pleural mesothelioma: clinical and cost considerations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The standard radiographic assessment of response to MPM therapy remains a poor surrogate for clinically relevant endpoints such as median survival. […] Furthermore, it is not currently known whether aggressive multimodality treatment for MPM will improve survival or quality of life above and beyond symptomatic care. […] MPM treatment is a costly public health issue; after efficacy is proven, additional studies are needed to measure the cost effectiveness of MPM treatment regimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1753419&#34; target=&#34;_blank&#34;&gt;Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is refractory to conventional therapy. […] The results suggest that local adoptive immunotherapy could be useful in the treatment of malignant effusion due to mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17534390&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: current concepts in treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With a peak incidence of MPM expected in Europe, Australia, and the US within the next 15 years, and the failure of current treatment approaches to offer long-term survival and improve quality of life, new therapeutic regimens are warranted. […] The role of radiotherapy in the treatment of MPM remains controversial, as the radiosensitivity of malignant mesothelial cells is modest. […] Presently, a multimodal approach is considered to be the cornerstone of treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17560792&#34; target=&#34;_blank&#34;&gt;Effect of the TAT-RasGAP(317-326) peptide on apoptosis of human malignant mesothelioma cells and fibroblasts exposed to meso-tetra-hydroxyphenyl-chlorin and light.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
5,10,15,20-Tetrakis(m-hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy (PDT) has shown insufficient tumor selectivity for the treatment of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/175652&#34; target=&#34;_blank&#34;&gt;Pseudomesotheliomatous carcinoma of the lung. A variant of peripheral lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tissues were stained with hematoxylin and eosin, PAS with and without diastase treatment (DPAS), mucicarmine, alcian blue, toluidine blue, and colloidal iron with and without digestion by testicular hyaluronidase.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17574045&#34; target=&#34;_blank&#34;&gt;The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This mechanistic study establishes a the translational framework for the clinical application of sequential CDDP/sFasL in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17583136&#34; target=&#34;_blank&#34;&gt;[Management of malignant pleural effusion].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Their treatment is essentially palliative but recently improved with new efficient chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17588698&#34; target=&#34;_blank&#34;&gt;A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with a histological diagnosis of pleural mesothelioma and an invasive procedure within the preceding 21 days were stratified by age, performance status and treatment centre. […] Patients were asked to complete questionnaires on treatment toxicity and on symptoms from any tract metastases detected.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17590095&#34; target=&#34;_blank&#34;&gt;[Peritoneal mesothelioma: an inusual clinical presentation in a patient without exposure to asbestos].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient received treatment with systemic palliative chemotherapy, cisplatin-pemetrexed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17607128&#34; target=&#34;_blank&#34;&gt;Constrictive pericarditis after left extrapleural pneumonectomy and radiotherapy for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report the devastating complication of constrictive pericarditis after multimodality therapy including left extrapleural pneumonectomy for malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17620427&#34; target=&#34;_blank&#34;&gt;Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a deadly disease with few systemic treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17622912&#34; target=&#34;_blank&#34;&gt;Trousseau syndrome due to pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although there were no risk factors for atherosclerosis, brain infarctions showed frequent relapses, even under anticoagulant therapy, and there was a marked hypercoagulable state.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17659810&#34; target=&#34;_blank&#34;&gt;DNA methylation profile of 28 potential marker loci in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with malignant mesothelioma (MM), an aggressive cancer associated with asbestos exposure, usually present clinically with advanced disease and this greatly reduces the likelihood of curative treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17670175&#34; target=&#34;_blank&#34;&gt;Polyhematoporphyrin-mediated photodynamic therapy and decortication in palliation of malignant pleural mesothelioma: a clinical pilot study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate the additional effect of intraoperative photodynamic therapy (PDT) under hyperbaric oxygenation (HBO) when compared with decortication alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17670215&#34; target=&#34;_blank&#34;&gt;Extended posterolateral-subcostal thoracotomy for extrapleural pneumonectomy: a surgical approach for radical operation of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy is an essential procedure in multimodality therapy of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17673616&#34; target=&#34;_blank&#34;&gt;Multidisciplinary treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As a result, multimodality treatment regimens have been developed. […] Radical surgery with extrapleural pneumonectomy and adjuvant treatments has become the preferred option in early disease, but the benefits of such an aggressive approach have been questioned because of significant treatment-related morbidity and mortality. […] In the past few years, there have been several major advances in the management of patients with MPM, including more accurate staging and patient selection, improvements in surgical techniques and postoperative care, novel chemotherapy regimens with definite activity such as antifolate (pemetrexed or raltitrexed)-platinum combinations, and new radiotherapy techniques such as intensity-modulated radiation therapy. […] A number of molecular alterations occurring in MPM have been reported, providing broader insights into its biology and leading to the identification of new targets for therapy. […] Further studies are needed to provide evidence-based recommendations for the treatment of early and advanced stages of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17674974&#34; target=&#34;_blank&#34;&gt;Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy (EPP) is an effective treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17686442&#34; target=&#34;_blank&#34;&gt;Optimising survival in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Standard treatment is the combination of cisplatin and pemetrexed based on phase III-study evidence, and therapy should be initiated as early as possible.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17704250&#34; target=&#34;_blank&#34;&gt;Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Semiquantitative (18)F-FDG PET using the volume-based parameter of TGV is feasible in mesothelioma and may predict response to chemotherapy and patient survival after 1 cycle of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17710208&#34; target=&#34;_blank&#34;&gt;Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because angiogenesis is necessary for the growth and metastasis of solid tumours, and VEGF is believed to have a pivotal role in that process, SUNITINIB treatment may have broad-spectrum clinical utility.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-02-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17720413&#34; target=&#34;_blank&#34;&gt;Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to examine the effect of aprotinin on blood loss in extrapleural pneumonectomy and to identify potential treatment-related complications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17763671&#34; target=&#34;_blank&#34;&gt;[Clinical utility of thoracoscopy under local anesthesia].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy has been recently established as an indispensable technique for diagnosis and treatment of respiratory diseases. […] These 3 diseases are the diseases with which medical thoracoscopy is most useful because they can be reliably diagnosed by biopsies and because early diagnosis and early treatment are essential. […] In case of the pneumothorax, treatment with bulla looping or cauterization may be possible, but we do not treat pneumothorax with medical thoracoscopy because it is impossible to approach and find air leaks of lesions located in or near blind spots such as the apex or mediastinal part In case of acute emphysema, it is important to release adhesions and perform effective drainage using thoracoscopy as soon as possible since deposition of fibrin tends to form quickly compartments that make drainage difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-10-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17764849&#34; target=&#34;_blank&#34;&gt;Assessment of tumor response in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New serum markers such as osteopontin and mesothelin-related proteins are under evaluation and in the future might play a role in assessing the response of MPM to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1783086&#34; target=&#34;_blank&#34;&gt;Correlations between findings at computed tomography (CT) and at thoracoscopy/thoracotomy/autopsy in pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Difficulties in defining the exact extent of the diseases for clinical staging and/or evaluation of treatment response arose at the following sites: diaphragmatic pleura, chest wall, pericardium, mediastinum and mediastinal lymph nodes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17886249&#34; target=&#34;_blank&#34;&gt;Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Promising results with trimodality therapy combining surgery, chemotherapy, and radiotherapy have been obtained in the management of patients with malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17908988&#34; target=&#34;_blank&#34;&gt;The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The vascular endothelial growth factor (VEGF) has been reported to be an ideal therapeutic target, and a multitargeted antifolate, pemetrexed, has been clinically used for the treatment of MPM. […] Treatment with bevacizumab effectively inhibited the production of thoracic tumors and dramatically prevented the production of pleural effusion by the EHMES-10 cells but not the MSTO-211H cells. […] Treatment with bevacizumab reduced the number of enlarged tumor-associated vessels and proliferating tumor cells. […] Moreover, treatment with bevacizumab in combination with pemetrexed more effectively suppressed the formation of the pleural effusion and prolonged the survival compared with the control and monotherapy in the EHMES-10 cell-bearing severe combined immunodeficient mice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-12-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17909360&#34; target=&#34;_blank&#34;&gt;Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality therapy including surgery was associated with a median survival of 20.1 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17909365&#34; target=&#34;_blank&#34;&gt;Malignant mediastinal tumor with bone formation–mesothelioma or sarcoma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since the tumor was pressing against the large vessels and heart, a debulking was performed, followed by Pemetrexed and Carboplatin treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17917097&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the tunica vaginalis testis: a case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite aggressive surgical and systemic therapy the prognosis remains poor with only rare long-term survivors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17919769&#34; target=&#34;_blank&#34;&gt;Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of second line treatment in malignant pleural mesothelioma (MPM) is currently undefined. […] This case series explores the possible role of retreatment with pemetrexed-based chemotherapy as a second line therapeutic option in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17945478&#34; target=&#34;_blank&#34;&gt;Mesothelin targeted cancer immunotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy. […] These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17947722&#34; target=&#34;_blank&#34;&gt;Phase II study of vinflunine in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a disease of increasing incidence for which treatment options are limited.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17952507&#34; target=&#34;_blank&#34;&gt;Increased pleural fluid adenosine deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemical pleurodesis using various sclerosing agents is accepted palliative therapy for patients with recurrent, symptomatic, malignant pleural effusions (MPE).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17953743&#34; target=&#34;_blank&#34;&gt;Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite progress in chemo- and in multimodality therapy, MPM remains a disease with a poor prognosis. […] Inducing apoptosis by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or agonistic monoclonal antibodies which target TRAIL-receptor 1 (TRAIL-R1) or TRAIL-R2 has been thought to be a promising cancer therapy. […] Furthermore, pre-treatment with cisplatin followed by Mapatumumab or Lexatumumab resulted in significant higher cytotoxic effects as compared to the reverse sequence. […] Combination-induced cell growth inhibition was significantly abrogated by pre-treatment of the cells with the antioxidant N-acetylcysteine. […] Our results suggest that the sequential administration of cisplatin followed by Mapatumumab or Lexatumumab deserves investigation in the treatment of patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17954021&#34; target=&#34;_blank&#34;&gt;Morphologic and functional imaging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It has been shown that FDG-PET is useful for the differentiation of benign from malignant lesions, for staging and monitoring metabolic response to therapy against MPM, and that it has prognostic value.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17954086&#34; target=&#34;_blank&#34;&gt;Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To improve local control, we have used intensity-modulated radiation therapy (IMRT) as it allows better dose distribution to regions at risk of recurrence as well as reduced radiation to surrounding organs. […] Intensity-modulated radiation therapy after EPP results in excellent local control for malignant pleural mesothelioma; however, distant metastases remain a significant problem and limit survival. […] This provides a strong rationale for combining aggressive local regimens with systemic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18006112&#34; target=&#34;_blank&#34;&gt;Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this open-label phase II SWOG study was to evaluate the activity of gemcitabine (Gemzar; Eli Lilly, Indiana, USA) and cisplatin combination therapy, in patients with unresectable malignant mesothelioma of the pleura. […] Treatment consisted of gemcitabine 1000mg/m(2) and cisplatin 30mg/m(2) on days 1, 8 and 15 of a 28-day cycle, until progression of disease or two cycles beyond complete response. […] There were no treatment-related deaths. […] Cisplatin-gemcitabine combination chemotherapy has modest activity with an acceptable toxicity profile, as first line treatment for patients with malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18038888&#34; target=&#34;_blank&#34;&gt;Solitary fibrous tumor of the anterior mediastinum: a rare extrapleural neoplasm.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Their accurate classification is important, as solitary fibrous tumors are intermediate (rarely metastasizing) neoplasms that require complete surgical excision and long-term clinical follow-up for optimum therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18048410&#34; target=&#34;_blank&#34;&gt;Radical surgery for malignant pleural mesothelioma: results and prognosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of surgical treatment for malignant pleural mesothelioma (MPM) continues to be controversial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18051806&#34; target=&#34;_blank&#34;&gt;[Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Combination therapy (extrapleural pneumonectomy, chemotherapy, and radiotherapy) was initiated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18063861&#34; target=&#34;_blank&#34;&gt;The potential role of pemetrexed in gastrointestinal cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 2004, the new-generation multitargeted antifolate pemetrexed was approved by the US Food and Drug Administration for the treatment of malignant pleural mesothelioma and as second-line monochemotherapy for advanced non-small cell lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18064685&#34; target=&#34;_blank&#34;&gt;Endoscopic ultrasound-guided fine needle aspiration is useful for nodal staging in patients with pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with malignant pleural mesothelioma and negative N2 stage lymph nodes may benefit from extrapleural pneumonectomy with adjuvant therapy. […] Follow-up included operative notes, treatment summaries, and surgical pathology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18089874&#34; target=&#34;_blank&#34;&gt;Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
HRQOL was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30/Lung Cancer 13 tool.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-12-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18154820&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: surgical management in 285 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite increasing incidence, no treatment modality is accepted standard of care.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18155556&#34; target=&#34;_blank&#34;&gt;Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Localised malignant pleural mesotheliomas are very rare and although there are sporadic reports in the literature showing that they have a different biological behaviour compared to diffuse MPM there is no major series published demonstrating results of surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18164622&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of malignant pleural mesothelioma (MPM) remains disappointing, although recent reports suggest that multimodality therapy including surgery may provide a significant survival benefit. […] The aims of this single institution study were: to investigate clinicopathologic characteristics and potential prognostic factors in MPM patients, and to ascertain whether surgery followed by adjuvant therapy had an independent prognostic role. […] Twenty-seven patients (6.8%) underwent surgical resection (extrapleural pneumonectomy 15, pleurectomy/decortication 12), followed by adjuvant therapy. […] Multimodality therapy including surgery yielded a median survival of 14.5 months and a 2-year survival rate of 29.6%. […] Using univariate analysis, age (p=0.009), chest pain (p=0.01), weight loss (p=0.001), performance status (p=0.0001), platelet count (p=0.008), histology (p=0.0001), macroscopic appearance of pleural surface (non-specific inflammation, tumor-like thickening, or nodules; p=0.0001), visceral pleura involvement (p=0.0001), degree of involvement of pleural cavity (less than or more than one third of the cavity; p=0.0001), and multimodality therapy (p&amp;lt;0.01) were found to be significant prognostic factors. […] At multivariate analysis, performance status, platelet count, histology, and degree of involvement of pleural cavity remained independently associated with survival, whereas multimodality therapy failed to enter the model. […] Within the confines of this retrospective study and the small number of patients undergoing multimodality therapy, the role of surgery in the treatment of MPM remains unclear. […] Further investigation is warranted to determine the optimal treatment strategy in this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18166941&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These advances create real hope for improvement, but also many interrogations since no standard treatment protocol has been clearly identified.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18167128&#34; target=&#34;_blank&#34;&gt;Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Protease involvement in mesothelin cleavage from the cellular surface was investigated by treatment of MPM cells with GM6001, a broad-spectrum MMP- and ADAM-family inhibitor. […] GM6001 treatment significantly impaired SMRP production by MPM cell lines, in favor of an enzymatic-mediated shedding process.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18188517&#34; target=&#34;_blank&#34;&gt;Helical tomotherapy. Experiences of the first 150 patients in Heidelberg.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mean age was 60 years with a minimum of 30 years and a maximum of 85 years. 79 of these patients received radiotherapy as a part of multimodal treatment pre- or postoperatively, 17 patients received treatment as a combined radiochemotherapy. 76% were treated with curative intent. […] A pretreatment MV-CT scan was performed in 98.2% of the 3,026 fractions applied. […] Mean time on table was 24.8 min for the mentioned tumor entities with fractionated radiation, mean treatment time 10.7 min. […] Image guidance with MV-CT allowed daily position correction and safe and precise treatment application. […] This technique allows precise intensity-modulated radiotherapy (IMRT) in standard cases and offers new treatment options in a huge variety of difficult cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18195605&#34; target=&#34;_blank&#34;&gt;Anesthetic management of patients undergoing extrapleural pneumonectomy for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prominent among the developing multimodal treatment options is the combination of extrapleural pneumonectomy with intraoperative intracavitary hyperthermic chemotherapy. […] Included are the anesthetic implications of intraoperative intracavitary hyperthermic chemotherapy in combination with extrapleural pneumonectomy - an emerging therapeutic option in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18207597&#34; target=&#34;_blank&#34;&gt;Evaluating target coverage and normal tissue sparing in the adjuvant radiotherapy of malignant pleural mesothelioma: helical tomotherapy compared with step-and-shoot IMRT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the potential of helical tomotherapy in the adjuvant treatment of malignant pleural mesothelioma and compare target homogeneity, conformity and normal tissue dose with step-and-shoot intensity-modulated radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18223309&#34; target=&#34;_blank&#34;&gt;Xanthomatous pleuritis mimicking mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our patient quickly recovered with steroid therapy and is without recurrence 18 months later.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18227828&#34; target=&#34;_blank&#34;&gt;Advances in the systemic therapy of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemotherapy is the mainstay of treatment, yet sufficiently robust evidence to substantiate the current standard of care has emerged only in the past 5 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18230573&#34; target=&#34;_blank&#34;&gt;[Environmental cancer: malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Significant advances are observed in the pathologic diagnosis, the staging, the knowledge of the mesothelial carcinogenesis, the identification of biological markers with potential interest in diagnosis or in treatment. […] Active and multidisciplinary therapeutic strategies are currently evaluated and the concept of multimodality treatment includes new effective chemotherapies improving survival and quality of life, modern modalities of radiotherapy and pleuropneumonectomy. […] This advances create hopes and interrogations because it is not currently know whether multimodality treatment will be the standard in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18235408&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma: impact of the staging for the therapeutic strategy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Realistic improvement has been recently done for the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18237355&#34; target=&#34;_blank&#34;&gt;Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Findings from the largest randomized phase III trial in patients with unresectable malignant pleural mesothelioma (EMPHACIS study; n = 448) were used to examine the cost-effectiveness of pemetrexed plus cisplatin therapy versus cisplatin monotherapy in patients with the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18248818&#34; target=&#34;_blank&#34;&gt;PTEN expression is a strong predictor of survival in mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a highly aggressive tumour with poor prognosis and limited response to therapy. […] The frequent loss of expression of the tumour suppressor gene PTEN suggests involvement of the PI3K-AKT/protein kinase B (PKB) pathway in MPMs, which may be relevant for future mesothelioma treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18262369&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, treatment-related pulmonary toxicity remains a significant concern.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18266129&#34; target=&#34;_blank&#34;&gt;Phase-contrast microscopy studies of early cisplatin-induced morphological changes of malignant mesothelioma cells and the correspondence to induced apoptosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cisplatin treatment efficacy of malignant pleural mesothelioma (MPM) is aggravated by resistance and adverse effects.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18278371&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the cases studied, an integrated multidisciplinary approach was used, and a highly complex hospital infrastructure was available for the diagnosis and treatment of MPM, as recommended in the literature.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18279069&#34; target=&#34;_blank&#34;&gt;Current concepts in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options for MPM remain limited and no consensus exists at this time. […] Multimodality therapy that combines surgery, chemotherapy and radiation offers the best chance for long-term survival in select patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18286536&#34; target=&#34;_blank&#34;&gt;Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed-cisplatin chemotherapy is the standard of care in the first-line treatment of unresectable malignant pleural mesothelioma (MPM). […] Second-line cytotoxic therapy is considered for a growing group of patients, but the optimal treatment has not been defined to date. […] Treatment was repeated for a maximum of 6 cycles or until progression or unacceptable toxicity. […] A partial response was observed in 3 patients (10%; 95% confidence interval [CI], 2.1-26.5%), and 10 patients (33.3%; 95% CI, 17.3-52.8%) had stable disease after treatment. […] The role of second-line treatment in MPM needs to be evaluated in prospective trials in large series of patients who are stratified according to previous treatment and prognostic factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18298333&#34; target=&#34;_blank&#34;&gt;Intracavitary radioimmunotherapy to treat solid tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radioimmunotherapy (RIT) potentially is an attractive treatment for radiosensitive early-stage solid tumors and as an adjuvant to cytoreductive surgery. […] We reviewed the results of locally applied radiolabeled monoclonal antibodies for the treatment of solid tumors. […] In studies that included patients with small-volume disease, adjuvant RIT in ovarian cancer and glioma showed to be at least as effective as standard therapy. […] Moreover, in patients with malignant pleural mesothelioma or malignant pleural effusion, RIT may play a role in the palliative treatment. […] The future of RIT may, therefore, not only be in the inclusion in contemporary multimodality treatment, but also in the expansion to palliative treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18298385&#34; target=&#34;_blank&#34;&gt;Biological characteristics of cancers involving the serosal cavities.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Unlike the majority of solid tumors, particularly at the primary site, cancer cells in effusions are not amenable to surgical removal and failure in their eradication is one of the main causes of treatment failure. […] The findings presented in this review underscore the need to take into consideration the unique biology of cancer cells in effusions if patient-tailored molecular therapy is to become a successful treatment modality in these malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18304688&#34; target=&#34;_blank&#34;&gt;Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In malignant pleural mesothelioma (MPM) patients, local dissemination (LD) of the tumor is frequently observed at the sites of intervention where diagnosis/treatment are performed. […] Of the 212 patients, 29 received supportive therapy, 157 received chemotherapy and 26 received multi-modal therapy. […] The most suitable candidate groups for PR are patients receiving supportive therapy, thoracotomy without multi-modal therapy or patients with sarcomatous and mixed cell type tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18304902&#34; target=&#34;_blank&#34;&gt;[New diagnostic markers for malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis of this tumor is poor and most of the patients are diagnosed late in the disease’s course when curative treatment is no more an option. […] The authors reviewed recent data concerning the utility of these two molecules in the diagnosis and the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18322411&#34; target=&#34;_blank&#34;&gt;Characterization of human mesothelioma cell lines as tumor models for suicide gene therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Furthermore, the efficacy of a potential suicide gene therapy using an rAAV2 suicide vector-transduced MPM cell line was determined in a proof-of-feasibility in vivo experiment. […] The characterized cell lines described here may serve as a model for in vitro and in vivo preclinical gene therapy for the treatment of MPM using rAAV2 suicide vectors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18329481&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Significant survival differences were seen for American Joint Committee on Cancer stages 1 to 4 (P &amp;lt; .001), epithelioid versus non-epithelioid histology (P &amp;lt; .001), extrapleural pneumonectomy versus pleurectomy/decortication (P &amp;lt; .001), multimodality therapy versus surgery alone (P &amp;lt; .001), and gender (P &amp;lt; .001). […] Multivariate analysis demonstrated a hazard rate of 1.4 for extrapleural pneumonectomy (P &amp;lt; .001) controlling for stage, histology, gender, and multimodality therapy. […] At present, the choice of resection should be tailored to the extent of disease, patient comorbidities, and type of multimodality therapy planned.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18336278&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment-resistant phenotype of mesothelioma is largely due to its ability to escape from the highly regulated apoptotic machinery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18338545&#34; target=&#34;_blank&#34;&gt;[Malignant pleural effusion].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical treatment has palliative purposes and finalized to reduction symptoms and to improve quality of life. […] Pleural aspiration is the first choice treatment but the recurrence rate equals to 100% within 1 month.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18338546&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: utility of 18 F-FDG PET.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because of the implications for management and therapy, it is important to assess the accurate staging. […] In particular it has been shown to be useful in the evaluation of the extent of pleural disease, in the establishment of lymph node involvement, in the evaluation of tumour invasion into the lung and thoracic wall, in the diagnosis of extrathoracic metastases, in the assessment of the response to treatment, and in planning radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1834113&#34; target=&#34;_blank&#34;&gt;Regional pharmacokinetic selectivity of intrapleural cisplatin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The intrapleural treatment did not produce haemotoxicity and the emetic toxicity was lower compared with that observed in patients receiving cisplatin intravenously.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-11-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18347916&#34; target=&#34;_blank&#34;&gt;Erionite series minerals: mineralogical and carcinogenic properties.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Consequently, understanding the exact mineralogical properties will help determination of the true carcinogenic mechanism(s) of the mineral for prevention and possibly treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18355497&#34; target=&#34;_blank&#34;&gt;Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A total of 44 patients underwent induction chemotherapy with cisplatin-based therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18358737&#34; target=&#34;_blank&#34;&gt;Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed produced similar treatment effects in older and younger patients, and appeared to be well tolerated in the elderly population. […] This analysis was limited by the pooling of different disease types and the lack of uniform treatment regimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18360826&#34; target=&#34;_blank&#34;&gt;Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here we describe the therapeutic effects of a novel combination therapy, Bcl-xL antisense oligonucleotide (ASO 15999) and cisplatin, on mesothelioma cell lines in vitro and in vivo; in addition, efficacy of ASO 15999 in decreasing tumor load as well as its effect on survival in an animal model. […] Local spread and development of IP xenografts was reduced with treatments of ASO alone, and survival of mice afflicted with these xenografts was prolonged after administration of ASO alone and ASO 15999 + cisplatin combination therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-06-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18362050&#34; target=&#34;_blank&#34;&gt;alpha-Toxin of Staphylococcus aureus overcomes acquired cisplatin-resistance in malignant mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The toxin/drug combination should be tested for cisplatin-resistant mesothelioma treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18364248&#34; target=&#34;_blank&#34;&gt;Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Once-daily oral treatment with vandetanib inhibited tumor angiogenesis, and reduced significantly the growth of thoracic tumors and the production of pleural effusions, resulting in the prolonged survival of mice in EHMES-10 orthograft model.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18369634&#34; target=&#34;_blank&#34;&gt;Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate and compare early therapy response according to RECIST (response evaluation criteria in solid tumours) and modified RECIST criteria using MRI techniques in patients with malignant pleural mesothelioma (MPM) in comparison with CT. […] Early therapy response was evaluated after 9 weeks [three of six chemotherapy (CHT)] cycles. […] Additionally patients were examined before chemotherapy, 4 weeks after early therapy response evaluation and after six cycles to evaluate diagnostic follow-up. […] Twenty-eight patients showed partial response, 12 patients stable disease and 10 patients progressive disease at early therapy response evaluation. […] Modified RECIST criteria especially in combination with high-resolution MRI is a very accurate and reproducible technique to correctly evaluate early therapy response in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-12-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18375898&#34; target=&#34;_blank&#34;&gt;Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Secondary end points included response rate, progression-free survival (PFS), time to tumor progression (TTP), time to treatment failure (TTF), and toxicity. […] Cox regression modeling suggested a trending survival benefit for patients who responded to first-line therapy. […] Postdiscontinuation therapy was initiated earlier for BSC than P+BSC patients (median time to initiation, 4.3 v 15.7 months, respectively; log-rank P &amp;lt; .0001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18381361&#34; target=&#34;_blank&#34;&gt;The role of muscle flap in preventing bronchus stump insufficiency after pneumonectomy for malignant pleural mesothelioma in high-risk patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thirty patients were suitable for surgery and thus received a multimodal treatment with neo-adjuvant chemotherapy using Cisplatin and Gemcitabin (Gemzar), EPP followed by 54 Gray (Gy) adjuvant radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18381869&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural effusion associated with trapped lung syndrome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An alternative treatment using a pleural catheter has been advocated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18392851&#34; target=&#34;_blank&#34;&gt;Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To identify possible candidates for EGFR tyrosine kinase in inhibitor therapy, the information on the EGFR gene status may be valuable.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18398658&#34; target=&#34;_blank&#34;&gt;Surgical treatment in the management of malignant pleural mesothelioma: a single institution’s experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To achieve a microscopically radical resection, combination with other treatment modalities is mandatory. […] In highly selected patients local control can be achieved with combination therapy but is accompanied by a high rate of (surgical) complications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18407510&#34; target=&#34;_blank&#34;&gt;Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy which was initially performed as a stand-alone treatment in patients with resectable disease is now currently almost uniformly applied as part of a multi-modal approach. […] We therefore analysed our experience with extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. […] Extrapleural pneumonectomy as part of a multi-modality treatment regimen is a good treatment option for selected patients with malignant pleural mesothelioma. […] The long-term results of this limited series compare favourably to non-surgical treatment regimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18409713&#34; target=&#34;_blank&#34;&gt;[Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Improved detection methods for diagnosis of asymptomatic malignant pleural mesothelioma (MPM) are essential for an early and reliable detection and treatment of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18409715&#34; target=&#34;_blank&#34;&gt;[Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural Malignant Mesothelioma (MM) is a highly aggressive neoplasm with a poor survival rate, hard diagnosis and treatment. […] The analysis of SMRP levels in these patients suggests that it may be a useful marker for monitoring the response to treatment. […] In fact, it was observed that SMRP increases in patients who did not respond to therapy, it tends to remain stable when therapies results into a clinical stabilization, while it decreases after surgical procedure and in case of clinical improvement.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18423312&#34; target=&#34;_blank&#34;&gt;Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because MM frequently demonstrates marked angiogenesis, it may be responsive to antiangiogenic therapy, but effective methods for selecting and monitoring of patients are further needed. […] Nineteen patients diagnosed with MM were enrolled and DCE-MRI was performed before antiangiogenic treatment. […] This multimodal characterization may be useful in selecting possible tumor subtypes that would benefit from antiangiogenic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18433927&#34; target=&#34;_blank&#34;&gt;Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In patients with malignant pleural mesothelioma undergoing a multimodality therapy, treatment toxicity may outweigh the benefit of progression-free survival. […] The subjective experience across different treatment phases is an important clinical outcome. […] Our findings suggest that the two measures are not interchangeable: the RSCL is to favor when mainly information related to the course of disease- and treatment is of interest.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18434338&#34; target=&#34;_blank&#34;&gt;Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed in combination with cisplatin (Pem/Cis) is used globally for the treatment of malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18443531&#34; target=&#34;_blank&#34;&gt;[Video-assisted thoracoscopic surgery in diagnostic and treatment of non-operable malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma is characterized by aggressive follow-up, difficult diagnosis and treatment fatal issue. […] In one side the restricted possibility for operative treatment and the other side the resistance of tumors for chemotherapy are the mean reasons for bad results in patients with malignant pleural mesothelioma. […] Because of the chemotherapy is insufficient, surgical treatment (radical or not) in huge number of cases help improvement of patient’s condition. […] Surgical treatment is decisive for diagnosis and treatment of malignant pleural mesothelioma even in advanced cases and have evident positive effects. […] VATS surgery is modern method for diagnosis and treatment and if it necessary we can continue by conventional operation for definitive treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18449002&#34; target=&#34;_blank&#34;&gt;Trimodality treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality treatment has achieved significant success in local control and treatment of early-stage malignant pleural mesothelioma patients. […] We have instituted a trimodality treatment protocol consisting of extrapleural pneumonectomy, adjuvant high-dose (54 Gy) hemithoracic irradiation, and platin-based chemotherapy in a multi-institutional setting. […] Trimodality treatment in malignant pleural mesothelioma seems to prolong survival in patients without lymph node metastasis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18473795&#34; target=&#34;_blank&#34;&gt;Molecular targets and targeted therapies for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The development of effective drug regimens against mesothelioma has proven extremely difficult and a standard first-line treatment for patients with unresectable tumors has not been established until recently.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18474335&#34; target=&#34;_blank&#34;&gt;MR imaging of benign and malignant pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Knowledge of MR imaging appearance of pleural diseases, including pleural effusions and empyema, benign and malignant pleural tumors, and especially mesothelioma, helps guide treatment decisions and surgical planning.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18486273&#34; target=&#34;_blank&#34;&gt;The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options remain limited and the outcome in relapsed disease is poor warranting new therapeutic options. […] Weekly vinorelbine appeared to have a reasonable response rate with an acceptable toxicity profile in the second-line treatment of MPM. […] Its use should be prospectively evaluated in a randomised trial in the first or second-line therapy of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18486741&#34; target=&#34;_blank&#34;&gt;Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is almost always fatal, and few treatment options are available. […] We investigated whether the addition of chemotherapy to ASC improved survival and quality of life. 409 patients with malignant pleural mesothelioma, from 76 centres in the UK and two in Australia, were randomly assigned to ASC alone (treatment could include steroids, analgesic drugs, bronchodilators, palliative radiotherapy [n=136]); to ASC plus MVP (four cycles of mitomycin 6 mg/m2, vinblastine 6 mg/m2, and cisplatin 50 mg/m2 every 3 weeks [n=137]); or to ASC plus vinorelbine (one injection of vinorelbine 30 mg/m2 every week for 12 weeks [n=136]).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18520115&#34; target=&#34;_blank&#34;&gt;Pulmonary paragonimiasis with coincidental malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 72-year-old man patient was referred to our institution for evaluation and treatment of right pleural effusion. […] Although Praziquantel, a highly effective agent for the treatment of lung flukes was repeatedly administered, the pleural effusion did not subside and the patient’s condition gradually deteriorated until his death due to circulatory insufficiency.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18520263&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma 2008.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality treatment including neoadjuvant chemotherapy in selected individuals followed by extrapleural pneumonectomy and radiation has been studied in recent trials for its effects on disease free and overall survival This review provides a general overview of malignant mesothelioma with a summary of the most significant articles from within the past year as well as from the past. […] Novel therapies including intrapleural chemotherapy, photodynamic therapy and hyperthermic perfusion have also been used with some success.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18520267&#34; target=&#34;_blank&#34;&gt;Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a uniformly fatal disease and active supportive care, minimizing patient morbidity, remains the accepted standard treatment. […] This strategy would optimize patient care and minimize hospital visits, but allow prompt instigation of treatment if symptoms develop.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18523361&#34; target=&#34;_blank&#34;&gt;Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with lipoplatin-gemcitabine was decided on in November 2006, and the patient showed important improvement in the clinical status and peritoneal effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18538178&#34; target=&#34;_blank&#34;&gt;Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18542071&#34; target=&#34;_blank&#34;&gt;Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, pooled data from two phase II trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18542078&#34; target=&#34;_blank&#34;&gt;Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment was vinorelbine 25 mg m(-2) i.v. weekly and cisplatin 100 mg m(-2) i.v. every 4 weeks with hydration and standard prophylactic antiemetic treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18543326&#34; target=&#34;_blank&#34;&gt;Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment continued until disease progression or development of significant toxicity. […] Twenty-four eligible patients initiated therapy with erlotinib and bevacizumab between February 2004 and October 2006. […] There were no complete or partial responses, although 12 patients achieved stable disease for at least 2 cycles of treatment. […] There were no treatment-related deaths, intracranial bleeding, or hemoptysis. […] This study demonstrates the feasibility of conducting trials in mesothelioma patients who have failed first-line therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18559536&#34; target=&#34;_blank&#34;&gt;Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Oncovirotherapy (i.e., the use of replication-competent virus for cancer treatment) is currently explored in clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18560222&#34; target=&#34;_blank&#34;&gt;Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed, a multi-targeted antifolate (MTA), is a promising agent in the treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC). […] With the aim of finding an optimal schedule for the combination therapy of MTA and gemcitabine (GEM), we investigated their interaction against an MPM cell line, 211H, and the NSCLC cell lines A549 and H1299. […] S phase accumulation by MTA treatment partly supported these results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18560526&#34; target=&#34;_blank&#34;&gt;Asbestos burden predicts survival in pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment strategy is determined in part using known prognostic factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18563687&#34; target=&#34;_blank&#34;&gt;[Multimodal therapy for malignant pleural mesothelioma including extrapleural pneumonectomy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodal therapy including neoadjuvant chemotherapy with subsequent extrapleural pneumonectomy and postoperative radiotherapy has been shown to improve the survival of patients with malignant pleural mesothelioma (MPM) if they are selected carefully. […] Careful patient selection is required in order to administer aggressive multimodal therapy only to patients who will benefit from such a treatment. […] Currently, neoadjuvant chemotherapy with pemetrexed and cisplatin followed by extrapleural pneumonectomy and postoperative radiotherapy is claimed to afford the best treatment results. […] Multimodal therapy of malignant pleural mesothelioma including extrapleural pneumonectomy should only be performed in specialised centres for thoracic surgery where uncomplicated interdisciplinary communication is the rule and which provide the required expertise in patient selection, operative technique and postoperative care.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18563688&#34; target=&#34;_blank&#34;&gt;[Chemotherapy of malignant pleural mesothelioma: have we made any progress?].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Besides first-line therapy, there are also data to support the efficacy of chemotherapy in pretreated patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18577247&#34; target=&#34;_blank&#34;&gt;Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The therapy was able to arrest the effusion in all patients for variable remission times: one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and one cat died due to progressive neoplastic growth after six months, when the patient developed a mesothelial cuirass.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18577894&#34; target=&#34;_blank&#34;&gt;Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite extensive clinical research, no effective therapy for advanced malignant pleural mesothelioma has been established. […] All patients, however, received perfusion treatment. […] No patient morbidity was associated with the perfusion treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18585112&#34; target=&#34;_blank&#34;&gt;Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The survival of patients with malignant pleural mesothelioma (MPM) who do not seek treatment ranges from 4 to 12 months. […] Between 1992 and 2000, 64 patients underwent pleurectomy as a palliative treatment for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18593991&#34; target=&#34;_blank&#34;&gt;Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognostic significance of telomere maintenance mechanisms was analyzed by Cox regression in the overall series and in a subset of 29 patients who underwent a uniform treatment regimen consisting of cytoreductive surgery and hyperthermic i.p. chemotherapy. […] These results held true also in the subset of patients submitted to uniform treatment with cytoreductive surgery and hyperthermic i.p. chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18605768&#34; target=&#34;_blank&#34;&gt;Primary pleural neoplasia: entities other than diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To review primary pleural neoplasms other than diffuse malignant mesothelioma, to better ensure correct diagnosis and optimal assessment of prognosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18607677&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: current status and perspective in Japan and the world.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this context, combination therapy with surgery plus chemotherapy and/or radiotherapy is currently considered the standard treatment for patients with respectable MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18614551&#34; target=&#34;_blank&#34;&gt;Incidence of atrial fibrillation after extrapleural pneumonectomy vs. pleurectomy in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy (EPP) and pleurectomy are the surgical procedures for the treatment of pleural mesothelioma. […] There were no significant differences between the two treatment groups for gender, age, side of affected lung, preoperative heart rate, history of beta-blocker use, coronary heart disease, and chronic obstructive pulmonary disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18633241&#34; target=&#34;_blank&#34;&gt;[Pemetrexed].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is approved in the United States and a number of European Union countries for use in the treatment of mesothelioma, and the second-line treatment of advanced NSCLC. […] However, in Japan, pemetrexed was approved for use only in combination with cisplatin in the treatment of mesothelioma in January 2007. […] Treatment with pemetrexed plus cisplatin and vitamin supplementation, resulted in superior survival time, time to progression, and response rates compared with treatment with cisplatin alone. […] In addition, in a phase III trial of pemetrexed versus docetaxel in patients with NSCLC previously treated with chemotherapy, treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects including grade 3 or 4 neutropenia , neutropenic fever, and alopecia, compared with docetaxel. […] Therefore, pemetrexed should be considered a standard treatment option for second-line NSCLC in US and most of EU.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18640301&#34; target=&#34;_blank&#34;&gt;A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tetrathiomolybdate should be evaluated for efficacy in combination with standard malignant pleural mesothelioma regimens, as well as for postsurgical maintenance therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18640302&#34; target=&#34;_blank&#34;&gt;Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The first 37 patients (group I) underwent combined modality treatment without preoperative mediastinoscopy. […] The second group included 16 patients (group II) with pretreatment mediastinoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18640937&#34; target=&#34;_blank&#34;&gt;Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed in combination with cisplatin is approved for the treatment of pleural mesothelioma and is active in malignant peritoneal mesothelioma (MPeM). […] Treatment consisted of gemcitabine 1,250 mg/m(2) on days 1 and 8, and pemetrexed 500 mg/m(2) on day 8, administered immediately before gemcitabine. […] Treatment was repeated every 21 days for six cycles or until disease progression. […] One patient death was attributed to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18653257&#34; target=&#34;_blank&#34;&gt;A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two patients, one with malignant pleural mesothelioma and one with a malignant short spindle cell tumor, received boron neutron capture therapy (BNCT).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1865600&#34; target=&#34;_blank&#34;&gt;[A case of malignant pleural mesothelioma presenting as pneumothorax].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After treatment of pneumothorax, pleural effusion appeared to decrease on chest X-ray.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18662397&#34; target=&#34;_blank&#34;&gt;Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor for which no effective therapy exists despite the discovery of many possible molecular and genetic targets.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18699838&#34; target=&#34;_blank&#34;&gt;Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous reaction, which in most cases, is related to medication. […] Pemetrexed is an antifolate drug, approved for treatment of metastatic non-small-cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18716551&#34; target=&#34;_blank&#34;&gt;Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After failure of medical therapy, the patient underwent LHIPEC with Cisplatin 25 mg/m/L and Doxorubicin 7 mg/m/L. […] LHIPEC could be a good therapeutic option to palliate malignant ascites from mesothelioma in cases not eligible for a radical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18722110&#34; target=&#34;_blank&#34;&gt;Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Human malignant pleural mesothelioma (MPM) is a dreadful disease and there is still no standard therapy available for a consistent therapeutic approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18728709&#34; target=&#34;_blank&#34;&gt;Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Until recently, chemotherapy had not been shown to be effective in the treatment of this slowly progressive disease. […] Ongoing research will further define the role of pemetrexed plus cisplatin in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18754710&#34; target=&#34;_blank&#34;&gt;Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In an orthotopic model, GLV-1h68 effectively prevented development of cachexia and tumor-related morbidity, reduced tumor burden, and cured MPM in both early and late treatment groups. […] These promising results warrant clinical investigation of GLV-1h68 as a novel agent in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18757427&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Gene therapy and virotherapy are one of the approaches used to treat malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18758312&#34; target=&#34;_blank&#34;&gt;Recent advances in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In patients with limited, resectable disease, surgical therapy with extrapleural pneumonectomy or pleurectomy is recommended, although, it is unclear which approach is superior. […] Vorinostat, a small molecule inhibitor of HDAC, which targets select members of class I and II HDACs, has shown early evidence of activity and is currently being evaluated in a randomized study for patients who progress with standard therapy for advanced mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18758965&#34; target=&#34;_blank&#34;&gt;Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Once the diagnosis is made, there is no universally accepted standard of care and treatment decisions are strongly influenced by physician bias. […] The choice of operation, extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D), depends on disease stage, pulmonary function, philosophy of the treating physician, and type of planned adjuvant therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1876594&#34; target=&#34;_blank&#34;&gt;[Therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radical surgical treatment results in 2-year survival in 10-37%. […] As pleuramesotheliomas are often resistant to radiotherapy, tumour remissions under this treatment are extremely rare. […] However, this therapy has a palliative analgesic benefit.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18765998&#34; target=&#34;_blank&#34;&gt;Protein kinase C beta in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of MPM cell lines with enzastaurin revealed an IC50 of 5 micromol/l, and strong synergism was observed when combined with cisplatin. […] Wound healing assay revealed that treatment of H2461 cells with enzastaurin reduced migration by 59.2%. […] Enzastaurin treatment led to disruption of F-actin architecture.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18769031&#34; target=&#34;_blank&#34;&gt;Acquisition of cisplatin-resistance in malignant mesothelioma cells abrogates Na+,K+,2Cl(-)-cotransport activity and cisplatin-induced early membrane blebbing.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Resistance mechanisms are important limiting factors in the treatment of solid malignancies with cis-diamminedichloroplatinum(II) (cisplatin).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18770063&#34; target=&#34;_blank&#34;&gt;Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
They were treated with electron external beam radiation therapy (21 Gy in 3 fractions over 1 week), directed to the surgical pathway after the invasive procedure. […] After completion of radiation treatment, 20 of 32 patients (63%) underwent chemotherapy. […] After a mean follow-up of 13.6 months (range 3-41) from the end of radiation therapy, no patient had tumour progression in the treated area. […] The treatment was well tolerated, as only erythema grade I (Radiation Therapy Oncology Group, RTOG, scale) was noted in 11 patients. […] The present study shows the efficacy and safety of local radiotherapy in preventing malignant seeding after thoracoscopy in patients with pleural mesothelioma although larger prospective trials are probably still needed to validate this treatment approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18775081&#34; target=&#34;_blank&#34;&gt;Clinical consequences of asbestos-related diffuse pleural thickening: A review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment is primarily supportive.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18787841&#34; target=&#34;_blank&#34;&gt;Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor for which no effective therapy exists despite the discovery of many possible molecular and genetic targets.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18791416&#34; target=&#34;_blank&#34;&gt;Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT and MRI were not able to detect distant metastases in 2 patients, which changed therapy (operable vs. inoperable).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18792097&#34; target=&#34;_blank&#34;&gt;Survival of pleural malignant mesothelioma in Italy: a population-based study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Univariate (Kaplan-Meier) and multivariate (Cox proportional hazards regression) analyses of survival were carried out according to selected individual characteristics, including limited information on treatment in a subset of 578 cases. […] Treatment was not associated with a statistically significant improvement in survival. […] Results regarding the effect of treatment were disappointing but may be useful to assess the future impact, at the population level, of recently introduced therapies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18792099&#34; target=&#34;_blank&#34;&gt;Survival of peritoneal malignant mesothelioma in Italy: a population-based study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Univariate (Kaplan-Meier) and multivariate (Cox proportional hazards regression) analyses of survival were performed according to selected individual characteristics, including limited treatment information in a subset of 194 cases. […] The effect of treatment was positive but not statistically significant. […] Treatment was not associated with a statistically significant improvement in survival, but our study included cases first diagnosed before the introduction of the most recent therapeutic approaches.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18827603&#34; target=&#34;_blank&#34;&gt;Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These results suggest that Hsp90 is strongly associated with the growth and survival of MM and that inhibition of Hsp90 may have therapeutic potential in the treatment of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18829506&#34; target=&#34;_blank&#34;&gt;Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The feasibility and yield of EUS-FNA in MLN staging were prospectively analyzed in patients with presumed early-stage MPM considered for multimodality therapy. […] EUS-FNA is feasible and sensitive for MLN staging in patients with MPM who are candidate for multimodality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18839036&#34; target=&#34;_blank&#34;&gt;Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment continued until disease progression or intolerable drug toxicity. […] Neutropenia, thrombocytopenia and anemia were the most severe (Grade 3 or 4) toxicities recorded during therapy and were reported in (14%), (9.5%), and (9.5%), respectively. […] The combination of gemcitabine and carboplatin is a safe and tolerable treatment with reasonable response rate, OS, and PFS compared with the historical phase II single agents and combined chemotherapy studies in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18841478&#34; target=&#34;_blank&#34;&gt;Peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current treatment options are unsatisfactory, and new approaches are needed. […] Recent publications have reported improved survival with an intensive loco-regional treatment strategy including cytoreductive surgery (CRS) along with hyperthermic intraperitoneal chemotherapy (HIPEC). […] We have noted at our institution prolonged survival in selected patients after intensive multimodality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18854268&#34; target=&#34;_blank&#34;&gt;Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Postoperative treatment was associated with DSS and with recurrence-free survival. […] Our study confirms that in many cases, final histopathologic typing of MPM is influenced by complete surgical resection and that initial biopsy should be carefully weighed in the treatment stratification.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18854270&#34; target=&#34;_blank&#34;&gt;A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The combination of these positive and negative markers may contribute to accurate diagnosis and adequate therapy for PM and ovarian SC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1889283&#34; target=&#34;_blank&#34;&gt;Tranexamic acid treatment of hemothorax in two patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Initiation of treatment with this potent anti-fibrinolytic drug resulted in rapid reduction of bleeding and of transfusion requirements.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-10-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18922905&#34; target=&#34;_blank&#34;&gt;Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
REIC/Dickkopf-3 (Dkk-3), a tumor suppressor gene, has been investigated in gene therapy studies. […] Thus, gene therapy with REIC/Dkk-3 may be a promising therapeutic tool for MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18926592&#34; target=&#34;_blank&#34;&gt;Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The endpoints were disease control rate, time to treatment failure, clinical improvement rate and overall survival. […] The median time to treatment failure was 4.6 months (95% CI 3.4-5.8) and median overall survival was 14 months (95% CI 9.5-18.5). […] The combination of carboplatin and pemetrexed may be a viable option in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18949431&#34; target=&#34;_blank&#34;&gt;The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with 5-Aza-dC restored BMP3b expression in methylated cell lines.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18958556&#34; target=&#34;_blank&#34;&gt;Diffuse malignant pleural mesothelioma: a multi-institutional clinicopathological study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, we performed a multiinstitutional study to evaluate the current status of diagnosis and treatment in Japan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18971844&#34; target=&#34;_blank&#34;&gt;[Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most of the patients are diagnosed late in the course of the disease when radical treatment is no more an option.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18971845&#34; target=&#34;_blank&#34;&gt;[Other thoracic cancers. Mesothelioma: treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Available therapeutics have restricted efficacy. […] Pleuro-pneumonectomy is the only treatment with curative intent but it could be offered to a limited and well selected group of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18978568&#34; target=&#34;_blank&#34;&gt;Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In multivariate analysis, histology, therapy, and SMRP were shown to be independent prognostic factors in all MPM patients (hazard ratio for SMRP: 1.96; p = 0.025). […] Nevertheless, SMRP might be a useful measure in treatment and monitoring of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18978569&#34; target=&#34;_blank&#34;&gt;Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma has a poor prognosis and there is limited effect of treatment. […] Some patients had their responses 4 to 6 months after last treatment. […] The treatment yields good results with a high number of responses and long survival, and a low toxicity. […] The long survival of the epitheloid subgroup with good prognostic factors is as good as or even better than some studies on “radical” surgery or multimodal treatment, underlining the need of randomized studies to evaluate such treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1898706&#34; target=&#34;_blank&#34;&gt;A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Retreatment with FM after chemotherapy had been stopped for 20 months yielded another continuing response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-02-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19004520&#34; target=&#34;_blank&#34;&gt;Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cisplatin plus pemetrexed has been standard systemic therapy for malignant pleural mesothelioma (MPM) since the landmark randomized trial reported in 2003. […] The clinical records of individuals referred to the BC Cancer Agency were reviewed, and those treated with a platinum analog plus gemcitabine or pemetrexed as first-line therapy were included in survival analyses.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19014568&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the tunica vaginalis of the testis without exposure to asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical orchidectomy remains the modality of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19020484&#34; target=&#34;_blank&#34;&gt;Compensator-based intensity-modulated radiation therapy for malignant pleural mesothelioma post extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present work investigated the potential of compensator-based intensity-modulated radiation therapy (CB-IMRT) as an alternative to multileaf collimator (MLC)-based intensity-modulated radiation therapy (IMRT) to treat malignant pleural mesothelioma (MPM) post extrapleural pneumonectomy. […] Treatment plans for 4 right-sided and 1 left-sided MPM post-surgery cases were generated using a commercial treatment planning system, XIO/CMS (Computerized Medical Systems, St. […] Post surgery, CB-IMRT for MPM is a feasible IMRT technique for treatment with a single isocenter.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19035624&#34; target=&#34;_blank&#34;&gt;Biomarkers for malignant pleural mesothelioma: current status.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Biomarkers would be helpful in managing three clinical aspects of MPM: early diagnosis, prognosis, and treatment outcome prediction.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19060016&#34; target=&#34;_blank&#34;&gt;Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is a highly aggressive tumour with poor prognosis and limited response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-06-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19082859&#34; target=&#34;_blank&#34;&gt;Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The issue of treatment failure has never been extensively addressed. […] The present study assessed the failure pattern, management, and outcome of progressive DMPM following comprehensive treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19088405&#34; target=&#34;_blank&#34;&gt;Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Experience of asbestos use and its adverse heath effects in developed countries such as Australia have resulted in development of expertise in the diagnosis and treatment of asbestos-related diseases as well as in screening and this can be used to help developing countries facing the issue of asbestos exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19088831&#34; target=&#34;_blank&#34;&gt;[Medical thoracoscopic talc pleurodesis for malignant pleural effusion: an analysis of 27 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the efficacy and safety of talc poudrage pleurodesis via semi-rigid medical thoracoscopy in the treatment of malignant pleural effusions, as well as the factors that may influence the outcomes. […] Medical thoracoscopic talc poudrage pleurodesis is a safe and effective method for the treatment of malignant pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19091133&#34; target=&#34;_blank&#34;&gt;Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Secondary endpoints included overall survival (OS), time to tumour progression (TTP), progression-free survival (PFS), time to treatment failure (TTF), and toxicity. […] The median overall survival (OS) was 71.7 weeks (30.6-243.3 weeks), whereas survival from the start of oxaliplatin/gemcitabine-treatment was 24.3 weeks (5.4-97.3 weeks). […] Partial response (PR) was observed in 2 patients (6.9%), stable disease (SD) for at least three courses of treatment in 11 patients (37.9%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19096314&#34; target=&#34;_blank&#34;&gt;Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A median of two cycles of therapy were administered. […] One patient died as a consequence of cardiac arrhythmia which was deemed ‘possibly’ related to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19118069&#34; target=&#34;_blank&#34;&gt;Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The established combination dose was identified before the addition of folic acid and vitamin B(12) to the treatment regimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19125709&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma treated in Clinic for Pulmonary Diseases and Tuberculosis “Podhrastovi” in ten-year period (from 1998 to 2007).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patients were analysed according to age, sex, histopathologic type of the tumour, cantonal distribution in Federation of Bosnia and Herzegovina and regimen of treatment. […] The therapy applied: chemotherapy (11-39,29%); radiotherapy (3-10,71%); chemotherapy + radiotherapy (4-14,29%); symptomatic therapy (10-35,71 %).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19131427&#34; target=&#34;_blank&#34;&gt;A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy. […] Secondary endpoints include treatment completion rate, adverse events, response rate by chemotherapy and 2-year overall and relapse-free survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19137122&#34; target=&#34;_blank&#34;&gt;Pemetrexed disodium for the treatment of NSCLC: an update.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Food and Drug Administration (FDA) initially for the treatment of malignant pleural mesothelioma, and in August 2004 for second-line treatment of non-small cell lung cancer (NSCLC). […] In September 2008, the FDA also approved pemetrexed and cisplatin as first-line therapy for NSCLC. […] Pemetrexed is also no longer recommended for treatment of NSCLC with squamous cell carcinoma histology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19142050&#34; target=&#34;_blank&#34;&gt;[Malignant pleural diseases: diagnosis and treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From 1999 to 2006, 169 patients underwent treatment in the Department of Thoracic Surgery and Oncology, Institute of Oncology, Vilnius University.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19151450&#34; target=&#34;_blank&#34;&gt;Malignant mesenterial mesothelioma in stroke patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although the result of treatment is very disappointing, the patient had to be treated optimally to increase quality of life.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19155997&#34; target=&#34;_blank&#34;&gt;Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All pathologic samples were from patients who underwent treatment with intrapleural preoperative interleukin-2 (18 x 10(6) IU/d for 3 days). […] These results suggest that tumor infiltrating tryptase mast cells, after interleukin-2 preoperative induction therapy, predict improved clinical outcome in patients with malignant pleural mesothelioma, and highlight the critical role of the local inflammatory response in mesothelioma cancer progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19162494&#34; target=&#34;_blank&#34;&gt;Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Animals were randomised into four treatment groups for intrapleural therapy: control (n=6), 500 microg cytosine phosphate guanosine oligodeoxynucleotide (CpG-ODN) (n=6), cisplatin-fibrin (n=6), cisplatin-fibrin+500 microg CpG (n=6). […] Treatment-related toxicity was monitored by measuring blood chemistry and complete blood count. […] Pro-inflammatory cytokines (Interferon-gamma (IFN-gamma), Interleukin-6 (IL-6), Interleukin-12 (IL-12)) were increased after treatment with cisplatin-fibrin+CpG in comparison to cisplatin-fibrin alone but differences were not statistically significant. […] No significant treatment-related toxicity was observed. […] Adjuvant treatment with chemotherapy or immuno-chemotherapy leads to significant reduction of mesothelioma recurrence after surgery in this rat MPM model.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-06-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19178995&#34; target=&#34;_blank&#34;&gt;Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with AG1024, an inhibitor of the IGF-1R pathway, significantly decreased cell proliferation and attenuated the phosphorylation of Akt and p44/42.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19192718&#34; target=&#34;_blank&#34;&gt;Gene therapy for malignant pleural mesothelioma: present and future.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical outcomes with the present treatment modalities are unsatisfactory and no effective prevention method has been reported. […] Gene therapy is a candidate for mesothelioma treatment because of its easy accessibility of a vector-mediated gene medicine into the intrapleural cavity. […] In this article, we review the current status of gene therapy and clinical trials targeting mesothelioma and address possible directions to improve the efficacy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19201924&#34; target=&#34;_blank&#34;&gt;Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We tested the hypothesis that this marker could also be useful for monitoring response to treatment. […] Serial measurements of SM were determined in 40 patients diagnosed with MPM and subjected to gene-transfer therapy using intrapleural infusion of an adenoviral vector expressing human IFN-beta or conventional treatment (mainly chemotherapy). […] In patients with baseline SM levels greater than 1 nM/L and disease progression after therapy, SM levels increased by 2.1 nM/L at two, 5.2 nM/L at four and 1.3 nM/L at 6 months. […] Patients who responded to treatment or were considered stable had an initial small decrease of SM followed by a return to baseline values after 6 months of follow-up. […] Increasing serum levels of SM were associated with disease progression and worse outcome, whereas stable or decreasing values suggested response to treatment. […] If confirmed in larger series, SM could be used to monitor patients with malignant pleural mesothelioma under treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19224855&#34; target=&#34;_blank&#34;&gt;Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We examined the results of trimodality therapy with cisplatin-based chemotherapy followed by extrapleural pneumonectomy (EPP) and adjuvant high-dose (50 to 60 Gy) hemithoracic radiation therapy for MPM. […] We conducted a retrospective review of all patients prospectively evaluated for trimodality therapy protocol between January 2001 and December 2007 in our institution. […] EPP was performed in 45 patients, and hemithoracic radiation therapy to at least 50 Gy was administered postoperatively to 30 patients. […] Completion of the trimodality therapy in the absence of mediastinal node involvement was associated with the best survival (median survival of 59 months v &amp;lt;or= 14 months in the remaining patients, P = .0003). […] Pathologic nodal status remained a significant predictor of poor survival despite completion of the trimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19233506&#34; target=&#34;_blank&#34;&gt;Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These results indicate that the two approaches act probably through different mechanisms and, thus, that DNMT1 silencing can be considered an effective alternative to Decitabine for cancer treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19236184&#34; target=&#34;_blank&#34;&gt;Chemotherapy of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although the outcome for patients remains poor, there has been definite progress in the systemic treatment of this disease within the past 5 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19247087&#34; target=&#34;_blank&#34;&gt;Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a key drug for the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1924981&#34; target=&#34;_blank&#34;&gt;[Remission of malignant pleural mesothelioma using high-dose cisplatin in monochemotherapy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Following a review of the literature the authors analyse the potential value of chemotherapy in this type of tumour whose treatment up to the present time has been particularly disappointing.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-11-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19251168&#34; target=&#34;_blank&#34;&gt;Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality therapy, including macroscopic complete resection, chemotherapy and/or radiotherapy, has improved survival relative to historical controls, but local recurrence remains problematic. […] Intracavitary chemotherapy (IC) can deliver higher doses of drug locally with less toxicity than corresponding systemic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19255316&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article will provide a comprehensive discussion of the latest developments in the treatment of MPM. […] We will provide an update of the major clinical trials that impact mesothelioma treatment in the resectable and unresectable settings, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. […] In addition, there are controversial issues, such as the role of extrapleural pneumonectomy, adjuvant radiotherapy, and use of intensity-modulated radiotherapy versus hemithoracic therapy that will also be addressed in this manuscript.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19261093&#34; target=&#34;_blank&#34;&gt;Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors have developed a novel mAb to human C-ERC/mesothelin, which performed well when used in western blotting, fluorescence-activated cell sorting, immunocytochemistry and immunohistochemistry, and which therefore will be useful in studying the molecular biology of mesothelin, in addition to improving the diagnosis and therapy of mesothelin-expressing cancers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19262009&#34; target=&#34;_blank&#34;&gt;Is FDG-PET/CT useful for managing malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Imaging techniques such as CT, MRI and PET/CT have essential pre- and post-treatment roles in detecting tumors and evaluating the extension of malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19267128&#34; target=&#34;_blank&#34;&gt;Chrysotile biopersistence: the misuse of biased studies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Bernstein’s results can only be explained by an aggressive pre-treatment of fibers, inducing many faults and fragility in the fibers’ structure, leading to rapid hydration and breaking of long fibers in the lungs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19269106&#34; target=&#34;_blank&#34;&gt;Pemetrexed in first-line treatment of non-small cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is an antitumor agent traditionally used as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) as well as in combination with cisplatin for the treatment of chemonaïve patients with unresectable malignant pleural mesothelioma. […] Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology. […] We detailed pemetrexed studies in the first-line setting of NSCLC treatment, in monotherapy, in combination with platinum and also, with other agents.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-06-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19289370&#34; target=&#34;_blank&#34;&gt;Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With improvements in systemic and intrapleural treatment options, a movement toward multi-modality therapy has become more common. […] Systemic treatment options largely consist of neoadjuvant chemotherapy with platinum doublets and most recently novel targeted agents, such as dasatinib. […] Intrapleural strategies have included injecting chemotherapy, chemotherapy with hyper thermic per fusion, gene therapy, and immunotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1931091&#34; target=&#34;_blank&#34;&gt;Diagnostic and therapeutic strategy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prognosis depended significantly on patient age, evidence of pain, loss of weight, tumour cell type, stage, local and distant metastasis, involvement of peritoneum and surgical treatment. […] The overall median survival rate was 238 days, after extended pleuropneumonectomy 284 days, and after decortication 315 days - significantly better than the prognosis in patients without surgical treatment or exploratory thoracotomy. […] Decortication seems nowadays to be the treatment of choice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-12-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19329206&#34; target=&#34;_blank&#34;&gt;Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To confirm the feasibility of accelerator-based BNCT (AB-BNCT) for treatment of multiple liver tumors and malignant pleural mesothelioma (MPM), we compared dose distribution and irradiation time between AB-BNCT and reactor-based BNCT (RB-BNCT). […] We constructed treatment plans for AB-BNCT and RB-BNCT of four multiple liver tumors and six MPM. […] Dose distribution analysis revealed that AB-BNCT is superior to RB-BNCT for treatment of deep-seated tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19351750&#34; target=&#34;_blank&#34;&gt;Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Targeting the ECM is becoming an increasingly promising therapeutic approach in cancer treatment. […] Thus, targeting the SP-IgV domain may be one of the therapeutic approaches in cancer treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-06-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19362945&#34; target=&#34;_blank&#34;&gt;Updated clinical information on multitargeted antifolates in lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed, a third-generation antifolate already indicated in combination with cisplatin for the systemic treatment of malignant pleural mesothelioma and, as a single agent, for the second-line treatment of non-small-cell lung cancer was in 2008 granted approval for histologically based first-line treatment by both the EMEA and FDA.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-06-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19364962&#34; target=&#34;_blank&#34;&gt;Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Neoadjuvant pemetrexed plus cisplatin was administered, followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT), to assess the feasibility and efficacy of trimodality therapy in stage I to III malignant pleural mesothelioma. […] Patients completing all therapy had a median survival of 29.1 months and a 2-year survival rate of 61.2%. […] This multicenter trial showed that trimodality therapy with neoadjuvant pemetrexed plus cisplatin is feasible with a reasonable long-term survival rate, particularly for patients who completed all therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19374545&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis and treatment of patients with malignant pleural mesothelioma requires a multidisciplinary approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19374599&#34; target=&#34;_blank&#34;&gt;Future developments in the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, chemotherapy remains the mainstay of treatment, considering that surgery and radiotherapy have a limited role in highly selected patients, and its results are still modest, with a median survival of approximately 1 year.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19375046&#34; target=&#34;_blank&#34;&gt;[First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The optimal treatment of MPM was not clearly defined, until the publication of the multicentre, controlled and randomized phase III trial by Vogelzang et al. in 2003, which made the pemetrexed-cisplatin association the gold standard for the non-operable stages.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-06-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19379903&#34; target=&#34;_blank&#34;&gt;Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prospectively collected clinicopathologic and treatment data were assessed for their correlations with actual 18-month survivors in both univariate and multivariate analyses.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19379936&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy with reconstruction of diaphragm and pericardium using autologous materials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The procedures and results for extrapleural pneumonectomy through a lower door open thoracotomy with reconstruction of the diaphragm and the pericardium using a reversed latissimus dorsi muscle flap and a fascia lata graft, respectively, for the treatment of malignant pleural mesothelioma are reported.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19380173&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We discovered a close relation between gene profile and resistance towards topoisomerase poisons, alkylating agents, antitubulines, antifolates, platinum compounds and radiation therapy. […] Targeted suppression of some of those key genes and pathways combined with chemotherapy or radiation could improve the outcome of mesothelioma therapy. […] We propose CHEK1, RAD21, FANCD2 and RAN as new co-targets for mesothelioma treatment. […] The pro-angiogenic AGGF1 mRNA and protein was highly overexpressed in all tumours and may serve as a target for anti-angiogenic treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19380521&#34; target=&#34;_blank&#34;&gt;Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We detected MET upregulation and phosphorylation (thus indicating activation) in 14 (70%) and 13 (65%) cell lines, but treatment with MET-specific inhibitors showed weak or modest effect of suppression in most of the cell lines. […] These results indicated that coactivation of RTKs was essential in mesothelioma cell proliferation and/or survival, thus suggesting that simultaneous inhibition of RTKs may be a more effective strategy for the development of molecular target therapy for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19404212&#34; target=&#34;_blank&#34;&gt;Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality therapy including extrapleural pneumonectomy (EPP), chemotherapy, and radiotherapy (RT) is often recommended for fit patients with early stage malignant pleural mesothelioma. […] We studied patterns of local and nodal recurrence in patients treated at our institution with EPP and RT, and whether advanced treatment planning techniques, such as intensity modulated radiotherapy (IMRT), could have been of potential benefit. […] After treatment, patients were followed with serial imaging and patterns of local and nodal failure were studied.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19414371&#34; target=&#34;_blank&#34;&gt;Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of cells with a non-cytotoxic dose of cisplatin at the end of the citrate exposure led to a strong cytotoxicity, almost all cells being killed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19416050&#34; target=&#34;_blank&#34;&gt;Can “steroid switching” improve steroid-induced psychosis in a patient with advanced cancer?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In palliative care, steroids are often used to alleviate symptoms such as pain, fatigue, anorexia, nausea, and vomiting. […] It has been reported that treatment of the steroid-induced psychiatric symptoms involves dosage reduction or discontinuation of steroid, and concomitant administration of psychotropics. […] There were few reports on effectiveness of treatment of steroid-induced psychiatric symptoms by switching from one steroid to the other. […] The symptoms disappeared gradually after re-switching from intravenous betamethasone 2 mg/day to oral prednisolone 10mg/day. “Steroid switching” may serve as a valid alternative treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19423005&#34; target=&#34;_blank&#34;&gt;Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a highly aggressive tumor originating in the pleura, peritoneum and pericardium, and the prognosis of patients undergoing current treatment remains poor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19425525&#34; target=&#34;_blank&#34;&gt;Asbestos–a legacy and a persistent problem.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no effective cure or treatment for any of the lung or pleural asbestos related diseases; malignant mesothelioma has a median survival of just 6-12 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1943191&#34; target=&#34;_blank&#34;&gt;Expanded applications of diagnostic and therapeutic thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy has been performed at an increasing frequency in recent years because of its expanded applications, especially in the areas of therapeutic or operative procedures such as carbon dioxide laser treatment of spontaneous pneumothorax or diffuse bullous emphysema, neodymium:yttrium-aluminum-garnet laser vaporization of pleural malignant tumors, and thoracoscope/laser-aided pleurectomy, pericardiectomy, or lung resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19432887&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Furthermore, the serum antibody titers decreased after surgical treatment of MPM and increased after recurrence of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19443527&#34; target=&#34;_blank&#34;&gt;All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These data may provide a rationale to explore the clinical use of ATRA for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19470726&#34; target=&#34;_blank&#34;&gt;Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Oncolytic viral therapy continues to be investigated for the treatment of cancer, and future studies in patients would benefit greatly from a noninvasive modality for assessing virus dissemination, targeting, and persistence. […] The inclusion of human reporter genes into recombinant oncolytic viruses enhances the potential for translation to clinical monitoring of oncolytic viral therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19482372&#34; target=&#34;_blank&#34;&gt;Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, there is growing interest in therapy response evaluation with FDG-PET/CT. […] The aim of the study was to evaluate the value of several FDG-PET/CT-parameters in therapy response evaluation concerning prediction of survival at baseline and after three cycles of therapy. […] Based on CT, after three cycles of therapy 10 patients were categorized as responders, 30 were classified as stable disease and 1 had progressive disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19487281&#34; target=&#34;_blank&#34;&gt;Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multivariate analysis of 78 malignant mesothelioma patients with pathologic stage, histologic type, therapy, sex, and age at diagnosis indicated that ERbeta expression is an independent prognostic factor of better survival. […] Moreover, studies in vitro confirmed that treatment with 17beta-estradiol led to an ERbeta-mediated inhibition of malignant mesothelioma cell proliferation as well as p21(CIP1) and p27(KIP1) up-regulation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19505418&#34; target=&#34;_blank&#34;&gt;[Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant ascites is a pathological condition, due to several abdominal and extra-abdominal neoplasms, representing a difficult challenge in treatment. […] A 49-years old woman with malignant ascites, secondary to peritoneal localization of right pleural mesothelioma, underwent, after failure of medical therapy, laparoscopic intraperitoneal chemotherapy (with Cisplatin 25 mg/m2/L and Doxorubicin 7 mg/m2/L). […] Laparoscopic intraperitoneal chemotherapy may be a good therapeutic option to palliative malignant ascites in patient not eligible for a radical cytoreductive treatment, but further investigations are needed to standardized dosage and perfusion procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19514499&#34; target=&#34;_blank&#34;&gt;[Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After 16 months, recurrence of the tumor with pleural effusion was observed, and single agent vinorelbine as second-line treatment (6 cycles) and single agent gemcitabine as third-line treatment (6 cycles) were administered sequentially. […] Partial remission was achieved, but this treatment was stopped after 6 cycles because of renal toxicity limiting further cisplatinum chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19514505&#34; target=&#34;_blank&#34;&gt;[Case of pemetrexed-induced acute lung injury].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Corticosteroid pulse therapy was started, but he died of respiratory failure 10 days after beginning chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19522163&#34; target=&#34;_blank&#34;&gt;Clinical utility of diagnostic markers for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early multimodal treatment, however, is expected to improve the outcome. […] Today, there is a strong need to have disease markers which could be used for screening, diagnosing, and/or monitoring tumour response to treatment. […] Mesothelin is also a promising marker for monitoring response to treatment but published data is still insufficient to make recommendations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19527361&#34; target=&#34;_blank&#34;&gt;18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It may be used to predict prognosis and to assess the metabolic response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19532013&#34; target=&#34;_blank&#34;&gt;Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of malignant pleural mesothelioma continues to be a clinical challenge. […] The question, however, is no longer whether to provide active treatment or not, but how aggressive the treatment should be in view of the limited life expectancy of patients with this disease. […] With platin and pemetrexed-based combination chemotherapy having become the preferred systemic therapy, the major questions now evolve around the identification of a suitable second line therapy and the quest for innovative new approaches. […] However, both extrapleural pneumonectomy and high-dose hemithoracic radiotherapy are associated with potential treatment-related mortality and morbidity and cannot yet be recommended outside specialized centres. […] More than ever, the diagnosis and treatment of patients with malignant pleural mesothelioma mandate a multidisciplinary approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19546819&#34; target=&#34;_blank&#34;&gt;Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Trimodality therapy (TMT), consisting of extrapleural pneumonectomy (EPP), preoperative or postoperative combination chemotherapy, and high-dose hemithoracic radiotherapy, is the only therapy reported to achieve long-term survival in selected patients with malignant pleural mesothelioma (MPM). […] However, TMT has never been compared with non-TMT therapy in the same patient population, thereby introducing a potential for selection bias. […] Although complete locoregional control was achieved with TMT, distant recurrence affected most EPP survivors despite careful patient selection and a high rate of completion of adjuvant therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19550246&#34; target=&#34;_blank&#34;&gt;Pleural well-differentiated papillary mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report the case of a 27-year-old woman with pleural well-differentiated papillary mesothelioma, who was treated with bilateral pleurodesis and pericardial window to control the production of malignant fluid, without significant systemic anticancer treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19551156&#34; target=&#34;_blank&#34;&gt;Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy with hyperthermal chemotherapy in pleural diffuse malignant mesothelioma had limited benefits for patients. […] Thus hyperthermia combined with suppression of p38 MAPK or Hsp40 may represent a novel approach to improve mesothelioma therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19552609&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: current treatments and emerging drugs.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection and radiotherapy represent the standard treatment in patient with resectable MPM. […] Chemotherapy is also necessary to reduce incidence of distant metastases, but the optimal setting of treatment (neoadjuvant, adjuvant and intrapleural) is not clarified. […] For the patients with unresectable MPM, the combination cisplatin and pemetrexed or ralitrexed is the standard treatment as supported by a Phase III study. […] This review discusses the current treatment option, the specific signal pathways activated in MPM and the novel agents under evaluation in clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19568885&#34; target=&#34;_blank&#34;&gt;Current therapies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Trimodality treatment using extrapleural pneumonectomy, radiation and chemotherapy has shown promising therapeutic value.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19577816&#34; target=&#34;_blank&#34;&gt;Pemetrexed in the treatment of advanced non-squamous lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Firstly, pemetrexed was approved in combination with cisplatin for the treatment of malignant pleural mesothelioma. […] Successively, it has been studied, as single-agent, in phase II and III trials for second-line therapy of non-small cell lung cancer (NSCLC). […] Based on these results, pemetrexed has been registered for the treatment of recurrent NSCLC. […] The next step was to test pemetrexed plus cisplatin versus gemcitabine plus cisplatin, as first-line therapy in advanced NSCLC patients, in a phase III, non-inferiority, randomized trial. […] The role of pemetrexed as maintenance therapy after first-line therapy for advanced NSCLC is currently being evaluated into a phase III trial. […] To date, pemetrexed is registered, at the dose of 500 mg/m(2) on day 1 of a 3-week schedule, in combination with cisplatin, for first-line therapy and, as single-agent, for second-line treatment of patients with non-squamous NSCLC.This review shows the latest and indicates the future developments of pemetrexed in the treatment of advanced NSCLC patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19588835&#34; target=&#34;_blank&#34;&gt;[Early malignant pleural mesothelioma; report of a case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
She was referred to our hospital for surgery, and was undergone an extrapleural pneumonectomy followed by postoperative treatment with cisplatin puls gemcitabine.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19615083&#34; target=&#34;_blank&#34;&gt;Lung cancer gene expression database analysis incorporating prior knowledge with support vector machine-based classification method.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A reliable and precise classification is essential for successful diagnosis and treatment of cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19619785&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We sought to prospectively determine the feasibility and safety of hyperthermic intraoperative intracavitary cisplatin perfusion immediately after extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19632388&#34; target=&#34;_blank&#34;&gt;Placenta growth factor expression has prognostic value in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is highly aggressive and recurs rapidly despite radical multimodality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19635932&#34; target=&#34;_blank&#34;&gt;The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a lethal neoplasm for which current therapy is unsatisfactory.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19642427&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The interest for this cancer has been stimulated by recent improvements in the diagnosis and in the treatment of mesothelioma, including new cytotoxic drugs and multimodal treatment, associating chemotherapy, radical surgery and radiotherapy in prospective, randomised and multicentric trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19650163&#34; target=&#34;_blank&#34;&gt;The role of surgery in the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytoreductive procedures, such as pleurectomy/ decortication (PD) and extrapleural pneumonectomy (EPP) are also used in multimodal treatment protocols. […] The available evidence until now suggests that EPP offers better palliation of dyspnea and orthopnea due to a trapped lung and ventilation perfusion mismatch and better adjuvant radiation therapy planning when compared to PD. […] EPP and thoracoscopic parietal pleurectomy are now tested in two ongoing prospective randomized trials for their efficacy in the treatment of this disease. […] In the absence of any controlled randomized trial, EPP should be considered as part of the treatment of MPM only within the context of a prospective randomized trial or in special centers with expertise in the procedure and always within a tri-modal or four-modal treatment protocol, including also chemotherapy, radiotherapy, intrapleural immunochemotherapy and laser photodynamic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19660355&#34; target=&#34;_blank&#34;&gt;Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The rate of venous thromboembolism in patients undergoing multimodality therapy for lung malignancy and the impact of preoperative venous thromboembolism on postoperative outcome have not been analyzed systematically. […] We performed a retrospective review of all patients undergoing induction therapy before lung resection for non-small cell lung cancer and malignant pleural mesothelioma at the University Health Network between January 1996 and December 2007. […] Venous thromboembolism developed in 23 (12.3%) of 186 patients undergoing induction therapy. […] The venous thromboembolism was diagnosed during induction therapy in 11 patients. […] The proportion of pulmonary embolism was higher during induction therapy (9/11 patients), whereas deep venous thromboses were observed predominantly postoperatively (7/12 patients) (P = .02). […] This study demonstrates that venous thromboembolism events in patients undergoing multimodality therapy for lung malignancies is high and deserves careful consideration. […] Patients with a venous thromboembolism diagnosis during induction therapy may potentially benefit from a temporary inferior vena cava filter before surgery to limit the risk of recurrent pulmonary embolism.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19661370&#34; target=&#34;_blank&#34;&gt;Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The cisplatin-pemetrexed and cisplatin-gemcitabine combinations are considered the standard treatment for malignant pleural mesothelioma. […] The treatment was scheduled for a maximum of 6 cycles or until disease progression or unacceptable toxicity. […] A total of 7 out of our 25 patients (28%) responded to treatment. […] The administration of gemcitabine and doctaxel appears to be promising first-line therapy for patients with mesothelioma, as it is well tolerated and appears to improve survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19661833&#34; target=&#34;_blank&#34;&gt;The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The effectiveness of extrapleural pneumonectomy (EPP) to extend quality-adjusted survival in malignant pleural mesothelioma within multimodality treatment should be proven in a randomized controlled trial if this radical surgery is to be regarded as the standard of care.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19698846&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present study supports the use of extrapleural pneumonectomy-based multimodal therapy in carefully selected patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19699914&#34; target=&#34;_blank&#34;&gt;Trimodality therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The optimal modality and sequence of therapy are controversial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19708533&#34; target=&#34;_blank&#34;&gt;[Epidermal growth factor receptor aberrations in malignant mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, we compared Epidermal Growth Factor Receptor (EGFR) aberrations in malignant mesotheliomas to those in lung cancers, to determine whether gefitinib may be useful for treatment of a malignant mesothelioma. […] These results suggest that it would be rare for a patient with malignant mesothelioma to benefit from gefitinib treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19713334&#34; target=&#34;_blank&#34;&gt;Solitary fibrous tumor of the pleura: surgery and clinical course in 18 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients underwent surgical treatment. […] Surgery is the treatment of choice, and careful long-term clinical follow-up is required.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19715403&#34; target=&#34;_blank&#34;&gt;Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the eight resistant lines, pretreatment with IFN-beta prevented lysis of cells by VSV.GFP, and VSV infection or addition of IFN-beta protein resulted in the upregulation of double-stranded RNA-dependent protein kinase (PKR), myxovirus resistance A (MxA), and 2’,5’-oligo-adenylate-synthetase (2’5’-OAS) mRNA. […] In the susceptible lines, there was no protection by pretreatment with IFN-beta protein and no IFN- or VSV-induced changes in PKR, MxA, and 2’5’-OAS mRNA.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19717307&#34; target=&#34;_blank&#34;&gt;Three decades of experience in the surgical multi-modality management of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report our 30-year surgical experience with DMPM with emphasis on surgical procedure and post-operative adjuvant therapy. […] Consecutive patients who underwent surgical treatment were included (n=139). […] Post-operative adjuvant therapy included either chemotherapy, radiotherapy, both or none. […] EPP whether or not combined with adjuvant therapy provided no significant survival advantage in comparison to pleurectomy/decortication (overall median survival 10.3 months vs 10.1 months, p=0.09). […] Multivariate analysis with the inclusion of histological type, surgical procedure and type of adjuvant therapy, EPP without adjuvant therapy was an independent risk-factor for decreased survival (Hazard Ratio=9.2). […] In this series, cytoreductive surgery combined with post-operative adjuvant therapy provided better survival despite either advanced disease or surgically less fit patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19717482&#34; target=&#34;_blank&#34;&gt;Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the absence of a uniform, robust and validated staging system, we advice use of the most recent TNM based classification, and propose a three step pre-treatment assessment. […] Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19727362&#34; target=&#34;_blank&#34;&gt;Update on pleural diseases–2007.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors selected articles to make recommendations on diagnostic and treatment aspects of pleural diseases. […] The basis of selection of the articles was the impact on daily practice, change in prior thinking of a disease process or specific treatment modality, as well as proper design and execution of the study. […] Administration of streptokinase in patients with empyema does not need for surgical drainage, length of hospital stay, or mortality as compared to conventional treatment with chest tube drainage and intravenous antibiotics. […] Pleural catheter may prove to be an important palliative modality in treating debilitated patients or patients with trapped lung who show symptomatic improvement with drainage; however, at the present time, these catheters cannot be considered a first line treatment option for patients with malignant pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19736192&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: an update on biomarkers and treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Newly described biomarkers, including soluble mesothelin-related peptide, megakaryocyte potentiation factor, and osteopontin, may predict which asbestos-exposed individuals will develop mesothelioma, and may prove useful in assessing response to treatment. […] As we learn more about mesothelioma biology, molecularly targeted agents may become treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19745767&#34; target=&#34;_blank&#34;&gt;Hemithoracic radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma: a dosimetric comparison of two well-described techniques.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two standard therapeutic approaches currently used to deliver adjuvant radiotherapy were compared in this study: intensity modulation radiation treatment (IMRT) with a planned dose of 45 Gray (Gy) and a modified electron-photon technique delivering 54 Gy. […] Treatment plans of 10 mesothelioma patients who underwent EPP and hemithoracic IMRT to a total dose of 45 Gy were analyzed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19752758&#34; target=&#34;_blank&#34;&gt;Prognostic factors according to the treatment schedule in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, we aimed to investigate the factors affecting the survival of patients with malignant pleural mesothelioma (MPM) according to their treatment schedules, including those treated with best supportive care, chemotherapy, and multimodality therapy. […] The patients were classified into three groups according to their treatment schedules: the best supportive care group, the chemotherapy group, and the multimodality therapy group. […] However, the effectiveness of treatment schedules as a prognostic factor was not evaluated in this study. […] After adjusting for therapy in a Cox model, a Karnofsky Performance Status (KPS) &amp;lt; or = 70, a right side tumor, serum lactate dehydrogenase &amp;gt;500 IU(-1), a nonepithelial subtype, and stage 3 to 4 disease were determined by multivariate analyses to be unfavorable prognostic factors for all the patients. […] A right side tumor and a nonepithelial subtype were associated with a poor prognosis for the multimodality therapy group. […] The patients with an epithelial subtype, a good KPS, and an early-stage tumor had a good prognosis, even if they did not receive any treatment. […] A mixed subtype and a right side tumor were unfavorable prognostic factors for the multimodality therapy group.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19761423&#34; target=&#34;_blank&#34;&gt;Pemetrexed for the treatment of non-small-cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a novel multi-targeted antifolate that is used in the treatment of both malignant pleural mesothelioma and non-small-cell lung cancer (NSCLC). […] Pemetrexed is the first NSCLC drug for which ‘treatment-by-histology’ has been determined. […] The advent of treatment-by-histology represents a significant step forward in the treatment of lung cancer, allowing physicians to tailor therapies to the individual patient. […] Ongoing trials aim to establish the place of pemetrexed in maintenance, in combination with other ‘targeted agents’, in adjuvant therapy in early NSCLC and in concurrent radio/chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19765853&#34; target=&#34;_blank&#34;&gt;Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We describe the feasibility and long-term outcomes associated with Radical Pleurectomy (RP) as surgical therapy modality in a standardized trimodality therapy concept of MPM. […] They underwent trimodality therapy, including RP followed by 4 cycles of chemotherapy with Cisplatin (75 mg/m(2))/Pemetrexed (500 mg/m(2)) and radiotherapy 4-6 weeks after operation. […] Surgical morbidity/mortality and trimodality treatment-related mortality were 20.0%, 2.9% and 5.8%, respectively. […] Thirty-three patients completed the trimodality therapy. […] The trimodality therapy concept with RP demonstrates promising results in terms of long-term survival, morbidity and mortality. […] We propose that a surgical philosophy of limiting the procedure related morbidity while achieving comparable cytoreductive results allows patients to maintain physiological reserve to be eligible for multimodality treatment options in the long-term. […] The observed and theoretical benefits of this trimodality treatment approach warrant confirmation in larger RCT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19766508&#34; target=&#34;_blank&#34;&gt;Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Animals without any adjuvant therapy were used as control. […] The secondary endpoints were treatment-related toxicity; cisplatin serum concentration evaluated at different time points; and cisplatin concentration in the pleura measured at autopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19781955&#34; target=&#34;_blank&#34;&gt;Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Univariate survival analysis revealed age, epithelioid histotype and any therapy as prognosticators for better OS. […] Multivariate Cox regression revealed any treatment, low cytoplasmic periostin and high cytoplasmic PTEN as independent prognosticators for better OS.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19808196&#34; target=&#34;_blank&#34;&gt;Pemetrexed-induced pneumonitis: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19815709&#34; target=&#34;_blank&#34;&gt;Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since activated CREB1 also is increased endogenously in human MM and modifies migration and resistance to Dox-induced apoptosis, inhibition of CREB1 may be a new strategy for MM therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19818589&#34; target=&#34;_blank&#34;&gt;Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An international expanded access program was initiated to provide access to treatment with pemetrexed prior registration and reimbursement for malignant mesothelioma (MM). […] Treatment of pleural MM with pemetrexed alone or in combination with platinum was safe and active as first and second-line therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822280&#34; target=&#34;_blank&#34;&gt;Current status of screening for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because the high-risk cohorts for mesothelioma are fairly well defined by the association with asbestos, and the exposure is usually in the workplace, it is hypothesized that early detection of the disease could (1) find patients at an earlier, more treatable stage and (2) result in prolonged survival over the present median 12 months from the start of therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822282&#34; target=&#34;_blank&#34;&gt;Current trends in radiologic management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Perfusion and diffusion MRI are promising new techniques for the assessment of tumor cellularity and microvasculature and can be used for quantitative and qualitative assessment of treatment response. […] Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for the differentiation of benign from malignant lesions, for staging, and for monitoring response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822283&#34; target=&#34;_blank&#34;&gt;Pathologic evaluation of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
They consult with the clinical care team at multiple points along the treatment spectrum, preoperatively, intraoperatively, and postoperatively. […] Finally, they are increasingly called on to guide selection of chemotherapy and measure treatment response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822284&#34; target=&#34;_blank&#34;&gt;Mesothelioma: path to multimodality treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality treatment of malignant pleural mesothelioma (MPM) with surgery, radiation therapy, and adjuvant or neoadjuvant chemotherapy is the sole path to extended survival for select patients with favorable prognostic factors. […] Much effort has been expended since first recognition of this insidious pleural cancer to elucidate the underlying cause and optimal treatment strategy. […] Despite these limitations, however, the results hold promise for improved survival with further refinement in patient selection and targeted therapy. […] Other approaches to multimodality treatment have capitalized on an array of innovative technologies in search of the silver bullet strategy that will ultimately undermine the biological behavior demonstrated by MPM. […] These range from the use of different means of radiation delivery, biological agents, virally mediated gene therapy, photodynamic therapy, and immunotherapy. […] In light of the current worldwide epidemic, the lessons learned over the past several decades serve as a humbling reminder of the treatment barriers that remain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822285&#34; target=&#34;_blank&#34;&gt;Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Trimodality treatment of malignant pleural mesothelioma with cytoreductive surgery followed by radiation and chemotherapy has resulted in long-term survival for a select group of patients. […] Knowledge of the similarities and differences between the two operations that have evolved-extrapleural pneumonectomy and pleurectomy/decortication-is prerequisite to understanding the complex issues associated with patient selection, diagnosis, pathologic staging, preoperative assessment, perioperative management, and adjuvant treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822286&#34; target=&#34;_blank&#34;&gt;Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two operations have evolved for the surgical treatment of malignant pleural mesothelioma (MPM): extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). […] The goal of surgery in the multimodality treatment approach is to achieve a macroscopic complete resection, with adjuvant therapies directed at residual microscopic disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822288&#34; target=&#34;_blank&#34;&gt;Radiation therapy options for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of radiation therapy (RT) in the curative treatment of malignant pleural mesothelioma remains undefined. […] No data clearly support treatment of unresected mesothelioma with definitive RT. […] Early reports showed that RT was associated with unacceptable toxicity, but recent limited data suggest that treatment with intensity-modulated radiation therapy (IMRT) may be tolerable. […] New techniques such as helical tomotherapy and/or IMRT with the addition of electrons may also have a role in future treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822289&#34; target=&#34;_blank&#34;&gt;Palliative care for the patient with mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of palliative care in the medical management of malignant mesothelioma is multifaceted, requiring proficiency in multiple disciplines. […] The palliative care provider also must be prepared to recognize and treat psychological disorders, to identify other social and spiritual sources of distress, including anxiety and depression, and to provide or arrange for counseling to patient and family for advance care planning, as well as grief and bereavement.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822290&#34; target=&#34;_blank&#34;&gt;Multimodality strategies in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Over the last decade, several improvements have been made in the diagnosis and treatment of malignant pleural mesothelioma, including better understanding of tumor biology, availability of more potent chemotherapeutic drugs, improved surgical management, and optimized multidisciplinary therapy. […] To date, the best survival data have been reported after multimodality treatment strategies that include surgical resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822291&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) of the pleura is an experimental treatment aimed at eradicating residual microscopic disease after macroscopic complete resection of malignant pleural mesothelioma (MPM) by means of intracavitary administration. […] A light-based treatment, PDT consists of 3 components: a nontoxic photosensitizing compound, oxygen, and visible light. […] The treatment is FDA-approved for several oncological targets, but remains experimental for MPM. […] PDT can be combined with lung-sparing pleurectomy and decortication and does not preclude other treatments such as adjuvant chemotherapy and/or radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822292&#34; target=&#34;_blank&#34;&gt;Making the case for molecular staging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an aggressive malignancy for which surgical treatment is an option for a subset of patients. […] A gene ratio test based on the relative expression levels of four genes has been validated in clinical trials to predict which patients will benefit from surgical therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19830126&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma with long-term tumor disappearance of a local relapse after surgery: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient confessed that he had self-administered a mushroom extract with alternative parasympathetic nerve stimulation therapy thereafter. […] The complete disappearance of the tumor was clinically achieved during a 29-month follow-up with continuing self-treatment. […] This event was a tumor regression possibly due to an immunological effect of combined complementary and alternative therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19843550&#34; target=&#34;_blank&#34;&gt;Staging algorithm for diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An algorithm of preoperative mediastinal nodal staging with endobronchial/endoesophageal ultrasonography (EBUS/EUS) and transcervical extended mediastinal lymphadenectomy (TEMLA) combined with laparoscopy/peritoneal lavage and cytology was analyzed to establish the realistic criteria for radical multimodality treatment of malignant pleural mesothelioma (MPM). […] There were 16 women and 26 men in ages ranging from 43 to 77 years (mean 57.8); 31 epithelioid, 2 sarcomatoid and 9 biphasic type MPM. 21/42 patients were considered possible candidates for multimodality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19846346&#34; target=&#34;_blank&#34;&gt;High-dose-rate surface brachytherapy to boost elongated, curvilinear incisional scars after extrapleural pneumonectomy for malignant pleural mesothelioma treated with adjuvant intensity-modulated radiation therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Providing adequate dosimetric coverage of elongated, curvilinear incisions during adjuvant intensity-modulated radiation therapy (IMRT) after extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM) creates technical challenges. […] Both en face electron and surface HDR plans were prepared and evaluated based on dosimetric coverage of the incisional scars, dose to normal tissues, reliability of setup, and treatment delivery. […] Advantages over electron beam therapy include avoidance of field abutments and feathering, less tissue-bone interface dose uncertainty and reproducibility of treatment delivery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19853261&#34; target=&#34;_blank&#34;&gt;Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We sought to determine whether combination treatment with sirolimus and cisplatin would enhance cell death in malignant pleural mesothelioma. […] To characterize phosphorylation status after treatment, Akt and downstream proteins of mammalian target of rapamycin pathway, p70 S6 kinase and 4E-BP1, were analyzed by Western blot. […] Effect of combination treatment was also analyzed with extreme drug resistance assay in 12 human malignant pleural mesothelioma tumors with varying resistance to cisplatin. […] Combined treatment caused dephosphorylation of Akt, 4E-BP1, and p70 S6 kinase.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19864204&#34; target=&#34;_blank&#34;&gt;Porcelain factory worker with asbestos-related mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A chest X-ray revealed right-side pleural effusion; however, pleural biopsy from drainage treatment confirmed a diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19879055&#34; target=&#34;_blank&#34;&gt;Second-line treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients affected by malignant pleural mesothelioma (MPM) are candidates for chemotherapy during the course of the disease, as single modality treatment or within the context of a multimodality approach. […] Unfortunately, nearly all MPM patients progress during or after first-line treatment. […] In pemetrexed-naïve patients, data from a randomized trial vs. best supportive care suggest the use of single-agent pemetrexed as a standard second-line treatment. […] In selected cases with a prolonged response to first-line pemetrexed-based chemotherapy, re-treatment with a pemetrexed-based regimen should be considered. […] However, second-line therapy in MPM remains an ideal field in which to test new chemotherapy agents as well as new therapeutic strategies, including anti-angiogenic compounds, small molecules or monoclonal antibodies that target different molecular pathways.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19885311&#34; target=&#34;_blank&#34;&gt;Estimation of pulmonary motion in healthy subjects and patients with intrathoracic tumors using 3D-dynamic MRI: initial results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Local and global parenchymal pathologies can be precisely located and might be a new tool used to quantify even slight changes in lung motion (e.g. in therapy monitoring, follow-up studies or even benign lung diseases).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1988578&#34; target=&#34;_blank&#34;&gt;Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleurodesis with tetracycline or other sclerosing agents is the usual treatment for malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19887624&#34; target=&#34;_blank&#34;&gt;Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In MPM, a separate subset of genes was silenced by H3K27me3 and could be reactivated by treatment with a histone deacetylase inhibitor alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19908112&#34; target=&#34;_blank&#34;&gt;Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality therapy has been applied to resectable malignant pleural mesothelioma, but the tolerability of the treatment and relapse pattern in detail remain unknown. […] We reviewed our experience of trimodality therapy as a single-institution study in Japan. […] A total of 16 patients with resectable malignant pleural mesothelioma were intended to treat with extra-pleural pneumonectomy followed by platinum-based chemotherapy and external beam radiation therapy. […] The tolerability to the combined treatment, the survival, and the relapse pattern were examined. […] Trimodality therapy showed a survival benefit in patients with stage III or lower malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19909234&#34; target=&#34;_blank&#34;&gt;Molecular targets in malignant pleural mesothelioma treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Relative chemotherapeutic and radiotherapeutic resistance makes malignant pleural mesothelioma (MPM) difficult to manage, even though encouraging results were achieved with multimodality treatment. […] Better knowledge of angiogenesis and molecular pathways involved in MPM seems to be the right way to define new targets for systemic treatment. […] Thus the introduction of new biologic drugs like vorinostat, bortezomib, everolimus and temsirolimus, in the treatment of MPM finds a strong rationale.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19932148&#34; target=&#34;_blank&#34;&gt;Neurotensin expression and outcome of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multivariate analysis showed that expression of NTS (p = 0.007) and non-surgical therapy (p = 0.004) were independent predictors of poor prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19934291&#34; target=&#34;_blank&#34;&gt;E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with E7080 potently inhibited the progression of these three MPM cell lines and markedly prolonged mouse survival, which was associated with decreased numbers of tumor-associated vessels and proliferating MPM cells in the tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19935710&#34; target=&#34;_blank&#34;&gt;A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM is characterized by rapid and diffuse local growth in the thoracic cavity, and it has a poor prognosis because it is often refractory to conventional therapy. […] Our results suggest that intrathoracic dual virotherapy with telomerase-specific oncolytic adenovirus in combination with heparanase-expressing adenovirus may be efficacious in the prevention and treatment of pleural dissemination of human malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19935800&#34; target=&#34;_blank&#34;&gt;Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study showed that IL-2 treatment leads to a significant increase of immunological parameters, concomitantly with a reduction in vasculature, providing new insight into the cancer mechanisms mediated by IL-2.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19960346&#34; target=&#34;_blank&#34;&gt;Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an asbestos-related tumor of the thoracic pleura that lacks effective treatment options. […] Velcade treatment resulted in G2M phase arrest, increased expression of cyclin-dependent kinase inhibitor p21 and pro-apoptotic protein Bax. […] Pretreatment of mesothelioma cells with Velcade showed synergistic effect with cisplatin combination regimens. […] This pilot study has paved way for further in-depth analysis of the downstream target molecules associated with presensitization of mesothelioma cells in finding effective therapeutic treatment options for both mesothelioma and recalcitrant breast cancers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19999567&#34; target=&#34;_blank&#34;&gt;[Diagnosis of malignant pleural mesothelioma–thoracoscopic biopsy and tumor marker].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis and treatment of malignant pleural mesotheliomav (MPM) are quite difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19999568&#34; target=&#34;_blank&#34;&gt;[Therapeutic strategies for resectable malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because no single treatment is very effective for MPM, a combination of preoperative chemotherapy, extrapleural pneumonectomy, and postoperative hemithoracic radiation is currently considered the “standard” therapy for resectable MPM. […] Very recently, the results of three major clinical trials of trimodality treatment for MPM have been reported from North America and Europe. […] Although the overall results were not encouraging, surprisingly good survival rates were noted in patients who had no mediastinal node involvement and completed the entire trimodality therapy regimen. […] This clearly illustrates that patient selection plays a key role in MPM treatment. […] The Mesothelioma and Radical Surgery (MARS) trial is a randomized clinical trial seeking to clarify the role of radical surgery in MPM treatment. […] An all-Japan clinical study of trimodality treatment for MPM is currently underway as a part of a national campaign entitled “Comprehensive Strategy against Asbestos-Related Diseases.”
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19999569&#34; target=&#34;_blank&#34;&gt;[What is the role of pleuropneumonectomy in malignant pleural mesothelioma?].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this report, the results of conventional pleuropneumonectomy in malignant diffuse mesothelioma are reviewed, and the role of this aggressive surgery in multidisciplinary treatment is discussed. […] The indications for this aggressive surgery are limited to stage I, II, and III disease based on an accurate staging system, with induction therapy for macroscopic radical resection and postoperative chemoradiation therapy. […] The natural history of this disease should be clarified to determine the effectiveness of various forms of therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19999570&#34; target=&#34;_blank&#34;&gt;[Intrapleural perfusion hyperthermo-chemotherapy with cisplatin in patients with malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The preferred treatment for patients with malignant pleural mesothelioma (MPM) has not been determined. […] In order to obtain adequate control of malignant effusion for multimodality therapy, we have introduced intrapleural perfusion hyperthermo-chemotherapy (IPHC) with cisplatin. […] Some literatures have reported the utility of IPHC for trimodality therapy on MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20010943&#34; target=&#34;_blank&#34;&gt;Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A major problem with cisplatin treatment is the development of acquired-drug resistance of the tumour cells. […] A strong super-additive effect of combined cisplatin and a sub-toxic concentration of VT-1 in cisplatin-resistant malignant pleural mesothelioma cells were observed, indicating a new potential clinical-treatment approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-03-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20021458&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: biology, diagnosis and therapeutic approaches.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is an aggressive neoplasm of serosal cavities, which is resistant to conventional therapy, with patient survival from presentation of &amp;lt;12 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20035240&#34; target=&#34;_blank&#34;&gt;Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer of the mesothelium with only a limited range of treatment options that are largely ineffective in improving survival. […] Recent efforts have turned toward the analysis of specific, dysregulated biologic pathways for insight into new treatment targets. […] The results of these efforts have led to a multicenter, randomized, placebo-controlled phase III study of the histone deacetylase inhibitor vorinostat in patients with advanced MPM, offering hope for a new and effective therapy in patients with this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20038816&#34; target=&#34;_blank&#34;&gt;Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive, rapidly progressive malignancy without effective therapy. […] Sorafenib therapy also decreased phosphorylation of B-Raf and mTOR in several cell lines. […] Within 3 h of sorafenib treatment, a number of known pro-survival molecules were dephosphorylated and/or downregulated in expression including MCL-1(L), c-FLIP(L), survivin and cIAP(1). […] These changes and eventual cell death did not elicit significant caspase-3 activation or PARP cleavage and pretreatment with the pan-caspase inhibitor, Z-VAD-FMK, did not block sorafenib efficacy but did block the effect of TRAIL monotherapy. […] Pre-treatment with Z-VAD-FMK did not block the synergistic effect of TRAIL and sorafenib in H28. […] In summary, single agent treatment with sorafenib results in widespread inhibition of the pro-survival machinery in vitro leading to cell death via a primarily caspase-independent mechanism. […] Combining sorafenib therapy with TRAIL, may be useful in order to provide a more efficient death signal and this synergistic effect appears to be caspase-independent. […] We document single agent activity of sorafenib against MPM, unravel novel effects of sorafenib on anti-apoptotic signaling mediators, and suggest the combination of sorafenib plus TRAIL as possible therapy for clinical testing in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20047972&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are developments in treatment, particularly chemotherapy with pemetrexed and cisplatin which prolongs survival and helps symptoms. […] Targeted agents for treatment are under investigation and may improve the outlook.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20051956&#34; target=&#34;_blank&#34;&gt;The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The standard treatment of choice for malignant pleural mesothelioma is chemotherapy with pemetrexed and platinum, but the clinical outcome is poor. […] There was no correlation between the presence of FRalpha and the outcome of pemetrexed treatment, and no significant difference between histological subtypes. […] Response to treatment with pemetrexed does not depend on the presence of FRalpha.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20068227&#34; target=&#34;_blank&#34;&gt;Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An understanding of the pathogenic features of asbestos fibers and dysregulation of signaling pathways allows strategies for the prevention and therapy of asbestos-related diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20075037&#34; target=&#34;_blank&#34;&gt;Cold-plasma coagulation in the treatment of malignant pleural mesothelioma: results of a combined approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We investigated the feasability of the implementation of cold-plasma coagulation (CPC) on the pleura, pericardium and diaphragm into an established therapeutic algorithm consisting of P/D and hyperthermic intrathoracal chemoperfusion (HITHOC) therapy. […] CPC was done as part of a multimodal therapy in stage III mesothelioma patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20085865&#34; target=&#34;_blank&#34;&gt;Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options are limited, and response to chemotherapy is poor. […] Treatment consisted of pemetrexed 500 mg/m2 and carboplatin area under the concentration-time curve of 5 mg/mL/min, both administered on day 1 of a 21-day cycle. […] The treatment continued until 6 cycles were completed or until unacceptable toxicity or disease progression were observed. […] This study confirmed the activity of the carboplatin/ pemetrexed combination in the first-line treatment of patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20087231&#34; target=&#34;_blank&#34;&gt;Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the role of 18-fluorodeoxyglucose positron emission tomography-computed tomography (18-FDG-PET-CT) in the surveillance of patients after multimodality treatment of malignant pleural mesothelioma. […] PET-CT was performed after multimodality therapy to evaluate response to treatment or when disease recurrence was suspected. […] Twenty-five patients had PET-CT performed after multimodality therapy. […] This was performed in 11 patients in whom disease recurrence was suspected at a median of 9 (range, 6-16) months after treatment. […] Surveillance PET-CT was performed in 14 asymptomatic patients at a median of 11 (range, 7-13) months after treatment. […] 18-FDG-PET-CT is useful in diagnosing disease recurrence after multimodality therapy for malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20088784&#34; target=&#34;_blank&#34;&gt;Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment with Gefitinib induced cell cycle arrest in both cell lines, while apoptosis was observed only for high concentrations and prolonged drug exposure. […] Gefitinib treatment increased EGFR Bmax, possibly through membrane stabilization of inactive receptor dimers that we show to be induced by the drug also in the absence of EGF.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20103236&#34; target=&#34;_blank&#34;&gt;Second surgery for recurrence of malignant pleural mesothelioma after extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy is a treatment option for malignant pleural mesothelioma (MPM), but disease recurrence is common. […] Of 57 patients for whom follow-up data were available, 11 patients experienced recurrent disease in the form of a solid mass, 1.5 to 12 years after the initial treatment; 8 of these patients had sufficiently good clinical conditions to undergo a second surgery with curative intent. […] In this series, the second surgery did not offer the expected survival benefit of curative treatment strategies and should therefore be considered palliative. […] Second surgery may be a treatment option in a subset of patients who experience a solid recurrence of MPM that is symptomatic or near vital organs and who cannot undergo additional radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-03-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20104519&#34; target=&#34;_blank&#34;&gt;Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, the simultaneous inhibition of the HGF-Met pathway and angiogenesis by NK4 for treatment of malignant pleural mesothelioma is significant, particularly to attenuate migration and invasive growth.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20104527&#34; target=&#34;_blank&#34;&gt;Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review examines the prospects for novel approaches in the prevention, diagnosis and treatment of malignant disease based on ASS1 pathophysiology and its rate-limiting product, arginine.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20108310&#34; target=&#34;_blank&#34;&gt;Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Proposed adjustments to TNM staging criteria improved outcome stratification of patients with epithelial tumor histology who received surgical therapy by EPP and complete pathologic assessment. […] Determining relevance to other treatment or staging modalities will require verification in additional cohorts.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20117025&#34; target=&#34;_blank&#34;&gt;Primary malignant mesothelioma of the pericardium.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pericardial mesothelioma carries a poor prognosis with few successful treatment strategies and little benefit from radiation and chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20142415&#34; target=&#34;_blank&#34;&gt;Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Using RNA interference, we showed that Bcl-x(L) depletion sensitized two highly chemoresistant mesothelioma cell lines to cisplatin and that under this treatment, one cell line, MSTO-211H, displayed an apoptotic type of cell death, whereas the other, NCI-H28, evidenced mainly necrotic-type cell death. […] Strikingly, we observed that the simultaneous inhibition of Bcl-x(L) and Mcl-1 using small interfering RNA (siRNA) induced a massive cell death in the absence of chemotherapy and was sufficient to avoid escape to treatment in MSTO-211H cells. […] In NCI-H28, the addition of a low cisplatin concentration allowed to impede the long-term recovery observed after treatment by the siRNA combination. […] Together, these findings provide a strong molecular basis for the clinical evaluation of therapies targeting both Bcl-x(L) and Mcl-1, alone or in combination with conventional chemotherapy, for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20142722&#34; target=&#34;_blank&#34;&gt;Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The combinations of cisplatin-pemetrexed and cisplatin-gemcitabine are considered the standard systemic therapy for malignant pleural mesothelioma (MPM), which is a rapidly progressive tumor. […] The purpose of the present study is to evaluate the efficacy, safety, and clinical benefit of the gemcitabine plus docetaxel regimen in the second-line treatment of this disease. […] The biweekly administration of docetaxel and gemcitabine, along with granulocyte colony-stimulating factor support, constitutes a safe, tolerable, and convenient regimen for the treatment of MPM, suggesting that this combination may be a viable option, especially in previously treated patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20153416&#34; target=&#34;_blank&#34;&gt;Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, there is no widely accepted treatment for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20160038&#34; target=&#34;_blank&#34;&gt;hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The inability to forecast outcomes for malignant mesothelioma prevents clinicians from providing aggressive multimodality therapy to the most appropriate individuals who may benefit from such an approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20160042&#34; target=&#34;_blank&#34;&gt;Gene therapy for mesothelioma and lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Unfortunately, current treatment regimens have had only a modest effect on their progressive course. […] Gene therapy for thoracic malignancies represents a novel therapeutic approach and has been evaluated in a number of clinical trials over the last two decades. […] Using viral vectors or anti-sense RNA, strategies have included induction of apoptosis, tumor suppressor gene replacement, suicide gene expression, cytokine-based therapy, various vaccination approaches, and adoptive transfer of modified immune cells. […] This review will consider the clinical results, limitations, and future directions of gene therapy trials for thoracic malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20167848&#34; target=&#34;_blank&#34;&gt;Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Peripheral blood mononuclear cells during the treatment were analyzed for immunological responses. […] This study demonstrated that autologous tumor lysate-pulsed dendritic cell-based therapy is feasible, well-tolerated, and capable of inducing immunological response to tumor cells in mesothelioma patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20172152&#34; target=&#34;_blank&#34;&gt;Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with sarcomatoid histology should therefore be considered separately in trials evaluating radical procedures and adjuvant treatment. […] The treatment of biphasic pleural mesothelioma remains debatable.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20179421&#34; target=&#34;_blank&#34;&gt;What’s the place of immunotherapy in malignant mesothelioma treatments?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, MPM immunotherapy is undoubtedly a highly promising but also very challenging approach to the treatment of this disease that has slipped through the defense lines of the immune system.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20185425&#34; target=&#34;_blank&#34;&gt;A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumour associated with asbestos exposure that has only a limited response to conventional therapy; therefore, diagnosing MPM early is very important.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20201694&#34; target=&#34;_blank&#34;&gt;Deciduoid mesothelioma of the pleura in an adolescent boy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient has been doing well 2 years after completion of this regime of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20213099&#34; target=&#34;_blank&#34;&gt;Clinical investigation of malignant mesothelioma in Japan.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical information was obtained including gender, age, site of origin, pathological subtype, radiological findings, and treatment outcome.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20224880&#34; target=&#34;_blank&#34;&gt;Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, no drugs have been approved for second-line treatment of MPM, with effective regimens remaining to be identified for patients in relapse. […] We have now evaluated the combination of cisplatin and pemetrexed for retreatment of patients with recurrent MPM. […] Four men with MPM, all of whom received initial treatment with cisplatin and pemetrexed, underwent retreatment with this drug combination. […] The two patients who showed an objective response to first-line chemotherapy showed a partial response to retreatment, with a time to progression of 5.0 or 8.2 months, whereas the other two patients had progressive disease with a time to progression of 1.0 or 1.4 months, respectively. […] Retreatment with cisplatin plus pemetrexed was generally well tolerated. […] Retreatment with cisplatin and pemetrexed is a potential therapeutic option for certain patients with recurrent epithelioid MPM, possibly including those who show tumor regression with a time to progression of 6 months or more after the initial chemotherapy. […] Further studies are warranted to evaluate the efficacy of such retreatment and to clarify the criteria for patient selection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20298310&#34; target=&#34;_blank&#34;&gt;Current concepts in chemotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cisplatin with either raltitrexed or pemetrexed has improved survival compared with cisplatin alone, and may be used as a reference treatment in randomized trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20298311&#34; target=&#34;_blank&#34;&gt;Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) has a poor prognosis and there is limited effect of treatment. […] Lately, pemetrexed and cisplatin have been established as the standard treatment. […] The present study was planned in 1998, when there was no standard treatment. […] Thus, despite the low response rate, liposomized doxorubicine remains an interesting drug for the treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20298508&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of MM requires a multidisciplinary approach, regardless of palliative or curative intent. […] Treatment options, such as surgery, chemotherapy, radiotherapy and active symptom control or a combination of these, may be used. […] Further research is needed to advance the therapeutic options for MM, and strategies to realize personalisation of therapy through discovery of predictive markers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20332689&#34; target=&#34;_blank&#34;&gt;[A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After this treatment, all of the lesions shrank, and the best overall response was partial response (PR) in Response Evaluation Criteria in Solid Tumors (RECIST).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20338775&#34; target=&#34;_blank&#34;&gt;May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The expression of cyclooxygenase-2 (COX-2) and cell-cycle proteins (p21 and p27) proves useful in predicting prognosis and orientating therapy in many malignant tumours. […] Malignant pleural mesothelioma is an uncommon and lethal cancer for which there are limited treatment options. […] Cox regression analysis showed that only immunohistochemical triple combination of high COX-2 and low p21 and p27 expression influenced survival (p=0.0001, hazard ratio 4.7, 95% confidence intervals 3-11) regardless of type of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20346340&#34; target=&#34;_blank&#34;&gt;Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, this disease invariably progresses and little is known about how this disease subsequently relapses after initial treatment. […] Data on second-line treatment are also scarce, especially outside the context of a clinical trial. […] We conducted a review to observe the presentation of MPM patients when their disease progresses after initial therapy and the use of second-line therapy and its associated outcomes. […] Data, including demographics, clinical presentation and treatment details at first line and beyond, together with its associated benefits, were collected. […] Related times to treatment failure (TTF), rates of symptom improvement and survival data were also collated. […] Second-line treatment was given in 45% of patients. […] Twenty-one patients (36%) received second-line chemotherapy outside the context of a clinical trial and most had retreatment with pemetrexed-based chemotherapy due to a prolonged TTF. […] In patients treated with second-line therapy outside the remit of a clinical trial, a disease control rate was achieved in nine patients (43%, 95% confidence interval 22-64), whereas improvement in symptoms were noted in 13 patients (62%, 95% confidence interval 41-83). […] Patients with a prolonged TTF after first-line treatment are more likely to relapse with neck and axillary lymphadenopathy. […] The use of second-line chemotherapy, including rechallenge treatment, in this disease is a viable option for a selected group of MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20347505&#34; target=&#34;_blank&#34;&gt;Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pre-treatment serum EGFR levels were measured using quantitative enzyme-linked immunosorbent assay. […] High pre-treatment levels of serum EGFR are associated with advanced stage but not with reduced OS.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20356754&#34; target=&#34;_blank&#34;&gt;Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We analysed published data concerning survival from diagnosis among four groups of patients with mesothelioma, identified by ascending level of intervention: (A) no surgery; (B) thoracotomy but no resection; (C) resection but no adjuvant treatment; and (D) resection as part of multimodality treatment. […] Mean survival was 16.8, 17.8 and 17 months for those having no surgery, thoracotomy alone and resection with no adjuvant treatment respectively (groups A, B and C) and 32.9 months for those having multimodality treatment (group D). […] This is the most optimistic estimate and requires all observed differences in survival to be attributed to the effect of treatment and none to selection for treatment. […] Furthermore, within this upper estimate is included any benefit from other components of multimodality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20369238&#34; target=&#34;_blank&#34;&gt;In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Four-hour pre-treatment with gemcitabine followed by 68-h exposure to cisplatin was found to exert synergistic activity in both epithelioid and sarcomatoid MPM subtypes, inducing a strong S-phase arrest that correlated with accumulation of double-strand breaks (DSBs). […] The antiproliferative effects of the gemcitabine/cisplatin combination in mesothelioma cells can be maximized by pre-treatment with gemcitabine, suggesting that this drug increases cisplatin-induced DSBs by inhibiting DNA adduct repair.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20371686&#34; target=&#34;_blank&#34;&gt;A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On univariate analysis, significant prognostic factors were: total glycolytic volume on FDG-PET (P = 0.003), sarcomatoid histology (P &amp;lt; 0.0005), weight loss (P = 0.031), computed tomography stage (P = 0.015), and European Organization for Research and Treatment of Cancer good prognostic score (P = 0.049).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20381267&#34; target=&#34;_blank&#34;&gt;Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The monitor units (MUs) and delivery time were scored to measure the treatment efficiency. […] The pretreatment portal dosimetry scored delivery to the calculation agreement with the Gamma Agreement Index. […] The treatment time was 3.7 +/- 0.3 min for RA and 13.4 +/- 0.1 min for IMRT. […] The number of MUs and the time required to deliver a 2-Gy fraction were much lower for RA, allowing the possibility to incorporate this technique in the treatment options for mesothelioma patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20385451&#34; target=&#34;_blank&#34;&gt;Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To perform comparative planning for intensity-modulated radiotherapy (IMRT) and proton therapy (PT) for malignant pleural mesothelioma after radical surgery. […] Proton therapy accomplished additional dose sparing of most organs at risk compared with IMRT. […] Proton therapy dose distributions were more susceptible to changing air cavities, emphasizing the need for adaptive RT and replanning.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20400397&#34; target=&#34;_blank&#34;&gt;[Surgical treatment of primary pleural tumours in our department].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors analyzed the results and outcome of surgical treatment of primary pleural tumors in patients treated in the last 11 years. 31 operations were performed for primary pleural tumors in 25 patients (17 males, 8 females). […] The PPN (EPP) and P/D are safe procedures providing relatively good survival when it is done as part of complete oncological treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20403196&#34; target=&#34;_blank&#34;&gt;Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The conditions of patients were assessed and graded before and after treatment concerning morbidity, mortality, success rate of pleurodesis and median survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20406091&#34; target=&#34;_blank&#34;&gt;Translational therapies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several chemotherapeutic agents have been tested for the treatment of this disease and doublet cisplatin with antifolates has been demonstrated to have significant efficacy in Phase III studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20414089&#34; target=&#34;_blank&#34;&gt;Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Management of patients with MPM remains complex, so an optimal treatment strategy has not yet been clearly defined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20421814&#34; target=&#34;_blank&#34;&gt;Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overall survival was measured using a landmark time at 3 months post-treatment start date such that all patients had already received two cycles of chemotherapy and a follow-up scan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-10-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20424652&#34; target=&#34;_blank&#34;&gt;Soluble mesothelin-related protein in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Higher levels are frequently seen in patients with high tumor burden, which could be helpful in monitoring response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20432521&#34; target=&#34;_blank&#34;&gt;Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: a review and case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The cases having pCR identified all had the epithelial or unknown subtype, and all had early-stage disease before treatment. pCR is possible but rare, and a pCR does not always require a cCR. […] So far reported cases of pCR have all had the epithelial or unknown subtype and pretreatment stages have been low.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2044044&#34; target=&#34;_blank&#34;&gt;Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Twelve of 24 patients (50%), including 6 with no radiologic evidence of response, had a clinical improvement as demonstrated by an objective reduction of symptom or performance status scores along treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20445731&#34; target=&#34;_blank&#34;&gt;[Malignant peritoneal mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The malignant mesothelioma peritoneal is a unfrequent entity, with limited therapeutic options; generally detected late, with a palliative treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20460481&#34; target=&#34;_blank&#34;&gt;Pemetrexed safety and pharmacokinetics in patients with third-space fluid.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. […] Seven grade 3/4 drug-related toxicities, including four hematologic, were reported; there were no treatment-related deaths.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20461469&#34; target=&#34;_blank&#34;&gt;Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the importance of assessing volume-based parameter of (18)F-FDG PET/CT in patients with malignant pleural mesothelioma (MPM) for the prediction of response and patient outcome early in the course of treatment. […] Multivariate analysis adjusted for treatment modality showed that MTV (HR 1.003, P = 0.025) and TLG (HR 1.001, P = 0.031) were independent factors associated with tumor progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20463022&#34; target=&#34;_blank&#34;&gt;Pro-tumorigenic effects of miR-31 loss in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Re-introduction of miR-31 suppressed the cell cycle and inhibited expression of multiple factors involved in cooperative maintenance of DNA replication and cell cycle progression, including pro-survival phosphatase PPP6C, which was previously associated with chemotherapy and radiation therapy resistance, and maintenance of chromosomal stability.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20465088&#34; target=&#34;_blank&#34;&gt;[Monitoring the effectiveness of surgical treatment of malignant pleural effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The success of the treatment was observed by ultrasound scan before drainage removal; during the first three months always at intervals of 1 month and then after 3 and 6 months, depending on the progression of a disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20466560&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: the standard of care and challenges for future management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The evidence was collected by a systematic analysis of the literature (2000-2009) using the databases Medline (National Library of Medicine, USA), Embase (Elsevier, Netherlands), Cochrane Library (Great Britain), National Guideline Clearinghouse (USA), HTA Database (International Network of Agencies for Health Technology Assessment - INAHTA), NIH database (USA), International Pleural Mesothelioma Program - WHOLIS (WHO Database) with the following keywords and filters: pleura, cancer, mesothelioma, guidelines, treatment, surgery, chemotherapy, radiotherapy, palliation, supportive care, pleurodesis, review.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20472457&#34; target=&#34;_blank&#34;&gt;A new technique of diaphragmatic patch fixation in extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy (EPP) is an established surgical treatment for malignant mesothelioma; this operation is, however, burdened by a high rate of perioperative morbidity, mostly related to the surgical procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20498407&#34; target=&#34;_blank&#34;&gt;Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 21 patients receiving systemic therapy, percentage change in SMRP more than 10% correlated with the radiologic assessment by a trained thoracic radiologist (P &amp;lt; .001), by formal Response Evaluation Criteria in Solid Tumors (RECIST; P = .008), or by modified RECIST (P &amp;lt; .001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20514576&#34; target=&#34;_blank&#34;&gt;Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results of trimodality therapy for malignant pleural mesothelioma (MPM) are related to stage. […] We investigated whether integrated PET-CT improved the intrathoracic staging of patients undergoing trimodality therapy for MPM. […] Twenty consecutive patients [18 male, median age 62 years (range 52-68)] who underwent 24 PET-CT scans prior to extrapleural pneumonectomy (EPP) as part of trimodality therapy for MPM were reviewed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20524919&#34; target=&#34;_blank&#34;&gt;Surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the multimodality treatment paradigm, the goal of surgery is to provide a macroscopic complete resection (i.e., complete removal of all grossly visible tumor). […] Despite having more advanced disease, a subset of patients with favorable prognostic factors can experience extended survival by undergoing trimodality therapy with extrapleural pneumonectomy, chemotherapy and/or radiation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20525721&#34; target=&#34;_blank&#34;&gt;Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) phase II trial investigated the feasibility of trimodality therapy consisting of induction chemotherapy followed by extrapleural pneumonectomy and post-operative radiotherapy in patients with malignant pleural mesothelioma (with a severity of cT3N1M0 or less). […] Our primary end-point was “success of treatment” and our secondary end-points were toxicity, and overall and progression-free survival. 59 patients were registered, one of whom was ineligible. […] Although feasible, trimodality therapy in patients with mesothelioma was not completed within the strictly defined timelines of this protocol and adjustments are necessary.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20530048&#34; target=&#34;_blank&#34;&gt;Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No treatment is recommended for patients with malignant mesothelioma (MM) failing after first-line cisplatin-based chemotherapy. […] Treatment consisted of doxorubicin (60 mg·m⁻²) plus valproic acid. […] Valproic acid, an HDACi, plus doxorubicin appeared an effective chemotherapy regimen in good PS (80-100) patients with refractory or recurrent MM, for which no standard therapy was available.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20532500&#34; target=&#34;_blank&#34;&gt;WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy consisted of six subcutaneous vaccinations administered with Montanide adjuvant on weeks 0, 4, 6, 8, 10, and 12, with 6 additional monthly injections for responding patients. […] A randomized trial testing this vaccine as adjuvant therapy in MPM is planned.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20534685&#34; target=&#34;_blank&#34;&gt;The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant peritoneal mesothelioma is a rare neoplasm that accounts for ∼1 per 1 million has limited data regarding its frontline therapy. […] We investigated the treatment outcomes in patients with malignant peritoneal mesothelioma receiving frontline cisplatin-based combination chemotherapy. […] There were no Grade 3 or 4 non-hematologic toxicities or treatment-related deaths. […] The platinum-based combination chemotherapy showed moderate activity and a favorable toxicity profile as a frontline treatment for patients with malignant peritoneal mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20541834&#34; target=&#34;_blank&#34;&gt;Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nevertheless, imaging in MPM plays a critical role in diagnosis, prognostication, prediction or measurement of response to therapy, and monitoring of disease recurrence after aggressive surgical management.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20580243&#34; target=&#34;_blank&#34;&gt;Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In total, the only prognostic factor across all ILK, pAKT and therapy subgroups was the histological subtype (p = 0.01).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20584744&#34; target=&#34;_blank&#34;&gt;Vinflunine: review of a new vinca alkaloid and its potential role in oncology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To review the pharmacology, pharmacokinetics, in vitro and in vivo efficacy, and safety profile of vinflunine in the treatment of various solid tumors. […] Vinflunine is a new vinca alkaloid for the treatment of advanced staged solid tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20593749&#34; target=&#34;_blank&#34;&gt;Multimodality approach to malignant pleural mesothelioma. A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient was treated by multimodality approach consisting in surgical treatment with Extrapleural Pleuropneumonectomy followed by chemotherapy with Cisplatin and Pemetrexed. […] Extrapleural pleuropneumonectomy was performed followed by a chemiotherapic treatment with Cisplatin and Pemetrexed. […] Single treatments do not demonstrate an acceptable efficacy on the treatment of DMPM. […] Multimodality therapy provides good survival improvement and acceptable quality of life for the patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20596654&#34; target=&#34;_blank&#34;&gt;Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a highly aggressive tumor with poor prognosis, and new treatment paradigms are urgently needed. […] These imaging models can be versatile and powerful tools to explore new treatment paradigms for malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20596671&#34; target=&#34;_blank&#34;&gt;Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Furthermore, we evaluated the chemotherapeutic resistance associated with each CSC marker by determining the change in CSC marker-mRNA levels as an index of drug-resistance following treatment with either cisplatin or pemetrexed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20603247&#34; target=&#34;_blank&#34;&gt;Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of second-line and salvage chemotherapy in malignant pleural mesothelioma treatment is not yet established.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20608936&#34; target=&#34;_blank&#34;&gt;In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The combination of TGZ and cisplatin showed an additive inhibitory effect on MPM cell growth compared to treatment with either individual drug. […] Treatment with 500 mg/kg or 1000 mg/kg TGZ effectively inhibited the production of thoracic tumors and pleural effusion in EHMES-10 cell-bearing SCID mice. […] Moreover, treatment with 500 mg/kg TGZ in combination with 3 mg/kg cisplatin more effectively prolonged survival compared to treatment with either individual drug. […] These results suggest that TGZ in combination with cisplatin may become a novel therapy for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20613995&#34; target=&#34;_blank&#34;&gt;Predominantly fibrous malignant mesothelioma in a cat.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here we describe the rare case of a malignant mesothelioma of the fibrous subtype in the thoracic cavity of a cat and discuss differential diagnoses and treatment options for this tumor type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20653100&#34; target=&#34;_blank&#34;&gt;Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Optimizing the multimodality treatment of malignant pleural mesothelioma depends on many factors including an adequate chemotherapeutic response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2067137&#34; target=&#34;_blank&#34;&gt;[Effect of cigarette smoking and/or N-bis(2-hydroxypropyl)nitrosamine (DHPN) on the development of lung and pleural tumors in rats induced by administration of asbestos].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The incidence of lung carcinoma was significantly increased in combined treatment with asbestos than DHPN alone. […] Carcinogenicity of asbestos for pleural tumors was significantly promoted by combined treatment with DHPN to an extent greater than DHPN alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20672705&#34; target=&#34;_blank&#34;&gt;Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A study for 110 patients with malignant pleural mesothelioma who presented to radiotherapy department, National Cancer Institute, Cairo and received radiation therapy in the period fromJanuary 1999 to July 2007. […] Forty-six patients (41.8%) received trimodality therapy (surgery &amp;amp; adjuvant or neoadjuvant chemotherapy &amp;amp; adjuvant radiotherapy), while bimodality therapy (chemotherapy &amp;amp; radiotherapy) in 38 patients (34.5%), while 26 patients (23.6%) received single modality therapy (palliative radiotherapy), 22 patients (20%) developed local recurrence, 22 patients (20%) developed distant metastases months, 14 patients (12.7%) developed local disease progression, 25 patients (22.7%) are still alive and free of disease at time of reporting.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20692828&#34; target=&#34;_blank&#34;&gt;Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In vitro cytotoxicity studies showed the STO cell line to be resistant to gefitinib and sensitive to sequential treatment with RAD001 and sorafenib; these findings were consistent with the presence of the KRAS mutation G12D in these cells although it was not detectable in the original tumour. […] Our results highlight the ligand-dependent activation and co-activation of EGFR and PDGFRB, as well as a connection between these activated RTKs and the downstream mTOR pathway, thus supporting the role of combined treatment with RTK and mTOR inhibitors in DMPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20699634&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intensity modulated radiation therapy (IMRT) has recently been proposed for the treatment of malignant pleural mesothelioma (MPM). […] Here, we describe our experience with a multimodality approach for the treatment of mesothelioma, incorporating extrapleural pneumonectomy, intraoperative photodynamic therapy and postoperative hemithoracic IMRT. […] The median radiation dose to the planning treatment volume (PTV) ranged from 45.4-54.5 Gy. […] Multimodality therapy combining surgery with increased doses of radiation using IMRT, and newer treatment modalities such as PDT , appears safe. […] Future prospective analysis will be needed to demonstrate efficacy of this approach in the treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2069994&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
If these active new therapies are identified, it would be useful to compare them to a best supportive care regimen in order to demonstrate an advantage of the treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-08-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2072706&#34; target=&#34;_blank&#34;&gt;The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is usually a fatal cancer for which operation has been the mainstay of treatment because chemotherapy and radiation are relatively ineffective. […] Patients who were not candidates for extrapleural pneumonectomy had a more limited operation with or without adjuvant therapy or had nonsurgical treatment. […] Extrapleural pneumonectomy was associated with a greater likelihood of relapse in distant sites than were limited operation and nonsurgical treatment. […] We conclude that (1) only a small proportion of all patients with malignant pleural mesothelioma are candidates for extrapleural pneumonectomy, (2) extrapleural pneumonectomy carries a significant operative mortality and does not seem to improve overall survival compared with more conservative forms of treatment, (3) extrapleural pneumonectomy alters the patterns of relapse, and (4) factors previously thought to have an impact on survival in other series did not affect outcome in this trial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2072707&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy alone has proved disappointing in the treatment of this disease, as have chemotherapy and radiotherapy. […] From 1980 to 1990, 31 patients with pleural mesothelioma underwent multimodality therapy that included extrapleural pneumonectomy with resection of the pericardium and diaphragm. […] All patients had the pathologic diagnosis reviewed before treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20802345&#34; target=&#34;_blank&#34;&gt;A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients who underwent trimodality therapy involving EPP and adjuvant chemoradiotherapy had a median overall survival of 13 to 23.9 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20802350&#34; target=&#34;_blank&#34;&gt;Prognostic factors for survival after surgical palliation of malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, an appreciation of the influence of selection on survival after surgical palliation of malignant pleural mesothelioma, especially that of unforeseen prognostic factors, is useful when evaluating the results of aggressive treatment such as chemoradiotherapy and radical surgery for these diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20853774&#34; target=&#34;_blank&#34;&gt;[Expectations after ban on asbestos].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sadly, the diagnosis of mesothelioma is seldom timely, and treatment is usually unsuccessful.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20857819&#34; target=&#34;_blank&#34;&gt;[Experience in treating patients with malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We should therefore consider selecting a multimodality treatment for such patients because the administration of either systemic chemotherapy or radiotherapy was found to be associated with a favorable prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2085857&#34; target=&#34;_blank&#34;&gt;[Diagnosis of pleural metastatic carcinoma with fibrous bronchoscope in thoracoscopy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hence it gives the feasibility of reasonable treatment in the patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20858727&#34; target=&#34;_blank&#34;&gt;Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Alternative treatment strategies such as oncolytic viral therapy may offer promising treatment options in the future. […] In vivo studies with MSTO-211H* cells showed complete response to viral therapy in 65% of the animals within 14 days after treatment initiation. […] Multiple treatment compared with single treatment showed a significantly better response (P = 0.005). […] NDV seems to be an efficient viral oncolytic agent in the therapy of malignant pleural mesothelioma in an orthotopic pleural mesothelioma tumor model.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20881372&#34; target=&#34;_blank&#34;&gt;A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pretreatment clinical, laboratory and radiographic features of each patient at the time of diagnosis were obtained from patients’ charts.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20887499&#34; target=&#34;_blank&#34;&gt;Prevention of malignant seeding at drain sites by hypofractionated radiotherapy in patients with pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients underwent surgery or thoracoscopy and/or talc pleurodesis, for diagnosis, staging procedures or as a treatment. […] All were treated with electron (12 MeV) external beam radiation therapy (21 Gy in three fractions over 3 days), directed to the instrumentation pathway after the invasive procedure. […] The most common side-effect was grade 1 erythema (Radiation Therapy Oncology Group [RTOG] scale), noted in 13 treated patients. […] Larger multicenter prospective trials are still needed to validate this treatment approach utility for it to be recommended routinely.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20933167&#34; target=&#34;_blank&#34;&gt;[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The SLC was a pemetrexed therapy in 21 patients and a new regime in 20 patients (gemcitabine alone or with oxaliplatin). […] Four of these 44 patients then received third-line (4.8 %) and two received fourth-line therapy (2.4 %). […] The optimal treatment has not been defined to date and prospective trials are needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20949562&#34; target=&#34;_blank&#34;&gt;Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis for which an effective therapy remains to be established. […] Our study investigated the therapeutic potential of the suppressor of cytokine signaling 3 (SOCS3), an endogenous inhibitor of intracellular signaling pathways, for treatment of MPM. […] Notably, AdSOCS3 treatment inhibited tumor growth in an MPM pleural xenograft model. […] These findings demonstrate that overexpression of SOCS3 has a potent antitumor effect against MPM both in vitro and in vivo and indicate the potential for clinical use of SOCS3 for MPM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20949774&#34; target=&#34;_blank&#34;&gt;Treatment of malignant pleural mesothelioma: current status and future directions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An optimal treatment for MPM is not established yet; new therapies and predictive tools are still needed in the management of this cancer. […] The authors also briefly reviewed the future directions in MPM treatment including targeted therapies, gene or cell therapies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20956618&#34; target=&#34;_blank&#34;&gt;High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with MM who had systemic therapy at participating institutes were studied. […] Overall survival from commencement of therapy was determined by the Kaplan-Meier method. […] A total of 173 MM patients undergoing systemic therapy including 119 patients receiving first-line therapy and 54 patients receiving second- or third-line therapy were included in this retrospective evaluation. […] Our results indicate that NLR is an independent predictor of survival for patients with MM undergoing systemic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20968144&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiation therapy with simultaneous integrated boost in unresected left-sided pleural mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two months after the end of radiotherapy the patient showed grade 2 lung toxicity (febrile episodes accompanied by dry cough) that was successfully treated with steroid therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20969861&#34; target=&#34;_blank&#34;&gt;MT1-MMP plays an important role in an invasive activity of malignant pleural mesothelioma cell.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) has a poor prognosis and is a treatment resistant tumor, which is increasing in frequency throughout the world.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21036757&#34; target=&#34;_blank&#34;&gt;TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, pemetrexed (PEM), a new generation antifolate, has been used for the treatment of patients with advanced non-squamous cell carcinoma (SQ) of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). […] Further investigations are necessary in order to develop biomarkers to determine the clinical benefits of PEM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21038142&#34; target=&#34;_blank&#34;&gt;Malignant pericardial mesothelioma following thoracal radiotherapy; dissemination from pericardium to pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A known effective treatment does not exist and the prognosis is poor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21042767&#34; target=&#34;_blank&#34;&gt;Inhibition of activated phosphatidylinositol 3-kinase/AKT pathway in malignant pleural mesothelioma leads to G1 cell cycle arrest.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, we found that the protein level of p27Kip1 was up-regulated and the protein level of cyclin D1 was down-regulated following LY294002 treatment in those MM cell lines. […] However, no noticeable apoptosis induction was observed following 24 h of LY294002 treatment in those MM cell lines.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21044230&#34; target=&#34;_blank&#34;&gt;Translational advances in pleural malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Examples are the establishment of folate antimetabolites in mesothelioma treatment, the use of PET in mesothelioma management and the discovery of mesothelin as a marker of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21079960&#34; target=&#34;_blank&#34;&gt;The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In vivo data showed that treatment with S-1 significantly reduced thoracic tumors and pleural effusion produced by Y-MESO-14 cells. […] Moreover, treatment with S-1 prolonged the survival of Y-MESO-14 cell-bearing SCID mice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21095037&#34; target=&#34;_blank&#34;&gt;Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We recently analyzed the introduction of Decitabine in therapy for malignant pleural mesothelioma (MPM) observing that, despite the ability to induce profound biological effects in MPM cells, the drug failed to generate a massive apoptotic response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21114785&#34; target=&#34;_blank&#34;&gt;Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a devastating malignancy that until recently has had no effective treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21123992&#34; target=&#34;_blank&#34;&gt;Brain metastasis in malignant pleural mesothelioma presenting as intratumoral hemorrhage.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intratumoral hemorrhage may occur in patients with solitary brain metastasis of MPM, so surgery should be considered as a general candidate treatment for metastatic tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21124760&#34; target=&#34;_blank&#34;&gt;Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study describes a role for ERβ in the modulation of cell proliferation and EGFR activation and provides a rationale to facilitate the targeting of a subgroup of MMe patients who would benefit most from therapy with Gefitinib alone or in combination with Akt inhibitors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21129871&#34; target=&#34;_blank&#34;&gt;Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To prospectively analyze different FDG-PET/CT-parameters (modified RECIST, SUVmax, TLG, PETvol) in patients with malignant pleural mesothelioma (MPM) under continued pemetrexed and platin based treatment. […] Patients with biopsy proven MPM undergoing treatment with pemetrexed and platin based treatment were prospectively included in the study. […] Integrated FDG-PET/CT imaging was performed within 2 weeks before therapy and after every three consecutive cycles of combined chemotherapy. […] Ongoing morphological response in CT using modRECIST had highest correlation with OS and predicted survival up to the 15th cycle of continued permetrexed and platin based treatment. […] Permetrexed and platin based treatment in MPM patients can be given over a prolonged time with good tolerance. […] Therapy response should be assessed by modRECIST in CT but not with SUVmax in FDG-PET. […] Long term permetrexed and platin therapy should be considered in MPM patients with good tolerance of treatment and ongoing morphological response in CT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21132036&#34; target=&#34;_blank&#34;&gt;Delayed bronchial stump dehiscence following trimodality treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Delayed fistula following tri modality treatment for mesothelioma is a serious problem regarding diagnosis and treatment. […] Only 58 patients completed the assigned tri modality treatment, five of them developed delayed bronchial stump dehiscence. […] The initial treatment consisted of tube thoracostomy followed by exploration through the previous thoracotomy incision with thorough curettage and wash of the infected space and removal of any exposed infected mesh.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21136185&#34; target=&#34;_blank&#34;&gt;Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The research on this subject has focused on the following five domains: (1) differentiation of MPM from other benign pleural diseases, (2) preoperative staging for the selection of appropriate candidates for surgery, (3) evaluation for therapy response and post-treatment surveillance for recurrence, (4) prognostication based upon the intensity of 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) uptake, and (5) planning of radiotherapy. […] From the available data, the major role of PET-CT at present appears to be in the preoperative disease staging, response to treatment assessment, and post-treatment disease surveillance of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2115034&#34; target=&#34;_blank&#34;&gt;Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The optimization of radiotherapy for the treatment of malignant mesothelioma highlights many of the currently outstanding problems in clinical radiation physics. […] Furthermore, great care needs to be exercised in the treatment planning calculations for this approach if absolute dosimetry errors as large as 50% are to be avoided.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21155649&#34; target=&#34;_blank&#34;&gt;Can “steroid switching” improve steroid-induced musical hallucinations in a patient with terminal cancer?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, on day 40, her dyspnea was aggravated again, so we started treatment with prednisolone (5 mg/d).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21163253&#34; target=&#34;_blank&#34;&gt;Identification of cancer stem cell markers in human malignant mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is an aggressive and therapy-resistant neoplasm arising from the pleural mesothelial cells and usually associated with long-term asbestos exposure. […] Recent studies suggest that tumors contain cancer stem cells (CSCs) and their stem cell characteristics are thought to confer therapy-resistance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21173534&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: a clinical study of 238 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival overall was poor (mean 8.8 months), but treatment was beneficial (mean 11.3 versus 6.4 months). […] Epithelioid histology conferred a survival advantage over sarcomatoid and responded better to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2117478&#34; target=&#34;_blank&#34;&gt;[Treatment of malignant mesothelioma using intrapleural gamma interferon].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Evaluation of responses was based on a CT scan performed 2 weeks after the end of treatment; and on a repeat thoracoscopy with histopathological verification. […] In 6 patients we observed a complete histopathological response, lasting for 2 months in 1 patient. 1 patient was operated on after failure of Interferon treatment, 1 patient died 1 month after the end of the treatment; the death has not apparent connexion with the treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21177406&#34; target=&#34;_blank&#34;&gt;Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings show the potential value of changes in mesothelin levels for prognostication and monitoring of treatment response in mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21178907&#34; target=&#34;_blank&#34;&gt;European guidelines for the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent progress has reshaped the clinical landscape in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21183281&#34; target=&#34;_blank&#34;&gt;Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. […] Targeted EGFR therapy has been successful in non-small cell lung cancer using small molecule tyrosine kinase inhibitors and in colorectal cancer using monoclonal anti-EGFR antibodies. […] However, phase II clinical trials based on EGFR tyrosine kinase inhibitor therapy have so far not shown promise in mesothelioma. […] This review includes a background to targeted EGFR treatment strategies, explores putative therapy resistance mechanisms, including the role of predictive biomarkers, and describes the current status of targeted EGFR therapeutic strategies for mesothelioma patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21196199&#34; target=&#34;_blank&#34;&gt;Antiangiogenic therapies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To explore molecular pathogenesis and evaluate the efficacy of vascular targeting therapy in MPM, we developed orthotopic implantation SCID mouse models of MPM. […] We found that selective VEGF inhibitors were effective only in the treatment of high-VEGF-producing MPM models.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2120965&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: CT manifestations in 50 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pretreatment CT findings from 50 patients with malignant pleural mesothelioma are illustrated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-11-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21210110&#34; target=&#34;_blank&#34;&gt;FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study investigated the diagnostic performance and prognostic value of fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in suspected malignant pleural mesothelioma (MPM) recurrence, in the context of patterns and intensity of FDG uptake, histologic type, and treatment algorithm. […] Fifty patients with MPM underwent FDG PET/CT for restaging 11 ± 6 months after therapy. […] Progression-free survival was defined as the time between treatment and the earliest clinical evidence of recurrence. […] Overall survival was defined as the time between initial treatment and death or last follow-up date. […] Treatment failure was confirmed in 42 patients (30 epithelial and 12 non-epithelial MPM). […] Lesion uptake was lower in patients previously treated with more aggressive therapy and higher in intrathoracic lesions of patients with distant metastases. […] FDG PET/CT helped in the selection of 12 patients (29%) who benefited from additional previously unplanned treatment at the time of failure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21216487&#34; target=&#34;_blank&#34;&gt;Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of second-line therapy in patients with malignant pleural mesothelioma (MPM) progressing after first-line pemetrexed-based chemotherapy (PBC) is currently undefined. […] Recent case series have suggested a possible role of re-treatment with PBC. […] Patients with complete response (CR), partial response (PR) or stable disease (SD) lasting for at least 3 months after first-line PBC were retreated with PBC, either as second-line (2L) or further-line (&amp;gt;2L) therapy. […] Between October 2004 and July 2009, 31 patients (21 males and 10 females) received re-treatment with PBC as 2L (18 patients) or beyond 2L therapy (13 patients). […] Nine patients (29%) had SD after treatment. […] Median PFS and overall survival (OS) after re-treatment with PBC were 3.8 months and 10.5 months, respectively. […] PFS and OS after re-treatment with PBC were correlated with PFS achieved after first-line PBC (FL-PFS). […] Patients with a FL-PFS &amp;gt;12 months had a median PFS after re-treatment of 5.5 months, while patients with a FL-PFS ≤12 months had a median PFS after re-treatment of 2.5 months; no patient in this group was progression-free at 1 year. […] In conclusion, re-treatment with PBC should be considered as second-line therapy in MPM patients achieving a durable (&amp;gt;12 months) disease control with first-line PBC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21226671&#34; target=&#34;_blank&#34;&gt;Dasatinib: an anti-tumour agent via Src inhibition.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several early- and late-phase clinical trials for chronic myelogeneous leukaemia (CML) have demonstrated the direct inhibition of BCR-ABL fusion protein and SFKs, which led to dasatinib approval by the Food and Drug Administration (FDA) and the European Union for the treatment of imatinib-resistant or -intolerant CML, and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). […] Ongoing clinical trials evaluate dasatinib in the treatment of several solid tumours, including gastrointestinal stromal tumours (GIST), prostate cancer, malignant pleural mesothelioma, sarcomas, NSCLC, colorectal cancer, glioblastoma and other haematologic malignancies as multiple myeloma. […] In respect of these encouraging studies investigating dasatinib in the treatment of patients with GIST, prostate cancer, multiple myeloma and sarcomas, ongoing phase III clinical trials warrant the drug evaluation as recommended agent for the treatment of these diseases, also in association with chemotherapy or other targeted therapies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21227534&#34; target=&#34;_blank&#34;&gt;Rat mesothelioma cell proliferation requires p38δ mitogen activated protein kinase and C/EBP-α.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From this rat model, we conclude that in pleural mesothelioma, p38δ in C/EBP-α mediate proliferation and thus may represent new targets in mesothelioma therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21258257&#34; target=&#34;_blank&#34;&gt;Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Image-guided interstitial (IRT) brachytherapy (BRT) is an effective treatment option as part of a multimodal approach to the treatment of isolated lung tumors. […] In this study, we report our results of computed tomography-guided IRT high-dose-rate (HDR) BRT in the local treatment of inoperable primary and secondary intrathoracic malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21262916&#34; target=&#34;_blank&#34;&gt;Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pemetrexed/platinum agent combination represents the standard of care in first-line treatment for malignant pleural mesothelioma (MPM). […] However, there are no established indicators of responsiveness that can be used to optimize the treatment. […] A significant correlation between low TS protein expression and disease control (DC) to carboplatin/pemetrexed therapy (P = 0.027), longer progression-free survival (PFS; P = 0.017), and longer overall survival (OS; P = 0.022) was found when patients were categorized according to median H-score.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21263312&#34; target=&#34;_blank&#34;&gt;Targeted therapies in malignant pleural mesothelioma: a review of clinical studies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We carried out a comprehensive review of the literature from January 2000 to May 2010 on studies that assessed targeted agents for the systemic treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21270668&#34; target=&#34;_blank&#34;&gt;A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is difficult to measure radiographically due to the nonradial and variable pattern of growth and response to therapy. […] With this consistency, we may be able to better estimate the prognosis and response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21273389&#34; target=&#34;_blank&#34;&gt;Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Volumetric measurement of MPM on CT using Myrian software is a reliable, reproducible and sensitive method to measure tumour volume and, thus, therapy response after induction chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21277646&#34; target=&#34;_blank&#34;&gt;Telomerase activity in pleural malignant mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conclude that MPM is a tumour that could be considered for anti-telomerase therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21288646&#34; target=&#34;_blank&#34;&gt;Advances in the biology of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, malignant pleural mesothelioma therapy is guided by clinical stage and patient characteristics rather than by the histological or molecular features of the tumor. […] A greater understanding of the molecular pathways involved in malignant pleural mesothelioma is needed to develop better diagnostics, therapeutics, and preventative measures. […] Moreover, understanding the biological basis of mesothelioma progression may facilitate personalized treatment approaches, and early identification of poor prognostic indicators may help reduce the heterogeneity of the clinical response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21296448&#34; target=&#34;_blank&#34;&gt;Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, after the first-line standard pemetrexed/platinum combination there is not a defined regimen for the second line treatment of MPM, and the clinical benefits in fit patients are uncertain. […] Eligible patients should have relapsed after first-line chemotherapy with pemetrexed plus cisplatin (24%) or carboplatin (76%); 53% of the patients had previously received trimodality treatment, 18% neoadjuvant chemotherapy followed by pleurectomy/decortication, 29% were inoperable. […] The combination of gemcitabine with carboplatin/cisplatin was administered as second line treatment in 13 (76%) patients, as third line in 4 (24%) patients. […] In the intent-to-treat population median survival was 28 weeks (range 13-168) and median time-to-treatment failure 15 weeks (range 3-75).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21303872&#34; target=&#34;_blank&#34;&gt;Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma–institutional review and current update.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy (EPP) has been established as a viable surgical option in the treatment of malignant pleural mesothelioma (MPM) for selected patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21310625&#34; target=&#34;_blank&#34;&gt;Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery-based multimodality therapy is associated with long-term survival in a significant number of pleural mesothelioma patients. […] These data support the role of macroscopic cytoreduction through extrapleural pneumonectomy in the context of multimodality therapy to extend survival for malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21317924&#34; target=&#34;_blank&#34;&gt;Onconase mediated NFKβ downregulation in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) results in disruption of protein translation and cell apoptosis. […] Treatment with 20 μg/ml of Onconase significantly decreased cell count and invasion. […] Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines. […] NFKB1 (p50) expression and downstream targets were also decreased with Onconase treatment, as well as with forced expression of miRNA mimic and inhibitors. […] Onconase treatment caused a significant decrease in cell proliferation, invasion and in expression of certain miRNAs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21334282&#34; target=&#34;_blank&#34;&gt;Platinum-bisphosphonate complexes have proven to be inactive chemotherapeutics targeted for malignant mesothelioma because of inappropriate hydrolysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Bisphosphonates (BPs), the synthetic analogues of pyrophosphate, are widely used in the treatment of metabolic bone diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21345818&#34; target=&#34;_blank&#34;&gt;Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The question addressed was whether pleurectomy/decortication (P/D) is superior to palliative care in the treatment of patients with malignant pleural mesothelioma (MPM). […] We conclude that P/D may lead to superior survival rates but at the expense of higher morbidity rates to palliative treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21346022&#34; target=&#34;_blank&#34;&gt;What is the role of radiotherapy in malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No randomized data exist to support the use of radiotherapy after radical surgery, although there are a large number of publications describing its use as an integral part of therapy, including seven phase II studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21348586&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy for malignant pleural mesothelioma: the future of treatment?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One such modality, photodynamic therapy, is a light-based cancer treatment that has features making it particularly well suited as a component of a surgery-based multimodal treatment plan. […] Utilizing intraoperative photodynamic therapy has enabled development of a less drastic surgical procedure that is also yielding some encouraging survival results. […] A unique aspect of photodynamic therapy is its stimulation of a tumor-directed immune response, a feature that offers promise for designing future treatments.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21351265&#34; target=&#34;_blank&#34;&gt;Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This research points to novel approaches using miRNAs whose decreased expression is unique to mesothelioma as potentially suitable for rapid diagnosis and reveals prospective new targets for the treatment of this deadly disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21361192&#34; target=&#34;_blank&#34;&gt;Computerized segmentation and measurement of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The current linear method to track tumor progression and evaluate treatment efficacy is insufficient for malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21364680&#34; target=&#34;_blank&#34;&gt;Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cisplatin (cis-diamminedichloroplatinum (II)) is a chemotherapeutic drug that is clinically used for the treatment of solid tumours.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21368492&#34; target=&#34;_blank&#34;&gt;[A case of coexisting malignant mesothelioma and squamous cell carcinoma of the lung].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemotherapy with carboplatin, gemcitabine and radiation therapy was performed, but the patient died from deterioration of his systemic condition.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21375472&#34; target=&#34;_blank&#34;&gt;Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM), an asbestos-related aggressive malignant tumor of mesothelial origin, shows limited response to therapy and overall survival remains very poor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21383961&#34; target=&#34;_blank&#34;&gt;Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Enzastaurin treatment resulted in significant loss in viability of VEGF induced cell proliferation; however, the effect of KRN633 was much less. […] Treatment of C. elegans with enzastaurin resulted in clear phenotypic changes and the worms were hypermotile with abnormal pattern and shape of eggs, suggesting altered fecundity. […] In addition, we show here that C. elegans can be used to screen for the next generation inhibitors as treatment with enzastaurin resulted in clear phenotypic changes that could be assayed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21388071&#34; target=&#34;_blank&#34;&gt;An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
When surgical treatment cannot be performed, systemic chemotherapy remains the main therapeutic option.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21388982&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The question addressed was whether extrapleural pneumonectomy (EPP) is superior to supportive care in the treatment of patients with malignant pleural mesothelioma (MPM). […] We conclude that EPP confers no advantage to chemotherapy and palliative treatment in terms of survival and symptom improvement. […] Two studies analysed palliative treatment in mesothelioma and reported a median survival of seven months and improvement in symptoms in 25% of patients at one-year post-treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21404104&#34; target=&#34;_blank&#34;&gt;The evolution of multimodality therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As such, surgical resection and other local therapies have long been pursued as a primary form of treatment. […] As such, many groups have pursued multimodality therapy, treating resectable patients with EPP, along with hemithoracic radiation to decrease the risk of local recurrence and chemotherapy to decrease the risk of distant metastatic disease. […] Additionally, many patients are unable to tolerate complete courses of adjuvant therapy after EPP. […] Yet, advances in radiation technique have allowed the exploration of high-dose radiation therapy after P/D.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21435101&#34; target=&#34;_blank&#34;&gt;Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Human malignant pleural mesothelioma (HMPM) is highly resistant to conventional therapy, and therefore novel therapies are required. […] We previously reported that overexpression of the FUSE-binding protein-interacting repressor (FIR), a c-myc transcriptional repressor, induces apoptosis via c-Myc suppression, and is thus a suitable cancer therapy. […] Combination therapy with SeV/ΔF/FIR plus cisplatin was evaluated in vitro and in a mouse model. […] Moreover, combination therapy with SeV/ΔF/FIR plus cisplatin demonstrated significant tumor reduction and improvement in survival rate in an animal model. […] Combination therapy with SeV/ΔF/FIR plus cisplatin has therapeutic potential against HMPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21451928&#34; target=&#34;_blank&#34;&gt;Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median time to treatment failure was 1.86 months (95% confidence interval [CI] 0-6.5). […] The results of this retrospective study and literature review show that pemetrexed is safe and efficacious in the treatment of Asian patients with NSCLC and mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21454801&#34; target=&#34;_blank&#34;&gt;An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pretreatment with an EGFR phosphorylation or mitogen-activated protein kinase kinase 1/2 inhibitor abrogated asbestos-induced phosphorylated ERK (pERK) 1/2 levels in both LP9/TERT-1 and MET5A cells as well as increases in pAKT levels in MET5A cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21465419&#34; target=&#34;_blank&#34;&gt;Surgical treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, survival rates remain dismal and there is no standard therapy or consensus regarding treatment. […] However, over the last fifteen years there have been substantial improvements in the diagnosis and treatment of MPM, including easier and more accurate diagnostic techniques, improved methods of staging, more effective systemic therapy, a remarkable decrease in operative mortality, marked improvements in local control with adjuvant therapy, and perhaps most important, an emphasis on multidisciplinary care and multimodality clinical trials. […] Despite these advances, optimal therapy for these patients remains highly controversial and the role of surgery is actively debated. […] To date, trimodality therapy that includes surgery, chemotherapy, and radiation offers the best survival advantage. […] Ultimately, the choice of operation depends on multiple factors including: disease stage, the patient’s cardiopulmonary reserve, surgeon experience and philosophy, and the extent of planned adjuvant therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21468683&#34; target=&#34;_blank&#34;&gt;Chemotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. […] For less fit patients, single agents can be used as frontline therapy. […] In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. […] Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21469421&#34; target=&#34;_blank&#34;&gt;Cytopathologic diagnosis in pleural effusion and cyto-histopathologic correlation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Identification of malignant effusions bears critical importance in treatment and prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21471536&#34; target=&#34;_blank&#34;&gt;Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The antiproliferative effects of three synthetic analogs of aliphatic acetogenins selected from a previous screening were compared to those of the drugs used for the treatment of malignant pleural mesothelioma (MPM) and pancreatic ductal adenocarcinoma (PDAC). […] Phosphorylated Akt levels rose after treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21473730&#34; target=&#34;_blank&#34;&gt;Soluble markers for diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, there has been increased interest in noninvasive, economic and well-accepted diagnostic tests for screening of asbestos-exposed subjects, as well as for monitoring response of MPM patients to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21479894&#34; target=&#34;_blank&#34;&gt;Imaging of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
FDG18-PET/CT provides anatamo-metabolic information and is superior to both CT and MRI in overall staging and monitoring response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21479898&#34; target=&#34;_blank&#34;&gt;Surgical therapy of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of malignant pleural mesothelioma is controversial, particularly regarding the role of surgery. […] Pleurectomy/decortication (PD) can achieve macroscopic complete resection; however, the ability to deliver effective postoperative radiation treatment is limited because of the risk of lung toxicity. […] Furthermore, no randomized data currently exist that demonstrate a survival benefit to any form of surgical cytoreduction over systemic treatment and supportive care.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21479899&#34; target=&#34;_blank&#34;&gt;Chemotherapy and radiotherapy for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover an optimal treatment for MPM is not defined yet, even if ERS/ESTS experts recently provided clear and up-to-date guidelines on MPM management.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21483773&#34; target=&#34;_blank&#34;&gt;Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Improved detection methods for diagnosis of malignant pleural mesothelioma (MPM) are essential for early and reliable detection as well as treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21500129&#34; target=&#34;_blank&#34;&gt;Update on malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Key questions about maintenance therapy and the optimal regimens for elderly and frail patients remain to be answered.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21503595&#34; target=&#34;_blank&#34;&gt;Medical treatment of mesothelioma: anything new?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, intensity-modulated radiation therapy and proton therapy have been introduced as new radiation methods into the combined modality. […] In addition, clinical studies that include molecular targeting agents, immunotherapy, and gene therapy have all been conducted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21504322&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: when is radiation therapy indicated?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an aggressive tumor of serosal surfaces resistant to many current treatment options. […] This article will provide a comprehensive discussion of the latest developments in the treatment of malignant pleural mesothelioma, with a focus on radiation therapy. […] We will discuss the role of radiotherapy as a prophylactic, palliative and potentially curative treatment of malignant pleural mesothelioma. […] An update will be provided of the latest clinical trials including new treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21512863&#34; target=&#34;_blank&#34;&gt;Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A number of quantitative, clinical, and treatment-related factors were identified to have significant impact on overall survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21532502&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Local therapy is becoming increasingly important as a part of the definitive treatment for malignant pleural mesothelioma after extrapleural pneumonectomy (EPP) because of the emergence of trimodality therapy consisted of chemotherapy, EPP, and adjuvant radiotherapy. […] Herein, we explore the current evidence and indications for adjuvant intensity-modulated radiotherapy (IMRT), as well as how to further improve this technique and adapt new technology in the delivering adjuvant radiotherapy in the setting of trimodality therapy. […] Local control remains poor despite the inclusion of conventional adjuvant radiation therapy in trimodality therapy. […] New advances in technology can allow for lower doses to the contralateral lung, decreased treatment delivery time, and improved target dose coverage. […] Post-treatment surveillance may be reliably conducted by periodical [18F]-fluorodeoxyglucose-positron emission tomography imaging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21537191&#34; target=&#34;_blank&#34;&gt;The diminishing role of surgery in pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Traditionally, many patients were subjected to surgery for diagnosis and treatment. […] Surgery as first-line therapy for empyema was studied in four randomized studies with mixed results and no consistent benefits.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21540305&#34; target=&#34;_blank&#34;&gt;Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, MUC1 expression and antigen presentation by MPM cells may represent an attractive target for immunotherapeutic treatment of MPM despite its hyperglycosylated profile.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21540307&#34; target=&#34;_blank&#34;&gt;A 5-aza-2’-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive tumour with a limited response to conventional therapy. […] In vivo, treatment with 5-azaCdR/VPA inhibited tumour growth, and promoted lymphocyte infiltration and an immune response against tumour cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21553148&#34; target=&#34;_blank&#34;&gt;Review on clinical trials of targeted treatments in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment in first- and second-line targeted agents induced response rates ranging from 0-14% and 0-16%, respectively. […] The tyrosine kinase inhibitor sunitinib induced partial response in 10% and stable disease in 66% of MPM patients as second-line treatment. […] A preliminary analysis of a phase II/III trial suggests that addition of bevacizumab to pemetrexed and cisplatin first-line treatment significantly improves disease control (CR + PR + SD) in the bevacizumab arm (73.5%) compared with treatment with pemetrexed and cisplatin without bevacizumab (43.2%) (P = 0.010). […] None of the hitherto explored targeted treatments can currently be recommended as standard treatment in MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21556556&#34; target=&#34;_blank&#34;&gt;Natural-killer cell-mediated cytotoxicity of blood-lymphocytes from patients with malignant mesothelioma treated by intrapleural interleukin-2.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have examined the kinetics of the NK cell-mediated cytotoxicity of blood lymphocytes in patients after intrapleural rIL-2 administered for the treatment of pleural cancer. […] Two patients received respectively 3 cycles and 2 cycles of treatment. […] These results likely point out the significance of NK-activity in the IL-2-induced antitumoral response and the interest of this in vitro assay for screening patients for further cycles of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21573909&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the past, the treatment of this disease was limited to marginally effective chemotherapy and morbid surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21594397&#34; target=&#34;_blank&#34;&gt;A patient-like human malignant pleural mesothelioma nude-mouse model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Human malignant pleural mesothelioma is an aggressive cancer with no effective treatment. […] A relevant animal model is required to study the biology and to develop effective treatment. […] This model provides for the first time a useful human model for biological studies of this disease and for developing effective treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21594471&#34; target=&#34;_blank&#34;&gt;Pleurectomy, intrapleural cisplatin and interferon followed by systemic carboplatin plus interferon in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since multimodality therapy initially showed promising results, we tested the feasibility of a new approach consisting of pleurectomy, immediately followed by intrapleural chemotherapy with cisplatin (100 mg/m(2) day 1) and alpha-interferon (12x10(6) U/m(2) days 1 and 2), followed by 4 cycles of carboplatin, 350 mg/m(2), repeated every 3 weeks and associated to alpha-interferon (3x10(6) U/x3/week). […] No treatment-related deaths have been observed. […] Since systemic chemotherapy is correlated with severe side effects, a phase II trial with surgery plus intrapleural treatment alone is ongoing.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21594647&#34; target=&#34;_blank&#34;&gt;Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although, platinum-based agents are the first line of therapy, there is an urgent need for second-line therapies to treat the drug-resistant MPM. […] Curcumin inhibited MPM cell growth in a dose- and time-dependent manner while pretreatment of MPM cells with curcumin enhanced cisplatin efficacy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21610146&#34; target=&#34;_blank&#34;&gt;Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A single intravenous injection of 20 million mesoCAR + CCR2b T cells into immunodeficient mice bearing large, established tumors (without any adjunct therapy) resulted in a 12.5-fold increase in T-cell tumor infiltration by day 5 compared with mesoCAR T cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21615608&#34; target=&#34;_blank&#34;&gt;Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, a strategy to normalize this signaling cascade may be the rationale for developing a new target therapy against MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21619970&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) is a light-based cancer treatment that acts to a depth of several millimeters into tissue. […] This study reviewed the results of patients who underwent a macroscopic complete resection, by two different surgical techniques, and intraoperative PDT as a treatment for malignant pleural mesothelioma. […] Given these results, we believe RP plus PDT is a reasonable option for appropriate patients pursuing a surgical treatment for malignant pleural mesothelioma and that this procedure can serve as the backbone of surgically based multimodal treatments.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21620489&#34; target=&#34;_blank&#34;&gt;Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Human malignant pleural mesothelioma (hMPM) is an aggressive asbestos-associated cancer, the incidence of which is increasing and which, despite progress in diagnosis and therapy, continues to have a poor prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21641092&#34; target=&#34;_blank&#34;&gt;[Usefulness of 18F-FDG PET-CT in the presurgical assessment of malignant pleural mesothelioma treated with neoadjuvant chemotherapy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most commonly used therapy is surgery accompanied by chemotherapy. […] However, these techniques cannot predict early response to therapy, because of the slow structural change of the tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21645831&#34; target=&#34;_blank&#34;&gt;[Value of tomotherapy in malignant pleural mesothelioma: first clinical results].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is little clinical data about the place of helicoidal tomotherapy (HT) in the treatment of malignant pleural mesothelioma (MPM). […] Of the 12 patients who survived treatment, six relapsed (in average 5.1 months after HT): distant.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21651743&#34; target=&#34;_blank&#34;&gt;Pemetrexed in malignant pleural mesothelioma and the clinical outcome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Altogether 197 patients were diagnosed with following histologies: 136 (69%) epithelioid, 19 (10%) sarcomatoid, 17 (9%) mixed, 25 (13%) not specified; 141 (72%) patients received treatment (five extrapleural pneumonectomy, 36 pleurectomy/decortication, 126 chemotherapy). […] Patient groups with various treatments or symptomatic care only reached survival results comparable to those reported in chemotherapy trials, thus emphasising the need for better subtyping of mesothelioma and individualising the treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21656164&#34; target=&#34;_blank&#34;&gt;Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The main challenge for mesothelioma treatment is to go beyond the drug resistance, in particular against cisplatin (CDDP), one of the most used chemotherapeutic drug. […] To improve the effects of CDDP by-passing the resistance of mesothelioma cells to this drug, in the present study we investigated the combined treatment of OMF with CDDP respectively in an established mesothelioma cell line (NCI) and primary mesothelioma cells (Mest).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21658936&#34; target=&#34;_blank&#34;&gt;Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To determine the objective response rate of malignant pleural mesothelioma (MPM) to short course radiation therapy. […] Pre- and post-treatment computed tomography scans were used to assess response. […] Response to treatment was correlated with the European Organisation for Research and Treatment of Cancer (EORTC) prognostic index (p=0.001), performance status (p=0.02) and histological subtype (p=0.04). […] Survival following treatment was correlated with the EORTC prognostic index (p&amp;lt;0.001), histological subtype (p&amp;lt;0.001), performance status (p=0.001), treatment response (p=0.002) and haemoglobin level (0.02). […] The EORTC prognostic index can be used to select patients who are most likely to benefit from this treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21672521&#34; target=&#34;_blank&#34;&gt;Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is known to be widely resistant to therapy and new treatment strategies are needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21673066&#34; target=&#34;_blank&#34;&gt;Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Expression of miR-34a and 34b/c in all methylated cell lines was reduced and restored with 5-aza-2’-deoxycytidine treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21680551&#34; target=&#34;_blank&#34;&gt;Intrathoracic chemo-thermotherapy with radiofrequency waves after extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although multimodal treatment is advocated for malignant pleural mesothelioma (MPM), a standard therapeutic regimen has not been established. […] This study evaluated the outcome of our aggressive treatment including extrapleural pneumonectomy (EPP) and postoperative intrathoracic chemo-thermotherapy (PICT). […] Eleven patients with MPM underwent treatment including EPP followed by PICT using 8 MHz radiofrequency waves. […] The present multimodal treatment including EPP and PICT is promising in local control for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21696568&#34; target=&#34;_blank&#34;&gt;Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We treated patients with locally advanced mesothelioma whose tumours had been sub optimally resected with high-dose three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) to large volumes of one hemithorax, using CT and positron emission tomography (PET) scan-based treatment planning. […] There were no serious treatment-related toxicities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21697784&#34; target=&#34;_blank&#34;&gt;Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Significant improvement of overall survival results has been achieved in the more recent 270 MPM patients through accumulated experience in a specialist treatment center.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21701086&#34; target=&#34;_blank&#34;&gt;[Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The use of blood-based biomarkers might solve this difficulty and allow detection of MM at an early stage when combined treatment involving surgery, chemotherapy and radiotherapy might be effective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21701087&#34; target=&#34;_blank&#34;&gt;[Current status and future direction of Japan’s clinical trial for malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The feasibility and efficacy of trimodality therapy for malignant pleural mesothelioma (MPM) are still controversial mainly due to the lack of clinical evidence. […] Although three major clinical trials on this therapy have been recently reported from North America and Europe, it remains unclear whether results in Caucasian populations may be directly applicable to Asian populations. […] Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21723781&#34; target=&#34;_blank&#34;&gt;Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We aimed to assess the clinical outcomes of patients who were randomly assigned to EPP or no EPP in the context of trimodal therapy in the Mesothelioma and Radical Surgery (MARS) feasibility study. […] Patients aged 18 years or older who had pathologically confirmed mesothelioma and were deemed fit enough to undergo trimodal therapy were included. […] The main endpoints were feasibility of randomly assigning 50 patients in 1 year (results detailed in another report), proportion randomised who received treatment, proportion eligible (registered) who proceeded to randomisation, perioperative mortality, and quality of life. […] Patients and investigators were not masked to treatment allocation. […] These data, although limited, suggest that radical surgery in the form of EPP within trimodal therapy offers no benefit and possibly harms patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21726997&#34; target=&#34;_blank&#34;&gt;Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, silencing of C/EBP homologous protein (CHOP) expression reduced DR5 expression, demonstrating that the transcriptional factor CHOP has a pivotal role on DR5 up-regulation following pemetrexed treatment. […] In addition, enforced expression of cellular FLICE-inhibitory protein (c-FLIP), a known inhibitor of caspase 8, protected neoplastic cells from apoptosis despite pemetrexed and/or TRAIL therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21737558&#34; target=&#34;_blank&#34;&gt;Predicting survival in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With increasing resources and treatment costs for MM over the past 40 yrs, there have been modest improvements in survival but no complete remissions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21739769&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, 40 patients with a definitive diagnosis, who had been followed up for at least 3 years were studied according to these: epidemiologic factors, stage and pathological types, treatment method and complications, and by using factors that influence patients survival, we evaluated them statistically. […] Of patients who underwent decortication and pleurectomy with adjuvant therapy, extrapleural was performed in 20% of patients, and pneumonectomy, in 17.5%; and 15% refused any type of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21755828&#34; target=&#34;_blank&#34;&gt;Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CRP and PCT were measured in pleural fluid and plasma before starting treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21774103&#34; target=&#34;_blank&#34;&gt;Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Expression of phosphorylated RTKs was analyzed by Western blotting and a membrane-based antibody array in normal growth conditions and after treatment by specific inhibitors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21787763&#34; target=&#34;_blank&#34;&gt;Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover, the treatment of IST-Mes2 with TKIs (gefitinib and imatinib mesylate) in combination with cisplatin and gemcitabine did not show additivity. […] Along with the molecular definition of TKIs pharmacological efficacy in vitro, these results may contribute to delve deep into the promising but still controversial role for targeted and conventional drugs in the therapy of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21792917&#34; target=&#34;_blank&#34;&gt;Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No treatment prolongs the survival of malignant mesothelioma (MM) patients. […] Treatment with the DNA hypomethylating agent 5-aza-2’-deoxycytidine did not significantly affect the expression of B7-H3 mRNA in MM cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21816418&#34; target=&#34;_blank&#34;&gt;The cytostatic effects of lovastatin on ACC-MESO-1 cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is known to be widely resistant to therapy, and new treatment strategies are needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21821492&#34; target=&#34;_blank&#34;&gt;SEOM guidelines for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery (radical extra-pleural pneumonectomy or pleurectomy/decortication) may be part of the initial treatment for carefully selected patients, generally combined with neoadjuvant or adjuvant chemotherapy and/or adjuvant radiotherapy, and should only be performed by experienced thoracic surgeons as part of a multidisciplinary team. […] Radiotherapy could be used as prophylaxis to reduce the incidence of recurrence at sites of diagnoses or therapeutic instrument insertion, in a multimodal treatment to improve locoregional control and to palliate symptoms. […] Based on the better compliance of neoadjuvant chemotherapy, lower rate of surgical morbidity and the possibility to select the optimal patients to be submitted to surgery, a neoadjuvant strategy is a better option than adjuvant chemotherapy, although there is no standard optimal sequence and types of treatment for multimodal therapy. […] At this time there is no widely approved salvage therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21831962&#34; target=&#34;_blank&#34;&gt;CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
By contrast, CBP501 does not similarly affect the accumulation of tumor cells at G(2)-M that is induced by radiation, doxorubicin, or 5-fluorouracil treatment. […] The enhanced accumulation of tumor cells at G(2)-M upon combined treatment with cisplatin and CBP501 results from an increase in intracellular platinum concentrations, which leads to increased binding of platinum to DNA.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21841505&#34; target=&#34;_blank&#34;&gt;Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study evaluates their use as markers of response to therapy and outcome. […] Blood samples and matched computed tomography scans were collected at diagnosis and, when possible, during and after therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21852688&#34; target=&#34;_blank&#34;&gt;Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These observations suggest that the interactions of TF and TFPI represent a novel therapeutic target in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21875258&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in Singapore.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Eight (21%) patients had surgery with 2 patients receiving trimodality treatment and adjuvant chemotherapy respectively. […] Three patients received adjuvant RT and one patient had no adjuvant therapy. […] Surgery did not affect survival outcomes although patients with dual modality treatment showed a trend towards improved survival. […] Future management of MPM will need to emphasize on both locoregional and systemic control and hence, inclusion of patients in clinical trials for multimodality treatment should be encouraged.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21876457&#34; target=&#34;_blank&#34;&gt;Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Observational prospective study of patients referred for multimodality therapy and operated on at our institution between October 2004 and May 2010. […] In our experience, P/D combined with hyperthermic pleural lavage with povidone-iodine and adjuvant chemotherapy is a well-tolerated multimodality treatment associated with low morbidity and mortality. […] This multimodality treatment compares favorably with classical trimodality regimens involving chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy, in our experience.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21890228&#34; target=&#34;_blank&#34;&gt;Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
More than 90% of patients received the first cycle of Pem/Cis treatment; median number of treatment cycles was 4.0. […] Treatment-associated death was reported in 0.8% of patients. […] Treatment with pemetrexed was generally well tolerated and showed safety and effectiveness comparable to prior clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21904690&#34; target=&#34;_blank&#34;&gt;Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Following treatment with the demethylating agent, 5-azacytidine (5-AZA), KLKB1 mRNA expression was consistently increased in both lung carcinoma and mesothelioma cells, whereas KLK1, BDKRB1 and BDKRB2 mRNA expression was decreased or unchanged. […] Increased expression of KLKB1 after 5-AZA treatment suggests it may function as a tumour suppressor gene in cancers of the lung and pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21916183&#34; target=&#34;_blank&#34;&gt;[Current status of surgical treatment for malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this context, preoperative chemotherapy with cisplatin and pemetrexed, followed by EPP and postoperative hemithoracic radiation is currently considered as “standard therapy” for resectable MPM. […] Results of recent major clinical trials on trimodality treatment (TMT) for MPM were not encouraging; TMT was completed in approximately 50% of enrolled patients, and overall survival ranged 14 to 18.4 months. […] This fact clearly illustrates that patient selection plays a key roll in MPM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21918389&#34; target=&#34;_blank&#34;&gt;Miliary mesothelioma: a new clinical and radiological presentation in mesothelioma patients with prolonged survival after trimodality therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, due to more efficient chemotherapy protocols and aggressive management strategies including induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation therapy, so called trimodality therapy, survival is prolonged in selected patients. […] Herein, we report two cases of treated mesothelioma patients who developed a miliary mesothelioma in the remaining lung 36 and 41 months after undergoing multimodal therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21928246&#34; target=&#34;_blank&#34;&gt;Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin-related peptide (SMRP) is a biomarker that has been proposed for differential diagnosis from pleural metastatic cancer, as well as prognosis and treatment monitoring of malignant pleural mesothelioma (MM). […] We also tested SMRP titers in 2 patients with MM at 5 different times of the disease, to evaluate the trend of the biomarker in the course of therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21937141&#34; target=&#34;_blank&#34;&gt;Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The National Institute for Health and Clinical Excellence (NICE) has previously recommended pemetrexed plus cisplatin for the treatment of patients with advanced malignant pleural mesothelioma (MPM) and WHO performance status 0-1. […] Relative treatment effects are taken from RCTs; cost and utility data from the literature. […] Raltitrexed plus cisplatin is a cost-effective first-line treatment for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21937142&#34; target=&#34;_blank&#34;&gt;Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). […] The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. […] The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. […] Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. […] According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p=0.017) and FL-TTP≥12 (OR: 3.50; p=0.006). […] In pemetrexed pre-treated patients, re-treatment with a pemetrexed/platinum combination significantly reduced the risk-of-death than pemetrexed alone (HR: 0.11; p&amp;lt;0.001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21964533&#34; target=&#34;_blank&#34;&gt;Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cediranib monotherapy has modest single-agent activity in MPM after platinum-based therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21996088&#34; target=&#34;_blank&#34;&gt;Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Following AUY922 treatment, an increase in the sub-G0-G1 cell population, as well as appearance of cleaved PARP expression, indicated the induction of apoptosis. […] In conclusion, AUY922 was effective against most NSCLC cell lines, independent of the type of known molecular alteration, and appears to be a promising new drug for the treatment of NSCLC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21997759&#34; target=&#34;_blank&#34;&gt;Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this review we summarize recent clinicopathological studies that have investigated periostin expression in lung, kidney, prostate, liver cancer, and malignant pleural mesothelioma and discuss the role of periostin isoforms in tumorigenesis and their potential as targets for stroma-targeted anticancer therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21999120&#34; target=&#34;_blank&#34;&gt;Raltitrexed in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Based on these results, raltitrexed is registered for the treatment of MPM in several European countries. […] New treatment options, such as a combination of cisplatin and raltitrexed, which improve patient outcomes with no detrimental effect on quality of life, are a welcome addition to our therapeutic portfolio.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22005473&#34; target=&#34;_blank&#34;&gt;Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After the failure of standard first-line cisplatin/antifolate chemotherapy, there is no accepted treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22020536&#34; target=&#34;_blank&#34;&gt;Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Expression of AQP1 correlated significantly with prognosis in MM, irrespective of treatment or established prognostic factors. […] An agonist or blocker may become useful for treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22024889&#34; target=&#34;_blank&#34;&gt;Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ninety patients who underwent 18F-FDG PET/CT scanning due to a clinical diagnosis or suspicion of MPM prior to therapy were reviewed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22025407&#34; target=&#34;_blank&#34;&gt;Evaluation of platinum-ethacrynic acid conjugates in the treatment of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After treatment, cellular GST activity remained consistently unchanged, while the GSH level increased.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22027538&#34; target=&#34;_blank&#34;&gt;A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment consisted of gemcitabine 250 mg/m in a 6-h infusion on days 1 and 8 and cisplatin at 75 mg/m on day 2 of a 3-week cycle for four cycles, followed by two additional cycles without cisplatin. […] Minimal response or stable disease was seen in 35 (44.9%), whereas only four (5.1%) patients progressed during treatment. […] Because of the acceptable toxicity, remarkable activity, and reasonable cost, this treatment should be further explored.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22028491&#34; target=&#34;_blank&#34;&gt;Polycomb repressor complex-2 is a novel target for mesothelioma therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Knockdown of EZH2 orEED, or DZNep treatment, decreased global H3K27Me3 levels, and significantly inhibited proliferation, migration, clonogenicity, and tumorigenicity of MPM cells. […] Common as well as differential gene expression profiles were observed following knockdown of PRC-2 members or DZNep treatment. […] Pharmacologic inhibition of PRC-2 expression/activity is a novel strategy for mesothelioma therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22031231&#34; target=&#34;_blank&#34;&gt;Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22046338&#34; target=&#34;_blank&#34;&gt;An in vivo platform for tumor biomarker assessment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumor biomarkers provide a quantitative tool for following tumor progression and response to therapy. […] In addition, assessment of biomarkers as indicators of therapy response is confounded by the concomitant use of multiple therapeutic interventions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22054892&#34; target=&#34;_blank&#34;&gt;Gene therapy for lung neoplasms.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Advances in treatment regimens for both diseases have had only a modest effect on their progressive course. […] Gene therapy for thoracic malignancies represents a novel therapeutic approach and has been evaluated in several clinical trials. […] Strategies have included induction of apoptosis, tumor suppressor gene replacement, suicide gene expression, cytokine-based therapy, various vaccination approaches, and adoptive transfer of modified immune cells. […] This review considers the clinical results, limitations, and future directions of gene therapy trials for thoracic malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2206537&#34; target=&#34;_blank&#34;&gt;Eosinophil colony-stimulating factor induced by administration of interleukin-2 into the pleural cavity of patients with malignant pleurisy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemotactic activity for eosinophils was also detected in the pleural fluid during IL-2 treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-11-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22104079&#34; target=&#34;_blank&#34;&gt;Diffuse malignant peritoneal mesothelioma–an update on treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemotherapy alone is considered as a palliative treatment for these patients who are not eligible for radical surgery. […] Due to peritoneal confinement of malignant mesothelioma and low occurrence of metastasis, a locoregional approach consisting of cytoreductive surgery and perioperative intraperitoneal chemotherapy has been introduced as a curative treatment option over the last decade with an overall 5-year survival rate of 29-63%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22123142&#34; target=&#34;_blank&#34;&gt;[Pleuro-pulmonary metastases from a malignant mesothelioma of the tunica vaginalis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The lack of any treatment for metastatic malignant MTV is discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22135283&#34; target=&#34;_blank&#34;&gt;Population-based survival for malignant mesothelioma after introduction of novel chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is known for its dismal prognosis and poor response to conventional treatment. […] To assess the impact of this development on clinical practice and survival at a population-based level, treatment patterns and survival trends were studied for patients diagnosed with mesothelioma in the period 1995-2006. 4,731 records were retrieved from the Netherlands Cancer Registry and chemotherapy use and median survival were analysed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22152931&#34; target=&#34;_blank&#34;&gt;[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, bevacizumab is the only drug that has demonstrated an impact on overall survival in first line treatment for stage IV non-squamous NSCLC, but VEGFR-TKI such as cediranib, aflibercept, vandetanib, pazopanib have shown encouraging results in phase II or III clinical trials. […] It is the only approved drug with an indication in first-line and maintenance treatment for stage IV non-squamous NSCLC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22152932&#34; target=&#34;_blank&#34;&gt;[Follow-up of subjects occupationally exposed to asbestos, what are the objectives, the benefits, and the possible risks?].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no effective treatment for asbestosis but this is an independent risk factor for bronchial carcinoma and it is evidence of heavy asbestos exposure. […] There is no effective treatment for asbestos-related benign pleural diseases but these are markers of exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22154545&#34; target=&#34;_blank&#34;&gt;Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 6/7 MPM cell lines, SAHA treatment resulted in significant levels of apoptosis induction.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2218350&#34; target=&#34;_blank&#34;&gt;[Treatment of pleural tumors].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no such thing as a standard treatment for diffuse malignant mesothelioma of the pleura (DMM). […] Metastatic pleuritis has no other treatment than that of the primary cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22185775&#34; target=&#34;_blank&#34;&gt;Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In fact, butein treatment severely affects tumor engraftment and potentiates the anticancer effects of pemetrexed in mouse xenograft models. […] The possibility of using butein as an additional treatment to current MPM therapies is discussed here.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22190288&#34; target=&#34;_blank&#34;&gt;BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The vinca alkaloid vinorelbine exhibits clinical activity; however, to date, treatment optimization has not been achieved using biomarkers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22194274&#34; target=&#34;_blank&#34;&gt;The application of cold-plasma coagulation on the visceral pleura results in a predictable depth of necrosis without fistula generation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment effect was almost linear and correlated to the generator energy applied. […] A potential clinical application of this technique is treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22219469&#34; target=&#34;_blank&#34;&gt;Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is a body of opinion that advocates extrapleural pneumonectomy (EPP) as the only radical treatment option for locally advanced (T3/T4) malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22223868&#34; target=&#34;_blank&#34;&gt;Novel therapies in phase II and III trials for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite the desperate need to develop better treatment for this disease, the rarity of the tumor type creates formidable challenges in clinical research. […] Most efforts are directed toward improving standard first-line therapy with pemetrexed and cisplatin, or developing effective second-line treatments.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22244608&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Seventy-seven patients affected by early-stage MPM received EPP (40) or P/D (37) associated with multimodal treatment between 1998 and 2009 at our institution. […] The last consecutive 39 (19 EPP and 20 P/D) were asked to answer the EORTC-QLQ-C30 questionnaire at baseline and at 6- and 12-months after treatment completion to evaluate the impact on QoL of both procedures. […] Both procedures caused a significant impairment of all the considered variables of the EORTC-QLQ-C30 questionnaire after treatment completion; only P/D patients returned at baseline levels after 12 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22261805&#34; target=&#34;_blank&#34;&gt;CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive and therapy-resistant neoplasm arising from the pleural mesothelial cells, without established indicators to predict responsiveness to chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22262998&#34; target=&#34;_blank&#34;&gt;Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy (EPP) has been used as a treatment option for selected patients with malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22263055&#34; target=&#34;_blank&#34;&gt;A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality treatment based on preoperative chemotherapy, surgery and adjuvant radiotherapy seems to be a feasible and effective therapeutic option in selected patients.We report on a case of pathological complete response in a patient affected by malignant pleural mesothelioma who was treated with four cycles of preoperative chemotherapy based on carboplatin plus pemetrexed followed by parietal pleurectomy and lung decortication. […] Carboplatin plus pemetrexed was a well tolerated regimen without grade 3-4 haematological toxicity, and this confirm the feasibility of such a treatment as an alternative to the current golden standard based on cisplatin plus pemetrexed.Complete resection allows the pathologist to better describe biological markers of mesothelioma cells, in order to select patients with different treatment outcome and prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22268178&#34; target=&#34;_blank&#34;&gt;Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to assess the usefulness of CT-derived tumor volume, with control for other prognostic factors, for stratifying survival after surgery-based multimodality treatment of a large cohort of patients with epithelial malignant pleural mesothelioma. […] The study cohort comprised 88 patients with epithelial subtype tumors, DICOM-format CT scans, and data regarding neoadjuvant and adjuvant therapy. […] Tumor volume was calculated, and Kaplan-Meier survival and Cox regression analyses were performed to compare the estimated survival functions of patient subgroups based on volume and other covariates related to outcome (sex, age, preoperative platelet count, hemoglobin concentration, WBC count, clinical and pathologic TNM category, and administration of neoadjuvant and adjuvant therapy). […] In univariate analysis, tumor volume, hemoglobin concentration, platelet count, pathologic TNM category, and administration of adjuvant chemotherapy or radiation therapy met the criteria for inclusion in the reverse stepwise regression analysis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22286213&#34; target=&#34;_blank&#34;&gt;Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pt(IV) analogs show good activity on the MPM cell lines, approaching or in some case bypassing that of cisplatin and represent quite promising drug candidates for the treatment of tumors whose chemoresistance is mainly based on glutathione overexpression, such as MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22286268&#34; target=&#34;_blank&#34;&gt;Mechanisms of pleurodesis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although it could–to some degree–interfere with the mechanisms leading to pleurodesis and a carefully balanced clinical decision has therefore to be made, prophylactic treatment with subcutaneous heparin is recommended during hospitalization (immediately before and after the pleurodesis procedure).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22287752&#34; target=&#34;_blank&#34;&gt;A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, other regimens, with or without a platinum agent, are reported to be effective in the treatment of MPM. […] Patients who were diagnosed with MPM and treated with chemotherapy between January 1999 and June 2010 at the Osaka Prefectural Medical Center for Respiratory and Allergic Diseases were studied, and the outcomes of these patients were retrospectively analyzed in relation to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22290897&#34; target=&#34;_blank&#34;&gt;Photodynamic drug delivery enhancement in tumours does not depend on leukocyte-endothelial interaction in a human mesothelioma xenograft model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pre-treatment of tumour neovessels by low-level photodynamic therapy (PDT) improves the distribution of concomitantly administered systemic chemotherapy. […] Low-level PDT pre-treatment selectively enhances the uptake of systemically circulating macromolecular drugs in malignant mesothelioma, but not in normal tissue.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22290898&#34; target=&#34;_blank&#34;&gt;Cyberknife radiosurgery for focal paravertebral recurrence after radical pleurectomy/decortication in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patient remains disease-free at 40 months without any other treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22307011&#34; target=&#34;_blank&#34;&gt;Inflammation-based prognostic indices in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In patients with histologically proven MPM, the inflammation-based prognostic scores modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio were studied and compared with the European Organization for the Research and Treatment of Cancer Prognostic Score (EPS) and other known potential prognostic factors such as gender, histologic subtype, Eastern Cooperative Oncology Group performance status, and baseline blood parameters.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22314292&#34; target=&#34;_blank&#34;&gt;BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multicycle treatment using BioKnife resulted in the efficient rescue of these models, in association with tumor-specific fusion and apoptosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22318326&#34; target=&#34;_blank&#34;&gt;Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intensity-modulated radiation therapy (IMRT) is the state-of-the-art treatment for patients with malignant pleural mesothelioma (MPM). […] The goal of this work was to assess whether intensity-modulated proton therapy (IMPT) could further improve the dosimetric results allowed by IMRT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22329847&#34; target=&#34;_blank&#34;&gt;¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study is to examine the relationship between the expression level of excision repair cross-complementation group 1 (ERCC1) and of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) in various thoracic neoplasm.Three hundreds-eight patients [non-small cell lung cancer (NSCLC)(n=56), malignant pleural mesothelioma (MPM)(n=21), pulmonary metastatic tumors (PMT)(n=148), thymic epithelial tumors (n=49) and pulmonary neuroendocrine tumor (n=34)] who underwent 18F-FDG PET before treatment were included in this study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22330319&#34; target=&#34;_blank&#34;&gt;Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Twenty-one patients with MPM who underwent (18)F-FDG PET before treatment were included in this study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22336237&#34; target=&#34;_blank&#34;&gt;[Clinical analysis of 45 patients with malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The methods of treatment include chemotherapy, surgical operation, radiotherapy and supportive treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22345416&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with MPM often require multimodal treatment with surgery, radiotherapy, and adjuvant or neoadjuvant (presurgical) chemotherapy. […] In Phase II and III clinical trials, combination therapy with pemetrexed and either cisplatin or carboplatin yielded some of the highest rates of tumor response (21-41%) and overall survival (about 12-14 months) reported to date. […] Dual-agent neoadjuvant chemotherapy (cisplatin plus gemcitabine or pemetrexed) followed by radical surgery with or without radiotherapy has been reported to yield median survival of up to 23-29 months in small clinical trials, but larger randomized controlled studies are needed to better define the role of neoadjuvant therapy in MPM management. […] Treatment approaches for MPM include surgery, radiation, and systemic chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22353806&#34; target=&#34;_blank&#34;&gt;First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemotherapy based on platinum is the standard treatment for unresectable malignant pleural mesothelioma (MPM). […] Patients that responded to chemotherapy treatment had better survival than patients who did not.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2237087&#34; target=&#34;_blank&#34;&gt;Diagnosis and treatment of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment appears to prolong survival which ranges from 6 to 12 months with supportive care alone. […] Surgical resection, either with extrapleural pneumonectomy or by pleurectomy/decortications remains the mainstay of treatment because of the relative ineffectiveness of radiation and chemotherapy. […] Surgical resection alone, however, is inadequate, so most current treatment regimens combine operation with radiation and/or chemotherapy. […] Even with aggressive multimodality treatment, the median survival currently ranges from 18 to 24 months. […] A better understanding of prognostic factors, a better staging system, and innovative treatment strategies are desperately needed in this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-12-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22374401&#34; target=&#34;_blank&#34;&gt;Hemithoracic intensity-modulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Postoperative hemithoracic irradiation is regarded as an important part of the curative treatment for resectable malignant pleural mesothelioma (MPM). […] Because the clinical target volume in postoperative MPM is irregular and surrounded by dose-limiting critical structures, intensity-modulated radiation therapy (IMRT) is thought to be suitable. […] There was no treatment-related pneumonitis. […] Hemithoracic IMRT using helical tomotherapy may play a crucial role in adjuvant treatment for MPM after EPP.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22374657&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite the progress made in diagnosis and therapy of this entity the optimal treatment remains a subject of debate. […] In this article we review the current state of treatment and diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22377706&#34; target=&#34;_blank&#34;&gt;Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to determine the differences in SMRP levels in patients with malignant mesothelioma before treatment and in various responses to treatment and to investigate whether SMRP level could be useful in evaluating tumor response to treatment. […] Blood samples were collected before treatment and/or in various responses to treatment. […] Mann-Whitney test was used to determine the differences in SMRP levels in various responses to treatment. […] Median SMRP was 2.80 nmol/L (range 0.00-34.80) before treatment, 0.00 nmol/L (range 0.00-0.00) in complete response, 0.48 nmol/L (range 0.00-4.40) in partial response, 1.65 nmol/L (range 0.00-20.71) in stable disease and 7.15 nmol/L (range 0.44-31.56) in progressive disease. […] Pre-treatment SMRP levels were significantly higher than in stable disease, partial response and complete response (p=0.006), as were SMRP levels in progressive disease compared to stable disease, partial response and complete response (p&amp;lt; 0.001). […] Our findings suggest that SMRP may be a useful tumor marker for detecting the progression of malignant mesothelioma and evaluating tumor response to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22380362&#34; target=&#34;_blank&#34;&gt;Is there a single spot size and grid for intensity modulated proton therapy? Simulation of head and neck, prostate and mesothelioma cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors vary the σ of the initial Gaussian size of the spot, from σ(x) = σ(y) = 3 mm to σ(x) = σ(y) = 8 mm, to evaluate the impact of the proton beam size on the quality of intensity modulated proton therapy (IMPT) plans. […] In our Hyperion treatment planning system (TPS), constrained optimization is applied with respect to the organs at risk (OARs), i.e., the optimization tries to satisfy the dose objectives in the planning target volume (PTV) as long as all planning objectives for the OARs are met.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22388865&#34; target=&#34;_blank&#34;&gt;Curcumin induces autophagy in ACC-MESO-1 cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is known to be widely resistant to therapy and new treatment strategies are needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22409465&#34; target=&#34;_blank&#34;&gt;Systemic treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of second-line chemotherapy is unproven, although pemetrexed can be regarded as the standard option in pemetrexed-naive patients and therapeutic rechallenge with pemetrexed may be considered in selected patients with prolonged disease control after first-line therapy. […] Targeted therapies failed to demonstrate any substantial activity; however, immunotherapies may complement other treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22425923&#34; target=&#34;_blank&#34;&gt;Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nonrandomized prospective study of patients treated by multimodality therapy and operated on between January 2004 and June 2011. […] Trimodality therapy was completed by 68%of the patients in the EPP group and 100%in the P/D group.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22425926&#34; target=&#34;_blank&#34;&gt;Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment. […] We also measured plasma vascular endothelial growth factor and platelet-derived growth factor b and colony stimulating factor 1 (CSF-1) and mesothelin-related protein at baseline and during therapy. […] Fifty percent of the first 12 patients enrolled experienced ≥grade 3 treatment-related adverse events, and therefore, the starting dose was reduced to 50 mg twice daily. […] Survival was markedly longer in patients with lower pretreatment CSF-1 levels and in patients whose CSF-1 levels decreased from baseline during therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22427768&#34; target=&#34;_blank&#34;&gt;Epidemiology of mesothelioma in Egypt. A ten-year (1998-2007) multicentre study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival for different grades and treatment modalities was significant (P &amp;lt; 0.001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22432060&#34; target=&#34;_blank&#34;&gt;Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The traditional treatment strategies have shown only modest improvement towards the disease. […] Despite advances in the diagnostic and treatment approaches the median survival rate for MPM is between 9 to 17 months. […] In this review we give an update on the conventional treatment modalities and discuss about various molecular targets including receptor EphA2, a novel target gene which may be considered as a biomarker for the diagnosis and treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22438785&#34; target=&#34;_blank&#34;&gt;Mesothelioma: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment for early stage disease with surgery and radiation is potentially curative, but many patients either are too ill to undergo aggressive surgery or present with advanced disease. […] Second-line therapy is disappointing. […] Palliative care remains an important component of the management of this devastating illness.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22453539&#34; target=&#34;_blank&#34;&gt;Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospitals.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of malignant pleural mesothelioma (MPM) remains controversial. […] Patients with MPM who were eligible for EPP and multimodality therapy were included in this study. […] Despite recent advances in chemotherapy, surgery, and radiotherapy, survival rates remain low for patients with MPM completing multimodality therapy including EPP.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22459200&#34; target=&#34;_blank&#34;&gt;An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM shows high refractoriety to systemic treatment, single-modality treatment was generally ineffective and did not achieve higher results than supportive care. […] This review will focus on the main clinical studies and overview the results of different chemotherapy regimens in the neoadjuvant treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22466824&#34; target=&#34;_blank&#34;&gt;Prognostic factors in malignant pleural mesothelioma: a retrospective study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The European Organization for Research and Treatment of Cancer prognostic score (EPS) was calculated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22475902&#34; target=&#34;_blank&#34;&gt;18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis of the disease is difficult, delaying effective treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22493390&#34; target=&#34;_blank&#34;&gt;Complete response and long-term survival in malignant pleural mesothelioma: case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current literature evidences the importance of radiation therapy in the adjuvant setting for local control of the disease, as part of a multidisciplinary treatment, with increment of progression-free survival rate, but also of disease-free survival. […] After 6 months, the patient was treated with three-dimensional external beam radiation therapy to the left hemithorax. […] A good staging system and a combined treatment, involving surgery, neoadjuvant chemotherapy and adjuvant radiation therapy, represent a useful strategy not only to contain local disease progression, but even to increase disease-free survival in pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22495008&#34; target=&#34;_blank&#34;&gt;[‘Malignant peritoneal mesothelioma’: a condition difficult to diagnose].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is not yet a consensus concerning the optimal treatment, but a small increase in survival can be achieved by systemic chemotherapy or intraperitoneal therapy consisting of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2250368&#34; target=&#34;_blank&#34;&gt;[A diffuse, pleural, malignant mesothelioma kept in long remission by chemotherapy combining pirarubicin and cisplatin].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors thus have concluded that a combined therapy of doxorubicin and cisplatin is effective for treating a malignant mesothelioma, and that pirarubicin is superior to doxorubicin with reference to side effects.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22510495&#34; target=&#34;_blank&#34;&gt;Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The marginal structural Cox model and the method of inverse probability of treatment weighting (IPTW) have been proposed, originally for observational studies, to make causal inference on time-dependent treatments. […] The improvement in efficiency does not depend on any additional assumptions other than those required by the IPTW method, which is achieved by exploiting the knowledge that the study treatment is independent of baseline covariates due to randomization.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22510946&#34; target=&#34;_blank&#34;&gt;The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although there has been significant progress in MPM treatment, development of more efficient therapeutic approaches is needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-12-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22516382&#34; target=&#34;_blank&#34;&gt;Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the impact of increasing experience with intensity-modulated radiation therapy (IMRT) after extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22519641&#34; target=&#34;_blank&#34;&gt;Anti-angiogenic therapies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, new agents and new treatment strategies are eagerly awaited by patients and clinicians.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22527088&#34; target=&#34;_blank&#34;&gt;What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This risk is higher following extrapleural pneumonectomy (EPP) as part of trimodality therapy, where VTE can be catastrophic.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22532243&#34; target=&#34;_blank&#34;&gt;SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis for which an effective therapy remains to be established. […] This study investigated the therapeutic potential of gene delivery using suppressor of cytokine signaling 1 (SOCS-1), an endogenous inhibitor of intracellular signaling pathways, for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22541196&#34; target=&#34;_blank&#34;&gt;Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to review our experience using RP and intraoperative photodynamic therapy (PDT) for mesothelioma. […] Thirty five of 38 (92%) patients also received systemic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22541236&#34; target=&#34;_blank&#34;&gt;Laparoscopic thoracic duct clipping for persistent chylothorax after extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Initial conservative treatment did not resolve the postoperative chylothorax.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22552400&#34; target=&#34;_blank&#34;&gt;Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed (PEM) is a novel, multitargeted, antifolate, antineoplastic agent for the treatment of non-small cell lung cancer and malignant pleural mesothelioma. […] Treatment with 100 nM NOC-18 for 3 days significantly enhanced PEM-induced cytotoxicity and increased the expression of RFC1 and FPGS in A549 cells. […] Treatment with 10 nM 8-bromo-cGMP (8-Br-cGMP) for 3 days also increased the expression of RFC1 and FPGS in A549 cells. […] Combination therapy with GTN and PEM significantly reduced tumor growth compared with PEM alone in the syngraft model.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22552784&#34; target=&#34;_blank&#34;&gt;The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After treatment with Res, apoptosis signaling cascades were activated by the activation of Bid, Bim, caspase-3 and PARP, upregulation of Bax and downregulation of Bcl-xL.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22562354&#34; target=&#34;_blank&#34;&gt;Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although cisplatin and pemetrexed are key drugs in the treatment of malignant pleural mesothelioma, their drug-drug interactions, cross-resistance and resistance mechanisms in malignant pleural mesothelioma are not well understood.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22566249&#34; target=&#34;_blank&#34;&gt;Huge malignant solitary fibrous tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In conclusion, definitive treatment for solitary fibrous tumor is radical surgical resection with close follow-up for the recurrences.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22574723&#34; target=&#34;_blank&#34;&gt;SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this orthotopic implantation model, treatment with SU6668 effectively reduced tumour weight and pleural effusion volumes, in association with inhibition of the growth of tumour vasculature. […] More importantly, treatment with SU6668 significantly prolonged survival time in mice with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22578202&#34; target=&#34;_blank&#34;&gt;Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In most of the cases the scope of the treatment is only palliative. […] The treatment included topotecan 1.2 mg/m2 i.v. on Days 1 - 3 and PLD 40 mg/m2 on Day 4, every 28 days. […] In all cases, symptoms were significantly improved after the 2nd treatment cycle.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22580933&#34; target=&#34;_blank&#34;&gt;Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive malignancy for which there is no approved targeted therapy. […] In addition, combined use of the MEK and PI3K inhibitors showed an additive or synergistic inhibitory effect on MPM cell growth compared to treatment with either individual drug. […] Treatment with MEK or PI3K inhibitor suppressed the production of thoracic tumors and pleural effusion and prolonged the survival time of EHMES-10 cell-bearing SCID mice. […] The combination therapy more effectively prolonged the survival time compared to treatment with either individual drug.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22584322&#34; target=&#34;_blank&#34;&gt;[The chemotherapy of peritoneal malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Peritoneal malignant mesothelioma is a rare disorder with a poor prognosis, and a standard treatment for it has not yet been established. […] Therefore, treatment of this disorder tends to be selected according to pleura malignant mesothelioma. […] A gemcitabine(GEM)plus cisplatin(CDDP)regimen had been selected as a conventional treatment, but subsequently, pemetrexed(MTA)was covered by health insurance for pleural malignant mesothelioma in 2007, and the MTA plus CDDP regimen became the standard treatment. […] In our institution, the MTA plus CDDP regimen was the first-line treatment, and the GEM plus CDDP regimen was the second-line treatment against peritoneal malignant mesothelioma. […] Palonosetron hydrochloride and aprepitant should be used actively in treatment. […] Also, carboplatin(CBDCA)is effective as an alternative therapy of the CDDP against renal disorder case, but hematotoxicity requires attention.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22590625&#34; target=&#34;_blank&#34;&gt;Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We tested Perifosine activity on human mesothelial cells and different mesothelioma cell lines, in order to provide evidence of its efficacy as single agent and combined therapy. […] This study provides a novel mechanism of action of perifosine, directly inhibiting EGFR/MET-AKT1/3 axis, providing a rationale for a novel translational approach to the treatment of MMe.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22607910&#34; target=&#34;_blank&#34;&gt;Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treating the intact lung with pleural IMRT in patients with malignant pleural mesothelioma is a safe and feasible treatment option with an acceptable rate of pneumonitis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22617507&#34; target=&#34;_blank&#34;&gt;Salvage therapy with topical antifungal for Aspergillus fumigatus empyema complicating extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We describe an unusual case of Aspergillus fumigatus empyema and bronchopleural fistulae after extrapleural pneumonectomy (EPP) and chemoradiotherapy (CRT), which was treated successfully under salvage conditions with debridement, an innovative topical antifungal application and supplemented systemic antifungal therapy and which went on for a definitive surgical procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22617814&#34; target=&#34;_blank&#34;&gt;Asbestos-related pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Advances in the treatment of MPM are limited, but a recent publication highlights the increased morbidity associated with surgical debulking procedures and questions the benefit of these procedures. […] Recent publications have suggested potential treatment benefit and point to areas that would require further investigation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22622048&#34; target=&#34;_blank&#34;&gt;Molecular pathogenesis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several growth factors and their receptors have a significant role in the oncogenesis, progression and resistance to therapy of mesothelioma. […] Epidermal growth factor (EGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF) have been shown as targets for therapy based on promising preclinical data.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22665541&#34; target=&#34;_blank&#34;&gt;Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A higher pretreatment plasma VEGF concentration (n = 56) was associated with shorter PFS (P = .02) and OS (P = .0066), independent of treatment arm.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22666659&#34; target=&#34;_blank&#34;&gt;Investigational approaches for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In view of the poor survival benefit from first-line chemotherapy and the lack of subsequent effective treatment options, there is a strong need for the development of more effective treatment approaches for patients with MPM. […] In an introductory section, the etiology, epidemiology, natural history, and standard of care treatment for MPM will be discussed. […] This review provide an update of the major clinical trials that impact mesothelioma treatment, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. […] The evidence was collected by a systematic analysis of the literature (2000-2011) using the databases Medline (National Library of Medicine, USA), Embase (Elsevier, Netherlands), Cochrane Library (Great Britain), National Guideline Clearinghouse (USA), HTA Database (International Network of Agencies for Health Technology Assessment - INAHTA), NIH database (USA), International Pleural Mesothelioma Program - WHOLIS (WHO Database), with the following keywords and filters: mesothelioma, guidelines, treatment, surgery, chemotherapy, radiotherapy, review, investigational, drugs. […] It is important that the molecular biologic research should first focus on mesothelioma-specific pathways and biomarkers in order to have more effective treatment options for this disease. […] Probably a central mesothelioma virtual tissue bank may contribute to the ultimate goal to identify druggable targets and to develop personalized treatment for the MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22670158&#34; target=&#34;_blank&#34;&gt;FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After TP treatment, there was a mean interval of 14 days (range: 9-22) and 125 days (range: 76-162) between FDG PET/CT staging and restaging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22677987&#34; target=&#34;_blank&#34;&gt;Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multivariate analysis confirmed that the prognosis was better for younger patients and cases of epithelioid type malignant pleural mesothelioma, whereas for patients receiving any single treatment the prognosis was not significantly better than for those given palliative care alone. […] However, patients receiving combined treatments or the multimodality approach had significantly longer median survival and the relative risk of death was respectively 0.57 and 0.61 compared to untreated patients (or those only given symptomatic therapy). […] This is the first study in Italy to assess the effectiveness of different treatment approaches in a significant number of patients treated in one hospital.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2269029&#34; target=&#34;_blank&#34;&gt;[Mesothelioma and mesothelial hyperplasia].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelial hyperplasia has rather good prognosis; but the strategy of therapy may be conservative.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-02-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22704893&#34; target=&#34;_blank&#34;&gt;Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have thus undertaken a combined-analysis of OS, from a 42day landmark, of 526 patients receiving systemic therapy for MPM. […] Analyses included nine MPM clinical trials incorporating six European Organisation for Research and Treatment of Cancer (EORTC) studies. […] Analysis of OS from landmark (from day 42 post-treatment) was considered regarding tumour response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22710421&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: from the bench to the bedside.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, further in-depth analysis still needs to be done for a more advanced deciphering of the step-by-step process leading from early increased mesothelial cell proliferation to invasive mesothelioma, from which we are expecting the development of definitively effective therapy. […] Thus, this review is an overview of the recent advances in the biology of MPM and their potential therapeutic applications in the field of MPM diagnosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22722790&#34; target=&#34;_blank&#34;&gt;Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In a prospective, nonrandomized study, all patients with histologically proven MPM were evaluated from January to December 2010 for trimodality therapy including RP as surgical procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22722923&#34; target=&#34;_blank&#34;&gt;Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The optimal modality of therapy is controversial. […] The median survival in patients who were administered adjuvant therapy after surgery was 24 months, while the median survival in patients who had only surgery was 6 months (p = 0.029). 106 patients were administered pemetrexed-platinum combination and 35 patients were administered gemcitabine-platinum combination as front-line chemotherapy. […] Results of our study suggest that multi-modality treatment regimens consisting of surgery, radiotherapy and chemotherapy prolong overall survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22733539&#34; target=&#34;_blank&#34;&gt;Role of hedgehog signaling in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of tumor-bearing mice with the SMO inhibitor HhAntag led to a significant inhibition of tumor growth in vivo accompanied by decreased Ki-67 and nuclear YAP immunostaining and a significant difference in selected gene expression profile in tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22734486&#34; target=&#34;_blank&#34;&gt;Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several clinical studies such as immunotherapy, gene therapy and molecular targeting agents have been tried for treatment of malignant mesothelioma, however, there is no application for effective clinical treatment. […] Regarding to the cancer-related functions, In this study, suppression of Sp1 protein level followed by induction of MSTO-211H cell apoptosis by cafestol and kahweol were investigated in oreder to determine Sp1’s potential as a significant target for human MPM therapy as well. […] Viability of MSTO-211H and H28 cells were decreased, and apoptotic cell death was increased in MSTO-211H as a result of cafestol and kahweol treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2273604&#34; target=&#34;_blank&#34;&gt;Gallium-67 scanning in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These results suggest that a diffusely increased uptake over the entire involved hemithorax is the most characteristic finding of Ga-67 scan in malignant pleural mesothelioma, and that Ga-67 scans may be helpful as a valuable indicator of the proper therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22750759&#34; target=&#34;_blank&#34;&gt;Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the prognostic and predictive relevance of pretreatment serum C-reactive protein (CRP) in malignant pleural mesothelioma (MPM) patients. […] MPM is a rare but aggressive disease with poor treatment outcome. […] Therapeutic decision is challenging, and predictive biomarkers for better treatment stratification are urgently needed. […] Clinical data, including survival and pretreatment CRP levels, were retrospectively collected from 115 patients with histologically proven MPM. […] Median pretreatment CRP of all patients was 1.19 mg/dL (range: 0.00-22.62 mg/dL). […] Most interestingly, we observed a significant interaction between CRP and treatment modality (P &amp;lt; 0.001). […] Among patients with normal CRP levels, radical tumor resection within multimodality therapy was associated with distinctly prolonged overall survival when compared with treatment protocols without surgery (HR 7.26, 95% CI 3.40-15.49; P &amp;lt; 0.001). […] Our results suggest that multimodality regimens including radical resection increase survival selectively in MPM patients with normal pretreatment serum CRP levels.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22753288&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While the benefit of chemotherapy for advanced disease has been established, many other aspects of treatment continue to be controversial, in particular in regard to surgery and radiotherapy. […] However, the best survival data is reported from groups using multimodality treatment including surgery for patients qualifying from a tumor stage - and functional perspective. […] Translational studies should be included with the final aim of finding reliable markers for response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22753293&#34; target=&#34;_blank&#34;&gt;[Chemotherapy for malignant tumors of lung and pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the current review we give on overview on the current treatment practice for small cell lung cancer (SCLC) as well as on non-small cell lung cancer (NSCLC). […] The main focus is on the novel treatment options for advanced, metastatic NSCLC and the current use of predictive biomarkers in order to personalize therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22770372&#34; target=&#34;_blank&#34;&gt;A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We evaluated the addition of bevacizumab to cisplatin and pemetrexed as first-line treatment in patients with advanced, unresectable MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22781392&#34; target=&#34;_blank&#34;&gt;An open-label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MTX levels were estimated in the pleural fluid and serum once daily throughout the treatment cycles.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22835614&#34; target=&#34;_blank&#34;&gt;Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelin and MPF have proved useful in assessing response to treatment. […] In the near future, their application in clinical practice is probably in monitoring response to therapy, rather than in guiding diagnostic decisions and risk assessment of asbestos-exposed populations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22857894&#34; target=&#34;_blank&#34;&gt;Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of overnight serum-starved cells with IGF increased phosphorylation of downstream target AKT, S6 and 4EBP1 and SP fraction in ZL55, ZL34 and SDM103T2 MPM cell lines. […] In conclusion, the PI3K pathway is playing an important role in regulating the SP phenotype in MPM cells and inhibition of this activity may contribute to a more efficient cancer treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2286397&#34; target=&#34;_blank&#34;&gt;[Cisplatin and cytosine arabinoside (ARA-C) for the therapy of primary and secondary pleural neoplasms].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment used was based on in vitro and in vivo studies which show a synergy between ARA-C and Cisplatin. […] The treatment was repeated weekly. […] All patients had not been previously treated with loco-regional therapy. […] We conclude that combination of Cisplatin and ARA-C is well-tolerated and produces a very high response rate in the treatment of malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22866124&#34; target=&#34;_blank&#34;&gt;Revisiting cutaneous adverse reactions to pemetrexed.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed (Alimta®) is a multitargeted antifolate drug approved as a single agent or in combination with cisplatin for the treatment of a small number of malignancies including advanced and metastatic non-squamous non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22870590&#34; target=&#34;_blank&#34;&gt;Asbestos-related disease: screening and diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite recent advances in the treatment of other types of cancer, patients with mesothelioma currently face a poor prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22879552&#34; target=&#34;_blank&#34;&gt;Prognostic factors in malignant pleural mesothelioma: role of talc pleurodesis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemotherapy was used in 41 patients, port-site radiation in 68, and combined therapy in 26.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22885228&#34; target=&#34;_blank&#34;&gt;Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A combination of cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion (HITHOC) was performed for the treatment of primary and secondary pleural malignancies. […] All the patients received multimodality therapy, including chemotherapy, radiation and surgical resection (pleurectomy/decortication) followed by the HITHOC procedure. […] Early clinical results may encourage the use of this surgical option to provide better local tumour control in a multimodality treatment setting.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22886525&#34; target=&#34;_blank&#34;&gt;Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with HA enhanced the proliferation in both mesothelioma cell lines in comparison to cells without HA treatment. […] The treatment with HA (25 μg/ml) also significantly upregulated the invasion of both types of cells. […] The silencing of CD44 significantly abrogated the effect of HA treatment on the proliferation of ACC-MESO-1 cells and significantly suppressed the proliferation of K921MSO cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22895141&#34; target=&#34;_blank&#34;&gt;Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed-based chemotherapy represents the standard of care in first-line treatment of advanced malignant pleural mesothelioma (MPM). […] Pretreatment tumor samples from 84 patients with histologically confirmed MPM, who received pemetrexed combined with platinum (79 of 84) or single-agent pemetrexed (5 of 84) as first-line treatment, were retrospectively analyzed. […] In addition, high TS protein expression was associated with progressive disease under pemetrexed-based therapy (p = 0.0383), and shorter OS (pCOX = 0.0071), but no association with PFS was observed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22895142&#34; target=&#34;_blank&#34;&gt;A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no accepted second-line therapy for patients with advanced malignant pleural mesothelioma (MPM), whose disease has progressed after first-line chemotherapy. […] Correlative biomarkers did not predict treatment response. […] Consideration should be given to different treatment schedules and examination of other biomarkers for further study of sunitinib in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22903737&#34; target=&#34;_blank&#34;&gt;‘It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An early palliative care referral would improve support and referral strategies during the first 3 months of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22905093&#34; target=&#34;_blank&#34;&gt;Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of malignant mesothelioma, but median survival is still one year. […] Here we report for the first time a genome-wide profile of acquired resistance in the tumour from an exceptional case with advanced pleural mesothelioma and almost six years survival after 39 cycles of second-line pemetrexed/carboplatin treatment. […] Genome-wide analysis with Illumina BeadChip Kit of 25,000 genes was performed on mRNA from pre-treatment and post-resistance biopsies from this individual as well on case and control samples from our previously published study (in total 17 samples).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22909129&#34; target=&#34;_blank&#34;&gt;Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The Chi-squared test was used to determine if there was an association between utilisation of treatment and geographical location. […] Treatment utilisation: 53.6% chemotherapy; 35.5% radiotherapy; 9.4% extrapleural pneumonectomy (EPP); and 72.5% had palliative care involvement. […] There were no major differences in treatment utilisation between patients living in major cities and those in regional NSW (chemotherapy P = 0.42; radiotherapy P = 0.13 and palliative care P = 0.60), except for a higher rate of EPP in regional patients (16.7% vs 5.6%; P = 0.03). […] Survival and treatment utilisation was not significantly different between MPM patients living in major cities and regional NSW, except for a higher rate of EPP in patients in regional NSW.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22918238&#34; target=&#34;_blank&#34;&gt;Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although there has been recent progress in the clinical treatment, current therapeutic approaches do not provide satisfactory results. […] Therefore, development of a molecularly targeted therapy for MM is urgently required.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22921241&#34; target=&#34;_blank&#34;&gt;Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an aggressive malignancy in which radical surgical treatment appears to improve survival. […] It is unknown, however, if radical surgical treatment affects quality of life (QoL) adversely. […] Health-related QoL was assessed using the European Organization for Research and Treatment of Cancer core Quality of Life Questionnaire-C30 tool (EORTC QLQ-C30) before operation and at 1, 5 to 6, and 8 to 9 months postoperatively. […] Patients who have symptoms at baseline can have significant improvement in their QoL after surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22922885&#34; target=&#34;_blank&#34;&gt;Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the mouse model, cetuximab treatment with or without IL-2 significantly inhibited intrathoracic tumor growth and prolonged their survival. […] Cetuximab has the potential to be used as a novel therapy for MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22931420&#34; target=&#34;_blank&#34;&gt;Histone deacetylase inhibitors as potential therapeutic agents for the treatment of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this aspect, the present review is aimed to summarize the existing data regarding the potential utility of HDACIs as therapeutic targets for the treatment of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22933897&#34; target=&#34;_blank&#34;&gt;3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MRI is particularly valuable because a patient is not exposed to the harmful radiation which is important if imaging methods are used repeatedly, like in screening programs or in monitoring of treatment results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22936495&#34; target=&#34;_blank&#34;&gt;Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Baseline anorexia, fatigue, cough, dyspnoea, pain, overall symptomatic distress, interference with normal activity, global QoL and total LCSS score were all significantly related to survival (p &amp;lt; 0.05) after adjusting for established prognostic factors (age, gender, histological subtype and performance status) and treatment effect.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22937937&#34; target=&#34;_blank&#34;&gt;Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This is particularly of relevance when the vasculitis becomes chronic, recurrent or treatment is no longer effective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22939880&#34; target=&#34;_blank&#34;&gt;Comprehensive treatment of malignant mesothelioma patients after the failure of systemic chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, no standard therapy is available. […] The most commonly used therapy is cytoreductive surgery combined with systematic chemotherapy, but the median overall survival (OS) is less than 12 months; moreover, treatments are lacking for patients in whom chemotherapy has failed and/or who cannot withstand surgery. […] We investigated multiple minimally invasive therapies (cryosurgery, photodynamic therapy and intracavity chemotherapy) for the treatment of MM patients in whom systemic chemotherapy had failed. […] Twenty-seven patients were divided into comprehensive (combination of the three therapies) and palliative (intracavity chemotherapy only) treatment groups. […] The OS of patients who received comprehensive treatment was significantly longer than that of those who received palliative treatment (median OS: 64 vs. 9 months, P&amp;lt;0.001). […] This interesting result was not associated with treatment timing, but was closely associated with repeated treatments.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22960937&#34; target=&#34;_blank&#34;&gt;A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment results may be improved by biomarker-directed therapy. […] We further explored the possibility of combining markers into a treatment-response profile to increase the predictive power. […] The ERCC1- and class III β-tubulin-status classified patients as treatment resistant (ERCC1 positive + class III β-tubulin positive) or treatment responsive (ERCC1 negative + class III β-tubulin negative). […] Median progression-free survival (PFS) was 6.7 months in the treatment-resistant group, 15.3 months in the treatment-responsive group, and 8.1 months in the inconclusive group (log-rank p = 0.03). […] Multivariate analysis revealed that treatment-resistant patients had a decreased PFS and overall survival (OS) compared with the treatment-responsive patients (HR 6.45, CI 95 % [2.02-20.64] p = 0.002 and HR 4.64, CI 95 % [1.56-13.79], p = 0.006, respectively). […] Combined negative ERCC1 and class III β-tubulin immunostaining is associated with significantly prolonged PFS and OS in MPM patients receiving cisplatin-vinorelbine therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22969998&#34; target=&#34;_blank&#34;&gt;Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Wnt2B is a potential molecular target for the treatment of Wnt2B-overexpressing MPMs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22982660&#34; target=&#34;_blank&#34;&gt;DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, the aim of our study was to evaluate the influence of genetic variability in DNA repair genes on treatment outcome in patients with malignant mesothelioma (MM) treated with gemcitabine-platinum combination chemotherapy. […] The influence of selected polymorphisms on tumor response and occurrence of treatment-related toxicity was determined by logistic regression analysis, whereas their influence on survival was estimated by Cox proportional hazards model. […] In addition, NBN 3474A&amp;gt;C, XRCC3 -316A&amp;gt;G, and Thr241Met polymorphisms showed significant associations with treatment-related toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22993354&#34; target=&#34;_blank&#34;&gt;Role of conservative (palliative) care-only in the management of advanced malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Outcomes of untreated patients are usually not reported, and whether a treatment can be delayed or avoided is still an open question.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23022841&#34; target=&#34;_blank&#34;&gt;Asbestos exposure and survival in malignant mesothelioma: a description of 122 consecutive cases at an occupational clinic.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
12 (9.8%) patients received tri-modal therapy, 66 (54.1%) received one-/two-modality treatment, and 36 (29.5%) received palliative care. […] Female sex, good WHO performance status (PS), epithelial histology and tri-modal treatment were associated with a favorable prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23028939&#34; target=&#34;_blank&#34;&gt;Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite the recent advances in targeted molecular therapies, there is a clear and urgent need for the identification of novel mesothelioma targets for the development of highly efficacious therapeutics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23036334&#34; target=&#34;_blank&#34;&gt;Carbonic anhydrase IX in malignant pleural mesotheliomas: a potential target for anti-cancer therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To improve both the clinical diagnostics and treatment it is necessary to identify novel molecular targets which are characteristic for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23036697&#34; target=&#34;_blank&#34;&gt;Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No effective therapy has yet been established for WDPMP, and the molecular basis of WDPMP tumorigenesis has never been reported.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23038233&#34; target=&#34;_blank&#34;&gt;Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic non-small cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It was first used in combination with cisplatin as a front-line treatment for malignant pleural mesothelioma. […] Treatment with systemic steroids and intravenous antibiotics as well as topical wound treatment led to resolution and improvement of his general condition.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23040690&#34; target=&#34;_blank&#34;&gt;Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Endostar, in combination with chemotherapy should be explored in the treatment of MM, especially its effect on pleural and ascitic fluid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23050525&#34; target=&#34;_blank&#34;&gt;Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New biomarkers are needed to detect pleural mesothelioma at an earlier stage and to individualize treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23055222&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery is the treatment option most likely to be associated with prolonged remission in patients with malignant pleural mesothelioma. […] Improvements in quality of life for appropriate patients with this rare yet incurable cancer may be obtained with less drastic lung-sparing surgical procedures along with intraoperative use of photodynamic therapy (PDT). […] Multi-institutional trials are necessary to duplicate these early findings and shed more light on the tumor-directed immune response of this surgically based multimodal treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23059782&#34; target=&#34;_blank&#34;&gt;Optimization of response classification criteria for patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Computed tomography measurements of tumor thickness were acquired at baseline and throughout treatment for 78 patients undergoing standard-of-care chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23060969&#34; target=&#34;_blank&#34;&gt;Tunneling Nanotubes: A new paradigm for studying intercellular communication and therapeutics in cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We hope that further understanding of the mechanisms, methods of transfer, and particularly the role of nanotubes in tumor-stromal cross-talk will lead to identification of new selective targets for cancer therapeutics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23064068&#34; target=&#34;_blank&#34;&gt;[One case of malignant mesothelioma that developed right pneumothorax after a diagnosis with left pneumothorax].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have made a diagnosis of malignant pleural mesothelioma with left pneumothorax here, and report our experience with this rare case that complicated the right pneumothorax throughout treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23077450&#34; target=&#34;_blank&#34;&gt;Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
During the last decade, several trials confirmed the benefit of systemic treatment with drugs such as doublets with cisplatina and gemcitabine or pemetrexed for carefully selected patients in good performance status. […] The purpose of this survey was to assess the impact of systemic treatment for the whole national population of patients with mesothelioma. […] Data from the Cancer Registry of Slovenia were supplemented by review of clinical records of the Institute of Oncology in Ljubljana where virtually all non-surgical treatment for mesothelioma was performed. […] We analysed the incidence, treatment, and survival of patients treated in the era of infrequent chemotherapy (1974-2003, the first period) and after it (2004-2008, the second period). […] With a total of 52 (11.7%) operated patients, surgical treatment was rare and used only for selected patients with early disease and without comorbidity, leading to their relatively long median survival of 13.6 months. […] For the whole population of patients regardless the mode of treatment, median survival was 7.4 and 12.6 months (p-value = 0.037) for the first and second period, respectively. […] Modern chemotherapy, and in particular treatment with low-dose gemcitabine in prolonged infusion and cisplatin significantly prolonged median survival of patients with malignant pleural mesothelioma in Slovenia.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23135895&#34; target=&#34;_blank&#34;&gt;Long term survival after trimodal therapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Trimodal therapy results in long term survival in a small fraction of patients with malignant pleural mesothelioma, particularly in patients having epithelial histology, R0-resection and no nodal involvement. […] This study analyses the outcome after trimodal therapy including extrapleural pneumonectomy. […] Diagnosis and nodal status were confirmed by surgery. 21 patients (51%) underwent trimodal therapy with 655 days (63-2,567 days) of median follow-up. […] In those receiving trimodal therapy long term survival is achieved only in a minority of patients. […] In view of the time consuming and intensive treatment it should be offered only in carefully selected patients as new surgical approaches such as pleurectomy/decortication have shown high efficacy rates regarding patients’ survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23144443&#34; target=&#34;_blank&#34;&gt;Disease volumes as a marker for patient response in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Over the course of treatment, disease volume decreased by an average of 19%, and median patient survival was 12.6 months from baseline.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23151824&#34; target=&#34;_blank&#34;&gt;Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate tumor response by means of volumetric assessment, survival, and changes in patient symptoms after the treatment of unresectable and/or recurrent pleural mesothelioma by using regional nonselective transarterial chemoperfusion as a palliative treatment option. […] This retrospective study was approved by the hospital ethical committee, and all patients signed an informed consent prior to treatment. […] The mean survival time was 14.2 months (range, 2.1-33.1 months) from the start of treatment. […] For patients with tumors that responded to treatment, mean survival time was 15 months (range, 4.5-33.1 months). […] Transarterial chemoperfusion may have the potential to yield positive results and response in the treatment of recurrent and/or unresectable pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23154557&#34; target=&#34;_blank&#34;&gt;Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The advent of antimetabolite treatment as pemetrexed, introduced in the early 2000s, may have increased survival on a population basis. […] There has been a significant increase in survival, most likely because of earlier diagnosis and improvements in cytostatic treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23155293&#34; target=&#34;_blank&#34;&gt;Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The best treatment is still debated, but talc remains the agent of choice to achieve pleurodesis. […] In conclusion, thoracoscopic large-particle talc pleurodesis is a feasible and effective treatment for MPE, significantly improving quality of life of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23169291&#34; target=&#34;_blank&#34;&gt;Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with activin A induced SMAD2 phosphorylation and stimulated clonogenic growth of mesothelioma cells. […] In contrast, treatment with kinase inhibitors of activin receptors (SB-431542, A-8301) inhibited MPM cell viability, clonogenicity and migration.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23171517&#34; target=&#34;_blank&#34;&gt;Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no standard treatment regimen, and particularly, the impact of radical surgery remains controversial. […] The main goal of our retrospective single-centre study was to evaluate the surgical and non-surgical treatment modalities applied at our division regarding their effect on the patient’s survival. […] Surgery as the first treatment modality was performed in 44 patients (72.1%). […] Additional intraoperative photodynamic therapy was administered in 20 patients, 34 underwent chemotherapy (55.7%) and 12 had radiotherapy (19.7%). […] The adequate treatment options have to be tailored to the specific particular needs of each patient considering histological subtype, tumour stage and patient’s individual functional assessment as well as comorbidity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23174177&#34; target=&#34;_blank&#34;&gt;Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hyperthermic chemotherapy perfusion has been used in the treatment of both pleural and peritoneal mesothelioma without an extensive basic science foundation. […] Clinical data are limited with no prospective randomized trials to support the use of this potentially toxic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23180523&#34; target=&#34;_blank&#34;&gt;Diagnosis of malignant pericarditis: a single centre experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate retrospectively the rate and clinical presentation of malignant pericarditis among patients undergoing invasive treatment, with a view to identification of optimal diagnostic modalities to distinguish this group among other patients. […] We studied 191 patients (100 men and 91 women, median age 57 years, range 19-88 years) with effusive pericarditis who underwent invasive treatment in the National Institute of Tuberculosis and Lung Diseases in Warsaw in 1982- -2008 due to a significant amount of pericardial fluid and/or echocardiographic evidence of cardiac tamponade. […] Malignancy was found in 58% of patients undergoing invasive treatment due to large pericardial effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23206719&#34; target=&#34;_blank&#34;&gt;Surgical management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although median survival remains poor, important strides have been made in the treatment of MPM, mainly in the form of multimodality therapeutic regimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23206832&#34; target=&#34;_blank&#34;&gt;18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For many authors, 18F-FDG-PET/CT is the cornerstone of the pre-therapeutic evaluation of mesothelioma patients, particularly when multimodal therapy (including extra-pleural pneumonectomy or omentectomy) is considered.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23207475&#34; target=&#34;_blank&#34;&gt;Mesothelioma: a soon to be forgotten disease in the United States?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We present a patient with malignant pleural mesothelioma who underwent evaluation and treatment during medical thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23225442&#34; target=&#34;_blank&#34;&gt;Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Progression-free survival, response, disease control and resection rate were similar in the two treatment groups. […] The lower tolerability to AP treatment could impair the clinical condition of patients undergoing surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23229133&#34; target=&#34;_blank&#34;&gt;Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although cisplatin is used in frontline therapy of this disease treatment remains palliative at best.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23242984&#34; target=&#34;_blank&#34;&gt;Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients having IMIG stage III MPM were identified within a prospective multimodality treatment study (RP followed by chemoradiation) between 2002 and 2010 at a single institution.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23244777&#34; target=&#34;_blank&#34;&gt;Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The approach to this disease remains difficult and complex in terms of pathogenic mechanism, diagnosis, staging and treatment thus an optimal strategy has not yet been clearly defined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23247629&#34; target=&#34;_blank&#34;&gt;Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We investigated safety, efficacy, and recurrence after postoperative hemithoracic intensity-modulated radiation therapy (IMRT) in patients with malignant pleural mesothelioma treated with extrapleural pneumonectomy (EPP), during the past decade at a single institution. […] On multivariate analysis, pretreatment forced expiratory volume in 1 second, nonepithelioid histology, and nodal status were associated with distant metastasis-free survival and OS. […] Tumor histology and nodal status can be helpful in identifying patients for this aggressive treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23259649&#34; target=&#34;_blank&#34;&gt;Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Adoptive T cell transfer is a new and rapidly expanding branch of immunotherapies focusing on cancer treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23272646&#34; target=&#34;_blank&#34;&gt;A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although complete surgical resection is considered the only curative treatment, the results of surgery have shown a median survival time of only one year. […] In inoperable cases, chemotherapy, radiotherapy, and a combination of both have been considered as palliative therapy. […] One month after treatment, a follow-up computed tomography scan showed no definitive abnormality in the thoracic space. […] The combination of hyperthermia and chemotherapy may be a novel and safe therapeutic option for malignant pleural mesothelioma, and can be considered for patients ineligible for radical treatment. […] Further clinical studies of the combination of hyperthermia and chemotherapy are needed to confirm the effects of this treatment on malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23276688&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: new insights into a rare disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In advanced disease, chemotherapy is the cornerstone of treatment, especially platinum-containing regimens. […] Most efforts are directed toward improving standard first-line therapy or developing effective second-line therapy, which is still not yet standardized 10years after the first-line standard of care was established. […] This review focuses on the systemic management of MPM in patients who are not considered suitable for surgical approaches, and it discusses some questions that remain open such as the benefits of administering a maintenance treatment, whether it is better to give cisplatin or carboplatin as first-line therapy, the role of new drugs as second-line therapy, and the treatment of the elderly population. […] It also summarizes the results from clinical trials that have evaluated new treatments as first- or second-line therapy, which are based on the understanding of mesothelioma biology, such as antiangiogenic drugs, immunotherapies and growth factors agents.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23301673&#34; target=&#34;_blank&#34;&gt;PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In conclusion, this study demonstrates that PARP1 overexpression defines increased responsiveness to its inhibition, then these results imply that a substantial fraction of patients could be candidates for therapy with PARP inhibitors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23317113&#34; target=&#34;_blank&#34;&gt;Asymptomatic primary tuberculous pleurisy with intense 18-fluorodeoxyglucose uptake mimicking malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient received antituberculous therapy for 6 months, with clearly decreased positive signals on a repeated FDG PET/CT scan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23324131&#34; target=&#34;_blank&#34;&gt;Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodal treatment has provided encouraging results. […] The primary endpoint was event-free survival, defined as the time from enrollment to time of first observation of disease progression, death due to any cause, or early treatment discontinuation. […] Fifty-four treatment-naïve patients with T1-3 N0-2 malignant pleural mesothelioma were enrolled, 52 (96.3%) completed chemotherapy, 45 (83.3%) underwent surgery, 22 (40.7%) completed the whole treatment including 90-day post-radiation follow-up. […] The most common treatment-emergent adverse events were nausea (63.0%), anemia (51.9%) and hypertension (42.6%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23328002&#34; target=&#34;_blank&#34;&gt;What is the survival after surgery for localized malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hence, aggressive treatment of LMM may be reasonable in appropriate patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23329519&#34; target=&#34;_blank&#34;&gt;Effects of treatment regimens on survival in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, we aimed to investigate the factors affecting the survival of patients with malignant pleural mesothelioma (MPM) according to their treatment regimens, including best supportive care (BSC), chemotherapy, surgical group and multimodality (MM) therapy. […] A retrospective analysis was performed on clinical data and treatment outcomes of 400 patients registered in our hospital with MPM between January 1989 and April 2010. […] Mean age (p &amp;lt; 0.001), presence of asbestos exposure (p = 0.0014), presence of smoking history (p &amp;lt; 0.001), Karnofsky performance status (p &amp;lt; 0.001), histological subtype (p = 0.034) and stage (p &amp;lt; 0.001) variables were found to be significantly different among the four treatment regimens. […] There were significant differences in mean survival time among the four treatment regimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23333048&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: diagnosis and treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of MPM relies mostly on chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23358691&#34; target=&#34;_blank&#34;&gt;Is survivin expression prognostic or predictive in malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an incurable cancer strongly associated with asbestos exposure and characterised by poor response to treatment. […] Survivin expression might contribute to treatment response prediction, but survivin expression in malignant pleural mesothelioma did not have prognostic significance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23361052&#34; target=&#34;_blank&#34;&gt;The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent preclinical studies identified Axl, a tyrosine kinase receptor implicated in tumour progression and epithelial-to-mesenchymal transition, as a putative therapeutic target in malignant pleural mesothelioma (MPM), an invariably fatal malignancy with limited treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23379358&#34; target=&#34;_blank&#34;&gt;SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is an aggressive, treatment-resistant tumor arising from mesothelium of pleura, peritoneum and pericardium. […] Therefore our findings revealed the hitherto unappreciated role of Hh activation in mesothelioma, and pinpointed Hh signaling antagonist as a potential new therapy against this devastating disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23392201&#34; target=&#34;_blank&#34;&gt;Gene therapy for malignant mesothelioma: current prospects and challenges.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A number of preclinical studies with different genes and vector systems demonstrated the therapeutic efficacy and raised the possibility of gene therapy in clinical settings. […] In this review we summarize major preclinical and clinical gene therapy for mesothelioma, and discuss the advantages of gene therapy in the context of stimulating host immune systems.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23393812&#34; target=&#34;_blank&#34;&gt;[Expression of thrombomodulin in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Low expression of TM was restored in MM cells by their treatment with 5-aza-2’-deoxycytidine while the epigenetic agent did not affect TM expression in Met-5A cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23405711&#34; target=&#34;_blank&#34;&gt;[A case report: an university professor suffering from malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 2011, after almost 40 years, the subject comes to the attention of the Apulia Regional Operative Center, with histologic and immunohistochemical diagnosis of epithelioid mesothelioma, after completing the diagnostic procedure in a thoracic surgery ward, for the assessment and treatment of a right pleural effusion revealed during health checks.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23405713&#34; target=&#34;_blank&#34;&gt;[Identification and characterization of microRNA involving in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This work represents the first step for the identification of a specific miRNA pattern for MPM, which will be useful in the diagnosis of MPM and for a personalized therapeutic treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23407570&#34; target=&#34;_blank&#34;&gt;Surgery in mesothelioma–where do we go after MARS?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because of the modest outcome of surgery as single-modality therapy, combinations of chemotherapy, surgery, and radiation therapy were initiated as a new treatment strategy to improve prognosis. […] This is the rationale for the next European Organisation for Research and Treatment of Cancer trial exploring the feasibility of P/D with perioperative chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23408016&#34; target=&#34;_blank&#34;&gt;Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is considered a treatment-resistant disease. […] We determined the proportion of patients who received treatment in the last month of life and potential factors associated with use of chemotherapy at the end of life. […] Patient, treatment and outcome details were obtained through the DDB, treating physicians and Medicare Australia. […] The association between potential factors (age, gender, geographical location, disease stage, histological subtype, palliative care referral, length of first line chemotherapy and lines of treatment) and chemotherapy use in the last month of life was determined. […] A total of 147 MPM patients were included in the analysis: 78 received chemotherapy, 50 had radiotherapy and 116 had surgery (77 received more than one treatment modality whilst 56 received one treatment modality). […] Twenty-one patients received treatment in their last month of life: nine received chemotherapy; six, radiotherapy and six had surgery. […] Those who were treated with second or subsequent lines of chemotherapy were more at risk of receiving chemotherapy until the end of life (six of 19 patients, i.e., 32 %) compared to those who were only treated with first-line therapy (three of 59 patients, i.e., 5 %; p &amp;lt; 0.01).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23408040&#34; target=&#34;_blank&#34;&gt;Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed plus carboplatin are a step forward in the treatment of mesothelioma, the prognosis for these patients remains poor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23411061&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality treatment programs that combine maximal surgical cytoreduction with novel forms of radiation therapy and more effective chemotherapy combinations may offer significant increases in survival for certain subgroups of patients with mesothelioma. […] Lung-sparing surgery may allow improvements in pulmonary function after surgery-based multimodality therapy, and potential longer overall survival than that seen with extrapleural pneumonectomy. […] Experimental treatments provide hope for all patients with mesothelioma, and in the future may be combined with standard therapy in multimodality protocols.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23411062&#34; target=&#34;_blank&#34;&gt;Rare pleural tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Their treatment must be targeted toward the specific tumor type and is often quite different from the treatment for mesothelioma or metastases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23412628&#34; target=&#34;_blank&#34;&gt;Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We examined whether the novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate, compound 2, might be an effective treatment for malignant pleural mesothelioma (MPM), reflecting its selective membrane transport by the proton-coupled folate transport (PCFT) over the reduced folate carrier (RFC).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23413596&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: factors influencing the prognosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy is currently guided by gross tumor characteristics and patient features; however, these seem less accurate than the biological fingerprint of the tumor. […] Here we summarize the principal and novel factors that influence prognosis and are thus potentially useful for selecting patients for targeted therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23421939&#34; target=&#34;_blank&#34;&gt;Laparoscopic repair of secondary parahiatal hernia with incarceration of the stomach: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report the case of a patient who suffered from gastric incarceration through an anatomically separate diaphragmatic defect, immediately lateral to a structurally normal esophageal hiatus, that developed after treatment of a malignant mesothelioma. […] A 70-year-old Japanese man, who had undergone treatment for a left malignant pleural mesothelioma a year ago at another hospital, was referred to our institution following a 4-day history of epigastric pain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23422483&#34; target=&#34;_blank&#34;&gt;M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm with few treatment options. […] Claudins seem to be attractive targets for cancer therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23428976&#34; target=&#34;_blank&#34;&gt;Hypoxia affects in vitro growth of newly established cell lines from patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differences of their growth between under hypoxia and under normoxia, and those depending on the cell density, may provide useful hints for developing a new strategy for diagnosis or therapy of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23434448&#34; target=&#34;_blank&#34;&gt;Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A favorable outcome and minimal incremental morbidity support the incorporation of hyperthermic intraoperative cisplatin chemotherapy into multimodality treatment strategies for patients with low-risk epithelial malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23449276&#34; target=&#34;_blank&#34;&gt;Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Antifolates belong to the most effective cytotoxic drugs for malignant pleural mesothelioma (MPM) treatment. […] The aim of the study was to explore potential correlations between TS, GARFT, AICARFT, RFC, and FPGS levels in MPM and associations with clinical benefit from pemetrexed treatment. […] No significant association was found between TS expression and survival or objective response of the tumors after pemetrexed treatment. […] Folate uptake mechanisms by RFC and activation by FPGS were associated with clinical benefit from pemetrexed treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23453339&#34; target=&#34;_blank&#34;&gt;Multimodality treatment of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although the treatment of malignant pleural mesothelioma has been refined during the past two decades, overall survival from this rather uncommon disease is still extremely poor. […] Here we review the current multimodal diagnostic and treatment options for patients with mesothelioma and discuss promising new experimental concepts in this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23453740&#34; target=&#34;_blank&#34;&gt;Snail expression is associated with a poor prognosis in malignant pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Snail could be a potential molecular target for the treatment of patients with MPMs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23463097&#34; target=&#34;_blank&#34;&gt;Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Females are found to survive longer than males after treatment, suggesting a possible involvement of hormonal factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23483902&#34; target=&#34;_blank&#34;&gt;Gli as a novel therapeutic target in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current treatment is rarely curative, thus novel meaningful therapies are urgently needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23486267&#34; target=&#34;_blank&#34;&gt;Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Levels of TS and FPGS were semi-quantitatively determined immunohistochemically using H-scores on tissue samples from 85 MPM patients receiving Pem as primary therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23486268&#34; target=&#34;_blank&#34;&gt;Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to investigate the continuous changes in three distinct response assessment methods during treatment as a marker of response for patients with mesothelioma. […] Median survival from pretreatment baseline imaging was 12.7 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23509402&#34; target=&#34;_blank&#34;&gt;A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The secondary endpoints are the pleurectomy/decortication rate, macroscopic complete resection rate by pleurectomy/decortication, pulmonary function at 3 months after surgery, adverse events, treatment-related mortality, response rate to chemotherapy and 3-year overall survival rate.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23517112&#34; target=&#34;_blank&#34;&gt;TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with 0.5-1 μM MG132 alone or 30 ng/mL Bortezomib alone induced a limited apoptosis in MPM cells associated with the elevated Mcl-1 protein level and hyperactive PI3K/Akt signaling. […] The combinatorial treatment using TRAIL and PI may represent an effective new treatment for MPMs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23522487&#34; target=&#34;_blank&#34;&gt;Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two cases of NE have been reported after the appliance of pemetrexed for treatment of non-small cell lung cancers. […] To our knowledge, NE has never been reported due to treatment with pemetrexed for malignant pleural mesothelioma (MPM). […] We present a case of MPM in a 77-year-old male suffering from severe NE one week after the seventeenth cycle of pemetrexed in the course of maintenance therapy for MPM, which could be treated successfully with antibiotic coverage and supportive measures.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23525508&#34; target=&#34;_blank&#34;&gt;Downregulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Novel therapeutic agents such as honokiol (HNK) improve the clinical outcomes of cancer therapy, yet the mechanisms involved have not been fully elucidated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23526965&#34; target=&#34;_blank&#34;&gt;Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a poor prognosis disease lacking adequate therapy. […] Here we evaluated a new combined therapy consisting of ascorbate/epigallocatechin-3-gallate/gemcitabine mixture (called AND, for Active Nutrients/Drug). […] In vitro effects of AND therapy on various MPM cell lines revealed a synergistic cytotoxic mechanism. […] The complex of data showed that the AND treatment is synergistic in vitro on MPM cells, and blocks in vivo tumor progression and metastasization in REN-based xenografts. […] Hence, the AND combination is proposed as a new treatment for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23550710&#34; target=&#34;_blank&#34;&gt;Current and future options for the diagnosis of malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Needle pleural biopsy is justified only if used with image-techniques (ultrasound or CT) guidance, and thoracoscopy is better for both diagnosis and immediate palliative treatment (pleurodesis). […] Animal models of MPE and ‘spheroids’ are promising for research involving both pathophysiology and therapy. […] Considering the possibility of direct pleural delivery of nanotechnology-developed compounds-fit to both diagnosis and therapy purposes (‘theranostics’)-MPE and mesothelioma in particular are likely to benefit sooner than later from this exciting perspective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23571475&#34; target=&#34;_blank&#34;&gt;Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment was well tolerated with few grade 3 or 4 toxicities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23583604&#34; target=&#34;_blank&#34;&gt;Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this open-label, multicentre, randomised phase 3 study, eligible patients had proven malignant pleural or peritoneal mesothelioma and had received a minimum of four cycles of first-line treatment containing at least pemetrexed, with or without cisplatin or carboplatin, and had not progressed on this treatment. […] Patients were required to be registered and to start treatment with thalidomide within 10 weeks after the end of the first-line chemotherapy. […] Different treatment strategies are needed to improve outcomes in patients with malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23585940&#34; target=&#34;_blank&#34;&gt;The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although N-ERC/mesothelin (N-ERC) is an attractive diagnostic and treatment monitoring biomarker for malignant pleural mesothelioma (MPM), its clinical utility for predicting the prognosis has not yet been clarified.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23595591&#34; target=&#34;_blank&#34;&gt;Calretinin is essential for mesothelioma cell growth/survival in vitro: a potential new target for malignant mesothelioma therapy?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors anticipate these findings to reveal CR as a highly interesting new putative therapeutic target for mesothelioma treatment of especially the epithelioid, as well as of the mixed and sarcomatoid type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23595855&#34; target=&#34;_blank&#34;&gt;[Intraoperative chemotherapy after radical pleurectomy or extrapleural pneumonectomy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Trimodality treatment including induction and/or adjuvant chemotherapy, surgical resection and in some cases radiotherapy offers a curative intention in selected patients with pleural malignancies (malignant pleural mesothelioma, thymoma with pleural spread). […] A few years ago an additional intraoperative chemotherapy perfusion was developed in order to improve local tumor control and prognosis after surgical resection in a multimodality treatment setting. […] The concept, techniques and perioperative management of this additional treatment option are presented along with a detailed review of the recent literature.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23621229&#34; target=&#34;_blank&#34;&gt;Survival of mesothelioma in a palliative medical care unit in egypt.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
That for patients who had received best supportive care was 7.57±1.85 months, for chemotherapy was 16.5±3.20 months, and multimodality treatment regimen 27±21.0 months (P=0.028). […] The median survival for performance status and treatment modalities was significant (P=0.001 and 0.028).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23624653&#34; target=&#34;_blank&#34;&gt;Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a highly aggressive and conventional treatment-resistant tumor with a dismal prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23638233&#34; target=&#34;_blank&#34;&gt;Good response of malignant pleural effusion from carcinoma of unknown primary site to the anti-tuberculosis therapy: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, there is still no very effective treatment to control malignant pleural effusion. […] Here we report that malignant pleural effusion in one patient was completely relieved for 15 months by the anti-tuberculosis therapy. […] One week after we tried anti-tuberculosis combined therapy with isoniazid, pyrazinamide, rifapentine and ethambutol. […] But the CEA increased gradually again when the anti-tuberculosis treatment was forced to discontinuation. […] Sixteen months after anti-tuberculosis treatment, the symptoms of cough and breathing difficulty relapsed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23656974&#34; target=&#34;_blank&#34;&gt;Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multivariate analysis of paired effusions in OC showed a significant increase in glucose and lipid levels in the post-treatment spectra (P = .039).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23675481&#34; target=&#34;_blank&#34;&gt;Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although treatment options for cancer patients are increasing every year, the drug resistance problem remains very present. […] It is very difficult to find a drug that acts equally on tumours of the same histology as the individual’s genetic characteristics often determine the response to treatment. […] Furthermore, tumours that initially respond to anti-tumour therapy are able to adapt and develop resistance to the drug, while others do not. […] Given this situation, it has been suggested that the most appropriate treatment would be able to act in parallel on multiple pathways constitutively altered in tumour cells. […] These results may be useful to employ targets gene expression as resistance markers, a valuable tool for identifying patients likely to receive combination therapy to prevent the development of resistance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23676957&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma: have we made any progress?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As the incidence of malignant pleural mesothelioma (MPM) is increasing in the next decades, treatment is a challenge. […] Treatment of a symptomatic malignant pleural effusion through indwelling pleural catheter (IPC) may allow for an individualized treatment. […] Advances in the systemic treatment with targeted agents will undoubtedly gain by the discovery of a driver mutation which may be selectively targeted. […] New techniques in radiation therapy, pleural intensity-modulated radiotherapy, helical tomography and proton-therapy are exciting advances in multimodality treatment enhancing local control and therefore improving overall survival. […] Where the treatment in multimodality therapy may lead to improved disease-free survival and overall survival, the type of cyto-reductive procedure should be selected on institutional and surgeon’s experience.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23687495&#34; target=&#34;_blank&#34;&gt;Secondary malignant peritoneal mesothelioma of the greater omentum after therapy for primary pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 69-year-old man with histologically proven pleural mesothelioma on the right side and no past medical history of asbestos exposure received palliative treatment consisting of a talc pleurodesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23688589&#34; target=&#34;_blank&#34;&gt;Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is unclear, if patients undergoing incomplete RP within a standardized multimodality treatment protocols have any advantage in terms of survival and if EPP could theoretically have avoided incomplete resections (R2). […] Eighty-eight patients underwent RP followed by chemoradiation from 2002 to 2011 within a prospective multimodality treatment study at a single institution. […] There is a need for further investigation of effective intrapleural additive treatment options for patients undergoing R2.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23690193&#34; target=&#34;_blank&#34;&gt;Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We aimed to investigate the relationship between the pre-treatment 18 FDG PET/CT results, together with other known clinical parameters, and the survival of patients with MPM in our region. […] Pre-treatment 18 FDG PET/CT scans were done on all patients. […] Significant predictors of survival include KPS, stage of disease, gender, treatment regimen and level of SUVmax.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23690472&#34; target=&#34;_blank&#34;&gt;A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with NZ-1 significantly reduced the growth of s.c. established tumors of MPM cells (ACC-MESO-4 or podoplanin-transfected MSTO-211H) in SCID mice, only when NZ-1 was administered with rat NK cells. […] Treatment with NZ-8 and human NK cells significantly inhibited the growth of MPM cells in vivo. […] These results strongly suggest that targeting therapy to podoplanin with therapeutic Abs (i.e., NZ-8) derived from NZ-1 might be useful as a novel immunotherapy against MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23714495&#34; target=&#34;_blank&#34;&gt;Peritoneal mesothelioma: the site of origin matters.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The etiology, gender distribution, pathology, natural history, and treatment options for mesothelioma (MM) differ substantially depending on the site of origin. […] In highly selected patients receiving treatment at experienced referral centers, an aggressive locoregional strategy that combines cytoreductive surgery to remove all gross disease and hyperthermic intraperitoneal chemotherapy to treat residual microscopic tumors yields a 3-year survival of 60% and a median survival approaching 5 years, far better than expected from historic controls.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23720698&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its diagnosis and treatment still present a major challenge for ambulatory and in-hospital care and will do so for years to come. […] Only limited data are now available to guide treatment with a combination of the available methods (chemotherapy, surgery, radiotherapy). […] Specialized treatment centers now increasingly provide multimodal therapy for treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23721559&#34; target=&#34;_blank&#34;&gt;EphB4 as a therapeutic target in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current best therapy produces a response in only half of patients, and the median survival with this therapy remains under a year. […] A search for novel targets and therapeutics is underway, and recently identified targets include VEGF, Notch, and EphB4-Ephrin-B2.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23729401&#34; target=&#34;_blank&#34;&gt;Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article reviews recent studies regarding some malignant mesothelioma molecular targets not only for cancer prevention but also for cancer therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23743993&#34; target=&#34;_blank&#34;&gt;[Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Screening and diagnostics should concentrate on locations with higher incidence of MPM to facilitate surgical therapy in a multimodal treatment regime.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23749908&#34; target=&#34;_blank&#34;&gt;Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since early detection is very difficult and there is no standard curative therapy, it is important to understand the biology of MPM, and to find biomarkers and molecular targets for its therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2375659&#34; target=&#34;_blank&#34;&gt;Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The contribution of effusion cytology to the final diagnosis and patient treatment was assessed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23760546&#34; target=&#34;_blank&#34;&gt;Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Belief that the modest survival times reported after radical surgery, whether alone or as part of multimodal therapy, are longer than they it would have been without surgery relies on data from highly selected, uncontrolled, retrospectively analysed case series.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23769317&#34; target=&#34;_blank&#34;&gt;Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleurectomy/decortication (P/D) in the treatment of malignant pleural mesothelioma includes a number of procedures with different clinical indications and therapeutic intents.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23787063&#34; target=&#34;_blank&#34;&gt;A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This phase II, single arm trial investigated the efficacy and safety of BNC105P as second line therapy in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23790315&#34; target=&#34;_blank&#34;&gt;The role of epigenetics in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The availability of compounds that modulate epigenetic modifications, such as histone acetylation or DNA methylation, offers new prospects for treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23791541&#34; target=&#34;_blank&#34;&gt;Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This was a prospective phase II study of cisplatin and bortezomib (CB) in the first line treatment of malignant pleural mesothelioma (MPM) with validation of progression free survival rate at 18 weeks (PFSR-18)(1) as primary end-point.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23791657&#34; target=&#34;_blank&#34;&gt;Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MicroRNA-183 (miR-183) family is proposed as promising biomarkers for early cancer detection and accurate prognosis as well as targets for more efficient treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23797722&#34; target=&#34;_blank&#34;&gt;Diffuse intrapulmonary malignant mesothelioma masquerading as interstitial lung disease: a distinctive variant of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two patients received no therapy and survived 3 and 4 weeks, respectively. “Diffuse intrapulmonary malignant mesothelioma” is a rare variant with a distinctive presentation that clinically mimics ILD.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23810210&#34; target=&#34;_blank&#34;&gt;ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Platinum-based chemotherapy is besides the standard antifolate therapy with pemetrexed, the cornerstone for treatment of patients with malignant pleural mesothelioma (MPM), and its efficacy depends on several DNA repair enzymes. […] Pre- or posttreatment specimens from a total of 103 patients with MPM who were undergoing first-line chemotherapy were tested separately. […] When considering only pretreatment specimens, MSH6 protein levels were correlated to progression during chemotherapy (P = .0281). […] Analyses of posttreatment specimens revealed significant associations between βIII-tubulin protein levels and progression-free survival (P = .0066).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23815672&#34; target=&#34;_blank&#34;&gt;Therapies currently in Phase II trials for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite an overall low response rate, the current first-line therapy is represented by combined chemotherapy with cisplatin and antifolate. […] Nonetheless, our understanding is that the treatment of MPM should not be merely ‘copied’ from that of other much better studied tumors. […] These evidences are disclosing a rather unusual model of malignancy, very likely to be more sensitive to novel ‘MPM cells- and microenvironment-tailored’ therapy addressing these characteristics rather than the sole cancer proliferation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23816056&#34; target=&#34;_blank&#34;&gt;Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Further studies are needed to characterize which subtypes of effector CD8+ T cells are involved, opening prospects for cell therapy in MPE and MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23825744&#34; target=&#34;_blank&#34;&gt;The challenge of prognostic markers in pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a very aggressive tumor, highly resistant to chemo- and radio-therapy. […] Treatment of MPM patients is often disappointing, regardless of the modality used. […] Inter-individual variability of response to multimodal treatment remains a challenge and generally the MPM prognosis continues to be poor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23835378&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The optimal treatment technique with photons remains undefined. […] Comparative planning for intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) was performed. […] VMAT seems currently the most suitable technique for the treatment of MPM patients when air cavities are remaining and no adaptive radiotherapy is performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23840993&#34; target=&#34;_blank&#34;&gt;Primary pericardial mesothelioma: a rare entity.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no standard treatment for pericardial mesothelioma; nonetheless, radical surgery is the mainstay of therapy for localized disease. […] The patient remained alive and free of disease for about 24 months; however, due to rapid local recurrence, the patient died 27 months after the surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23846294&#34; target=&#34;_blank&#34;&gt;Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sixty-four DPM treated by initial cytoreductive therapy were retrospectively reviewed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23851502&#34; target=&#34;_blank&#34;&gt;Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of mice with malignant ascites due to mesothelioma with rapamycin led to a marked reduction in ascites, extended survival and a 95-99% reduction in the mesothelioma tumor volume, in comparison with vehicle-treated mice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23851735&#34; target=&#34;_blank&#34;&gt;Pemetrexed-induced eyelid edema in lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a novel, multitargeted antifolate approved for the treatment of malignant pleural mesothelioma and non-small cell lung cancer. […] Pemetrexed-induced eyelid edema is a rare side effect of pemetrexed treatment, and until this moment few cases were reported in the medical literature.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23856136&#34; target=&#34;_blank&#34;&gt;[Prognosis related clinical and molecular factors in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical and pathological data were collected, including age, gender, smoking status, treatment, response, and molecular biomarkers such as thymidylate synthetase (TS) expression, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) gene rearrangement. […] Univariate survival analysis revealed that treatment factors including receiving operation, systemic chemotherapy, pemetrexed-based chemotherapy and capability of receiving second (or above) line chemotherapy were significantly related with OS. […] Correlation between TS expression or EML4-ALK rearrangement and outcome of pemetrexed-based chemotherapy for MPM may contribute to future individualized treatment, which needs further validation from large-scale prospective studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23868066&#34; target=&#34;_blank&#34;&gt;SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although treatment with SMC in the presence of TNFα promoted interaction between caspase 8 and the necrosis-promoting RIPK1, the cell death induced by combined treatment with SAHA and SMC was apoptotic and mediated by caspase 8.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2386894&#34; target=&#34;_blank&#34;&gt;A phase II study of pirarubicin in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment was repeated every 3 to 4 weeks (median duration per cycle, 23 days) up to progression or severe toxicity. […] Five patients achieved minor response, and a further 14 patients were stable under treatment with Pirarubicin. […] Pirarubicin is an active drug in the treatment of pleural mesothelioma with fewer severe side effects than doxorubicin.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23883236&#34; target=&#34;_blank&#34;&gt;FDG PET/CT in the management of primary pleural tumors and pleural metastases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PET/CT has an established role in the diagnosis and staging and shows promise in therapy planning, therapy response assessment, and providing prognostic information in patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23887083&#34; target=&#34;_blank&#34;&gt;The use of indwelling pleural catheters for the management of malignant pleural effusion–direct costs in a Dutch hospital.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Indwelling pleural catheters (IPCs) are increasingly used in the treatment of malignant pleural effusion (MPE). […] Unfortunately, insurance companies in the Netherlands do not reimburse these catheters in either first-line treatment or following failed talc pleurodesis. […] Four patients were admitted to hospital for treatment of complications. […] Mean costs for IPC placement was similar when inserted as frontline treatment and after failed pleurodesis. […] Direct costs for IPC placement turn out to be acceptable when compared with estimated hospitalization costs for pleurodesis treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23887168&#34; target=&#34;_blank&#34;&gt;Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
EPHB2 seems to play an important role in MM pathogenesis and these findings indicate that EPHB2 could serve as a potential novel therapeutic target for treatment of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23890748&#34; target=&#34;_blank&#34;&gt;An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this work was to examine the ability of an oncolytic vaccinia virus expressing the human sodium iodine transporter (hNIS) to provide real time monitoring of viral therapy and effective treatment of malignant pleural mesothelioma (MPM). […] Intrapleural treatment of orthotopic MPM xenografts resulted in a significant decrease in tumor burden 1 week after treatment and an improvement in survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23896451&#34; target=&#34;_blank&#34;&gt;Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite recent advances in treatment, malignant pleural mesothelioma (MPM) remains a deadly disease. […] Targeted therapy generated broad interests and is highly expected for the treatment of MPM, yet promising preclinical results have not been translated into substantial clinical benefits for the patients. […] In this study, we tried to identify the genes which play functional roles in cell migration as well as to test whether they can be used as novel targets for molecular targeted therapy for MPM in preclinical model. […] Our study suggests that PAPPA plays a functional role in promoting MPM cell migration and it might serve as a potential therapeutic target for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23898070&#34; target=&#34;_blank&#34;&gt;Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intrinsic or acquired resistance of pancreatic cancer to gemcitabine (2’-deoxy-2’-difluorodeoxycytidine) is an important factor in the failure of gemcitabine treatment. […] Finding further candidate proteins is necessary for achieving effective gemcitabine therapy for patients with pancreatic cancer. […] These results suggest that DDX39 is a possible candidate biomarker for predicting the response of patients with pancreatic cancer to treatment with gemcitabine.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23899648&#34; target=&#34;_blank&#34;&gt;Epidemiology of malignant pleural mesothelioma in the province of Sassari (Sardinia, Italy). A population-based report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The relative 5 years survival was low, suggesting the necessity to further intensify research and cure methods for the treatment of this extremely aggressive disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23911347&#34; target=&#34;_blank&#34;&gt;Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study we tested the potential of epigallocatechin-3-gallate (EGCG), a natural polyphenol known to target mitochondria, in inducing OXPHOS impairment and cell energy deficit in human epitheliod (REN cells) and biphasic (MSTO-211H cells) malignant pleural mesothelioma (MMe), a rare but highly aggressive tumor with high unmet need for treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23915043&#34; target=&#34;_blank&#34;&gt;Risk factors associated with asbestos-related diseases: a community-based case-control study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A better understanding of asbestos-related diseases should improve i) the clinical and epidemiological follow up of patients with this condition; ii) the design of new treatment strategies; iii) and the development of preventive activities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23927330&#34; target=&#34;_blank&#34;&gt;Variability of tumor area measurements for response assessment in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The measurement of malignant pleural mesothelioma is critical to the assessment of tumor response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23932389&#34; target=&#34;_blank&#34;&gt;18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
18F-FDG PET/CT whole-body explorations are useful to monitor the follow-up and evaluate the metabolic response to chemo- and radiotherapy, modifying the scheduled treatment plan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23937772&#34; target=&#34;_blank&#34;&gt;Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because of its expression on the cell surface, FAP is an attractive target for adoptive T cell therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23963351&#34; target=&#34;_blank&#34;&gt;Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This was a retrospective study of 65 patients treated with a multimodality therapy including P/D between October 2004 and March 2012.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23963927&#34; target=&#34;_blank&#34;&gt;BAP1 protein is a progression factor in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Human malignant pleural mesothelioma (MPM) is an aggressive cancer due to former asbestos exposure with little knowledge about prognostic factors of outcome and resistance to conventional therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23975423&#34; target=&#34;_blank&#34;&gt;Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a very aggressive tumor with no known curative treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23976967&#34; target=&#34;_blank&#34;&gt;Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently accurate diagnosis of MPM is difficult due to the lack of sensitive biomarkers and despite minor improvements in treatment, median survival rates do not exceed 12 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23977533&#34; target=&#34;_blank&#34;&gt;Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Trimodality therapy (TMT) involving extrapleural pneumonectomy with neoadjuvant or adjuvant chemotherapy and adjuvant radiotherapy is a recognized treatment option with a curative intent. […] Despite encouraging results from institutional studies, TMT in the treatment of MPM remains controversial. […] Four prospective series involving a standardised treatment regimen with neoadjuvant chemotherapy indicated encouraging results based on intention-to-treat analysis. […] However, a small study assessing the feasibility of conducting a randomized controlled trial for TMT versus conservative treatment reported poor short- and long-term outcomes for patients who underwent pneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23977534&#34; target=&#34;_blank&#34;&gt;Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After a median follow-up of 15 months, a number of clinicopathological and treatment-related prognostic factors were found to significantly influence overall survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23978876&#34; target=&#34;_blank&#34;&gt;Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a form of cancer that is highly resistant to conventional cancer therapy for which no major therapeutic advances have been introduced. […] Treatment of gremlin-1-silenced mesothelioma cells with paclitaxel or pemetrexed resulted in efficient loss of cell survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23982605&#34; target=&#34;_blank&#34;&gt;Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of these, 159 received chemotherapy, 10 had tri-modality therapy, 2 underwent surgery only and 103 received supportive care alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24018024&#34; target=&#34;_blank&#34;&gt;Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The measurement of tumor thickness on computed tomography (CT) scans is the current standard of care in the assessment of MPM tumor response to therapy; in this context, variability among observers in the measurement task and in the tumor response classification categories derived from such measurements was reported. […] Also reported was the use of PET/CT in the management of patients who undergo high-dose radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24023280&#34; target=&#34;_blank&#34;&gt;The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review aims to provide insight into treatment of malignant pleural mesothelioma (MPM) considering effects on survival, quality of life (QoL) and costs, in order to determine the value of pemetrexed in MPM treatment. […] The cost-effectiveness of pemetrexed-cisplatin was found to be acceptable in advanced MPM compared with cisplatin, but raltitrexed-cisplatin was found to be a more cost-effective treatment option. […] As yet platinum-doublet therapy is the most effective palliative treatment of MPM. […] To provide a more cost-effective treatment approach for advanced MPM, further research should include randomized controlled trials comparing the recommended pemetrexed-cisplatin directly with platinum doublets with raltitrexed, gemcitabine, or vinorelbine.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24028146&#34; target=&#34;_blank&#34;&gt;Cytoreductive surgery and post-operative heated pleural chemotherapy for the management of pleural surface malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There was no systemic toxicity or treatment-related mortality. […] It is suggested that HPC may have a potential role for local control as adjuvant treatment for cytoreductive surgery in patients with minor pleural spread.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24035405&#34; target=&#34;_blank&#34;&gt;Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, we noted disease control in nine (31%) patients and a median progression-free survival of 6·2 months (95% CI 1·3-11·1) and a median overall survival of 10·7 months (0·0-21·9). 27 patients (93%) had at least one grade 1-2 treatment-emergent adverse event (mainly cutaneous rash, pruritus, colitis, or diarrhoea), and four patients (14%) had at least one grade 3-4 treatment-emergent adverse event (two gastrointestinal, one neurological, two hepatic, and one pancreatic).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24055913&#34; target=&#34;_blank&#34;&gt;Pulmonary mucinous cystadenocarcinoma presenting as a pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is important to differentiate this rare pathological feature of the lung from other lung tumors as the treatment is surgical rather than medical.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24057459&#34; target=&#34;_blank&#34;&gt;The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a disease with poor prognosis despite multimodal therapy but there is variation in survival between patients. […] In order to determine the relationships between metabolic activity and prognosis we reviewed all (18)F-FDG PET/CT scans used for pretreatment staging of MPM patients in our institution between January 2005 and December 2011 (n = 60) and measured standardised uptake values (SUV) including mean, maximum and peak values, metabolic tumour volume (MTV) and total lesion glycolysis (TLG).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24061575&#34; target=&#34;_blank&#34;&gt;Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Estrogen receptor (ER)-β has been shown to possess a tumor suppressive effect, and is a potential target for cancer therapy. […] On the whole, our data highlight an unforeseen interaction between ERβ-mediated tumor suppression and energy metabolism that may be exploited to improve on the therapy for clinical management of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2406555&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma with bone metastases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient then received radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24088916&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma presenting as acute empyema with severe leukocytosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Five months after the treatment for acute empyema, a 75-year-old woman was referred to our hospital because of marked elevation of the white blood cell (WBC) count and C-reactive protein (CRP) level, and a right pleural mass detected by chest computed tomography.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24102013&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: current and future perspectives.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although we have new targeted treatments and radical surgery as arrows in the quiver, the type of mesothelioma and early diagnosis still remain the best treatment approach. […] Novel treatment modalities have been explored and several others are already on the way.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24113019&#34; target=&#34;_blank&#34;&gt;Clinical indications and results after chest wall resection for recurrent mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Salvage treatment has generally been ineffective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2411478&#34; target=&#34;_blank&#34;&gt;Treatment of malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The modalities employed in local treatment consisted of thoracocentesis in 62 patients, tube thoracotomy in 111 cases with local instillation of adriamycin, MMC, CQ, 5FU, OK432 or talc. […] Tube drainage with local instillation of drugs was more effective than thoracocentesis with or without local therapy. […] The tumor cells disappeared in 79.4 percent of primary cancer pleurisy cases and 81.1 percent of patients with metastases while disappearance or significant decrease in pleural effusion following treatment was obtained in 75.2 and 77.8 percent respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2412719&#34; target=&#34;_blank&#34;&gt;Intracavitary chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several malignancies, in particular ovarian carcinoma and malignant mesothelioma, which remain confined to body cavities for much of their natural history, might be most rationally treated by the intracavitary treatment approach. […] Whether or not combination intracavitary chemotherapy will significantly improve survival of patients with malignant disease confined to body cavities must await carefully controlled clinical trials comparing this treatment approach to standard systemically administered chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24128712&#34; target=&#34;_blank&#34;&gt;Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We reviewed the charts of 121 patients with MPM tumors diagnosed between 1991 and 2009 tested for BAP1 mutation, and extracted the following information: age at diagnosis, sex, histology, stage, smoking status, asbestos exposure, family or personal history of malignancy, and treatment including surgery, chemotherapy, and radiation as well as survival status.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24142233&#34; target=&#34;_blank&#34;&gt;Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We analyzed the impact of nodal involvement on overall survival (OS) in patients treated by multimodal therapy including extra pleural pneumonectomy (EPP).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24148817&#34; target=&#34;_blank&#34;&gt;Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is recalcitrant to treatment and new approaches to therapy are needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24149776&#34; target=&#34;_blank&#34;&gt;Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mean pretreatment PNI was 44.6. […] Pretreatment PNI is a novel independent prognostic factor in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24158772&#34; target=&#34;_blank&#34;&gt;Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although treatment with pemetrexed in combination with cisplatin serves as first-line chemotherapy for MPM, the optimal second-line and beyond therapy has not yet been fully examined. […] A further multicenter phase II trial is warranted to confirm the efficacy and safety of this combination treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24173608&#34; target=&#34;_blank&#34;&gt;¹⁸F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In total, 392 patients [non-small cell lung cancer (NSCLC) (n=140), malignant pleural mesothelioma (MPM) (n=21), pulmonary metastatic tumors (PMT) (n=148), thymic epithelial tumors (n=49) and pulmonary neuroendocrine (NE) tumor (n=34)] who underwent ¹⁸F-FDG PET before treatment were included in this study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24179709&#34; target=&#34;_blank&#34;&gt;Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Following TGFβ blockade therapy, clinical safety and patient survival were monitored along with the effects of anti-TGFβ antibodies on serum biomarkers and peripheral blood mononuclear cells (PBMC). […] All participants tolerated therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24207061&#34; target=&#34;_blank&#34;&gt;Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Serum biomarkers can improve diagnosis and treatment of malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24216141&#34; target=&#34;_blank&#34;&gt;Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
High dose radiation therapy following radical P/D led to excellent loco-regional control and survival results in MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24216529&#34; target=&#34;_blank&#34;&gt;The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Though not yet clearly defined there does appear to be a subset of patients who benefit from a surgery-based multimodal treatment plan, beyond what would be expected with current nonoperative therapies. […] Whether or not radical pleurectomy is the optimal approach for any or all patients undergoing surgery-based multimodal treatment for malignant pleural mesothelioma is not known, but the described technique does offer an operation that can serve as a consistent foundation for any surgery-based treatment strategy where achieving a macroscopic complete resection, while sparing the lung, is desired.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24225007&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: 2013 state of the art].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed and cisplatin-based chemotherapy remains the reference treatment, which has proved in mesothelioma some efficacy on overall survival in randomized trials, with a 13-15 months median-overall survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2422942&#34; target=&#34;_blank&#34;&gt;Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
When the anti-CEA antiserum was absorbed with NCA, the number of positively reacting adenocarcinomas decreased considerably to 76%; however, after this treatment, none of the mesotheliomas gave positive reactions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24240684&#34; target=&#34;_blank&#34;&gt;Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of MPM cell lines with mir-145 agonists negatively modulated some protumorigenic properties of MPM cells, such as clonogenicity, cell migration and resistance to pemetrexed treatment. […] Increased intracellular levels of mir-145 decreased the levels of OCT4 and its target gene ZEB1, thereby counteracting the increase of OCT4 induced by pemetrexed treatment which is known to favor the development of chemoresistant cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24248693&#34; target=&#34;_blank&#34;&gt;Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We identified 22 patients who developed PDMM after chest radiation as part of their treatment for lymphoma (mean latency time, 21.4 years; 95% CI, 17.0 to 25.8 years).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24258567&#34; target=&#34;_blank&#34;&gt;Surgical pathology of lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis, treatment, and management of lung tumors represent a complex set of decision algorithms and require the cooperation and interaction of a team of experts and support systems. […] The surgical pathologist, an early, important member of the diagnostic team, uses clinical and radiological evidence to differentiate benign from malignant tumors and renders a unique diagnosis that provides both prognostic and treatment information. […] These distinctions are necessary based on differences in tumor biology, response to therapy, and prognosis for these different histological types.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24269017&#34; target=&#34;_blank&#34;&gt;[Helical tomotherapy in the treatment of malignant pleural mesothelioma: The impact of low doses on pulmonary and oesophageal toxicity].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the adjuvant treatment of malignant pleural mesothelioma by helical tomotherapy and the impact of low doses on esophageal and pulmonary toxicity. […] Helical tomotherapy is a promising technique in the multimodality treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24281913&#34; target=&#34;_blank&#34;&gt;FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Between June 2007 and May 2013, 21 patients who underwent surgical treatment with curative intent for MPM that had been previously diagnosed on a video-assisted thoracic surgery (VATS) biopsy were included in this study. […] However, this condition is related to tumor aggressiveness; therefore, performing careful staging and determining the appropriate treatment strategy are required in such patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24283112&#34; target=&#34;_blank&#34;&gt;Malignant cardiac tamponade.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Oncologic therapy is evidently indicated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24293999&#34; target=&#34;_blank&#34;&gt;Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, the expression of target gene Ras was significantly repressed following miR-ephrin-A1-LNP treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24301913&#34; target=&#34;_blank&#34;&gt;Effects of cisplatin and panobinostat on human mesothelial (Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New therapeutic approaches are still needed for effective malignant pleural mesothelioma treatment. […] The combined treatment was found to be more effective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2431665&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for diffuse, malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Postoperative adjunctive therapy consisting of chemotherapy or irradiation or both was given to approximately one-half of the patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-01-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24321581&#34; target=&#34;_blank&#34;&gt;Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed-platinum chemotherapy is the standard first-line treatment of unresectable malignant pleural mesothelioma (MPM). […] The optimal treatment has not yet been defined. […] Vinorelbine 25 mg/m(2) was administered intravenously as a single agent on days 1, 8 every three weeks, either as second-line (2L) or further-line (&amp;gt;2L) therapy. […] Treatment was repeated for a maximum of 6 cycles, until progression, or unacceptable toxicity. […] Vinorelbine was given to 34 patients as 2L, and to 25 as &amp;gt; 2L treatment. […] No difference was observed in terms of DCR, PFS, and OS in relation to age, histology, sex, line of vinorelbine therapy, or response to FL treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24326857&#34; target=&#34;_blank&#34;&gt;Solitary fibrous tumors of the pleura: a case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection is the treatment of choice and is usually curative, even though local recurrence can occur many years after an adequate resection. […] For malignant cases complete surgical resection may not be adequate and studies are needed to define the role of preoperative and postoperative systemic treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24327015&#34; target=&#34;_blank&#34;&gt;An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These results suggest that RNAi-based screening has utility in identifying new targets for MPM, and that inhibition of NDC80, CDK1 and PLK1 may hold promise for treatment of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24331147&#34; target=&#34;_blank&#34;&gt;Current readings: improvements in intensity-modulated radiation therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of malignant pleural mesothelioma with radiation therapy has always been a technical challenge. […] Early experience with intensity-modulated radiation therapy demonstrated troubling toxicity. […] Recent reports from institutions have demonstrated that with greater experience, intensity-modulated radiation therapy can be delivered safely, both in the setting of pneumonectomy or pleurectomy. […] The rates of fatal pneumonitis are approximately 3%-8% in these studies, which demonstrate the considerable toxicity of treatment, even with improved technique.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24345738&#34; target=&#34;_blank&#34;&gt;Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
RITA reduced tumor growth in a MSTO-211H-derived xenograft model of mesothelioma and synergized with cisplatin, which is the mainstay of treatment for this tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24360321&#34; target=&#34;_blank&#34;&gt;A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although it must be emphasized that patient selection and treatment strategies differ between EPP and extended P/D, a number of comparative studies have recently been conducted to compare these two surgical techniques for patients with resectable MPM. […] The present study indicated that selected patients who underwent extended P/D had lower perioperative morbidity and mortality with similar, if not superior, long-term survival compared to EPP, in the context of multi-modality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24378576&#34; target=&#34;_blank&#34;&gt;Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, we evaluated the efficacy of temsirolimus and the antiangiogenic effect of temsirolimus in the treatment of MPM. […] Combined treatment with temsirolimus and cisplatin inhibited the viability of all MPM cell lines more effectively than temsirolimus alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24403465&#34; target=&#34;_blank&#34;&gt;Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment response, progression-free survival, and overall survival were examined. […] Toxicities of therapy were also evaluated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24414726&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy was introduced in the 1940s for the treatment of extensive infections of the lung and pleural space. […] Over the past 20 years, the extrapleural pneumonectomy technique has been modified and applied to the treatment of locally advanced malignant pleural mesothelioma, achieving substantial reductions in mortality.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24415579&#34; target=&#34;_blank&#34;&gt;Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a neoplastic disease linked to asbestos exposure whose diagnosis is limited, so detection methods for an early diagnosis and treatment result essential. […] Overall, our results suggest potential biomarkers that can be useful in occupational medicine for the early identification of the onset of disease in health surveillance of past asbestos-exposed workers, for monitoring the progress of disease and for assessing the response to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24416534&#34; target=&#34;_blank&#34;&gt;Radiotherapy applications of patients with malignant mesothelioma: A single center experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients had surgery or thoracoscopic biopsy for diagnosis, staging or treatment and all received palliative or prophylactic radiotherapy. […] During treatment, 12 patients had grade 1 erythema according to the RTOG scale. […] In 3 (12%) patients, a local failure at treatment field was observed. […] Our experience showed that prophylactic and palliative radiotherapy are effective and safe therapy modalities in malignant pleural mesothelioma in preventing seeding metastasis at intervention sites or relieving pain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24419422&#34; target=&#34;_blank&#34;&gt;PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival analysis showed that high p-S6 and Ki-67 expression in samples of treatment naïve patients of cohort 1 was associated with shorter PFS (p = 0.02 and p = 0.04, respectively). […] These novel data reveal a prognostic significance of expression changes of PI3K/mTOR pathway components during induction chemotherapy if confirmed in other patient cohorts and support the growing evidence to target the PI3K/mTOR pathway in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24434429&#34; target=&#34;_blank&#34;&gt;Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the clinical utility of pretreatment plasma fibrinogen levels in malignant pleural mesothelioma (MPM) patients. […] Most interestingly, fibrinogen (cutoff 75th percentile per 750 mg dl(-1)) proved to be a predictive biomarker indicating treatment benefit achieved by surgery within multimodality therapy (interaction term: P=0.034). […] Accordingly, only patients below the 75th percentile benefit from surgery within multimodality therapy (31.3 vs 5.3 months OS). […] Most importantly, fibrinogen predicted treatment benefit achieved by surgery within multimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24441503&#34; target=&#34;_blank&#34;&gt;Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is a continuing unmet need to develop better systemic treatment for this disease, but the rarity of the tumor type creates formidable challenges in clinical trial research. […] Most efforts aim at improving standard first-line therapy, or developing effective second-line treatments. […] This review focuses on several ongoing or recently completed clinical trials investigating novel, promising agents as first-line or second-line therapy for advanced MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24443521&#34; target=&#34;_blank&#34;&gt;Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The assessment of tumor response to therapy can be improved by a deeper phenotypical classification of the tumor, with emphasis on its clinico-biological heterogeneity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24445595&#34; target=&#34;_blank&#34;&gt;A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the “SMART” approach for resectable malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We developed an innovative approach for malignant pleural mesothelioma (MPM) with a short accelerated course of high-dose hemithoracic intensity-modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP). […] This phase I/II study assessed the feasibility of Surgery for Mesothelioma After Radiation Therapy (SMART). […] The primary end point was treatment-related mortality and secondary end points were overall survival, disease-free survival, treatment-related morbidity, and patterns of failure. […] One patient (4%) died from treatment-related toxicity (empyema) during follow-up.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24456714&#34; target=&#34;_blank&#34;&gt;Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radiotherapy (RT) is currently under investigation as part of a trimodality treatment of malignant pleural mesothelioma (MPM). […] Twenty-five patients were treated with 3DCRT, and 14 with HCRT (Intensity modulated radiotherapy or volumetric modulated arc therapy).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24457242&#34; target=&#34;_blank&#34;&gt;ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ZIC1 expression was low in MPM cells, and was correlated with ZIC1 promoter methylation and reversed upon decitabine treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24457947&#34; target=&#34;_blank&#34;&gt;Prognostic factors in patients presenting with pleural effusion revealing malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These factors may help physicians select patients for treatment and/or interventional procedures.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24471939&#34; target=&#34;_blank&#34;&gt;Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nevertheless, our data support the potential use of therapeutics targeting CAIX in patients with advanced mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2449084&#34; target=&#34;_blank&#34;&gt;Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Reactions of wheat germ (WGA) and peanut (PNA) agglutinin with neuraminidase treatment lectins were positive in 5 of 6 (83%) and 3 of 6 (50%) cases, respectively, in reactive mesothelial lesions. […] Thirteen of 23 (57%) malignant mesotheliomas of the pleura showed a positive reaction for WGA and PNA with neuraminidase treatment; other lectins were low-positive, below 9%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24492162&#34; target=&#34;_blank&#34;&gt;Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The 6 patients who completed all 6 treatment cycles had better OS (P = .006); the median PFS was 9.6 months and the OS was 22.4 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24515241&#34; target=&#34;_blank&#34;&gt;The journey of mesothelioma: from postmortem to FNA.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with palliative chemotherapy was planned, but the patient’s clinical status rapidly deteriorated and he passed away prior to the beginning of therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24518090&#34; target=&#34;_blank&#34;&gt;Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to investigate the impact of surgical treatment on the outcome of patients with MPM. […] Patients received chemotherapy alone (n = 172), best supportive care (n = 690), or surgical treatment (n = 503), by either P/D (n = 202) or EPP (n = 301) with or without chemotherapy. […] After a median follow-up of 6.7 years (range, 1.1-14.8), 230 patients (16.8%) were alive; median survival for patients who received palliative treatment or chemotherapy alone, P/D, and EPP were 11.7 (95% CI, 10.5-12.5), 20.5 (95% CI, 18.2-23.1), and 18.8 (95% CI, 17.2-20.9) months, respectively. […] In the subset of 313 patients (25.5%) with all favorable prognostic factors, median survival was 18.6 months after medical therapy alone, 24.6 months after P/D, and 20.9 months after EPP (p = 0.596). […] Our data suggest that patients with good prognostic factors had a similar survival whether they received medical therapy only, P/D, or EPP. […] The modest benefit observed after surgery during medical treatment requires further investigation, and a large multicenter, randomized trial, testing P/D after induction chemotherapy versus chemotherapy alone in MPM patients with good prognostic factors, is needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24523818&#34; target=&#34;_blank&#34;&gt;A Case Report of IgG4-Related Disease Clinically Mimicking Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is important for pathologists and clinicians to recognize this rare entity and its histologic finding, because it can be confused with malignant tumors on the radiologic examination although it can be treated with steroid therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24525443&#34; target=&#34;_blank&#34;&gt;Multimodal management of malignant pleural mesothelioma: where are we today?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis of patients with malignant pleural mesothelioma remains poor and although it is clear that multimodal therapy is necessary to improve long-term results, precise treatment schemes have not yet been unequivocally established. […] Single-modality therapy does not have a major impact on long-term survival and combined-modality therapies are being further evaluated. […] Further treatment options that are currently explored include hyperthermic intrapleural chemotherapy, immunotherapy, gene therapy and photodynamic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24528057&#34; target=&#34;_blank&#34;&gt;CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Determination of the cause of malignant pleural effusions is important for treatment and management, especially in cases of unknown primaries. […] Our findings implied that the two tumor markers may improve the diagnosis and treatment for effusions of unknown primaries.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2453008&#34; target=&#34;_blank&#34;&gt;Intrapleural natural beta interferon in the treatment of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Effusion recurrence is a major problem in the palliative care of patients with disseminated cancer. […] In conclusion, intrapleural beta-interferon is promising as a palliative in the treatment of recurrent malignant effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-06-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24535876&#34; target=&#34;_blank&#34;&gt;Pleural resection and pleural infusion chemotherapy for therapy of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate effective treatment methods of malignant pleural mesothelioma (MPM). […] Surgery-oriented comprehensive treatment was adopted for MPM, which could improve the prognosis and life quality of patients to some extent.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24550969&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Different treatment options are available but Surgery can achieve a complete or incomplete resection and Radical resection is the preferred treatment. […] Chemotherapy has an important role in palliative treatment. […] Photodynamic therapy is also an option under trial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24553485&#34; target=&#34;_blank&#34;&gt;Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our results indicate that adenovirus-mediated miR-34b/c gene therapy could be useful for the clinical treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24567297&#34; target=&#34;_blank&#34;&gt;Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a rare but devastating cancer of the pleural lining with no effective treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24579088&#34; target=&#34;_blank&#34;&gt;Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Off-target toxicity due to the expression of target antigens in normal tissue represents a major obstacle to the use of chimeric antigen receptor (CAR)-engineered T cells for treatment of solid malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24579249&#34; target=&#34;_blank&#34;&gt;Pathologic complete remission of malignant pleural mesothelioma after combined modality treatment: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 50-year-old patient with malignant pleural mesothelioma (epithelial subtype, clinically staged cT1bN0M0) underwent a combined modality treatment, including induction chemotherapy, followed by extrapleural pneumonectomy (EPP) and radical radiotherapy. […] The complete disappearance of solid tumour tissue after induction chemotherapy is a rarely observed and documented finding in the combined modality treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24591971&#34; target=&#34;_blank&#34;&gt;Malignant intraperitoneal mesothelioma-Başkent University experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate diagnostic and treatment results of malignant intraperitoneal mesothelioma in one setting. 12 patients treated for malignant peritoneal mesothelioma from January 2007 to June 2009 in Başkent University Ankara Hospital, Department of Gynaecology and Obstetrics were evaluated. […] Disease free survival of 4.4±1.0 months after completing particular treatment and overall 1-year survival of 85.7 % was observed. […] Because of the low number of patients and different treatment approaches data from a particular patient setting are inconclusive, but from the literature there is evidence that patients with malignant intraperitoneal mesothelioma should undergo optimal cytoreduction and receive a combination of cisplatin and pemetrexed as a first line chemotherapy for intravenous or cisplatin in different chemotherapy regimens using the intraperitoneal administration route, if accessible, with even higher overall survival rates.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24595274&#34; target=&#34;_blank&#34;&gt;Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite some improvements in treatment, therapy is not considered curative and median survival following diagnosis is less than 1 year.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24602395&#34; target=&#34;_blank&#34;&gt;Surgery for malignant pleural mesothelioma: why, when and what?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Various therapies have been tried in the past 50 years including surgery, radiotherapy, chemotherapy, immunotherapy and more recently, targeted therapy. […] Despite growing evidence that EPP might be detrimental, many believe that radical surgery should still be part of multimodality therapy in patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24615668&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: new aspects of medical therapy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the early stages of the disease, trimodal therapy combining surgery, radiation and chemotherapy is used as standard care. […] In advanced stages, the combination of cisplatin and pemetrexed has been approved as first-line therapy, but there is a lack of randomised controlled drug trials for second-line treatment. […] Monotherapy with pemetrexed, vinorelbine or gemcitabine may provide some survival benefit compared to treatment aiming at symptom control only. […] Clinical studies exploring this avenue of treatment are being awaited with great excitement.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24623168&#34; target=&#34;_blank&#34;&gt;Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Today, molecular-profile-directed therapy is a guiding principle of modern thoracic oncology. […] The knowledge of new biomolecular technology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic surgeons’ professional competence.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24624305&#34; target=&#34;_blank&#34;&gt;Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This systematic review suggests that surgery in the context of trimodality therapy offers acceptable perioperative outcomes and long-term survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24645844&#34; target=&#34;_blank&#34;&gt;Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patients’ demographic and clinical data, laboratory results, radiological signs, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and treatment outcomes were evaluated. […] Platinum-based combination chemotherapy in combination with supportive care was used in the treatment of 68.6% of the patients, while supportive treatment alone was used in the others.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24649221&#34; target=&#34;_blank&#34;&gt;Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We evaluated the feasibility of sequential administration of these agents in the treatment of MPM. […] Twenty-four hours following the administration of methotrexate, leucovorin rescue therapy was initiated (10 mg/m&lt;sup&gt;2&lt;/sup&gt; leucovorin administered 4 times at 6-h intervals). […] These treatments were administered weekly, with 4 weekly administrations constituting a cycle of therapy. […] There was no treatment-related mortality. […] Our results suggest that methotrexate and gemcitabine combination therapy is feasible and effective in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24659659&#34; target=&#34;_blank&#34;&gt;Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To compare treatment modalities and investigate potential prognostic factors for survival in patients with malignant pleural mesothelioma (MPM). […] Surgical resection (pleurectomy/decortications (P/D), and extrapleural pneumonectomy (EPP)) was performed in 32 (36.7%) patients; 87 patients (58%) received chemotherapy alone and 16 (10.7%) had surgery, chemotherapy and radiotherapy (trimodal treatment).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24669013&#34; target=&#34;_blank&#34;&gt;Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a lethal neoplasm exhibiting resistance to most treatment regimens and requires effective therapeutic options. […] Though an effective strategy in many cancer, targeted therapy is relatively unexplored in MPM because the therapeutically important oncogenic pathways and networks in MPM are largely unknown.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24675492&#34; target=&#34;_blank&#34;&gt;Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Determining the pre-treatment prognostic factors in malignant pleural mesothelioma is important in terms of estimating the course of the disease and selecting patients who are candidate for multimodal therapy. […] We showed that histological subtype and stage of disease were the most important parameters in planning the treatment, especially in determining the patients who were candidate for multimodal treatment and in estimating the prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24687408&#34; target=&#34;_blank&#34;&gt;A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We included 39 patients; 82.1 % were low risk according to the European Organisation for Research and Treatment of Cancer prognostic group.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24690410&#34; target=&#34;_blank&#34;&gt;Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No drugs have been shown to improve survival as second-line therapy, yet vinorelbine and gemcitabine are prescribed based on the results of small phase II trials. […] We reviewed charts of patients with MPM treated with vinorelbine and/or gemcitabine as second- or third-line therapy between 2003 and 2010.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24690739&#34; target=&#34;_blank&#34;&gt;Disulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Dithiocarbamate compound Disulfiram (DSF) that binds with copper and functions as an inhibitor of aldehyde dehydrogenase is a Food and Drug Administration approved agent for treatment of alcoholism.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24714722&#34; target=&#34;_blank&#34;&gt;Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PEM treatment with SPP1/OPN knockdown inhibited the PEM-induced cell growth-inhibitory effect in PEM-sensitive cells. […] Expression of SPP1/OPN and AKT phosphorylation significantly decreased after PEM treatment of the PEM-sensitive cells. […] Our results suggest that SPP1 may be used as a single predictive biomarker of the effectiveness of PEM treatment in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24716080&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma: clinicopathological characteristics of two cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Peritoneal mesothelioma is a rare tumor, presenting difficulties in diagnosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24716935&#34; target=&#34;_blank&#34;&gt;Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to investigate whether pretreatment white blood cell (WBC), neutrophil, lymphocyte, monocyte, platelet, basophil and eosinophil counts, LDH level, NLR and PLR are associated with prognosis in patients with malignant pleural mesothelioma (MPM). […] Demographic and clinical characteristics, treatments, response to treatment and prognostic factors were evaluated, along with relationships between pretreatment blood parameters and prognosis. […] In the assessment after therapy, it was found that there was complete response in 4 cases (8%), partial response in 10 cases (20%), stable disease in 17 cases (34%) and progression in 19 cases (38%). […] In univariate and multivariate analyses, it was found that factors significantly affecting overall survival included stage (p=0.030), response to treatment (p=0.026) and monocyte count (p=0.004), while factors affecting disease-free survival included NLR (p=0.018), response to treatment (p=0.001), and PLR score (p=0.003).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24722292&#34; target=&#34;_blank&#34;&gt;Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Inhibition of AKT reduced the transcriptional activity of β-catenin-dependent reporters and sensitized the cells to senescence-induced clonogenic death after pemetrexed treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24726598&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Induction chemotherapy was administered in 271 patients (52.3%) and adjuvant therapy in 373 patients (72.0%), including radiotherapy in 213 patients (41.1%), adjuvant chemotherapy in 43 patients (8.3%), and both in 117 patients (22.6%). […] At multivariable analysis adjusted for age and disease stage, male sex (hazard ratio [HR] 1.47, 95% confidence interval [CI]: 1.12 to 1.92), nonepithelial histology (HR 1.96, 95% CI: 1.48 to 2.58), and trimodality treatment using induction chemotherapy (HR 0.61, 95% CI: 0.43 to 0.85) were significantly associated with survival. […] The success of EPP in the context of a multimodality treatment depends on a series of patient characteristics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24727854&#34; target=&#34;_blank&#34;&gt;Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to determine the utility of 18F-FDG-PET for evaluating the presence and the extent of malignant peritoneal mesothelioma (MPM), for disease surveillance/recurrence detection and for evaluating response to therapy. […] Eleven patients had baseline pretreatment scans and all 11 scans showed 18F-FDG avid diffuse, nodular or mixed disease distribution patterns characteristic of MPM. […] Four patients out of eleven had an early post-treatment 18F-FDG scan (&amp;lt;6 months) and all scans were accurate in determining response to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24743707&#34; target=&#34;_blank&#34;&gt;Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Finally, using an in vivo xenograft model, we demonstrate that the anti-tumour effect of anti-CD26 mAb is enhanced when combined with SSTR4 agonist treatment, and that SSTR4 is highly coexpressed with CD26 on epithelioid or biphasic types of MPM tissues obtained from patients’ surgical specimens. […] Combination therapy with humanised anti-CD26 mAb and SSTR4 agonist may therefore potentiate anti-tumour effect on MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24754309&#34; target=&#34;_blank&#34;&gt;Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Taken together, the results of the present study indicate that HUHS1015 could be developed as an effective anticancer drug for treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24769661&#34; target=&#34;_blank&#34;&gt;Wide complex ventricular tachycardia presenting sign of metastatic pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Oncology was involved and as there were no further treatment options available, the patient was discharged home with hospice care.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24773769&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma metastatic to the submandibular salivary gland, simulating glandular hypertrophy, diagnosed by fine-needle aspiration biopsy: a case report and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Seven months after the last treatment, he developed a right submandibular enlargement: clinical examination, ultrasound and computerized tomography scans revealed a salivary gland hypertrophy. […] Anti-inflammatory and antibiotic treatment was then started, without improvement. […] A diagnosis of right submandibular salivary gland involvement from mesothelioma was established, allowing an adequate treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24807157&#34; target=&#34;_blank&#34;&gt;Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Scenario A (all parameters): best pathologic stage, histology, sex, age, type of surgery, adjuvant treatment, white blood cell count (WBC) (≥15.5 or not), and platelets (≥400 k or not) (n = 550). […] Scenario B (no surgical staging): clinical stage, histology, sex, age, type of surgery, adjuvant treatment, WBC, hemoglobin (&amp;lt;14.6 or not), and platelets (n = 627). […] Refinement of these models could define not only the appropriate patient preoperatively for best outcomes after cytoreductive surgery but also stratify surgically treated patients after clinical and pathologic staging who do or do not receive adjuvant therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24838635&#34; target=&#34;_blank&#34;&gt;Signal transducer and activator of transcription 1 (STAT1) acts like an oncogene in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The expression of STAT1 phosphorylated on tyrosine 701 (Y701) was increased by interferon-gamma (IFN-γ) treatment, whereas SOCS1 was not expressed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24842043&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a single-center experience in Turkey.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this retrospective study, we aimed to analyse demographic, clinical, and pathological data and treatment-related features in 54 patients. […] Overall treatment success seems to be comparable to what is currently expected.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24848258&#34; target=&#34;_blank&#34;&gt;Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The goal of targeted therapy is to match a selective drug with a genetic lesion that predicts for drug sensitivity. […] Merlin expression is often lost in malignant pleural mesothelioma (MPM), an asbestos-induced aggressive cancer with limited treatment options. […] This provides one explanation of why Merlin-negative cells are vulnerable to FAK inhibitor treatment. […] Whereas pemetrexed and cisplatin, standard-of-care agents for MPM, enrich for CSCs, FAK inhibitor treatment preferentially eliminates these cells. […] Furthermore, our data suggest that patients with Merlin-negative tumors may especially benefit from FAK inhibitor treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24856077&#34; target=&#34;_blank&#34;&gt;Autofluorescence thoracoscopy in pleural disease: does it have clinical relevance?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It will neither increase the (already very high) diagnostic yield of thoracoscopy nor change treatment in patients suffering from malignant pleural disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24867690&#34; target=&#34;_blank&#34;&gt;Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cells within MPEs may be used to stratify patients for targeted therapy. […] Targeted therapy with poly(ADP ribose) polymerase inhibitors (PARPi) depends on identifying homologous recombination DNA repair (HRR)-defective cancer cells. […] HRR function can be successfully detected in MPE cells demonstrating the potential to stratify patients for targeted therapy with PARPi.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24868442&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma-The European experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several aspects of mesothelioma treatment are discussed controversially, in particular, regarding extent and best type of surgery, radiotherapy, and the role of neoadjuvant or adjuvant treatment. […] However, best survival data is reported from groups using multimodality treatment including macroscopic complete resection (MCR) achieved by either extrapleural pneumonectomy (EPP) or (extended) pleurectomy/decortication for patients qualifying from the tumor biology, stage, and patient’s performance status and comorbidities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2487155&#34; target=&#34;_blank&#34;&gt;Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clonal karyotypic abnormalities were detected in four patients, none of whom had received cytotoxic therapy prior to karyotypic evaluation. […] We also reviewed data on 24 previously reported pretreatment patients and determined that alterations of chromosomes 1, 3, and 22 are frequently associated with malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-03-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24872472&#34; target=&#34;_blank&#34;&gt;Assessment of cisplatin concentration and depth of penetration in human lung tissue after hyperthermic exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The penetration of cisplatin into lung tissue may affect the local therapy of residual tumour cells on the lung surface using hyperthermic intrathoracic chemotherapy perfusion in patients with malignant pleural tumours.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24882384&#34; target=&#34;_blank&#34;&gt;Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New strategies for treatment are needed and phase 1 trials appear as a rationale alternative. […] Including MPM patients in phase I trials beyond first line of treatment can result in modest clinical benefits with an acceptable toxicity profile.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24884875&#34; target=&#34;_blank&#34;&gt;Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cis- diamminedichloroplatinum (II) (cisplatin) treatment failed to reduce ALDH activity and conferred only a short-term inhibition of sphere generation in both ALDH(high) and ALDH(low) fractions of the three MPM cell lines. […] The combined use of CD44 and ALDH widens the window for identification and targeting of a drug-resistant population which may improve the current treatment modalities in mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24918816&#34; target=&#34;_blank&#34;&gt;Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Age, gender, histology, International Mesothelioma Interest Group (IMIG) stage, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), Charlson Comorbidity Index (CCI) and treatment modalities were analysed and correlated to overall survival (OS). […] Treatment was multimodality therapy including surgery in 18, chemotherapy alone in 180 (75%) and best supportive care in 43 cases (18%). […] Treatment with pemetrexed was associated with improved OS (HR 0.40; 95% CI 0.28-0.56, P&amp;lt;0.001). […] Treatment with pemetrexed-based chemotherapy was feasible in this setting.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24926545&#34; target=&#34;_blank&#34;&gt;Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a deadly disease with poor prognosis and few treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24928677&#34; target=&#34;_blank&#34;&gt;Women with malignant pleural mesothelioma have a threefold better survival rate than men.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The effect of female gender on survival persisted when stratified by age (dichotomized at 50 years), stage, or race, but differed depending on treatment. […] Even when adjusted for age, stage, race, and treatment, female MPM patients experienced longer survival than men (hazard ratio = 0.78; 95% confidence interval 0.75 to 0.82). […] This large data set confirms that although MPM is less common in women, they present with similar stage and are offered similar treatment options compared with men. […] Nevertheless, survival is far better in women compared with men, independent of confounders such as age, stage, and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24934863&#34; target=&#34;_blank&#34;&gt;Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed (PEM) is a multi-targeted antifolate similar to MTX approved for the treatment for malignant pleural mesothelioma and non-small cell lung cancer. […] Current recommendations for patients receiving treatment with PEM prescribe draining of the pleural fluid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24935356&#34; target=&#34;_blank&#34;&gt;ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We retrospectively assessed whether there is a correlation between ERCC1 and response to anti-neoplastic therapy or survival. […] In the assessment after therapy, it was found that there was partial response in 12 cases (20%), stable disease in 19 cases (31.4%) and progression in 25 cases (41.7%). […] Mean OS was 11.7 months and mean DFS was 9.5 months in ERCC1-positive cases regardless of therapy, while they were 19.2 months and 17.1 months in ERCC1-negative cases, respectively. […] In univariate analysis, stage, comorbidity, response to treatment and ERCC1 expression were found to be significantly associated with OS (p=0.083; p=0.043; p=0.041; p=0.050). […] In multivariate analysis, response to treatment remained to be significant for OS (p=0.005). […] In univariate and multivariate analyses, response to treatment and ERCC1 were found to be significantly associated with DFS (p=0.049; p=0.041).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24942631&#34; target=&#34;_blank&#34;&gt;Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Eligible patients were randomly assigned (1:1) to either VAT-PP or talc pleurodesis by computer-generated random numbers, stratified by European Organisation for Research and Treatment of Cancer risk category (high vs low). […] The primary outcome was overall survival at 1 year, analysed by intention to treat (all patients randomly assigned to a treatment group with a final diagnosis of mesothelioma). […] VAT-PP is not recommended to improve overall survival in patients with pleural effusion due to malignant pleural mesothelioma, and talc pleurodesis might be preferable considering the fewer complications and shorter hospital stay associated with this treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24947955&#34; target=&#34;_blank&#34;&gt;Interventional therapies for malignant pleural effusions: the present and the future.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is now a realization that patient-reported outcome measures should be the primary goal of MPE treatment, and this now is the focus in most clinical trials. […] Pleurodesis is the conventional and for a long time the only definitive therapy available. […] Recent studies support the effectiveness of IPC treatment and provide reassurance regarding its safety.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24958517&#34; target=&#34;_blank&#34;&gt;Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
According to our results, we may consider gemcitabine-based regimens as second-line chemotherapy after treatment with pemetrexed plus platinum in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24966347&#34; target=&#34;_blank&#34;&gt;Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is associated with asbestos exposure and is a cancer that has not been significantly affected by small molecule-based targeted therapeutics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24991206&#34; target=&#34;_blank&#34;&gt;Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A combination of pemetrexed and cisplatin has been shown to improve the outcome in patients with malignant pleural mesothelioma (MPM), however, there is a great heterogeneity in treatment response among patients. […] The aim of our study was to evaluate the influence of polymorphisms in folate pathway and transporter genes on pemetrexed treatment outcome in Slovenian patients with MPM. […] Logistic regression was used to assess the influence of polymorphisms on treatment efficacy and toxicity, while Cox regression was used to determine their influence on progression-free and overall survival. […] MTHFD1 polymorphism affected treatment response and survival, while polymorphisms in ABCC2 and SLCO1B1 transporter genes influenced the risk for toxicity. […] These polymorphisms could serve as potential markers of pemetrexed treatment outcome in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24991768&#34; target=&#34;_blank&#34;&gt;Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed, a folate antimetabolite, combined with cisplatin is used as a first-line therapy for malignant pleural mesothelioma (MPM) and locally advanced or metastatic non-small-cell lung cancer (NSCLC).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24996387&#34; target=&#34;_blank&#34;&gt;Prognostic coronary surgery in a case of malignant mesothelioma previously managed with trimodality treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report a case of malignant pleural mesothelioma treated with trimodality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25023662&#34; target=&#34;_blank&#34;&gt;The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a highly aggressive neoplasm with a poor prognosis and limited treatment options. […] High-EMX2 expression was associated with decreased progression-free survival after neoadjuvant therapy, suggesting that induction therapy should be avoided in these patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25026285&#34; target=&#34;_blank&#34;&gt;CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a deadly tumor whose diagnosis and treatment remain very challenging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25028262&#34; target=&#34;_blank&#34;&gt;EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mechanistic target of rapamycin signaling pathway, inhibited by RAD001, was shown to be deregulated in MPM development and considered a novel target for the MPM therapy. […] Pretreatment with EF24 or RAD001 followed by cisplatin increased the effects of cisplatin alone application. […] EF24 and RAD001 pretreatment decreased DNA fragmentation rate when compared with cisplatin alone treatment in Met-5A cells. […] Our preliminary results suggest that pretreatment with EF24 or RAD001 may reduce cytotoxic effect of cisplatin on nonmalignant mesothelial cells and increase cell death response of MPM cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25045139&#34; target=&#34;_blank&#34;&gt;Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis of mesothelioma remains disappointing despite multimodal treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25048065&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy enhanced by hyperbaric oxygenation in palliation of malignant pleural mesothelioma: clinical experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical debulking followed by radiotherapy/chemotherapy are the standards in the palliative treatment schedule of malignant pleural mesothelioma. […] The aim of this study was to evaluate the additional effect of intraoperative photodynamic therapy (PDT) under hyperbaric oxygenation (HBO) if compared to decortication alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25048089&#34; target=&#34;_blank&#34;&gt;The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma–a short review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Global occurrence in combination with poor overall survival, difficulty in diagnosis, and limited effective treatment options signal the need for further exploration of miRNA involvement in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25048673&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy in the management of malignant pleural mesothelioma: A review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the present trend of multi-modal treatment for MPM we aim to evaluate the current status of photodynamic therapy (PDT) in the management of MPM through a review study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25051913&#34; target=&#34;_blank&#34;&gt;Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our aim was to evaluate the prognostic role of the pretreatment serum albumin level in patients with malignant pleural mesothelioma (MPM) receiving platinum-based systemic chemotherapy. […] Multivariate analysis indicated that pretreatment albumin was an independent prognostic factor in MPM. […] The pretreatment serum albumin level is a simple, inexpensive and easily measurable marker with prognostic significance in MPM patients treated with platinum-based systemic chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25053821&#34; target=&#34;_blank&#34;&gt;Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study might help to identify those subpopulations of patients who would respond well to the CBP501 and CDDP combination treatment of NSCLC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25054098&#34; target=&#34;_blank&#34;&gt;Sarcomatoid malignant mesothelioma presenting with intramedullary spinal cord metastasis: a case report and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Methods This report describes the case of a 62-year-old man with Brown-Séquard syndrome and radiculopathy of the left C5 nerve root detected during treatment for pleural sarcomatoid MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25059234&#34; target=&#34;_blank&#34;&gt;Predictive value of systemic and local inflammation parameters in talc pleurodesis assessment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One option for the palliative treatment of recurrent malignant pleural effusion is powdered talc using thoracoscopy. […] The group was retrospectively divided according to treatment results into Group A (N1 = 98 - successful) and Group B (N2 = 16 - relapsing). […] The time interval of local inflammatory development and duration was related to the treatment efficacy and showed a significant rise 2 h after talcage in Group A.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25059587&#34; target=&#34;_blank&#34;&gt;Diagnosis and treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Given the difficulties of reaching an early diagnosis, cure is not generally achieved with radical surgery (pleuropneumonectomy), so liberation of the tumor mass with pleurectomy/decortication combined with chemo- or radiation therapy (multimodal treatment) has been gaining followers in recent years. […] Radiation therapy is reserved for treatment of pain associated with infiltration of the chest wall or any other neighboring structure. […] In any case, comprehensive support treatment for pain control in specialist units is essential: this acquires particular significance in this type of malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25061089&#34; target=&#34;_blank&#34;&gt;Current issues in malignant pleural mesothelioma evaluation and management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite great efforts, the prognosis of MPM remains poor, especially at progression after initial treatment. […] Pemetrexed and platinum combination chemotherapy has become the cornerstone of therapy for patients with unresectable disease because the combination is associated with improved survival and quality of life in treated patients. […] However, MPM eventually becomes resistant to initial therapy, and benefit to further lines of therapy has not been substantiated in randomized clinical trials. […] These advances hold the promise of a new era in the treatment of MPM and suggest that this disease will not be left behind in the war on cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25073664&#34; target=&#34;_blank&#34;&gt;Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We previously reported our technique for delivering intensity modulated radiation therapy (IMRT) to the entire pleura while attempting to spare the lung in patients with malignant pleural mesothelioma (MPM). […] Pretreatment imaging, treatment plans, and posttreatment imaging were retrospectively reviewed to determine failure location(s).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25079105&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We describe the treatment of two cases of pleural mesothelioma with CNS metastases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25120691&#34; target=&#34;_blank&#34;&gt;Metastasis of mesothelioma to the maxillary gingiva.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is currently no effective standard treatment for mesothelioma and the prognosis for patients is poor; the majority of patients with malignant mesothelioma succumb between 12 and 17 months following diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25123375&#34; target=&#34;_blank&#34;&gt;A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The effects of the treatment on mesothelioma cells were evaluated in vitro and further tested in two validated murine models. […] Intratumoural delivery of the treatment in BALB/c mice induced tumour necrosis and local activation of T cells. […] Tumour growth was significantly inhibited in the treatment group during and after the treatment period (size of tumour 58.8 ± 10.3 mm(2) vs 118.3 ± 6.7 mm(2) from saline controls at day 23, n = 9-12 per group), P &amp;lt; 0.001. […] Tumour growth resumed on cessation of treatment, confirming the inhibition was treatment related. […] Treatment benefits were further validated in an orthotopic peritoneal model of mesothelioma and the compound significantly reduced the mesothelioma load (P &amp;lt; 0.05 vs saline controls). […] Mice in the treatment group had a significant increase in the percentage of activated CD4(+) and CD8(+) T cells in tumour-draining lymph nodes. […] No histological side-effects were observed with the treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25130005&#34; target=&#34;_blank&#34;&gt;Gamma knife radiosurgery of brain metastasis from malignant pleural mesothelioma–report of three cases with autopsy study in a case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
GKR was found effective also for the treatment of brain metastasis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25138167&#34; target=&#34;_blank&#34;&gt;Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Regarding that also EGFR amplifications in MPM are absolute rarities, our findings may be a hint that TKI’s will not satisfy the hope for a new era in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25142706&#34; target=&#34;_blank&#34;&gt;Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The onset of hyponatraemia (serum sodium &amp;lt;135 mEq/L) during the treatment was significantly related to a worsened median overall survival (7.93 vs 13.48 months; p = 0.0069). […] Results were also similar in the subgroup receiving a second-line treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25155251&#34; target=&#34;_blank&#34;&gt;Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results were validated independently in the European Organisation for Research and Treatment of Cancer (EORTC) 08052, a phase II study in MPM. […] Response to therapy was assessed according to World Health Organisation (WHO) criteria in all except the two most recent trials, which used Response Evaluation Criteria in Solid Tumours (RECIST).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25174276&#34; target=&#34;_blank&#34;&gt;Identification of actionable mutations in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Genetic alterations that are potential targets for molecular targeted therapy were detected in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25187665&#34; target=&#34;_blank&#34;&gt;Should we continue to offer extrapleural pneumonectomy to selected mesothelioma patients? A single center experience comparing surgical and non-surgical management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Though not yet clearly defined, a subset of patients may benefit from a surgery-based multimodal treatment plan, beyond what would be expected with non-surgical therapies only. […] Indeed, despite some disappointing results on the feasibility of a multimodality treatment (chemotherapy ± surgery and post-operative radiation therapy) based on a lung sacrificing surgery (extrapleural pleuropnemonectomy) have been recently reported, the question concerning the role of extrapleural pneumonectomy in selected mesothelioma patients is still unanswered. […] In the light of this, we have reviewed our mono-institutional retrospective experience in the mesothelioma management, discussing on the role of extrapleural pneumonectomy in the multimodality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25188816&#34; target=&#34;_blank&#34;&gt;Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Fibroblast growth factors (FGFs) and their receptors are potential targets for cancer therapy, but their significance in mesothelioma has remained largely undefined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25192022&#34; target=&#34;_blank&#34;&gt;Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
8 MPM patients who received induction chemotherapy and surgical treatment were matched on age, sex, tumor histology, TNM stage and EORTC score with 8 patients who received chemotherapy only. […] CD8 positive T-cells and the total macrophage count, using the CD68 pan-macrophage marker, and CD163 positive M2 macrophage count were determined in tumor specimens prior to treatment. […] Our data revealed that the CD163/CD68 ratio is a potential prognostic marker in epithelioid mesothelioma patients independent of treatment but cannot be used as a predictive marker for outcome after surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25203873&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We review our 24-year experience with extrapleural pneumonectomy (EPP) in the treatment of epithelioid malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25217189&#34; target=&#34;_blank&#34;&gt;Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We included articles published between January 1, 2000 and March 20, 2014 in which subjects received first or second line systemic therapy for malignant pleural mesothelioma. […] Studies investigating multi-modality therapy including surgery were excluded. […] In total, there were 323 responses (21.9%, complete and partial responses, 95% CI: 16.3, 28.8) to systemic therapy across all histological subtypes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25231400&#34; target=&#34;_blank&#34;&gt;Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median of five cycles (range, 1-6) of combination treatment was administered, and 56 (63%) patients received amatuximab maintenance. […] Combination therapy resulted in no overlapping toxicities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25238873&#34; target=&#34;_blank&#34;&gt;A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For patients not fit for systemic anticancer treatment, best supportive care remains the mainstay of management. […] A study from the United States examining advanced lung cancer showed that early specialist palliative care input improved patient health related quality of life and depression symptoms 12 weeks after diagnosis. […] While mesothelioma and advanced lung cancer share many symptoms and have a poor prognosis, oncology and palliative care services in the United Kingdom, and many other countries, vary considerably compared to the United States. […] The aim of this trial is to assess whether regular early symptom control treatment provided by palliative care specialists can improve health related quality of life in patients newly diagnosed with mesothelioma. […] Current practice in the United Kingdom is to involve specialist palliative care towards the final weeks or months of a life-limiting illness. […] This study aims to investigate whether early, regular specialist care input can result in significant health related quality of life gains for patients with mesothelioma and if this change in treatment model is cost-effective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25246386&#34; target=&#34;_blank&#34;&gt;Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Greater risk of early disease progression (PD), and shortening of PFS and OS were associated with several clinical factors (eg, anemia for early PD and OS), weight loss (for PFS and OS), and previous surgical treatment (for early PD, PFS, and OS).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25253633&#34; target=&#34;_blank&#34;&gt;Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with malignant mesothelioma have a poor prognosis and only 40% respond to first line treatment; a combination of pemetrexed and cisplatin or carboplatin. […] We used primary malignant mesothelioma cells and an ex vivo chemosensitivity assay with future purpose to predict best choice of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25266654&#34; target=&#34;_blank&#34;&gt;Local and systemic therapies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For early-stage MPM, patients should be evaluated for trimodality therapy in an experienced cancer center. […] If deemed a good surgical candidate, patients should receive surgical resection (pleurectomy/decortication or extrapleural pneumonectomy), adjuvant radiation therapy (hemithoracic external beam or intensity modulated radiation therapy), and either neoadjuvant or adjuvant chemotherapy (cisplatin-pemetrexed for 4 cycles). […] Several trials are currently underway to examine intraoperative therapies, vaccines, immunotherapy additions, and novel radiation therapy techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25277603&#34; target=&#34;_blank&#34;&gt;Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Selective activation of ERβ with KB9520 sensitized the cells to treatment with cisplatin, resulting in enhanced growth inhibition and increased apoptosis. […] Together, the data presented suggest that selective targeting of ERβ may be an efficacious stand-alone treatment option and/or become an important add-on to existing malignant mesothelioma therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25279180&#34; target=&#34;_blank&#34;&gt;Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, we retrospectively enrolled 31 patients with non-squamous NSCLC who had achieved disease control with initial pemetrexed treatment, followed by rechallenge with pemetrexed-based chemotherapy (PBC) upon disease progression. […] The treatment was generally well tolerated, with a low rate of toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25301502&#34; target=&#34;_blank&#34;&gt;Naftopidil is useful for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This raises the possibility that naftopidil could be developed as an effective drug for the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25310424&#34; target=&#34;_blank&#34;&gt;Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, improved survival and decreased morbidity and mortality have been demonstrated when the diagnosis is made in the early stages of disease and specific treatment strategies are implemented. […] Radiologists should recognize the manifestations of MPM across multiple imaging modalities, translate these findings into the updated staging system, and understand the effects of appropriate staging on treatment and survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25316393&#34; target=&#34;_blank&#34;&gt;Impact of New Chemotherapeutic agents on the outcome of Egyptian patients with Advanced Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Aim of this work was to evaluate the efficacy and safety of new chemotherapeutic agents for the treatment of Egyptian MPM patients. […] Both cisplatin/pemetrexed and cisplatin/ raltitrexed are effective and safe regimens in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25318801&#34; target=&#34;_blank&#34;&gt;Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because his serum creatinine increased, pemetrexed maintenance therapy (PMT) was adopted, and 18 cycles were successfully delivered and the patient achieved a complete response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25331029&#34; target=&#34;_blank&#34;&gt;Advances in malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The management of MPM has evolved from single chemotherapy to multimodality treatment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), chemotherapy, radiotherapy, and immunotherapy. […] Promising results have been achieved after a combined treatment of CRS and HIPEC, with an elevated median survival time of 29.5-92 months and a 5-year survival rate of 39-63%. […] CRS and HIPEC represent the standard treatment strategy for selected patients with MPM, and patients with unresectable tumors can benefit from the combined treatment of chemotherapy, radiotherapy, and immunotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25335113&#34; target=&#34;_blank&#34;&gt;Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the H226 xenograft model, the relative tumor growth was aborted, and E2F1 was downregulated while cleaved caspase-3 was elevated and localized to the nucleus in the ATO treatment group. […] There is sound scientific evidence to support the clinical application of ATO in treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25361002&#34; target=&#34;_blank&#34;&gt;Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The first line treatment for MPM is a combination of cisplatin and Pemetrexed, which displayed limited efficacy and severe side effects. […] We thus aim at evaluating PEITC used alone or in combination with cisplatin in order to improve MPM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25374217&#34; target=&#34;_blank&#34;&gt;Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is almost always fatal and few treatment options are available. […] The aim of this study was to evaluate the efficacy of oral cyclophosphamide and etoposide for patients who underwent standard treatment for advanced MM. […] Under the treatment of oral EE, median progression- free survival was 7.7 months [95%CI HR (4.3-11.1)] and median overall survival was 28.1 months [95%CI HR (5.8-50.3)]. […] The treatment response rates were as follows: 4 patients (27.3%) had a partial response (PR), 12 (54.5%) had stable disease (SD), and progressive disease (PD) was observed in 6 (35.9%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25378643&#34; target=&#34;_blank&#34;&gt;Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Translating the recent success of chimeric antigen receptor (CAR) T cell therapy for hematological malignancies to solid tumors will necessitate overcoming several obstacles, including inefficient T cell tumor infiltration and insufficient functional persistence. […] The ability of intrapleurally administered T cells to circulate and persist supports the concept of delivering optimal CAR T cell therapy through “regional distribution centers.” On the basis of these results, we are opening a phase 1 clinical trial to evaluate the safety of intrapleural administration of mesothelin-targeted CAR T cells in patients with primary or secondary pleural malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25382807&#34; target=&#34;_blank&#34;&gt;Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An optimal chemotherapy utilization model for MPM was constructed using indications for chemotherapy identified from evidence-based MPM treatment guidelines.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25385189&#34; target=&#34;_blank&#34;&gt;Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To identify a possible new treatment modality for malignant pleural mesothelioma (MPM), we examined whether combination treatment consisting of pemetrexed chemotherapy and photodynamic therapy (PDT) using the photosensitizer NPe6, enhanced the antitumor effect in both in vitro and in vivo models. […] We also investigated preclinical treatment schedules. […] Four human malignant mesothelioma cell lines (MSTO‑211H, H2052, H2452 and H28) were assayed using the WST assay after treatment with pemetrexed and NPe6‑PDT. […] The treatment schedule for the combination treatment was examined using nude mice. […] Pemetrexed pre‑treatment enhanced the lethal effect of NPe6‑PDT in the four malignant mesothelioma cell lines, but NPe6‑PDT followed by pemetrexed treatment did not enhance cell lethality in the in vitro assay. […] Pemetrexed pre‑treatment did not enhance the intracellular accumulation of NPe6, which is one of the determinants of the antitumor effect of PDT. […] In nude mice injected with MSTO‑211H cells and then treated using a combination of pemetrexed and NPe6‑PDT (10 mg/kg NPe6, 10 J/cm(2) laser irradiation), the tumor volume decreased by 50% but subsequently increased, reaching the pre‑treatment value after 14 days. […] Pemetrexed treatment followed by NPe6‑PDT resulted in an 80% reduction in the tumor size and inhibited re‑growth. […] NPe6‑PDT followed by pemetrexed treatment resulted in a 60% reduction in tumor size but did not inhibit re‑growth. […] NPe6‑PDT induced the expression of thymidylate synthase (TS), which confers resistance to pemetrexed, and NPe6‑PDT followed by pemetrexed treatment did not enhance the treatment outcome in vivo. […] In conclusion, combination treatment, consisting of pemetrexed followed by NPe6‑PDT, should be further investigated as a new treatment modality for MPM. […] In the future, this combination treatment may contribute to a reduction in local recurrence and a prolonged survival period in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25403555&#34; target=&#34;_blank&#34;&gt;Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Quantitative analyses on FDG PET for response assessment are increasingly used in clinical studies, particularly with respect to tumours in which radiological assessment is challenging and complete metabolic response is rarely achieved after treatment. […] We present our results concerning the use of semiquantitative and quantitative parameters, evaluated at the baseline and interim PET examinations, for the prediction of treatment response and disease outcome in patients with MPM. […] We retrospectively analysed data derived from 131 patients (88 men, 43 women; mean age 66 years) with MPM who were referred to our institution for treatment between May 2004 and July 2013. […] Responses were determined using modified RECIST criteria based on the best CT response after treatment. […] These results confirm the role of FDG PET in the assessment of disease prognosis and treatment efficacy in MPM patients receiving first-line pemetrexed-based chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25421609&#34; target=&#34;_blank&#34;&gt;Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, there is a compelling need to develop novel therapeutics with different modes of action.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25422081&#34; target=&#34;_blank&#34;&gt;CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover, treatment with a small-molecule CK2α inhibitor CX-4945 led to dose-dependent inhibition of Gli1 expression and transcriptional activity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25422196&#34; target=&#34;_blank&#34;&gt;Caring for patients with malignant pleural mesothelioma in Japan: evaluation of a Palliative Care Educational Program.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study evaluated the effect of an Educational PROGRAM on Palliative Care for MPM for Nurses in Japan. […] This study used a pretest-posttest design with a single cohort of nurses and included a Difficulties in Palliative Care for Patients with MPM (DPCMPM) Scale with 15 items. […] The Palliative Care for MPM Handbook for Nurses was developed as an educational tool for clinical settings. […] The Educational PROGRAM on Palliative Care for MPM for Nurses was effective in reducing nursing difficulties.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25425731&#34; target=&#34;_blank&#34;&gt;FISH analysis of intrapulmonary malignant mesothelioma without a clinically detectable primary pleural lesion: an autopsy case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite corticosteroid therapy, follow-up chest computed tomography showed enlargement of multiple nodules accompanied by the appearance of pleural thickening and effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25441141&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for pleural malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Additional prospective studies are needed to better characterize the role of EPP in the multimodality treatment of patients with pleural dissemination of malignancy, including NSCLC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25442335&#34; target=&#34;_blank&#34;&gt;Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate safety, efficacy, and recurrence after hemithoracic intensity modulated radiation therapy after pleurectomy/decortication (PD-IMRT) and after extrapleural pneumonectomy (EPP-IMRT). […] Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication produced little high-grade toxicity but led to progressive declines in pulmonary function; OS and PFS were better in PD-IMRT compared with EPP-IMRT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25463163&#34; target=&#34;_blank&#34;&gt;Current controversies in the management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPE consists of a heterogenous group of diseases and careful phenotyping of malignant effusion patients can provide important clinical information that will advance the field and allow better stratification of patients and planning of therapy accordingly.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25467107&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prognosis of MPM patients is modest since the vast majority of patients are diagnosed at advanced stage and because platinum-based chemotherapy remains the cornerstone of treatment, with no standard second line treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25474713&#34; target=&#34;_blank&#34;&gt;Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The decision to undertake “definitive therapy” (pleurodesis, indwelling pleural catheter [IPC], or both) for MPEs is decided on a case-by-case basis. […] Identifying factors that predict definitive therapy may help guide early initiation of treatment. […] The aim of the study was to identify clinical, laboratory, and radiologic predictors associated with clinicians’ prescription of definitive therapy for patients with MPE. […] Logistic regression was performed to determine the variables useful for predicting definitive therapy. […] Definitive therapy was used in 288 patients (53.6%): 199 received a pleurodesis and 89 an IPC. […] Univariate analysis of the combined cohort revealed that definitive therapy was more likely if the effusion has low pH, either as a continuous variable (OR, 30.30; P &amp;lt; .01) or with a pH cutoff of &amp;lt; 7.2 (OR, 2.09; P = .03); was large (&amp;gt; 50% of hemithorax) (OR, 2.75; P &amp;lt; .01); or was associated with mesothelioma (OR, 1.83; P &amp;lt; .01). […] Following multivariate analysis, low pleural pH (OR, 37.04; P &amp;lt; .01), large effusions (OR, 3.31; P &amp;lt; .01), and increasing age (OR 1.02, P = .01) were associated with the use of definitive therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2549127&#34; target=&#34;_blank&#34;&gt;[A clinical study of six surgically treated patients with malignant tumors arising from chronic pleuritis and pyothorax].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two patients had suffered from chronic pleuritis, who both had received artificial pneumothorax therapy for pulmonary tuberculosis, and the other 4 patients had suffered from chronic pyothorax, with mean duration of thirty years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-09-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25497279&#34; target=&#34;_blank&#34;&gt;MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prognosis of malignant pleural mesothelioma (MPM) is poor, and predicting the outcomes of treatment is difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25499640&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy for lung cancer and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) is a form of non-ionizing radiation therapy that uses a drug, called a photosensitizer, combined with light to produce singlet oxygen ((1)O2) that can exert anti-cancer activity through apoptotic, necrotic, or autophagic tumor cell death. […] For early-stage non-small cell lung cancer (NSCLC), PDT is primarily employed as an endobronchial therapy to definitively treat endobronchial or roentgenographically occult tumors. […] Intraoperative PDT can be safely combined with macroscopically complete surgical resection and other treatment modalities for malignant pleural mesothelioma (MPM) to improve local control and prolong survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25503125&#34; target=&#34;_blank&#34;&gt;Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Using flow cytometry, we showed that the combination treatment (ADI-PEG20 at 50 ng/ml and TRAIL at 10 ng/ml) for 24 h resulted in profound cell death with 67% of cells positive for caspase-3 activity, while ADI-PEG20 alone or TRAIL alone resulted in only 10-15% cell death. […] Our work represents a new strategy for treating patients with malignant pleural mesothelioma using targeted molecular therapeutics based on selected tumor markers, thus avoiding the use of potentially cytotoxic chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-03-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25506370&#34; target=&#34;_blank&#34;&gt;Clinicopathologic and survival characteristics of malignant pleural mesothelioma registered in hospital cancer registry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We aimed at presenting clinicopathological and treatment outcomes of 60 patients of MPM registered in our hospital cancer registry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25519011&#34; target=&#34;_blank&#34;&gt;Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We investigated whether the presence of CTC was correlated with prognosis factors and treatment efficacy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25527013&#34; target=&#34;_blank&#34;&gt;Novel induction therapies for pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although much research has been done on the optimal treatment for this disease, the overall prognosis remains grim. […] The main components of therapy are surgery, chemotherapy, and radiation therapy, but there is controversy in the literature about the optimal inclusion and sequencing of these treatments, as each has unique risk profiles. […] We have developed a new Surgery for Mesothelioma After Radiation Therapy protocol consisting of induction-accelerated hemithoracic radiation followed by extrapleural pneumonectomy. […] In this article, we reviewed the current literature on induction chemotherapy for mesothelioma as well as described the Surgery for Mesothelioma After Radiation Therapy protocol and upcoming studies of novel induction therapies for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25532843&#34; target=&#34;_blank&#34;&gt;1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1- yloxy)propan-2-ol may be a promising anticancer drug.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here we show how HUHS1015 might offer brilliant hope for cancer therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25547995&#34; target=&#34;_blank&#34;&gt;Adenosine deaminase inhibitor EHNA exhibits a potent anticancer effect against malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor and an effective therapy has been little provided as yet. […] The present study investigated the possibility for the adenosine deaminase (ADA) inhibitor EHNA as a target of MPM treatment. […] EHNA induced apoptosis of human MPM cell lines in a concentration (0.01-1 mM)- and treatment time (24-48 h)-dependent manner, but such effect was not obtained with another ADA inhibitor pentostatin. […] EHNA increased intracellular adenosine concentrations in a treatment time (3-9 h)-dependent manner. […] This suggests that EHNA may be useful for treatment of the tragic neoplasm MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25552068&#34; target=&#34;_blank&#34;&gt;[Hyperthermic chemoperfusion of the pleural cavity in the combined treatment for malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The literature and our own experience were analyzed in multimodal approach to the treatment of patients with malignant pleural mesothelioma (MPM). […] Survival and quality of life of patients with MPM who underwent multimodal treatment, according to modern standards, are often limited by the occurrence of local recurrences. […] The value of a number of local therapy methods is still being explored in order to determine the possible side effects as well as the duration of disease-free survival. […] Photodynamic therapy and intraoperative hyperthermic chemoperfusion of the pleural cavity are the methods of the local treatment of this disease, applied after surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25554663&#34; target=&#34;_blank&#34;&gt;[Pemetrexed-induced scleroderma-like changes in the lower legs].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The first case concerned a 66-year-old man diagnosed with pulmonary adenocarcinoma metastatic from the outset and in whom maintenance treatment comprised pemetrexed after first-line therapy comprising six courses of cisplatin-pemetrexed. […] From the first course of pemetrexed, given as maintenance therapy, she presented erythematous oedema of both legs, without fever. […] A diagnosis of bilateral erysipelas was made, and antibiotic treatment with cloxacillin was given.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25572666&#34; target=&#34;_blank&#34;&gt;Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to describe our experience implementing intensity modulated proton therapy (IMPT) for lung-intact malignant pleural mesothelioma (MPM), including patient selection, treatment planning, dose verification, and process optimization. […] Four patients received IMPT and 3 received intensity modulated radiation therapy. […] Treatment plans for the other modality were created for dosimetric comparisons. […] Treatment with IMPT was well tolerated and completed without breaks. […] Total daily treatment time was approximately 45 minutes (20 minutes for setup and 25 minutes for delivery).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25572813&#34; target=&#34;_blank&#34;&gt;Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, combination of carboplatin, liposomised doxorubicin (Caelyx) and gemcitabine (CCG regimen) has revealed noteworthy activity when used as first-line treatment. […] The aim of this study is to assess efficacy and toxicity profile for patients with MPM receiving CCG regimen as a third-line treatment. […] Response to treatment was assessed by CT scan using Modified RECIST criteria for mesothelioma. […] First-line treatment was platinum and pemetrexed in 42 cases. […] Second-line treatment was vinorelbine in 42 cases and pemetrexed in one patient. […] Median lead time from cessation of second-line treatment to start of third CCG was 1 month. […] Twenty-eight per cent of the patients received six cycles, while treatment was postponed due to toxicities, mainly haematological, in 56 % of cases. […] Medians of overall survival (OS) from diagnosis and from start of CCG treatment were 25.2 months (18.4-31.5 months) and 6.8 months (5.4-8.4 months), respectively. […] Less toxic and more active treatment options are clearly needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25586574&#34; target=&#34;_blank&#34;&gt;Acute lower limb ischemia complicating pemetrexed and carboplatin combination chemotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed and Carboplatin are two well-known chemioterapic agents used for the treatment of many tumors, especially for lung cancer and mesothelioma. […] We herein report a case of lower limb acute ischemia related to combined treatment of Pemetrexed and Carboplatin. […] A 68-year-old woman was given the chemiotherapic treatment with combination of Pemetrexed and Carboplatin after pleural resection for a malignant pleural mesothelioma. […] Immediately after the second cycle of treatment, the patient experienced sudden acute left lower limb ischemia. […] Symptoms resolved after an intra-operative thrombolytic and spasmolytic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25589810&#34; target=&#34;_blank&#34;&gt;Fluoro deoxyglucose positron emission tomography-computerized tomography in primary staging and response assessment of a rare case of primary pleural synovial sarcoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pretreatment and postchemotherapy FDG PET-CT scans are presented.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25595163&#34; target=&#34;_blank&#34;&gt;[Current surgical therapy for malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival time( MST) was 8.9 months for those treated by palliative care only. […] For a radical treatment, total removal of the tumor is the main therapy as well as other solid tumors, but these diffuse and infiltrate growth pattern of tumor make it difficult. […] There are negative opinions for invasive surgical treatment such as extrapleural pneumonectomy (EPP). […] Currently surgical treatment of mesothelioma is conducted as part of the multidisciplinary treatment combined with chemotherapy and radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25599996&#34; target=&#34;_blank&#34;&gt;Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to evaluate the efficacy and safety of volumetric modulated arc therapy (VMAT) after extrapleural pneumonectomy (EPP) in patients with malignant pleural mesothelioma (MPM). […] Treatment-related toxicities were evaluated by Common Terminology Criteria for Adverse Events (CTCAE) ver.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25611229&#34; target=&#34;_blank&#34;&gt;SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median duration of treatment was 2 cycles (56 days).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25616202&#34; target=&#34;_blank&#34;&gt;Fast neutron radiotherapy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a fatal disease lacking standardized treatment. […] We describe the use of fast neutron radiation therapy in MPM patients referred to the Department of Radiation Oncology at the University of Washington Medical Center. […] Retrospective chart review of MPM patients receiving neutron radiotherapy treatment from 1980 to 2012. […] A total of 30 MPM patients received fast neutron radiotherapy as part of their treatment regimen. […] Eighteen patients received fast neutron radiotherapy as a component of trimodality treatment. […] One patient receiving radiotherapy alone as a palliative measure died during radiation treatment. […] One patient was unable to tolerate radiotherapy and stopped before completing prescribed treatment. […] No significant differences in survival were observed when comparing patients who received trimodality treatment compared to those who did not. […] However, treatment with fast neutron radiotherapy did not significantly improvement outcome, even when used in a trimodality regimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25632963&#34; target=&#34;_blank&#34;&gt;Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that has a poor prognosis, limited treatment options, and a worldwide incidence that is expected to increase in the next decade.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25633038&#34; target=&#34;_blank&#34;&gt;Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After multivariate survival analyses, Ki67 proved to be-beside histology and treatment-an independent prognostic marker in MPM (hazard ratio (HR): 2.1, P&amp;lt;0.001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25653696&#34; target=&#34;_blank&#34;&gt;A case of advanced malignant pleural mesothelioma treatment with chemotherapy and photodynamic therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive, treatment-resistant, and generally fatal disease. […] We advised him to take combination chemotherapy but he refused to take the treatment. […] Thus, we recommended photodynamic therapy (PDT) to deal with the dyspnea and MPM. […] Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25654216&#34; target=&#34;_blank&#34;&gt;Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this trial was to assess the role of radiotherapy for the treatment of pain in MPM. […] Key follow-up points were 5 and 12 weeks posttreatment. […] Radiotherapy for pain control in MPM is an effective treatment in a proportion of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25662329&#34; target=&#34;_blank&#34;&gt;Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: preliminary experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This experience confirms that cytoreductive surgery and HITHOC is a good option in the treatment of MPD.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25668009&#34; target=&#34;_blank&#34;&gt;MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Until now, predictive and prognostic biomarkers are lacking, making it a non-tailored therapy regimen with unknown outcome. […] MDM2 is a prognostic and predictive marker for a platin-pemetrexed therapy of patients with MPMs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25670260&#34; target=&#34;_blank&#34;&gt;Itraconazole therapy in a pancreatic adenocarcinoma patient: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To report the case of a patient receiving itraconazole for the treatment of histoplasmosis and his subsequent reduction in pancreatic tumor size.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25670913&#34; target=&#34;_blank&#34;&gt;New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here, we summarize significant new preclinical and early clinical developments in treatment of MPM, which include mesothelin specific antibody and toxin therapies, interleukin-4 (IL-4) receptor toxins, dendritic cell vaccines, immune checkpoint inhibitors, and gene-based therapies. […] In addition, several local modalities such as photodynamic therapy, postoperative lavage using betadine, and cryotherapy for local recurrence, have also shown to be effective for local control of disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25679073&#34; target=&#34;_blank&#34;&gt;Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of malignant pleural mesothelioma (MPM) remains very challenging. […] Assessment of response to treatment is necessary for modifying treatment and using new drugs. […] Nineteen subjects with histologically proven MPM who had undergone fluoride-18-fluorodeoxyglucose PET/computed tomography ((18)F-FDG PET/CT) before and after treatment were included in this study. […] Treatment response was assessed by the European Organisation for Research and Treatment of Cancer (EORTC) criteria and the changes of GTG. […] The SUVmax of patients before treatment was 5.95 (SD: 2.93) and after the treatment it increased to 6.38 (SD: 3.19). […] Also we were able to demonstrate the potential use of this technique in the monitoring of treatment response. […] More studies comparing this technique with conventional and other global disease assessment methods are needed in order to clarify its role in the assessment of treatment response and prognosis of these patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25690520&#34; target=&#34;_blank&#34;&gt;New biomarkers in the selection of patients for talcage of pleural cavity in the palliative therapy of malign pleural exudate.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemical pleurodesis using videothoracoscopically applied powdered talc under general anaesthesia and selective pulmonary ventilation is the most effective method of palliative therapy for malign pleural exudate. […] The need for repeated thoracic punctures or drainage over the course of a 12-month monitoring period was a criterion of treatment failure. […] This pilot study showed that high values of sCD163 and sApo/Fas in the pleural exudate can predict treatment failure. […] Unsuitable candidates for this type of therapy couldbe selected in this way.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25722383&#34; target=&#34;_blank&#34;&gt;Searching for targets for the systemic therapy of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Increasing knowledge about the molecular characteristics of mesothelioma had led to the identification of novel potential targets for systemic therapy. […] This review elaborates on the rationale behind targeted approaches that have been and are undergoing exploration in mesothelioma and summarizes available clinical results and ongoing efforts to improve the systemic therapy of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25726562&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Translational research is currently unravelling novel circulating biomarkers for earlier diagnosis and novel treatment targets.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25726878&#34; target=&#34;_blank&#34;&gt;Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients received prophylactic radiotherapy postoperatively and all were supposed to receive systemic chemotherapy, either preoperatively or as adjuvant therapy. […] P/D, hyperthermic pleural lavage with povidone-iodine, prophylactic chest wall radiotherapy, and systemic chemotherapy is a safe and well-tolerated multimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25727644&#34; target=&#34;_blank&#34;&gt;Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differentiating metastatic breast carcinoma in the lungs from primary lung tumors and mesotheliomas is important for determining prognosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25731566&#34; target=&#34;_blank&#34;&gt;[A case of malignant peritoneal mesothelioma without deletion of p16].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient was a man in his 60s with a history of 2 operations for the treatment of malignant neurogenic tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25742001&#34; target=&#34;_blank&#34;&gt;Intrapleural Fibrinolysis for the Treatment of Indwelling Pleural Catheter-Related Symptomatic Loculations: A Multicenter Observational Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To our knowledge, this is the first study to describe intrapleural fibrinolytic therapy for IPC-related symptomatic loculations. […] All patients who received intrapleural fibrinolytic therapy for symptomatic loculations between January 1, 2002, and June 30, 2014, in four established IPC centers were retrospectively included. […] Patient outcomes, treatment effectiveness, and adverse events were recorded. […] Pleural fluid drainage increased in 93% of patients, and dyspnea improved in 83% following therapy. […] The median cumulative pleural fluid volume drained at 24 h posttreatment was 500 mL (interquartile range 300-1,034 mL). […] Intrapleural fibrinolytic therapy can improve pleural fluid drainage and symptoms in selected patients with IPC and symptomatic loculation, but it carries a small risk of pleural bleeding.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25749175&#34; target=&#34;_blank&#34;&gt;Changing pattern in malignant mesothelioma survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent advances in the understanding of pathophysiology and treatment of mesothelioma may impact therapy to improve survival that may not be evident from available clinical trials that are often small and not randomized. […] Cases were either drawn from treatment referrals, independent medical evaluation for medical legal purposes, or volunteers who were diagnosed with mesothelioma. […] Peritoneal mesothelioma was more likely associated with non-occupational exposure, thus emphasizing the importance of exposure history in enhancing early diagnosis and treatment impact.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25750109&#34; target=&#34;_blank&#34;&gt;Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From June 2010 to April 2014, 14 patients with MPM were intended to treat with multimodality therapy including surgery. […] Ten patients received trimodality treatment of EPP, systemic chemotherapy, and intensity modulated radiation therapy for hemithorax. […] All patients obtained macroscopic complete resection and received multimodality treatment in P/D and EPP groups.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25753747&#34; target=&#34;_blank&#34;&gt;Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Toxicity and outcomes at an Australian institution.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Between July 2004 and March 2013, 53 patients were referred for radiation treatment following EPP, of whom 49 were suitable for adjuvant treatment. […] Radiation treatment initially involved a 3D conformal, mixed electron/photon technique, delivering 45-50.4 Gy in 25-28 fractions (31 patients) and subsequently a nine-field intensity-modulated radiotherapy technique, delivering 50.4-54 Gy in 28-30 fractions (18 patients). […] We assessed toxicity, disease-specific and overall survival in patients who commenced radiation treatment. […] Forty-one patients (84%) completed treatment as prescribed. […] Most patients complete the prescribed treatment, and clinically significant late toxicities are rare.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25756395&#34; target=&#34;_blank&#34;&gt;The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patient-individualised prognostication and prediction of treatment response from chemotherapy is useful but little evidence exists to guide practice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25756396&#34; target=&#34;_blank&#34;&gt;The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Robust markers that predict prognosis and detect early treatment response in malignant pleural mesothelioma (MPM) would enhance patient care. […] Serum mesothelin is a useful early treatment response marker when measured serially during chemotherapy and may have a role in evaluating patients’ treatment response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25772281&#34; target=&#34;_blank&#34;&gt;Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have previously described patterns of failure after extrapleural pneumonectomy and multimodality therapy for malignant pleural mesothelioma and sought to update our results with a larger cohort of recent patients. […] Data for treatment, recurrence, and survival were determined from medical records. […] A total of 132 patients (78%) received heated intraoperative chemotherapy; 77 patients (45%) received adjuvant chemotherapy, and 71 patients (42%) received adjuvant radiation therapy. […] Median radiation therapy dose was 54 Gy. […] The most common site of recurrence after extrapleural pneumonectomy and planned multimodality therapy remains the ipsilateral hemithorax (including mediastinum), and true distant failure (other than the abdomen or contralateral hemithorax) remains unusual.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25774992&#34; target=&#34;_blank&#34;&gt;Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The increasing incidence and poor outcome associated with MPM requires finding effective treatment for this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25791825&#34; target=&#34;_blank&#34;&gt;Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cancer-directed surgery is associated with significantly improved survival for MPM patients with epithelioid histology, but patients with sarcomatoid and biphasic histologies have poor prognoses that may not be favored by operative treatment. […] The specific histology should be identified before treatment, so that surgery can be offered to patients with epithelioid histology, as these patients are most likely to benefit.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25793652&#34; target=&#34;_blank&#34;&gt;Unusual appearance of malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural and extrapleural mesothelioma can arise in the setting of asbestos exposure, but other reported causes of MPM include exposure to silicate fibers and radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25794996&#34; target=&#34;_blank&#34;&gt;[Role of the Sonic Hedgehog pathway in thoracic cancers].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These results incite to develop targeted therapies against Shh pathway in the treatment of thoracic cancers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25800891&#34; target=&#34;_blank&#34;&gt;Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On the basis of the clinical benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 study of vorinostat, we designed this phase 3 trial to investigate whether vorinostat given as a second-line or third-line therapy improved patients’ overall survival. […] After stratification for Karnofsky performance status, histology, and number of previous chemotherapy regimens, patients were randomly assigned (1:1) by use of an interactive voice response system with a block size of four to either treatment with vorinostat or placebo. […] In this randomised trial, vorinostat given as a second-line or third-line therapy did not improve overall survival and cannot be recommended as a therapy for patients with advanced malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25818740&#34; target=&#34;_blank&#34;&gt;The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the present study was to evaluate the efficacy and safety of pemetrexed chemotherapy combined with intrapleural injection of pemetrexed and bevacizumab in the treatment of malignant pleural mesothelioma (MPM)-mediated malignant pleural effusion, and analyze the objective response rate (ORR), the median progression-free survival (PFS) and the median overall survival (OS). […] The expression of VEGF in the pleural effusion and serum plays a guiding role in monitoring the efficacy of bevacizumab in the treatment of malignant pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25819643&#34; target=&#34;_blank&#34;&gt;Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Participants received tremelimumab 10 mg/kg once every 4 weeks for six doses, then every 12 weeks until disease progression, unacceptable toxic effects, or refusal to continue treatment. […] Grade 1-2 treatment-related adverse events occurred in 26 (90%) patients and grade 3-4 adverse events in two (7%) patients. […] The most common treatment-related adverse events were gastrointestinal, dermatological, and fever.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25821338&#34; target=&#34;_blank&#34;&gt;Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, no biomarkers for a specific targeted therapy are available. […] Here we determine whether AQP1 inhibition has therapeutic potential in the treatment of MM. […] Further work is warranted to fully evaluate treatment potential in vivo.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25823924&#34; target=&#34;_blank&#34;&gt;NF2 blocks Snail-mediated p53 suppression in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of silica induced p-Erk and Snail through RKIP reduction. […] In addition, p53 and E-cadherin were decreased by silica-treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25824607&#34; target=&#34;_blank&#34;&gt;Prognostic factors in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several of these molecules may become relevant for pathologists as part of the effort to select patient sub-populations for targeted therapy in the future.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25827675&#34; target=&#34;_blank&#34;&gt;Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The European Organization for Research and Treatment of Cancer Core Quality of Life Questionaire-C30 was used to evaluate HRQoL before operation, and at 4 to 5 and 7 to 8 months postoperatively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25863904&#34; target=&#34;_blank&#34;&gt;Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Only 67% have anti-cancer treatment, and this also varies across organisations, but there has been an annual increase in the proportion receiving chemotherapy. […] Our data provide a large scale, detailed assessment of MPM epidemiology, treatment choices and outcomes. […] Incidence is increasing in line with predictions and uptake of treatments has generally mirrored publication of key MPM treatment trials, in particular increasing use of chemotherapy but low uptake of radical surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25868979&#34; target=&#34;_blank&#34;&gt;A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here we studied the relevance and modulation of aldehyde dehydrogenase (ALDH) expression in malignant pleural mesothelioma (MPM) chemoresistant cell subpopulations (ALDH(bright) cells), which survive pemetrexed + cisplatin treatment in vitro and in vivo. […] RNAi mediated downregulation of ALDH1A3 reduced the survival of the ALDH(bright) cells at steady state and, much more, after pemetrexed + cisplatin treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25879365&#34; target=&#34;_blank&#34;&gt;Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Using univariate analysis leukocytosis (P = 0.009), rind-like pleural thickening (P = 0.037), advanced disease stage (P = 0.004), best supportive therapy alone (P = 0.004), SUVmax higher than 8 (P = 0.023), MAI higher than 1 (P = 0.033), and presence of tumor necrosis (P = 0.037) were found as poor prognostic factors. […] At multivariate analysis, leukocytosis (P = 0.026, HR: 2.27), advanced disease stage (P = 0.021, HR: 2.46), best supportive therapy alone (P = 0.029, HR: 5.12), and MAI higher than 1 (P = 0.01, HR: 3.01) were independently associated with survival, whereas SUVmax of the tumor failed to enter the model (P = 0.07, HR: 1.89). […] Presence of leukocytosis, advanced disease stages, supportive therapy alone, and higher MAI were found to be negative prognostic factors in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25889843&#34; target=&#34;_blank&#34;&gt;BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our findings suggest a major role for BAP1 in peritoneal MM susceptibility and oncogenesis and indicate important molecular differences to pleural MM as well as potential strategies for therapy and prevention.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25908647&#34; target=&#34;_blank&#34;&gt;Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed (Alimta®) is a novel anti-folate antimetabolite agent that is used in combination with cisplatin for the treatment of patients with unresectable malignant pleural mesothelioma and as a single agent or in combination with cisplatin for patients with locally advanced or metastatic non-small-cell-lung-cancer. […] Cutaneous adverse reactions are common side effects of pemetrexed for which the manufacturer recommends 3-day premedication with dexamethasone 4 mg by mouth twice daily-(the day before, the day of, and the day after treatment).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25912746&#34; target=&#34;_blank&#34;&gt;Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the surgical multimodal management of malignant pleural mesothelioma, it seems crucial to proceed with an efficient local adjuvant treatment to kill residual tumor cells. […] Intrapleural photodynamic therapy has recently emerged as a potential candidate in this goal. […] In this review, we analyzed and classified 16 articles in which patients with malignant pleural mesothelioma received intrapleural photodynamic therapy after maximal surgical resection. […] After two decades of clinical studies, intrapleural photodynamic therapy after surgical resection became a safe treatment that significantly improved the survival of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25935651&#34; target=&#34;_blank&#34;&gt;Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the limited cldn15 expression in normal tissues and high expression in tumors make it an attractive candidate for cancer therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25941579&#34; target=&#34;_blank&#34;&gt;Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8&lt;sup&gt;+&lt;/sup&gt; T-cell response, prominent infiltration of CD8&lt;sup&gt;+&lt;/sup&gt; lymphocytes and Th1 type polarization.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The presence of tumor infiltrating lymphocytes (TILs) and specific gene-signatures prior to treatment are linked to good prognosis, while the opposite is true for extensive immunosuppression. […] The treatment resulted in prominent infiltration of CD8&lt;sup&gt;+&lt;/sup&gt; lymphocytes to tumor, marked induction of systemic antitumor CD8&lt;sup&gt;+&lt;/sup&gt; T-cells and induction of Th1-type polarization in the tumor. […] These results indicate that ONCOS-102 treatment sensitizes tumors to other immunotherapies by inducing a T-cell positive phenotype to an initially T-cell negative tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25950487&#34; target=&#34;_blank&#34;&gt;Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Given the limited effect of chemotherapy, a big effort is being made to find new treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25952930&#34; target=&#34;_blank&#34;&gt;The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Combination therapy is a promising therapeutic strategy against MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25964522&#34; target=&#34;_blank&#34;&gt;Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. […] The present review aims at describing available data from randomized trials considering systemic medical treatment for this patient category.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25967566&#34; target=&#34;_blank&#34;&gt;Mesothelioma treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Until now any new therapy showed advantage in the median survival and time to progression. […] Chemoterapy as soon as possible and second lines treatment it is very important thinking in the survival this fatal tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25970771&#34; target=&#34;_blank&#34;&gt;Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histone deacetylases are important targets for cancer therapeutics, but their regulation is poorly understood.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25979846&#34; target=&#34;_blank&#34;&gt;The established and future biomarkers of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Lack of accurate biomarkers makes diagnosis, prognostication and treatment prediction of MPM challenging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25984775&#34; target=&#34;_blank&#34;&gt;Amplatzer Device in Bronchial Stump Fistula after Extrapleural Pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Paul, Minnesota, United States) septal occluder plug was successfully used in the treatment of septic right main bronchus fistula having developed after extrapleural pneumonectomy and heated chemotherapy in two patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25988069&#34; target=&#34;_blank&#34;&gt;Localized malignant pleural mesothelioma with renal metastasis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its epidemiology, biology, natural history and optimal treatment are poorly understood.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25995987&#34; target=&#34;_blank&#34;&gt;An IR Navigation System for Pleural PDT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural photodynamic therapy (PDT) has been used as an adjuvant treatment with lung-sparing surgical treatment for malignant pleural mesothelioma (MPM). […] A treatment planning system uses the laser source positions obtained from the IR camera to calculate light fluence distribution to monitor the light fluence uniformity on the surface of the pleural cavity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25999306&#34; target=&#34;_blank&#34;&gt;Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent studies suggest that immunotherapy may offer a promising treatment strategy for early-stage malignant pleural mesothelioma (MPM), but advanced tumor burden may limit the efficacy of immunotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25999640&#34; target=&#34;_blank&#34;&gt;Monte Carlo simulation of light fluence calculation during pleural PDT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
When considering PDT in the thoracic cavity for treatment of malignant, localized tumors such as those observed in malignant pleural mesothelioma (MPM), changes in light dose caused by the cavity geometry should be accounted for in order to improve treatment efficacy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26004871&#34; target=&#34;_blank&#34;&gt;Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Acquired resistance to cisplatin treatment is a caveat when treating patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). […] Therapy with GCS activity inhibitors or toxin targeting of the Gb3 receptor may substantially reduce acquired cisplatin drug resistance of NSCLC and MPM cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26011325&#34; target=&#34;_blank&#34;&gt;Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is quite clear that multimodality therapy is necessary to improve long-term results but precise treatment schemes have not yet been equivocally accepted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26021419&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma : Rationale for a New TNM Classification.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this regard, a well-defined staging system is of utmost importance in order to correctly diagnose and assign an appropriate treatment to the patient. […] Patients with stage I-III are considered for surgery, while palliative treatment is indicated for stage IV patients according to the current classification. […] In addition, the role of specific treatment modalities including surgery, has yet to be determined, especially for treatment of early-stage disease. […] An improved staging system will contribute to the design of prospective multi-institutional clinical trials investigating novel treatment strategies for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26029542&#34; target=&#34;_blank&#34;&gt;An unusual cause of an anterior mediastinal mass.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis for this aggressive tumour remains poor, despite combination treatment modalities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26044908&#34; target=&#34;_blank&#34;&gt;Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural mesothelioma has a dismal prognosis and is refractory to local treatment. […] Elderly patients may be unfit for chemotherapy but little is known about age-related treatment practice. […] To determine treatment patterns and current survival outcome, three large population-based registries were queried in a uniform manner. […] Treatment patterns and survival rates were compared between countries and age-groups. […] Combined analysis of data from three countries with high mesothelioma rates demonstrates that chemotherapy has become standard treatment for younger patients. […] Elderly patients currently account for more than half of all cases and less toxic treatment options will be required to improve their prospects.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2606200&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in the southwestern part of The Netherlands.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival was 11 months while different ways of treatment could not prolong survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-02-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26063951&#34; target=&#34;_blank&#34;&gt;Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We used a large population-based dataset to study the role of race in MPM presentation, treatment, and survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26072418&#34; target=&#34;_blank&#34;&gt;Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Adoptive cell therapy using gene-modified T-cells has achieved impressive results in the treatment of B-cell malignancies. […] To address these challenges, we have developed a gene-modified cellular therapy called T4 immunotherapy. […] Targeting of the extended ErbB network using CAR T-cells is supported by prevalence of ErbB dysregulation in diverse solid tumors and the clinical impact of monoclonal antibody therapy directed against members of this family. […] In that setting, regional (intracavitary) approaches will be used to administer this therapy to patients with epithelial ovarian cancer and malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26082103&#34; target=&#34;_blank&#34;&gt;Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Anti-angiogenic gene therapy represents a promising strategy for cancer; however, it has rarely been tested in malignant mesothelioma, a highly aggressive tumor associated with asbestos with poor prognosis. […] These results suggest that combinatorial anti-angiogenic gene therapy targeting different pathways of endothelial growth factor signaling has the potential for greater therapeutic efficacy than that of a single-agent regimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2608642&#34; target=&#34;_blank&#34;&gt;[Prognostic factors in diffuse malignant mesothelioma of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant pleural mesothelioma (DMM) is associated with a very poor prognosis and is only partially accessible to treatment. […] In 32% of the patients, treatment was purely symptomatic, in 42% a palliative surgical procedure with decortication of the tumour and tumour-pleurectomy was performed, while in 26% the palliative procedure was followed by adjuvant chemotherapy using doxorubicin and cisplatin. […] A significant influence was found for the histological type of the tumour and therapy administered, epithelial and biphasic tumour forms, as also surgical and combined surgical/chemotherapeutic treatment resulting in a more prolonged survival. […] On the basis of these results, surgical therapy should always be employed, despite the fact that there is almost always no curative option; postoperative adjuvant therapy is capable of further improving the prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26108172&#34; target=&#34;_blank&#34;&gt;Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Age, sex, tumor histology, the treatment regimen, the timing of fever onset, the number of days for which the fever persisted, the cause of the fever, the presence or absence of radiotherapy, and the use of granulocyte colony-stimulating factor (G-CSF) were examined. […] Fever occurred most frequently on posttreatment days 4 (8 %), 3 (7 %), and 12 (7 %), and the distribution of fever episodes exhibited two peaks on posttreatment days 3 and 4 and 10-14. […] Fever on posttreatment days 3 and 4 was most commonly observed in patients treated with gemcitabine (20 %) or docetaxel (18 %). […] The causes of fever included infection (47 %; including febrile neutropenia [24 %]), adverse drug effects (24 %), unknown causes (19 %), and tumors (7 %). […] The febrile episodes that occurred on posttreatment days 3 and 4 were considered to represent adverse drug reactions after cancer chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26115838&#34; target=&#34;_blank&#34;&gt;Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma is almost invariably fatal, and more research is required, not only to find more effective treatments, but also to achieve an earlier diagnosis and improve palliative care. […] The partnership brought together patients, carers, health professionals and support organisations to agree the top 10 research priorities relating to the diagnosis, treatment and care of patients with mesothelioma. […] Following the established James Lind Alliance priority setting process, mesothelioma patients, current and bereaved carers, and health professionals were surveyed to elicit their concerns regarding diagnosis, treatment and care. […] The top 10 questions cover a wide portfolio of research (including assessing the value of immunotherapy, individualised chemotherapy, second-line treatment and immediate chemotherapy, monitoring patients with pleural thickening, defining the management of ascites in peritoneal mesothelioma, and optimising follow-up strategy).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26124370&#34; target=&#34;_blank&#34;&gt;Prophylactic Radiotherapy to Intervention Sites in Malignant Pleural Mesothelioma–Single-institution Experience and Literature Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This approach is easily integrated into general treatment concepts.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2612745&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma: a series of 19 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the majority of patients no therapy except pain relief was given and the median survival from the time of diagnosis was 6 months (range: 0-29 months). […] Only in 2 patients survival exceeded 1 year, although these patients did not receive therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-02-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26136339&#34; target=&#34;_blank&#34;&gt;Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We found that Cynara scolymus treatment affects strongly cell growth, migration and tumor engraftment of mesothelioma cell lines. […] Strikingly, dietary feeding with Cynara scolymus leaf extract reduces the growth of mesothelioma xenografted tumors similarly to pemetrexed, a commonly employed drug in the treatment of mesothelioma. […] In aggregate our findings suggest that leaf extract of Cynara scolymus holds therapeutic potential for the treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26140556&#34; target=&#34;_blank&#34;&gt;Medical and oncological management of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma is an aggressive cancer, for which no curative oncological treatment currently exists.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26150910&#34; target=&#34;_blank&#34;&gt;Pleural mesothelial cells in pleural and lung diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural-based therapies targeting PMCs for treatment of IPF and other lung diseases need further exploration.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26156019&#34; target=&#34;_blank&#34;&gt;The endoplasmic reticulum mitochondrial calcium cross talk is downregulated in malignant pleural mesothelioma cells and plays a critical role in apoptosis inhibition.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The failure of apoptosis may contribute to the formation of cancer and to its resistance to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26156324&#34; target=&#34;_blank&#34;&gt;The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival time from treatment to death or the last day of follow-up with a 95% confidence interval was 11.0 ± 0.99 months (95% CI: 9.06-12.94) for group 1 and 11.0 ± 1.52 months (95% CI: 8.02-13.97) for group 2 (Log-Rank: 0.584; p = 0.445). […] The treatment was generally well tolerated, and the side effects were similar in both groups.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26162564&#34; target=&#34;_blank&#34;&gt;Second line therapy in malignant pleural mesothelioma: A systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After the implementation of standard first line chemotherapy with platinum and antifolates in pleural mesothelioma, patients are confronted with a need for second line treatment at relapse or progression. […] We conducted a systematic review of the literature for the activity, effectiveness and toxicity of second line treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26163973&#34; target=&#34;_blank&#34;&gt;Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite ongoing efforts to improve therapy in malignant pleural mesothelioma, few patients undergoing extrapleural pneumonectomy experience long-term survival (LTS). […] Our prognostic model facilitates the prediction of LTS after surgery for malignant pleural mesothelioma and can help to stratify the outcome and, eventually, tailor postoperative treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26191485&#34; target=&#34;_blank&#34;&gt;A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We planned to conduct a clinical study of gene therapy with adenoviruses expressing the NK4 gene (Ad-NK4) to control the local tumor growth.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26208479&#34; target=&#34;_blank&#34;&gt;Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In both models, the treatment with the ERβ agonist results in reduced cell proliferation, decreased expression of MCT4 and CD147/Basigin and increased acetylation and inactivation of AKT1. […] The possibility to reverse the more aggressive biphasic mesothelioma histotype by targeting ERβ with a selective agonist could represent a new effective treatment strategy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26211743&#34; target=&#34;_blank&#34;&gt;Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is an aggressive and therapy-resistant neoplasm arising from mesothelial cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26218750&#34; target=&#34;_blank&#34;&gt;Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (mesothelioma) is a highly aggressive cancer without an effective treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26222965&#34; target=&#34;_blank&#34;&gt;Primary Peritoneal Mesothelioma Resulting in Small Bowel Obstruction: A Case Report and Review of Literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aggressive nature and vague presentation pose many obstacles in not only diagnosis but also the treatment of patients with this disease. […] A concise review of the current diagnostic and surgical treatment of primary peritoneal mesothelioma demonstrates that early diagnosis and implementation remains vital.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26238284&#34; target=&#34;_blank&#34;&gt;Inhibition of NADPH oxidase 4 induces apoptosis in malignant mesothelioma: Role of reactive oxygen species.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, DPI treatment and knockdown of Nox4 attenuated phosphorylation of AKT and ERK. […] Taken together, our results indicate that Nox4-mediated ROS, at least in part, transmit cell survival signals and their depletion leads to apoptosis, thus highlighting the Nox4-ROS-AKT signaling pathway as a potential therapeutic target for MPM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26242152&#34; target=&#34;_blank&#34;&gt;[MULTIMODAL APPROACH IN THE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL LESIONS].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The study includes data on 54 patients with pleural malignant lesions (39 with metastatic pleural malignant tumors and 15 with pleural malignant mesothelioma) received treatment using a multimodal approach: maximum cytoreduction, intraoperative photodynamic therapy and hyperthermic chemoperfusion of pleural cavity. […] A control group of patients with malignant pleural mesothelioma consisted of 21 patients who had undergone only conservative treatment. […] The use of multimodal treatment was accompanied by relatively low (1.85%) postoperative mortality on the background of a relatively high number (79.6%) of postoperative complications, easily cured in the early postoperative period. […] The use of multimodal therapy in treatment for metastatic pleural malignant lesions was accompanied by a median of disease-free survival of 11 months and a median of overall survival of 23 months. […] The proposed multimodal treatment compared with conservative methods of therapy improved disease-free (12 months vs. […] Thus the use of a multimodal approach in treatment for pleural malignant lesions is relatively safe but requires further study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26257929&#34; target=&#34;_blank&#34;&gt;Mesothelioma treatment: Are we on target? A review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Targeted treatment is a therapy directed at a specific molecular target close to a hallmark of cancer. […] The target should be measurable with a biomarker and measurement of the target should correlate with clinical outcome when targeted treatment is administered. […] Current clinical guidelines do not recommend targeted or biological therapy in MPM. […] This review updates the use of targeted and biological treatment in patients with mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26259878&#34; target=&#34;_blank&#34;&gt;Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hypoxia is increasingly recognized as an important factor in tumor aggressiveness and cellular resistance to chemotherapy and radiation treatment. […] Twenty prospectively recruited patients with histologically or cytologically confirmed MPM not currently receiving systemic or local treatment underwent both FMISO and fluorodeoxyglucose (FDG) PET-CT scans within 2 weeks. […] The relationship of tumor hypoxia to effectiveness of chemotherapy and/or radiation therapy warrants prospective assessment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26281826&#34; target=&#34;_blank&#34;&gt;Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To prospectively assess the survival, patterns of failure, and prognostic factors in a large cohort of patients with malignant pleural mesothelioma who had undergone a novel trimodal therapeutic approach, including lung-sparing surgery, chemotherapy, and subsequent treatment with high doses of intensity modulated radiation therapy (IMRT) to the whole hemithorax.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26294214&#34; target=&#34;_blank&#34;&gt;Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because current treatment options are largely ineffective, novel therapeutic strategies based on molecular mechanisms and the disease characteristics are needed to improve the outcomes of patients with this disease. […] Our findings suggest an important role for the Aki1-CREB axis in DMM pathogenesis and provide a preclinical rationale to target Aki1 by intrathoracic therapy in locally advanced tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26298162&#34; target=&#34;_blank&#34;&gt;Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Presented topics include the imaging of hypoxia in a murine model through positron emission tomography (PET), the use of diffusion-weighted magnetic resonance imaging (MRI) to assess the histologic composition of biphasic mesothelioma and to assess early response to chemotherapy, the correlation of CT-based tumor volume with the volume of the post-surgical tumor specimen, the development of volumetric tumor response criteria, and pre-treatment tumor volume growth considerations for tumor response assessment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26303419&#34; target=&#34;_blank&#34;&gt;Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the absence of a satisfactory treatment of malignant pleural mesothelioma (MPM), novel therapeutic strategies are urgently needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26308799&#34; target=&#34;_blank&#34;&gt;Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Novel treatments are needed, as current treatment modalities may improve the quality of life, but have shown modest effects in improving overall survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26316950&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Data collected included age, gender, asbestos exposure, presenting signs/symptoms, performance status, histology, stage, bloodwork, treatment modalities including chemotherapy, and date of death or last follow-up.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26317916&#34; target=&#34;_blank&#34;&gt;A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of malignant pleural mesothelioma (MPM) remains a clinical challenge. […] The aim of this study was to identify selection factors for allocation of MPM patients to multimodal therapy based on survival data from 12 years of experience. […] A prognostic score was defined considering tumor volume, histology, C-reactive protein level, and response to chemotherapy that identified patient groups not benefitting from multimodality treatment which was confirmed in an independent cohort.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26319490&#34; target=&#34;_blank&#34;&gt;Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A survival advantage has been observed among patients with malignant pleural mesothelioma undergoing maximal cytoreductive surgery and adjuvant therapy. […] Elderly patients are considered higher risk for these radical operations and are commonly not offered surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26353120&#34; target=&#34;_blank&#34;&gt;Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a deadly disease with varying treatment options. […] This study retrospectively describes treatment practices at the University of Washington Medical System from 1980 to 2011, and evaluates the impact of trimodality therapy and radiation (photon and neutron) on survival. […] Survival analysis of trimodality therapy was performed using a propensity score method to control for baseline characteristics. […] On multivariate analysis, the significant predictors of improved survival were age, smoking history, location, and receipt of radiation therapy or chemotherapy. […] In the 48 patients receiving radiation therapy, the difference in survival between neutron therapy and non-neutron therapy patients was not statistically significant: hazard ratio, 1.20 (95% confidence interval, 0.68-2.13), P=0.52. […] Patients receiving trimodality therapy were more likely to have early-stage disease (60% vs. 30%) and epithelioid histology (86% vs. […] In a propensity score-weighted Cox proportional hazards model, trimodality therapy patients had improved overall survival, hazard ratio 0.45, P=0.004, median 14.6 versus 8.6 months. […] Trimodality therapy was significantly associated with prolonged survival in patients with MPM, even when adjusting for baseline patient factors. […] Radiation therapy was associated with improved survival, but the modality of radiation therapy used was not associated with outcome.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26358421&#34; target=&#34;_blank&#34;&gt;Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, MDM2 might be a target for anticancer treatment because of its antiapoptotic and proangiogenetic role. […] The present review gives a complete landscape about the role of MDM2 in cancer pathogenesis, prognosis and treatment, with particular focus on Malignant Pleural Mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2635926&#34; target=&#34;_blank&#34;&gt;The diagnosis, therapy and prognosis of diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The conservative and postoperative treatment depended on the patients’ symptoms and included radiotherapy and chemotherapy alone or in combination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26366399&#34; target=&#34;_blank&#34;&gt;Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis of MPM is poor due to the difficulty of making diagnosis in the early stage, the rapid progression, the high invasiveness and the lack of effective treatment. […] The current treatment of MPM is multimodality therapy including surgery, radiotherapy, chemotherapy and immunotherapy. […] The diagnosis, treatment and prognosis still remain a major challenge for clinical research and will do so for years to come.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26366804&#34; target=&#34;_blank&#34;&gt;Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We believe that the best salvage treatment for MPM would be inclusion into appropriately designed clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26376466&#34; target=&#34;_blank&#34;&gt;Epithelioid pleural mesothelioma concurrently associated with miliary pulmonary metastases and minimal change nephrotic syndrome - A hitherto undescribed case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Steroid therapy was started but showed no effect.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26376726&#34; target=&#34;_blank&#34;&gt;Successful palliation for an aged patient with primary pericardial mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical oncologists and thoracic surgeons should be aware of this disease because the accumulation of knowledge on PPM may lead to successful treatment even in aged patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26411589&#34; target=&#34;_blank&#34;&gt;Which is the Role of Pneumonectomy in the Era of Parenchymal-Sparing Procedures? Early/Long-Term Survival and Functional Results of a Single-Center Experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In current practice, pneumonectomy is still performed for malignancy, sometimes after induction treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26417297&#34; target=&#34;_blank&#34;&gt;Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differential diagnosis of MPM versus lung adenocarcinoma (AD) is particularly difficult, yet clinically important since the two neoplasias call for different treatment approaches.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26432677&#34; target=&#34;_blank&#34;&gt;Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of the study was to determine whether intensity modulated radiation therapy delivered via helical tomotherapy improves local control (LC) after pleurectomy/decortication (P/D) for malignant pleural mesothelioma compared with 3-dimensional conformal radiation therapy (3D-CRT). […] On univariate analysis, treatment modality was the only significant predictor of LC (P &amp;lt; .05).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26433514&#34; target=&#34;_blank&#34;&gt;Targeting immune checkpoints: New opportunity for mesothelioma treatment?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Platinum-based palliative chemotherapy is the only treatment with proven benefit on outcome, resulting in selected patients in a median overall survival of about 1 year.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26443279&#34; target=&#34;_blank&#34;&gt;Response evaluation in mesothelioma: Beyond RECIST.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
By quantifying how these measurements change with treatment, it is possible to observe treatment effects. […] In this review, we survey the existing roles of CT and MRI for the management of MPM, including the currently applied size measurement criteria for the assessment of treatment response. […] New functional imaging techniques, such as positron emission tomography (PET), diffusion-weighted MRI (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) that may potentially improve the assessment of treatment response will be highlighted and discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26453534&#34; target=&#34;_blank&#34;&gt;Tomotherapy PET-guided dose escalation: A dosimetric feasibility study for patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the first strategy (standard treatment), treated comprised a prescribed median dose to the planning target volume (PTV) boost (PTV1) of 64.5 Gy (range: 56 Gy/28 fractions to 66 Gy/30 fractions) and 51 Gy (range: 50.4 Gy/28 fractions to 54 Gy/30 fractions) to the pleura PTV (PTV2). […] NTCP values for OARs did not increase significantly compared with the standard treatment (p &amp;gt; 0.05), except for the ipsilateral lung.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26459178&#34; target=&#34;_blank&#34;&gt;Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MTS, chemotaxis, soft agar, β-galactosidase, and Apo-BrdUrd techniques were used to assess proliferation, migration, clonogenicity, senescence, and apoptosis in MPM cells following SP1 knockdown, p53 overexpression, or mithramycin treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26462016&#34; target=&#34;_blank&#34;&gt;Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We prove that Enzastaurin treatment decreases eIF6 phosphorylation rate, but not eIF6 protein stability. […] The growth of REN, in vivo, and metastasis are reduced by either Enzastaurin treatment or eIF6 shRNA.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26476173&#34; target=&#34;_blank&#34;&gt;Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This therapeutic strategy of direct intrapleural administration of liposomal PMX, along with the great advances in CL-guided therapeutics, might be a promising therapeutic approach to conquering the poor prognosis for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26481865&#34; target=&#34;_blank&#34;&gt;Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis is poor and chemotherapy seems the best treatment option. […] The aim of this review is to discuss the most recent news on systemic therapy for advanced malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26485154&#34; target=&#34;_blank&#34;&gt;Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The enormous upsurge of interest in immune-based treatments for cancer such as vaccines and immune checkpoint inhibitors, and increased understanding of the role of the tumor microenvironment in treatment response, collectively point to the need for immune-competent orthotopic models for pre-clinical testing of these new therapies. […] Analyzing circulating immune cell levels using this single tube method may also assist in monitoring the response to immune-based treatments and understanding the underlying mechanisms leading to success or failure of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26493618&#34; target=&#34;_blank&#34;&gt;The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In summary, homozygous deletions in CDKN2A and hemizygous loss of NF2 as detected by fluorescence in situ hybridization would confer a poor clinical outcome and may guide future treatment decisions for patients with peritoneal mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26503698&#34; target=&#34;_blank&#34;&gt;Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It was reported that the tyrosine kinase inhibitor (TKI) lapatinib enhanced trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) in HER2-positive breast cancer, suggesting that this combination is a promising strategy for MPM treatment. […] Of the three TKIs, only lapatinib enhanced trastuzumab-mediated ADCC via the upregulation of HER2 expression in MPM cells, suggesting that sequential combination of lapatinib and trastuzumab may be a promising strategy for MPM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26509028&#34; target=&#34;_blank&#34;&gt;Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Physicians should be aware of MPM when patients with empyema are refractory to the standard treatment, and PET-CT may be helpful in establishing a precise diagnosis in such cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26521826&#34; target=&#34;_blank&#34;&gt;Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Administration of ≥1.5 mg of corticosteroids on day 2 and day 3 significantly reduced the severity of the rash compared to no supplementary treatment (grades 2/3, 13.3% vs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26526504&#34; target=&#34;_blank&#34;&gt;Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The combination of pemetrexed with a platinum compound is the standard of care in the first-line setting, while no established treatment exists in the second and beyond-line setting. […] Vinorelbine has shown activity in MPM patients as neoadjuvant therapy, first-line treatment, and in the second and third-line setting. […] While the role of vinca alkaloids in the first-line treatment of MPM seems marginal, treatment with vinorelbine remains a reasonable option for pemetrexed-pretreated patients in clinical practice, based on an acceptable rate of stable disease, confirmed by several trials. […] Ongoing studies on predictive biomarkers for vinorelbine will hopefully be able to individualize treatment, increasing response rates and survival outcomes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26544728&#34; target=&#34;_blank&#34;&gt;MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis and limited treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26560442&#34; target=&#34;_blank&#34;&gt;Tremelimumab for the treatment of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A literature search using the PubMed database was conducted using the search terms tremelimumab, MPM, current therapy, immune checkpoint blockage and cytotoxic T lymphocyte-associated antigen-4. […] Among these drugs, tremelimumab has been attracting attention as a potential new treatment for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26577445&#34; target=&#34;_blank&#34;&gt;Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conducted a prospective multi-institutional study to determine the feasibility of trimodality therapy (TMT) comprising induction chemotherapy followed by extrapleural pneumonectomy (EPP) and radiation therapy in Japanese patients with malignant pleural mesothelioma (MPM). […] Major eligibility criteria were histologically confirmed diagnosis of MPM, including clinical subtypes T0-3, N0-2, M0 disease; no prior treatment for the disease; age 20-75 years; Eastern Cooperative Oncology Group performance status 0 or 1; predicted postoperative forced expiratory volume &amp;gt;1000 ml in 1 s; written informed consent. […] Treatment methods comprised induction chemotherapy using pemetrexed (500 mg/m(2)) plus cisplatin (60 mg/m(2)) for three cycles, followed by EPP and postoperative hemithoracic radiation therapy (54 Gy). […] Primary endpoints were macroscopic complete resection (MCR) rate for EPP and treatment-related mortality for TMT. […] The trial met the primary endpoints, with an MCR rate of 71 % (30/42) and treatment-related mortality of 9.5 % (4/42).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2658538&#34; target=&#34;_blank&#34;&gt;Brain metastases in malignant pleural mesothelioma. Case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent advances in pleural malignant mesothelioma include the sequential use of palliative surgery, perioperative radiation therapy, and systemic chemotherapy. […] The difficulties in diagnosis, the role of immunoperoxidase stains in malignant mesothelioma, excellent tolerance of different modalities of treatment, and a review of the literature of brain metastases in mesothelioma are discussed. […] Based on our report, the possibility of brain metastases should be investigated by careful clinical examination prior to a radical treatment in patients with progressive refractory mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26590183&#34; target=&#34;_blank&#34;&gt;Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To analyse the relapse pattern and influence of second-line treatment after recurrence of malignant pleural mesothelioma (MPM) in patients who had previously undergone multimodality treatment. […] A total of 78 patients received a second-line therapy after tumour recurrence: chemotherapy (n = 48), local radiotherapy (n = 9), surgery (n = 10) or a combination thereof (n = 11). […] Patients undergoing second-line treatment survived significantly longer compared with patients not receiving therapy (P &amp;lt; 0.0005). […] Local recurrence of MPM remains the most frequent type of relapse even after multimodality treatment including MCR. […] In the present cohort, active treatment seems beneficial to the patient since surgical excision of local tumour relapse has good long-term outcome in selected patients. […] Thus, second-line treatment may prolong PRS; however, these results need to be confirmed in a prospective manner.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26590581&#34; target=&#34;_blank&#34;&gt;Current surgical strategies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The main components of multimodality treatment include surgery, chemotherapy, and radiation therapy. […] However, the precise treatment schemes and surgical procedures are yet to be established. […] Moreover, we highlight the aspects of the multimodality treatments that are offered to MPM patients, including chemotherapy, radiotherapy, intensity-modulated radiation therapy, and other types of therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26605294&#34; target=&#34;_blank&#34;&gt;Biologic therapy and gene therapy in the multimodality treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The last years have witnessed an abrupt paradigm shift in cancer treatment owing to the discoveries concerning the relationships between the immune system and neoplastic cells. […] In the field of malignant mesothelioma, which, despite painstaking efforts, remains an incurable form of cancer, the researchers’ attention has been seized by a variety of new biologic approaches, including both viral gene therapy and active immunotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26608297&#34; target=&#34;_blank&#34;&gt;Isolation of Chemoresistant Cell Subpopulations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemoresistance is a major challenge for cancer therapy and drives tumor relapse. […] The emergence, within the treated tumor mass, of specific cancer cell subpopulations endowed with high tolerance to the microenvironment stress induced by therapy is being growingly recognized as a mechanism of tumor progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26611742&#34; target=&#34;_blank&#34;&gt;Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Uni- and multivariate analyses showed that epithelioid histology, stage N0, and trimodality treatment were associated with better survival (P = .039, P = .012, and P &amp;lt; .001, respectively). […] Adoption of PD as the main surgical approach is not associated with survival disadvantage in the surgical treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26614413&#34; target=&#34;_blank&#34;&gt;Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate a new protocol of accelerated hemithoracic intensity-modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP) for patients with resectable malignant pleural mesothelioma (MPM). […] EPP was performed at 6 ± 2 days after the end of radiation therapy. […] One patient died in the hospital 2 months after EPP, for an operative mortality of 1.6%, and 2 died after discharged from the hospital for an overall treatment-related mortality (grade 5 toxicity) of 4.8%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26631501&#34; target=&#34;_blank&#34;&gt;Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pembrolizumab (MK-3475, lambrolizumab, Keytruda(®)) is a PD-1 inhibitor that has shown clinical activity in a variety of solid tumors and is currently approved for the second-line treatment of PD-L1-positive non-small-cell lung cancer and for unresectable/metastatic melanoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26635184&#34; target=&#34;_blank&#34;&gt;Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, its use is still limited due to the development of resistance to the treatment. […] In clinical specimens of lung cancer, the number of fibrocyte-like cells is significantly increased in bevacizumab-treated tumours, and correlates with the number of treatment cycles, as well as CD31-positive vessels. […] Our results identify fibrocyte-like cells as a promising cell biomarker and a potential therapeutic target to overcome resistance to anti-VEGF therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26638915&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for malignant pleural mesothelioma: is this an operation that should now be consigned to history?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this paper, presented at the Second Mediterranean Conference in Thoracic Oncology, I argue that we can now set aside extrapleural pneumonectomy (EPP) as a treatment for malignant pleural mesothelioma and consign it to the history of surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26638917&#34; target=&#34;_blank&#34;&gt;The MesoVATS trial: is there a future for video-assisted thoracoscopic surgery partial pleurectomy?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, there was some evidence that VAT-PP improved EQ5D measured quality of life after 6 months particularly in the European Organisation for Research and Treatment of Cancer low-risk subgroup.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26638918&#34; target=&#34;_blank&#34;&gt;Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This small experience confirms that pleurectomy/decortication and HITHOC are a good therapeutic option in the multimodality treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26638919&#34; target=&#34;_blank&#34;&gt;Management of recurrence after initial surgery for malignant pleural mesothelioma: a mini-review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recurrence after surgery in the multimodality therapy for malignant pleural mesothelioma is a common problem. […] As the majority of patients experience not only local but also distant metastases, a systemic treatment strategy in addition to local control measures remains necessary.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26638920&#34; target=&#34;_blank&#34;&gt;Biomarkers and prognostic factors for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The increasing incidence and the dismal prognosis of malignant pleural mesothelioma calls for the identification of biomarkers that will allow a timely diagnosis; display prognostic value; and, predict the response to pharmacological agents employed for the treatment of the disease. […] As for prognostic biomarkers, the Cancer and Leukemia Group B (CALGB) and the European Organization for Research and Treatment of Cancer (EORTC) scores take into account different hematological and clinical parameters that distinguish patients with good prognosis from those with inferior outcomes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26652184&#34; target=&#34;_blank&#34;&gt;Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the decrease in number of peripheral blood regulatory T cells during combination therapy of low-dose cyclophosphamide and dendritic cell immunotherapy and determine the induction of immunologic responses with this treatment in patients with mesothelioma. […] During the treatment, peripheral blood mononuclear cells were analyzed for regulatory T cells and immunologic responses. […] Low-dose cyclophosphamide reduced the percentage of regulatory T cells of total CD4 cells in peripheral blood from 9.43 (range, 4.34-26.10) to 4.51 (range, 0.27-10.30) after 7 days of cyclophosphamide treatment (P = 0.02). […] Consolidation therapy with autologous tumor lysate-pulsed dendritic cell-based therapy and simultaneously reducing the tumor-induced immune suppression is well-tolerated and shows signs of clinical activity in patients with mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26653237&#34; target=&#34;_blank&#34;&gt;[Analysis of the clinical diagnosis of asbestosis complicated with malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To discuss the clinical characteristics, diagnosis and treatment of the clinical characteristics and prognosis of asbestosis complicated with malignant mesothelioma patients. […] One case of the pleural mesothelioma misdiagnosed as tuberculous pleurisy. 3 patients were in CT or B ultrasound guided biopsy pathology confirmed to be malignant mesothelioma. 2 patients received systemic chemotherapy, another received symptomatic and supportive treatment. […] The treatment effect is not ideal, the prognosis is poor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26660351&#34; target=&#34;_blank&#34;&gt;Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Better survival has been reported with surgery-based multimodality therapy, but to date, no trial has demonstrated survival benefit of surgery over other therapies. […] On multivariable analysis, female gender, younger age, early stage, and treatment with surgery were independent predictors of longer survival. […] In comparison to no treatment, surgery alone was associated with significant improvement in survival [adjusted hazard ratio (adj HR) 0.64 (0.61-0.67)], but not radiation [adj HR 1.15 (1.08-1.23)]. […] Cancer-directed surgery is independently associated with better survival, suggesting that multimodal surgery-based therapy can benefit these patients. […] Further research in adjuvant treatment is necessary to improve prognosis in this challenging disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26664569&#34; target=&#34;_blank&#34;&gt;Pleural epitheliod hemangioendothelioma: What started as a liver fluke and ended up being almost mistaken for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is currently no standard treatment for EHE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26680633&#34; target=&#34;_blank&#34;&gt;Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Being approved for the first-line treatment of non-squamous advanced NSCLC, the addition of bevacizumab should be considered for patients presenting with MPE. […] However, the beneficial results on OS reported in comparison with historical cohorts and the statistically significant benefit on PFS and OS observed in the phase III MAPS trial foretell an eventual role for the combination of platinum/pemetrexed/bevacizumab as front-line systemic therapy for pleural MM. […] To date, no other anti-angiogenic drug has showed significant benefit in the treatment of patients with either MPE or MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26703019&#34; target=&#34;_blank&#34;&gt;[Analysis of misdiagnosis of 38 cases of solitary fibrous tumor of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All the patients received thoracic surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26715491&#34; target=&#34;_blank&#34;&gt;Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We investigated the clinical outcome and the toxicity of trimodal therapy of malignant pleural mesothelioma (MPM) treated with neoadjuvant chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant intensity-modulated radiotherapy (IMRT). […] Mature clinical results of trimodal treatment for MPM were presented. […] However, the optimal prospective patient selection for this aggressive trimodal therapy approach remains unclear. […] This study can serve as a benchmark for current and future therapy concepts for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26715913&#34; target=&#34;_blank&#34;&gt;Non-islet Cell Tumour Hypoglycaemia (NICTH) in Malignant Mesothelioma: Case Report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We herein describe an uncommon clinical manifestation of malignant mesothelioma and provide an overview of the pathophysiology of this syndrome, as well as explore a different treatment regimen as reported in the literature.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26716028&#34; target=&#34;_blank&#34;&gt;Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of 85 patients who underwent EPP for MPM over 10 years at Toronto General Hospital, 65 patients whose blood test results before initial therapy were available were retrospectively analyzed as a training cohort to identify and develop a prognostic score. […] Further study should be done to examine the role of this scoring system to optimize treatment strategy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26719230&#34; target=&#34;_blank&#34;&gt;Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We aimed to assess the effect on survival of bevacizumab when added to the present standard of care, cisplatin plus pemetrexed, as first-line treatment of advanced malignant pleural mesothelioma. […] Exclusion criteria were presence of central nervous system metastases, use of antiaggregant treatments (aspirin ≥325 mg per day, clopidogrel, ticlopidine, or dipyridamole), anti-vitamin K drugs at a curative dose, treatment with low-molecular-weight heparin at a curative dose, and treatment with non-steroidal anti-inflammatory drugs. […] Treatment was open label. […] From Feb 13, 2008, to Jan 5, 2014, we randomly assigned 448 patients to treatment (223 [50%] to PCB and 225 [50%] to PC). […] Addition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26722577&#34; target=&#34;_blank&#34;&gt;Infant pleuropulmonary blastoma: report of a rare case and review of literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
So as to provide proper and timely treatment, the differential diagnosis includes pulmonary blastoma, sarcomatoid mesothelioma, fetal rhabdomyoma, synovial sarcoma, and primitive neuroectodermal tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26762744&#34; target=&#34;_blank&#34;&gt;Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Furthermore, the proliferation, migration, and invasion of MPM cells were decreased after treatment with anti-AM (αAM) and anti-AM receptor antibodies, thus indicating that MPM cells are regulated by AM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26770519&#34; target=&#34;_blank&#34;&gt;Efficacy of medical thoracoscopic talc pleurodesis in malignant pleural effusion caused by different types of tumors and different pathological classifications of lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The efficacy in the treatment of effusion caused by adenocarcinoma (66.7%) was slightly less than that caused by other types of lung cancer (P = 0.311). […] In conclusion, medical thoracoscopic talc pleurodesis is a palliative and effective treatment for malignant pleural effusion. […] However, thoracoscopic pleurodesis is less effective for the treatment of effusion caused by lung cancer and pleural mesothelioma compared with that caused by other types of cancers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26780987&#34; target=&#34;_blank&#34;&gt;KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of cells with a small molecule inhibitor of KAT5 (MG-149) caused significant inhibition of cellular proliferation (p&amp;lt;0.0001), induction of apoptosis and was accompanied by significant induction of pro-inflammatory cytokines/chemokines.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26791801&#34; target=&#34;_blank&#34;&gt;Non-coding RNA repertoires in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are limited treatment options, with no second line standard of care for those who fail first line chemotherapy. […] Recent advances have been made to characterise the underlying molecular mechanisms of mesothelioma, in the hope of providing new targets for therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26802143&#34; target=&#34;_blank&#34;&gt;Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PS (P = 0.002), epithelioid histology (P &amp;lt; 0.001), specimen weight (P &amp;lt; 0.001), volume (P &amp;lt; 0.001), platelet count (P = 0.015), T1 stage (P = 0.04) and adjuvant therapy (P = 01) were predictive of survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26816537&#34; target=&#34;_blank&#34;&gt;Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover, MPE may accompany potentially curable cancers or those with a favorable survival prognosis with adequate treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26817512&#34; target=&#34;_blank&#34;&gt;Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To date, there are very few treatment options available and the refractoriness to the majority of therapeutic strategies, leading to consider MPM a relevant problem in public health.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26839306&#34; target=&#34;_blank&#34;&gt;Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Daily treatment with vismodegib efficiently downregulated Hh target genes Gli1, Hedgehog Interacting Protein (Hhip), and Ptch1, and caused a significant reduction of tumor volume and tumor growth delay. […] Immunohistochemical analyses revealed that vismodegib treatment primarily downregulated GLI1 and HHIP in the stromal compartment along with a reduced expression of previously described fibroblast Hh-responsive genes such as Fibronectin (Fn1) and Vegfa Primary cells isolated from the rat model cultured in 3% O2 continued to express Dhh but did not respond to vismodegib in vitro However, culture supernatant from these cells stimulated Gli1, Ptch1, and Fn1 expression in mouse embryonic fibroblasts, which was suppressed by vismodegib. […] Our study provides new evidence regarding the role of Hh signaling in MPM stroma in the maintenance of tumor growth, emphasizing Hh signaling as a treatment target for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26845118&#34; target=&#34;_blank&#34;&gt;Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Variables correlated with overall survival (OS) included sex, performance status (PS), asbestos exposure, tumor laterality, histology, clinical stage, initial positron emission tomography maximum standardized uptake value, hemoglobin level, platelet count, lymphocyte count, white cell and neutrophil counts, treatment type, and clinical benefit from treatment. […] Our results confirm the significance of elements of the Cancer and Leukemia Group B and European Organisation for Research and Treatment of Cancer prognostic scoring systems, identify factors associated with clinical benefit from chemotherapy, and emphasize the impact of histology and clinical benefit of chemotherapy on outcomes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26845191&#34; target=&#34;_blank&#34;&gt;A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Before treatment and after three cycles of chemotherapy, a thoracoscopy was performed to evaluate vascular changes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26847426&#34; target=&#34;_blank&#34;&gt;Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
TS shRNA effectively enhanced the in vitro cell growth inhibition upon treatment with PMX via downregulating TS expression in the MSTO-211H cell line. […] In in vivo orthotopic tumor model, the combined treatment of PMX and TS shRNA lipoplex efficiently combated the progression of orthotopic thoracic tumors and as a result prolonged mouse survival, compared to each single treatment. […] Our findings emphasize the pivotal relevance of RNAi as an effective tool for increasing the therapeutic efficacy of PMX, a cornerstone in the treatment regimens of MPM, and thereby, raising the possibility for the development of a novel therapeutic strategy, combination therapy of TS-shRNA and PMX, that can surpass many of the currently applied, but less effective, therapeutic regimens against lethal MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26848772&#34; target=&#34;_blank&#34;&gt;Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with 5-aza-2’-deoxycytidine and analysis of TCGA data indicated that promoter methylation is not likely to be involved.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26861734&#34; target=&#34;_blank&#34;&gt;Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our findings indicate that the cell-free hlMSC-CM confers in vitro antitumor activities via soluble factors in the tested mesothelioma cells and, hence, may serve as a therapeutic tool to augment the current treatment strategies in malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2687807&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment includes surgery, chemotherapy, and radiotherapy. […] This article explores the epidemiology and etiology of the disease, offers a summary of current treatment options, and discusses nursing strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26893272&#34; target=&#34;_blank&#34;&gt;Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We assessed the relationship between patients’ features and disease evolution in order to choose the best treatment able to prolong overall survival (OS) and progression-free survival (PFS). […] Data on age, sex, smoking history, asbestos exposure, performance status, tumor stage, histology, type of treatment, and routine laboratory tests including complete blood count panel, date of death, or censored status were collected. […] Univariate analysis showed that histologic type, performance status, response to first-line therapy, pretreatment hemoglobin levels, and plasmatic Ca125 were significant prognostic factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26894775&#34; target=&#34;_blank&#34;&gt;Cutaneous Metastases From Malignant Mesothelioma of the Tunica Vaginalis Testis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of this rare tumor remains challenging because there are currently no recommended guidelines, but radical inguinal orchiectomy is an optimal choice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26903362&#34; target=&#34;_blank&#34;&gt;Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the multivariable analyses, prognostic factors were adjusted for the European Organisation for Research and Treatment of Cancer (EORTC) prognostic index (PI) of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26925688&#34; target=&#34;_blank&#34;&gt;Evaluation of Machine Learning Algorithm Utilization for Lung Cancer Classification Based on Gene Expression Levels.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Errors in lung cancer type or malignant growth determination lead to degraded treatment efficacy, because anticancer strategy depends on tumor morphology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26938529&#34; target=&#34;_blank&#34;&gt;Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
LGM2605 treatment significantly (p &amp;lt; 0.0001) reduced asbestos-induced cytotoxicity and ROS generation, while decreasing levels of MDA and 8-isoP by 71%-88% and 41%-73%, respectively. […] Importantly, exposure to asbestos fibers induced cell protective defenses, such as cellular Nrf2 activation and the expression of phase II antioxidant enzymes, HO-1 and Nqo1 that were further enhanced by LGM2605 treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26943000&#34; target=&#34;_blank&#34;&gt;A catalogue of treatment and technologies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26968202&#34; target=&#34;_blank&#34;&gt;Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
“In situ vaccination” using immunogene therapy has the ability to induce polyclonal antitumor responses directed by the patient’s immune system. […] Treatment was generally well tolerated. […] No biologic parameters were found to correlate with response, including numbers of activated blood T cells or NK cells, regulatory T cells in blood, peak levels of IFNα in blood or pleural fluid, induction of antitumor antibodies, nor an immune-gene signature in pretreatment biopsies. […] Results of this study support proceeding with a multicenter randomized clinical trial of chemo-immunogene therapy versus standard chemotherapy alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26968653&#34; target=&#34;_blank&#34;&gt;Safety of indwelling pleural catheter use in patients undergoing chemotherapy: a five-year retrospective evaluation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Indwelling pleural catheters (IPC) are increasingly becoming a first-line treatment in the management of malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26976977&#34; target=&#34;_blank&#34;&gt;Novel Hyaluronan Formulation Enhances the Efficacy of Boron Neutron Capture Therapy for Murine Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Boron neutron capture therapy (BNCT) is a radiotherapy in which cancer cells that selectively take up (10)Boron-containing compounds are destroyed, and normal cells are uninjured. […] Modifying BSH with HA is a promising strategy for enhancing the efficacy of BNCT for therapy of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26980049&#34; target=&#34;_blank&#34;&gt;Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive tumor with no effective therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27005976&#34; target=&#34;_blank&#34;&gt;Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with malignant pleural mesothelioma (MPM) eligible for extrapleural pneumonectomy (EPP) may benefit from induction chemotherapy (CT) as historically described, or from induction-accelerated hemithoracic intensity-modulated radiation therapy (IMRT) as a potential alternative. […] However, the impact of the type of induction therapy on postoperative morbidity and mortality remains unknown. […] Patients without induction treatment (n = 7) or undergoing both induction CT and IMRT (n = 2) were then excluded. […] The remaining patients (study group) were divided according to the type of induction treatment in Group 1-CT and Group 2-IMRT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27015594&#34; target=&#34;_blank&#34;&gt;The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
More randomized prospective trial data are needed to fully understand the role of radical surgery in the treatment of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27026891&#34; target=&#34;_blank&#34;&gt;An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We propose that administration of bisphosphonates in a closed cavity is a treatment strategy for tumors developed in the cavity probably through the direct cytotoxic activity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27034865&#34; target=&#34;_blank&#34;&gt;Primary Malignant Neuroendocrine Tumour of Pleura: First Case Report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical presentations of inflammatory lesions like tuberculous pleuritis and benign and malignant neoplasms of pleura are indistinguishable; hence, fluid cytology, pleural biopsy, and immunohistochemistry are necessary for exact tissue diagnosis of the tumours, which is mandatory for correct treatment and prognostic assessment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27053826&#34; target=&#34;_blank&#34;&gt;Deformable medical image registration of pleural cavity for photodynamic therapy by using finite-element based method.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
When the pleural cavity is opened during the surgery portion of pleural photodynamic therapy (PDT) of malignant mesothelioma, the pleural volume will deform. […] This impacts the delivered dose when using highly conformal treatment techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27055148&#34; target=&#34;_blank&#34;&gt;Advances in treatment of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To date, MPM prognosis is poor and very few treatment options are available for both localized and advanced MPM. […] The aim of this review is to focus on the current available treatment for MPM through the analysis of the results comes from the phase III trials and to discuss the future perspectives in the pathogenesis, diagnosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27057918&#34; target=&#34;_blank&#34;&gt;Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Data have shown that the adoption of pemetrexed maintenance therapy (PMT) following first-line treatment appears extremely promising.We describe a 57-year-old man diagnosed as advanced MPM. […] We further entail a review of the literature on the first-line treatment, continuation maintenance therapy, switch maintenance therapy, and second-line treatment of patients with advanced MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27074478&#34; target=&#34;_blank&#34;&gt;A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This pilot study investigates the feasibility of using volumetric-modulated arc therapy (VMAT) for malignant pleural mesothelioma (MPM), and compares VMAT to static field intensity-modulated radiotherapy (IMRT) for five patients. […] To identify the best treatment technique for MPM, in five patients, we made a representative comparative analysis of two kinds of techniques for radiation therapy planning: IMRT and VMAT. […] The plans were created for an Elekta Synergy linear accelerator with 6 MV photons using Oncentra version 4.3 treatment planning system.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27075290&#34; target=&#34;_blank&#34;&gt;[Localized Malignant Mesothelioma of the Pleura with Hemothorax].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The biologic association between LMM and diffuse malignant mesothelioma of the pleura (DMM) remains unclear, and the standard treatment for LMM has not been established to date.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27088262&#34; target=&#34;_blank&#34;&gt;Chronic mesothelial reaction and toxicity of potassium octatitanate fibers in the pleural cavity in mice and F344 rats.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In Experiment 1, four strains of mice, A/J, C3H, ICR, and C57BL, were examined for 52 weeks after experimental treatment with TISMO.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27098557&#34; target=&#34;_blank&#34;&gt;Multiwalled carbon nanotubes intratracheally instilled into the rat lung induce development of pleural malignant mesothelioma and lung tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For the present study, 10-week-old F344/Crj male rats were divided into five groups: no treatment, vehicle control, MWCNT-N before filtration, MWCNT-N flow-through and MWCNT-N retained groups.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27117437&#34; target=&#34;_blank&#34;&gt;Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study was undertaken as part of a trial examining radiotherapy for the treatment of pain in MPM (ISRCTN 10644347).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27127763&#34; target=&#34;_blank&#34;&gt;Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Breast cancer susceptibility gene 1 (BRCA1) expression has been suggested as a predictor in anti-neoplastic treatment with anti-microtubule agents.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27143930&#34; target=&#34;_blank&#34;&gt;Massive chest wall resection and reconstruction for malignant disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A recent case series of 20 consecutive patients is reported in order to find any possible correlation between tumor histology, extent of resection, type of reconstruction, and adjuvant treatment with short- and long-term outcomes. […] Adjuvant oncologic treatment was administered in 13 patients. […] Three patients died during the study period because of recurrent disease or complications of treatment for recurrent disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27167294&#34; target=&#34;_blank&#34;&gt;Geometric dose prediction model for hemithoracic intensity-modulated radiation therapy in mesothelioma patients with two intact lungs.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The presence of two intact lungs makes it challenging to reach a tumoricidal dose with hemithoracic pleural intensity-modulated radiation therapy (IMRT) in patients with malignant pleural mesothelioma (MPM) who underwent pleurectomy/decortications or have unresectable disease. […] Parameters obtainable directly from planning scan anatomy predict achievable prescription doses for hemithoracic IMRT treatment of MPM patients with two intact lungs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27168021&#34; target=&#34;_blank&#34;&gt;Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To increase efficacy, a prerequisite is that treatment is tailored, so precision immune-oncology is the logical next step. […] In order to tailor treatment, characterization of the patient’s tumor environment is key. […] These dynamics could in part be attributed to the treatment regimen consisting of standard chemotherapy and dendritic cell (DC)-based immunotherapy. […] In this proof-of-concept study with limited sample size, we demonstrate that the composition of PE is dynamic and influenced by treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27169584&#34; target=&#34;_blank&#34;&gt;[Surgical therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are two established surgical techniques for treatment of MPM, extrapleural pneumonectomy and tumor pleurectomy with decortication. […] Within multimodal therapy concepts including cytoreductive surgery, long-term remission is possible in selected patients. […] When choosing the appropriate surgical therapy the high incidence of recurrence has to be borne in mind.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27169699&#34; target=&#34;_blank&#34;&gt;The role of “closed abdomen” hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment was well tolerated. […] The treatment was generally well tolerated considering the limited treatment options available for these patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2717559&#34; target=&#34;_blank&#34;&gt;Thoracoscopy in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy is a suitable diagnostic method in malignant mesothelioma, since it enables simultaneously histopathological diagnosis, identification of asbestos fibres, staging of tumour spread, and pleurodesis therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27184482&#34; target=&#34;_blank&#34;&gt;Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although pleural and peritoneal mesotheliomas have different risk factors, different therapeutics, and different prognosis; these data provide support to combine pleural and peritoneal mesothelioma in same clinical assays.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27185582&#34; target=&#34;_blank&#34;&gt;Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This in turn has led to the first clinical trials of miRNA replacement therapy. […] This special report focuses on the development of TargomiRs - miRNA mimics delivered by targeted bacterial minicells - and the very first clinical experience of a miRNA replacement therapy in thoracic cancer patients in the Phase I MesomiR-1 trial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27197170&#34; target=&#34;_blank&#34;&gt;Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, a combination of SK-216 and the chemotherapeutic agent cisplatin significantly reduced tumor weights compared with monotherapy, prolonging the survival of animals compared with cisplatin treatment alone. […] These findings suggest that PAI-1 inactivation by SK-216 may represent a general strategy for inhibiting angiogenesis, including for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27210080&#34; target=&#34;_blank&#34;&gt;[Clinical Pathological Diagnosis, and Treatment for Pleural Mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For surgical treatment for pleural mesothelioma, extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D) are usually performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27222020&#34; target=&#34;_blank&#34;&gt;Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We discuss different stages of patient management in malignant pleural mesothelioma, including diagnosis, initial staging, therapy planning, early treatment response assessment, re-staging, and prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27232931&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
SUV and ADC were assessed in therapy-naive pleural lesions. […] The inverse correlation ADC/SUV indicates that future research on multiparametric therapy response evaluation may be warranted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27236386&#34; target=&#34;_blank&#34;&gt;Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although malignant pleural mesothelioma (MPM) is generally a disease associated with more advanced age, the association of age, treatment, and outcomes has not been well-characterized. […] We evaluated the impact of age on outcomes in patients with MPM to provide data for use in the treatment selection process for elderly patients with potentially resectable disease. […] Surgical treatment is associated with improved survival compared with nonoperative management for both patients younger than 70 years and patients aged 70 years or older.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27245839&#34; target=&#34;_blank&#34;&gt;KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Utilizing mRNA-microRNA correlations based on differential gene expression using Gene Set Enrichment Analysis (GSEA), we systematically combined publicly available gene expression datasets with our own MPM data in order to identify candidate targets for MPM therapy. […] Similarly, treatment with paxilline, a small molecule inhibitor of KCa1.1, resulted in suppression of MPM cell migration.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2725943&#34; target=&#34;_blank&#34;&gt;[Diagnosis and prognosis of malignant mesothelioma. A description of 8 clinical cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histology was re-examined for each case and clinical records was also looked at so as to identify onset symptomatology, diagnostic procedures and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27266287&#34; target=&#34;_blank&#34;&gt;[Drug carrier nanosystems in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM), the incidence increased with each passing day, is an important lethal disease due to the limited survive with available treatment methods and with the lack of a standard treatment. […] Response and survive rates of cytotoxic agents which is used in MPM treatment are not good enough. […] Therefore, treatment studies of MPM seem to quite important and urgent. […] In cancer therapy, convensional chemotherapeutic agent applications, due to the lack of selectivity, lead to systemic toxicity. […] It is very difficult to the pass through cellular barriers, particularly, drug resistance may develop to the treatment. […] All of these reasons lead to failure in the treatment process. […] Because of the fact that cytotoxic drugs either kill the rapidly growing and dividing cells or make them disfunctional by showing toxic effect on them, to avoid the side effects and to make an inherent effect for cytotoxic drug of active ingredient given for treatment on tumor, different studies have been under investigation. […] It seems that use of the nanocarrier in the treatment of mesothelioma has a potential, as effective alternative a method, with improve of the drug efficacy and reduce of toxicity in normal tissues.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27274438&#34; target=&#34;_blank&#34;&gt;Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a rare and aggressive, treatment-resistant cancer. […] We experienced one remarkable case of highly effective S-1 combined therapy for pemetrexed refractory MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27279560&#34; target=&#34;_blank&#34;&gt;Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, treatment options for MPM are limited, and new molecular targets for treatments are urgently needed. […] These results provide that inhibition of KIF11 and KIF23 may hold promise for treatment of MPMs, raising the possibility that kinesin-based drug targets may be developed in the future.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27282309&#34; target=&#34;_blank&#34;&gt;The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Notwithstanding the increasing incidence of MPM and the fact that patients with MPM face a poor prognosis, currently available treatment options are limited.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27286698&#34; target=&#34;_blank&#34;&gt;The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The disease remains challenging in terms of diagnosis, staging and treatment and an optimal strategy has not yet been clearly defined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27286996&#34; target=&#34;_blank&#34;&gt;Effect of renal function on pemetrexed-induced haematotoxicity.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed (PEM) is an anticancer agent used for the treatment of non-small cell lung cancer, malignant pleural mesothelioma and thymoma. […] We retrospectively reviewed 221 patients with lung cancer, malignant pleural mesothelioma or thymoma who received treatment with a PEM-containing regimen between 2009 and 2014. […] Subgroup analyses were performed on the basis of pre-treatment renal function: group A [creatinine clearance (CLcr), &amp;lt;45 mL/min]; group B (CLcr, 45-80 mL/min); and group C (CLcr, ≥80 mL/min).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27287512&#34; target=&#34;_blank&#34;&gt;Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently there are no curative treatment modalities for malignant mesothelioma, however treatments such as surgery, chemotherapy and radiotherapy can help to improve patient prognosis and increase life expectancy. […] Pemetrexed-Cisplatin is the only standard of care (SoC) chemotherapy for malignant mesothelioma, but the median PFS/OS (progression-free survival/overall survival) from the initiation of treatment is only up to 12 months. […] Therefore, new treatment strategies against malignant mesothelioma are in high demand. […] In this preclinical study, we evaluated the antineoplastic activity of combination treatment with SoC chemotherapy (Pemetrexed, Cisplatin, Carboplatin) and ONCOS-102 in xenograft BALB/c model of human malignant mesothelioma. […] We demonstrated that ONCOS-102 is able to induce immunogenic cell death of human mesothelioma cell lines in vitro and showed anti-tumor activity in the treatment of refractory H226 malignant pleural mesothelioma (MPM) xenograft model.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27288978&#34; target=&#34;_blank&#34;&gt;Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Given the promising results of anti-cytotoxic T-lymphocyte associated protein-4 and anti-programmed cell death-1/programmed death ligand-1 antibodies in the treatment of advanced NSCLCs, these immune checkpoint inhibitors are now also under investigation in SCLC and MPM, as well as in thymic epithelial tumors (TETs). […] Current immune checkpoint blockers targeting cytotoxic T-lymphocyte associated protein-4 and the programmed cell death-1/programmed death ligand-1 axis, administered alone or in combination and as multimodality treatment, are likely to be a valuable addition to the therapeutic array for managing SCLC and MPM; studies in TETs, which are currently in their infancy, are merited.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27294004&#34; target=&#34;_blank&#34;&gt;Nanoparticle-based targeted gene therapy for lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In recent years, targeted gene therapy with nanoparticles is one of the most rapidly evolving and extensive areas of research for lung cancer. […] The major goal of targeted gene therapy is to bring forward a safe and efficient treatment to cancer patients via specifically targeting and deterring cancer cells in the body. […] In this review article we provide an overview on the latest developments in nanoparticle-based targeted gene therapy for lung cancers. […] Firstly, we outline the conventional therapies and discuss strategies for targeted gene therapy using nanoparticles.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27294401&#34; target=&#34;_blank&#34;&gt;Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with NZ-1 and rat NK (CD161a(+) ) cells inhibited the growth of tumors and the production of pleural effusion in NCI-H290/PDPN or NCI-H226 orthotopic xenograft mouse models. […] Antitumor effects were observed following treatment with NZ-12 and human NK (CD56(+) ) cells in MPM orthotopic xenograft mice. […] These results strongly suggest that combination therapy with podoplanin-targeting immunotherapy using both NZ-12 and pemetrexed might provide an efficacious therapeutic strategy for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2731122&#34; target=&#34;_blank&#34;&gt;A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The serum hyaluronan levels of 37 patients with malignant mesothelioma were followed during the course of treatment (high doses of methotrexate were given to 32 of these patients). […] The patients could be divided into the following two groups: (1) those with progressive disease (n = 17) or (2) those showing improvement during therapy (complete remission [n = 2], partial remission, or no change [n = 18]). […] There was a significant increase in serum hyaluronan levels during treatment in patients with progression (P less than 0.01).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27312601&#34; target=&#34;_blank&#34;&gt;Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite advances in chemotherapy, radiation therapy and surgical management of LC and MM, the median survival remains less than 12 months. […] Early detection represents one of the most promising approaches to reducing the growing cancer burden by increasing chemotherapy treatment efficiency. […] The same predictive biomarkers can be used as therapy targets.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2731313&#34; target=&#34;_blank&#34;&gt;A phase II study of vincristine in malignant mesothelioma–a negative report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The result suggests that vincristine has little or no therapeutic value in the treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27323398&#34; target=&#34;_blank&#34;&gt;Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, it appears that agents reducing estradiol levels could be useful to MPM therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27325859&#34; target=&#34;_blank&#34;&gt;Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conducted a two-center phase II study to determine the safety of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) after chemotherapy and pleurectomy-decortication (P/D) as part of a multimodality lung-sparing treatment. […] A total of 45 patients were enrolled; 18 were not evaluable (because of disease progression before radiation therapy [RT], n = 9; refusal of surgery or RT, n = 5; extrapleural pneumonectomy at time of surgery, n = 2; or chemotherapy complications, n = 2). […] Its incorporation with chemotherapy and P/D forms a new lung-sparing treatment paradigm for patients with locally advanced MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27330149&#34; target=&#34;_blank&#34;&gt;Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical treatment of MPM remains debatable.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27347127&#34; target=&#34;_blank&#34;&gt;Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery is the treatment of choice, but numerous cases are inoperable. […] For the treatment of inoperable or metastatic cases, systemic chemotherapy is required. […] However, a standard chemotherapeutic regimen for the treatment of pericardial mesothelioma has not yet been established. […] Chemotherapy involving pemetrexed and cisplatin has been actively used in the treatment of pleural or peritoneal mesothelioma, and may be considered for the treatment of PMPM. […] The present study reports the case of a patient with PMPM with lung metastasis who demonstrated a positive response to treatment with pemetrexed and cisplatin followed by pemetrexed maintenance chemotherapy, leading to prolonged progression-free survival for 21 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2737035&#34; target=&#34;_blank&#34;&gt;[Thoracoscopy using flexible fiberoptic bronchoscopy–a preliminary report of experimental and clinical studies].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It was observed that its respiratory and circulatory effects were negligible as there were only transient fever in all the cases and local subcutaneous emphysema in one case with prompt recovery without treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27378628&#34; target=&#34;_blank&#34;&gt;Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
If confirmed, these markers may be used to identify subgroups of patients benefitting from additional treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27381209&#34; target=&#34;_blank&#34;&gt;Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Enrolment of 86 participants will detect a mean difference of VAS score of 14 mm between the treatment arms (5% significance, 90% power) assuming a common between-group SD of 18.9 mm and a 10% lost to follow-up rate.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27391069&#34; target=&#34;_blank&#34;&gt;P2X7 targeting inhibits growth of human mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive tumor refractory to anti-blastic therapy. […] Our findings suggest that the P2X7R might be a novel target for the therapy of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27391433&#34; target=&#34;_blank&#34;&gt;Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thymidylate synthase (TS), one of the key enzymes for thymidine synthesis, is a target of pemetrexed (PEM), a key agent for the systemic therapy of malignant pleural mesothelioma (MPM) and its overexpression has been correlated to PEM-resistance. […] Dasatinib treatment impaired cells migration, and both sequential and co-administration with PEM significantly increased apoptosis. […] Dasatinib pretreatment improved sensitivity to PEM, downregulated TS promoter activity and, in association with PEM, modulated the downstream PI3K-Akt-mTOR signaling.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27407123&#34; target=&#34;_blank&#34;&gt;NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. […] The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. […] The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27408810&#34; target=&#34;_blank&#34;&gt;MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A recent study, however, showed that cisplatin/pemetrexed + bevacizumab (a recombinant humanized monoclonal antibody that inhibit VEGF) treatment has a survival benefit of 2.7 months Zalcman et al. […] It remains to be seen if this targeted therapy will be accepted as a new standard for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27413774&#34; target=&#34;_blank&#34;&gt;Safety and Complications of Medical Thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
HAI is of low risk and can be controlled by medical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27418105&#34; target=&#34;_blank&#34;&gt;Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cocultures of macrophages with mesothelioma cells were performed to study cancer cell proliferation and resistance to treatment. […] Finally, we showed that M2 macrophages increased mesothelioma cell proliferation and resistance to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27418604&#34; target=&#34;_blank&#34;&gt;Cochrane corner: interventions for the management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The overall survival remains poor, necessitating an evidence based treatment strategy that provides the best outcomes for individual patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27422678&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma with lacrimal gland metastasis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To describe a rare clinical case of biopsy-proven metastatic mesothelioma of the lacrimal gland which responded well to chemo and radiation therapy. […] Her lacrimal and lung tumours showed a marked regression following palliative chemo (carboplatin) and radiation therapy. […] A combined chemo and radiation therapy may reduce the size of the metastatic and primary tumour.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27427530&#34; target=&#34;_blank&#34;&gt;Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of surgical resection in malignant pleural mesothelioma (MPM) is based on the principle of macroscopic resection of a solid tumor with adjuvant therapy to treat micrometastatic disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27431778&#34; target=&#34;_blank&#34;&gt;New therapeutic strategies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The recommended systemic therapy for MPM is cisplatin/pemetrexed regimen with a mean overall survival of about 12months and a median progression free survival of less than 6months. […] For some tumors, such as lung cancer and breast cancer, druggable oncogenic alterations have been identified and targeted therapy is an important option for these patients. […] For MPM, clinical guidelines do not recommend biological targeted therapy, mainly because of poor target definition or inappropriate trial design. […] This review updates pre-clinical and clinical data on the efficacy of targeted therapy and immune checkpoint inhibition in the treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27438907&#34; target=&#34;_blank&#34;&gt;Silencing Receptor EphA2 Enhanced Sensitivity to Lipoplatin™ in Lung Tumor and MPM Cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report that silencing EphA2 significantly enhanced the cellular sensitivity of lung tumor and MPM cells to Lipoplatin and maybe a potential therapy for lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27440191&#34; target=&#34;_blank&#34;&gt;Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is an aggressive disease with dismal prognosis despite multimodal treatment including chemotherapy, surgery and radiotherapy. […] At progression it is possible to provide systemic second-line treatment but its effects are limited.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-12-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27449804&#34; target=&#34;_blank&#34;&gt;A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no approved second-line systemic therapy option for malignant pleural mesothelioma (MPM), but targeting angiogenesis is an area of investigation. […] In conclusion, PF-03446962, despite being generally well tolerated, failed to demonstrate efficacy in the treatment of advanced MPM as a single agent.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27452468&#34; target=&#34;_blank&#34;&gt;Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We identify a synthetic lethal dependence between ASS1 deficiency and polyamine metabolism, which could potentially be exploited for the treatment of ASS1-negative cancers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27457872&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of malignant pleural mesothelioma (MPM) depends on performance status of the patient, tumor stage, and histological differentiation. […] Chemotherapy (CHT) can be administered as first- and second-line treatment in unresectable MPM or as neoadjuvant or adjuvant treatment before or after surgery. […] Several targeted and immunotherapies are in evaluation and further studies are warranted to determine the therapeutic value of these new treatment options. […] Radiotherapy (RT) can be considered either as adjuvant treatment after surgery or for palliation of pain-related tumor growth. […] Surgery should only be applied as part of a multimodality treatment (MMT) in combination with chemo- and/or radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27457873&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of the patients, 30 (14.3 %) received best supportive care (BSC) only, 71 (33.8 %) chemotherapy (CHT) alone, four (1.9 %) radiotherapy (RT) alone, 23 (11.9 %) CHT/RT, two (0.9 %) surgery alone, and 76 (36.2 %) curative surgery within a multimodality treatment (MMT), which was more frequently performed for patients younger than 65 years and with early-stage disease (I + II).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27509983&#34; target=&#34;_blank&#34;&gt;Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These results suggest potential clinical use of calpeptin for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27512118&#34; target=&#34;_blank&#34;&gt;Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is characterized by widespread resistance to systemic therapy. […] Trabectedin is an antineoplastic agent targeting both the malignant cells and the tumor microenvironment that has been approved for the treatment of advanced soft tissue sarcoma and ovarian cancer. […] The activity of trabectedin against MPM cells was synergistically enhanced by coadministration of cisplatin, a drug routinely used for systemic MPM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27514524&#34; target=&#34;_blank&#34;&gt;Quercetin and Cisplatin combined treatment altered cell cycle and mitogen activated protein kinase expressions in malignant mesotelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a locally aggressive and highly lethal neoplasm of pleural, peritoneal and pericardial mesothelial cells without successful therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27524142&#34; target=&#34;_blank&#34;&gt;Treatment offers hope in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) might be a useful treatment for malignant mesothelioma of the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27543082&#34; target=&#34;_blank&#34;&gt;Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We describe a 62-year old patient diagnosed with malignant pleural mesothelioma who experienced ten days after the second dose of third line therapy with pembrolizumab sudden onset of generalized edema including legs and eyelids and weight gain of 15 kg resulting from nephrotic syndrome and acute renal failure. […] Physicians should be aware of this side effect in patients presenting with edema and weight gain and initiate prompt renal function testing, serum albumin and urinalysis followed by steroid treatment if pembrolizumab-related MCD is suspected.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27543099&#34; target=&#34;_blank&#34;&gt;Co-existing tuberculosis and malignant mesothelioma with multiple sites venous thrombosis: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On examination he was found to have pleural effusion for which he received anti-tuberculosis therapy empirically. […] Despite anti-tuberculosis therapy he did not improve and was suspected to be a multidrug resistant case. […] In a diagnosed case of tuberculosis with clinical findings compatible with it but not responding to anti tubercular therapy, underlying secondary co-existing pathology should be explored.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27594045&#34; target=&#34;_blank&#34;&gt;Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It was the most effective drug in MPM473 xenografts and showed a similar level of activity as the most efficient treatment in the other two MPM models (gemcitabine in MPM487 and cisplatin in MPM484).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27597274&#34; target=&#34;_blank&#34;&gt;How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is little evidence regarding the use of chemotherapy as part of multimodality treatment of malignant pleural mesothelioma (MPM). […] We aimed to determine whether, in those patients fit for chemotherapy, a delay in this treatment affected survival. […] Outcome was compared between 4 chemotherapy strategies: true adjuvant therapy, neo-adjuvant therapy, therapy reserved until evidence of disease progression in those otherwise fit in the post-operative setting, and those unfit for chemotherapy. […] There was no effect of the timing of chemotherapy on overall or progression free survival in patients fit enough for treatment (p=0.39 and p=0.33 respectively). […] Further analysis of 169 patients receiving platinum/pemetrexed as first line treatment, showed similar results; there was no effect of the timing of chemotherapy on OS or PFS (p=0.80 and p=0.53 respectively) and an improved OS in patients with non-epithelioid disease, and improved PFS in those with lymph node metastases, if chemotherapy was given in the immediate adjuvant setting (p=0.001 and 0.038) when therapy was not delayed until disease progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27599565&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its pretreatment pathological diagnosis is difficult, with fibrous pleuritis and reactive mesothelial hyperplasia as potential differential diagnoses. […] Among 60 patients with MPM, four patients with the desmoplastic subtype were identified and their clinical characteristics, including asbestos exposure, treatment, and prognosis, were reviewed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27612329&#34; target=&#34;_blank&#34;&gt;[Malignant Pleural Mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate staging with invasive tests, if needed, is an important step before an interdisciplinary team can decide on an optimal (multi-modal) treatment approach. […] A multi-modal treatment approach (surgery, radiation oncology and chemotherapy) is superior to all approaches relying only on a single modality, if the patient qualifies for it from an oncological and functional standpoint. […] The goal of the surgical therapy is to achieve macroscopic complete resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27621868&#34; target=&#34;_blank&#34;&gt;Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the trend of our surgical patients affected by malignant pleural mesothelioma (MPM) and submitted to diagnostic/palliative or curative surgical procedures and to validate the European Organisation for Research and Treatment of Cancer (EORTC) prognostic score in our patient population.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27623107&#34; target=&#34;_blank&#34;&gt;PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of MPM cells with these inhibitors also significantly decreased cell migration, and the combination of them was synergistic. […] Treatment with BKM120 alone or in combination with crizotinib induced G2-M arrest and apoptosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-06-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27644679&#34; target=&#34;_blank&#34;&gt;Mesotheliomas in Lebanon: Witnessing a Change in Epidemiology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of the 21 patients, 10 (47.6%) underwent surgery during their treatment, 16 (76.2%) received chemotherapy and 3 (14.3%) received best supportive care.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27646775&#34; target=&#34;_blank&#34;&gt;Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of our study was to evaluate the usefulness of these substances as markers of the clinical response to treatment in patients suffering from epithelioid mesothelioma. 219 serum samples from 56 patients were collected during follow-up and the clinical response to therapy was recorded.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27651129&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiotherapy for relapsed malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The use of novel radiotherapy techniques is widely increasing, allowing clinicians to treat diseases that were previously difficult to treat with radiation therapy. […] Intensity-modulated radiation therapy has allowed to respect the QUANTEC (quantitative analyses of normal tissue effects in the clinic) dose constraints, patient has experienced a 14 months progression-free time, without relevant subacute or late lung toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27683181&#34; target=&#34;_blank&#34;&gt;Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In multivariable analysis, patients whose tumors formed a PDX had significantly poorer survival when the model was adjusted for preoperative treatment (HR, 2.46; 95% confidence interval, 1.1-5.52; &lt;i&gt;P&lt;/i&gt; = 0.028).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27696931&#34; target=&#34;_blank&#34;&gt;Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Other antiangiogenics such as nintedinib show early promise, although the Phase III trial results are eagerly awaited before this therapy enters treatment paradigms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27698933&#34; target=&#34;_blank&#34;&gt;Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality therapy consisting of platinum-based chemotherapy is the treatment of choice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27713145&#34; target=&#34;_blank&#34;&gt;Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The glycodelin serum levels correlated with the tumor response to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27716620&#34; target=&#34;_blank&#34;&gt;Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Altogether, these data indicate that the identification of new and specific markers are of a paramount importance for an early diagnosis and treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27725905&#34; target=&#34;_blank&#34;&gt;MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ephrin-A1 treatment up regulates miR-302b expression in MPM cells and attenuates cell proliferation and tumorsphere formation via repression of myeloid cell leukemia-1 (Mcl-1). […] To confirm that ephrin-A1 regulates the expression of Mcl-1 mRNA through miR-302b up regulation, cells were transfected with and without miR-302b and miR-302b inhibitor prior to ephrinA1 treatment. […] Ephrin-A1 treatment induced several fold increases of miR-302b expression in MM cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27740765&#34; target=&#34;_blank&#34;&gt;Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, the combined treatment of PMX with systemic injection of PEG-coated TS shRNA-lipoplex exerted a potent antitumor activity in a s.c. xenograft tumor model, compared to a single treatment with either PMX or PEG-coated TS shRNA-lipoplex. […] Metastasis, or the spread, of mesothelioma substantially dedicates the effectiveness of treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27755778&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery improves local control but is not sufficient as a single treatment modality. […] The recommended treatment strategy for a select group of patients is multimodal therapy that includes surgery, radiotherapy and chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27755841&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prospective randomized trials comparing multimodality approaches to other forms of treatment and including quality of life assessment are warranted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27765170&#34; target=&#34;_blank&#34;&gt;Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The percentage of epithelioid differentiation is an independent predictor of survival in MPM and should be taken into careful consideration when recommending surgical treatment for patients with biphasic MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27768834&#34; target=&#34;_blank&#34;&gt;Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate the relationship of the pre-treatment blood neutrophil/lymphocyte count ratio (NLR) with the maximum standard uptake value (SUVmax) of primary masses on positron emission tomography/computed tomography (PET/CT) taken before treatment in patients diagnosed with malignant pleural mesothelioma (MPM) and to evaluate the contribution to prognosis. […] The SUVmax value of the primary mass on pre-treatment PET/CT, the haemogram parameters (Hb, Hct, NLR, MPV, PLT) at the time of diagnosis, the progression history, the date of the final visit, and the date of death of exitus patients was recorded from patient files PET/CT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27777372&#34; target=&#34;_blank&#34;&gt;Current best practice in the evaluation and management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent well-designed randomized trials have provided a broader evidence base for an expanding range of treatment options. […] Together, with new prognostic scoring systems and a greater understanding of how different patient phenotypes respond to treatment, this allows greater personalization of management.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27780599&#34; target=&#34;_blank&#34;&gt;Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) continues to be a disease with poor prognosis and limited treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27783867&#34; target=&#34;_blank&#34;&gt;Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, no curative treatment for MM of advanced stage is available.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27793915&#34; target=&#34;_blank&#34;&gt;Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma Cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent evidence points to oestrogen receptor (ER)-β having a tumour-suppressor role in MPM progression, and this raises the question of whether selective modulators of ERs could play a role in augmenting MPM therapy. […] Tamoxifen treatment repressed the expression of cyclins by MPM cells, resulting in cell-cycle arrest and caspase-3-coupled apoptosis signaling.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27803412&#34; target=&#34;_blank&#34;&gt;Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This unusual case had a relatively long progression-free period without treatment before the appearance of pleural tumors that showed the histological features of malignant sarcomatoid mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27806086&#34; target=&#34;_blank&#34;&gt;In Vitro and In Vivo Antitumor Activity of [Pt(O,O’-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is an urgent need for effective therapy inasmuch as resistance, intrinsic and acquired, to conventional therapies is common. […] The purpose of this study was to examine the efficacy of Ptac2S treatment in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27813512&#34; target=&#34;_blank&#34;&gt;Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options for all malignant mesotheliomas are currently limited, with no known targeted therapies available.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27819788&#34; target=&#34;_blank&#34;&gt;[Update on epidemiology, pathophysiology, diagnosis and treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Regarding the treatment of this tumor, it mainly comprises palliative care, even though chemotherapy, radiotherapy, and, in selected cases, surgical treatments have been used.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27822122&#34; target=&#34;_blank&#34;&gt;Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this investigation was to describe mesothelioma patient characteristics, treatment patterns, and overall survival (OS) utilizing the National Cancer Institute’s Surveillance, Epidemiology, and End Results-Medicare database. […] We examined both patient and tumor characteristics at time of diagnosis and subsequent treatment patterns (surgery, radiation, and chemotherapy). […] Among patients treated with chemotherapy, we determined chemotherapy regimen and OS by line of therapy. […] Nearly a third of patients (30%) had surgery as part of their treatment and 45% were given chemotherapy. […] Among chemotherapy patients, the most commonly (67%) prescribed regimen for first-line therapy was cisplatin or carboplatin (Ca/Ci) combined with pemetrexed (Pe). […] Among those prescribed Ca/Ci + Pe as first-line therapy, retreatment with Ca/Ci + Pe (28%) or treatment with gemcitabine (30%) were the most common second-line therapies. […] Median OS for those receiving first-line chemotherapy was 7 months, and among those receiving second-line therapy median OS was extended an additional 5 months. […] Irrespective of surgical resection, mesothelioma patients receiving some form of chemotherapy survived longer than patients who did not, with an additional survival benefit among those patients receiving multimodal treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27823648&#34; target=&#34;_blank&#34;&gt;The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no standard second-line treatment in MPM. […] Unfortunately none of the explored targeted treatments can currently be recommended as routine treatment in MPM. […] We reviewed the biological pathways involved in MPM, the clinical trials about targeted therapy, and possible related mechanisms of resistance. […] We suggest that specific genetic markers are needed as targets of selective therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27825687&#34; target=&#34;_blank&#34;&gt;Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to assess survival for patients with malignant pleural mesothelioma (MPM), epithelial subtype, utilizing extended pleurectomy-decortication combined with intraoperative photodynamic therapy (PDT) and adjuvant pemetrexed-based chemotherapy. […] This is a mature dataset for MPM that demonstrates the ability to safely execute a complex treatment plan that included a surgical technique that consistently permitted achieving a macroscopic complete resection while preserving the lung.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27833109&#34; target=&#34;_blank&#34;&gt;Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present study was aimed to investigate the mechanism by which EPCR suppresses MPM tumor growth and evaluate whether EPCR gene therapy could suppress the progression of MPM in a mouse model of MPM. […] Ad.EPCR treatment elicited recruitment of macrophages and NK cells into the tumor microenvironment and increased IFNγ and TNFα levels in the pleural space. […] Ad.EPCR treatment resulted in a marked increase in tumor cell apoptosis. […] In summary, our data show that EPCR expression in MPM cells promotes tumor cell apoptosis, and intrapleural EPCR gene therapy suppresses MPM progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27840913&#34; target=&#34;_blank&#34;&gt;SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Given high-dose PLK1 inhibitor induced drug-related adverse effects in several clinical trials, our results suggest inhibition SORORIN-PLK1 axis may hold promise for the treatment of MPMs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27856426&#34; target=&#34;_blank&#34;&gt;Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PD-L1 immunohistochemical staining does not always predict whether a cancer will respond to treatment with PD-1 inhibitors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2786360&#34; target=&#34;_blank&#34;&gt;Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is an aggressive tumor of the pleura for which, at present, there is no effective therapy. […] As interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells lyse many solid tissue malignancies that are unresponsive to conventional forms of therapy, the aim of this study was to evaluate the susceptibility of human malignant mesothelioma cells to lysis by natural killer (NK) and LAK cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27867002&#34; target=&#34;_blank&#34;&gt;Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemical analysis showed that trametinib treatment alone significantly reduced expression of programmed cell death 1 ligand 1. […] Furthermore, the combination of trametinib and 4-MU resulted in higher expression of programmed cell death 1 and programmed cell death 1 ligand 1 than did the 4-MU treatment alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27880851&#34; target=&#34;_blank&#34;&gt;Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Some trials recently demonstrated the benefit of targeted treatment for malignant disease; therefore, adequate tissues are needed to detect the targeted gene.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27881012&#34; target=&#34;_blank&#34;&gt;Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Significant prognostic factors on univariate analysis were performance status (PS), serum albumin, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), monocyte, platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and treatment strategy. […] Multivariate analysis showed PS, AST, monocyte, and treatment strategy were statistically significant (p&amp;lt;0.05). […] In conclusion, our data show that PS&amp;lt;2, normal AST level, lower monocyte count, and multimodality treatment are independent positive prognostic factors of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2788546&#34; target=&#34;_blank&#34;&gt;Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The ability of indomethacin to restore suppressed LAK cell activity in patients with MM suggests that the concomitant use of this agent in ex vivo LAK cell generation and in patients undergoing interleukin/LAK cell therapy may be beneficial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27900005&#34; target=&#34;_blank&#34;&gt;Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results showed that only treatment with FE was associated with fibulin-3 overexpression at both the transcript and protein levels. […] It was previously demonstrated that mesothelial cells exhibited low levels of p27 following treatment with FE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27900083&#34; target=&#34;_blank&#34;&gt;Primary malignant pericardial mesothelioma with increased serum mesothelin diagnosed by surgical pericardial resection: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, an early definitive diagnosis and timely treatment are crucial for the management of PMPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27903668&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options are summarised, including the importance of palliative care and methods of controlling pleural effusions. […] The evidence for chemotherapy, radiotherapy and surgery is reviewed, both in the palliative setting and in the context of trimodality treatment. […] Finally new treatment developments and novel therapeutic approaches are summarised.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27906635&#34; target=&#34;_blank&#34;&gt;A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Finally, the mRNA expression levels of the human equilibrative transporter-1 (hENT1) were significantly down-regulated under hypoxia, but treatment with NHI-1 was associated with a recovery of hENT1 expression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27926627&#34; target=&#34;_blank&#34;&gt;Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Novel Mini-Invasive Technique.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three cycles of adjuvant chemotherapy followed by radiation therapy were administered.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27929427&#34; target=&#34;_blank&#34;&gt;A Comparison of Singlet Oxygen Explicit Dosimetry (SOED) and Singlet Oxygen Luminescence Dosimetry (SOLD) for Photofrin-Mediated Photodynamic Therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate photodynamic therapy (PDT) dosimetry is critical for the use of PDT in the treatment of malignant and nonmalignant localized diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27932892&#34; target=&#34;_blank&#34;&gt;The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an uncommon and aggressive thoracic malignancy that is rarely curable, even when multimodality therapy is used. […] Systemic chemotherapy is the primary treatment for the majority of patients with this disease; however, surgical resection may benefit a subset of patients with early-stage disease. […] Uniform treatment approaches have been difficult to develop due to the relatively small numbers of patients with this disease, the use of a staging system that does not readily identify those who may benefit from more aggressive therapy, and the institutional biases that have resulted from the growth of multimodality centers of excellence.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27942413&#34; target=&#34;_blank&#34;&gt;The role of surgical intervention in lung cancer with carcinomatous pleuritis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The extrapleural pneumonectomy (EPP) is a radical surgical procedure that is commonly employed in the treatment of malignant pleural mesothelioma. […] Two authors reported that they have successfully performed EPPs for the treatment of patients with carcinomatous pleuritis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27979465&#34; target=&#34;_blank&#34;&gt;Open access phone triage for veterans with suspected malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess feasibility of national open access telephone triage using evidence-based treatment recommendations for patients with MPM, measure timelines of the triage and referral process and record the impact on “intent to treat” for patients using our service. […] The treatment plan was altered for 71% of patients evaluated at VA Boston Healthcare system based on 2012 International Mesothelioma Interest Group guidelines. […] Guideline-based treatment recommendations (“intent to treat”) changed the therapeutic course for the majority of patients who used our service.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27979596&#34; target=&#34;_blank&#34;&gt;Percutaneous Cryoablation for the Treatment of Recurrent Malignant Pleural Mesothelioma: Safety, Early-Term Efficacy, and Predictors of Local Recurrence.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To determine safety and early-term efficacy of CT-guided cryoablation for treatment of recurrent mesothelioma and assess risk factors for local recurrence.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27993826&#34; target=&#34;_blank&#34;&gt;Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Given the poor general condition, palliative care was initiated and the patient died from respiratory failure 3 months later.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27997741&#34; target=&#34;_blank&#34;&gt;Advances in pleuroscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To describe the technique of pleuroscopy, its clinical uses such as diagnosis of exudative pleural effusion, treatment of pleural infection, treatment of pneumothorax, and diagnosis and pleurodesis of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28003305&#34; target=&#34;_blank&#34;&gt;Co-occurring Mutations of Tumor Suppressor Genes, &lt;i&gt;LATS2&lt;/i&gt; and &lt;i&gt;NF2&lt;/i&gt;, in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cell proliferation, viability, apoptosis, mobility, and invasion were determined after siRNA knockdown or YAP (verteporfin), mTOR (rapamycin), and mTOR/PI3K/AKT (PF-04691502) inhibitor treatment.&lt;b&gt;Results:&lt;/b&gt; The &lt;i&gt;LATS2&lt;/i&gt; gene was altered in 11% of MPM by point mutations and large exon deletions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28003826&#34; target=&#34;_blank&#34;&gt;Pericardial Effusion due to Primary Malignant Pericardial Mesothelioma: A Common Finding but an Uncommon Cause.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, when the pericardial effusion recurred and empirical therapy for tuberculosis failed, a pericardial window was performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28007619&#34; target=&#34;_blank&#34;&gt;Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are few effective treatment options for mesothelioma, and patients have a very poor prognosis with a median survival of &amp;lt; 12 months from diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28026144&#34; target=&#34;_blank&#34;&gt;Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The best treatment strategy of deciduoid mesothelioma is a matter of debate; nevertheless a multidisciplinary approach is currently the best option for the choice of the adequate therapeutic scheme.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28027744&#34; target=&#34;_blank&#34;&gt;Prognostic value of pretreatment volume-based quantitative &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT parameters in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the relationships between pretreatment volume-based quantitative &lt;sup&gt;18&lt;/sup&gt;F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) parameters and overall survival (OS) in patients with malignant pleural mesothelioma (MPM). […] We retrospectively reviewed data from 201 MPM patients, of whom 38 underwent surgical resection, and calculated the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), including primary tumors and nodal or distant metastatic lesions, on pretreatment &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT. […] Relationships between clinicopathological factors (age, sex, performance status, European Organization for Research and Treatment of Cancer [EORTC] score, histological subtype, TNM stage, and treatment strategy), volume-based quantitative PET/CT parameters, and OS were evaluated using a Cox proportional hazards model and log-rank test. […] In a univariate analysis of all patients, older age (p&amp;lt;0.05), high EORTC score (p&amp;lt;0.001), non-epithelioid histological subtype (p&amp;lt;0.001), high T stage (p&amp;lt;0.001), positive N/M status (p&amp;lt;0.05, p&amp;lt;0.001), advanced TNM stage (p&amp;lt;0.001), non-surgical treatment (p&amp;lt;0.001), and high SUVmax (p&amp;lt;0.001), MTV (p&amp;lt;0.001), or TLG (p&amp;lt;0.001) were associated with significantly shorter OS. […] A multivariate analysis confirmed non-epithelioid subtype (hazard ratio [HR]: 1.69, 95% confidence interval [CI]: 1.14-2.48; p&amp;lt;0.05), non-surgical treatment (HR: 0.58, 95% CI: 0.34-0.95; p&amp;lt;0.05), and high TLG (HR: 1.97, 95% CI: 1.14-3.44; p&amp;lt;0.05) as independent negative predictors. […] Pretreatment volume-based quantitative &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT parameters, especially TLG, could serve as potential surrogate markers for MPM prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28031827&#34; target=&#34;_blank&#34;&gt;Pemetrexed for epithelioid haemangioendothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After the fourth course of treatment, the disease was well controlled with a 90% reduction of the left pleural effusion. […] Additionally, there has been no report of pemetrexed for treatment of EHE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28034829&#34; target=&#34;_blank&#34;&gt;BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Taking advantage of the extensive French National Network for the Diagnosis of Malignant Pleural Mesothelioma and Rare Peritoneal Tumors and the French National Network for the Treatment of Rare Peritoneal Surface Malignancies, we collected biological material and clinical and epidemiological data for 46 patients with peritoneal mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2803935&#34; target=&#34;_blank&#34;&gt;Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clonal chromosomal abnormalities were detected in 25 patients, 19 of them studied before treatment. […] Nine patients, seven of them studied before treatment, had normal karyotypes and/or non-clonal chromosomal abnormalities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28054314&#34; target=&#34;_blank&#34;&gt;Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The tumor is characterized by a strong local invasiveness and a poor response to any single modality therapy. […] WT1 reduces malignancy of malignant mesothelioma cell lines and might be a new molecular target in mesothelioma therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28090191&#34; target=&#34;_blank&#34;&gt;Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Also, ursolic acid treatment accumulated the sub-G1 population, attenuated the expression of procapase 9, cyclin D1, pAKT, p-glycogen synthase kinase 3-alpha/beta (pGSK3α/β), β-catenin and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) and also cleaved caspase 3 and poly (ADP-ribose) polymerase (PARP) in mesothelioma cells. […] Furthermore, ursolic acid treatment blocked epithelial and mesenchymal transition (EMT) molecules by activating E-cadherin as an epithelial marker and attenuating Vimentin, and Twist as mesenchymal molecules. […] Overall, our findings suggest that ursolic acid induces apoptosis via inhibition of EMT and activation of let7b in mesothelioma cells as a potent chemotherapeutic agent for treatment of malignant mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28105159&#34; target=&#34;_blank&#34;&gt;Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM is regarded as an incurable disease, with a median survival of ~2 years following intensive multimodality treatment. […] The majority of patients with pancreatic cancer are diagnosed with an advanced stage of disease and experience a poor response to therapy. […] The present study describes a patient with synchronous, biphasic MPM and pancreatic adenocarcinoma, who was treated with a multimodal therapeutic approach with stereotactic body radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2810965&#34; target=&#34;_blank&#34;&gt;[Prognostic factors in cases of diffuse malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Among 56 cases of diffuse malignant pleural mesothelioma (including three cases from our institute and 53 reported in Japan from 1978 to 1987), we investigated several prognostic factors, such as age, sex, exposure to asbestos, smoking history, symptom duration, tuberculin skin test, localization of the lesion, pleural effusion, histologic type, metastasis, treatment and some laboratory data, concerning periods from the appearance of symptoms to death. […] In subjects receiving surgery, anticancer chemotherapy, or no treatment, the fifty percent survival period was about 16, 9, or 6 months, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-11-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28117611&#34; target=&#34;_blank&#34;&gt;Long-term outcomes of intensity-modulated radiotherapy following extra-pleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival time was 17.5 and 27.0 months since the IMRT and the initial treatment, respectively. […] However, treatment burden including acute and late toxicities should be considered in this treatment approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28125734&#34; target=&#34;_blank&#34;&gt;Identification of MiR-21-5p as a Functional Regulator of Mesothelin Expression Using MicroRNA Capture Affinity Coupled with Next Generation Sequencing.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover, in vitro experiments showed that treatment with miR-21-5p mimic reduced proliferation of MPM cell lines.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28130567&#34; target=&#34;_blank&#34;&gt;Malignant pericardial mesothelioma : A systematic review of current practice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present study is a review of the literature published in recent decades focusing on the advances in clinical manifestations, radiological findings, diagnosis, differential diagnosis, and treatment of malignant pericardial mesothelioma (MPM). […] Imaging plays an important role in the detection, characterization, staging, and posttreatment follow-up. […] Surgery is the most important treatment modality and remains palliative in most cases, while the roles of chemo- and radiotherapy are unsatisfactory. […] Multimodality treatment of surgery, chemotherapy, radiotherapy, and immunotherapy is expected to have a role in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28133237&#34; target=&#34;_blank&#34;&gt;[Malignant Pleural Mesothelioma with Excessive Inflammation and High Level of Interleukin 6 - A Case Report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the treatment was discontinued due to side effects, after which time the diarrhea, ascites, and fever became progressively more severe. […] Therefore, “anti-IL-6 therapy” may have to be tested as a potential treatment for symptoms associated with high IL-6 levels.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28139858&#34; target=&#34;_blank&#34;&gt;Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We analysed the relationship between geographic and socioeconomic factors upon survival and treatment provision in a large series of patients with MPM. […] The impact of geographic remoteness, distance from oncological multidisciplinary team (MDT) and Index of Relative Socioeconomic Advantage and Disadvantage (IRSAD) upon survival, clinical features and treatment received was analysed. […] This study provides evidence for differences in the treatment and survival according to socioeconomic status for compensated MPM patients in NSW.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28140044&#34; target=&#34;_blank&#34;&gt;Clinical Experience With Pemetrexed in Breast Cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A randomized phase II study comparing pemetrexed 600 and 900 mg/m&lt;sup&gt;2&lt;/sup&gt; with vitamin supplementation as first-line treatment for metastatic breast cancer is ongoing.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28151477&#34; target=&#34;_blank&#34;&gt;Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Understanding the expression and function of TG2 in the adaptation to the hypoxic environment may provide useful information for novel promising therapeutic options for MPM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28152555&#34; target=&#34;_blank&#34;&gt;Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Purpose&lt;/b&gt; The purpose of this paper is the retrospective analysis of endovascular therapy for the treatment of superior vena cava syndrome (SVCS) of malignant cause. […] This study focuses on the effectiveness of the therapy regarding the duration of remission, symptom control and practicability. &lt;b&gt;Materials and Methods&lt;/b&gt; From January 2003 to November 2012, therapeutic implantation of one or more stents was performed in 141 patients suffering from SVCS. […] The median survival was 101 days, and the median occlusion-free survival was 80 days. &lt;b&gt;Conclusion&lt;/b&gt; The symptomatic therapy of SVCS with endovascular stents is effective and safe. […] · Endovascular therapy is safe and effective.. &lt;b&gt;Citation Format&lt;/b&gt; · Büstgens FA, Loose R, Ficker JH et al.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28153512&#34; target=&#34;_blank&#34;&gt;Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Further studies and in vivo testing are required to confirm our preliminary in vitro results as a potential new mesothelioma therapy based on cell drug delivery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28158568&#34; target=&#34;_blank&#34;&gt;Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Interstitial lung disease (ILD) is important drug related toxicity because it commonly forced to discontinue the treatment. […] Onset of ILD in MPM varied between the first and the fifth courses of pemetrexed treatment, and the latest onset was 48 days after the last administration.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28170372&#34; target=&#34;_blank&#34;&gt;Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radiological markers of treatment response and prognostication in malignant pleural mesothelioma have limitations due to the morphology of the disease. […] Twenty studies investigated the role of serum soluble mesothelin with majority suggesting that it has variable utility as a baseline test but when measured serially correlates with treatment response and prognosis. […] However, a falling serum soluble mesothelin might correlate with treatment response and improved survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2817912&#34; target=&#34;_blank&#34;&gt;[A case of remission induced in diffuse pleural malignant mesothelioma by the treatment with cisplatin and doxorubicin].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Regression of the tumor and decrease of pleural effusion were observed after the treatment. […] Cisplatin and doxorubicin were thought to be the most active cytotoxic agents in the treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28191281&#34; target=&#34;_blank&#34;&gt;Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the present review, we categorize commonly identified genomic aberrations of mesotheliomas into their canonical pathways and discuss targeting these pathways in the context of tumor hypoxia, a hallmark of cancer known to render solid tumors more resistant to radiation and most chemo-therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28197385&#34; target=&#34;_blank&#34;&gt;Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemotherapy influences the expression of immune checkpoints and therefore further research on the best combination treatment schedule is required.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28197626&#34; target=&#34;_blank&#34;&gt;Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As such our results demonstrate that whilst members of the Kdm6 family are overexpressed in MPM they may not be suitable candidates for therapy and may elicit a cytokine storm.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28197653&#34; target=&#34;_blank&#34;&gt;Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two sets of volumetric modulated arc therapy (VMAT) treatment plans were generated: a “selective” pleural irradiation plan (SPI plan) and an “elective” pleural irradiation plan (EPI plan, planned with a simultaneous integrated boost technique [SIB]). […] This strategy may form the basis for nonsurgical radical combined modality treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28205183&#34; target=&#34;_blank&#34;&gt;Large primary pleural synovial sarcoma with severe dyspnea: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We suspected there was microscopic residual tumor in the left diaphragm and therefore performed radiation therapy. […] Although the best treatment for this rare condition has not been defined, we thought that tumor resection and adjuvant therapy were appropriate to control the disease in this case.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28210162&#34; target=&#34;_blank&#34;&gt;Modern management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Curative therapy for MPM remains elusive, and the primary treatment option for fit patients is platinum-based chemotherapy. […] Selected patients may be considered for aggressive surgical approaches, but there is considerable controversy regarding the true benefit of surgery and multimodality therapy in this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28213002&#34; target=&#34;_blank&#34;&gt;A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Following failure of a platinum-antifolate combination regimen, there is no standard therapy for advanced malignant pleural mesothelioma (MPM). […] This open-label multicentre phase II trial [NCT01769547] enrolled fit, consenting adult patients with advanced MPM who had previously received platinum-antifolate combination chemotherapy and up to one additional line of systemic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28213004&#34; target=&#34;_blank&#34;&gt;Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
IPHC with cisplatin showed favorable pharmacokinetic profiles for an optional treatment to control malignant pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2821313&#34; target=&#34;_blank&#34;&gt;Pleural carcinogenic potency of mineral fibers (asbestos, attapulgite) and their cytotoxicity on cultured cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with amosite and crocidolite resulted in the occurrence of 57 and 56% of mesotheliomas. […] Acid-treatment of amphiboles did not significantly modify the percentage of mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-11-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28223167&#34; target=&#34;_blank&#34;&gt;Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite the established ability of T4 immunotherapy to elicit cytokine release syndrome in SCID Beige mice, therapy was very well tolerated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28237609&#34; target=&#34;_blank&#34;&gt;Radiation therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of malignant pleural mesothelioma with radiation has always been a technical challenge. […] For many years, conventional radiation therapy was delivered after extrapleural pneumonectomy with acceptable results. […] Novel radiation treatment techniques, such as intensity modulated radiation therapy (IMRT) were introduced, but the early experience with IMRT demonstrated troubling toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28254624&#34; target=&#34;_blank&#34;&gt;Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Complete and homogeneous illumination of the target is necessary for the success of a photodynamic therapy (PDT) procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28274663&#34; target=&#34;_blank&#34;&gt;Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We analyzed our 10-year experience in the treatment of early stage mesothelioma with surgery and Hyperthermic IntraTHOracic Chemotherapy. […] Our lung sparing approach for the treatment of pleural mesothelioma in early stages allows promising long term outcomes with a complete sparing of pulmonary and diaphragmatic function.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28274690&#34; target=&#34;_blank&#34;&gt;The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a devastating neoplasm; however, some patients exhibit a good response to chemotherapy or multidisciplinary therapy, including surgery and chemotherapy. […] It is therefore important to discover the factors that can be used to select patients who will benefit from such treatment. […] The data of 83 patients, who were treated with surgery, chemotherapy, or multidisciplinary therapy, were analyzed in the present study. […] This score provides useful information for selecting patients who will benefit from the treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28288645&#34; target=&#34;_blank&#34;&gt;Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis of lung cancer and mesothelioma is extremely poor due to limited treatment modalities and lack of understanding of the disease mechanisms. […] Since EMT is an important process in tumor progression and metastasis, and MSLN is nonessential in most normal tissue, our findings on MSLN may provide new insights into the disease mechanisms and may aid in the development of novel targeted therapy for lung cancer and mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28289860&#34; target=&#34;_blank&#34;&gt;The PD-L1/PD-1 pathway promotes dysfunction, but not “exhaustion”, in tumor-responding T cells from pleural effusions in lung cancer patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PD-L1 was up-regulated in lung cancer cell lines upon treatment with IFN-gamma, but not under hypoxic conditions, as detected by RT-qPCR and flow cytometry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28291584&#34; target=&#34;_blank&#34;&gt;Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few treatment options following progression on platinum-containing chemotherapy. […] Key eligibility criteria included measurable disease, failure of standard therapy, and Eastern Cooperative Oncology Group performance status of 0 or 1. […] As of June 20, 2016, 25 patients received pembrolizumab. 16 (64%) patients reported a treatment-related adverse event; the most common adverse event were fatigue (six [24%]), nausea (six [24%]), and arthralgia (five [20%]). […] Five (20%) patients reported grade 3 treatment-related adverse events. […] No treatment-related deaths or discontinuations occurred. […] Responses were durable (median response duration 12·0 months [95% CI 3·7 to not reached]); two patients remained on treatment at data cutoff.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28293123&#34; target=&#34;_blank&#34;&gt;Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the approval of checkpoint blockade immunotherapy has shifted the treatment paradigm and provides hope for improved survival. […] In early studies, treatment with pembrolizumab led to dramatic and durable responses in select patients (PD-L1+ tumors). […] Most recently, data in the first-line setting from the KEYNOTE-024 study have redefined the SOC therapy for a selected subset of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28298401&#34; target=&#34;_blank&#34;&gt;Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumour thickness was assessed to determine if this parameter could refine patients’ selection for multimodality therapy in malignant pleural mesothelioma.We reviewed 65 consecutive treatment-naïve malignant pleural mesothelioma patients undergoing surgery for mesothelioma after radiation therapy (SMART). […] This parameter could potentially be used to refine the clinical staging of malignant pleural mesothelioma and optimise patient selection for radical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28335760&#34; target=&#34;_blank&#34;&gt;Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In contrast, elevated baseline levels of midkine were independently associated with a poor prognosis of mesothelioma patients after adjusting for the stage, the histological subtypes and treatment schedules (HR = 1.84; 95% CI: 1.09-3.09) (p = 0.022).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28337371&#34; target=&#34;_blank&#34;&gt;Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover, targeting MET and EGFR drugs have gained promising results on anti-tumor therapy. […] In addition, treatment with combination of crizotinib and afatinib showed stronger inhibition on cell proliferation of MPM than the treatment by either one in vitro and in vivo.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28341225&#34; target=&#34;_blank&#34;&gt;Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, we compare our institutional multimodality therapy experience of adjuvant chemotherapy and hemithoracic intensity-modulated pleural RT (IMPRINT) with previously used adjuvant conventional RT (CONV) in patients with malignant pleural mesothelioma (MPM) treated with lung-sparing pleurectomy/decortication (P/D). […] Univariate analysis and multivariate analysis were performed with relevant clinical and treatment factors. […] Patients receiving IMPRINT had significantly higher rates of the epithelial histological type, advanced pathological stage, and chemotherapy treatment. […] Trimodality therapy including adjuvant hemithoracic IMPRINT, chemotherapy, and P/D is associated with promising OS rates and decreased toxicity in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28342657&#34; target=&#34;_blank&#34;&gt;Targeting BAP1: a new paradigm for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New treatment strategies for malignant pleural mesothelioma (MPM) are important. […] BAP1 mutations are present in 47-67% of the MPM tumors, making this a good target for treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28348450&#34; target=&#34;_blank&#34;&gt;A Novel Panel of Serum Biomarkers for MPM Diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These results, if confirmed in a larger series, may have a strong impact in this area, because early detection of this cancer in people at high risk could significantly improve the course of the disease and the clinical approach to an individualized therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28371288&#34; target=&#34;_blank&#34;&gt;Intensity modulated radiation therapy after extra-pleural pneumonectomy for malignant pleural mesothelioma is feasible without fatal pulmonary toxicity and provides good survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To analyze patterns of failure, toxicity, relapse-free survival (RFS), and overall survival (OS) in malignant pleural mesothelioma (MPM) patients treated with intensity-modulated radiation therapy following extrapleural pneumonectomy (EPP). […] We reviewed 18 charts of patients with MPM from 2005 to 2014 who underwent EPP followed by hemithoracic intensity-modulated radiation therapy. […] Intensity-modulated radiation therapy dose delivery adhered to published lung dose constraints. […] Intensity-modulated radiation therapy following EPP for MPM resulted in RFS and OS comparable to the published literature without significant toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28388291&#34; target=&#34;_blank&#34;&gt;Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Conclusion Target engagement with depletion of arginine was maintained throughout treatment with no dose-limiting toxicities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28389374&#34; target=&#34;_blank&#34;&gt;A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM cell lines expressing more than 20% of BAP1Δ are more sensitive to olaparib (a PARP1 inhibitor) cytotoxicity, and this sensitivity is enhanced when olaparib treatment is combined with GDC0980 (a dual PI3K-mTOR inhibitor), which induces downregulation of BRCA1.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28399779&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A significant difference in survival was observed in patients undergoing surgery versus no surgery (p = .008), between the different histological types (p &amp;lt; .0001) and treatment with chemotherapy alone versus chemotherapy with surgery (p &amp;lt; .0001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28410823&#34; target=&#34;_blank&#34;&gt;The case for performing pleural biopsies for the aetiological diagnosis of exudates. Yes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural biopsies are especially indicated in the following circumstances: a) inconclusive pleural fluid analysis and negative sputum study, if adenosine deaminase (ADA) levels are unavailable; b) suspected multi-resistant tuberculosis; c) a need for differentiating tuberculous pleurisy (if it progresses with neutrophilia) and complicated parapneumonic effusion; d) malignant pleural effusion coexisting with very high ADA levels; e) effusion coexisting with lung cancer and negative pleural cytology; f) suspected mesothelioma; and g) need for implementing re-treatment for patients with relapse after chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28415584&#34; target=&#34;_blank&#34;&gt;Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Implementing this marker profile in MPM stratification may help to individualize MPM-therapy more efficiently.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28419212&#34; target=&#34;_blank&#34;&gt;Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate the outcome after multimodality treatment of MPM involving different types of P/D and to analyse the prognostic factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28426148&#34; target=&#34;_blank&#34;&gt;Three-dimensional finite-element based deformable image registration for evaluation of pleural cavity irradiation during photodynamic therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) is used after surgical resection to treat the microscopic disease for malignant pleural mesothelioma and to increase survival rates. […] In this study, a three-dimensional finite element-based (3D FEM) deformable image registration is proposed to directly match the volume of lung to the volume of pleural cavity obtained during PDT to have accurate representation of the light fluence accumulated in the lung, heart and liver (organs-at-risk) during treatment. […] A wand, comprised of a modified endotrachial tube filled with Intralipid and an optical fiber inside the tube, is used to deliver the treatment light. […] The position of the treatment is tracked using an optical tracking system with an attachment comprised of nine reflective passive markers that are seen by an infrared camera-based navigation system. […] Implementing this method in real-time for clinical applications and in situ monitoring of the under- or over- exposed regions to light during PDT can significantly improve the treatment for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28435296&#34; target=&#34;_blank&#34;&gt;Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. […] This combination is now included in the National Comprehensive Cancer Network guidelines (with a category 2A recommendation) as a possible first-line treatment for unresectable MPM in appropriately selected patients. […] The use of small-molecule inhibitors of angiogenesis in the treatment of MPM is also discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28439676&#34; target=&#34;_blank&#34;&gt;Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A retrospective review was conducted of 59 consecutive patients who underwent bi-/tri-modal treatment with induction chemotherapy, EPP, and radiation therapy from July 2004 to August 2013 at Hyogo College of Medicine (Nishinomiya, Japan). […] Additional systemic chemotherapy was successfully administered in more than 50% of relapsed patients after bi-/tri-modal treatment, which included EPP, and resulted in a longer survival in comparison with best supportive care alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28460459&#34; target=&#34;_blank&#34;&gt;Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the present study, 1562 tumors were immunohistochemically analyzed for mesothelin expression using two different types of mouse monoclonal antibodies (5B2 and MN-1) to determine the clinical usefulness of mesothelin immunohistochemistry as well as to pinpoint potential targets for future anti-mesothelin therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28462689&#34; target=&#34;_blank&#34;&gt;Intensity-Modulated Radiation Therapy Improves the Target Coverage Over 3-D Planning While Meeting Lung Tolerance Doses for All Patients With Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate high conformality on target coverage and the ability on creating strict lung dose limitation of intensity-modulated radiation therapy in malignant pleural mesothelioma. […] Twenty-four radiation therapy plannings were evaluated and compared with dosimetric outcomes of conformal radiation therapy and intensity-modulated radiation therapy. […] Hemithoracal radiation therapy was performed on 12 patients with a fraction of 1.8 Gy to a total dose of 50.4 Gy. […] Radiotherapy plannings were differed according to the technique; conformal radiation therapy was planned with conventionally combined photon-electron fields, and intensity-modulated radiation therapy was planned with 7 to 9 radiation beam angles optimized in inverse planning. […] Intensity-modulated radiation therapy was statistically superior in target coverage and dose homogeneity (intensity-modulated radiation therapy-planning target volume 95 mean 100%; 3-dimensional conformal radiation therapy-planning target volume 95 mean 71.29%, P = .0001; intensity-modulated radiation therapy-planning target volume 105 mean 11.14%; 3-dimensional conformal radiation therapy-planning target volume 105 mean 35.69%, P = .001). […] The dosimetric results of the remaining lung was below the limitations on intensity-modulated radiation therapy planning data (intensity-modulated radiation therapy-lung mean dose mean 7.5 [range: 5.6%-8.5%]; intensity-modulated radiation therapy-lung V5 mean 55.55% [range: 47%-59.9%]; intensity-modulated radiation therapy-lung V20 mean 4.5% [range: 0.5%-9.5%]; intensity-modulated radiation therapy-lung V13 mean 13.43% [range: 4.2%-22.9%]). […] With a complex and large target volume of malignant pleural mesothelioma, intensity-modulated radiation therapy has the ability to deliver efficient tumoricidal radiation dose within the safe dose limits of the remaining lung tissue.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28464918&#34; target=&#34;_blank&#34;&gt;Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Apoptosis (PARP cleavage in 211H xenografts; Bcl-2 downregulation, and cleavage of PARP and caspase 3 in H226 xenografts; positive TUNEL staining in both) and G1 arrest (downregulation of cyclin A2, D3, E1 and CDK4 in 211H xenografts; suppression of cyclin A2, E1, H and CDK4 in H226 xenografts) were evident with BCT-100 treatment. […] The findings provide scientific evidence to support further clinical development of BCT-100 in treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28468780&#34; target=&#34;_blank&#34;&gt;Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses &lt;i&gt;NF2&lt;/i&gt; Loss-Driven Tumorigenesis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To develop a targeted therapy for &lt;i&gt;NF2&lt;/i&gt;-mutant tumors, we have exploited the recent realization that Merlin loss drives tumorigenesis by activating the E3 ubiquitin ligase CRL4&lt;sup&gt;DCAF1&lt;/sup&gt;, thereby inhibiting the Hippo pathway component Lats. […] Further analysis revealed that depletion of DCAF1 or treatment with MLN4924 does not affect mTOR hyperactivation in &lt;i&gt;NF2&lt;/i&gt;-mutant tumor cells, suggesting that loss of Merlin activates mTOR independently of CRL4&lt;sup&gt;DCAF1&lt;/sup&gt; Intriguingly, combining MLN4924 with the mTOR/PI3K inhibitor GDC-0980 suppresses the growth of &lt;i&gt;NF2&lt;/i&gt;-mutant tumor cells &lt;i&gt;in vitro&lt;/i&gt; as well as in mouse and patient-derived xenografts.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28469343&#34; target=&#34;_blank&#34;&gt;Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Bimodal treatment was stared with cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy procedure, followed by pemetrexed systemic monotherapy. […] After the disease progression, and because of a very good previous treatment response to pemetrexed, we decided to rechallenge systemic pemetrexed, along with the introduction of cisplatin. […] Although the intent behind systemic treatment was at first solely palliative, overall survival after the initial diagnosis was 50 months. […] Treatment based on rechallenging pemetrexed with or without cisplatin in patients with advanced DMPM can result in a quite satisfactory disease control and symptom management.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28470935&#34; target=&#34;_blank&#34;&gt;Targeting YAP in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is an aggressive cancer that is resistant to current therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28472807&#34; target=&#34;_blank&#34;&gt;Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments. […] Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. […] Response to therapy, progression-free survival, and overall survival were evaluated. 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. […] Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. […] A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. […] Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28481375&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma in household members of asbestos-exposed workers in Friuli Venezia Giulia, Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The overall mean survival was 16 months (median 11 months) but treatment was beneficial (mean 16 months vs. 7 months).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28482086&#34; target=&#34;_blank&#34;&gt;Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While the best approach to malignant pleural mesothelioma has yet to be demonstrated, surgery remains the mainstay of treatment. […] We analysed a group of candidates for trimodality treatment, aiming to identify prognostic factors guiding patient selection. […] Between 2003 and 2015, 83 (31.6%) of the 283 patients with malignant pleural mesothelioma were considered for trimodality treatment to perform induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy. […] The trimodality treatment was completed in 37 (44.6%) patients. […] Median overall survival was 35.6 months, with 1- and 3-year overall survival of 82% and 48% for patients who completed the trimodality treatment compared with 32% and 14% for patients who did not undergo radiotherapy. […] Only 45% of patients completed the planned trimodality treatment, and morbidity/mortality remained high. […] Nonetheless, the patients who completed treatment showed good loco-regional disease control and better overall survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28496089&#34; target=&#34;_blank&#34;&gt;[Malignant Pleural Mesothelioma Presenting Refractory Pneumothorax Successfully Treated by Intrapleural Administration of Diluted Fibrin Glue;Report of a Case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
But air leakage continued, and the surgery was performed, however the treatment failed to stop the air leakage. […] Finally, the intrapleural administration of diluted fibrin glue was challenged and the air leakage stopped immediately after the treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28502785&#34; target=&#34;_blank&#34;&gt;CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunotherapy is a promising field that harnesses the power of the immune system as a therapeutic agent for cancer treatment. […] Beneficial outcomes shown in patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM) with relatively higher tumor-infiltrating T cells, combined with impressive responses obtained in a cohort of patients with NSCLC following checkpoint blockade therapy, lays a strong foundation to promote effector immune responses in these patients. […] This review summarizes target antigens for CAR T-cell therapy that are being investigated in preclinical studies and clinical trials for both NSCLC and MPM patients. […] Additionally, we have highlighted the challenges and strategies for overcoming the obstacles facing translation of CAR T-cell therapy to solid tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28507279&#34; target=&#34;_blank&#34;&gt;Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin is beneficial to detect the progression and the treatment response of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28517082&#34; target=&#34;_blank&#34;&gt;SU-E-T-595: Comparison of Volumetric Modulated Arc Therapy (VMAT) and Static Intensity Modulated Radiotherapy (IMRT) for Malignant Pleural Mesothelioma in Patients with Intact Lungs/Post Pleurectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Both VMAT and IMRT are feasible techniques for the treatment of malignant pleural mesothelioma with intact lungs, with less MU and a shorter delivery time for VMAT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28528059&#34; target=&#34;_blank&#34;&gt;Diode-Pumped Laser for Lung-Sparing Surgical Treatment of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection represents one of the essential cornerstones in multimodal treatment of malignant pleural mesothelioma. […] Innovative surgical techniques are therefore required to enable salvage of the lung parenchyma and optimization of surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28529903&#34; target=&#34;_blank&#34;&gt;Immunotherapy and radiation therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early investigations of interleukin-2 (IL-2) and interferon alfa-2a/b have been limited by modest response rates and toxicity, whereas cytokine gene therapy is currently being investigated and shows early promise. […] With the increasing recognition of the immune potential of mesothelioma, interest in the immunomodulatory properties of radiation therapy has emerged. […] The combination of immunotherapy and radiation therapy may allow for complimentary immunologic effects that can enhance antitumor response. […] This article reviews the existing literature on the efficacy of immunotherapy for MPM, describes the rationale for combining immunotherapy with radiation therapy, and discusses early literature on this treatment combination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28536345&#34; target=&#34;_blank&#34;&gt;Viroimmunotherapy of Thoracic Cancers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, intense research is now underway to rationally develop combination therapies to expand the range of patients who will respond to and benefit from immune therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28545562&#34; target=&#34;_blank&#34;&gt;The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Persistence of tumor-initiating cells (TICs, or cancer stem cells) after cytotoxic drug treatment is responsible for tumor relapse, and represents one of the main reasons for the poor prognosis of mesothelioma. […] Western blotting was performed to reveal the modulation of protein expression and the phosphorylation status of pathways associated with sorafenib treatment. […] Patients with constitutive FGFR1 activation via an autocrine loop may be more sensitive to sorafenib treatment and the analysis of this possibility warrants further clinical investigation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28558669&#34; target=&#34;_blank&#34;&gt;Calretinin as a blood-based biomarker for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Calretinin and mesothelin were determined by ELISA (enzyme-linked immunosorbent assay) in serum or plasma collected prior to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28560410&#34; target=&#34;_blank&#34;&gt;DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Furthermore, XML184 and XMD8-92 treatment impaired invasion and tumor sphere formation ability of H290 mesothelioma cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28562336&#34; target=&#34;_blank&#34;&gt;Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our results suggest that the combined targeting of MDM2 and TRAIL might provide a novel therapeutic option for treatment of MPM patients, particularly in the case of sarcomatoid MPM with MDM2 overexpression and functional inactivation of wild-type p53.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28580813&#34; target=&#34;_blank&#34;&gt;Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Areas covered: This article focuses on the multimodality treatment of mesothelioma. […] A systematic review was performed by using electronic databases to identify studies that considered induction and adjuvant approaches in MPM therapy in a multidisciplinary setting, including surgery. […] Expert commentary: This systematic review offers a comprehensive view of current multidisciplinary therapeutic strategies for MPM, suggesting that multimodality therapy offers acceptable outcomes with better results reported for trimodality approaches. […] Individualization of care for each patient is fundamental in choosing the most appropriate treatment. […] The growing complexity of treatment protocols mandates that MPM patients be referred to specialized Centers, in which every component of the interdisciplinary team can provide the necessary expertise and quality of care.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28590338&#34; target=&#34;_blank&#34;&gt;Surgery as part of radical treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It should be part of multimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28594258&#34; target=&#34;_blank&#34;&gt;First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma of peritoneal origin has wider variation in treatment outcomes than mesothelioma of pleural origin, likely because peritoneal mesothelioma comprises borderline malignant variants and aggressive malignant peritoneal mesothelioma (MPeM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28600498&#34; target=&#34;_blank&#34;&gt;Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In order to broaden the knowledge in this field, the miRNA expression was investigated in a large series of MPM to discover new pathways helpful in diagnosis, prognosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28634559&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma with Marked Lymphatic Involvement: A Report of Two Autopsy Cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
They received chemotherapy, but the treatment was only palliative.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28652837&#34; target=&#34;_blank&#34;&gt;A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a rare malignancy with a dismal median survival of &amp;lt;12 months with current therapy. […] We investigated the role of zoledronic acid in a pilot, single-arm trial of MPM patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 who had progressed on prior treatments or had not received systemic therapy due to poor PS. […] Exploratory end points include the effect of zoledronic acid therapy on vascular endothelial growth factor (VEGF), basic fibroblast growth factor, interleukin 8, transforming growth factor beta, mesothelin, and osteopontin levels. […] No treatment-related toxicities were observed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28669341&#34; target=&#34;_blank&#34;&gt;JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, the pharmacological modulation of BET activity could represent a promising tool for future MPM therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28676211&#34; target=&#34;_blank&#34;&gt;Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The combination of bevacizumab with PC chemotherapy is not a cost-effective treatment option for MPM in China.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28679291&#34; target=&#34;_blank&#34;&gt;Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three main areas are discussed: immunotherapy (immune checkpoint blockade and cancer vaccines, among others), multitargeted therapy (such as targeting pro-angiogenic genes) and gene therapy (such as suicide gene therapy).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28681207&#34; target=&#34;_blank&#34;&gt;Optimal Therapy of Advanced Stage Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The optimal treatment of patients with advanced malignant pleural mesothelioma (MPM) has not yet been discovered. […] The personalization of treatment by cell cultures and pathway analysis attracts more attention nowadays. […] It is conceivable that in the near future the treatment of patients with MPM will consist of a combination of IO drugs or specific pathway inhibitors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28686500&#34; target=&#34;_blank&#34;&gt;Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These guidelines are meant to be a practical diagnostic reference for the pathologist; however, some new pathologic predictors of prognosis and response to therapy are also included.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28687356&#34; target=&#34;_blank&#34;&gt;Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study shows that germline variants in several genes may increase MPM susceptibility in the presence of asbestos exposure and may be important for specific treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28690011&#34; target=&#34;_blank&#34;&gt;LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Standard first-line treatment for patients with unresectable MPM is cisplatin/pemetrexed, with a median overall survival (OS) of approximately 1 year. […] Improvements in first-line treatment options are needed. […] With the benefit of combining bevacizumab with standard therapy shown in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS), vascular endothelial growth factor (VEGF) pathway inhibition has gained renewed interest as a treatment approach. […] Patients without disease progression who are eligible to continue study treatment will receive maintenance treatment with nintedanib or placebo until disease progression or undue toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28697647&#34; target=&#34;_blank&#34;&gt;Antimetabolites in the treatment of advanced pleural mesothelioma: a network meta-analysis of randomized clinical trials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CP and CR can be considered comparable in terms of efficacy in the treatment of metastatic pleural mesothelioma, with a modest increased risk of grade III-IV side effects for CP.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28704484&#34; target=&#34;_blank&#34;&gt;Apoptosis by [Pt(O,O’-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The worst prognosis is associated with sarcomatoid phenotype and resistance to therapy is affected by cells heterogeneity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28704762&#34; target=&#34;_blank&#34;&gt;Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After palbociclib treatment, the sequential association with PI3K inhibitors synergistically hampered cell proliferation and strongly increased the percentage of senescent cells. […] These findings suggest that the sequential association of palbociclib with PI3K inhibitors may represent a valuable therapeutic option for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706898&#34; target=&#34;_blank&#34;&gt;The impact of surgical approach on quality of life for pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Given the need for multimodality therapy and the aggressive nature of MPM, QoL outcomes should be strongly considered when recommending type of surgery for patients with this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706899&#34; target=&#34;_blank&#34;&gt;Intra-abdominal manifestations of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, after aggressive local-regional treatment using surgery, regional chemotherapy, radiation therapy, and systemic chemotherapy, metastases outside of the pleural space may become the chief obstacle to long-term survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706900&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy (EPP) &lt;i&gt;vs.&lt;/i&gt; pleurectomy decortication (P/D).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical techniques for treatment of malignant pleural mesothelioma (MPM) have improved over the decades. […] Completion of multimodality treatment was also shown to be a prognostic factor. […] However, neither surgical technique (EPP &lt;i&gt;vs.&lt;/i&gt; P/D), nor types of multimodality treatment protocols were found to be prognostic in MPM. […] Epithelioid histology, metastasis to extrapleural lymph nodes and completion of multimodality treatment were prognostic in most of the series. […] In conclusion, based on the current evidence, the choice of a less morbid and mortal procedure (P/D) seems to be the logical choice in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706901&#34; target=&#34;_blank&#34;&gt;Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality therapy including surgical macroscopic complete resection is performed to treat operable MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706903&#34; target=&#34;_blank&#34;&gt;Overview of treatment related complications in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite recent advances in therapy for MPM, the prognosis remains poor, with considerable treatment associated morbidity. […] Radiological assessment plays a central role in the timely identification and subsequent management of treatment related complications in MPM. […] This review highlights common and uncommon complications associated with and encountered in the post treatment phase.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706904&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While treatment advances have been made for MPM, the disease is universally fatal from either abdominal complications secondary to the spread of disease or starvation. […] Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) has become the mainstay of therapy with systemic therapies still being developed. […] We will review the epidemiology of MPM and discuss diagnostic and treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706905&#34; target=&#34;_blank&#34;&gt;A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality treatment including macroscopic complete resection (MCR) is currently the most effective therapy for patients with malignant pleural mesothelioma (MPM). […] In the past years, relevant new information about the disease and the outcome of different treatment modalities have been generated, which allows a more individual allocation to the best treatment. […] For many years extrapleural pneumonectomy (EPP)-the most aggressive procedure to achieve a MCR-was the first choice in combination with adjuvant or neo-adjuvant chemotherapy and radiation therapy for all patients except those with minimal disease. […] But also today, EPP is still a valuable option in selected cases and the entire treatment concept requires a nuanced view, which will be discussed in this review.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706909&#34; target=&#34;_blank&#34;&gt;Volumetric assessment in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical staging allows for selection of patients for treatment strategies, but has not been found to be prognostic and is plagued by high interobserver variability.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706910&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: adjuvant therapy with radiation therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is a challenge to treat malignant pleural mesothelioma with radiation therapy (RT). […] Intensity modulated radiation therapy (IMRT) has been used, but some of the early experiences revealed fatal toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706913&#34; target=&#34;_blank&#34;&gt;Novel immunotherapy clinical trials in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current clinical trials modulating the MPM immune microenvironment and the combination of these novel agents with standard of care therapy provide a promising area of investigation for MPM therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28713674&#34; target=&#34;_blank&#34;&gt;Intraoperative adjuncts for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Novel intraoperative adjunctive therapies including heated intraoperative chemotherapy (HIOC), heated intraoperative povidone-iodine (PVP-I), and photodynamic therapy (PDT) target micrometastatic disease and aim to improve local control.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28713675&#34; target=&#34;_blank&#34;&gt;Novel systemic therapy against malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Standard first-line systemic treatment consists of a platinum analog, an anti-metabolite, and sometimes anti-angiogenic therapy, but there is currently no well-established standard therapy for refractory or relapsed disease. […] This review focuses on efforts to develop improved systemic therapy for the treatment of malignant pleural mesothelioma (MPM) including cytotoxic systemic therapy, a variety of tyrosine kinase inhibitors and their downstream effector pathways, pharmacologic targeting of the epigenome, novel approaches to target proteins expressed on mesothelioma cells (such as mesothelin), arginine depletion therapy, and the emerging role of immunotherapy. […] Overall, these studies demonstrate the challenges of improving systemic therapy for MPM and highlight the need to develop therapeutic strategies to control this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28713676&#34; target=&#34;_blank&#34;&gt;Immunotherapy for malignant pleural mesothelioma: current status and future directions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current standard of care for this deadly disease results in sub-optimal improvements in overall survival (OS), which has prompted researchers to explore innovative treatment alternatives. […] Using ClinicalTrials.gov we searched the terms “immunotherapy” and “immune therapy” combined with “pleural mesothelioma”. […] Our search identified immune checkpoint blockade, immunotoxin therapy, anticancer vaccines, oncolytic viral therapy, and adoptive cell therapy as the most common and pertinent methods of immunotherapy currently being assessed in clinical trials. […] We have reviewed the most up-to-date clinical trials involving immunotherapeutic approaches for the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28713677&#34; target=&#34;_blank&#34;&gt;Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Novel radical radiation techniques using intensity modulated radiation therapy (IMRT) have become an important component of therapy in mesothelioma. […] However, how best to integrate immunotherapy with standard therapy such as radiation, chemotherapy and surgery remains unknown. […] The integration of immunotherapy into a multimodality approach is opening new avenue of treatment for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28713678&#34; target=&#34;_blank&#34;&gt;Drug development against the hippo pathway in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Conventional cytotoxic drugs fail in MPM in part because they do not address the cancer stem cell population or stem cell pathways that drive tumor resistance and resurgence following treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28713680&#34; target=&#34;_blank&#34;&gt;Targeting the epigenome in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesotheliomas (MPM) are notoriously refractory to conventional treatment modalities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28715648&#34; target=&#34;_blank&#34;&gt;Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
TUSC2 restoration has been exploited as an anti-cancer therapy in various cancers in preclinical models, and clinically in patients with lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28727277&#34; target=&#34;_blank&#34;&gt;High-dose palliative radiotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
High-dose radiotherapy to the hemithorax for patients with malignant pleural mesothelioma is a controversial treatment. […] There were two, possibly three, treatment-related deaths.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28729154&#34; target=&#34;_blank&#34;&gt;Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients were randomly assigned (2:1) in blocks of three, stratified by European Organisation for Research and Treatment of Cancer status (low risk vs high risk), line of therapy (second line vs third line), and anatomic site (pleural vs peritoneal), by use of an interactive voice or web system, to receive intravenous tremelimumab (10 mg/kg) or placebo every 4 weeks for 7 doses and every 12 weeks thereafter until a treatment discontinuation criterion was met. […] Between May 17, 2013, and Dec 4, 2014, 571 patients were randomly assigned to receive tremelimumab (n=382) or placebo (n=189), of whom 569 patients received treatment (two patients in the tremelimumab group were excluded from the safety population because they did not receive treatment). […] Median overall survival in the intention-to-treat population did not differ between the treatment groups: 7·7 months (95% CI 6·8-8·9) in the tremelimumab group and 7·3 months (5·9-8·7) in the placebo group (hazard ratio 0·92 [95% CI 0·76-1·12], p=0·41). […] Treatment-emergent adverse events of grade 3 or worse occurred in 246 (65%) of 380 patients in the tremelimumab group and 91 (48%) of 189 patients in the placebo group; the most common were dyspnoea (34 [9%] patients in the tremelimumab group vs 27 [14%] patients in the placebo group), diarrhoea (58 [15%] vs one [&amp;lt;1%]), and colitis (26 [7%] vs none). […] Treatment-emergent events leading to death occurred in 36 (9%) of 380 patients in the tremelimumab group and 12 (6%) of 189 in the placebo group; those leading to the death of more than one patient were mesothelioma (three [1%] patients in the tremelimumab group vs two [1%] in the placebo group), dyspnoea (three [1%] vs two [1%]); respiratory failure (one [&amp;lt;1%] vs three [2%]), myocardial infarction (three [1%] vs none), lung infection (three [1%] patients vs none), cardiac failure (one [&amp;lt;1%] vs one [&amp;lt;1%]), and colitis (two [&amp;lt;1%] vs none). […] Treatment-related adverse events leading to death occurred in five (1%) patients in the tremelimumab group and none in the placebo group.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28730230&#34; target=&#34;_blank&#34;&gt;Magnetic nanoparticles-based therapy for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
They highlighted a strong antitumor effect of the SaMNPs on the rat and human MPM cells and open new perspectives in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28740930&#34; target=&#34;_blank&#34;&gt;Functional image guided radiation therapy planning in volumetric modulated arc therapy for patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the incorporation of functional lung image-derived low-attenuation area (LAA) based on 4-dimensional computed tomography (4D-CT) in volumetric modulated arc therapy (VMAT) planning for patients with malignant pleural mesothelioma (MPM) after extrapleural pneumonectomy. […] Two radiation therapy plans were designed: (1) Plan C, conventional VMAT and (2) Plan F, functional VMAT plan based on the functional lung. […] LAA-based functional image guided radiation therapy planning in VMAT is a feasible method to spare the functional lung in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28756516&#34; target=&#34;_blank&#34;&gt;Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesotheliomas (MPM) are most often surgically unresectable, and they respond poorly to current chemotherapy and radiation therapy. […] More importantly, these data demonstrate that the PARP1 inhibitors could be effective in the treatment of MPM, for which little effective therapy exists.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28789867&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma segmentation for photodynamic therapy planning.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This paper presents a method that detects the MPM in the thoracic cavity and plans the photodynamic therapy in the preoperative phase. […] Finally, the contact surface between the tumor region and the thoracic cavity curves is reconstructed in order to plan the photodynamic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28790839&#34; target=&#34;_blank&#34;&gt;Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy of malignant pleural mesothelioma and especially the adequate role of surgery in this context remain the subject of controversial discussions. […] ITP-F for patients with advanced pleural mesothelioma, progressive after standard therapies, is an effective and well-tolerated treatment modality, offering comparably long survival data at a good QoL.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28800871&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy, with a response rate of 20% of patients and for this reason an efficient treatment is still a challenge. […] Platinum-based chemotherapy in association with a third-generation antifolate is the front-line standard of care whereas any second-line treatment was approved for MPM thus making it a pathology that evokes the need for new therapeutic agents. […] Different platinum-drugs were synthesised and tested as an option for patients who are not candidates to cisplatin-based therapy. […] Alternative strategies to the commonly used combination-therapy resulted from the use of Mesenchymal Stromal Cells (MSC) widely used in the field of regenerative medicine and recently proposed as natural carriers for a selective delivery of chemotherapeutic agents and from the use of immune checkpoint and kinase inhibitors. […] The present short review shed light on the recent state of art and the future perspectives relative to MPM therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-12-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28811252&#34; target=&#34;_blank&#34;&gt;Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, a combination of these 2 markers might be useful for prognostication and planning the treatment of patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28816162&#34; target=&#34;_blank&#34;&gt;Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To determine clinically helpful dose-volume and clinical metrics correlating with symptomatic radiation pneumonitis (RP) in malignant pleural mesothelioma (MPM) patients with 2 lungs treated with hemithoracic intensity modulated pleural radiation therapy (IMPRINT). […] Treatment plans and resulting normal organ dose-volume histograms of 103 consecutive MPM patients treated with IMPRINT (February 2005 to January 2015) to the highest dose ≤50.4 Gy satisfying departmental normal tissue constraints were uniformly recalculated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28817374&#34; target=&#34;_blank&#34;&gt;Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our purpose was to evaluate survival after treatment of MPM with cancer-directed surgery and to explore the effect surgery interaction with chemotherapy or radiation therapy on survival by using the National Cancer Database. […] Results Of 20,561 patients with MPM, 6,645 were identified in the matched cohort, among whom 2,166 underwent no therapy, 2,015 underwent chemotherapy alone, 850 underwent cancer-directed surgery alone, 988 underwent surgery with chemotherapy, and 274 underwent trimodality therapy. […] Cancer-directed surgery, chemotherapy, and radiation therapy were independently associated with improved survival (hazard ratio, 0.77, 0.74, and 0.88, respectively). […] Stratified analysis revealed that surgery-based multimodality therapy demonstrated an improved survival compared with surgery alone, with no significant difference between surgery-based multimodality therapies; however, the largest estimated effect was when cancer-directed surgery, chemotherapy, and radiation therapy were combined (hazard ratio, 0.52). […] For patients with the epithelial subtype who underwent trimodality therapy, median survival was extended from 14.5 months to 23.4 months. […] Surgery-based multimodality therapy was associated with improved survival and may offer therapeutic benefit among carefully selected patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28831280&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma - Pleural cavity irradiation after decortication with helical tomotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a rare and aggressive disease that poses a treatment challenge in spite of recent technical developments. […] In addition to clinical and diagnostic findings from regular follow-up examinations, we evaluated the dose distribution for other organs at risk to assess treatment in relation to toxicity, with special regard for the underlying intact lung. […] The mean lung dose on the treatment site was 32.8 Gy (±6.8). […] No treatment-related toxicity that exceeded grade III according to common toxicity criteria (CTC) was observed. […] The findings of this analysis provide data indicating that sparing the underlying lung in patients with MPM after P/D is not only feasible with helical tomotherapy, but that this treatment also causes reasonably few side effects.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28838403&#34; target=&#34;_blank&#34;&gt;Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A small proportion of patients with malignant pleural mesothelioma (MPM) achieve pathological complete response (CR) following treatment with current practice induction chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28843224&#34; target=&#34;_blank&#34;&gt;Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Results: Among 114 patientslisted during the study period, 82 had good PS=0-I (median age 45years, 43 men, 30 smokers, median weight=77Kg,pretreatment haemoglobin (Hb) level=12g/dL, platelet count=372,000/μL, leukocytes=9,700/μL, neutrophils=6,100/μL,lymphocytes=1,890/μL and neutrophil/lymphocyte ratio (NLR)=3.60 ).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28843362&#34; target=&#34;_blank&#34;&gt;National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients receiving P/D were older (p = 0.028), whereas those undergoing EPP were more likely to live in a rural area (p = 0.044), live farther from the treating facility (p = 0.039), and receive treatment at an academic center (p = 0.050).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28859932&#34; target=&#34;_blank&#34;&gt;The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a devastating disease with limited treatment options and a dismal prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28860886&#34; target=&#34;_blank&#34;&gt;Clinical staging of malignant pleural mesothelioma: current perspectives.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Molecular reclassification of MPM and gene expression or miRNA prognostic models have the potential to improve prognostication and patient selection for a proper treatment algorithm; however, they await prospective validation to be introduced in clinical practice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28862644&#34; target=&#34;_blank&#34;&gt;Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We list other attractive potential targets for CAR T cell therapy for MPM, and discuss augmentation strategies of CAR T cell therapy with other forms of immunotherapy in this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28870611&#34; target=&#34;_blank&#34;&gt;Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The dose-escalation steps planned were 5 × 10&lt;sup&gt;9&lt;/sup&gt;, 7 × 10&lt;sup&gt;9&lt;/sup&gt;, and 9 × 10&lt;sup&gt;9&lt;/sup&gt; TargomiRs either once or twice weekly, but after analysis of data from the first eight patients, all subsequent patients started protocol treatment at 1 × 10&lt;sup&gt;9&lt;/sup&gt; TargomiRs. […] The primary endpoints were to establish the maximum tolerated dose of TargomiRs as measured by dose-limiting toxicity, define the optimal frequency of administration, and objective response (defined as the percentage of assessable patients with a complete or partial response), duration of response (defined as time from the first evidence of response to disease progression in patients who achieved a response), time to response (ie, time from start of treatment to the first evidence of response) and overall survival (defined as time from treatment allocation to death from any cause). […] Between Sept 29, 2014, and Nov 24, 2016, we enrolled 27 patients, 26 of whom received at least one TargomiR dose (one patient died before beginning treatment).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28881848&#34; target=&#34;_blank&#34;&gt;Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The disease is usually detected in an advanced stage which precludes curative treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28884088&#34; target=&#34;_blank&#34;&gt;Oncolytic Viral Therapy for Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The limited effectiveness of conventional therapy for malignant pleural mesothelioma demands innovative approaches to this difficult disease. […] Even with aggressive multimodality treatment of surgery, radiation, and/or chemotherapy, the median survival is only 1-2 years depending on stage and histology. […] Oncolytic viral therapy has emerged in the last several decades as a rapidly advancing field of immunotherapy studied in a wide spectrum of malignancies. […] Therefore, despite being a relatively uncommon disease, the multitude of viral studies for mesothelioma can provide insight for applying such therapy to other malignancies. […] This article will begin with a review of the general principles of oncolytic therapy focusing on antitumor efficacy, tumor selectivity, and immune system activation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28884702&#34; target=&#34;_blank&#34;&gt;Radiotherapy for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Over the past 15 years, the development of new, highly conformal radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT), has enabled investigators to optimise the delivery of high-dose radiotherapy to the whole of the hemithorax. […] This Review focuses on recent observations on the role of radiotherapy in the treatment of malignant pleural mesothelioma, with particular emphasis on the results of clinical trials that evaluate the role of high-dose hemithoracic radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28889523&#34; target=&#34;_blank&#34;&gt;The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prospective identification of these longer-term survivors may help to guide treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28892431&#34; target=&#34;_blank&#34;&gt;Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). […] The median number of pemetrexed and cisplatin cycles was six; the median treatment duration for nintedanib was 7.8 months and 5.3 months for placebo.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28910456&#34; target=&#34;_blank&#34;&gt;Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with ALK-rearranged peritoneal mesotheliomas were women and younger than patients without ALK rearrangement (median age 36 vs 62; Mann-Whitney test, P = .02), but all other clinicopathologic characteristics (size of tumor nodules, histology, treatment, and survival) were not different. […] Identification of clinically actionable ALK rearrangements may represent a novel pathogenetic mechanism of malignant peritoneal mesothelioma with promise for targeted therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28920252&#34; target=&#34;_blank&#34;&gt;Role of new radiation techniques in the treatment of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery remains the main therapeutic standard in the treatment of MPM with the goal of complete gross cytoreduction of the tumor. […] There is no role for radical RT alone, but the role of RT as part of multimodality therapy is discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28920270&#34; target=&#34;_blank&#34;&gt;Clinical and biologic prognostic factors in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, malignant pleural mesothelioma therapy is guided by clinical stage and patient characteristics, which are quite unreliable, rather than by the histological or molecular features of the tumor. […] These novel factors may play an important role in defining the prognosis of the disease and, subsequently, may have a place in addressing therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28920322&#34; target=&#34;_blank&#34;&gt;Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrapleural pneumonectomy (EPP) is often performed for resectable MPM as part of a multidisciplinary treatment; however, available data on treatments for recurrence after EPP are limited. […] Aggressive treatment for recurrent MPM after EPP, including locoregional control and/or systemic chemotherapy, was important for achieving long-term survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28922567&#34; target=&#34;_blank&#34;&gt;Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PD-L1 is up-regulated in cancer cells, and the PD-1/PD-L1 pathway plays a critical role in tumor immune evasion, thus providing a target for antitumor therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28932538&#34; target=&#34;_blank&#34;&gt;The value of delayed phase enhanced imaging in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since accurate staging is vital optimal choice of therapy, techniques that optimize pleural imaging are needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28941158&#34; target=&#34;_blank&#34;&gt;Prognostic and predictive role of [&lt;sup&gt;18&lt;/sup&gt; F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover, use of ∆SUV ≥ 25% and ∆TLG ≥ 30% as cut-off values to define early metabolic response supported the role of FDG-PET in predicting disease outcome and treatment response in patients not receiving pleurodesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28945836&#34; target=&#34;_blank&#34;&gt;Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thymidylate synthase (TS) has a predictive role in pemetrexed treatment of mesothelioma; however, additional chemoresistance mechanisms are poorly understood.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28960045&#34; target=&#34;_blank&#34;&gt;A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To better understand the clinical, pathologic features and treatment outcome of this entity, we reviewed 23 cases described in the English literature from 2009, together with our case, provided a total of 24 cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28960945&#34; target=&#34;_blank&#34;&gt;Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite recent advances in MPM treatment, overall survival of patients with MPM is very low.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28972039&#34; target=&#34;_blank&#34;&gt;A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Purpose:&lt;/b&gt; Determine the 1-year progression-free survival (PFS) rate among patients with malignant pleural mesothelioma (MPM) receiving the WT1 peptide vaccine galinpepimut-S after multimodality therapy versus those receiving control adjuvants.&lt;b&gt;Experimental Design:&lt;/b&gt; This double-blind, controlled, two center phase II trial randomized MPM patients after surgery and another treatment modality to galinpepimut-S with GM-CSF and Montanide or GM-CSF and Montanide alone. […] Treatment-related adverse events were mild, self-limited, and not clinically significant. […] The treatment arm was subsequently closed because of the resultant unblinding. […] The PFS rate at 1 year from beginning study treatment was 33% and 45% in the control and vaccine arms, respectively. […] On the basis of these promising results, the investigators are planning a larger randomized trial with greater statistical power to define the optimal use and benefit of galinpepimut-S in the treatment of MPM. &lt;i&gt;Clin Cancer Res; 23(24); 7483-9. &lt;/i&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29030093&#34; target=&#34;_blank&#34;&gt;Estimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This method is of potential clinical value in developing novel treatment approaches for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29049744&#34; target=&#34;_blank&#34;&gt;Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent series have shown the feasibility of extended pleurectomy decortication in the elderly, but with continuing debate about the efficacy of this treatment, we reviewed our experience to identify more detailed selection criteria. […] On multivariable analysis, age was not a significant prognostic factor, although lack of adjuvant therapy (P = 0.001) and admission to the intensive care unit (P &amp;lt; 0.001) remained poor prognostic factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29061644&#34; target=&#34;_blank&#34;&gt;Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Purpose:&lt;/b&gt; Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage. […] BAP1 protein loss enriches for this subgroup and could serve as a potential biomarker to select patients for FGFR inhibitor treatment. […] These data identify a clinically relevant MPM subgroup for consideration of FGFR therapeutics in future clinical studies. &lt;i&gt;Clin Cancer Res; 24(1); 84-94. &lt;/i&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29066506&#34; target=&#34;_blank&#34;&gt;Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Purpose:&lt;/b&gt; Finding new treatment options for patients with malignant pleural mesothelioma is challenging due to the rarity and heterogeneity of this cancer type. […] Current treatment options are therefore limited, and prognosis remains poor.&lt;b&gt;Experimental Design:&lt;/b&gt; We performed drug screening on primary mesothelioma cultures to guide treatment decisions of corresponding patients that were progressive after first- or second-line treatment.&lt;b&gt;Results:&lt;/b&gt; We observed a high concordance between &lt;i&gt;in vitro&lt;/i&gt; results and clinical outcomes. […] Chemical profiling of primary mesothelioma cultures allows personalizing treatment for a group of patients with a rare tumor type where clinical trials are notoriously difficult. […] This personalized treatment strategy is expected to improve the poor prospects of patients with mesothelioma. &lt;i&gt;Clin Cancer Res; 24(7); 1761-70. &lt;/i&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29076876&#34; target=&#34;_blank&#34;&gt;Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the distinction between a reactive process and MM is important for prognosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29078517&#34; target=&#34;_blank&#34;&gt;Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Unfortunately, chemotherapy only marginally extends patient survival and palliative care often remains the sole therapeutic option. […] Nonetheless, for a selected group of patients that present with an early disease stage and an epithelioid histology, a personally tailored multimodality therapeutic (MMT) protocol comprising of cyto-reductive surgery and chemotherapy with or without radiation therapy may significantly prolong survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29078648&#34; target=&#34;_blank&#34;&gt;Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis heavily depends on patients’ response to systemic therapy however, regardless of the causing pathology and histopathologic form, malignant pleural disease is normally associated with a poor prognosis. […] The rate of re-accumulation of the pleural effusion, the patient’s prognosis, and the severity of the patient’s symptoms should guide the subsequent choice of therapy. […] In contemporary medicine, not many cancers have managed to generate as intense debates concerning treatment, as malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29086616&#34; target=&#34;_blank&#34;&gt;A review of bevacizumab in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Systemic chemotherapy is the primary treatment modality for the majority of patients. […] The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. […] This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29092096&#34; target=&#34;_blank&#34;&gt;Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to identify the characteristics of hypersensitivity reactions and to assess the value of skin tests for platinum salts and pemetrexed in the treatment of patients with non-small cell lung cancers or malignant pleural mesothelioma. […] Typical clinical features of immediate hypersensitivity reactions associated with treatment were observed for nine patients (anaphylactic reactions for three cases, angioedema and hypotension associated with asthenia and heat in one case, respectively, and other cutaneous symptoms in the remaining four cases).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29094504&#34; target=&#34;_blank&#34;&gt;A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with recombinant FGF2 prevented growth inhibition and further reduced the levels of FGF/R-targeting microRNAs, indicating a vicious cycle between miR-15/16 down- and FGF/FGFR signaling upregulation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29100460&#34; target=&#34;_blank&#34;&gt;Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this review, we highlight the current challenges associated with the diagnosis and treatment of mesothelioma and discuss how targeting miRNA may improve diagnostic, prognostic and therapeutic approaches.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29105302&#34; target=&#34;_blank&#34;&gt;PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). […] Thirty one patients (53%) received best supportive care and twenty seven patients (47%) received chemotherapy or combination treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29107016&#34; target=&#34;_blank&#34;&gt;Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The remarkable clinical response rates achieved by adoptive transfer of T cells that target CD19 in patients with leukemia and lymphoma have led to a growing number of clinical trials exploring CAR T-cell therapy for solid tumors. […] Herein, we review the evolution of adoptive T-cell therapy; highlight advances in CAR T-cell therapy for thoracic malignancies; and summarize the targets being investigated in clinical trials for patients with lung cancer, malignant pleural mesothelioma, and esophageal cancer. […] We further discuss the barriers to successfully translating CAR T-cell therapy for solid tumors and present strategies that have been investigated to overcome these hurdles.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29110856&#34; target=&#34;_blank&#34;&gt;External validation of prognostic indices for overall survival of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The participants comprised 183 patients who underwent surgical treatment (n=61), chemotherapy (n=101), and best supportive care (BSC, n=21). […] The respective discriminations (95% confidence interval) of the Eastern Cooperative Oncology Group Performance Status, the European Organisation for Research and Treatment of Cancer index, regimen, PS, histology or stage (rPHS) index, and Tagawa index for the OS of MPM patients were 0.532 (0.444-0.620), 0.560 (0.472-0.648), 0.584 (0.452-0.716), and 0.525 (0.453-0.596) for surgery; 0.632 (0.539-0.724), 0.622 (0.548-0.696), 0.677 (0.587-0.766), and 0.545 (0.436-0.653) for chemotherapy; and 0.504 (0.365-0.644), 0.583 (0.456–0.710), 0.704 (0.508-0.899), and 0.583 (0.436-0.730) for BSC. […] Each PI showed poor discrimination for MPM patients who underwent surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29111830&#34; target=&#34;_blank&#34;&gt;Surgical and non-surgical management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinicians should be aware of the evidence supporting the use of different modalities to guide treatment choice. […] Future trials should compare VATS with contemporary, non-surgical approaches (especially combined Indwelling Pleural Catheter (IPC) and chemical pleurodesis therapy).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29113949&#34; target=&#34;_blank&#34;&gt;Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, YBX1 represents a potential target for novel MPM treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29116477&#34; target=&#34;_blank&#34;&gt;4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Translatome-wide polysome microarray analysis revealed a large cohort of genes that were translationally regulated upon treatment with 4EGI-1. […] Genome wide translational profiling identified a large cohort of promising target genes that should be further evaluated for their potential significance in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29129162&#34; target=&#34;_blank&#34;&gt;Mesothelioma in Australia: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemotherapy can have a modest treatment effect in some people. […] New therapies, such as immunotherapy, do not yet have a defined role in the treatment of malignant mesothelioma. […] As treatment options for malignant mesothelioma are limited and no cure is available, there is no established role for early detection or screening of at risk populations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29132803&#34; target=&#34;_blank&#34;&gt;High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role played by radiation therapy after pleurectomy/decortication or surgical biopsy in malignant pleural mesothelioma is uncertain. […] We treated patients with accelerated hypofractionated radiotherapy using helical tomotherapy and intensity-modulated arc therapy in an attempt to keep lung toxicity to a minimum. […] Treatment of intact lung with pleural intensity-modulated arc irradiation in malignant pleural mesothelioma patients with malignant pleural mesothelioma proved safe and feasible, with an acceptable rate of pneumonitis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29137310&#34; target=&#34;_blank&#34;&gt;&lt;i&gt;Ex vivo&lt;/i&gt; evaluation of tumor cell specific drug responses in malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Such estimations of tumor cells from effusions have so far not been implemented in the clinical routine as a basis for individualized choice of therapy. […] The second way of estimating drug effects specifically on tumor cells employs multi parameter flow cytometry, measuring apoptosis with the propidium iodide / AnnexinV technique and, particularly for pemetrexed, possible effects on cell cycle progression in immunologically identified tumor cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29142184&#34; target=&#34;_blank&#34;&gt;Efficacy of Cell-Free and Concentrated Ascites Reinfusion Therapy for Palliative Care in a Patient with Malignant Pleural Mesothelioma: A Case Report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cell-free and concentrated ascites reinfusion therapy (CART) is recognized as a useful treatment to improve the symptoms caused by refractory ascites. […] This is the first report that demonstrates the efficacy of CART for palliative care in a patient with MPM. […] Our experience indicates that CART should be considered as a treatment option to control refractory malignant ascites regardless of the type of cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29147606&#34; target=&#34;_blank&#34;&gt;Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A significant increase in PD-L1 expression was observed in all 3 MM cell lines (p &amp;lt; 0.003 each) following exposure to vinorelbine but not to pemetrexed. &lt;b&gt;Conclusion&lt;/b&gt;: Overall there is good agreement in PD-L1 expression between paired MM lesions; however, the 19-31% of cases with discordant PD-L1 expression, and the dynamics of PD-L1 expression may limit its use as a predictive biomarker for therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29149911&#34; target=&#34;_blank&#34;&gt;The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our recent phase I clinical trial investigated microRNA-based therapy in patients with malignant pleural mesothelioma. […] Treatment with TargomiRs, microRNA mimics with novel sequence packaged in EGFR antibody-targeted bacterial minicells, revealed clear signs of clinical activity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29159011&#34; target=&#34;_blank&#34;&gt;Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Due to its large, circumferential clinical target volume (CTV) and proximity to major structures, including the heart and contralateral lung, delivering hemithoracic intensity-modulated radiotherapy (IMRT) with photon therapy to achieve loco-regional control following macroscopic complete resection is challenging. […] Intensity-modulated proton therapy (IMPT) has been shown to be a method for achieving higher therapeutic doses while limiting exposure to organs at risk (OARs), but patient outcomes after treatment have yet to be reported. […] All three tolerated treatment well and received doses to OARs markedly lower than those seen in comparison volumetric-modulated arc therapy (VMAT) IMRT photon plans.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29163783&#34; target=&#34;_blank&#34;&gt;Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive cancer with an increasing incidence, poor prognosis and limited effective treatment options. […] Hence, new treatment strategies are warranted which include immune checkpoint blockade approaches with encouraging preliminary data. […] Our data provide a basis for more elaborate research on MPM effusion material in the context of treatment follow-up and prognostic biomarkers and the development of immune checkpoint-targeted immunotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29164255&#34; target=&#34;_blank&#34;&gt;Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients (n = 146) with symptomatic malignant pleural effusion who had not undergone indwelling pleural catheter or pleurodesis treatment were included. […] Among patients with malignant pleural effusion, treatment with an indwelling pleural catheter vs talc pleurodesis resulted in fewer hospitalization days from treatment to death, but the magnitude of the difference is of uncertain clinical importance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29179896&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma: Diagnosis, Staging, Pitfalls and Follow-up.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Imaging evaluation is essential in diagnosis, staging, and assessment of treatment response in malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29191582&#34; target=&#34;_blank&#34;&gt;Patterns of care and survival among patients with malignant mesothelioma in the United States.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Logistic regression and Cox proportional hazard regression were utilized to identify factors associated with receipt of therapy and all-cause mortality, respectively, among patients with pleural mesothelioma. […] Almost a third (29.3%) of the pleural patients and 21.5% of the non-pleural patients received no therapy. […] Additionally, approximately 60% of both patient groups received systemic therapy. […] Among pleural mesothelioma patients, receipt of therapy was less likely among older patients. […] Receipt of either surgery or systemic therapy and particularly the combination of these two modalities was associated with better all-cause survival. […] Comorbidity score was not found to be associated with receipt of treatment nor was it independently associated with survival among pleural mesothelioma patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29191688&#34; target=&#34;_blank&#34;&gt;Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The best surgical treatment for malignant pleural mesothelioma is still under a debate, but recent evidence points toward a less-invasive approach to reduce morbidity and mortality.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29209570&#34; target=&#34;_blank&#34;&gt;CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Aberrant MET expression is prevalent in mesothelioma, although targeting using small molecule-based therapeutics has proven disappointing.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29211849&#34; target=&#34;_blank&#34;&gt;Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an aggressive and rare malignancy that frequently recurs despite aggressive therapy. […] We evaluated the frequency of treatment with surgery, radiation or chemotherapy, changes in therapy and survival over time and factors associated with the receipt of trimodality therapy. […] Treatment over time was evaluated using the Armitage trend test. […] Factors associated with the receipt of trimodality therapy were analysed using logistic regression. […] Among 20 561 patients, only 4028 (20%) underwent cancer-directed surgery; 533 (2.6%) of whom received trimodality therapy. […] From 2004 to 2014, the use of surgery with chemotherapy increased 87% (P &amp;lt; 0.01), with no statistically significant change in the use of trimodality therapy. […] Patients who were treated at an academic centre or who travel &amp;gt;26 miles for treatment were more likely to undergo trimodality therapy. […] Additional factors associated with the receipt of trimodality therapy include age less than 70, Charlson comorbidity score of 0 and presence of private insurance. […] Many malignant pleural mesothelioma patients are not treated with trimodality therapy, with significant variation in treatment patterns.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29212185&#34; target=&#34;_blank&#34;&gt;Hyaluronic acid enhances cell migration and invasion via the YAP1/TAZ-RHAMM axis in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Notably, HA treatment increased cell motility and invasion, and this was abolished by RHAMM knockdown, suggesting that HA may augment local progression of MPM cells via RHAMM. […] Furthermore, treatment with fluvastatin, which regulates RHAMM transcription by modulating YAP1/TAZ activity, decreased the motility and invasion of MPM cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29223422&#34; target=&#34;_blank&#34;&gt;National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the treatment paradigm of MPM has evolved, and the national practice patterns are unknown. […] This study examined the national trends in the epidemiology, national treatment patterns, and survival of patients with this disease. […] We analyzed patient, tumor characteristics, and treatment patterns using descriptive statistics and used Kaplan-Meier and Cox proportional hazards models to estimate survival stratified by the type of therapy administered. […] Most patients did not receive any specific modality of treatment (40.2%). […] Chemotherapy alone was the most common treatment used (31.8%). […] Trimodality treatment with chemotherapy, surgical resection, and radiation therapy was associated with the best survival (adjusted hazard ratio, 0.43; p &amp;lt; 0.001), followed by combination chemotherapy and resection (adjusted hazard ratio, 0.49; p &amp;lt; 0.001). […] Although survival remains poor, multimodality therapy with surgical resection is associated with the best survival for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-10-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29228566&#34; target=&#34;_blank&#34;&gt;Targeting CXCR4 with [&lt;sup&gt;68&lt;/sup&gt;Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hence, robust cell surface expression should be confirmed prior to targeting this chemokine receptor for diagnosis and/or therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29246008&#34; target=&#34;_blank&#34;&gt;Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hyperthermic intrathoracic chemotherapy (HITHOC) has been used in the treatment of malignant pleural mesothelioma, but the results were controversial. […] The aim of the current study was, therefore, to conduct a systematic review and meta-analysis on the effect of HITHOC on MPM therapy. […] In addition, HITHOC as palliative therapy was favored (Hedges’s g = 0.591 ± 0.201, 95% CI: 0.196∼0.967, &lt;i&gt;P&lt;/i&gt; &amp;lt; 0.001) in terms of recurrence free interval.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29300270&#34; target=&#34;_blank&#34;&gt;18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to compare the use of fluorine-18-fluorodeoxyglucose (F-FDG) PET with computed tomography (CT) and dynamic contrast-enhanced (DCE) MRI to predict prognosis and monitor treatment in malignant pleural mesothelioma. […] F-FDG PET/CT and DCE-MRI studies were carried out before treatment, and after two cycles of chemotherapy, on patients treated with pemetrexed and cisplatin.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29303291&#34; target=&#34;_blank&#34;&gt;[Malign pleural mesothelioma - so far an undefeated tumor].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The basic therapy used over the past 10 years is chemotherapy with cisplatin - pemetrexed combinations. […] Numerous studies are going on with a different biologically targeted therapy, immunotherapy and other drugs which may improve patients prognosis. […] However even the combined therapy with adjuvant or neoadjuvant chemotherapy or radiotherapy has not considerably extended survival.Key words: diagnostics - epidemiology - malign pleural mesothelioma - therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29303405&#34; target=&#34;_blank&#34;&gt;Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with PF-573228, PF-431396 and VS-6063 cells resulted in a dose-dependent inhibition of growth and anchorage-independent colony formation in both cancer cell lines. […] Using the ECIS (Electric cell-substrate impedance sensing) system, we found that treatment of both PF compounds suppressed adherence and migration of PDAC cells on fibronectin. […] Taken together, our results show that FAK is an important target for mesothelioma and pancreatic cancer therapy that merit further translational studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29309720&#34; target=&#34;_blank&#34;&gt;Radical multimodality therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an almost always fatal tumour, for which palliative platinum-based chemotherapy is currently the standard treatment. […] Multimodal therapeutic strategies incorporating surgery, radiation therapy or photodynamic therapy and chemotherapy have been recommended for selected patients but there is no consensus about their effectiveness. […] To assess the benefits and harms of radical multimodal treatment options (including radical surgery ± radical radiotherapy ± photodynamic therapy ± systemic therapy) compared to each other or to palliative treatments, for people with malignant pleural mesothelioma. […] We included parallel-group randomised controlled trials of multimodal therapy for people with malignant pleural mesothelioma (stages I, II or III) that measured at least one of the following endpoints: overall survival, health-related health-related quality of life, adverse events or progression-free survival. […] The other trial compared EPP plus postoperative hemithoracic radiotherapy with standard (non-radical) therapy alone following platinum-based chemotherapy (patients in the standard therapy arm received continued oncological management according to local policy, which could include further chemotherapy or palliative radiotherapy). […] For the second trial, median overall survival was 14.4 months (95% CI 5.3 to 18.7) for patients allocated to EPP and 19.5 months (95% CI 13.4 to time not yet reached) for patients randomised to standard non-radical therapy. […] In the second trial, 12 serious adverse events were reported during the study period: ten in the EPP group and two in the non-radical therapy group. […] The overall strength of the evidence gathered in this review is low and there is a lack of available evidence to support the use of radical multimodality therapy in routine clinical practice (particularly as one trial suggests greater harm). […] Given the added cost of multimodality treatment and the possible increase in risk of adverse effects, the lack of evidence of their effectiveness probably means that these interventions should currently be limited to clinical trials alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29310415&#34; target=&#34;_blank&#34;&gt;Cisplatin-induced sudden cardiac death with hemodynamic collapse: a severe adverse drug reaction: Case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cisplatin therapy should be thoroughly monitored including electrolyte, especially magnesium levels.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29311642&#34; target=&#34;_blank&#34;&gt;HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Adaptive resistance to therapy is a hallmark of cancer progression. […] To date, it is not entirely clear how microenvironmental stimuli would mediate emergence of therapy-resistant cell subpopulations, although a rearrangement of the cancer cell secretome following therapy-induced stress can be pivotal for such a process.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29312753&#34; target=&#34;_blank&#34;&gt;Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive tumor and the prognosis is still dismal despite the various proposed multimodal treatment plans. […] This review shows that there is limited research on the survival rate after talc pleurodesis compared to surgery in the treatment of malignant pleural mesothelioma. […] A comparison study is necessary to accurately assess the best way to treat MPM patients, including assessment of the quality of life after treatment as an outcome measure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29312767&#34; target=&#34;_blank&#34;&gt;Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
VAE are often used as an adjunct treatment in cancer patients but have rarely been investigated in MPM. […] Helleborus niger extracts (HNE) have been used in anticancer therapy since antiquity, and also show tumor specific cytotoxic effects. […] Deciding against the recommended radio-chemotherapy, surgery and pleurodesis, she opted for an integrative treatment approach and was treated with VAE and HNE. […] After 6 weeks’ treatment, the pleural and nodal MPM manifestations were reduced by about 15%. […] This is a rare case of an MPM patient not receiving any standard anticancer treatment; it still shows an extraordinary long survival and good performance status.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29313814&#34; target=&#34;_blank&#34;&gt;Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No significant responses were seen after 4 weeks of dasatinib therapy; however, modulation of median p-Src&lt;sup&gt;Tyr419&lt;/sup&gt; immunohistochemistry (IHC) scores was seen: the median pretreatment score was 70 (interquartile range 37.5-110), and the median posttreatment score was 41.9 (interquartile range 4.2-60) (p = 0.004). […] Low (less than the median) cytoplasmic p-PDGFR alpha IHC levels were predictive of a decrease in positron emission tomography/computed tomography standard uptake values levels after dasatinib therapy (p = 0.04), whereas higher-than-median IHC scores of PDGFRB (cytoplasmic [HR = 2.8, p = 0.03] and nuclear [HR = 6.795, p = 0.02]) were correlated with rising standard uptake values levels.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29320805&#34; target=&#34;_blank&#34;&gt;Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: A single-centre experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleurodesis is the preferred palliative and supportive treatment option, targeting symptom relief.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29341576&#34; target=&#34;_blank&#34;&gt;Pseudomesotheliomatous carcinoma of the lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Due to difficulties in the form of dry cough, feeling of dis-comfort and pain in the right hemithorax, fatigue, heavy breathing, sweating, fever up to 39.6°C the patient was treated as with combined antibiotic therapy (macrolides, cephalosporins and penicillin), but without improving of his condition.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29342862&#34; target=&#34;_blank&#34;&gt;Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently; instead of relying on molecular signatures and histological typing; MPM treatment options are guided by clinical stage and patient characteristics because the mechanism of carcinogenesis has not been fully elucidated; although about 80% of cases can be linked to asbestos exposure. […] Given the complex heterogeneity of the tumor microenvironment in MPM; a better understanding of the interplay between stromal; endothelial and immune cells at the molecular level is required; to chaperone the development of improved personalized therapeutics. […] Many recent advances at the molecular level have been reported and several exciting new treatment options are under investigation. […] Here; we review the challenges and the most up-to-date biological advances in MPM pertaining to the molecular pathways implicated; progress at the genomic level; immunological progression of this fatal disease; and its link with developmental cell pathways; with an emphasis on prognostic and therapeutic treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29346042&#34; target=&#34;_blank&#34;&gt;Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recommendations Evidence-based recommendations were developed for diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy, and multimodality therapy in patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29354180&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma as a difficult interdisciplinary problem.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Subsequently, they present methods of multimodal treatment (surgery, chemotherapy, and radiotherapy) recommended by the International Mesothelioma Interest Group (IMIG). […] Finally, they discuss complications and long-term results associated with these methods of MPM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29362358&#34; target=&#34;_blank&#34;&gt;Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because the consequent clinical outcome is often unsatisfactory, a different approach in MPM treatment is required.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29367501&#34; target=&#34;_blank&#34;&gt;Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival of patients with MPM remains poor despite multidisciplinary treatment. […] P/D is comparable with EPP and could be a safe and another surgical treatment for patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29386699&#34; target=&#34;_blank&#34;&gt;&lt;i&gt;SFRP&lt;/i&gt; Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study investigated the expression and DNA methylation of &lt;i&gt;SFRP&lt;/i&gt; genes in MPM cells lines with and without demethylation treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29387394&#34; target=&#34;_blank&#34;&gt;Multiple intracranial metastases from postoperative giant sarcomatoid malignant pleural mesothelioma: A case report and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sarcomatoid malignant pleural mesothelioma (SMPM) is a rare tumor with poor response to treatment and a dismal prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29399399&#34; target=&#34;_blank&#34;&gt;Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Systemic treatment of malignant pleural mesothelioma (MPM) is moderately active for the intrinsic pharmacological resistance of MPM cell and its ability to induce an immune suppressive environment. […] Thereby, we propose that, among novel drugs, BBIs should be investigated for MPM treatment for their combined activity on both tumor cells and surrounding immune-environment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29400553&#34; target=&#34;_blank&#34;&gt;Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Materials &amp;amp; methods: We report our experience concerning eight cases treated with the use of static step-and-shoot intensity-modulated radiotherapy to the whole pleural cavity, in patients already undergoing surgical and/or antiblastic therapy. […] Results &amp;amp; conclusion: Results at a median follow-up of 16 months showed a median survival from the initial treatment of 29 months, with lung toxicity of grade II reported only in two patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29410265&#34; target=&#34;_blank&#34;&gt;Radiofrequency Ablation Effectively Treated Focal Recurrence of Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 55-year-old man with malignant pleural mesothelioma underwent multimodality treatment comprising induction chemotherapy followed by extrapleural pneumonectomy and radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29413055&#34; target=&#34;_blank&#34;&gt;Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Appropriate clinical staging of malignant pleural mesothelioma (MPM) is critical for correct treatment decisions. […] TS could be used for prognostic purposes and it may be a useful method for assessing therapy responses.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29413505&#34; target=&#34;_blank&#34;&gt;Progress and challenges in Mesothelioma: From bench to bedside.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Finally, we will attempt to identify critical knowledge gaps that currently prevent more effective treatment, including the challenges involved in early detection and chemoprophylaxis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29415822&#34; target=&#34;_blank&#34;&gt;[Anti-tumor immunotherapy in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its prognosis is poor and there is no validated curative therapy to date. […] Surgery of MPM, done only by few expert teams within a multimodal treatment is of limited and still disputed value. […] The standard treatment of MPM, relying on first-line chemotherapy by combined cisplatin-pemetrexed is often poorly effective, even if combination with bevacizumab anti-VEGF antibodies has slightly improved the results. […] Moreover, no second line treatment is recommended in case of failure of this chemotherapy. […] Moreover, many questions still need to be answered about immunotherapy: what is its potential value as first line treatment?
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29430427&#34; target=&#34;_blank&#34;&gt;Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of malignant pleural mesothelioma (MPM) is challenging, and multimodal treatment including surgery is recommended; however, the role of surgery is debated. […] The treatment outcomes of MPM in Korea have not been reported. […] We analyzed the outcomes of MPM in the context of multimodal treatment, including surgery. […] The treatment outcomes of the surgery and non-surgery groups were compared. […] The treatment outcomes between the surgery and non-surgery groups were not significantly different (3-year survival rate: 31.3% vs. […] In a subgroup analysis, there was no significant difference in the treatment outcomes between the extrapleural pneumonectomy group and the non-surgery group (3-year survival rate: 45.5% vs. […] Multimodal treatment incorporating surgery did not show better outcomes than non-surgical treatment. […] A nationwide multicenter data registry and prospective randomized controlled studies are necessary to optimize the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29433474&#34; target=&#34;_blank&#34;&gt;Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with advanced lung cancer (LC) or malignant pleural mesothelioma (MPM) exhibit limitation of exercise capacities and alteration of quality of life (QoL) induced by cancer and its treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29454314&#34; target=&#34;_blank&#34;&gt;A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Serial serum mesothelin measurement has shown utility in the assessment of treatment response during chemotherapy but has never been assessed in the longer term follow up of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29475935&#34; target=&#34;_blank&#34;&gt;Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the present study was to assess the prognostic utility of the pretreatment blood neutrophil-to-lymphocyte ratio (NLR) and the C-reactive protein-to-albumin ratio (CAR) in patients with inoperable malignant pleural mesothelioma (MPM). […] On multivariate analysis, pretreatment CAR was an independent factor associated with worse OS (hazard ratio(HR)=1.72; 95% confidence interval(CI)=1.11-2.67; p=0.016).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29492898&#34; target=&#34;_blank&#34;&gt;Stem Cells Application in Thoracic Surgery: Current Perspective and Future Directions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two main fields of clinical applications of stem cells in thoracic surgery have been explored: (a) regenerative medicine, that is a branch of translational research in tissue engineering and molecular biology dealing with the replacement, engineering or regeneration of cells, tissues and organs to restore normal function; (b) drug loading and delivery, that is an emerging field proposing stem cells as vectors to deliver anti-cancer agents for targeted therapies.Bronchopleural fistula is a pathological connection between the bronchus and the pleural cavity that may develop after lung resection, thus causing pleural empyema due to colonization by resident airway bacteria; stem cells and regenerative medicine approach can effectively contribute to impaired bronchial healing, thus preventive a septic and ventilator catastrophe.In the field of thoracic oncology, MSC are probably one of the best choice for anticancer drug delivery, emerging as potential experimental approach to malignant mesothelioma treatment.The goal of this review is to focus on clinical applications of stem cell technologies in thoracic surgery, emphasizing regenerative medicine aspects as well as drug loading and delivery in thoracic oncology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29498536&#34; target=&#34;_blank&#34;&gt;&lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To compare the N- and M-staging accuracy of PET vs CT, as per the American Joint Committee on Cancer (AJCC) eighth edition in patients with malignant pleural mesothelioma (MPM) being considered for multimodality therapy in a tertiary referral center. […] A retrospective, single institution comparison of PET and CT was performed in patients with histologically proven MPM being considered for multimodality therapy. […] Surgery was performed in 61/101 patients (60.4%), most of whom had multimodality therapy. […] PET identifies significantly more patients with nodal or distant metastatic disease than CT and may contribute to more appropriate selection of patients with MPM for surgery or multimodality therapy. […] PET/CT can help in the selection of patients with MPM who would benefit from surgery or multimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29500763&#34; target=&#34;_blank&#34;&gt;The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM), a devastating neoplasm, is traditionally considered to be resistant to antitumor therapy. […] This prognostic index contributes to clinicians’ ability to predict benefit from treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507787&#34; target=&#34;_blank&#34;&gt;Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma treatment is unsatisfactory and recurrence is common. […] Here an innovative locoregional treatment for malignant pleural mesothelioma is presented. […] The cisplatin-loaded hyaluronate films provided higher C&lt;sub&gt;max&lt;/sub&gt; and AUC compared to a solution of cisplatin administered intrapleurally, but did not show any sign of treatment related toxicity. […] Hyaluronate-based films appear as an optimal platform for the development of drug delivery systems suitable for the loco-regional post-surgical treatment of lung malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507788&#34; target=&#34;_blank&#34;&gt;Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Some years ago, our interest focused on polymeric films loaded with cisplatin for the adjuvant intrapleural treatment of surgical patients. […] Animals were divided into four groups according to pharmacologic treatment: control group (three animals undergoing left pneumonectomy and saline-NaCl solution); intrapleural hyaluronate cisplatin films (HYALCIS) group (six animals undergoing left pneumonectomy and intrapleural application of polymeric films loaded with cisplatin); intrapleural cisplatin solution (six animals undergoing left pneumonectomy and intrapleural application of cisplatin solution); intravenous cisplatin (five animals undergoing left pneumonectomy and intravenous administration of cisplatin solution). […] The primary objective was the plasmatic and pleural concentration of cisplatin in the treatment groups. […] The secondary objective was the treatment-related toxicity evaluated by plasmatic analysis performed at prearranged time intervals and histological examinations of tissue samples collected during animal autopsy. […] Despite the high cisplatin plasmatic concentrations, treatment related-toxicity towards kidneys and liver was comparatively lower compared to the intravenous and intrapleural cisplatin administration and closer to the control levels. […] Polymeric films loaded with cisplatin allowed to reach significantly higher intrapleural and plasmatic cisplatin concentrations compared to intrapleural and intravenous cisplatin solution, providing at the same time, a significant reduction of treatment related toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507790&#34; target=&#34;_blank&#34;&gt;Hyperthermic intrathoracic chemotherapy after extended pleurectomy and decortication for malignant pleura mesothelioma: an observational study on outcome and microcirculatory changes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the treatment of malignant pleural mesothelioma the Hyperthermic Intra THOracic Chemotherapy (HITHOC) can improve the efficacy of pleurectomy and decortication with a local cytotoxic effect.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507793&#34; target=&#34;_blank&#34;&gt;Clinical diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM diagnosis requires imaging procedures X-ray and computed tomography (CT) scans; magnetic resonance imaging (MRI) better defines the extension of the tumor while PET scanning provides additional information on metabolic activity, metastases, and response to treatment. […] Multimodality treatment including surgery, chemotherapy and radiotherapy has been associated with a better survival in selected patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507797&#34; target=&#34;_blank&#34;&gt;Surgery for malignant pleural mesothelioma: an international guidelines review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently there is no universally accepted surgical therapy for malignant pleural mesothelioma (MPM). […] Initially, EPP was considered the only surgical option with a curative aim, but during the decades P/D have acquired a role of increasing importance in MPM therapy. […] Several randomized prospective trials are required to establish the best strategy in the treatment of pleural mesothelioma. […] The aim of this study is to examine the currently available international guidelines in the surgical diagnosis and treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507798&#34; target=&#34;_blank&#34;&gt;The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery is one of the steps of multimodality approach for the treatment of MPM. […] Different agents might be administered intrapleurally: chemotherapy drugs are the most widely used, but also photodynamic therapy (PDT) showed to lead to satisfactory long-term outcomes; furthermore, immunotherapies and gene therapies have been also reported.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507800&#34; target=&#34;_blank&#34;&gt;Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite treatment improvements, it carries a dismal prognosis. […] For such patients, chemotherapy (CT) represents the gold-standard treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507801&#34; target=&#34;_blank&#34;&gt;Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Considering that the contribution of surgery and radiation therapy in the management of this disease is not yet established, systemic treatments are predominantly considered during the course of MPM. […] New treatment strategies are needed. […] A deeper knowledge of the biology and pathogenesis of this disease is required to develop more effective tools for diagnosis, therapy and prevention. […] This paper reviews therapeutic advances in MPM, with a particular focus on new drugs and new association of drugs of target therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507802&#34; target=&#34;_blank&#34;&gt;New horizons from immunotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medical treatment for MPM unresectable patients is still unsatisfactory; therefore novel therapeutic approaches are urgently needed. […] Immunotherapy represents a promising treatment for MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507803&#34; target=&#34;_blank&#34;&gt;Medical treatment of malignant pleural mesothelioma relapses.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To date, genome wide analyses did not show molecular targets suitable for therapy and biological drugs did not exert a significant efficacy in clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507805&#34; target=&#34;_blank&#34;&gt;Serum mesothelin and other biomarkers: what have we learned in the last decade?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the last decade there is been much interest in noninvasive, economic and well-accepted diagnostic tests for screening of subjects exposed to asbestos, and in patients with malignant pleuric mesothelioma (MPM) for diagnosis or monitoring response to treatment. […] In this type of disease, a key role could be played by miRNAs, which expression has been investigated in a large series of MPM to examine new pathways useful in diagnosis, prognosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507807&#34; target=&#34;_blank&#34;&gt;Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The biomarkers proposed so far do not lead to a sufficiently early diagnosis for a radical treatment of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29508763&#34; target=&#34;_blank&#34;&gt;Novel therapies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with malignant pleural mesothelioma have poor outcomes with suboptimal therapeutic options and currently no treatment is curative. […] The standard frontline treatment, cisplatin plus pemetrexed chemotherapy, has only short and insufficient efficacy, and no validated treatment beyond first-line therapy is available.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29510939&#34; target=&#34;_blank&#34;&gt;Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients who underwent surgical resection (n = 132) were analyzed according to MCR as a whole group and after propensity score matching based on gender, age, histology, clinical T and N status, adjuvant chemotherapy, and trimodality treatment. […] One hundred thirty-three patients underwent adjuvant treatment (45 had chemoradiation).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29514216&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumor immune microenvironment (TME) plays a key role in malignant pleural mesothelioma (MPM) pathogenesis and treatment outcome, supporting a role of immune checkpoint inhibitors as anticancer approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29519924&#34; target=&#34;_blank&#34;&gt;Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Additionally, the antitumour and antiangiogenic effects of MT95-4, a fully humanised anti-APN/CD13 monoclonal antibody, were evaluated in mice orthotopically implanted with EHMES-10 (abundantly expressing APN/CD13) and MSTO-211H (scarcely expressing APN/CD13) MPM cells.High tumour APN/CD13 expression was associated with poor prognosis in MPM patients (p=0.04), and MT95-4 treatment reduced tumour growth and angiogenesis in mice harbouring EHMES-10 but not MSTO-211H cells. […] Here, MT95-4 treatment reduced tumour progression likely by inhibiting angiogenesis, suggesting APN/CD13 as a potential molecular target for MPM treatment. […] Additionally, combination treatment with MT95-4 and cisplatin could represent a promising approach to treating MPM exhibiting high APN/CD13 expression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29523930&#34; target=&#34;_blank&#34;&gt;DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overall, we observed 243 and 302 differentially methylated CpGs (≥ 10%) between the asbestos dose at 5 µg/cm&lt;sup&gt;2&lt;/sup&gt; and untreated control, in chrysotile and crocidolite treatment, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29524617&#34; target=&#34;_blank&#34;&gt;Progress in the Management of Malignant Pleural Mesothelioma in 2017.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New and effective strategies for diagnosis, prognostication, and treatment are urgently needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29527515&#34; target=&#34;_blank&#34;&gt;Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated. […] Our results illustrate that the establishment of a large live-cell MPM biobank contributes to a better understanding of therapy resistance observed &lt;i&gt;in vivo&lt;/i&gt;, which eventually may lead to a more logical approach for developing new treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29529693&#34; target=&#34;_blank&#34;&gt;[Implementation of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Germany].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For several years, hyperthermic intrathoracic chemotherapy (HITHOC) has been performed in a few departments for thoracic surgery in a multimodality treatment regime in addition to surgical cytoreduction.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29540495&#34; target=&#34;_blank&#34;&gt;Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Consequently, drug repurposing appears as an attractive strategy for drug development in MPM, since the known pharmacology and safety profile based on previous approvals of repurposed drugs allows for faster time-to-market for patients and lower treatment cost.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29545973&#34; target=&#34;_blank&#34;&gt;Post-irradiation pericardial malignant mesothelioma with deletion of p16: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesotheliomas are rather uncommon neoplasms associated primarily with asbestos exposure; however, they may also arise as second primary malignancies after radiation therapy, with a latency period of 15-25 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29553973&#34; target=&#34;_blank&#34;&gt;Updates in the diagnosis and treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review article describes current diagnostic and treatment modalities for malignant pleural mesothelioma (MPM). […] A randomized trial of first-line chemotherapy with and without bevacizumab in unresectable MPM is the only randomized trial of a new treatment regimen to demonstrate a survival benefit since cisplatin with pemetrexed became the standard of care for unresectable MPM in 2003. […] Currently, there are no FDA approved second-line therapies, and clinical trial enrollment is recommended for second-line treatment. […] MPM remains difficult to treat and has an overall poor prognosis despite current multimodality treatment. […] Thoracoscopy with multiple pleural biopsies can provide adequate tissue specimens for diagnostic testing to distinguish histologic MPM subtypes and perform molecular profiling, which influence prognosis and treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29565815&#34; target=&#34;_blank&#34;&gt;Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Together, these data indicate the Hippo pathway as a therapeutic target for the treatment of MM, and support the development of new strategies to effectively target the activation status of YAP1/TAZ as a promising therapeutic modality for this formidable disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29579286&#34; target=&#34;_blank&#34;&gt;Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to elucidate the mode of action and biological significance of heparanase in mesothelioma and test the efficacy of heparanase inhibitors in the treatment of this malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29587685&#34; target=&#34;_blank&#34;&gt;Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
QOL was assessed with the European Organization for Research and Treatment of Cancer 16 questionnaire (QLQ) and the short version of the core domains of the Comprehensive Quality of Life Outcome questionnaire (CoQoLo).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29594241&#34; target=&#34;_blank&#34;&gt;SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Standard palliative (20 Gy/5#) or dose escalated treatment (36 Gy/6#) will be delivered using advanced radiotherapy techniques and pain responses will be compared at week 5.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29601534&#34; target=&#34;_blank&#34;&gt;Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with limited therapy options and dismal prognosis. […] In this review, we discuss the current knowledge of heterogeneity in immune cell content and checkpoint expression in MPM in relation to prognosis and prediction of treatment efficacy. […] As such, there is a strong rationale for thoroughly mapping the TME to better target therapy in mesothelioma. […] Therefore, no “one size fits all” treatment is likely to be found and focus should lie on the heterogeneity of the tumors and TME.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29615010&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, old age, male gender, smoking history, histological type, poor staging, no treatment, low total protein level in pleural fluid, and computed tomographic findings such as pulmonary consolidation or infiltration, mediastinal lymphopathy, pulmonary mass or nodules, and pleural nodularity were also poor prognostic factors for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29635378&#34; target=&#34;_blank&#34;&gt;FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We demonstrate that treatment with FGF2 or EGF induced a fibroblastoid morphology in several cell lines from biphasic MPM, accompanied by scattering, decreased cell adhesion and increased invasiveness.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-10-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29651248&#34; target=&#34;_blank&#34;&gt;Carbon Nanotubes and Other Engineered Nanoparticles Induced Pathophysiology on Mesothelial Cells and Mesothelial Membranes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From a molecular aspect, some nanoparticle categories are shown to be cytotoxic and genotoxic after acute treatment, whereas chronic incubation may lead to malignant-like transformation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29656754&#34; target=&#34;_blank&#34;&gt;Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural effusion tumour cells provide an opportunity for the monitoring of tumour dynamics, treatment response and the clonal evolution of MM tumours.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29669524&#34; target=&#34;_blank&#34;&gt;Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with recurrent malignant epithelioid mesothelioma (MM) after surgery and standard chemotherapy with cisplatin and pemetrexed have limited treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29682466&#34; target=&#34;_blank&#34;&gt;Video-assisted thoracoscopic PlasmaJet ablation for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While extensive operations and longer recovery periods can be justified for a group of carefully selected patients, many will present at an advanced stage of their disease or with associated co-morbidities which will exclude them from selection criteria for radical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29690982&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment is often limited to palliation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29701689&#34; target=&#34;_blank&#34;&gt;In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At present, treatment options are limited, with no second line chemotherapy for those who fail first line therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29707353&#34; target=&#34;_blank&#34;&gt;Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The Japanese Joint Committee of Lung Cancer Registry (JJCLCR) employs a project of prospective registry database of patients in Japan with MPM in order to clarify MPM’s epidemiology, current management practices, and prognosis and also to investigate the potential capabilities to target the best patients for therapy. […] We will analyze the data in this registry to determine the most recent outcomes and trends related to MPM treatment in Japan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29709339&#34; target=&#34;_blank&#34;&gt;Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are scarce reports on the prognostic factors and treatment outcomes of patients with malignant pleural mesothelioma (MPM) in Asia. […] Variables including age, gender, performance status, asbestos exposure, smoking history, histology subtype, staging, and treatment received were recorded. […] After adjustment for prognostic factors, surgery in stage I-III MPM (HR 0.36, 95% CI 0.15-0.83) and systemic therapy in stage III/IV disease (HR 0.42, 95% CI 0.19-0.94) conferred a survival benefit. […] Surgery in potentially resectable disease and systemic therapy in advanced MPM confer a survival benefit in Asian patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29724868&#34; target=&#34;_blank&#34;&gt;Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth &lt;i&gt;In Vivo&lt;/i&gt;.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Purpose:&lt;/b&gt; Malignant pleural mesothelioma (MPM) is an aggressive thoracic tumor type with limited treatment options and poor prognosis. […] Reduced MPM cell proliferation and migration and the inhibition of Erk1/2 phosphorylation were also observed upon nintedanib treatment &lt;i&gt;in vitro&lt;/i&gt; Additive effects on cell viability were detected when nintedanib was combined with cisplatin, a drug routinely used for systemic MPM therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29742520&#34; target=&#34;_blank&#34;&gt;Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with methylprednisolone and intravenous immunoglobulin along with clonazepam and valproic acid resulted in a rapid clinical improvement. […] A variant of opsoclonus-myoclonus-ataxia syndrome may occur following treatment with ipilimumab and nivolumab.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29748013&#34; target=&#34;_blank&#34;&gt;Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The association of proteasome and lysosome inhibitors reverses cisplatin resistance by restoring LIP levels and may represent a new adjuvant strategy in MPM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29748018&#34; target=&#34;_blank&#34;&gt;Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients were dichotomized into those receiving therapy at a high-volume facility (HVF), defined a priori at the 90th percentile of case volume, with all others categorized as lower-volume facilities (LVFs).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29748183&#34; target=&#34;_blank&#34;&gt;Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Purpose:&lt;/b&gt; Combination therapy of adoptively transferred redirected T cells and checkpoint inhibitors aims for higher response rates in tumors poorly responsive to immunotherapy like malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29753120&#34; target=&#34;_blank&#34;&gt;A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D) treatment arms were based on investigators’ assessment of patient fitness and potential for macroscopic complete resection. […] From 2007 to 2011, 141 patients were enrolled and 104 completed treatment. […] The median age of those completing treatment was 65 years (range 43-85 years), and 22 (21%) were female.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29753703&#34; target=&#34;_blank&#34;&gt;NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It has poor prognosis and few treatment options after failure of first-line chemotherapy. […] In this trial, we aimed to investigate the efficacy and safety of NGR-hTNF in patients with malignant pleural mesothelioma who had progressed during or after a first-line treatment. […] At the cutoff date (April 29, 2014), the median follow-up was 18·7 months (IQR 15·1-24·4), and overall survival did not differ between the two treatment groups (median 8·5 months [95% CI 7·2-9·9] in the NGR-hTNF group vs 8·0 months [6·6-8·9] in the placebo group; hazard ratio 0·94, 95% CI 0·75-1·18; p=0·58). […] Treatment-related serious adverse events occurred in 17 (9%) patients in the NGR-hTNF group and 20 patients (10%) in the placebo group. […] There were 12 deaths in the NGR-hTNF group and 13 deaths in the placebo group, but none were treatment related. […] The hypothesis-generating findings from the subgroup analyses deserve a confirmatory randomised trial because patients who rapidly progress after first-line treatment have a poor prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29755688&#34; target=&#34;_blank&#34;&gt;Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway are expected to be a novel therapy for combating future increases in numbers of malignant pleural mesothelioma (MPM) patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29755689&#34; target=&#34;_blank&#34;&gt;A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The ALK/MET inhibitor crizotinib enhanced the anti-tumor effect of the mTOR-inhibitor rapamycin in a patient-derived MPM xenograft with co-activated ALK/mTOR: combined therapy achieved tumor shrinkage in 4/5 tumors and growth stagnation in one tumor. […] Treatment effects on proliferation, apoptosis, autophagy and pathway signaling were assessed using Ki-67 immunohistochemistry, TUNEL assay, LC3B immunofluorescence, and immunoblotting. […] Co-treatment significantly suppressed cell proliferation and induced autophagy and caspase-independent, necrotic cell death. […] In conclusion, co-treatment with rapamycin and crizotinib is effective in suppressing MPM tumor growth and should be further explored as a therapeutic alternative in mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29773326&#34; target=&#34;_blank&#34;&gt;Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Baseline tumour PD-L1 expression did not correlate with the proportion of patients who had an immune-related objective response or immune-related disease control, with immune-related progression-free survival, or with overall survival. 30 (75%) patients experienced treatment-related adverse events of any grade, of whom seven (18%) had grade 3-4 treatment-related adverse events. […] Treatment-related toxicity was generally manageable and reversible with protocol guidelines.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29774102&#34; target=&#34;_blank&#34;&gt;Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is resistant to currently used treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29799130&#34; target=&#34;_blank&#34;&gt;A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to establish a murine model by which therapeutic responses to photodynamic therapy (PDT) can be studied in the context of surgical inflammation. […] However, investigations that combine resection with another therapy make it necessary to grow tumors for resection to a larger volume than those that receive secondary therapy alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29804728&#34; target=&#34;_blank&#34;&gt;Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with epithelioid MPM (n=305) were categorized using modified pleural Response Evaluation Criteria in Solid Tumors by whether they responded to treatment. […] Patients who responded to frontline therapy had a significantly longer OS (hazard ratio, 0.34; 95% CI, 0.24-0.49; median, 20.6 months; 95% CI, 15.3 months to not reached) than did those who did not respond (median, 9.4 months; 95% CI, 8.1-11.0 months) (P&amp;lt;.001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29805789&#34; target=&#34;_blank&#34;&gt;&lt;sup&gt;18&lt;/sup&gt;F-fluorodeoxyglucose imaging of primary malignant pericardial mesothelioma with concurrent pericardial and pleural effusions and bone metastasis: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient survived for &amp;gt;1.5 years with comprehensive treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29845408&#34; target=&#34;_blank&#34;&gt;Is there a role for immunotherapy in malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29848954&#34; target=&#34;_blank&#34;&gt;Heterogeneity in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite advances in malignant pleural mesothelioma therapy, life expectancy of affected patients remains short. […] The limited efficiency of treatment options is mainly caused by inter- and intra-tumor heterogeneity of mesotheliomas. […] Molecular analyses reveal a high heterogeneity (i) between patients; (ii) within different areas of a given tumor in terms of different clonal compositions; and (iii) during treatment over time.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29853412&#34; target=&#34;_blank&#34;&gt;A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Then, maintenance therapy with nivolumab will be administered until disease progression, unacceptable toxicities, or the patient’s condition meets the withdrawal criteria.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29854276&#34; target=&#34;_blank&#34;&gt;Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cisplatin is the drug of choice for the treatment of MPM, and carboplatin seems to have comparable efficacy. […] Nevertheless, cisplatin treatment results in a response rate of merely 14% and a median survival of less than seven months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29854664&#34; target=&#34;_blank&#34;&gt;Surgical Options for Malignant Mesothelioma: A Single-Center Experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A fair 5-year survival rate of 21.3% was observed after surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29876318&#34; target=&#34;_blank&#34;&gt;Proton beam therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radiation therapy has historically been used only in the palliative setting or as adjuvant therapy after extrapleural pneumonectomy, but recent advances in treatment planning and delivery techniques utilizing intensity-modulated radiation therapy and more recently pencil-beam scanning (PBS) proton therapy, have enabled the delivery of radiation therapy as neoadjuvant or adjuvant therapy after an extended pleurectomy and decortication or as definitive therapy for patients with recurrent or unresectable disease. […] In particular, PBS proton therapy has the potential to deliver high doses of irradiation to the entire effected pleura while significantly reducing doses to nearby organs at risk. […] This article describes the evolution of radiation therapy for MPM and details how whole-pleural PBS proton therapy is delivered to patients at the Maryland Proton Treatment Center.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29904909&#34; target=&#34;_blank&#34;&gt;Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is a therapy-resistant cancer arising primarily from the lining of the pleural and peritoneal cavities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29905765&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma: is the surgeon still there?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite more knowledge on histology, tumor biology and staging, there is still a relevant discrepancy between clinical and pathologic staging resulting in difficult prediction of prognosis and treatment outcome, making treatment allocation more challenging than in most other malignancies. […] After years of nihilism in the late 80s, a period of activism started evaluating different treatment protocols combined with research driven mainly by academic centers; at the time, selection was based on histology and stage only. […] Not surprisingly, until now there is no common agreement on best treatment even among specialists. […] Hence, a review of our current concepts is indicated and personalized treatment should become applicable in the future. […] In principle, surgery is an effective approach as it allows macroscopic complete elimination of a tumor, which is relatively resistant to medical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29908324&#34; target=&#34;_blank&#34;&gt;Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) has limited treatment options and a poor outcome. […] Pre- and on-treatment biopsy specimens were obtained to analyze biomarkers for response. […] Treatment-related adverse events of any grade occurred in 26 patients (76%), most commonly fatigue (29%) and pruritus (15%). […] Grades 3 and 4 treatment-related adverse events were reported in 9 patients (26%), with pneumonitis, gastrointestinal disorders, and laboratory disorders mostly seen. […] One treatment-related death was due to pneumonitis and probably initiated by concurrent amiodarone therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29921948&#34; target=&#34;_blank&#34;&gt;Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Standard treatment for advanced malignant pleural mesothelioma (MPM) is a cisplatin/pemetrexed (MTA) regimen; however, this is confronted by drug resistance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29943157&#34; target=&#34;_blank&#34;&gt;Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of malignant pleural mesothelioma (MPM) represents a highly unmet medical need. […] Here, we discuss the results and therapeutic potential of first- and second-generation immunomodulatory antibodies targeting distinct immune checkpoints for the treatment of MPM, as well as their prospective therapeutic role in combination strategies. […] We also discuss the role of appropriate radiological criteria of response for MPM and the potential need of ad hoc criteria of disease evaluation in MPM patients undergoing treatment with immunotherapeutic agents.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29946373&#34; target=&#34;_blank&#34;&gt;Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, this combination induced PD-L1 expression which suggests that an association with anti-PD-L1 therapy should be performed to induce an efficient anti-tumor immune response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29949929&#34; target=&#34;_blank&#34;&gt;Experimental Model of Human Malignant Mesothelioma in Athymic Mice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This reliable orthotopic model recapitulates human mesothelioma and may be used for the study of new treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-10-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29959059&#34; target=&#34;_blank&#34;&gt;Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis for patients with mesothelioma is poor, which prompts the need for the development of better treatment options. […] Trophoblast glycoprotein (5T4) is an oncofetal protein overexpressed in mesothelioma with low expression in normal tissue and therefore a good candidate for ADC treatment. […] Here, we evaluated and manipulated 5T4 as a suitable antigen for ADC targeted therapy in patients with mesothelioma. […] 5T4-based ADCs would be a selective strategy for the treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29966799&#34; target=&#34;_blank&#34;&gt;Scientific Advances and New Frontiers in Mesothelioma Therapeutics.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. […] The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29967955&#34; target=&#34;_blank&#34;&gt;Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this pilot study was to investigate the utility of haemodynamic parameters derived from dynamic contrast-enhanced computed tomography (DCE-CT) scans in the assessment of tumour response to treatment in malignant pleural mesothelioma (MPM) patients. […] Mean relative changes in tumour DCE-CT parameters between scans were compared between the on-treatment and on-observation cohorts. […] Differing trends in the relative change of BF and BV between patients on treatment and on observation indicate the potential of DCE-CT for the assessment of pharmacodynamic endpoints with respect to treatment in MPM. […] A future study with a larger patient cohort and unified treatment regimens should be undertaken to confirm the results of this pilot study. […] • CT-derived haemodynamic parameters show differing trends between malignant pleural mesothelioma patients on treatment and patients off treatment • Changes in haemodynamic parameters do not correlate with changes in tumour bulk as measured according to the modified RECIST protocol • Differing trends across the two patient groups indicate the potential sensitivity of DCE-CT to assess pharmacodynamic endpoints in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29970876&#34; target=&#34;_blank&#34;&gt;Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Frontline therapy relies on systemic cisplatin and pemetrexed chemotherapy and has a response rate of ~35-41%; currently, there are no US Food and Drug Administration approved second-line therapies for MPM. […] Herein, we present a patient with MPM who experienced rapid disease progression after standard therapy but who had an exceptional and sustained response to immune checkpoint inhibition with single agent nivolumab. […] CONCLUSIONS We report the first case of a patient with MPM who experienced rapid disease progression after standard therapy but had an exceptional and sustained response to immune checkpoint inhibition with single agent nivolumab.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29980753&#34; target=&#34;_blank&#34;&gt;Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Consequently, RAPTA-T pre-treatment followed by the application of cisplatin or liposomal cisplatin (Lipoplatin) leads to increased levels of the cytotoxin in the tumor and enhanced mesothelioma growth inhibition.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29983902&#34; target=&#34;_blank&#34;&gt;The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed (Alimta&lt;sup&gt;TM&lt;/sup&gt;) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. […] In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30030099&#34; target=&#34;_blank&#34;&gt;Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM treatments include surgery, chemotherapy, and radiation therapy, with the combination pemetrexed and cisplatin being the standard chemotherapy approach. […] Despite this multimodality therapy one of the major issues after surgery is the high rate of local recurrence of the tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30040460&#34; target=&#34;_blank&#34;&gt;Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;ul&gt;
&lt;li&gt;Early diagnosis of malignant mesothelioma (MM) is urgently needed because life expectancies and treatment options are limited in advanced stages of the disease. […] When diagnosed in this way, subsequent therapy should be initiated without further delay.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30053976&#34; target=&#34;_blank&#34;&gt;A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Advanced malignant pleural mesothelioma (MPM) is generally treated with platinum/pemetrexed-based first-line therapy. […] To assess the effects of cytostatic or targeted therapy for treating MPM, we performed a systematic review and meta-analysis. […] Based on this meta-analysis, palliative chemotherapy or other experimental agents can be considered for patients with MPM who desire further treatment after their disease has progressed, during or after first-line therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30054348&#34; target=&#34;_blank&#34;&gt;ERS/EACTS statement on the management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There was no evidence to support the use of oncological therapies as an alternative to MPE drainage, and the literature supported the use of tissue biopsy as the gold standard for diagnosis and treatment planning.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30056163&#34; target=&#34;_blank&#34;&gt;Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an aggressive malignancy with limited systemic therapy options. […] Promising results have been reported with use of anti-programmed cell death 1 therapy; however, its benefits appear to be confined to a subgroup of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30060030&#34; target=&#34;_blank&#34;&gt;ERS/EACTS statement on the management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There was no evidence to support the use of oncological therapies as an alternative to MPE drainage, and the literature supported the use of tissue biopsy as the gold standard for diagnosis and treatment planning.Management options for malignant pleural effusions have advanced over the past decade, with high-quality randomized trial evidence informing practice in many areas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30078293&#34; target=&#34;_blank&#34;&gt;The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This cost decreases to € 320.18 in the case of enrollment in an experimental trial of first-line treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30101018&#34; target=&#34;_blank&#34;&gt;Double cancer comprising malignant pleural mesothelioma and squamous cell carcinoma of the lung treated with radiotherapy: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleurectomy/decortication (P/D) is the surgical treatment of choice for early malignant mesothelioma, but it remains unclear whether radiotherapy along with P/D should be used as multimodal treatment for this disease. […] The present case indicates the value of radiotherapy in the treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30109162&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma, Biphasic Type: An Unusual and Insidious Case of Rapidly Progressive Small Blue Cell Tumor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient refused further imaging and treatment, and palliative care was consulted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30112000&#34; target=&#34;_blank&#34;&gt;Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus Nutlin-3A, a potent inhibitor of MDM2, is associated with a significant induction of senescence and apoptosis in MPM cell lines, making Nutlin-3A a promising substance for a targeted therapy in the subgroup of MPM showing MDM2 overexpression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30121394&#34; target=&#34;_blank&#34;&gt;Surgery in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical intervention plays an important role in the diagnosis, staging, and treatment of malignant pleural mesothelioma (MPM) and can be applied with curative or palliative intent. […] Herein, we summarize the role of surgical resection, specifically macroscopic complete resection, performed as extrapleural pneumonectomy or extended pleurectomy/decortication in multimodality treatment settings and advocate for optimal patient selection for one or the other procedure. […] In addition, the roles of surgery in diagnosis of MPM and in palliative care are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30142389&#34; target=&#34;_blank&#34;&gt;Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no approved second-line treatment for malignant pleural mesothelioma (MPM). […] Pembrolizumab was the second-line treatment in 48 of 93 patients (52%). […] In patients with an Eastern Cooperative Oncology Group performance status of 0 or 1 and only one previous systemic treatment (n = 35), the ORR was 37%, the mPFS was 3.7 months, and the median overall survival was 10.2 months. […] Anti-PD-L1 immunotherapy is a reasonable second-line therapy in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30144378&#34; target=&#34;_blank&#34;&gt;ADP sensitizes ZL55 cells to the activity of cisplatin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor in which cisplatin therapy is commonly used, although its effectiveness is limited. […] These findings suggest that the combination of ADP and cisplatin may be a promising strategy for the clinical treatment of cisplatin-resistant MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30150440&#34; target=&#34;_blank&#34;&gt;Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overall survival rates were determined and compared with pathological features, histology, and treatment. […] Bimodal therapy resulted in a longer survival rate than trimodal therapy. […] Surgical treatment using pleurectomy/decortication resulted in higher patient survival outcomes than therapy with extrapleural pneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30156768&#34; target=&#34;_blank&#34;&gt;Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Molecular and other biomarker testing can be performed on even modestly cellular fluid specimens and may allow patients to benefit from targeted therapy without the need for additional tissue biopsies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30157247&#34; target=&#34;_blank&#34;&gt;BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results reported here indicate that BAMLET and BLAGLET may be effective second-line treatment options for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30157910&#34; target=&#34;_blank&#34;&gt;Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Semi-structured interviews to gather data on acceptability of trial procedures, tolerability of ZA and other relevant information will take place after the participants have completed their six cycles of treatment. […] The qualitative and quantitative data gathered in this feasibility trial will hopefully pave the way to designing a robust full phase III trial to investigate the potential synergistic effect of ZA and current standard treatment for MPM, cisplatin-pemetrexed combination chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30160859&#34; target=&#34;_blank&#34;&gt;[PLEURECTOMY/DECORTICATION].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery is performed as multimodality therapy in MPM, combining extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). […] Tumor recurrence is more frequent after P/D, but it is possible to perform additional treatment because cardiopulmonary function is preserved and QOL is maintained. […] P/D is a feasible curative surgical treatment for MPM, and it will be performed more frequently in Japan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-10-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3017091&#34; target=&#34;_blank&#34;&gt;Pleural malignant mesothelioma following Wilms’ tumor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At age four, she had undergone a left nephrectomy for Wilms’ tumor and had received radiation therapy to the left renal fossa and to the right lung, the latter for a presumed diagnosis of metastatic tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30187393&#34; target=&#34;_blank&#34;&gt;Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The MD Anderson Symptom Inventory (MDASI) is a patient-reported outcome (PRO) measure of symptom burden, the combined impact of disease-related and treatment-related symptoms on functioning. […] Patients with MPM were qualitatively interviewed about experiences of disease and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30197002&#34; target=&#34;_blank&#34;&gt;Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
HuCD26mAb treatment induces a decrease in USP22 level through its interaction with the CD26 molecule, leading to increased levels of ubiquitinated histone H2A and p21.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30197333&#34; target=&#34;_blank&#34;&gt;Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a highly lethal and refractory to multimodal treatment tumor. […] The results provide new evidence of Numb and Gli1 on the clinical characteristics of MPM, which may be helpful in clinical diagnosis and targeted therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30197343&#34; target=&#34;_blank&#34;&gt;Evaluation of the photon dose calculation accuracy in radiation therapy of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These may influence the dose calculation accuracy, calculated by treatment planning systems (TPS). […] This study aimed to evaluate the dose calculation accuracy of TiGRT TPS in radiation therapy of MPM. […] Based on the results, MC calculation can be used in matched photon-electron beam radiation therapy of MPM to modify the TPS photon dose calculations in the presence of heterogeneity, interfaces, and shield in MPM radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30224273&#34; target=&#34;_blank&#34;&gt;Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On multivariable analysis, factors predictive of poorer OS included advanced age, male gender, uninsured status, urban residence, treatment at community centers, and T4/N2 disease (all P &amp;lt; .05).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30226590&#34; target=&#34;_blank&#34;&gt;Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) following lung-sparing extended pleurectomy for malignant pleural mesothelioma (MPM) has been investigated as a potential means to kill residual microscopic cells. […] The present study developed FOLR1‑targeting porphyrin-lipid nanoparticles (folate-porphysomes, FP) for the treatment of PDT. […] Furthermore, the combination of pretreatment with EGFR-TKI and FP-PDT induced a marked improvement of treatment responses. […] In conclusion, FP-based PDT induced selective destruction of MPM cells based on FOLR1 targeting, and pretreatment with EGFR-TKI further enhanced the therapeutic response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30240138&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As no reports of the treatment of this disease have ever been published from Israel, we report our experience with MPM and intensity-modulated radiotherapy (IMRT). […] Patients were followed up from the date of diagnosis to death or treatment failure. […] All patients completed therapy and only 16% had grade 1-2 radiation pneumonitis, with no incidence of grade 3 or higher. […] The mean time to progression following radiation therapy was 26.7 months. […] IMRT for localized pleural mesothelioma is a tolerable and effective therapy both post-EPP or without surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30245692&#34; target=&#34;_blank&#34;&gt;Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Introduction:&lt;/b&gt; Malignant pleural mesothelioma (MPM) is a malignancy with a very poor prognosis for which new treatment options are urgently needed. […] We have previously shown that dendritic cell (DC) immunotherapy provides a clinically feasible treatment option. […] In the current study, we set out to assess the immunological changes induced by DC immunotherapy in peripheral blood of MPM patients. &lt;b&gt;Methods:&lt;/b&gt; Peripheral blood was collected from nine patients enrolled in a phase I dose escalation study, before and after treatment with DCs that were pulsed with an allogeneic tumor lysate preparation consisting of a mixture of five cultured mesothelioma cell lines. […] Therapy-induced T cell reactivity was assessed in peptide/MHC multimer stainings using mesothelin as a prototypic target antigen with confirmed expression in the clinical tumor lysate preparation. […] T cell receptor (TCR) diversity was evaluated by &lt;i&gt;TCRB&lt;/i&gt; gene PCR assays. &lt;b&gt;Results:&lt;/b&gt; We observed an increase in the numbers of B cells, CD4 and CD8 T cells, but not NK cells at 6 weeks post-treatment. […] Notably, we did observe enhanced proportions of CD4 T cells expressing HLA-DR, PD-1 (at 2 weeks after onset of treatment) and ICOS (6 weeks) and a CD8 T cell population expressing LAG3 (2 weeks). &lt;b&gt;Discussion:&lt;/b&gt; DC immunotherapy using allogeneic tumor lysate resulted in enhanced frequencies of B cells and T cells in blood.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30246568&#34; target=&#34;_blank&#34;&gt;Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In advanced non-small cell lung cancer, molecular targeted therapy is the standard first-line treatment for patients with identified driver mutations; on the other hand, chemotherapy is the standard treatment for patients without EGFR mutations or ALK rearrangement or those with unknown mutation status. […] Once considered an ineffective therapy in pulmonary neoplasms, immunotherapy has been now established as one of the most promising therapeutic options. […] Molecular targeted therapy and immunotherapy are the new alternatives to standard chemotherapy. […] Mesenchymal stromal cells are a new promising tool in oncology and-although not yet utilized in the clinical practice, we think they will represent another main tool for cancer therapy and will probably play a leading role in the field of nanovectors and molecular medicine.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30253920&#34; target=&#34;_blank&#34;&gt;Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The objective of this study was to present the outcomes of moderately hypofractionated helical intensity-modulated radiation therapy (HT) with/without simultaneous integrated boost (SIB) on fluorodeoxyglucose-positron emission tomography (FDG-PET) positive areas (gross tumor volume [GTV]-PET) for patients with progressive malignant pleural mesothelioma (MPM) after previous treatments.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30259910&#34; target=&#34;_blank&#34;&gt;What’s new in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis, prognosis and therapy are often challenging and include several issues.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30268449&#34; target=&#34;_blank&#34;&gt;Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently there are many uncertainties in the optimal treatment of malignant pleural mesothelioma (MPM), this is reflected in discrepancies between current guidelines. […] The current controversy surrounding the use of surgery and radiotherapy within multimodal therapy strategies will not be answered by these trials in the coming years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30268460&#34; target=&#34;_blank&#34;&gt;Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This can be explained by difficulties in early diagnosis, effective treatment and treatment monitoring. […] Whole exome sequencing was performed on paired tumor and germline DNA of ten MPM patients, of which five were treatment naïve. […] Interestingly, all patients whose circulating DNA samples contained tumor-specific variants, were treatment naïve. […] We demonstrated for the first time the presence of ctDNA within circulating DNA of treatment naïve MPM patients. […] This finding opens perspectives towards the use of ctDNA as a biomarker for (early and differential) diagnosis, treatment and treatment monitoring of MPM, which all remain challenging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30268471&#34; target=&#34;_blank&#34;&gt;Antibody drug conjugates in thoracic malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Antibody drug conjugates (ADCs) have the potential to alter the efficacy: toxicity ratio of cytotoxic therapy utilizing surface markers on cancer cells as antibody targets to preferentially deliver toxic payloads to tumor cells while limiting systemic toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30272283&#34; target=&#34;_blank&#34;&gt;Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In conclusion, curcumin may be potent enough to be developed as a novel therapeutic agent for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30272347&#34; target=&#34;_blank&#34;&gt;Berberine induces mitochondrial‑mediated apoptosis and protective autophagy in human malignant pleural mesothelioma NCI‑H2452 cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, inhibition of autophagy may be an effective treatment strategy in the management of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30278171&#34; target=&#34;_blank&#34;&gt;Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The cancer-directed surgery is associated with improved survival in early-stage MPM patients with nonepithelioid histology compared with those who did not undergo resection or chose medical therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30301262&#34; target=&#34;_blank&#34;&gt;Genomic Deletion of &lt;i&gt;BAP1&lt;/i&gt; and &lt;i&gt;CDKN2A&lt;/i&gt; Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a deadly cancer that is caused by asbestos exposure and that has limited treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30311833&#34; target=&#34;_blank&#34;&gt;Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Interestingly, MGCD516 treatment also results in altered mitochondrial morphology in these cell lines. […] Considered together, the present study has uncovered a novel mechanism underlying mitochondrial regulation by MET that involves crosstalk with DRP1, and suggests that a combination therapy targeting both MET and DRP1 could be a novel strategy for NSCLC and MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30312759&#34; target=&#34;_blank&#34;&gt;Iron addiction with ferroptosis-resistance in asbestos-induced mesothelial carcinogenesis: Toward the era of mesothelioma prevention.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This tendency has increased as various medical therapeutics have advanced, which suggests that we cannot escape carcinogenesis, although the final outcome may be modified by exposomes and statistics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30316293&#34; target=&#34;_blank&#34;&gt;p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical decisions related to MPM personalized therapy based on individual patients’ genetic profile and previous chemotherapeutic treatment could be reached using computational tools and the predictions reported in this study upon further testing in animal models.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30316650&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: The role of surgery].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radical surgical treatment is only offered in therapeutic trials or multimodal treatment. […] New therapies associated to surgical treatment are being studied.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30319062&#34; target=&#34;_blank&#34;&gt;Incidence of cutaneous reactions with pemetrexed: Comparison of patients who received three days of oral dexamethasone twice daily to patients who did not.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The objective of this study was to determine if there is a difference between patients who received three days of oral dexamethasone starting the day before pemetrexed infusion and patients who did not by determining incidence of cutaneous reactions, delay in therapy, and therapy change due to adverse reactions. […] 25.0%; &lt;i&gt;p&lt;/i&gt; = 0.384), delay in pemetrexed therapy between groups (44.8% vs. […] 32.1%; &lt;i&gt;p&lt;/i&gt; = 0.2), or therapy change due to adverse events (34.5% vs. […] Results suggest three days of oral dexamethasone 4 mg twice daily did not significantly affect incidence rates of cutaneous reactions, delay in therapy, or therapy change in patients who received intravenous dexamethasone before pemetrexed infusion at University of New Mexico Comprehensive Cancer Center.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30324544&#34; target=&#34;_blank&#34;&gt;Mesothelin as a target for cervical cancer therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The cell surface glycoprotein Mesothelin is overexpressed in several tumor entities and novel immune-based therapies are currently under the early clinical evaluation for the treatment of malignant pleura mesothelioma, ovarian cancer, and pancreatic cancer. […] To exploit a possible role of Mesothelin in cervical cancer treatment, we analysed Mesothelin expression in 79 cervical carcinomas and aligned expressions patterns with tumor growth parameters. […] Mesothelin should be taken into account as a target in cervical cancer therapy and histological determination of Mesothelin expression should be considered in routine diagnostics of cervical carcinomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30349716&#34; target=&#34;_blank&#34;&gt;Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The findings highlight the benefit of nintedanib rechallenge and the potential use of continuous anti-angiogenic therapy in MPM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30366103&#34; target=&#34;_blank&#34;&gt;Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Presence of weight loss, anemia, and low albumin should confer caution when considering surgical therapy for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30367010&#34; target=&#34;_blank&#34;&gt;Experimental study of the inhibition effect of CXCL12/CXCR4 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The tumor weights of each treatment group were lower than that of the control group (p&amp;lt;0.05). […] The bioluminescence of the tumor of the AMD3100 treatment group and the AMD3100 plus pemetrexed treatment group were lower than that of the control group (p&amp;lt;0.05), and AMD3100 was shown to have synergistic effects with pemetrexed (p&amp;lt;0.05).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30369425&#34; target=&#34;_blank&#34;&gt;Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is a folate analog inhibitor for the treatment of non-small-cell lung cancer (NSCLC) and malignant pleural mesothelioma. […] There was a significant difference noted in treatment delay in C3 [28/114 (24.6%) group A vs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30369878&#34; target=&#34;_blank&#34;&gt;Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In order to select the most suitable patients for effective therapy with drugs targeting specific metabolic pathways, there is a need for better predictive metabolic biomarkers. […] Here we found that MPM cell lines could be categorized into two groups according to their sensitivity or resistance to pemetrexed treatment. […] Metabolomic analysis revealed that glycine and choline, which are involved in one-carbon metabolism, were altered after drug treatment in pemetrexed-sensitive but not resistant MPM cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30375909&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in Finland: regional and gender variation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Even with a multimodality treatment approach, the treatment outcomes remain unsatisfactory. […] Patients without chemotherapy treatment had an inferior survival (RR 1.8 [95% CI 1.5-2.0]). […] Significant gender and regional variation exists among patients, with notable differences in diagnostic and treatment practices. […] Emphasize centralized consult services for the diagnosis, treatment and support that patients receive for MPM, facilitating equal outcomes and compensation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30389446&#34; target=&#34;_blank&#34;&gt;Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our aim was to assess the clinical, radiologic, and pathologic factors impacting survival in BPM and to better identify patients most likely to benefit from active treatment. […] Ninety patients underwent chemotherapy (n = 18) or radiotherapy alone (n = 9), 63 received combination therapy, and 27 received best supportive care. […] BPM prognosis remains poor despite multimodality treatment. […] Anticancer treatment is associated with superior outcome in this nonrandomized retrospective series. […] When planning active treatment, the potential survival benefits require balancing against associated morbidity and recovery period.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30407323&#34; target=&#34;_blank&#34;&gt;Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Until now there is no standard third-line treatment for patients who have failed second-line therapy. […] Apatinib as a third-line treatment after failure from pemetrexed/cisplatin (PC) as the first-line chemotherapy and gemcitabine/cisplatin (GP) as the second-line chemotherapy. […] Apatinib may be a potential therapeutic drug for MPM, particularly as a third-line treatment in cases resistant to chemotherapeutic options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30410726&#34; target=&#34;_blank&#34;&gt;Multimodality treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The main therapeutic strategies for MPM are surgery, chemotherapy, and radiation therapy (RT). […] Therefore, researchers have started to explore different multimodality treatment approaches, in which often combinations of surgery, chemotherapy, immunotherapy, and RT are investigated. […] There is still no definitive answer to the question of which multimodality treatment combinations are most effective in improving the poor prognosis of MPM. […] Research into the effects of trimodality treatment approaches have found that radical approaches such as EPP and hemithoracic RT post-EPP are less effective than was previously assumed. […] In general, there are still a great number of unanswered questions and unknown factors regarding the ideal treatment approach for MPM. […] Hopefully, more research into multimodality therapy will provide insight into which combination of treatment modalities is most effective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30410729&#34; target=&#34;_blank&#34;&gt;Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Significant prognostic factors associated with improved survival of malignant mesothelioma cases in this NMVB cohort were younger than 45, female gender, epithelioid histological subtype, stage I, peritoneal occurrence, and having combination treatment of surgical therapy with chemotherapy. […] Combined surgical and chemotherapy treatment was associated with improved survival of 23 months in comparison to single line therapies. &lt;b&gt;Conclusions:&lt;/b&gt; There has not been improvement in the overall survival for patients with malignant mesothelioma over many years with current available treatment options. […] Our findings show that combined surgical and chemotherapy treatment in peritoneal mesothelioma is associated with improved survival compared to local therapy alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30411729&#34; target=&#34;_blank&#34;&gt;&lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (&lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT) in therapy response assessment according modified response evaluating criteria of solid tumors (mRECIST) and the predictive role of volume-based semi-quantitative parameters in patients with malignant pleural mesothelioma (MPM). […] Furthermore modified RECIST criteria for MPM mRECIST and the European Organization for Research and Treatment of Cancer (EORTC) criteria were compared and the predictive role of &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT in the post-therapy outcome. […] Thirty five selected patients with MPM underwent &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT scan at baseline (1) and after therapy (2). […] Radiologic response to therapy was assessed by using the mRECIST and EORTC. […] The correlation between response to therapy assessed by EORTC and mRECIST criteria was moderate (K=0.418; 95%CI:0099-0736). […] The semi-quantitative analysis of &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT has an important role in MPM therapy response assessment and has a predictive role in distinguishing responders and non-responders.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3041546&#34; target=&#34;_blank&#34;&gt;Reactivity of tumor cells in malignant effusions with a panel of monoclonal and polyclonal antibodies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Serial effusions were evaluated in 4 patients during the course of chemotherapy, allowing an assessment of effect of therapy on the antigenic characteristics of the tumor cells. […] There was a tendency to develop changes in the pattern of reactivity during therapy, and the pattern of reactivity was more restricted in tumor nodules than in effusions. […] One of the mAb in our panel (2G3) was consistently shown to produce strong staining of a high proportion of tumor cells in effusions and tumor nodules from patients with ovarian or breast cancer and may be of value in immunocytochemical diagnosis and therapy of epithelial malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-09-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30417500&#34; target=&#34;_blank&#34;&gt;Establishment and characterization of CRISPR/Cas9-mediated NF2&lt;sup&gt;-/-&lt;/sup&gt; human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM), a highly refractory tumor, is currently incurable due to the lack of an early diagnosis method and medication, both of which are urgently needed to improve the survival and/or quality of life of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30423827&#34; target=&#34;_blank&#34;&gt;Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As the success of chemotherapeutic agents is often questioned by the occurrence of multidrug resistance (MDR), a multiple cross-resistance towards different anti-cancer drugs represent a major obstacle to cancer treatment. […] The present study has clarified the involvement of the carbon metabolites in a more aggressive tumor colon adenocarcinoma phenotype and in a chemoresistant mesothelioma, and the role of pyruvate treatment in the reversion of the potentially related resistance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30429030&#34; target=&#34;_blank&#34;&gt;Real-life treatment practice for malignant pleural mesothelioma in Belgium.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, for which treatment is often limited to palliative combination chemotherapy. […] Multimodality-therapy, including radical surgery, is largely restricted to clinical trials, leaving its benefit currently unclear. […] This study aimed to get a comprehensive view on real-world MPM treatment at the Belgian population level, to assess survival and to identify prognostic factors. […] Starting from the Belgian Cancer Registry, additional information regarding patient characteristics, diagnosis and treatment was retrieved from multiple data sources. […] Adjusted cox proportional-hazard regression models using time-dependent covariates were performed to assess survival in relation to treatment patterns and centre volume. […] Sixty-nine percent of patients underwent tumour-directed treatment, mostly cisplatin-pemetrexed chemotherapy. […] This large population-based study provides insights in MPM treatment practice in Belgium.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3043626&#34; target=&#34;_blank&#34;&gt;[Surgical treatment of pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma which is the primary tumor of the pleura has recently been subject to many researches because of its poor prognosis and the difficulties met in radical therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-09-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30448972&#34; target=&#34;_blank&#34;&gt;Extended pleurectomy decortication for thymoma with pleural dissemination.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Complete resection is the mainstay of treatment for thymoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30449771&#34; target=&#34;_blank&#34;&gt;Amelanotic Malignant Melanoma with Dense Pleural Thickening Mimicking Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The tumor was treatment-refractory, and left-sided pleural effusion emerged 1.5 years later.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450288&#34; target=&#34;_blank&#34;&gt;The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment options are for most patients limited to palliative chemotherapy and best supportive care. […] Such instruments are the EORTC QLQ-LC13, LCSS-Meso and FACT-L, which measure the impact of malignant mesothelioma and its treatment on patients. […] Assessments should be made on baseline and post-treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450290&#34; target=&#34;_blank&#34;&gt;Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, diagnosis is made too late for curative treatment because of non-specific symptoms mainly appearing at advanced stage disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450291&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The gold standard in treatment remains cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). […] An exciting finding was the demonstration of ALK rearrangements in a small subset of patients with MPM and it is hoped for that at least this small subgroup of patients could benefit from treatment with ALK inhibitors. […] Ongoing immunotherapy trials will offer a possible new treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450293&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy: still indicated?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The optimal treatment of malignant pleural mesothelioma (MPM) has not yet been established and is still under investigation. […] On the other hand, no randomized-controlled trials regarding surgical treatment with (e)P/D or EPP exist and therefore level A evidence favoring one surgical procedure is lacking. […] In this review we provide a nuanced and well-considered answer to the question whether EPP is still indicated in the surgical treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450295&#34; target=&#34;_blank&#34;&gt;Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A selected minority (&amp;lt;10%) of patients is eligible for a radical treatment with a combination of systemic chemotherapy (CT) and/or surgery and/or radiotherapy (RT), in an effort to maintain locoregional tumor control after achieving a macroscopically complete resection (MCR). […] However, as of yet there is no standard of care for this so-called multimodality treatment. […] Several combined modality treatment trials are currently ongoing using novel techniques in surgery, RT and/or CT in an attempt to reduce the morbidity and mortality associated with older multimodality treatment protocols. […] Guidelines are following suit and are now including or mentioning this treatment option.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450296&#34; target=&#34;_blank&#34;&gt;Current chemotherapy strategies in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The only registered therapy for MPM is platinum-pemetrexed doublet therapy, although only up to half of patients have clinical benefit from this palliative treatment. […] Of the anti-angiogenesis agents, only bevacizumab and nintedanib have shown activity with platinum-pemetrexed doublet therapy. […] Eventually, all patients will get a recurrence and no active second line therapy has been identified to date. […] The clinical benefit of (switch) maintenance therapy after first line treatment and combination strategies of different chemotherapies with angiogenesis inhibitors are currently under investigation. […] The major challenges are finding optimal treatment combinations and to select the adequate treatment for an individual patient. […] This review focusses on the current standard of chemotherapy and new systemic therapy strategies under investigation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450298&#34; target=&#34;_blank&#34;&gt;A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radical multimodality treatment for malignant pleural mesothelioma (MPM) is controversial, with intense debate (but lack of data) about which surgical procedure to perform [extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD)], if any. […] Primary outcome parameter is successful completion of multimodality treatment; secondary outcome parameters are surgical quality parameters (in order to standardize the procedure), progression free survival (PFS) and overall survival (OS), treatment-failure free survival, operative morbidity and mortality, toxicity and safety.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30454981&#34; target=&#34;_blank&#34;&gt;Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are 2 main treatment paradigms recognized by the National Comprehensive Cancer Network for resectable malignant pleural mesothelioma (MPM): induction chemotherapy followed by resection (IC/R), and up-front resection with postoperative chemotherapy (R/PC).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3045724&#34; target=&#34;_blank&#34;&gt;Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the duration of treatment is limited by gastrointestinal toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30478189&#34; target=&#34;_blank&#34;&gt;Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality therapy with preoperative radiation (RT) followed by extrapleural pneumonectomy (EP) for patients with operable malignant pleural mesothelioma (MPM) has demonstrated encouraging results. […] At relapse, there are few data on the tolerance and efficacy of systemic therapies after prior multimodality therapy. […] We conducted a retrospective analysis of patients with relapsed MPM after RT and EPP ± adjuvant chemotherapy to determine overall survival (OS; date of relapse to death) and the proportion of patients that received systemic therapy and associated response rate (RR). […] Thirty-six percent of patients received any systemic therapy, whereas it was omitted in 62% because of poor PS. […] Therapy was discontinued because of toxicity (6/15) or disease progression (5/15), and median number of cycles was four. […] Patients with relapsed MPM following RT and EPP, especially those with ECOG PS ≥2, DFI &amp;lt;1 year, and hemoglobin ≤110 g/L at recurrence, have poor prognosis and low RR to first-line systemic therapy. […] Earlier detection and novel diagnostic markers of relapse as well as potential neoadjuvant or adjuvant systemic therapy should be investigated in future studies. […] The results of this study have reinforced the importance of careful selection of appropriate candidates for this combined-modality approach and favor prompt detection of recurrence with early and regular postoperative imaging and biopsy of suspected relapsed disease along with rapid initiation of systemic therapy even in patients with very low burden of disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30485439&#34; target=&#34;_blank&#34;&gt;3D Culture Models of Malignant Mesothelioma Reveal a Powerful Interplay Between Photodynamic Therapy and Kinase Suppression Offering Hope to Reduce Tumor Recurrence.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results suggest that erlotinib-enhanced photodynamic therapy could further improve the efficacy of intraoperative light-activation to mop up residual tumor deposits in the clinic following surgical removal of macroscopic mesothelioma metastases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30485442&#34; target=&#34;_blank&#34;&gt;A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma remains difficult to treat, with high failure rates despite optimal therapy. […] We present a novel prospective trial combining proton therapy (PT) and photodynamic therapy (PDT) and the largest-ever mesothelioma PT experience (n = 10). […] PT was delivered to a median of 55.0 CGE/1.8-2.0 CGE (range 50-75 CGE) adjuvantly (n = 8) or as salvage therapy (n = 2) following extended pleurectomy/decortication (ePD)/PDT. […] Our prolonged survival in very advanced-stage patients compares favorably to survival for PT without PDT and photon therapy with PDT, suggesting possible spatial or systemic cooperativity and immune effect.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30497433&#34; target=&#34;_blank&#34;&gt;Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Few studies have focused on quality of life (QoL) after treatment of malignant pleural mesothelioma (MPM). […] QoL outcomes should be factored into the choice of surgical procedure for MPM patients, and the possible effects on lung function and QoL should be discussed with patients when presenting surgical treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30499112&#34; target=&#34;_blank&#34;&gt;Modeling Epidermal Growth Factor Inhibitor-mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have demonstrated that lung-sparing surgery with intraoperative photodynamic therapy (PDT) achieves remarkably extended survival for patients with malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30501113&#34; target=&#34;_blank&#34;&gt;Biodistribution and Tumor Uptake of &lt;sup&gt;67&lt;/sup&gt;Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Only a multimodal-approach to treatment, based on surgical resection, chemotherapy and/or radiation, has shown some benefits. […] Nimotuzumab (h-R3), an anti-EGFR (epidermal growth factor receptor) humanized antibody, is proposed as a promising agent for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30510783&#34; target=&#34;_blank&#34;&gt;Management of database: European Society of Thoracic Surgeons mesothelioma database-difficulties in improving quality data for rare tumour.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a rare tumour but very aggressive with a median survival of 6 to 9 months from diagnosis without any treatment, The European Society of Thoracic Surgeons (ESTS) created a dedicated prospective mesothelioma registry to collect data on patients with malignant mesothelioma treated surgically to monitor the quality of surgery performed. […] About 25% received trimodality treatment including surgery and many of them were upstaged to pathological stage III and IV. […] Thirty percent to 40% of patients in the registry had missing information regarding clinical and pathological staging and more than 70% of patients do not have complete information on their multimodality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30524880&#34; target=&#34;_blank&#34;&gt;A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment-related adverse events were comparable to those observed in patients with chemotherapy alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30524884&#34; target=&#34;_blank&#34;&gt;Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, the combination of autologous tumor lysate-pulsed dendritic cells (DC) and metronomic cyclophosphamide (mCTX) was reported as a feasible and well-tolerated treatment in malignant pleural mesothelioma patients and further as a method to reduce circulating Tregs. &lt;b&gt;Objectives&lt;/b&gt;: The aim of this study was to establish the immunological effects of mCTX alone and in combination with DC-based immunotherapy on circulating Treg and other T cell subsets in mesothelioma patients. &lt;b&gt;Methods&lt;/b&gt;: Ten patients received mCTX and DC-based immunotherapy after chemotherapy (n = 5) or chemotherapy and debulking surgery (n = 5). […] Peripheral blood mononuclear cells before, during and after treatment were analyzed for various Treg and other lymphocyte subsets by flow cytometry. &lt;b&gt;Results&lt;/b&gt;: After one week treatment with mCTX, both activated FoxP3&lt;sup&gt;hi&lt;/sup&gt; and naïve CD45RA&lt;sup&gt;+&lt;/sup&gt; Tregs were effectively decreased in all patients. […] Survival analysis showed that overall Treg levels before treatment were not correlated with survival, however, nTreg levels before treatment were positively correlated with survival. […] After completion of mCTX and DC-based immunotherapy treatment, all cell subsets returned to baseline levels, except for the proportions of proliferating EM CD8 T cells, which increased. &lt;b&gt;Conclusions&lt;/b&gt;: mCTX treatment effectively reduced the proportions of circulating Tregs, both aTregs and nTregs, thereby favoring EM T cell subsets in mesothelioma patients. […] Interestingly, baseline levels of nTregs were positively correlated to overall survival upon complete treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30533375&#34; target=&#34;_blank&#34;&gt;Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite aggressive anticancer drug therapy, he expired due to disease progression 2.5 years after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30535191&#34; target=&#34;_blank&#34;&gt;Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Combined modality treatment (CMT) for malignant pleural mesothelioma (MPM) remains a matter of debate regarding the choice of surgical procedure: extrapleural pneumonectomy (EPP) or pleurectomy/decortication.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30539198&#34; target=&#34;_blank&#34;&gt;The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
FAK phosphorylation was reduced upon treatment but activation of Erk, Akt, or S6 remained unaffected.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30544524&#34; target=&#34;_blank&#34;&gt;The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunotherapy targeting the PD-L1/PD-1 axis has been developed as an anti-cancer therapy and used in treating advanced human non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30553477&#34; target=&#34;_blank&#34;&gt;BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with MPM have a poor prognosis, with estimated 1 year median survival and currently no treatment is curative. […] The presence of BAP1 mutations associated significantly with BAP1 protein expression (p &amp;lt; 0.001), the incidence of organ metastasis (p = 0.04), PFS after second line treatment (p = 0.04) and clinical response after second line treatment (p = 0.01) only. […] BAP1 mutations are associated with disease progression especially after second line therapy and the incidence of organ metastasis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30557956&#34; target=&#34;_blank&#34;&gt;Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conducted a historical cohort study of patients who underwent neoadjuvant chemotherapy (NAC) and curative-intent surgery as a multimodal treatment for MPM from January 2007 to June 2016. […] Pleural thickness after NAC was an independent prognostic factor in patients who underwent multimodal treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30558734&#34; target=&#34;_blank&#34;&gt;Metachronous Lung Cancer After Pleurectomy/Decortication.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, predicting lung cancer after treatment for MPM is difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3059081&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical treatment, chemotherapy, and irradiation, alone or in combination, have been used for malignant mesothelioma. […] Except for the palliative effect of irradiation, most treatment protocols have not altered the dismal median survival of approximately 11 months seen in untreated patients with malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30595194&#34; target=&#34;_blank&#34;&gt;NA&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ICIs are currently placed early in the course of the treatment of patients with non-small cell lung cancer (NSCLC). […] In France, approvals have been pronounced for nivolumab and pembrolizumab (anti-PD-1 antibodies) as second-line treatments after chemotherapy in patients with advanced NSCLC, and pembrolizumab has been approved as a first-line treatment in patients with advanced NSCLC, without EGFR mutation or ALK rearrangement, with strong (≥50%) PD-L1 (Programmed Death Ligand 1) expression. […] Atezolizumab is currently soon to be approved as a second-line treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30603603&#34; target=&#34;_blank&#34;&gt;Case report: Steroid responsive mesothelioma-related pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here we present the first reported case of steroid treatment responsive pleural effusion in a 72 year-old-male that initially was misdiagnosed as rheumatoid related effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30605211&#34; target=&#34;_blank&#34;&gt;Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. […] Phase 1b open-label study (JAVELIN Solid Tumor) in patients with unresectable mesothelioma that progressed after platinum and pemetrexed treatment, enrolled at 25 sites in 3 countries between September 9, 2014, and July 22, 2015. […] Twenty patients (38%) had 3 or more previous lines of therapy (median, 2; range, 1-8). […] Five patients (9%) had a grade 3 or 4 treatment-related adverse event, and 3 (6%) had a grade 3 or 4 immune-related, treatment-related adverse event. […] There were no treatment-related deaths.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30639549&#34; target=&#34;_blank&#34;&gt;Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients underwent multimodal treatment comprising chemotherapy (neoadjuvant and/or adjuvant) and surgery with or without 54 Gy hemithoracic radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30642542&#34; target=&#34;_blank&#34;&gt;Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, targeting mesothelioma stem cells by depleting M2-polarized macrophages in tumor microenvironment or blocking Tnfsf18 (GITRL)-GITR signalling might be translated into therapeutic modalities in mesothelioma treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30649229&#34; target=&#34;_blank&#34;&gt;Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Other factors significantly associated with better survival were younger age at diagnosis, higher income, lower comorbidity score, epithelial histology, earlier stage and receipt of surgical or medical treatment. […] These findings may lead to exploring new therapeutic options, such as targeting estrogen receptor beta, and considering hormonal therapy including estrogens for patients with otherwise limited prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30651596&#34; target=&#34;_blank&#34;&gt;ADAM10 mediates malignant pleural mesothelioma invasiveness.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic options and treatment efficiency.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30654090&#34; target=&#34;_blank&#34;&gt;Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We aimed to determine dose-volume constraints that correlate with severe (grade ≥3) radiation pneumonitis (RP) in patients diagnosed with malignant pleural mesothelioma, treated using volumetric modulated arc therapy. […] Data from 40 patients with malignant pleural mesothelioma who underwent pleurectomy decortication and adjuvant radiation therapy at our institution between December 2010 and October 2016 were retrospectively analyzed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30659154&#34; target=&#34;_blank&#34;&gt;Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overall, these results suggest that treatment with GHRH antagonists, alone or in association with chemotherapy, may offer an approach for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30660511&#34; target=&#34;_blank&#34;&gt;Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment was continued for up to 2 years or until confirmed progression or unacceptable toxicity. […] All patients who received at least one dose of therapy were included in safety analysis and all patients who received one dose of therapy and at least one radiological assessment were included in the primary analysis. […] Of 36 eligible patients, one deteriorated before the start of the study so was not included in any analyses and one withdrew consent after one treatment cycle before radiological assessment so was included in the safety population only. 34 patients were evaluable for response assessment at 12 weeks. […] Treatment-related adverse events were reported in 33 (94%) patients. […] Grade 3 treatment-related adverse events were reported in 12 (34%) of 35 patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30660609&#34; target=&#34;_blank&#34;&gt;Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and platinum-based chemotherapy. […] Central randomisation was stratified by histology (epithelioid vs non-epithelioid), treatment line (second line vs third line), and chemosensitivity to previous treatment (progression ≥3 months vs &amp;lt;3 months after pemetrexed treatment) and used a minimisation method with a 0·8 random factor. […] Efficacy analyses were also done in the intention-to-treat population and safety analyses were done in all patients who received at least one dose of their assigned treatment. […] Anti-PD-1 nivolumab monotherapy or nivolumab plus anti-CTLA-4 ipilimumab combination therapy both showed promising activity in relapsed patients with malignant pleural mesothelioma, without unexpected toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30661019&#34; target=&#34;_blank&#34;&gt;Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Evidence from other cancer types suggests some benefit in health-related quality of life (HRQoL) with early specialist palliative care (SPC) integrated with oncological services, but the certainty of evidence is low. […] HRQoL was assessed at baseline and every 4 weeks with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30. change in EORTC C30 Global Health Status 12 weeks after randomisation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30679948&#34; target=&#34;_blank&#34;&gt;Learning from the past to design better trials in second-line treatment for mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The standard treatment remains platinum-based chemotherapy with pemetrexed. […] All the patients, unfortunately, will progress, and currently, there is no standard treatment approved in second-line. […] Despite encouraging data achieved in previous phase I and phase II studies, the NGR-hTNF drug failed to meet the primary endpoint of the study, although a signal of activity was observed in the group of patients who had a shorter treatment failure interval from the first-line treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30684047&#34; target=&#34;_blank&#34;&gt;Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nurses described their roles as providing patient support (100%); information (95%); intermediary (74%); and link to palliative care (74%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30685089&#34; target=&#34;_blank&#34;&gt;Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In conclusion, these observations strongly support a role for collagen in mesothelioma growth and establish the potential for inhibitors of collagen synthesis in mesothelioma treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30687504&#34; target=&#34;_blank&#34;&gt;MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The primary objective is to measure the SD of visual analogue scale scores for dyspnoea following randomisation and examine the patterns of change over time in each treatment group.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30689034&#34; target=&#34;_blank&#34;&gt;Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study was conducted in order to describe the computed tomography (CT) features of local pleural recurrence in patients with malignant pleural mesothelioma undergoing intensity-modulated pleural radiation therapy (IMPRINT) as part of multimodality treatment. […] • In patients with mesothelioma receiving intensity-modulated pleural radiation as part of multimodality therapy, increasing multiple pleural nodules is the computed tomography feature most commonly present at local recurrence.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30697290&#34; target=&#34;_blank&#34;&gt;Histomorphological and Immunohistochemical Analysis of Pleural Neoplasms.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Analysis of histopathological pattern along with a panel of appropriate IHC markers distinguished the rare entities of pleural neoplasms essential to determine the prognosis and treatment modality.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30700254&#34; target=&#34;_blank&#34;&gt;Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality treatment with pemetrexed combined with cisplatin shows unsatisfying response-rates of 40%. […] The reasons for the rather poor efficacy of chemotherapeutic treatment are largely unknown. […] However, it is conceivable that DNA repair mechanisms lead to an impaired therapy response. […] We investigated the response of three MPM cell lines and lung fibroblasts serving as a control to treatment with pemetrexed, cisplatin and olaparib. […] A BRCAness-dependent increase of apoptosis and senescence during olaparib-based treatment of BRCA-associated-protein 1 (BAP1)-mutated cell lines was observed. […] Thus, this combination therapy might be effective for up to 2/3 of patients, promising to enhance patients’ clinical management and outcome.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30706690&#34; target=&#34;_blank&#34;&gt;Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The overall response rate to first-line chemotherapy was 40.4%, progression-free survival to first-line treatment was 5.7 months (95% CI 4.9-6.5), and 63 (20.8%) patients had pemetrexed maintenance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30723653&#34; target=&#34;_blank&#34;&gt;Fluorodeoxyglucose versus Choline Positron Emission Tomography/Computed Tomography Response Evaluation in Two Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Neoadjuvant Chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus we suggest choline-PET/CT may show little choline uptake to granulomatous inflammation and evaluate treatment response in malignant pleural mesothelioma patients treated with talc pleurodesis and NAC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30762130&#34; target=&#34;_blank&#34;&gt;Use of Immune Checkpoint Inhibitors in Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Based on the growing body of literature, it is anticipated that checkpoint inhibitors will receive regulatory approval in the USA and Europe soon for salvage therapy. […] Additional research efforts will determine whether earlier stage patients and frontline unresectable patients will benefit from the addition of immunotherapy to their treatment regimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30774332&#34; target=&#34;_blank&#34;&gt;Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is still no effective therapy for MPM. […] The use of gold nanoparticles (GNPs) as a drug delivery system promises several advantages, including specific targeting of malignant cells, with increased intracellular drug accumulation and reduced systemic toxicity, and, in the case of MPM, direct treatment administration into the pleural space. […] Both cell viability and motility were significantly affected by nanoparticle treatment compared to Pe. […] GNP-HCPe treatment displays in vitro antineoplastic action and is more effective than Pe alone in inhibiting MPM cell line malignant phenotype.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30779366&#34; target=&#34;_blank&#34;&gt;Vascular-targeted low dose photodynamic therapy stabilizes tumor vessels by modulating pericyte contractility.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Vascular-targeted low-dose photodynamic therapy (L-PDT) was shown to improve chemotherapy distribution in malignant pleural tumors such as malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30785691&#34; target=&#34;_blank&#34;&gt;[Possibilities of cytological diagnosis of the nature of the exudate at the stage of emergency.]&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytological diagnosis by effusions is currently the only reliable method of morphological verification of the diagnosis, it has prognostic significance and determines the choice of treatment strategy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30785827&#34; target=&#34;_blank&#34;&gt;Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On this basis, we designed a randomized, phase II trial to investigate whether defactinib as maintenance therapy after standard first-line chemotherapy could improve progression-free survival (PFS) in patients with malignant pleural mesothelioma (MPM). […] Although shorter survival for both defactinib- and placebo-treated patients was observed, in the patients who had merlin-low MPM compared with the patients who had merlin-high MPM, there were no statistical differences in response rate, PFS, OS, or QoL between the treatment groups. […] Defactinib cannot be recommended as maintenance therapy for advanced MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30788836&#34; target=&#34;_blank&#34;&gt;Multiple sclerosis outcomes after cancer immunotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Neurological immune-related adverse events are a rare but potentially deadly complication after immune checkpoint inhibitor (ICI) treatment. […] As multiple sclerosis (MS) is an immune-mediated disease, it is unknown how ICI treatment may affect outcomes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30790063&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
First-line combination therapy with pemetrexed and a platinum analog allows a modest survival benefit, while no clear therapeutic options exist for the second-line therapy. […] In this setting, pemetrexed seems to be the most active drug; however, the inclusion in front-line treatment limits its use in further lines. […] Among other options, targeted therapy has unfortunately produced disappointing results as salvage treatment probably due to the lack of a clear understanding of the tumor biology. […] In contrast, recent data suggest moderate efficacy and mild toxicity of immunotherapy also for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30794891&#34; target=&#34;_blank&#34;&gt;Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No significant difference in PD-L1 expression was observed by patient sex, age, treatment history, pathologic stage, or histologic subtype.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30798447&#34; target=&#34;_blank&#34;&gt;The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Local recurrence represents the majority of treatment failures and overall survival (OS) outcomes remain dismal. […] Adding locoregional treatment with radiotherapy after surgical resection has been considered but its role remains uncertain. […] The purpose of this study was to evaluate the outcomes of adjuvant radiation therapy (RT) for patients with malignant pleural mesothelioma. […] In the treatment of malignant pleural mesothelioma, adjuvant radiotherapy after surgical intervention was associated with improved OS.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30809599&#34; target=&#34;_blank&#34;&gt;Relations between approved platinum drugs and non-coding RNAs in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Platinum(II) complexes such as cisplatin and carboplatin are clinically approved for the therapy of mesothelioma often in combination with antimetabolites such as pemetrexed or gemcitabine. […] Suitable non-coding RNA-modulating agents with potentially beneficial effects on cisplatin treatment of mesothelioma diseases are mentioned. […] The understanding of mesothelioma diseases concerning the interactions of non-coding RNAs and platinum drugs will optimize existing therapy schemes and pave the way to new treatment options in future.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30809600&#34; target=&#34;_blank&#34;&gt;Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Gemcitabine and pemetrexed are clinically approved antimetabolites for the therapy of mesothelioma diseases. […] Further to this, various non-coding RNA-modulating agents are discussed which displayed positive effects on gemcitabine or pemetrexed treatment of mesothelioma diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30810270&#34; target=&#34;_blank&#34;&gt;Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have reviewed the literature to provide a comprehensive summary of novel intrapleural immunotherapeutic paradigms, including oncolytic virus therapy, gene-mediated cytotoxic immunotherapy, direct cytokine-mediated immunotherapies, innate immunomodulators and adoptive transfer of intrapleural chimeric antigen receptor T-cell therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30813957&#34; target=&#34;_blank&#34;&gt;Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Dynamic contrast-enhanced (DCE) MRI is a functional imaging technique used to analyze tumor microvascular properties and to monitor therapy response. […] Patient underwent DCE-MRI studies at three time points: prior to therapy, during and after cisplatin-based chemotherapy. […] Receiver operating characteristic curve analysis was used to examine specificity and sensitivity of DCE parameters for predicting response to therapy. […] Significant correlation with response to therapy was found for AATH-calculated median pre-treatment efflux rate (k&lt;sub&gt;ep&lt;/sub&gt;) showing sensitivity of 83% and specificity of 100% (AUC 0.9). […] ET-calculated maximal pre-treatment k&lt;sub&gt;ep&lt;/sub&gt; showed 100% sensitivity and specificity for predicting treatment response during the early phase of the therapy and reached a favorable trend to significant prognostic value post-therapy. […] Both models show potential in predicting response to therapy in MPM. […] High pre-treatment k&lt;sub&gt;ep&lt;/sub&gt; values suggest MPM disease control post-chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30840717&#34; target=&#34;_blank&#34;&gt;Deep convolutional neural networks for the automated segmentation of malignant pleural mesothelioma on computed tomography scans.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumor volume has been a topic of interest in the staging, prognostic evaluation, and treatment response assessment of malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30863365&#34; target=&#34;_blank&#34;&gt;When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options are limited at best and drug resistance is common. […] Recombinant MST1 treatment was unable to overcome the effect of LCRF-0004 in terms of either proliferation or apoptosis. […] The &lt;i&gt;in vivo&lt;/i&gt; and &lt;i&gt;in vitro&lt;/i&gt; data generated by this study indicates that a multi-TKI, targeting the MST1R/MET/TAM signaling pathways, may provide a more effective therapeutic strategy for the treatment of MPM as opposed to targeting MST1R alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30886321&#34; target=&#34;_blank&#34;&gt;Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Outcome measures included objective activity levels (Actigraph GT3X) and health-related quality of life (HRQoL; Functional Assessment of Cancer Therapy General).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30911616&#34; target=&#34;_blank&#34;&gt;Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, it has a great potential to select patients for the optimal treatment option, thereby offering a tool for personalized cancer therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30911636&#34; target=&#34;_blank&#34;&gt;Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Peritoneal metastases from gynecologic and gastrointestinal cancer is of increasing interest to surgical and medical oncologists because of newly recognized benefits of treatment. […] In three high grade malignancies with the preponderance of cytoreductive surgery (CRS) and HIPEC treatment failures within the peritoneal space, NIPEC-LT has been favorably reported in the oncology literature. […] In ovarian cancer and malignant peritoneal mesothelioma the NIPEC-LT is used an adjuvant treatment in an attempt to preserve a surgical complete response of CRS. […] In gastric cancer, NIPEC-LT is given as a neoadjuvant treatment with responders going on to radical surgical resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30915490&#34; target=&#34;_blank&#34;&gt;Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A planning study was performed for helical tomotherapy treatment. […] With helical tomotherapy, postoperative treatment for malignant pleural mesothelioma after pleurectomy achieves good target coverage combined with simultaneous dose sparing to the (especially contralateral) OARs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30917938&#34; target=&#34;_blank&#34;&gt;Patterns of care and survival of older patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, we studied the impact of advancing age on treatment utilisation and clinical outcomes in an extensive series of minimally selected MPM patients. […] They were categorised by age (&amp;lt;70 years, 70-80 years or &amp;gt; 80 years) and chi-square testing was used to assess the relationship between clinical and demographic variables, age, treatment and overall survival (OS). […] Advancing age group of NSW patients with MPM was associated with reduced treatment utilisation and a decline in OS. […] Prospective studies are warranted to verify if current treatment guidelines are relevant for the older adults with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30920878&#34; target=&#34;_blank&#34;&gt;Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prophylactic irradiation to the chest wall after diagnostic or therapeutic procedures in patients with malignant pleural mesothelioma (MPM) has been a widespread practice across Europe, although the efficacy of this treatment is uncertain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30941506&#34; target=&#34;_blank&#34;&gt;Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of definite IgG4-related disease was made, and treatment with prednisone 50 mg/day was started.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30941737&#34; target=&#34;_blank&#34;&gt;The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The MTS assay was used to assess cell viability following 72 h treatment with the lipoxygenase pathway inhibitors baicalein, licofelone, MK-886 and zileuton in the MPM cell lines NCI-H2052, NCI-H2452 and MSTO-211H. […] We have demonstrated that the inhibition of the LOX pathway using baicalein may be effective as a novel treatment for MPM, however further human pharmacokinetic studies are required in order to establish whether the concentration used in vitro is clinically achievable.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30944296&#34; target=&#34;_blank&#34;&gt;Pseudomesotheliomatous Carcinoma with a High Pleural Hyaluronic Acid Concentration Arising from a Primary Esophageal Squamous Cell Carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient received cisplatin and 5-FU combination chemotherapy as first-line treatment, and docetaxel chemotherapy as second-line treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30944991&#34; target=&#34;_blank&#34;&gt;A survey of patient and caregiver experience with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most participants felt informed about treatment options but only 69% thought all treatment options were discussed. […] Palliative care referral: 31% patients, 85% caregivers. […] Satisfaction with treatment was high, but participants identified need for improved communication and quality information, discussion about all treatments, end-of-life assistance, and caregiver support after the patient’s death.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30951250&#34; target=&#34;_blank&#34;&gt;Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The nomogram is a reliable tool that can help clinicians turn individualized prediction into reality and maximize patient benefit by identifying the most beneficial treatment approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30963379&#34; target=&#34;_blank&#34;&gt;Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Major patients and treatment characteristics were the following: median age 62 years, epithelioid histology in 51 (94%) cases, locally advanced disease in 41 (90%) cases, and metastatic mediastinal lymph nodes in 27 patients (50%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30977408&#34; target=&#34;_blank&#34;&gt;The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Introduction&lt;/b&gt;: Trimodality therapy (including surgery, chemotherapy and radiation therapy) represents an important management approach of early-stage malignant pleural mesothelioma (MPM). […] It evaluates also how to select patients for induction chemotherapy and how to assess the response to treatment. &lt;b&gt;Expert Opinion&lt;/b&gt;: Management of patients with early-stage MPM must be completed in a multidisciplinary team in tertiary centers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31004585&#34; target=&#34;_blank&#34;&gt;Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cancer-directed surgery was significantly underutilized in epithelial MPM, with 29.3% having no treatment. […] Median survival estimates for no treatment, chemotherapy alone, surgery plus chemotherapy, and trimodal therapy were 10.2, 15.4, 21.1, and 21.7 months, respectively (log rank P &amp;lt; .001). […] In epithelial MPM, a significant increase in overall survival was observed in surgery plus chemotherapy (hazard ratio 0.62, 95% CI, 0.53 to 0.73, P &amp;lt; .001) and trimodality (hazard ratio 0.61, 95% CI, 0.49 to 0.76, P &amp;lt; .001; reference: no treatment). […] There is a suboptimal compliance with national guidelines for the treatment of MPM, particularly in low-volume nonacademic settings. […] Adherence to recommended surgery-based multimodal therapy is associated with an overall survival improvement.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31011908&#34; target=&#34;_blank&#34;&gt;Management of Malignant Pleural Mesothelioma in the Elderly Population.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Elderly patients pose unique management challenges because of the increased risk of therapy-related toxicities and mortality. […] Because there are no high-volume retrospective studies, prospective trials, or dedicated treatment recommendations for this population, this investigation addresses a major knowledge gap by examining national practice patterns and postoperative/survival outcomes in elderly MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31019759&#34; target=&#34;_blank&#34;&gt;Pathological evaluation of the visceral pleura in the radical pleurectomy/decortication for malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radical pleurectomy/decortication (P/D) is applied as a surgical treatment of resectable malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31019792&#34; target=&#34;_blank&#34;&gt;Extra-pleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The extra-pleural pneumonectomy (EPP) is a standardised surgical procedure born for pleural tuberculosis and later used in pleural cancer treatment, especially in malignant pleural mesothelioma (MPM). […] In referral centres and selected patients, EPP is a cytoreductive or radical surgical treatment in extended pleural malignancies. […] Prospective studies are needed to standardise the timing of the procedure in a multimodality treatment program, according to the oncological and functional indications, to keep an acceptable complications rate and post-operative quality of life status.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31023248&#34; target=&#34;_blank&#34;&gt;Physician requests by patients with malignant pleural mesothelioma in Japan.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment and care requests made by MPM patients to their physicians were collected and analyzed. […] Specific responses to two open-ended questions related to patients’ requests regarding treatment and care were quantified, analyzed and divided into categories based on content. […] Patients wanted clear and understandable explanations about MPM and wanted their physician to deliver treatment based on the patient’s perspective by accepting and empathizing with their anxiety and pain. […] A multidisciplinary care system that includes respiratory and palliative care for MPM patients should be established.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31037036&#34; target=&#34;_blank&#34;&gt;Pain management in patients with malignant mesothelioma: challenges and solutions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A variety of treatment modalities, including pharmacological and non-pharmacological options, are often required to achieve adequate pain control in this challenging disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31054476&#34; target=&#34;_blank&#34;&gt;Metadherin Is a Prognostic Apoptosis Modulator in Mesothelioma Induced via NF-κB-Mediated Signaling.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MTDH represents a new MPM-associated gene that can contribute to insights of MPM biology and, as such, suggest other treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31057996&#34; target=&#34;_blank&#34;&gt;First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While there is growing interest in using immunotherapy and immuno-gene therapy to treat MPM, very limited data currently exist for combining these modalities with radiotherapy. […] We report the first-ever case of abscopal effect in a patient with MPM, following radiotherapy and immuno-gene therapy. […] He enrolled in a clinical trial in which he received intrapleural interferon-alpha gene therapy but needed to discontinue therapy due to supraventricular tachycardia and superior vena cava syndrome induced from tumor burden. […] His subsequent chest CT scan two months after radiotherapy completion showed a dramatic treatment response within, as well as outside of, the irradiated field. […] Herein, we highlight the feasibility and efficacy of combining immuno-gene therapy with palliative radiotherapy to produce a substantial treatment response and an abscopal effect in a patient with unresectable MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31065954&#34; target=&#34;_blank&#34;&gt;A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Methods A multicenter, open-label, phase Ib study evaluated weekly GSK3052230 added to pemetrexed/cisplatin in patients with treatment-naive, unresectable malignant pleural mesothelioma. […] The most common treatment-related adverse events (AEs) were nausea (56%), decreased appetite (36%), infusion reactions (36%), decreased neutrophil counts (36%), and fatigue (33%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31065962&#34; target=&#34;_blank&#34;&gt;50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most common sites of malignant mesothelioma are the pleura and peritoneum, but little is known about the incidence, prognosis, or treatment of patients with disease in both cavities. […] Previous series suggest that multimodality treatment improves overall survival for pleural or peritoneal disease, but studies typically exclude patients with disease in both cavities. […] Well-selected patients with both pleural and peritoneal mesothelioma have a survival benefit over palliative treatment that is comparable with that seen in single-cavity disease. […] The presence of disease in both cavities is not a contraindication to multimodality treatment aimed at prolonging survival, whether the disease is diagnosed synchronously or metachronously.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31092517&#34; target=&#34;_blank&#34;&gt;Advances in pulmonary and pleural malignant disorders.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic pathways aim to reduce the time taken for patients to reach a diagnosis and treatment, with the use of positron emission tomography and endobronchial ultrasound to provide staging information alongside diagnostics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31092657&#34; target=&#34;_blank&#34;&gt;Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent advances in treatment strategies focusing on cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have resulted in improved median survival of 53 months and a 5 year survival of 47%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31097101&#34; target=&#34;_blank&#34;&gt;Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Consecutive patients with biopsy-proven MPM undergoing EPD with intraoperative photodynamic therapy (PDT) at our institution from 2008 to 2014 were included in this retrospective study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31099677&#34; target=&#34;_blank&#34;&gt;Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The success of immune checkpoint inhibitor (ICI) therapy in NSCLC has led to enthusiasm to expand the reach of these drugs into other thoracic malignancies such as thymic epithelial tumors (TETs), mesothelioma, and small cell lung cancer (SCLC). […] Unfortunately, the improvement in outcomes with ICI therapy in these rarer thoracic tumors has been somewhat modest, and in the case of thymoma, rates of adverse events are too high to routinely justify their use. […] Although the response rates seen in ICI therapy in these tumor types are similar to those seen with other available single-agent therapies for advanced disease, ICIs do present another option for clinicians treating patients with mesothelioma, small cell carcinoma, and thymic carcinoma (TC), diseases in which approved treatment options are limited. […] Here we review the latest trials of ICI therapy in mesothelioma, SCLC, and TETs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31103412&#34; target=&#34;_blank&#34;&gt;Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median treatment duration was 5·3 months (IQR 2·8-7·3) in the nintedanib group and 5·1 months (2·7-7·8) in the placebo group. […] The most frequently reported grade 3 or worse adverse event in both treatment groups was neutropenia (73 [32%] in the nintedanib group vs 54 [24%] in the placebo group).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31118810&#34; target=&#34;_blank&#34;&gt;High systemic immune-inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The optimal cutoff value of pretreatment systemic immune-inflammation index (SII) was determined by receiver operating characteristic curve. […] On univariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS)&amp;lt;2 points, low SII and adjuvant treatment (&lt;i&gt;P&lt;/i&gt;&amp;lt;0.05) were found to be closely correlated with a better prognosis of MPM. […] Only ECOG PS (&lt;i&gt;P&lt;/i&gt;=0.036) and SII (&lt;i&gt;P&lt;/i&gt;=0.009) held statistical significance on multivariate analysis. &lt;b&gt;Conclusion:&lt;/b&gt; Pretreatment SII is easy to access to, and it represents an efficiency and noninvasive biomarker of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31125736&#34; target=&#34;_blank&#34;&gt;The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Detailed guidelines regarding the use of radiation therapy for malignant pleural mesothelioma (MPM) are currently lacking because of the rarity of the disease, the wide spectrum of clinical presentations, and the paucity of high-level data on individual treatment approaches. […] Here we present consensus recommendations on the use of radiation therapy for MPM in three discrete scenarios: (1) hemithoracic radiation therapy to be used before or after extrapleural pneumonectomy; (2) hemithoracic radiation to be used as an adjuvant to lung-sparing procedures (i.e., without pneumonectomy); and (3) palliative radiation therapy for focal symptoms caused by the disease. […] We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints. […] We also assess the role of particle beam therapy, specifically, proton beam therapy, for MPM. […] The recommendations provided in this consensus statement should serve as important guidelines for developing future clinical trials of treatment approaches for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31136816&#34; target=&#34;_blank&#34;&gt;A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, it is anticipated that significant strides in the surgery-based treatment of this cancer will require trials that determine which complementary treatments best augment the cytoreductive efficacy of surgery. […] It is not currently possible to rigorously assess the contribution of the adjuvant treatments combined with surgery because of the variability in procedures used to debulk this cancer, the extreme variability of the cancer itself, the variability in patient selection, the variability in treatment of the inevitable recurrence, and even the variability in follow up schedules.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31151962&#34; target=&#34;_blank&#34;&gt;Inactivation of &lt;i&gt;Bap1&lt;/i&gt; Cooperates with Losses of &lt;i&gt;Nf2&lt;/i&gt; and &lt;i&gt;Cdkn2a&lt;/i&gt; to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural malignant mesothelioma is a therapy-resistant cancer affecting the serosal lining of the thoracic cavity. […] Adenoviral-Cre treatment of normal mesothelial cells from &lt;i&gt;Bap1;Nf2;Cdkn2a&lt;/i&gt; CKO mice, but not from mice with knockout of one or any two of these genes, resulted in robust spheroid formation &lt;i&gt;in vitro&lt;/i&gt;, suggesting that mesothelial cells from &lt;i&gt;Bap1;Nf2;Cdkn2a&lt;/i&gt; mice have stem cell-like potential.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31164373&#34; target=&#34;_blank&#34;&gt;Clinical Efficacy and Safety of Nivolumab: Results of a &lt;u&gt;M&lt;/u&gt;ulticenter, Op&lt;u&gt;e&lt;/u&gt;n-label, Single-a&lt;u&gt;r&lt;/u&gt;m, Japanese Phase II study in Mal&lt;u&gt;i&lt;/u&gt;gnant Pleural Meso&lt;u&gt;t&lt;/u&gt;helioma (MERIT).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with MPM who do not respond to standard first-line chemotherapy have limited treatment options. […] We evaluated the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for the treatment of advanced or metastatic MPM. […] Adverse events (AEs) and treatment-related AEs (TRAEs) were evaluated. […] Nivolumab met the primary endpoint as second- or third-line treatment for patients with MPM and showed promising efficacy with manageable toxicity.&lt;i&gt;See related commentary by Mansfield and Zauderer, p. 5438&lt;/i&gt;.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31167266&#34; target=&#34;_blank&#34;&gt;[Recent Developments in the Regional Treatment of Peritoneal and Pleural Tumours (incl. HIPEC and HITOC)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The multimodal treatment of limited peritoneal metastases may improve prognosis in selected patients (pseudomyxoma peritonei, malignant peritoneal mesothelioma, colorectal, gastric and ovarian cancer) provided complete cytoreduction can be performed. […] If the treatment is undertaken in experienced (and certified) centres, associated mortality is low.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31175096&#34; target=&#34;_blank&#34;&gt;Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
HRQoL was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 and the lung cancer-specific module QLQ-LC13 at randomization and then every 9 weeks until disease progression.HRQoL deterioration-free survival (QFS), used to analyze longitudinal HRQoL data, was defined as the interval between randomization and the occurrence of the first clinically relevant definitive deterioration compared with the HRQoL score at baseline, or death.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31179006&#34; target=&#34;_blank&#34;&gt;Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Particular challenges are associated with communicating a diagnosis of MPM, including explaining the disease and its prognosis, treatment options and legal and financial implications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31179069&#34; target=&#34;_blank&#34;&gt;Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodality therapy may prolong survival among resectable malignant pleural mesothelioma (MPM). […] Adjuvant radiation included intensity modulated radiation therapy or conformal 3D radiation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31179088&#34; target=&#34;_blank&#34;&gt;Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overexpression of estrogen receptors in malignant pleural mesothelioma has shown an independent relation with a better prognosis of survival, and the use of selective estrogen receptor beta (ERβ) agonists increases the susceptibility to antitumor treatment. […] The response to treatment as by RECIST 1.1, 12 (54.5%) had partial response, 5 (22.7%) had stable disease, and 3 (13.6%) had progression. […] High and moderate expression of ERβ group with advanced clinical stage malignant pleural mesothelioma was associated with a tendency of higher OS and better response to chemotherapy treatment resulting in longer PFS although statistical significance was not achieved.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31191742&#34; target=&#34;_blank&#34;&gt;Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is a rare, but fatal disease with few treatment options. […] The diagnosis and treatment response are challenging in MM. […] The aim of our study was to investigate matrix metalloproteinase 9 (MMP9) as a potential serum biomarker of treatment response and survival in MM. […] Serum samples were collected before treatment, at the end of chemotherapy, and at the time of progression. […] The role of serum MMP9 and &lt;i&gt;MMP9&lt;/i&gt; polymorphisms in treatment response was determined using the nonparametric tests and logistic or Cox regression. […] Median serum MMP9 was 706.7 (499.6-1224.9) ng/ml before treatment, 440.5 (255.9-685.2) ng/ml after chemotherapy, and 502.8 (307.2-851.4) ng/ml at disease progression. […] At disease progression, 47 (65.3%) patients had lower serum MMP9 compared to pretreatment values, with the median change of -163.7 (-466.6 to 108.6) ng/ml (&lt;i&gt;P&lt;/i&gt; = 0.001). […] Patients with higher performance status had higher serum MMP9 before treatment (&lt;i&gt;P&lt;/i&gt; = 0.010). […] Among investigated polymorphisms, only rs17576 was associated with serum MMP9 levels before treatment (&lt;i&gt;P&lt;/i&gt; = 0.041). […] Median serum MMP9 levels differed significantly before and after treatment of MM, but failed to reach significance as a standalone biomarker.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31194830&#34; target=&#34;_blank&#34;&gt;Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These novel anti-CD26 mAbs are potentially useful for the analysis of CD26 expression in cancer patients with bony metastasis, and may help decide the appropriateness of YS110 therapy for future cancer patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31207975&#34; target=&#34;_blank&#34;&gt;Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The identification of diagnostic VOCs pattern, through breath sample characterization and the statistical data treatment, allows to obtain a strategic information for clinical diagnostics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31209661&#34; target=&#34;_blank&#34;&gt;Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM) was adapted from the general (core) MDASI to assess the severity of cancer-related and treatment-related symptoms specific to patients with this condition. […] In this secondary analysis of data from a Phase II trial, 248 patients provided MDASI-MPM data at multiple timepoints during therapy. […] Cronbach coefficient alpha values for all MDASI-MPM subscales were at least 0.88 at baseline and 0.91 during treatment, indicating good internal consistency reliability. […] Symptoms specific to a particular cancer, treatment method, or treatment site can be added to the core MDASI to create a tailored, “fit for purpose” instrument.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31212997&#34; target=&#34;_blank&#34;&gt;miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Combining neo-adjuvant chemotherapy and surgery is part of multimodality treatment of malignant pleural mesothelioma (MPM), but not all patients benefit from this approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31213801&#34; target=&#34;_blank&#34;&gt;Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Finally, no difference was noticed in liposomal-DiR retention between tumor-inoculated (MPE) and healthy mice, indicating the stability of liposomes in the presence of effusion (in MPE mice). &lt;b&gt;Conclusion:&lt;/b&gt; The current study provides novel insights for using liposomes by intrapleural administration for the treatment of lung diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31218434&#34; target=&#34;_blank&#34;&gt;[Hyperthermic intrathoracic chemotherapy in thoracic surgery].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The main indications are for malignant pleural mesothelioma and thymoma with pleural spread (stage IVa), whereas treatment of secondary pleural carcinomatosis is indicated only in selected patients suitable for resection followed by HITOC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31226401&#34; target=&#34;_blank&#34;&gt;Management of Clinically Lymph Node-Positive Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This was primarily owing to undeniable selection biases in these heterogeneous datasets; the presence of incomplete and inadequately granular clinical information (eg, intent and selection of treatment, preoperative assessment) cannot be accounted for by propensity matching or other such algorithms, thus potentially leading to misinterpretation. […] Overall, 13% received surgery/chemotherapy, 47% underwent chemotherapy alone, 30% were observed, and 5% received resection without chemotherapy (5% had unknown treatment information).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31242986&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma: A Multi-Disciplinary Approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery is used as a radical treatment modality but the risk of local relapse is very high. […] Therefore, radiation therapy is used in postoperative setting to improve local control. […] The case was discussed in multidisciplinary team meeting and adjuvant radiation therapy was offered. […] The patient was planned with a blend of modern intensity modulated radiation therapy technique and conventional three-dimensional conformal radiation therapy technique, to keep doses of adjacent organs within tolerance limits and at the same time deliver the intended dose of radiation to the tumor site. […] However, despite advances in radiation techniques, current treatment modalities have not significantly made an impact on survival of these patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31262194&#34; target=&#34;_blank&#34;&gt;What can independent research for mesothelioma achieve to treat this orphan disease?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Firstly, chemotherapy-based trials are described, followed by immunotherapy and multitargeted therapy. […] Finally, we highlight potential molecular pathways that may play a role in mesothelioma biology and therapy. &lt;b&gt;Expert Opinion&lt;/b&gt;: Numerous biases are present in the clinical trials due to a restricted number of cases, inappropriate endpoints and inaccurate stratification of patients which delay the finding of a treatment for MPM. […] However, this approach is not necessarily scientific given the low mutational load of mesothelioma relative to other cancers, and therefore patients need a more solid rationale to have a good chance of successful treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31262908&#34; target=&#34;_blank&#34;&gt;2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a therapy-resistant neoplasm of the pleura. […] In 3D MPM spheroid growth 2-DG synergism with CPDD+PEM treatment is not maintained.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31263030&#34; target=&#34;_blank&#34;&gt;Clinical Response of Live-Attenuated, &lt;i&gt;Listeria monocytogenes&lt;/i&gt; Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No unexpected treatment-related serious adverse events or deaths were observed. […] IHC analysis of pre- and post-CRS-207 treatment tumor biopsies revealed possible reinvigoration and proliferation of T cells, increased infiltration of dendritic and natural killer cells, increased CD8:T&lt;sub&gt;reg&lt;/sub&gt; ratio, and a shift from immunosuppressive M2-like to proinflammatory M1-like macrophages following CRS-207 administration.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31266291&#34; target=&#34;_blank&#34;&gt;Preliminary results of entire pleural intensity-modulated radiotherapy in a neoadjuvant setting for resectable malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study is to evaluate the safety and efficacy of the multimodality treatment with neoadjuvant intensitymodulated radiotherapy (IMRT) for resectable clinical T1-3N0-1M0 malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31280996&#34; target=&#34;_blank&#34;&gt;Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Unresectable MPM has a poor prognosis and limited treatment options and, as such, there is a broad range of therapeutic targets of interest, including angiogenesis, immune checkpoints, mesothelin, as well as chemotherapeutic agents. […] This review examines the scientific rationale for targeting angiogenesis in the treatment of unresectable MPM and analyzes recent clinical results with antiangiogenic agents in development (bevacizumab, nintedanib, and cediranib) for the management of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31287877&#34; target=&#34;_blank&#34;&gt;Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While cisplatin plus pemetrexed, the standard treatment for malignant pleural mesothelioma (MPlM), is usually used for MPeM, its efficacy remains unclear. […] Non-hematological toxicities were mild, and there were no treatment-related deaths. […] Cisplatin plus pemetrexed, showing consistent efficacy with MPlM, can be recommended as first-line treatment for unresectable MPeM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31289611&#34; target=&#34;_blank&#34;&gt;Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Epigenetic control of microRNA expression was inferred following decitabine and Trichostatin A (TSA) treatment which did not substantially affect microRNA expression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31302213&#34; target=&#34;_blank&#34;&gt;Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed (PMX) is a multi-targeted antifolate drug used for the treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer. […] On the other hand, intrapleural administration of 76 kDa HA-ADH-PMX resulted in a survival rate of MPM model mice comparable to that with native PMX, suggesting the potential for future MPM therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31315884&#34; target=&#34;_blank&#34;&gt;Nivo-lution in Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. […] MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.&lt;i&gt;See related article by Okada et al., p. 5485&lt;/i&gt;.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31316876&#34; target=&#34;_blank&#34;&gt;Prostate Carcinoma and Pleural Mesothelioma: An Extremely Rare Co-occurrence.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 67-year-old male, diagnosed case of carcinoma prostate with bone metastasis, was treated with chemotherapy and hormone therapy. […] He responded well to chemotherapy and hormone therapy. […] The long-life expectancy, old age, late effects of the treatment, genetic predisposition and lifestyle factors of patients with carcinoma prostate expose them to the possibility of developing second primary tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31348117&#34; target=&#34;_blank&#34;&gt;Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pemetrexed is an antifolate cytostatic drug that targets multiple enzymes involved in folate biosynthesis and is indicated for treatment of non-small-cell lung cancer and malignant pleural mesothelioma. […] As evidence for an exposure-response/toxicity relationship is accumulating, dose individualization using therapeutic drug monitoring may be a feasible strategy to optimize treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31353039&#34; target=&#34;_blank&#34;&gt;Perioperative anesthetic management of patients with malignant pleural mesothelioma undergoing cytoreductive surgery and intraoperative chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytoreductive surgery with hyperthermic intraoperative chemotherapy (HITHOC) is a therapeutic option for treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31367541&#34; target=&#34;_blank&#34;&gt;A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive, treatment resistant neoplasm. […] The current treatment, consisting of antifolate and platinum-based chemotherapy, improves the median overall survival with only 3 months. […] Dendritic cell (DC) therapy can induce an immune response and activate tumor-specific CD8&lt;sup&gt;+&lt;/sup&gt; T-cells. […] Allogeneic mesothelioma tumor-lysate loaded DC therapy has proven effective in mice and safe and feasible in humans. […] We have designed a randomized, phase II/III, multicenter, open-label trial to examine the efficacy of DC therapy in humans with histologically proven MPM. […] In this open-label, multicenter, randomized phase II/III trial patients will be randomized to receive either DC therapy plus best supportive care (BSC) or BSC alone according to the discretion of the local investigator after first line chemotherapy treatment. […] This phase II/III trial will determine whether DC therapy in patients with MPM is safe and effective as a maintenance treatment and subsequently might be a new treatment option for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31372931&#34; target=&#34;_blank&#34;&gt;Heterologous sarcomatoid pleural mesothelioma with osteosarcomatous differentiation: a report of autopsy case that accomplished trimodality therapy and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After 12-month disease-free period post treatment, rapid intraperitoneal recurrence resulted in death. […] We present here a case of heterologous osteosarcomatous pleural mesothelioma that followed a unique clinical course after trimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31376434&#34; target=&#34;_blank&#34;&gt;Mesothelioma of the tunica vaginalis testis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three men with MM had received either chemotherapy or radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31377142&#34; target=&#34;_blank&#34;&gt;The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The association between TNM, tumor size (T), TV, NPS, TV and NPS, and overall survival was assessed using Cox models adjusted for age, sex, histology, and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31386610&#34; target=&#34;_blank&#34;&gt;Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31394644&#34; target=&#34;_blank&#34;&gt;Immune Signature of Malignant Pleural Mesothelioma as Assessed by Transcriptome Analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As immunotherapy has been shown to offer promising and targeted treatment of MPM patients, the knowledge of the immunoresistance level of MPM may be a valuable tool for “à la carte” therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31399037&#34; target=&#34;_blank&#34;&gt;Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Metabolomic profiling revealed that Dropwort treatment affected both glycolysis/tricarboxylic acid cycle as for the decreased consumption of glucose, pyruvate, succinate and acetate, and the lipid metabolism.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31413910&#34; target=&#34;_blank&#34;&gt;Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In syngeneic murine models of MM, P4D2 mAb treatment inhibited tumor growth and improved survival, with tumors from P4D2-treated mice exhibited reduced infiltration of tumor-associated M2 macrophages. […] These data suggest that using an antigalectin 9 mAb with agonistic properties similar to those exerted by galectin-9 may provide a novel multitargeted strategy for the treatment of mesothelioma and possibly other galectin-9 expressing tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31417958&#34; target=&#34;_blank&#34;&gt;MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The standard frontline treatment of MPM is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) unless the peritoneal disease is considered unresectable. […] For unresectable patients the standard frontline treatment is a combination of cisplatin and pemetrexed but the prognosis remains ominous with only 13 months of overall survival (OS). […] The proposed study is a multicenter randomized non-comparative study evaluating the association of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy vs. systemic chemotherapy alone as first-line treatment of MPM. […] Primary objective is OS and secondary objectives include progression-free survival (PFS), safety, compliance, feasibility, conversion to resectability, histological response to treatment and quality of life. […] We expect to show that intensification of the first line treatment with PIPAC for initially unresectable MPM patients increases OS.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31420241&#34; target=&#34;_blank&#34;&gt;Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cyclophosphamide pre-treatment enhanced CART-meso expansion but did not improve persistence beyond 28 days.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31424688&#34; target=&#34;_blank&#34;&gt;Multidisciplinary palliative treatment including isolated thoracic perfusion for progressive malignant pleural mesothelioma: a retrospective observational study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the relative importance of isolated thoracic perfusion (ITP) in the multidisciplinary palliative treatment of progressive malignant pleural mesothelioma (MPM) patients. […] After the last ITP, 14 patients received further therapies, including targeted therapy with cetuximab or bevacizumab. […] ITP is safe, tolerable, and useful but its inclusion in the multidisciplinary palliative treatment of progressive MPM patients should be investigated in a larger multicentre controlled study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31428531&#34; target=&#34;_blank&#34;&gt;Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This may be especially relevant in deciding who might benefit most from checkpoint blockade or agonist antibody therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31428586&#34; target=&#34;_blank&#34;&gt;Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Collectively, these data suggest that the combination of p-Tvax with an OX40 agonist could be an effective strategy for MM treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31428834&#34; target=&#34;_blank&#34;&gt;Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We analyzed the National Cancer Database (NCDB) to assess current trends in disease incidence, patient demographics, cancer treatment, and survival. […] The proportion of patients undergoing treatment increased from 34 to 54%. […] Factors associated with improved survival included younger age, female sex, epithelioid histology, treatment in an academic center, health insurance, higher income, and multimodality therapy. […] Multimodal therapy and treatment at academic centers are modifiable risk factors associated with improved survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31430846&#34; target=&#34;_blank&#34;&gt;Return to intended oncologic treatment after surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Trimodality therapy may prolong survival for patients with resectable malignant pleural mesothelioma. […] However, many patients are unable to complete therapy. […] We sought to identify risk factors for failing to complete adjuvant intensity-modulated radiation therapy after cytoreduction for malignant pleural mesothelioma. […] Multivariable logistic regression was used to assess preoperative or intraoperative risk factors associated with failing to complete adjuvant intensity-modulated radiation therapy. […] Adjuvant intensity-modulated radiation therapy was completed among 105 patients (66%). […] Reasons for failing to complete adjuvant intensity-modulated radiation therapy included mortality (19), dose constraints (21), postoperative morbidity or delayed recovery (11), and refused or unknown status (4). […] On multivariable analysis, American Society of Anesthesiologists 3+ classification (P = .002) and smoking history (P = .022) were associated with failure to complete adjuvant intensity-modulated radiation therapy, whereas forced expiratory volume in 1 second 70% or less of predicted and pStage 4 (T4) were significant on univariable analysis only. […] Other factors, including extrapleural pneumonectomy or pleurectomy/decortication, margin status, age, and histology, were not associated with receiving adjuvant intensity-modulated radiation therapy. […] Many patients are unable to complete adjuvant intensity-modulated radiation therapy after cytoreduction. […] Failure to complete adjuvant intensity-modulated radiation therapy was associated with worse preoperative comorbidity, but not the type of surgery or margin status.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31443309&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Effusion and Its Current Management: A Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment guidelines offer a patient-centric approach with the use of new scoring systems, an out of hospital approach and ultrasound. […] However, the role of biomarkers in a clinical setting, possible new treatment modalities and certain specific situations still present a challenge for new research.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31444292&#34; target=&#34;_blank&#34;&gt;Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumor-treating fields (TTFields) are a noninvasive antimitotic cancer treatment consisting of low-intensity alternating electric fields delivered to the tumor or tumor bed via externally applied transducer arrays. […] In multiple in vitro and in vivo cancer cell lines, TTFields therapy inhibits cell proliferation, disrupts cell division, interferes with cell migration and invasion, and reduces DNA repair. […] In addition, because TTFields are a previously unrecognized antimitotic therapy with a unique mode of delivery, the oncological community must address obstacles to widespread patient and provider acceptance. […] TTFields will likely join surgery, systemic therapy, and radiation therapy as a component of multimodality management of patients with solid malignancies. […] The emergence of TTFields has changed the treatment regimen for glioblastoma. […] With ongoing clinical trials, TTFields likely will become another treatment modality for solid malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31455014&#34; target=&#34;_blank&#34;&gt;Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In light of the promising results of immune checkpoint blockade (ICPB) in malignant pleural mesothelioma (MPM), we investigated the effect of different chemotherapeutic agents on the expression of immune checkpoints (ICPs) in order to rationally design a good treatment schedule for their combination with ICP blocking antibodies. […] We looked into cisplatin and pemetrexed because their combination is used as first-line treatment of MPM. […] Cisplatin might be a promising treatment to combine with ICP blocking antibodies since our MPM cell lines were most susceptible to this stand-alone treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31484920&#34; target=&#34;_blank&#34;&gt;EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Squamous cell carcinoma (SCC) and malignant pleural mesothelioma (MPM) are thoracic malignancies with very poor prognosis and limited treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31495751&#34; target=&#34;_blank&#34;&gt;Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This follows the most active areas of research in targeted therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31519636&#34; target=&#34;_blank&#34;&gt;Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
SMRP level in PE was tested using an enzyme-linked immunosorbent assay (ELISA) in 109 patients with MPM at diagnosis before any treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31525809&#34; target=&#34;_blank&#34;&gt;Molecular Testing on Pleural Fluid Samples.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate pleural fluid analysis is critical to the appropriate staging of cancers with significant prognostic and treatment implications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31525810&#34; target=&#34;_blank&#34;&gt;Malignant Mesothelioma: Has Anything Changed?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its worldwide incidence has been increasing, and treatment options are currently suboptimal and noncurative. […] An increased understanding of disease pathophysiology has led to more accurate diagnosis and staging, and the establishment of the standard of care first-line pemetrexed/platin doublet chemotherapy regimen in 2003 initially revolutionized treatment. […] While significant debate remains regarding the preferred approach to surgical and radiation therapy in the context of multimodal therapy, recent breakthroughs in immunotherapy offer hope for another paradigm shift in the near future. […] This review will summarize the current clinical approach to diagnosis, staging, and treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31527449&#34; target=&#34;_blank&#34;&gt;Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From 13 of these patients, we were able to establish stable cell lines, which were subjected to FGFR1-4 staining, transcript analysis by quantitative RT-PCR, and treatment with the FGFR inhibitor infigratinib. […] Neither transcript nor protein expression of FGFR1-4 correlated with response to infigratinib treatment in MPM cell lines.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31528168&#34; target=&#34;_blank&#34;&gt;The Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis of malignant pleural mesothelioma (MPM) is the key point of its treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31537897&#34; target=&#34;_blank&#34;&gt;V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since most malignant pleural mesotheliomas do not respond to anti-programmed cell death(-ligand)1 (PD-(L)1)/cytotoxic T-lymphocyte-associated protein 4 (CTLA4) therapy and given the recent finding of The Cancer Genome Atlas Study that pleural mesothelioma displays the highest expression of VISTA among all cancers studied, we examined VISTA expression in a large pleural mesothelioma cohort.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31546009&#34; target=&#34;_blank&#34;&gt;Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since 2003, combined treatment with a platinum-based agent and pemetrexed has been the first-line therapy and no effective or approved second-line treatments have emerged. […] Rather, we suggest that a key hurdle in successfully translating basic discovery into novel MPM therapeutics is the underlying assumption that as a rare cancer, it will also be molecularly and genetically homogeneous.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31546041&#34; target=&#34;_blank&#34;&gt;EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recommendations include: (1) classification should be updated to include architectural patterns and stromal and cytologic features that refine prognostication; (2) subject to data accrual, malignant mesothelioma in situ could be an additional category; (3) grading of epithelioid malignant pleural mesotheliomas should be routinely undertaken; (4) favorable/unfavorable histologic characteristics should be routinely reported; (5) clinically relevant molecular data (programmed death ligand 1, BRCA 1 associated protein 1 [BAP1], and cyclin dependent kinase inhibitor 2A) should be incorporated into reports, if undertaken; (6) other molecular data should be accrued as part of future trials; (7) resection specimens (i.e., extended pleurectomy/decortication and extrapleural pneumonectomy) should be pathologically staged with smaller specimens being clinically staged; (8) ideally, at least three separate areas should be sampled from the pleural cavity, including areas of interest identified on pre-surgical imaging; (9) image-acquisition protocols/imaging terminology should be standardized to aid research/refine clinical staging; (10) multidisciplinary tumor boards should include pathologists to ensure appropriate treatment options are considered; (11) all histologic subtypes should be considered potential candidates for chemotherapy; (12) patients with sarcomatoid or biphasic mesothelioma should not be excluded from first-line clinical trials unless there is a compelling reason; (13) tumor subtyping should be further assessed in relation to duration of response to immunotherapy; and (14) systematic screening of all patients for germline mutations is not recommended, in the absence of a family history suspicious for BAP1 syndrome.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31551134&#34; target=&#34;_blank&#34;&gt;Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For each patient, we calculated the maximum standardized uptake value (SUVmax), metabolic tumor volume, and total lesion glycolysis (TLG) on pretreatment &lt;sup&gt;18&lt;/sup&gt;F-fluoro-2-deoxyglucose-positron emission tomography/computed tomography.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31557561&#34; target=&#34;_blank&#34;&gt;Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Each 6-week treatment cycle consisted of YS110 administration weekly for 5 weeks followed by a 1-week rest period. […] Treatment was continued until disease progression, death, or intolerable toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31562297&#34; target=&#34;_blank&#34;&gt;PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pharmacological (PFK158 treatment) and genetic inhibition of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), a critical control point in the glycolytic pathway, decreases glucose uptake, ATP production, and lactate dehydrogenase activity and arrests malignant pleural mesothelioma (MPM) cells in the G0/G1 phase to induce cell death. […] Since most cancer cells exhibit an increased glycolytic rate, these results provide evidence for PFK158, in combination with standard chemotherapy, may have a potential in the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31563545&#34; target=&#34;_blank&#34;&gt;Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We investigated the possible role of volumetric modulated arc therapy (VMAT) in the setting of adjuvant treatment of malignant pleural mesothelioma (MPM) after lung-sparing surgery with pleurectomy and decortication. […] The treatment was well tolerated, with just 2 grade 3 acute toxicities, 1 grade 5, and 2 grade 4 toxicities recorded during the follow-up period.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31569615&#34; target=&#34;_blank&#34;&gt;In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The main treatment for MPM is doublet chemotherapy with Cisplatin and Pemetrexed, while ongoing trials test the efficacy of pemetrexed monotherapy. […] Mean tumor spheroid perimeter was reduced after treatment with Pemetrexed or the doublet therapy in all cell lines, while Cisplatin reduced the mean spheroid perimeter of MeT-5A and MSTO cells. […] Doublet treatment reduced the invasive capacity of spheroids of cell lines into collagenous matrices, while Cisplatin lowered the invasion of the MSTO and ZL34 cell lines, and Pemetrexed lowered the invasion of MeT-5A and ZL34 cell lines. […] Treatment with Pemetrexed or the combination significantly reduced the collagen gel contraction of all cell lines, while Cisplatin treatment affected only the MeT-5A and M14K cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31576173&#34; target=&#34;_blank&#34;&gt;Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. […] MSTO-211H responded to cisplatin only, whereas the other two cell lines were considered therapy resistant (Met-5A, NCI-H2452). […] Bortezomib is not suitable for the treatment of MPM, and biomarker-based stratification could have improved both clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3159086&#34; target=&#34;_blank&#34;&gt;Establishment and characterization of human malignant pleural mesothelioma cell line SMC-1.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The establishment of this cell line will serve as a useful tool in clinical research of diagnosis and treatment of this devastating disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31590949&#34; target=&#34;_blank&#34;&gt;Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of 80 adverse events, 9 were classified serious, but none of these were related to study treatment. […] In 1 patient with epithelioid malignant pleural mesothelioma (International Mesothelioma Interest Group stage I), there was no sign of relapse 48 months after treatment (44 mg/m&lt;sup&gt;2&lt;/sup&gt; body surface area).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31590954&#34; target=&#34;_blank&#34;&gt;Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A multimodal treatment including pleurectomy/decortication was performed in 58 patients (27.2%), chemotherapy alone in 99 patients (46.5%), and best supportive care in 56 (26.3%). […] A univariate analysis revealed that survival was significantly associated with the percentage forced expiratory volume in 1 second (P &amp;lt; .0001), performance status (P = .0002), multimodal treatment including surgery (P &amp;lt; .0001), and TNM stage (P = .011).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31596154&#34; target=&#34;_blank&#34;&gt;Approved and emerging treatments of malignant pleural mesothelioma in elderly patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To date, data regarding the tolerability and efficacy of anticancer treatments for elderly patients affected by MPM are still lacking.&lt;b&gt;Areas covered&lt;/b&gt;: The current state-of-the-art of approved treatments employed in the treatment of MPM elderly patients is reviewed and discussed, with a look to emerging therapies. […] Treatment of elderly patients with MPM is one of the major challenges to the clinician.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31596628&#34; target=&#34;_blank&#34;&gt;Types of surgery post-neoadjuvant chemotherapy for pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Introduction&lt;/b&gt;: The surgical arm of the Mesothelioma and Radical Surgery (MARS) trial involved a multimodal approach, with combined therapy consisting of chemotherapy, complete gross resection, and radiation therapy. […] Nonetheless, the most effective therapy remains unclear.&lt;b&gt;Areas covered&lt;/b&gt;: Here, surgery post-neoadjuvant chemotherapy for malignant pleural mesothelioma with either EPP or P/D has been discussed, along with trimodal and bimodal therapies.&lt;b&gt;Expert opinion&lt;/b&gt;: With the development of post-P/D radiation therapy, it is currently possible to truly compare EPP with P/D. […] Therefore, there is a need to rebuild the status of surgery as a multimodal therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31597321&#34; target=&#34;_blank&#34;&gt;Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a lethal cancer with limited treatment options. […] No targeted therapy has emerged yet.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31602673&#34; target=&#34;_blank&#34;&gt;Adequate nephroprotection reduces renal complications after hyperthermic intrathoracic chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hyperthermic intrathoracic chemotherapy (HITOC) is used for the treatment of malignant pleural tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31610664&#34; target=&#34;_blank&#34;&gt;Treatment of Malignant Peritoneal Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are no generally accepted guidelines for radical treatment of MPM. […] However, median survival of patients who are suitable candidates for radical therapy is currently 3-5 years. […] Systemic chemotherapy remains the only treatment option for patients who are unsuitable for CRS and HIPEC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31616640&#34; target=&#34;_blank&#34;&gt;Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Introduction:&lt;/b&gt; Therapy options for patients with oligoprogressive malignant pleural mesothelioma (MPM) are limited. […] Stereotactic Body Radiotherapy (SBRT) may be a promising therapeutic option, as it delivers a localized ablative dose of radiation and therefore balances efficacy and treatment related toxicities. […] Initial treatment of MPM consisted of induction chemotherapy (&lt;i&gt;n&lt;/i&gt; = 12) prior to a macroscopic complete resection (&lt;i&gt;n&lt;/i&gt; = 18). […] Three patients received additional intracavitary chemotherapy and another three patients were treated with chemotherapy alone without another treatment at the time of first diagnosis. […] The median total treatment dose was 30 Gy (20-50 Gy) with a median prescription isodose line (IDL) of 65% (65-100%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31619462&#34; target=&#34;_blank&#34;&gt;Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to investigate whether this aspect could be exploited for targeted therapy. […] Upregulation of RRM2 upon gemcitabine and hydroxyurea treatment was more profound in &lt;i&gt;BAP1&lt;/i&gt; mut/del cell lines. […] Our observations reveal a potential clinical application where BAP1 status could serve as predictive or stratification biomarker for RNR inhibition-based therapy in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31620941&#34; target=&#34;_blank&#34;&gt;Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, focus has shifted toward a more aggressive and multimodal treatment approach. […] Data regarding diagnosis, staging, treatment, and survival were extracted. […] Surgical treatment has become more common in recent years, which most likely has resulted in improved survival rates. […] Nonetheless, most patients (67%) do not receive any form of anti-cancer treatment. […] The survival rates in the Netherlands have improved slightly in the past decade, most likely due to more aggressive treatment approaches and increased use of surgery. […] However, most patients still do not receive cancer-directed treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31628016&#34; target=&#34;_blank&#34;&gt;Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumour Treating Fields (TTFields) are a regional, antimitotic treatment for solid tumours, which is based on the delivery of low-intensity alternating electric fields. […] The aim of the STELLAR study was to test the activity of TTFields delivered to the thorax in combination with systemic chemotherapy for the front-line treatment of patients with unresectable malignant pleural mesothelioma. […] STELLAR was a prospective, single-arm, phase 2 trial done at 12 European academic and non-academic sites (five in Italy, three in Poland, one in France, one in Belgium, one in Spain, and one in the Netherlands) for treatment-naive patients with histologically confirmed unresectable malignant pleural mesothelioma. […] Patients not progressing after completion of chemotherapy received TTFields as maintenance treatment until progression, patient or physician decision, or unacceptable toxic effects. […] Survival analyses were done in the intention-to-treat population, and safety analyses were done in all patients who received at least 1 day of TTFields treatment. […] No treatment-related deaths were observed. […] TTFields (150 kHz) delivered to the thorax concomitant with pemetrexed and platinum was an active and safe combination for front-line treatment of unresectable malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31632972&#34; target=&#34;_blank&#34;&gt;Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Lung cancers and malignant pleural mesothelioma (MPM) have some of the worst 5-year survival rates of all cancer types, primarily due to a lack of effective treatment options for most patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31634442&#34; target=&#34;_blank&#34;&gt;Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These nodes warrant further investigation, including nonoperative techniques to identify and factor them into treatment decision making.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31639216&#34; target=&#34;_blank&#34;&gt;CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These markers might be useful in MPM for prognostic evaluations as well as targeted therapeutics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31661685&#34; target=&#34;_blank&#34;&gt;Detection of Anaplastic Lymphoma Kinase-Rearranged Mesothelioma Cells in Ascites by Companion Diagnostics.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Companion diagnostics-based cytology may provide a useful means of monitoring and evaluating a molecular-targeted therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31667333&#34; target=&#34;_blank&#34;&gt;Multicystic peritoneal mesothelioma: a systematic review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To date, there is no standard treatment recommended for MCPM. […] However, some studies suggest proceeding with a cytoreductive surgery and a hyperthermic intraperitoneal chemotherapy combining CISPLATIN and DOXORUBICIN, due to a high incidence of recurrence rate after medical treatment or surgery alone and potential malignant transformation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31667596&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early detection and treatment are critical to prolong survival of patients with MPM because of the rapid progression and resistance to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3166920&#34; target=&#34;_blank&#34;&gt;24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thirteen patients with malignant mesothelioma of the pleura have been treated with 24-hour cyclophosphamide infusion (2.5 g/m2) therapy. […] Three patients (23%) had a partial response, and a further three patients who did not fulfil the criteria for objective response, had subjective benefit from therapy with increase in performance status. […] The overall median survival from the onset of therapy was 6 months (range 2-19 months). […] High dose cyclophosphamide offers no advantage over standard dose therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-11-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31670225&#34; target=&#34;_blank&#34;&gt;Emerging therapies in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is characterized by a poor prognosis even for patients treated with trimodality therapy, including surgery, chemotherapy and radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31674841&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomies for pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most effective multimodality treatment in prolonging survival is still matter of debate. […] Surgery remains one of the cornerstones in the multimodality therapy for MPM. […] The complexity of the surgical treatment mandates that patients be referred to specialized centers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31680229&#34; target=&#34;_blank&#34;&gt;Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The main therapeutic options for MPM include surgery, chemotherapy, and radiation therapy (RT). […] Although multimodality therapy has been reported to improve survival, not every medically operable patient is able to undergo all recommended therapy. […] In this review, we discuss the current literature on MPM management and propose afunctional treatment algorithm.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31704853&#34; target=&#34;_blank&#34;&gt;The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We performed multimodality therapy comprising preoperative chemotherapy, extrapleural pneumonectomy (EPP), and radiation therapy for patients with malignant pleural mesothelioma (MPM). […] Although multimodality therapy resulted in good prognosis, further improvement is required. […] Therefore, herein, we analysed the prognostic factors using surgical specimens and searched for suitable molecular targets to improve the prognosis after multidisciplinary treatment. […] Forty-six patients with MPM underwent multimodality therapy. […] The prognosis of MPM is affected by p-mTOR expression, suggesting that molecular-targeted treatment might be used during multimodal therapy for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31741710&#34; target=&#34;_blank&#34;&gt;Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A combination localized antibody-based immunotherapy with or without cellular therapy may be justified in this uniformly fatal condition.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31751008&#34; target=&#34;_blank&#34;&gt;Extended pleurectomy decortication for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery for malignant pleural mesothelioma should be part of a multimodality treatment approach and the aim of surgery should be macroscopic complete tumor resection. […] This video tutorial illustrates the main steps of extended pleurectomy decortication for the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31783178&#34; target=&#34;_blank&#34;&gt;Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Both patients, a 14-year-old female and a 27-year-old male, had peritoneal mesothelioma and had no history of asbestos exposure, prior radiation therapy, or predisposing germline mutations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31788420&#34; target=&#34;_blank&#34;&gt;Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
He declined standard of care treatment following his own research and he was enrolled in a named patient programme of IMM-101.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31812554&#34; target=&#34;_blank&#34;&gt;Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pembrolizumab is approved for the treatment of advanced cancer in adults; however, no information is available on safety and efficacy in paediatric patients. […] Of the 154 patients treated, 69 (45%) experienced grade 3-5 adverse events, most commonly anaemia in 14 (9%) patients and decreased lymphocyte count in nine (6%) patients. 13 (8%) of the 154 patients had grade 3-5 treatment-related adverse events, most commonly decreased lymphocyte count in three (2%) patients and anaemia in two (1%) patients. 14 (9%) patients had serious treatment-related adverse events, most commonly pyrexia (four [3%]), and hypertension and pleural effusion (two [1%] each). […] Four patients (3%) discontinued treatment because of treatment-related adverse events, and two (1%) died (one due to pulmonary oedema and one due to pleural effusion and pneumonitis).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31817531&#34; target=&#34;_blank&#34;&gt;Prognostic Immune Cell Profiling of Malignant Pleural Effusion Patients by Computerized Immunohistochemical and Transcriptional Analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural effusion (MPE) is a severe condition of advanced tumors without effective therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31823764&#34; target=&#34;_blank&#34;&gt;Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapies are being developed that target CCL2/CCR2 and tumor resident myeloid cells, and clinical trials are being pursued that use these therapies as part of the treatment regimen. […] The results of trials with patients with a similar serum CCL2 pattern as MPM patients will have important implications for the treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31825692&#34; target=&#34;_blank&#34;&gt;Nivolumab for the treatment of unresectable pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Introduction&lt;/b&gt;: Platinum-based chemotherapy is the current first-line standard therapy for unresectable malignant pleural mesothelioma (MPM). […] Recently, immune-checkpoint inhibitors (ICI) have been intensively investigated as treatment options for this disease. […] The efficacy and safety of nivolumab have been investigated mostly in second-line or later treatment settings as both monotherapy and in combination with other ICIs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31827724&#34; target=&#34;_blank&#34;&gt;Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma - Comparison with contrast-enhanced CT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment failure was confirmed in 40 patients. […] The findings of FDG-PET/CT resulted in a change of management for 14 of the 50 patients (28%) by initiating new treatment. […] Of six patients judged as not having recurrence by contrast-enhanced CT but truly having recurrence based on FDG-PET/CT findings, 4 patients received new treatment due toFDG-PET/CT. […] FDG-PET/CT findings were shown to be more accurate for assessing MPM recurrence and more often led to therapy change than contrast-enhanced CT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31832406&#34; target=&#34;_blank&#34;&gt;&lt;i&gt;In-vitro&lt;/i&gt; proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report the first case, to the best of our knowledge, of massive ascites due to recurrent malignant pleural mesothelioma that was controlled using KM-cell-free and concentrated ascites reinfusion therapy (KM-CART). […] Treatment with gemcitabine maintained stable disease for 4 mo. […] The combination of KM-CART and CD-DST may be a promising treatment option for malignant ascites associated with malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31833271&#34; target=&#34;_blank&#34;&gt;[How I manage… Malignant pleural mesothelioma in 2019].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The tumor is generally extended at the time of diagnosis and the treatment consists of a systemic palliative therapy. […] To date, there is no second-line treatment approved for this disease and therefore inclusion in trials is recommended. […] Currently, various studies are investigating target therapy, immunotherapy and intrapleural perioperative treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31838086&#34; target=&#34;_blank&#34;&gt;Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Toll-like receptor 3 (TLR3) is an immune receptor that behaves like a death receptor in tumor cells, thereby providing an original target for cancer therapy. […] The combined cisplatin/Poly(I:C) treatment enhanced apoptosis of 3/4 Poly(I:C)-sensitive cell lines and overcame resistance to Poly(I:C) or cisplatin alone in 2/4 cell lines. […] Efficacy of the combined treatment relied on cisplatin-induced downregulation of c-FLIP, the main regulator of the extrinsic apoptotic pathway, leading to an enhanced caspase-8-mediated pathway. […] Patient-derived cells were sensitive to Poly(I:C) alone while the combined cisplatin/Poly(I:C) treatment induced dramatic cell death.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31866087&#34; target=&#34;_blank&#34;&gt;Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sixty-nine consecutive patients undergoing the protocol of Surgery for Mesothelioma after Radiation Therapy (SMART) between November 2008 and February 2016 were analyzed for the presence of PD-L1 on tumor cells, PD-1 on inflammatory cells, and CD8+ TILs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31872928&#34; target=&#34;_blank&#34;&gt;A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Encouraging findings in frontline treatment warrant further investigations in combination with chemotherapy or immunotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31887429&#34; target=&#34;_blank&#34;&gt;Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our study lends further support for the role of aberrations in DNA damage repair genes in the pathogenesis of MPMs and suggests that targeting the members of these pathways for screening and treatment warrants further study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31901768&#34; target=&#34;_blank&#34;&gt;A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, there is no optimal salvage therapy for patients with malignant pleural mesothelioma (MPM) who relapse after treatment with first-line chemotherapy. […] In line with the strong preclinical rationale for targeting fibroblast growth factor receptor (FGFR) signalling in malignant mesothelioma, we conducted a phase II study assessing the efficacy of AZD4547, an oral tyrosine multi-kinase FGFR 1-3 inhibitor, as a second or third-line treatment. […] The FGFR 1-3 inhibitor AZD4547 did not demonstrate efficacy in patients with MPM who had progressed after first line treatment with platinum-based chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31911549&#34; target=&#34;_blank&#34;&gt;Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This constitutes a novel targeted therapy for a poor prognosis and frequently chemoresistant group of patients with MM, for whom therapeutic options are currently lacking. […] Building on a genetic mouse model, a novel combination therapy is uncovered that is relevant to human tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31921422&#34; target=&#34;_blank&#34;&gt;LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Effective therapeutics as well as early diagnostics for the MPM are still lacking.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31929796&#34; target=&#34;_blank&#34;&gt;Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multimodal therapy consisting of platinum-based chemotherapy is the treatment of choice. […] For this exploratory study, we screened MPM cell lines (NCI-H2452, NCI-H2052, and MSTO-211H) differing in response to cisplatin and benign control fibroblasts (MRC-5) for overall phosphorylation patterns as well as kinase activity with respect to cellular response to cisplatin-based therapeutics. […] Based on our results, the induction of p38 or JNK1/3, or inhibition of AKT1 by, for example, BIA-6, might offer a positive synergistic effect by induction of an apoptotic response to cisplatin-based treatment, thus potentially enhancing the clinical outcome of MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31930123&#34; target=&#34;_blank&#34;&gt;Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To compare volumetric arc therapy (VMAT) and helical tomotherapy (HT) plans in terms of dosimetric parameters in positron emission tomography- (PET-) computerized tomography- (CT-) based radiation therapy planning in unresectable malignant pleural mesothelioma (MPM). […] The major disadvantage of the HT technique was the requirement for longer treatment times (7.4 versus 2.5 minutes/fr; &lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001) to accomplish the intended treatment. […] Clinically, considering their poor prognosis, these promising findings may open a potential new window for curative treatment of unresectable MPM patients, if further confirmed by future clinical studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31962118&#34; target=&#34;_blank&#34;&gt;Clinical Outcomes With Recurrence After Pleurectomy/Decortication for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients with malignant pleural mesothelioma experience recurrence after treatment. […] This study aimed to clarify postrecurrence survival, treatment, prognostic factors, and recurrence pattern after pleurectomy/decortication. […] Forty-three patients (75.4%) underwent a postrecurrence treatment. […] Multivariate analysis revealed that postrecurrence treatment (hazard ratio, 0.2; 95% confidence interval, 0.07-0.55; P = .002), performance status 0 to 1 (hazard ratio, 0.24; 95% confidence interval, 0.08-0.76; P = .01), and disease-free interval more than 12 months (hazard ratio, 0.4; 95% confidence interval, 0.16-0.99; P = .04) were the independent, favorable, and significant prognostic factors of postrecurrence survival. […] Postrecurrence survival after pleurectomy/decortication is acceptable, and postrecurrence treatment, performance status, and disease-free interval are important prognostic factors of postrecurrence survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31970729&#34; target=&#34;_blank&#34;&gt;Not everything is what it seems: malignant pleural mesothelioma mimicking lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite its rarity, intraparenchymal malignant pleural mesothelioma should always be taken into account, when lung nodules are present, to prevent misdiagnosis and avoid delayed treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31977466&#34; target=&#34;_blank&#34;&gt;99mTc-HDP Bone Scintigraphy, SPECT/CT, and 18F-FDG PET/CT Diagnosis Imaging of Incidental Pleural Mesothelioma in a Patient With Biochemical Recurrences of Prostate Cancer: Is it Really a Coincidence?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We present the case of a 69-year-old man with history of prostate carcinoma treated with prostatectomy and subsequently with external beam radiotherapy and hormone therapy because of biochemical recurrences.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32002298&#34; target=&#34;_blank&#34;&gt;Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Wild-type non-binding to mutant binding predicted neoantigens increased risk of death in a model adjusting for age, sex, smoking status, histology and treatment (HR: 33.22, CI: 2.55-433.02, &lt;i&gt;p&lt;/i&gt; = .007). […] Despite the challenges associated with the identification of bonafide neoantigens, there is growing evidence that these molecular changes can provide an actionable target for personalized therapeutics in difficult to treat cancers. […] Our findings support the existence of candidate neoantigens in MM despite the low mutation burden of the tumor, and may present improved treatment opportunities for patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32011691&#34; target=&#34;_blank&#34;&gt;The Role of Neoadjuvant Chemotherapy in Patients with Resectable Malignant Pleural Mesothelioma - An Institutional and National Analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The risks and benefits of induction therapy should be weighed before offering it to patients with resectable MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32016133&#34; target=&#34;_blank&#34;&gt;Deep learning-based segmentation of malignant pleural mesothelioma tumor on computed tomography scans: application to scans demonstrating pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumor volume is a topic of interest for the prognostic assessment, treatment response evaluation, and staging of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32039010&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These include angiogenesis inhibitors, synthetic lethal treatment, miRNA replacement, oncoviral therapies, and the fast-growing field of immunotherapy alone or in combination with chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32042427&#34; target=&#34;_blank&#34;&gt;Primary squamous cell carcinoma of the pleura treated with nivolumab.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our knowledge about its treatment or prognosis is limited due to its rarity. […] Positron emission tomography staging demonstrated metastatic lung and lymph node involvement precluding surgical therapy. […] We provide information about treatment, including immunotherapy as well as extended follow-up course.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32044093&#34; target=&#34;_blank&#34;&gt;Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a lethal malignancy with poor survival and high local recurrence rates despite multimodal therapy with cytoreduction and chemoradiation. […] Animals were randomized into 2 models of disease treatment chemotherapy with PTX-eNPs alone delivered locally for early limited disease or cytoreductive surgery plus local PTX-eNP chemotherapy for advanced disease. […] Local multidose treatment with PTX-eNPs alone in limited stage disease more than doubled survival compared with drug-empty nanoparticles (P ≤ .0001) and standard formulation paclitaxel (P = .0004). […] In the model of advanced disease, local multidose treatment with PTX-eNPs following cytoreductive surgery also prolonged survival by 126% and 69.4% compared with drug-empty nanoparticles (P = .0018) and standard formulation paclitaxel (P = .03457), respectively. […] Local delivery of paclitaxel via eNPs confers prolonged survival in a murine model of malignant pleural mesothelioma as single modality treatment for limited disease and in combination with cytoreductive surgery for advanced disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32048732&#34; target=&#34;_blank&#34;&gt;Light Fluence Rate and Tissue Oxygenation (S&lt;sub&gt;t&lt;/sub&gt; O&lt;sub&gt;2&lt;/sub&gt; ) Distributions Within the Thoracic Cavity of Patients Receiving Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distributions of light and tissue oxygenation (S&lt;sub&gt;t&lt;/sub&gt; O&lt;sub&gt;2&lt;/sub&gt; ) within the chest cavity were determined for 15 subjects undergoing macroscopic complete resection followed by intraoperative photodynamic therapy (PDT) as part of a clinical trial for the treatment of malignant pleural mesothelioma (MPM). […] Nevertheless, the treatment-averaged fluence rate was similar among sites, ranging from a median of 40-61 mW cm&lt;sup&gt;-2&lt;/sup&gt; during periods of light exposure to a detector. […] Overall, PDT of the thoracic cavity resulted in moderate treatment-averaged fluence rate that was consistent among treated tissue sites, despite instantaneous exposure to high fluence rate. […] Mild oxygen depletion after PDT was experienced at tissue sites with high pre-PDT S&lt;sub&gt;t&lt;/sub&gt; O&lt;sub&gt;2&lt;/sub&gt; , which may suggest the presence of a treatment effect.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32049443&#34; target=&#34;_blank&#34;&gt;Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, a delay of more than 6 months after first symptoms was seen in many patients in the histopathology group, resulting in late onset of treatment. […] Our finding enables the initiation of treatment as soon as the cytological diagnosis is established, avoiding further delay and deterioration of patient survival and possibilities for treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32053799&#34; target=&#34;_blank&#34;&gt;Infrared navigation system for light dosimetry during pleural photodynamic therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural photodynamic therapy (PDT) is performed intraoperatively for the treatment of microscopic disease in patients with malignant pleural mesothelioma. […] An optical infrared (IR) navigation system was used to monitor reflective passive markers on a modified and improved treatment delivery wand to track the position of the light source within the treatment cavity during light delivery. […] Calculated light fluence at the end of treatment delivery was compared to measured values from isotropic detectors. […] This is useful in determining the light dose delivered to areas of the pleural cavity between detector locations, and can serve to improve treatment delivery with implementation in real-time in the surgical setting.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32082839&#34; target=&#34;_blank&#34;&gt;A case of surgically treated bilateral metachronous malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After the patient was determined to be operable, right parietal pleurectomy + pericardial resection + diaphragmatic resection were performed and four cycles of cisplatin and pemetrexed combination as adjuvant treatment were added. […] Four cycles of pemetrexed single-agent therapy was performed as an adjuvant treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32082887&#34; target=&#34;_blank&#34;&gt;Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The combination or individual use of serum cancer antigen 125, 15-3, folic acid, vitamin B12, and ferritin levels may be helpful for early diagnosis and treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32085891&#34; target=&#34;_blank&#34;&gt;Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment was given intravenously at 3.2 mg/m&lt;sup&gt;2&lt;/sup&gt; dose every 3 weeks until progression or unacceptable toxicity. […] Lurbinectedin showed promising activity regardless of histology, prior immunotherapy, or outcome on prior treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32087959&#34; target=&#34;_blank&#34;&gt;Preoperative prediction of unresectability in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Preoperative identification of DCWI will avoid unnecessary thoracotomy and accelerate initiation of nonsurgical therapy in malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32088429&#34; target=&#34;_blank&#34;&gt;Disease-Related Outcomes and Toxicities of Intensity Modulated Radiation Therapy After Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review explores the use of intensity modulated radiation therapy (IMRT) after lung-sparing surgery in malignant pleural mesothelioma (MPM). […] Because severe toxicities have been documented after radiation therapy for MPM, its use remains controversial, especially as modern surgical management has shifted toward lung-sparing pleurectomy/decortication. […] IMRT is an advanced technique that may allow for safer radiation therapy delivery, but there remains limited data (including no summative data) to support this notion. […] Grade 4 and 5 pneumonitis were observed in less than 1.5% of cases, except in one publication that used hypofractionated radiation therapy to doses &amp;gt;60 Gy. […] P-IMRT produces relatively few higher-grade toxicities and has reasonable disease-related outcomes, especially when delivered using conventionally fractionated regimens to doses of 45 to 54 Gy and exercising careful attention to dose constraints during treatment planning.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32088605&#34; target=&#34;_blank&#34;&gt;Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options for malignant pleural mesothelioma (MPM) are limited but some studies on immune checkpoint inhibitors (ICIs) in MPM have reported antitumor activity. […] She was diagnosed with malignant epithelioid pleural mesothelioma with brain metastasis and peritoneal carcinosis, refractory to initial standard chemotherapy treatment. […] Chemotherapy with cisplatin and pemetrexed was started, imaging studies showing stable disease after 3 treatment cycles.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32100581&#34; target=&#34;_blank&#34;&gt;Prolonged Progression-Free Survival in a Patient With Malignant Pleural Mesothelioma Following Korean Herbal Medicine Treatment Alone: A Case Report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Korean herbal medicine treatment (KHMT) involves treating with a combination of natural products, which have been used for thousands of years. […] The multidisciplinary care team recommended multimodal treatment based on an extrapleural pneumonectomy, but he refused this because the treatment was aggressive and the effectiveness was unclear. […] He visited the Korean Medicine Cancer Center for alternative treatment options. […] At 21 months into treatment (September 2019), no significant adverse events have occurred. […] This case, therefore, suggests that KHMT is a potential treatment option for MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32102735&#34; target=&#34;_blank&#34;&gt;A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Second-line chemotherapy is not a standard of care in patients with malignant pleural mesothelioma (MPM) that progresses after first-line treatment with cisplatin and pemetrexed. […] Grade 3 treatment-related adverse events were observed in four (17 %) patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3210656&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Between March 1981 and February 1985, 93 out of 132 patients with a histologically confirmed diagnosis of malignant pleural mesothelioma were eligible for therapy and were prospectively assigned to receive either combined therapy or best supportive care, according to their personal preferences. […] Fifty-seven patients underwent multimodal therapy including surgical resection where possible, polychemotherapy, and radiation therapy in case of partial remission. […] Thirty-six patients received maximal supportive care only, as did 39 patients who were not eligible for treatment. […] The median survival was 13 months for treated patients compared to 7 for those receiving best supportive care and 5 for patients not amenable to treatment. […] Prognostic nontreatment variables related to prolonged survival were: good performance status, stage I and II, absence of chest pain, age below 50 years, and epithelial histology. […] Although in the Cox model analyses the survival improvement of patients being treated could be greatly attributed to other cofactors, multimodal treatment showed some prolongation of life expectancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32114955&#34; target=&#34;_blank&#34;&gt;MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study might be helpful in enhancing our understanding of the biological mechanisms underlying asbestos-induced MPM and for acquiring greater insights into targeted therapy.&lt;b&gt;Abbreviations&lt;/b&gt;: FDR: false discovery rate; MM: malignant mesothelioma; MPM: malignant pleural mesothelioma; mRNA: messenger RNA; miRNA: microRNA; SAM: significance analysis of microarrays; TCGA: the cancer genome atlas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32117755&#34; target=&#34;_blank&#34;&gt;Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this review we will highlight the studies providing evidence for therapeutic effects of modulating microRNA levels in MPM, and discuss these results in the context of emerging approaches to miRNA-based therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32148838&#34; target=&#34;_blank&#34;&gt;Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD-L1.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite treatment with carboplatin and pemetrexed, the primary lesion rapidly progressed and new multiple pleural metastases were observed. […] After the nivolumab treatment, CT showed a significant reduction in pleural tumours with a marked improvement in symptoms. […] The patient has continued this treatment with sustained and remarkable effectiveness with good quality of life (QOL).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32154179&#34; target=&#34;_blank&#34;&gt;Immunotherapy in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. […] Another immune treatment is Dendritic Cell (DC) immunotherapy, which is recently tested in mesothelioma, shows remarkable anti-tumor activity in three clinical studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32156681&#34; target=&#34;_blank&#34;&gt;How I treat malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In advanced disease, the combination of pemetrexed and platinum remains the only established treatment, while efficacy evidence of second line chemotherapy is lacking.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32169873&#34; target=&#34;_blank&#34;&gt;Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Whole exome sequencing demonstrated a reduction in tumor mutational burden consistent with subclone elimination by immune checkpoint inhibitor (CPI) therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32170970&#34; target=&#34;_blank&#34;&gt;Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While the epithelioid type is associated with a more favourable outcome, additional factors are needed to further stratify prognosis and to identify patients who can benefit from multimodal treatment. […] Patients with tubulopapillary or microcystic tumours showed a greater improvement in OS after receiving multimodal therapy than those with solid or trabecular tumours. […] Histological subtypes of epithelioid MPM have a prognostic impact, and might help to select patients for intensive multimodal treatment approaches.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32175161&#34; target=&#34;_blank&#34;&gt;Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study aims to evaluate gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma both which have a distinct treatment and prognosis. […] After treatment of the fresh samples of lung adenocarcinoma stored at -80°C for ribonucleic acid isolation, and paraffin-embedded tissues of patients with malignant pleural mesothelioma were deparaffinized, complementary deoxyribonucleic acid synthesis and expression of 84 genes associated with deoxyribonucleic acid repair were analyzed via real-time polymerase chain reaction assay.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32179179&#34; target=&#34;_blank&#34;&gt;Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This has led to the introduction of ICI consolidation therapy in stage III NSCLC, creating a platform for future therapeutic developments in earlier-stage disease. […] The development of innovative strategies to overcome ICI resistance, standardization of new patterns of ICI progression, identification of predictive biomarkers of response, optimal treatment duration, and characterization of ICI efficacy in special populations, represent crucial issues to be adequately addressed, with the aim of improving the therapeutic benefit of ICI in patients with thoracic malignancies. […] In this article, an international panel of experts in the field of thoracic malignancies discussed these topics, evaluating currently available scientific evidence, with the final aim of providing clinical recommendations, which may guide oncologists in their current practice and elucidate future treatment strategies and research priorities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32181176&#34; target=&#34;_blank&#34;&gt;Intramedullary Metastasis to the Cervical Spinal Cord from Malignant Pleural Mesothelioma: Review of the Literature and Case Reports.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient underwent surgical treatment through a C6-C7 laminectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32181989&#34; target=&#34;_blank&#34;&gt;Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After treatment, grade 3 diarrhea (600 mg once a day) was found as dose-limiting toxicity (DLT). […] Among all patients, four of the five patients who did not receive any treatment, one of the two patients who had received treatments with crizotinib, and five of the six patients who received standard chemotherapy achieved partial response (PR).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32194667&#34; target=&#34;_blank&#34;&gt;Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the current study, the expression of MSLN in 270 primary and 44 metastatic colorectal tumors was immunohistochemically analyzed to determine the clinical usefulness of MSLN immunohistochemistry and to identify potential candidates for future anti-MSLN therapy. &lt;i&gt;In vitro&lt;/i&gt; experiments using colon cancer cell lines were performed to investigate the biological significance of MSLN expression in tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32206573&#34; target=&#34;_blank&#34;&gt;Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Today there are several options for the treatment of patients with malignant pleural mesothelioma (MPM). […] A renewed interest has occurred in the combination of surgery, chemotherapy and radiation therapy. […] In this review we present the available data on previous and running studies and try to give a recommendation how to select the best patient for the most optimal therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32206574&#34; target=&#34;_blank&#34;&gt;Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is a lack of randomized evidence to support a survival benefit when major surgical resection is included in multi-modality treatment regimens. […] Current data from retrospective single institution reviews and prospective trials such as the Surgery for Mesothelioma After Radiation Therapy (SMART) trial are limited by biased patient selection to include only the healthiest patients with most limited disease burden. […] Surgery in MPM has risks and is of questionable benefit with outcomes data biased by patient selection of those who will have longer overall survival times regardless of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32206878&#34; target=&#34;_blank&#34;&gt;IgG4-related pleural disease with aortitis and submandibular glands involvement successfully treated with corticosteroid: case-based review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Systemic corticosteroid therapy was effective at reducing serum IgG4, improving bilateral submandibular gland enlargement, and regressing pleural thickening and periaortic soft tissue.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32213537&#34; target=&#34;_blank&#34;&gt;Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A single-centre, phase II, randomised, placebo-controlled cross-over pilot study with 28-day treatment periods and 3-day washout.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32214647&#34; target=&#34;_blank&#34;&gt;Not gene therapy, but genetic surgery-the right strategy to attack cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this review, I will suggest to divide all the approaches united now under common term “gene therapy” into two broad strategies of which the first one uses the methodology of targeted therapy with all its characteristics, but with genes in the role of agents targeted at a certain molecular component(s) presumably crucial for cancer maintenance. […] While the first strategy is “true” gene therapy, the second one is more like genetic surgery when a surgeon just cuts off a tumor with his scalpel and has no interest in knowing delicate mechanisms of cancer emergence and progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32226777&#34; target=&#34;_blank&#34;&gt;Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an uncommon but aggressive and treatment resistant neoplasm with low survival rates. […] In this review, we describe the most promising emerging therapies for the treatment of MPM, discussing the biological rationale underlying their development as well as the issues surrounding clinical trial design and proper selection of patients for every treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32234848&#34; target=&#34;_blank&#34;&gt;T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a highly lethal malignancy in need for new treatment options. […] To explore the differences in TCRβ repertoire prior-DC-therapy and post-DC-therapy, for each patient the TCRβ clones present in the total CD3&lt;sup&gt;+&lt;/sup&gt; T cell fractions were classified into five categories, based on therapy-associated frequency changes: expanding, decreasing, stable, newly appearing and disappearing clones. […] DC-therapy primarily induced TCRβ repertoire changes in the PD1&lt;sup&gt;+&lt;/sup&gt;CD4&lt;sup&gt;+&lt;/sup&gt; and PD1&lt;sup&gt;+&lt;/sup&gt;CD8&lt;sup&gt;+&lt;/sup&gt; T cell fractions. […] We conclude that the clinical response to DC-mediated immunotherapy is dependent on both the pre-existing TCRβ repertoire of total CD3&lt;sup&gt;+&lt;/sup&gt; T cells and on therapy-induced changes, in particular expanding PD1&lt;sup&gt;+&lt;/sup&gt;CD8&lt;sup&gt;+&lt;/sup&gt; T cell clones.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32234874&#34; target=&#34;_blank&#34;&gt;Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Molecular targeted agents have been successfully developed against solid tumors and their use is also being investigated for the treatment of malignant pleural mesothelioma (MPM). […] NCI-H28 MPM cells harboring the VHL L89H mutation were sensitive to YC-1, known as an inhibitor of hypoxia inducible factor (HIF)-1α, and YC-1treatment induced massive apoptosis in a dose-and-time-dependent manner.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32238865&#34; target=&#34;_blank&#34;&gt;Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural effusion (MPE) confers dismal prognosis and has limited treatment options. […] In summary, histological and circulating biomarkers should also be taken into account as potential biomarkers in ICI therapy and they may have an impact on the prognostic power of PD-L1.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32249197&#34; target=&#34;_blank&#34;&gt;Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Studies of bevacizumab and pembrolizumab in the treatment of malignant pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective of real-world patients. […] We aimed to determine the proportion of real-world patients who would be eligible for trials, identify patients who participated in clinical trials, and examine treatment and outcome data. […] Prognostic information, treatment use, and overall survival (OS) data were also collected. […] A total of 133 patients were included: 50% and 37%, respectively, did not meet trial eligibility for MAPS or KEYNOTE-028, most commonly owing to age ≥75 (23%), Eastern Cooperative Oncology Group performance status of ≥2 (21%), concomitant medication (21%), or comorbidity (12%). […] Patients who received an investigational anticancer therapy on any clinical trial had improved OS: 32.4 (95% CI, 23.9-40.9) months versus 20.5 (95% CI, 15.8-25.3) months (P = .01).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32266156&#34; target=&#34;_blank&#34;&gt;Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Background:&lt;/b&gt; The optimal treatment sequence for localized malignant pleural mesothelioma (MPM) is controversial. […] We aimed to assess outcomes and toxicities of treating localized MPM with neoadjuvant radiation therapy (RT) followed by extrapleural pneumonectomy (EPP). &lt;b&gt;Methods:&lt;/b&gt; Patients were enrolled on an institutional protocol of surgery for mesothelioma after radiation therapy (SMART) between June 2016 and May 2017. […] Five fractions of RT were delivered using intensity modulated radiation therapy (IMRT), with 30 Gy delivered to gross disease and 25 Gy to the entire pleura. […] While all patients were clinically node negative by pretreatment staging, three had positive nodal disease at surgery. […] Three patients received salvage chemotherapy. &lt;b&gt;Conclusions:&lt;/b&gt; SMART provided promising oncologic outcomes at the cost of significant treatment related morbidity. […] Due to the significant treatment associated morbidity and favorable treatment alternatives, we have not broadly adopted SMART at our institution.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32269966&#34; target=&#34;_blank&#34;&gt;The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To develop new therapeutic strategies and define predictors of treatment response to existing therapy, better knowledge of the cellular and molecular mechanisms of MM tumors and sound preclinical models are needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32276524&#34; target=&#34;_blank&#34;&gt;Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Additionally, next-generation sequencing analysis of B-cell receptor repertoire pre- and post-therapy in memory B-cells from responders allows for the identification of clones expanded and matured upon treatment. […] Human antibodies identified can be subsequently reformatted to generate a plethora of therapeutics like antibody-drug conjugates, immunotoxins, and advanced cell-therapeutics such as chimeric antigen receptor-transduced T-cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32279197&#34; target=&#34;_blank&#34;&gt;Treatment of bronchial fistula after extraplural pneumonectomy using flexible bronchoscopy with the administration of OK432, fibroblast growth factor basic and fibrin glue sealant.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options for bronchial fistula (BF) after pneumonectomy are often limited and carry significant morbidity and mortality. […] Two weeks after this treatment, we confirmed the improvement of the fistula by bronchography. […] Bronchoscopic therapy for BF was useful for a small, early fistula without infection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32326079&#34; target=&#34;_blank&#34;&gt;Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) has extremely limited treatment despite a poor prognosis. […] Moreover, molecular targeted therapy for MPM has not yet been implemented; thus, a new targeted therapy is highly desirable. […] Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed cancer therapy that combines the specificity of antibodies for targeting tumors with toxicity induced by the photoabsorber after exposure to NIR-light. […] This study suggests that PDPN-targeted NIR-PIT could be a new promising treatment for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32364316&#34; target=&#34;_blank&#34;&gt;Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We aimed to describe the treatment patterns among MPM patients across different Italian regions and to identify factors associated with the treatment patterns across the regions. […] To identify factors associated with treatment patterns, across the different regions, we fitted a multinomial logistic regression model adjusted by age, sex, stage, histology and hospital with thoracic surgical department. […] MPM patients mostly received chemotherapy alone (41%) or no cancer-directed therapy (36%) especially the older patients. […] The first course of treatment for MPM patients differed across regions. […] Patients from Piedmont, Liguria and Campania were more likely to receive no cancer-directed therapy; those living in Tuscany and Sicily were more likely to get surgery; patients from Marche and Lazio were more likely to receive chemotherapy. […] Significant findings of the study: MPM patients mostly received chemotherapy alone or no cancer-directed therapy especially the older patients. […] The first course of treatment for MPM patients differed across Italian regions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32369821&#34; target=&#34;_blank&#34;&gt;Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment options are currently limited, with no known targeted therapies available. […] Interestingly, 2 variants observed in the PDGFRA gene are classic imatinib-sensitive therapy. […] We concluded that Brazilian MPM harbor mutation in classic tumor suppressor and oncogenic genes, which might help in the guidance of personalized treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32372095&#34; target=&#34;_blank&#34;&gt;Low-dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a deadly disease with limited treatment options. […] Previously, we have demonstrated interesting vascular modulating properties of low-dose photodynamic therapy (L-PDT) on MPM. […] Second, we characterized the tumour immune cell infiltrate by 15-colour flow cytometry analysis 2 and 7 days after L-PDT treatment of the murine MPM model.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32445818&#34; target=&#34;_blank&#34;&gt;Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma - A rare thoracic cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The obtained results establish the effectiveness of chitosomes as delivery carrier for Met as treatment alternative for malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32448904&#34; target=&#34;_blank&#34;&gt;ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. […] Because of limited data on the best combination treatment, we emphasize that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32451346&#34; target=&#34;_blank&#34;&gt;ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. […] Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32458750&#34; target=&#34;_blank&#34;&gt;Analysis of survival of patients with metastatic malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To report the outcomes and prognosis of patients with malignant pleural mesothelioma (MPM) who present with or develop metastases during treatment. […] Logistic regression was used for propensity score matching of patients to assess chemotherapy treatment effect.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32463095&#34; target=&#34;_blank&#34;&gt;Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment consisted of 240-mg intravenous nivolumab administration every 2 weeks until progressive disease (PD) or serious adverse events (AEs). […] Additional post-treatment data were evaluated, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), post-treatment survival and AEs. […] The median treatment duration was 3 months (range: 1-14 months), and median of 8 cycles (range: 2-32 cycles) was administered. […] Nivolumab treatment in patients with post-operative recurrence of MPM seems safe and clinical efficacy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32475823&#34; target=&#34;_blank&#34;&gt;Irinotecan inducing sinus pause bradycardia in a patient with small round cell cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It can be used as a single chemotherapy agent in colonic cancer treatment or in combination with 5-fluorouracil. […] Irinotecan has been found a better salvage therapy in patients who are resistant to 5-fluorouracil.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32481365&#34; target=&#34;_blank&#34;&gt;Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant peritoneal mesothelioma is a rare tumor with a poor prognosis and has no recommended therapy after first-line pemetrexed and platinum-based chemotherapy. […] After 4 cycles of cisplatin plus pemetrexed and 13 subsequent cycles of pemetrexed maintenance therapy showed beneficial responses until CT revealed liver metastasis. […] Nivolumab was then administered as the second-line therapy. […] CT revealed an intraperitoneal mass growing much more rapidly than ever, indicating hyperprogressive disease after nivolumab treatment. […] To our knowledge, this is the first report of hyperprogressive disease in a case of peritoneal mesothelioma after nivolumab treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32517259&#34; target=&#34;_blank&#34;&gt;TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The multi-targeted inhibition of histone deacetylase (HDAC), HER2 and TGFα receptor (epidermal growth factor receptor/EGFR) improved treatment efficacy in vitro and reduced tumor growth in two MPM mouse models. […] This observation may contribute to casting light on the promising but still controversial role of EGFR signaling in MPM therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32526602&#34; target=&#34;_blank&#34;&gt;Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The combination of anti-PD-1/PD-L1 antibody with chemotherapy has been approved for the first-line therapy of lung cancer. […] The combination of anti-PD-1 antibody with CDDP + PEM may be a promising therapy for MPM via inhibiting the accumulation of MDSCs and vessels in tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32526924&#34; target=&#34;_blank&#34;&gt;Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These parameters are easy to analyse at the time of DMPM diagnosis and may support better patient stratification, prediction of treatment effectiveness and therapeutic optimization.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32529589&#34; target=&#34;_blank&#34;&gt;Racial Disparities in Treatment Patterns and Survival Among Surgically Treated Malignant Pleural Mesothelioma Patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We examined treatment and survival in black and white surgical MPM patients using the National Cancer Database (NCDB). […] Among patients with pleurectomy/decortication (PD) or extrapleural pneumonectomy (EPP), multivariable logistic regressions were used to evaluate racial differences in surgical extent, additional treatment, and 30-/90-day mortality.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32530527&#34; target=&#34;_blank&#34;&gt;Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In conclusion, the interaction between MPM cells and TAMs through a IL-1β/IL-1R signal could be a promising candidate as the target for novel treatment of MPM (Hyogo College of Medicine clinical trial registration number: 2973).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32531717&#34; target=&#34;_blank&#34;&gt;Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We used a population-level database to evaluate the impact of radiotherapy as a component of trimodality therapy on overall survival (OS) in MPM. […] A propensity score-matched analysis with inverse probability of treatment weighting (IPTW) was performed. […] Weight-adjusted univariate KM analysis was performed and doubly robust, IPTW-adjusted multivariable cox proportional hazards regression modeling was also performed to quantify the effect of radiotherapy on OS in trimodality therapy for MPM. 1015 patients were identified. 678 patients received surgery and chemotherapy, and 337 patients received trimodality therapy. […] For patients with localized disease, OS was significantly improved with trimodality therapy (HR 0.56, CI 0.4 - 0.8, p = 0.001), which persisted with IPTW adjustment (HR 0.65, CI 0.49 - 0.95, p = 0.0248). […] These findings support a significant benefit to OS by incorporating radiotherapy as a component of trimodality therapy for patients with localized MPM compared to only surgery and chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32532926&#34; target=&#34;_blank&#34;&gt;Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Introduction:&lt;/b&gt; Fixed-dose pembrolizumab (200 mg abs., d1, q3w) for the treatment of malignant pleural mesothelioma did not result in survival benefit in the phase 3 PROMISE-meso trial compared to 2nd-line chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32535843&#34; target=&#34;_blank&#34;&gt;Secondary renal amyloidosis associated with asbestos-related pleuropulmonary diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As these benign asbestos-related diseases have no standard treatment, we administered low-dose angiotensin II receptor blocker to preserve kidney function.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32540558&#34; target=&#34;_blank&#34;&gt;NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
None of the patients received targeted treatment. […] Our data suggest that IHC could be a useful screening test in such patients to ensure that all therapeutic strategies including targeted therapy are utilized.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32553000&#34; target=&#34;_blank&#34;&gt;Asbestos-related diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The principles of treatment are as for all cases of lung cancer. […] As MM is non-resectable and poorly responsive to chemotherapy and radiotherapy, curative treatment is not possible and screening not justified.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32562788&#34; target=&#34;_blank&#34;&gt;RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment planning for malignant pleural mesothelioma (MPM) is a challenging task due to the relatively large size of the target and the need to spare critical organs that overlap with or are within the target volume. […] Data from 57 patients treated with volumetric modulated arc therapy (VMAT) were chosen for training the dose estimation model at a single dose level. […] Time taken with RP was 20 minutes, 45 seconds versus at least 4 hours for an experienced treatment planner. […] The RP model for MPM showed improved sparing of critical organs with a reduced treatment planning time and increased prescription dose.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32574520&#34; target=&#34;_blank&#34;&gt;Role of inflammation in the malignant transformation of pleural mesothelial cells induced by multi-walled carbon nanotubes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings also provide novel ideas and references for the treatment of mesothelioma and offers options for the occupational safety of nanomaterial practitioners.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32582537&#34; target=&#34;_blank&#34;&gt;Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a treatment recalcitrant tumor with a poor overall survival (OS). […] Current approved treatment consists of first line chemotherapy that only modestly increases OS, illustrating the desperate need for other treatment options in MPM. […] Unfortunately, clinical studies that investigate the effectivity of checkpoint inhibitor (CI) treatment failed to improve clinical outcome over current applied therapies. […] In general, MPM is characterized as an immunological cold tumor with low T-cell infiltration, which could explain the disappointing results of clinical trials investigating CI treatment in MPM. […] In this review we will discuss these novel treatment approaches for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32600123&#34; target=&#34;_blank&#34;&gt;Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this case report, we describe a patient with &lt;i&gt;EML4-ALK&lt;/i&gt;-rearranged stage IIIB MPM who was administered with alectinib and lorlatinib as first-line and fourth-line therapy, respectively. […] His plasma samples were collected during the treatment course and submitted for targeted sequencing to understand the molecular mechanisms of his therapeutic resistance. […] Moreover, our case also revealed acquired mechanisms of lorlatinib resistance mediated by multiple mutations &lt;i&gt;ALK&lt;/i&gt; I1171N, L1196M, and G1202R, contributing an incremental step to our understanding of the complexity of acquired resistance mechanisms in sequential ALK inhibitor therapy. &lt;i&gt;The reviews of this paper are available via the supplemental material section.&lt;/i&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32605213&#34; target=&#34;_blank&#34;&gt;TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intra-operative photodynamic therapy (IO-PDT) in combination with surgery for the treatment of non-small cell lung cancer and malignant pleural mesothelioma has shown promise in improving overall survival in patients. […] Human lung adenocarcinoma (A549) cell viability was assessed after treatment with TLD1433-mediated PDT illuminated with either 532- or 630-nm light with a micro-lens laser fiber. […] Our studies indicate that TLD1433-mediated PDT with the OSA and light simulations have the potential to become a platform for treatment planning for IO-PDT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32608142&#34; target=&#34;_blank&#34;&gt;A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with the Aurora kinase A inhibitor yields often durable disease control, but limited tumor regression, in heavily pretreated patients with unresectable malignant pleural or peritoneal mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32611504&#34; target=&#34;_blank&#34;&gt;Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is unclear if there are gender-based differences in receipt of treatment or disease-related outcomes for patients with MPM. […] The overall treatment effect was tested in subsets of patients by treatment strategy, histology, and clinical stage.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32624414&#34; target=&#34;_blank&#34;&gt;Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overall survival remains dismal, partly owing to poor response to available treatment. […] In multivariate analysis, we showed tumor size, Eastern Cooperative Oncology Group performance status, and first-line treatment (both surgery and chemotherapy) to be associated with survival time. […] The prolonged survival time is most likely explained by a combination of tumor-, patient-, and treatment-related factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32629507&#34; target=&#34;_blank&#34;&gt;[Five Years PLEURATUMOR Register of the German Society of Thoracic Surgery].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of these patients, 522 data sets were complete and 516 patients received surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32631662&#34; target=&#34;_blank&#34;&gt;Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Severe acute kidney injury requiring renal replacement therapy developed in 16 patients (3.2%). […] Strategies to prevent postoperative acute kidney injury are needed to improve multimodal treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32633902&#34; target=&#34;_blank&#34;&gt;Video-assisted biopsy and talc pleurodesis for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment, preferably in a multimodal setting, cannot provide cure, but can prolong survival and improve quality of life in selected cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32661672&#34; target=&#34;_blank&#34;&gt;FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Careful selection of malignant pleural mesothelioma (MPM) patients for curative treatment is of highest importance, as the multimodal treatment regimen is challenging for patients and harbors a high risk of substantial toxicity. […] Radiomics-a quantitative method for image analysis-has shown its prognostic ability in different tumor entities and could therefore play an important role in optimizing patient selection for radical cancer treatment. […] Pre-treatment Fluorine-18 fluorodeoxyglucose (FDG) PET and CT scans were used for radiomics outcome modeling. […] Radiomics could serve as a tool to aid clinical decision support systems for treatment of MPM in future.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32676326&#34; target=&#34;_blank&#34;&gt;Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patient characteristics, including age, sex, subtype and previous treatment were captured. […] Patients who received ICIs as first-line therapy had greater PFS than those who received it as second or third line post-chemotherapy. […] These data support the expansion of trials utilizing single and combination ICIs as first-line therapy in sarcomatoid MPM and warrants further studies testing the impact or detriment of chemotherapy pre-ICI.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32676359&#34; target=&#34;_blank&#34;&gt;Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Beside preventive measures and ban the use of asbestos, early diagnosis would largely improve the chance of curative treatment. […] Recurrent, hemorrhagic and cell rich effusion should always be suspicious for MM and adequately prepared and analyzed to provide necessary information for subsequent therapy. […] Thus, a conclusive positive MM cytology should lead to treatment without delay.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32682189&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this investigation was to describe mesothelioma patient characteristics, treatment patterns, and outcomes in Spain. […] Nearly two-thirds of patients (71 %) received chemotherapy, mainly platinum-pemetrexed combination, as part of their treatment. […] Results of multivariate analyses showed significant association of ECOG-performance status, histology and treatment response with improved OS in MPM patients treated with palliative chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32682370&#34; target=&#34;_blank&#34;&gt;Progress in the understanding of the immune microenvironment and immunotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or without chemotherapy, and/or radiation therapy. […] The tumor immune microenvironment (TME) has been proven to play an important role in MPM pathogenesis and treatment outcome.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32684102&#34; target=&#34;_blank&#34;&gt;Ovarian metastasis from malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A whole-body computed tomography (CT) scan with contrast enhancement and possibly positron emission tomography-CT should be performed to identify any distant metastases before deciding on treatment strategy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32693945&#34; target=&#34;_blank&#34;&gt;Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with &amp;lt; 1 cm MPM thickness, prior pleurectomy, pleurodesis, pleural radiotherapy, or antiangiogenic therapy were excluded.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32705221&#34; target=&#34;_blank&#34;&gt;Connective tissue growth factor produced by cancer‑associated fibroblasts correlates with poor prognosis in epithelioid malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The data suggest that CTGF+ CAFs are involved in mesothelioma progression and represent a potential molecular target for mesothelioma therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32714828&#34; target=&#34;_blank&#34;&gt;Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We present a case of recurrent MPM who responded to nivolumab treatment and experienced nivolumab-induced immune thrombocytopenia (ITP). […] The careful and intensive management of ITP treatment is necessary in cases who show no response or relapse to initial glucocorticoids treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32727552&#34; target=&#34;_blank&#34;&gt;Determinants of plasma calretinin in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The value of plasma calretinin for therapy monitoring or as a prognostic marker should be further investigated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32727707&#34; target=&#34;_blank&#34;&gt;Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of maintenance therapy for malignant pleural mesothelioma (MPM) is unknown.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-08-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32731396&#34; target=&#34;_blank&#34;&gt;Multiplex Soluble Biomarker Analysis from Pleural Effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a highly aggressive and therapy resistant pleural malignancy that is caused by asbestos exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32732073&#34; target=&#34;_blank&#34;&gt;Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Epithelioid patients with MPM received trabectedin as second-line while biphasic/sarcomatoid patients with MPM as first- or second-line therapy. […] Treatment was given intravenously at an initially planned dose of 1.3 mg/m&lt;sup&gt;2&lt;/sup&gt; every 3 weeks, until progression or unacceptable toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3293765&#34; target=&#34;_blank&#34;&gt;Mesothelioma of childhood.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Four of the 80 children had exposure to known risk factors (two had history of exposure to asbestos, one had received radiation therapy, and one had been exposed in utero to isoniazid).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3317170&#34; target=&#34;_blank&#34;&gt;[Toxicity of the CYVADIC modification in patients with soft tissue sarcomas or malignant mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CYVADIC (cyclophosphamide + vincristine + adriamycin + dacarbazine = DTIC) is frequently used in the treatment of patients with soft tissue sarcomas or malignant mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3335148&#34; target=&#34;_blank&#34;&gt;Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, there was no significant difference in survival with respect to the type of treatment given: surgery, chemotherapy, talc poudrage or their combination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3335886&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965-1985.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Factors at diagnosis associated with prolonged survival for the subset of patients with pleural mesothelioma included epithelial histology, 0 to 1 performance status, the absence of chest pain, an interval of greater than 6 months from onset of symptoms, and treatment with chemotherapy and pleuropneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3351560&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This was similar for all comparable treatment groups. […] The stepwise addition of treatment modalities did not increase survival, which remained the same as that reported for untreated patients. […] Therefore, phase II trials of new agents offer the only hope for advance in the treatment of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3386291&#34; target=&#34;_blank&#34;&gt;The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Between October 1983 and April 1987, 20 patients with malignant mesothelioma underwent computed tomography scans of the chest and upper abdomen to evaluate the extent of disease before treatment. […] Despite its limitations, computed tomography is probably the most accurate way to provide follow-up for patients during treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3387952&#34; target=&#34;_blank&#34;&gt;Clinicopathologic studies on mesothelioma of the pleura. Differentiated approach to treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite the generally poor prognosis, the results of radical surgery in this study appear to warrant an aggressive approach to treatment of benign or localized malignant pleural mesothelioma, and possibly also to stage I diffuse malignant mesothelioma of epithelial type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3414598&#34; target=&#34;_blank&#34;&gt;Flow cytometric analysis of ploidy in immunohistochemically confirmed examples of malignant epithelial mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Each mesothelioma lacked staining with periodic acid-Schiff (PAS) after diastase pretreatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-10-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3541812&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Correct diagnosis of the benign variant is rarely made preoperatively, and resection is the treatment of choice and is curative. […] Their diagnosis and treatment do not differ from those for soft-part sarcomas seen elsewhere. […] Wide en-bloc excision is the treatment of choice and can be curative. […] Treatment is generally unsatisfactory, and long-term survival is rare. […] Steps in selecting the best surgical mode of treatment are presented.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3542255&#34; target=&#34;_blank&#34;&gt;Asbestos-related malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of mesothelioma remains unsatisfactory. […] However, anecdotes report long-term disease-free survival after intensive treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3542270&#34; target=&#34;_blank&#34;&gt;Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment was well tolerated without severe side-effects.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3542271&#34; target=&#34;_blank&#34;&gt;A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Primary cytotoxic drug resistance is a major obstacle to successful treatment of mesothelioma, and phase II studies of novel agents should continue in an effort to circumvent this problem.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3543239&#34; target=&#34;_blank&#34;&gt;Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There was no significant difference in response duration or survival between treatment arms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3616223&#34; target=&#34;_blank&#34;&gt;The cytologic diagnosis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A positive cytoplasmic staining of tumor cells with periodic acid-Schiff (PAS) after diastase digestion, and with mucicarmine stain after hyaluronidase treatment are against the diagnosis of mesothelioma, while positive staining with alcian blue, which becomes negative after the treatment with hyaluronidase is strongly suggestive of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3619593&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma of the pleura–intrapleural treatment with doxorubicin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The drug was applied intrapleurally for cases with pleural fluid in doses of 20 to 30 mg, weekly during the first month of treatment and later on monthly. […] The effect will be controlled directly and during the continued treatment, using cytological examination of the sediment of the pleural fluid and by simultaneous measurement of the level of hyaluronic acid in the same fluid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3704398&#34; target=&#34;_blank&#34;&gt;[Malignant diffuse peritoneal mesothelioma: clinical and therapeutic aspects. Apropos of a case with gelatinous ascites].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment consists of surgery combined with radiotherapy and chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-06-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3708543&#34; target=&#34;_blank&#34;&gt;Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One of eight patients (12.5%) receiving intrapleural therapy and nine of 13 patients receiving intraperitoneal therapy demonstrated objective evidence of a clinical response, including three surgically defined major tumor regressions (23%). […] Patients receiving intrapleural treatment had more advanced disease prior to therapy than those receiving intraperitoneal therapy. […] It was concluded that intraperitoneal cisplatin is an active treatment program for intra-abdominally localized mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3726417&#34; target=&#34;_blank&#34;&gt;[Primary malignant tumors of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy-resistant refractory thoracic pain was the principal clinical sign.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-08-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3753125&#34; target=&#34;_blank&#34;&gt;Minimal-change nephrotic syndrome associated with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The proteinuria did not respond to treatment with prednisone and cyclophosphamide. […] The proteinuria then improved during treatment with doxorubicin hydrochloride and dacarbazine, without noticeable improvement in the tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3859121&#34; target=&#34;_blank&#34;&gt;The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This technique will be diagnostically useful in selected cases and may be helpful in avoiding more invasive procedures as well as delays in diagnosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3891207&#34; target=&#34;_blank&#34;&gt;Benign and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of this disease remains unsatisfactory. […] Occasional patients have remained disease-free for periods in excess of 5 years after intensive treatment, however. […] While many authors have advocated supportive care alone because “current treatments have not demonstrated increased survival,” we believe patients with mesothelioma should be offered investigational therapy.(
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3907825&#34; target=&#34;_blank&#34;&gt;Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The effect of doxorubicin and cyclophosphamide in the treatment of diffuse, malignant pleural mesothelioma was evaluated in a randomized study. […] All patients were treated on an outpatient basis and none had previously received antineoplastic treatment. […] The treatment consisted of doxorubicin at a dose of 60 mg/m2 every 3 weeks, to a total dose of 550 mg/m2, or cyclophosphamide at a dose of 1500 mg/m2 every 3 weeks for 1 year. […] At disease progression the treatment was changed to the alternate drug. […] During treatment with doxorubicin, none of the patients developed cardiotoxicity, while one patient developed hemorrhagic cystitis during treatment with cyclophosphamide. […] Sepsis or bleeding was not observed in either of the treatment arms. […] Thus, the trial showed no antineoplastic activity of either doxorubicin or cyclophosphamide in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-01-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3925387&#34; target=&#34;_blank&#34;&gt;[Monoclonal gammopathies in the aged].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differences between the two groups with respect to different types of gammapathy, median survival rates, response to therapy, are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/4062141&#34; target=&#34;_blank&#34;&gt;[Bromocriptine in Parkinson’s disease: pleuropulmonary toxicity].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors report a case of pleuro-pulmonary fibrosis after 9 months of high dose bromocriptine therapy for the treatment of Parkinson’s disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/4067615&#34; target=&#34;_blank&#34;&gt;Tetracycline sclerosis in the management of malignant pericardial effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intrapericardial tetracycline instillation is a safe and efficacious treatment for malignant pericardial effusion and should be considered the first treatment modality in this situation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6083969&#34; target=&#34;_blank&#34;&gt;Immunohistological study of malignant diffuse mesotheliomas of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The three mesotheliomas which were positive for CEA were also positive for alcian blue after hyaluronidase treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-03-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6201454&#34; target=&#34;_blank&#34;&gt;Thymostimulin in malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Complete remission was obtained in 4 patients after 3 weeks and in 4 within 8 weeks of treatment. […] This preliminary trial has shown that intrapleural treatment of neoplastic pleural effusion with a thymic hormone preparation can induce rapid and efficient palliation without subjecting the patients to distressing or toxic procedures.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6287988&#34; target=&#34;_blank&#34;&gt;Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival was better in younger subjects and subjects selected for surgery but was unrelated to sex, symptoms at onset, history of asbestos exposure, tumour morphology, therapy other than surgery or year of presentation. […] The outlook for patients with this disease remains poor and there is still no optimism for future advances in therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6327010&#34; target=&#34;_blank&#34;&gt;Mesothelioma following Wilms’ tumor in childhood.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A high percentage of children with Wilms’ tumor are cured with multimodal treatment. […] A small percentage of these children will develop second tumors, perhaps related to a genetic predisposition to neoplasia or possibly secondary to the treatment utilized for Wilms’ tumor. […] Two patients are reported who developed malignant mesothelioma of the pleura after treatment for Wilms’ tumor in childhood.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6406317&#34; target=&#34;_blank&#34;&gt;[Thoracoscopic and computer tomographic findings in pleural mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT is an advance in the diagnosis of these rare tumours; it aids in arriving at a prognosis and in formulating treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6426072&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have carried out sequential prospective studies of treatment with surgery alone, chemotherapy, and radiotherapy in malignant mesothelioma of the pleura. […] There was no significant difference in survival between treatment groups or between treated and untreated patients, and no difference when mesotheliomas of epithelial, sarcomatous, and mixed cell types were examined separately. […] Treatment of this disease appeared to fail because of the unresponsiveness of the tumour to existing forms of treatment and the advanced stage of the disease at clinical presentation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-06-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/646225&#34; target=&#34;_blank&#34;&gt;Mesothelioma associated with the syndrome of inappropriate secretion of antidiuretic hormone.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The electrolyte abnormalities were corrected by treatment with demethylchlortetracycline.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1978-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6601367&#34; target=&#34;_blank&#34;&gt;CT of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The initial pretreatment scans showed a typical lobulated rind of pleural tumor encasing the lung associated with variable amounts of pleural fluid. […] Serial scans during treatment provided objective evidence of either regression or growth of tumor mass, even when the patients’ clinical status and plain films appeared stable.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6692252&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma. The University of Minnesota experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is being increasingly recognized in Minnesota and has a grim prognosis in spite of doxorubicin therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6692681&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: the role of computed tomography.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This permits appropriate selection of therapy and may demonstrate that surgery or radiotherapy is not indicated. computed tomography often permits more accurate evaluation following chemotherapy and may be the only means by which to follow a patient after radical surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6706729&#34; target=&#34;_blank&#34;&gt;Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment at thoracotomy consisted of as complete a parietal pleurectomy as was possible to remove the bulk of the tumor. […] External radiation therapy was given 4-6 weeks postoperatively to the involved hemi-thorax, shielding the lung and utilizing a combination of electron and a photon beam.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6719076&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma. A clinical review of 19 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radiotherapy and cytostatic medication had no demonstrable effect on survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6723826&#34; target=&#34;_blank&#34;&gt;Diagnosis and prognosis in malignant pleural mesothelioma: a prospective study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The morphological type and the patient’s age had an impact on the survival time, whereas sex and extensive surgical treatment seemed less important.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6761970&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment modalities including surgical procedures and chemotherapy with doxorubicin and 5-azacytidine offer prospects for palliation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-04-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6789635&#34; target=&#34;_blank&#34;&gt;CT of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This is important because the diagnosis of mesothelioma is difficult and because treatment and prognosis may depend on the extent of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-09-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6845257&#34; target=&#34;_blank&#34;&gt;Intrapleural Corynebacterium parvum for malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A pilot study of topical (intrapleural) treatment with Corynebacterium parvum was carried out in 10 patients with malignant pleural effusions complicating primary or secondary neoplasms and necessitating frequent thoracocentesis for symptomatic relief. […] The treatment was repeated in each case as clinical conditions called for further thoracocentesis. […] In eight of these 10 patients the treatment resulted in prompt reduction of the rate of accumulation of pleural fluid and a striking change of cell sediment composition, with appreciable reduction in or complete disappearance of malignant cells and a rise in lymphocyte and neutrophil polymorph counts.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6863663&#34; target=&#34;_blank&#34;&gt;Computed tomography of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy was altered in these four cases. […] By demonstrating lesions not detectable on conventional imaging studies, CT may alter staging and therapy in many patients with this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6866894&#34; target=&#34;_blank&#34;&gt;[Clinical aspects and course of 38 cases of malignant pleural mesothelioma observed in the Marseilles region].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Their therapy involves preventive irradiation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6884940&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma. Problems, therapy and results].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical findings, therapy, and prognosis of pleural mesothelioma are demonstrated by the review of 17 cases of malignant and 3 cases of benign tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6980698&#34; target=&#34;_blank&#34;&gt;High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report nine cases of malignant mesothelioma which temporarily responded to treatment with high-dose methotrexate-citrovorum rescue and vincristine.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7051806&#34; target=&#34;_blank&#34;&gt;Chemotherapy for malignant mesothelioma; CAMEO.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mean survival from the time of tissue diagnosis an start of protocol treatment was 15.7 and 12.6 months, respectively. […] Median survival from the time of tissue diagnosis and start of protocol treatment was 11 and 6.5 months, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7058460&#34; target=&#34;_blank&#34;&gt;Immunotherapy with BCG vaccine in 30 cases of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Techniques of therapy are detailed and the importance of ‘tumour load’ reduction and prolonged injection schedule, is stressed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7067338&#34; target=&#34;_blank&#34;&gt;Computed tomography in the assessment of malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Computed tomography (CT) and plain radiography have been performed on 32 patients with malignant mesothelioma of the pleura, in order to assess the extent of disease and suitability for radical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/709531&#34; target=&#34;_blank&#34;&gt;The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Adriamycin appears to be of benefit in the treatment of diffuse malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7105050&#34; target=&#34;_blank&#34;&gt;Combined doxorubicin and radiation therapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three patients derived significant clinical benefit from this treatment, although only one of the three had measureable tumor shrinkage that could be defined as partial response. […] The treatment was subjectively well-tolerated and hematopoietic toxicity was acceptable. […] Although the combined treatment could be given with acceptable toxic effects and although four patients benefited from it, the best objective assessment, namely, survival time, did not appear to be adequately influenced to justify an extension of this series.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7144218&#34; target=&#34;_blank&#34;&gt;Surgical treatment of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Resection was the main mode of treatment in benign and fibrosarcomatous mesothelioma. […] Treatment of diffuse epithelial mesothelioma presented the greatest challenge. […] Surgical therapy, radiation therapy, and chemotherapy were used in combination in these patients. […] The review of our patients treated prior to 1972 had shown no benefit from including pulmonary resection in the surgical treatment of these tumors. […] Both internal and external radiation therapy were also used to enhance local control. […] Despite the poor prognosis in malignant mesothelioma, better survival was achieved when the treatment included operation combined with radiation and chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7226012&#34; target=&#34;_blank&#34;&gt;Monophasic mesenchymal synovial sarcoma: its identification by tissue culture.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The topographic distribution and the response to therapy of the neoplasms were also similar to that found in the usual biphasic tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7228311&#34; target=&#34;_blank&#34;&gt;A review of the treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, most mesotheliomas are already diffuse by the time they are diagnosed; and no treatment has been shown to be effective. […] Large, cooperative, controlled trials are needed to evaluate the usefulness of one or a combination of the treatment methods described.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7281500&#34; target=&#34;_blank&#34;&gt;Secreting peritoneal mesothelioma. Report of a case with cytological, ultrastructural, morphometric and histological studies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment with chemotherapy and radiation resulted in temporary remission, lasting for 20 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7302349&#34; target=&#34;_blank&#34;&gt;[Current indications for thoracoscopy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Talc pleurodesis in the treatment of chronic recurrent malignant pleural effusions is successful in 80%. […] In the treatment of spontaneous pneumothorax with a mean follow up of 10 years, only 6.6% recurred after talc poudrage, and functional sequelae were minimal; no talcomas induced mesotheliomas were seen in a review of 151 cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-01-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7306467&#34; target=&#34;_blank&#34;&gt;Diffuse malignant pleural mesothelioma in Glasgow.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No treatment improved life expectancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7312760&#34; target=&#34;_blank&#34;&gt;[Intrapleural talc in malignant pleural effusions (author’s transl)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Both series were compared retrospectively in terms of age, sex, exposure to asbestos, histological type and the interval between the first symptom and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7375884&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The heterogenous treatment reported in cases of malignant pleural mesothelioma illustrates the poor results achieved hitherto. […] Now treatment with either combination chemotherapy or radioactive drugs is recommended.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1980-07-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7392647&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: a metastasis to the face.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although it usually causes death rapidly by local and regional spread, distant metastases may be seen more frequently as more effective therapy controls local disease and prolongs life. […] Our patient’s local and then regional mesothelioma was controlled by aggressive treatment, which allowed him nearly two years of productive life before a metastasis to the right infraorbital region occurred.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1980-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7421277&#34; target=&#34;_blank&#34;&gt;Malignant mesotheliomas and chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chemotherapy appears moderately effective in the treatment of mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1980-12-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7458474&#34; target=&#34;_blank&#34;&gt;Diffuse, mixed malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ten patients received no definitive therapy and survived an average of 9.1 months (1 lived for 16 months).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/746601&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A series of 12 cases of mesothelioma is presented, and the data in the literature is reviewed in an attempt to formulate a program of treatment for this malignant, fast-growing and rapidly fatal tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7518666&#34; target=&#34;_blank&#34;&gt;Aggressive multimodality therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nineteen patients with clinical stage I malignant pleural mesothelioma were treated with aggressive multimodality therapy. […] We conclude that despite major toxicity, in select patients with clinical stage I malignant pleural mesothelioma, aggressive multimodality therapy offers effective palliation and occasional long-term disease-free survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7524472&#34; target=&#34;_blank&#34;&gt;Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients presenting with malignant mesothelioma of the pleura (MMP) are only suitable for palliative treatment. […] More than half of the patients whose response could be assessed had some symptomatic relief from the radiotherapy treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-10-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7526476&#34; target=&#34;_blank&#34;&gt;[The clinical picture and therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are different therapeutic modalities (surgical treatment, radiotherapy, chemotherapy), which are used alone or in combination to influence the poor outcome of pleural mesothelioma. […] We report about 7 of our own cases, treated with surgery and radiotherapy (4) or with a combination of surgery, radiotherapy and chemotherapy (3) and discuss the clinical aspects, diagnosis and the different ways of treatment of malignant pleural mesothelioma and its influence on survival. […] Palliative surgery such as pleurectomy is the treatment of choice for extended disease. […] Prospective trials are necessary to further clarify the role of multimodality treatment programs for malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/753150&#34; target=&#34;_blank&#34;&gt;Surgical management of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of these patients, 7 received limited treatment–pleurectomy or biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7542832&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma after Thorotrast exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The clinical manifestation was a serosal effusion, which required weekly ascites puncture until therapy with intraperitoneal bleomycin was initiated. […] The latter treatment led to a significant reduction of ascites without any influence on tumor progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7551944&#34; target=&#34;_blank&#34;&gt;Clinical features and current treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment remains controversial and ranges from supportive care alone to aggressive multimodality therapy. […] Prospective clinical trials in carefully staged patients are needed to determine what approaches to treatment may confer a survival benefit.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7555126&#34; target=&#34;_blank&#34;&gt;A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Investigation of the behavior and treatment of the diffuse malignant pleural mesothelioma (MPM) is hindered by the lack of an accurate universally accepted staging system.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7555639&#34; target=&#34;_blank&#34;&gt;[Pseudomesotheliomatous carcinoma in HIV infection].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As the effusion was refractory to treatment (301 of effusion were drained over several days), thoracoscopy was performed despite the patient’s poor general condition.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7560168&#34; target=&#34;_blank&#34;&gt;OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the reaction of antibodies OV 632 and MOC 31 in paraffin wax sections as opposed to frozen sections and cytological preparations; to evaluate their usefulness in the differential diagnosis of malignant mesothelioma and secondary adenocarcinoma of the pleura; and to assess the efficacy of microwave pretreatment of sections in unmasking their associated epitopes. […] Immunohistochemistry, using a standard avidin-biotin technique, with microwave pretreatment and trypsinisation in a certain proportion of cases. […] Reactions to both antibodies were abolished by microwave pretreatment, and also by prior trypsinisation in the case of OV 632. […] Microwave pretreatment does not enhance the reactions with either antibody.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-10-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7564374&#34; target=&#34;_blank&#34;&gt;Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a generally fatal disease with no standard treatment. […] One of three patients who developed chemotherapy-related nephrotoxicity died, the only treatment-related mortality.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7569558&#34; target=&#34;_blank&#34;&gt;Use of photodynamic therapy for the management of pleural malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) is a surface oriented, locally cytotoxic intervention being investigated for oncologic therapy. […] A series of investigations have been performed at the National Cancer Institute since 1985 studying the possible use of PDT for large cavity treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7569559&#34; target=&#34;_blank&#34;&gt;Intracavitary photodynamic therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A total of 31 patients with malignant pleural mesothelioma disease, limited to one hemithorax, were entered into a phase II study of surgery and intracavitary photodynamic therapy. […] The light dose for photodynamic therapy will be carefully increased to find the maximal tolerated dose.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7600028&#34; target=&#34;_blank&#34;&gt;Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Larger studies are needed to assess the importance of TNM staging in the selection of treatment and as a prognostic factor for malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7618973&#34; target=&#34;_blank&#34;&gt;Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although malignant mesothelioma is refractory to current therapies, its localized nature and the accessibility of the pleural space make it a potential target for a similar type of in vivo gene therapy using adenovirus. […] Administration of Ad.RSVtk into the peritoneal space of animals with established multifocal human mesothelioma followed by GCV therapy resulted in the eradication of macroscopic tumor in 90% of animals and microscopic tumor in 80% of animals when evaluated after 30 days.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7641017&#34; target=&#34;_blank&#34;&gt;A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of malignant pleural mesothelioma (MPM) continues to be inadequate with the use of standard techniques, including surgery, radiotherapy and chemotherapy. […] One treatment-related death (2%) occurred, from myocardial infarction.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7677485&#34; target=&#34;_blank&#34;&gt;Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Novel therapeutic strategies such as gene therapy clearly are needed to improve the survival of patients with this neoplasm. […] To aid in the evaluation of new treatment strategies, animal models that closely mimic human disease are required. […] The model described here offers the opportunity to study a variety of new treatment modalities, especially somatic gene transfer, against pleural-based malignant mesothelioma in an immune competent setting.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/768710&#34; target=&#34;_blank&#34;&gt;Pleural mesotheliomas–an analysis of 18 cases and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No treatment was curative of malignant mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7695406&#34; target=&#34;_blank&#34;&gt;Characteristics of nine newly derived mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These new cell lines derived from human mesotheliomas can now be used to aid in the design of innovative treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7697307&#34; target=&#34;_blank&#34;&gt;Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Preliminary studies have suggested that the intracavitary administration of cytokines may represent a new effective palliative therapy of malignant effusions. […] To define further the therapeutic role of cytokines in the treatment of neoplastic fluid accumulation, 70 cancer patients with pleural, pericardial or peritoneal cytologically proven neoplastic effusions were randomized to receive intracavitary cycles with interleukin-2 (IL-2; 6 x 10(6) IU), interferon (IFN alpha; 2 x 10(7) U) or IFN beta (6 x 10(6) U) every week for 2 or 3 weeks. […] According to preliminary data, this study demonstrates that intracavitary administration of cytokines, including IL-2, IFN alpha and -beta, is a new well-tolerated palliative therapy for malignant effusions, with an efficacy substantially comparable to that described with the most commonly used treatments with tetracyclines or cytostatic agents.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7705189&#34; target=&#34;_blank&#34;&gt;Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival time of the patients with diploid tumors was 19, 16, and 14 months from the onset of symptoms, diagnosis, and treatment, respectively. […] The median survival in patients with aneuploid tumors was 8, 7, and 7 months from the onset of first symptoms, diagnosis, and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7708227&#34; target=&#34;_blank&#34;&gt;[Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The complete response rate of this treatment was 90% (86 pt) with a mean treatment period of 32.9 days (range 12-62). […] These findings indicate that this technique is an adequate treatment for the control of MPE inducing a clinical and quality-life improvement.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7728570&#34; target=&#34;_blank&#34;&gt;Parietal pleurectomy for malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Standard treatment usually consists of complete drainage of the pleural space via a chest tube and instillation of a pleural irritant to obtain pleural symphysis. […] In a majority of instances, such treatment effectively controls the pleural space; however, standard treatment fails in some cases. […] Twenty-four patients who did not respond to standard treatment for malignant pleural effusion were subjects for parietal pleurectomy, which was usually performed through an axillary thoracotomy. […] However, because of its significant morbidity and mortality, it should be reserved for failures of standard treatment, and patient selection is important.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7742009&#34; target=&#34;_blank&#34;&gt;The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is an asbestos-associated cancer that is increasing in incidence worldwide and is refractory to conventional therapy. […] Improved therapy of MM, particularly cytokine-based approaches, is likely to benefit from further elucidation of the patterns and regulation of cytokine expression associated with MM tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7756687&#34; target=&#34;_blank&#34;&gt;Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma is a malignant tumor of the serous surfaces in the thorax and abdomen, which has proved exceptionally resistant to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7781415&#34; target=&#34;_blank&#34;&gt;Current approach to malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current treatment measures, including surgery, radiation therapy, chemotherapy, intrapleural therapy, and combined-modality therapies, have had varying impacts on survival. […] This paper explores current trends in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7781416&#34; target=&#34;_blank&#34;&gt;Mesothelioma and radical multimodality therapy: who benefits?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery plays a role in the diagnosis, staging, and treatment of this malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7802534&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pericardium. An anatomo-clinical study of 10 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At present, there is no effective treatment for mesothelioma and the physician’s goal is to make the patient’s short survival time as comfortable as possible with respect to the severe pain and recurrent pleuro-pericardial effusions. […] The authors underline the utility of histological analysis of the utility of histological analysis of the pericardium if only to establish the diagnosis of mesothelioma and to enable administration of curative treatment of other pathologies (tuberculosis, malignant lymphoma) with identical clinical presentations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7812707&#34; target=&#34;_blank&#34;&gt;Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment was repeated every 4 weeks until progression. […] Toxicity was acceptable and no treatment-related deaths occurred.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7828700&#34; target=&#34;_blank&#34;&gt;Implantable access system for prolonged intrapleural immunotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In our opinion, the Port-A-Cath system is the most suitable device for intra-cavitary long-term therapy of malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7923001&#34; target=&#34;_blank&#34;&gt;Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This report presents the results of a prospective multi-institutional study of intrapleural treatment with gamma-interferon in patients with Butchart’s Stages I and II epithelial or mixed malignant pleural mesothelioma. […] Thoracoscopic or surgical biopsy was performed if computed tomography scan 2 weeks after the end of treatment demonstrated a reduction in tumor size. […] Treatment was performed on an outpatient basis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7925870&#34; target=&#34;_blank&#34;&gt;Prognostic factors and survival in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These prognostic factors should be taken into account when starting or evaluating treatment studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-11-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7942942&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma following radiation therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Studies of the growing population of long-term survivors of cancer have led to increased recognition of the neoplastic complications of therapy. […] The causes of secondary malignancies are probably multifactorial, but radiation therapy and chemotherapy have certainly been implicated in the development of posttherapy neoplasia. […] A case of pleural mesothelioma after successful radiation therapy for Hodgkin’s disease is described with a review of radiation-associated mesotheliomas reported in the literature. […] In Hodgkin’s disease, patients may receive radiation, chemotherapy, or combined treatment; the most common secondary malignancy is acute nonlymphocytic leukemia while sarcomas are the second most common solid tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7944821&#34; target=&#34;_blank&#34;&gt;Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From April 1991 to May 1993, 23 patients entered a phase II clinical study of surgical resection and adjuvant intracavitary photodynamic therapy for malignant pleural mesothelioma. […] Six patients underwent a pleuro-pneumonectomy, and 15 patients a pleurectomy, after which intracavitary photodynamic therapy was administered.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7947012&#34; target=&#34;_blank&#34;&gt;Spectrum of peritoneal mesothelioma in childhood: clinical and histopathologic features, including DNA cytometry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These cases illustrate the variable behavior of this tumor in childhood and highlight the difficulties encountered in diagnosis and treatment. […] Three different groups of mesothelioma are recognized: a classic, asbestos-related, malignant mesothelioma of adults, typically occurring in the pleural cavity; a multicystic mesothelioma, predominantly affecting the pelvic peritoneum of young women and associated with a good prognosis; and mesotheliomas in children, which are not associated with asbestos exposure and have an unpredictable biologic behavior requiring individual treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7953479&#34; target=&#34;_blank&#34;&gt;Thoracoscopy for the evaluation and treatment of pleural space disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In cases of metastatic disease or inoperable malignant mesothelioma, treatment of the effusion by talc poudrage can be combined with a diagnostic procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7953481&#34; target=&#34;_blank&#34;&gt;Contemporary approaches in the investigation and treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical trials studying a variety of innovative treatment strategies are being performed at centers with a significant referral base for the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7954042&#34; target=&#34;_blank&#34;&gt;Pleural and pericardial mesothelioma in a general teaching hospital during the last fourteen years.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival seemed better in epithelial type and those who received surgical treatment of malignant mesothelioma. […] Survival of malignant mesothelioma seems better in epithelial type and in those who received surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7956434&#34; target=&#34;_blank&#34;&gt;Localized pleural mesothelioma. The clinical spectrum.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Complete surgical resection is the preferred treatment for both types and is usually curative with the benign mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7967270&#34; target=&#34;_blank&#34;&gt;[A case of the localized fibrous mesothelioma which size decreased temporarily].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After a few weeks, the size of the shadow decreased with no treatment, then we followed up her with roentgenograms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7977250&#34; target=&#34;_blank&#34;&gt;Thoracic mesothelioma associated with abdominal mesenteric panniculitis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report a patient with MP, severe enough to require immunosuppressant treatment, who developed a recurrent pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7988264&#34; target=&#34;_blank&#34;&gt;Trials in malignant mesothelioma. LCSG 851 and 882.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This experience prompted the LCSG to explore combining a potentially less morbid operation, pleurectomy/decortication, with adjuvant therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7988265&#34; target=&#34;_blank&#34;&gt;Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although chemotherapy has the potential advantage of treating the underlying malignancy in addition to controlling the malignant effusion, intracavitary cisplatin and cytarabine therapy as administered in this trial appears inferior to existing sclerosing agents for the control of malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7993844&#34; target=&#34;_blank&#34;&gt;A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The limiting toxicity for further dose increments and more courses of treatment, was cumulative thrombocytopenia. […] However, the overall toxicity and the poor response duration limit the use of this schedule in the treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8010779&#34; target=&#34;_blank&#34;&gt;Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the localized nature of the disease, the potential accessibility of the tumor, and the relative lack of distant metastases make it a particularly attractive candidate for somatic gene therapy. […] These studies demonstrate that adenoviral vectors hold promise as vehicles to deliver gene therapy in human malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8011694&#34; target=&#34;_blank&#34;&gt;Neoplasms of the mediastinum, chest wall, and pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Improvement in treatment outcome among patients with mesothelioma has been slow, due in part to the rarity of the disease and in part to resistance to treatment. […] Groupwide or intergroup studies are needed to assess the biology and treatment of these disorders. […] Active studies to define the optimal treatment regimen continue.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8034521&#34; target=&#34;_blank&#34;&gt;[Localized pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Resection is the treatment of choice and can be curatively even in the malignant type. […] Clinical, radiological and pathological findings, therapy and prognosis are described.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8043983&#34; target=&#34;_blank&#34;&gt;Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two weeks after initiation of interferon-alpha 2 treatment the patient improved and the pleural effusion vanished.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8044791&#34; target=&#34;_blank&#34;&gt;Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This treatment was associated with in situ activation of macrophages and cytotoxic T-lymphocytes, as indicated by increased intrapleural neopterin and soluble CD8 concentrations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-08-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8055276&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This retrospective study reviews a single institution’s experience with extrapleural pneumonectomy and pleurectomy in the multimodality treatment of diffuse malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8055277&#34; target=&#34;_blank&#34;&gt;Adjuvant therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with malignant pleural mesothelioma appear to have gained little benefit from even the most intensive multimodality therapy. […] Although the reported median survival of patients who undergo some surgical procedure as part of their therapy appears to be superior to that of those patients treated in a nonoperative fashion, the lack of a randomized trial renders these data suspect.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8075038&#34; target=&#34;_blank&#34;&gt;Weekly high-dose cisplatin in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The response duration is short, however, possibly due to lack of effective maintenance therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8110720&#34; target=&#34;_blank&#34;&gt;Malignant pleural tumor in a child mimicking a mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A second operation, a new course of chemotherapy with stage IV SIOP MMT, followed by a second bone-marrow graft and mediastinal radio-therapy, resulted in remission. […] At the time of this report, after three and a half years of evolution, the child’s condition is satisfactory and she leads a normal life without treatment. […] Although these tumors generally have a weak response to chemo- and radiotherapy, we think that close follow-up and active therapy, rapidly initiated at the slightest sign, can improve the quality of life of the patients and increase their survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8112139&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma: a clinicopathologic study of 42 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Resection was considered as the treatment of choice for localized mesothelioma. […] The histologic type, stage and treatment were identified as significant prognostic factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8128091&#34; target=&#34;_blank&#34;&gt;[The kinetics of IL-2 after pleural administration in the treatment of neoplastic pleurisy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Studies have shown good tolerance and efficacy of elevated doses of recombinant IL-2 after intrapleural administration in the treatment of neoplastic pleurisy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8131480&#34; target=&#34;_blank&#34;&gt;AIDS and malignant mesothelioma–is there a connection?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
He developed AIDS in 1987 and began treatment with zidovudine in 1989.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8141698&#34; target=&#34;_blank&#34;&gt;Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While the addition of interferon to chemotherapy improves response rates in some other malignancies, such a combination has not been evaluated in the treatment of mesothelioma. […] To assess the anti-tumour effects and toxicity of interferon-alpha combined with doxorubicin in the treatment of pleural mesothelioma. […] Response status was assessed by tumour measurements on clinical examination and thoracic CT scans before and after treatment. […] It cannot be recommended in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/81715&#34; target=&#34;_blank&#34;&gt;Diffuse pulmonary malignant mesothelioma: response to doxorubicin and 5-azacytidine.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A dramatic clinical and radiologic response occurred after treatment with a combination of doxorubicin (Adriamycin) and 5-Azacytidine.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8191642&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma presenting as an axillary lymph node metastasis with anemone cell appearance.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient refused treatment and died 3 years after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-06-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8201377&#34; target=&#34;_blank&#34;&gt;A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study investigated the feasibility of a novel approach to the treatment of malignant pleural mesothelioma by combining surgical resection with immediate postoperative intrapleural chemotherapy and subsequent systemic chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-07-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8204275&#34; target=&#34;_blank&#34;&gt;Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment was based on biochemical and clinical studies which show a synergy between cytosine-arabinoside (Ara-C) and cisplatin. […] If it was possible, the treatment was repeated weekly for 3 times and, after a 6-week rest, it could be started again with the same schedule. […] We conclude that the combination of Ara-C and cisplatin is well tolerated and produces a high response rate in the treatment of malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8208519&#34; target=&#34;_blank&#34;&gt;Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Eighty-two treatment cycles were administered to 19 evaluable patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8218802&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma. A diagnostic and therapeutic challenge].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a tumor very difficult to diagnose and with a very controversial therapy. […] Surgical resection combined with radiotherapy and/or chemotherapy is the current therapeutics. […] We describe the state-of-the-art advances in the immunohistochemical diagnosis and therapeutics and we stress the need to conduct cooperative studies in order to achieve a better knowledge of the prognosis factors, an effective step-by-step approach and innovative therapy strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8219174&#34; target=&#34;_blank&#34;&gt;Diagnostic and therapeutic thoracoscopy: techniques and indications in pulmonary medicine.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently thoracoscopy has been used with increasing frequency for the diagnosis and treatment of pleuropulmonary diseases. […] For spontaneous pneumothorax, pleurodesis must be associated with treatment of the causal lesions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8242812&#34; target=&#34;_blank&#34;&gt;[Thoracoscopy in pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The resection was considered as a proper treatment of choice for localized pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-12-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8252214&#34; target=&#34;_blank&#34;&gt;Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapies?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is resistant to most standard forms of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/826313&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment at Memorial Hospital consisted of surgery, with or without radiation therapy, and supplemental chemotherapy. […] Survival was related to extent of disease and to treatment. […] When irradiation was the primary treatment, the median survival was 8 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1977-02-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8275441&#34; target=&#34;_blank&#34;&gt;High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After the second cycle of intrapleural treatment, the systemic AUC for filterable platinum was reduced by 40%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8293393&#34; target=&#34;_blank&#34;&gt;Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Neither of the patients with undetectable rIL-2 levels had response to therapy. […] This study demonstrates that continuous intrapleural infusion of rIL-2 is an active method of treatment for malignant pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8311014&#34; target=&#34;_blank&#34;&gt;Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results of this study indicate only marginal activity of r-alpha-IFN in the treatment of DMPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8317897&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Among the pretreatment variables studied (age, sex, asbestos exposure, pathological type, chest pain and dyspnea at the time of diagnosis), the only one of prognostic value in the univariate analysis was the histological subtype: median survivals were 12, 7 and 4 months for the patients in the epithelial, mixed, and fibrosarcomatous groups, respectively (p = 0.0012).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8319170&#34; target=&#34;_blank&#34;&gt;Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To prevent parietal seeding, radiation therapy at a dose of 21 Gy was administered during a period of 3 days to all points of entry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8336195&#34; target=&#34;_blank&#34;&gt;Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median time to treatment failure was 3.6 months for CM and 4.8 months for CD, and median survival duration from study entry was 7.7 and 8.8 months, respectively, with no significant differences between treatments. […] Both regimens were well tolerated and there were no treatment-related deaths due to toxicity. […] In this randomized phase II trial, the overall response rates, time to treatment failure, and overall survival appear to be similar for the two regimens tested.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8344608&#34; target=&#34;_blank&#34;&gt;[Malignant peritoneal mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment is a combination of surgery, chemotherapy and irradiation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8375935&#34; target=&#34;_blank&#34;&gt;In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is resistant to various forms of therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8377505&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a clinicopathological study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Six patients received no treatment, and the median survival was seven months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8378029&#34; target=&#34;_blank&#34;&gt;A new device for the treatment of pleural malignancies: intrapleural chemohyperthermia preliminary report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, ITCH appears to be a safe and reliable therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-10-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8413003&#34; target=&#34;_blank&#34;&gt;Hypertrophic osteoarthropathy in childhood malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A striking feature of HOA in these instances is the reversibility of the complaints after successful treatment of the disorder of the chest, both in benign and malignant conditions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8417880&#34; target=&#34;_blank&#34;&gt;Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients were evaluated before treatment and 36 days after treatment by computed tomography scan and thoracoscopy with biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8462329&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The use of extrapleural pneumonectomy in a multimodality treatment setting for malignant pleural mesothelioma is described, presenting first the right-sided approach and then the left-sided.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8462330&#34; target=&#34;_blank&#34;&gt;Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is an uncommon and usually fatal cancer, for which there is no standard treatment. […] However, surgical resection remains the mainstay of treatment because of the inability to treat the entire hemithorax effectively with radiation and the lack of effective chemotherapy drugs. […] Because of the high risk of local recurrence after surgical resection by either extrapleural pneumonectomy or pleurectomy/decortication, efforts have been directed at developing effective adjuvant treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8501504&#34; target=&#34;_blank&#34;&gt;Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From 1980 to 1992, 52 selected patients, underwent treatment. […] Pathologic diagnosis was reviewed and confirmed before therapy. […] Multimodality therapy including extrapleural pneumonectomy has acceptable morbidity and mortality for selected patients. […] These data provide a rationale for a revised staging system for malignant pleural mesothelioma; furthermore, they permit stratification of patients into groups likely to benefit from aggressive multimodality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8520817&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: clinical characteristics, prognostic factors and treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma soon leads to death no matter what type of treatment is provided. […] We discuss the clinical signs, prognostic factors and treatment given in 41 cases managed over the past 13 years in our oncology department. 32% had been exposed to asbestos, 61% were 60 years old or younger, 71% had a Karnofsky’s index &amp;gt; or = 80% and 63% were stage I (Butchart). […] Nine were given symptomatic treatment only. […] Only 11 (27%) patients experienced full remission after treatment: 7 had had extrapleural pneumonectomy, 2 had been given CHT and RT series and 4 had undergone PP with or without RT and/or CHT follow-up.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-01-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8521705&#34; target=&#34;_blank&#34;&gt;Thoracoscopic management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its role, however, in the diagnosis and treatment of patients with malignant pleural effusions is undeniable.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-01-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8528480&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: newer aspects of carcinogenesis, molecular genetics, and prospects for future therapies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There has been a surge of information regarding data on mesothelial transformation, mesothelioma molecular genetics and somatic gene therapy for this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/854717&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of 17 years’ duration with high pleural fluid concentration of hyaluronate.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The disease proved fatal after 17 years’ duration, which is the longest ever described without treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1977-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8551737&#34; target=&#34;_blank&#34;&gt;Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Postoperatively, adjuvant chemotherapy and radiation therapy were given to 46% and 73% of the patients respectively. […] Median survival from date of treatment was 11.5 months. […] Whether adjuvant chemotherapy or radiation therapy were given had no significant effect on survival. […] These data suggest that although this treatment regimen can be administered with very limited morbidity and no mortality, the role of this approach in the treatment of malignant pleural mesothelioma appears limited and cannot currently be recommended.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-02-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8553940&#34; target=&#34;_blank&#34;&gt;The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the past, response to standard therapy has been poor [1-3], but recent studies suggest that some patients may benefit from various therapeutic options, including surgical resection, combined technique treatment, and immunotherapy [4-7]. […] With improvements in therapy, an accurate, widely accepted staging system will be important in selecting homogeneous groups of patients for entry into clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8603371&#34; target=&#34;_blank&#34;&gt;Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The following data were obtained using a standard questionnaire and medical record review; age, sex, date of diagnosis, history of asbestos exposure, smoking history, method of diagnosis, histologic subtype, type of treatment, parental cancer history and tumor type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8608519&#34; target=&#34;_blank&#34;&gt;Post-irradiation malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Within a large, population-based survey of patients with cancer, temporal patterns and demographic features of most second primary mesotheliomas were similar to asbestos-related tumors, although the late effects of cancer treatment might have contributed to the occurrence of cancer in some patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8614142&#34; target=&#34;_blank&#34;&gt;The importance of surgical staging in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Progress in the therapy of malignant pleural mesothelioma is limited by the lack of an adequate staging system and controversy about prognostic factors. […] Adjuvant therapy was given as required by serial clinical trials. […] By univariate analysis, type of resection, T and N status, stage, histologic type, and adjuvant therapy, but no gender or age, significantly affected survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-06-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8622005&#34; target=&#34;_blank&#34;&gt;Chemotherapy in malignant pleural mesothelioma. A review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intrapleural therapy using interferon gamma, particularly for small-volume disease, shows promise. […] The successful treatment of unresectable pleural mesothelioma awaits the discovery of active drugs. […] Off-protocol combination therapy cannot be recommended over single-agent therapy, but studies that use combinations of the newer agents should be conducted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8622036&#34; target=&#34;_blank&#34;&gt;Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Initially planned as a 5-weeks-on/3-weeks-off treatment cycle, poor patient tolerance observed in the first 12 patients treated (group A) led to schedule adaptation with a shorter treatment sequence and prolongation of the rest period (4 weeks on/4 weeks off) in the following 14 patients (group B). […] Toxicity was mainly clinical, with progressive anorexia, asthenia, and prolonged nausea/emesis; these side effects have limited treatment acceptance in many patients. […] Thrombocytopenia and leukopenia were rarely noted as treatment-limiting toxicities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8623505&#34; target=&#34;_blank&#34;&gt;Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Data from the literature indicate that single modality treatment (surgery or intrapleural and/or systemic chemotherapy) does not significantly affect survival. […] No treatment-related death have been observed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8625125&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma after radiation therapy for breast cancer. A report of two additional patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The selection criteria included the development of a unilateral pleural effusion years after successful treatment with thoracic irradiation for a proven malignancy. […] The development of a unilateral pleural effusion occurring years after successful treatment of a proven malignancy with thoracic irradiation should alert the clinician to the possibility of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8625674&#34; target=&#34;_blank&#34;&gt;Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with histologically confirmed malignant mesothelioma were evaluated for treatment with methotrexate, vinblastine, and cisplatin chemotherapy. […] If the patient had preexisting hearing loss or neuropathy, or was significantly disabled (eg, spending greater than half of the day in bed or a chair), cisplatin therapy was withheld.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8635025&#34; target=&#34;_blank&#34;&gt;Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients have stopped treatment, and eight are still alive.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8678664&#34; target=&#34;_blank&#34;&gt;Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 66-year-old woman presented with a bronchoesophagopleural fistula 10 weeks after thoracic photodynamic therapy for malignant mesothelioma. […] This is the third reported case of an esophagopleural fistula developing subsequent to photodynamic therapy for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8683242&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma following treatment for Hodgkin’s disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Asbestos exposure is the major known risk factor for mesothelioma, but several case reports have suggested a link between radiation therapy and subsequent development of malignant mesothelioma. […] This report explores a possible association between radiation therapy for Hodgkin’s disease and mesothelioma. […] The mean interval between radiation treatment for Hodgkin’s disease and development of mesothelioma was 15 years, which emphasizes the need for continued follow-up and evaluation of these patients and supports a causal relationship. […] Mesothelioma may need to be added to the list of second malignancies that arise following radiation therapy for Hodgkin’s disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8687108&#34; target=&#34;_blank&#34;&gt;Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude mouse model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The model should serve as a basis for assessing the impact of experimental and existing therapy on malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8696713&#34; target=&#34;_blank&#34;&gt;A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
investigation of the behavior and treatment of diffuse malignant pleural mesothelioma (MPM) is hindered by the lack of an accurate universally accepted staging system.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8702248&#34; target=&#34;_blank&#34;&gt;Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The influence of treatment on clinical outcome in pleural mesothelioma (PM) is uncertain. […] We studied 83 patients with PM treated at our institution to evaluate the impact of treatment modality on survival, Methods. […] The following data were tabulated for each patient; age, sex, date of diagnosis, history of asbestos exposure, smoking history, method of diagnosis, histologic subtype, type of treatment and survival from diagnosis. […] Four treatment groups were analyzed; chemotherapy (C), surgery (S), combined modality (CM i.e. […] S + C with or without radiation therapy) and supportive care alone (SC). […] Treatment groups did not vary according to smoking or asbestos history. […] This analysis suggest prolonged survival among patients with PM receiving CM versus SC or single modality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8708749&#34; target=&#34;_blank&#34;&gt;Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our schedule consisted of 10 mg/m2 mitomycin C i.v. infusion, 50 mg/m2 cisplatin i.v. infusion, 10 mil Ur-alpha interferon i.m. and 10 mil Ur-alpha interferon i.v. infusion on the first day of treatment. […] In our multimodal therapy protocol, we found no difference in survival and relapse rates between our combined modal therapy and other single modal therapies in the literature.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-09-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8725138&#34; target=&#34;_blank&#34;&gt;Cytologic effects of photodynamic therapy in body fluids.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) has been used in phase I clinical trials at the National Institutes of Health for the treatment of malignancies disseminated within the peritoneal and pleural cavities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-11-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8732113&#34; target=&#34;_blank&#34;&gt;[Diagnosis and treatment of pleural mesothelioma: a report of 40 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of 33 surgical resections, 10 (31%) received combined therapy. […] Of the 3 thoracotomy biopsy cases, postoperative irradiation was given to one, irradiation plus chemotherapy to the second and no treatment to the third. […] In 4 who were not operated, one died without treatment, two accepted chemotherapy and the fourth was treated with irradiation plus chemotherapy. […] The authors sum-up their 31-year (1963-1994) experience of this disease and discuss the occupational factors in etiology, clinical diagnosis, treatment options and the significance of pathological types on prognosis of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8788165&#34; target=&#34;_blank&#34;&gt;Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Administration of Ad.RSVtk into the pleural space of animals with established multifocal tumor followed by systemic GCV therapy resulted in significant tumor regression at 20 days in HSVtk/GCV-treated animals (average tumor weight 0.6 +/- 0.2 gram; n = 12) versus control animals (average weight 5.4 +/- 0.2 grams; n = 21; p &amp;lt; 0.001). […] These studies demonstrate the Ad.RSVtk/GCV system is effective in the treatment of pleural-based tumors in an immunocompetent host. […] However, there are limitations to this treatment approach that result in only small increments in survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-10-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8813257&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors examine the feasibility and efficacy of trimodality therapy in the treatment of malignant pleural mesothelioma and identify prognostic factors. […] From 1980 to 1995, 120 patients underwent treatment for pathologically confirmed malignant mesothelioma at Brigham and Women’s Hospital and Dana-Farber Cancer Institute (Boston, MA). […] Extrapleural pneumonectomy with adjuvant therapy is appropriate treatment for selected patients with malignant mesothelioma selected using a revised staging system.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8822117&#34; target=&#34;_blank&#34;&gt;Small cell carcinoma of lung simulating pleural mesothelioma. Report of 4 cases with autopsy confirmation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our findings indicate that small cell carcinoma should be added to the group of pseudomesotheliomatous lung carcinomas and, above all, that it deserves distinction from ordinary mesothelioma, especially the small cell variant, because of its medico-legal implications and possible antitumoral treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8826866&#34; target=&#34;_blank&#34;&gt;Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-11-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8858892&#34; target=&#34;_blank&#34;&gt;Endobronchial inflammatory pseudotumour in a patient with B-cell chronic lymphocytic leukemia and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical presentation, pathology and treatment of this uncommon tumour-like lesion are briefly discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-11-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8882441&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Single or combined therapeutic modalities such as surgery (in 5 patients), chemotherapy (in 10 patients) and radiotherapy (in 3 patients) were used with additional symptomatic treatment in the majority of the cases. […] There was no difference in survival among patients had received different treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8911060&#34; target=&#34;_blank&#34;&gt;[A case report of surgical resection of renal cell carcinoma with intrathoracic metastasis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because there is no effective medical treatment for these two diseases, and the functions of patient’s other organs were good, a left pleuropneumonectomy and left nephrectomy was performed at once.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8966273&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura: correlations between thoracoscopy and radiology].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy should not be started before the tumor has been correctly diagnosed and staged with thoracoscopy and computed tomography (CT) which have replaced plain chest radiography.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-11-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8992400&#34; target=&#34;_blank&#34;&gt;[Solitary fibrous tumor of the pleura. Clinical case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As there are no criteria to determine the possible aggressive or malignant behaviour of the tumor, surgical resection of the lesion is indispensable both to resolve the diagnosis and to carry out the only proposable therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8996002&#34; target=&#34;_blank&#34;&gt;The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of malignant mesothelioma (MM) at an early stage results in increased survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9001354&#34; target=&#34;_blank&#34;&gt;A case of malignant pleural mesothelioma with metastasis to the orbit.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Marked reduction of pleural effusion was obtained with intrapleural interleukin-2 therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9028075&#34; target=&#34;_blank&#34;&gt;[A case of localized pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Even in cases difficult to diagnose, operation should not be delayed by repeating easy-going needle-biopsy or a long-term treatment with antitubercular drugs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9033296&#34; target=&#34;_blank&#34;&gt;Patterns of failure after trimodality therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is uncommon, and presently, no standard treatment of this disease exists. […] The objective of our analysis was to study the patterns of failure for malignant pleural mesothelioma after trimodality treatment consisting of extrapleural pneumonectomy, chemotherapy, and radiation therapy. […] Thirty-five of the surviving patients received adjuvant chemotherapy (32/35 received cyclophosphamide, doxorubicin, and cisplatin) followed by hemithorax radiation therapy. […] Ten patients received chemotherapy but no radiation therapy, and 1 patient received no adjuvant therapy. […] The most common site of failure after trimodality therapy was the ipsilateral hemithorax.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9033608&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
According to Cahan’s criteria, this mesothelioma may be considered as treatment-related.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9042640&#34; target=&#34;_blank&#34;&gt;Immunohistochemical differences between hyaluronan- and non-hyaluronan-producing malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Both of these characteristics (immunophenotype and ability to produce hyaluronan) may, therefore, be of importance in studies concerning the prognosis and treatment of the malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9113147&#34; target=&#34;_blank&#34;&gt;[Venous endoprosthesis. Palliative treatment of superior caval syndrome of neoplastic origin].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Stenting is a safe and effective treatment of SVC syndrome in patients with malignant conditions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9115227&#34; target=&#34;_blank&#34;&gt;Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Gene therapy may be an important adjuvant for treating cancer in the pleural space. […] First, treatment of the effusions with mammalian hyaluronidase or chondroitinases, but not Streptomyces hyaluronidase, abolished the inhibitory activity. […] These results suggest that drainage of the malignant pleural effusion, and perhaps enzymatic pretreatment of the pleural cavity, will be necessary for efficient retroviral vector mediated gene delivery to pleural metastases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-06-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9139208&#34; target=&#34;_blank&#34;&gt;[Problems in diagnosis and therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Long term survival is occasional even in case of multimodal treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9142382&#34; target=&#34;_blank&#34;&gt;Surgically debulked malignant pleural mesothelioma: results and prognostic factors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with poor prognostic indicators should probably enter nonsurgical, innovative trials where toxicity or response to therapy can be evaluated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9149015&#34; target=&#34;_blank&#34;&gt;Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients had pretreatment symptoms: 13 had chest pain, 9 had pleural effusion, and 7 had dyspnea. […] One patient was not evaluable because of treatment refusal.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-06-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9156307&#34; target=&#34;_blank&#34;&gt;Localized benign pleural mesothelioma arising in a radiation field.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 65-year-old woman had a localized benign pleural mesothelioma of her left upper chest 22 years following adjuvant radiation therapy to the left breast and axillary region for a breast carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9166476&#34; target=&#34;_blank&#34;&gt;High CD44 expression on human mesotheliomas mediates association with hyaluronan.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hyaluronan attachment was specific in that it could be abolished by preincubation with epitope-specific anti-CD44 antibodies or soluble substrate or by hyaluronidase treatment of attachment surfaces.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9176512&#34; target=&#34;_blank&#34;&gt;Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nevertheless, a strong tumor growth inhibition was observed following treatment with IG.Ad.CMV.TK recombinant adenovirus and GCV. […] This treatment prolonged symptom-free survival time from 19 days in the controls to 33 days in the treated group. […] These responses can be best explained by assuming continued tk expression in or around the tumor tissue during GCV treatment. […] Our results confirm and extend earlier findings with the same model and demonstrate the potential of the herpes simplex virus thymidine kinase suicide gene therapy as a local treatment for malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-06-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9179072&#34; target=&#34;_blank&#34;&gt;Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, the objective of this multi-institutional, cooperative group Phase II trial was to determine the efficacy of dihydro-5-azacytidine (DHAC), a pyrimidine analogue, in the treatment of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-07-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9216206&#34; target=&#34;_blank&#34;&gt;[Thoracoscopic surgery for diagnosis and treatment of pleural and mediastinal disease].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We studied the usefulness of thoracoscopic surgery in the diagnosis and treatment of pleural and mediastinal lesions. […] Thoracoscopic surgery is indicated for treatment of the following five pleural diseases: (1) benign pleural tumors; (2) localized mesothelioma; (3) persistent pleural effusions; (4) pyothorax; and (5) chylothorax. […] Benign mediastinal tumor is a clear indication for thoracoscopic surgery, but utmost caution must be exercised in applying this technique to the treatment of malignant tumors. […] Thoracoscopic extended thymectomy with a collar incision of the neck is a useful and relatively non-invasive technique for the treatment of myasthenia gravis without thymoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9247101&#34; target=&#34;_blank&#34;&gt;Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pattern of progression was similar in each treatment group.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9248101&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma. Diagnosis and treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A new international TNM classification has been proposed to allow comparison of series and to choose a treatment appropriate to the stade: at stage I, intrapleural, local immuno-chemotherapy treatment gives good results; at stages II and III, surgery followed by radiation therapy are indicated; at stage IV, symptomatic treatment alone is justified.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9294306&#34; target=&#34;_blank&#34;&gt;[Photomicrographs of a pleural biopsy specimen, showing malignant mesothelioma and necrosis–malignant pleural mesothelioma in a patient with sarcoidosis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pleurisy become less severe and the lymph nodes shrank without any treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9310252&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Five patients with a pleural malignancy (four malignant mesotheliomas and one localized low grade carcinoid) were treated with maximal surgical resection of the tumour followed by intraoperative adjuvant photodynamic therapy (PDT). […] The additional photodynamic treatment was performed with light of 652 nm from a high power diode laser, and meta-tetrahydroxy phenylchlorin as the photosensitizer. […] This combination of light delivery and dosimetry is well suited for adjuvant treatment with PDT in malignant pleural tumours.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-10-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9337302&#34; target=&#34;_blank&#34;&gt;Innovative therapies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy for malignant pleural mesothelioma is in a transitional stage. […] Recent trials of multimodality therapy for this disease suggest that selected patient subgroups may benefit from extensive treatment. […] This report discusses new approaches to the treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9337303&#34; target=&#34;_blank&#34;&gt;Multimodality therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma is a rare disease for which neither single modality nor bimodality therapy improves survival. […] For this reason, from 1980 to 1995, we used trimodality therapy in an attempt to improve survival in selected patients at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. […] One hundred twenty patients underwent trimodality treatment involving extrapleural pneumonectomy followed by combination chemoradiotherapy. […] Twenty-seven women and 93 men (mean age, 56 years) were evaluable for response and treatment-related morbidity. […] Thus, extrapleural pneumonectomy with adjuvant therapy is appropriate and effective treatment for patients with stage I disease according to the revised staging system.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9337304&#34; target=&#34;_blank&#34;&gt;Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article reviews the indications, techniques, and results of brachytherapy in the treatment of non-small cell lung cancer (NSCLC) and selected chest neoplasms. […] Most of the published data relate to the treatment of NSCLC, but other intrathoracic malignancies, such as malignant pleural mesothelioma and malignant thymoma, have been treated with brachytherapy. […] With continued innovations in the development of radioactive isotopes, computerized treatment planning and targeting, and source delivery, brachytherapy should continue to offer an attractive alternative and complement to conventional treatment approaches, and may offer patients improved local control and survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9352951&#34; target=&#34;_blank&#34;&gt;Pathology of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An accurate diagnosis is essential to a rational approach to the treatment of diffuse malignant pleural mesothelioma and generally requires pathological examination with the application of special techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9352953&#34; target=&#34;_blank&#34;&gt;Chemotherapy for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of malignant mesothelioma (MM) has been challenging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9352954&#34; target=&#34;_blank&#34;&gt;Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite these disappointing results, pleurectomy/decortication may still be the best treatment option for some patients, particularly those with early stage disease whose medical condition precludes pneumonectomy. […] The role of pleurectomy/decortication in conjunction with newer treatment strategies such as neoadjuvant therapy or gene therapy warrants investigation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9352955&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant pleural mesothelioma, a rare disease, is characterized by an aggressive local behavior and scant response to therapy. […] The first series using single modality therapy showed failure in terms of survival and local control. […] More recently, multimodality therapy has been used against this disease with better results, but still with more room for substantial improvement. […] The current multimodality series reported are isolated, single-institutional experiences with different treatment schemes, using different staging systems, most of which have not been validated. […] There is an enormous need for multiinstitutional prospective trials to evaluate the current treatment schemes in light of the steady increase in the incidence of this lethal tumor. […] The trimodality therapy used at the Brigham and Women’s Hospital for selected patients is described.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9352956&#34; target=&#34;_blank&#34;&gt;New therapies in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It can be safely stated that currently there exists no standard therapy for malignant mesothelioma. […] The “standard” methods of chemotherapy, radiation therapy, and surgery have all been used with little improvement in overall survival. […] Trimodality therapy that involves a combination of all three standard treatment modalities has been shown to improve survival in selected patients. […] New and innovative treatment strategies clearly are needed for a disease which, because of the disappointment with standard therapy, is most commonly approached with only palliative intent. […] The location of this malignancy and its tendency to remain localized make it an ideal target for intracavitary approaches using photodynamic therapy, targeted cytokines, and gene therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9363074&#34; target=&#34;_blank&#34;&gt;Pleural malignancies including mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of malignant mesothelioma remains a big problem. […] Some success has been reported with local interferon treatment. […] As for treatment of metastatic pleural disease, the main purpose is symptomatic relief of dyspnea caused by fluid accumulation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9370396&#34; target=&#34;_blank&#34;&gt;Experimental assessment of photodynamic therapy with chlorins for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Photodynamic therapy (PDT) with two chlorin sensitisers was assessed on nude mice bearing human mesothelioma xenografts, and on intrathoracic tissues of minipigs with the same drug-light conditions to optimise the antitumour activity of PDT while preventing photosensitising injury to normal tissues.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9400682&#34; target=&#34;_blank&#34;&gt;A case of malignant pleural mesothelioma following exposure to atomic radiation in Nagasaki.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Asbestos is the leading cause of malignant mesothelioma, but radiation therapy is the primary non-asbestos-related cause. […] In the case of radiation therapy, the interval between exposure and the occurrence of malignant mesothelioma tends to be many years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9416409&#34; target=&#34;_blank&#34;&gt;Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This report describes the results of a Phase III trial comparing maximum debulking surgery and postoperative cisplatin, interferon alpha-2b, and tamoxifen (CIT) immunochemotherapy with and without intraoperative photodynamic therapy (PDT) to determine (1) whether such a multimodal approach can be performed with minimum morbidity and mortality in malignant pleural mesothelioma (MPM), and (2) whether first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT impacts on local recurrence of survival. […] Aggressive multimodal therapy can be delivered for patients with higher stage MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9427783&#34; target=&#34;_blank&#34;&gt;Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Toxicity was acceptable and no treatment-related deaths occurred.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-01-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9438692&#34; target=&#34;_blank&#34;&gt;Multimodality management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Trimodality therapy was performed at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital Thoracic Oncology Program. […] From 1980 to 1995, we prospectively followed up a series of 120 patients with confirmed malignant pleural mesothelioma who underwent trimodality therapy. […] Extrapleural pneumonectomy in the context of trimodality therapy is a potential surgical option for a selected group of patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9438693&#34; target=&#34;_blank&#34;&gt;A review of chemotherapy trials for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment of malignant pleural mesothelioma continues to be frustrating regardless of the modality employed. […] Dose-escalated chemotherapeutic regimens may offer an advantage, whereas combination chemotherapy has not shown any benefit over single-agent therapy. […] Further trials and the investigation of new agents in the treatment of this disease are necessary.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9440736&#34; target=&#34;_blank&#34;&gt;Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From October 1984 to October 1993, 204 eligible adult patients with malignant pleural mesothelioma were entered into five consecutive prospective European Organization for Research and Treatment of Cancer (EORTC) phase II clinical trials designed to assess the efficacy of various anticancer drugs (mitoxantrone, epidoxorubicin, etoposide, and paclitaxel).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9468586&#34; target=&#34;_blank&#34;&gt;Effects of interleukin-2 for the treatment of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The hematological profile, and clinical parameters in mesothelioma affected patients undergoing a clinical trial to evaluate the efficacy of IL-2 treatment were investigated. […] Six patients were monitored for 6 weeks following therapy. […] Blood cell count, morphological and immunophenotypical analysis were performed, as well as clinical evaluations of the patients before and after therapy. […] The treatment was well tolerated: our patients had only mild adverse reactions controlled by symptomatic therapy. […] A slight decrease in CD4-positive subset of lymphocytes was observed after rIL-2 treatment. […] The therapy did not induce significant changes in the progression of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9469352&#34; target=&#34;_blank&#34;&gt;Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Paclitaxel was administered as a 120-hour (5-day) continuous infusion repeated every 3 weeks during the course of radiation therapy. […] In mesothelioma patients, hemithoracic irradiation was delivered as the initial treatment field with a conedown to the tumor volume for a total dose of 5,760 to 6,300 cGy. […] Tumor biopsies were obtained, if possible, before and during paclitaxel treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-03-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9470808&#34; target=&#34;_blank&#34;&gt;Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The second trial investigated a daily oral dose of 100 mg for 21 days followed by a 2-week treatment-free period, and then recycling. […] In both trials, the treatment was given until disease progression, intolerable toxicity or patient refusal.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9470855&#34; target=&#34;_blank&#34;&gt;Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Management of advanced malignant mesothelioma (MM) still requires innovative systemic therapy as its prognosis is poorly affected by currently available chemotherapy. […] The treatment protocol consisted of two cycles of 4 weeks on/4 weeks off followed by two shorter cycles of 3 weeks on/3 weeks off, in the absence of life-threatening toxicity or progressive disease. […] The main treatment-limiting side-effects were digestive intolerance (nausea, vomiting) and severe asthenia.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9475525&#34; target=&#34;_blank&#34;&gt;Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our objective was to analyze the impact of preoperative and postresection solid tumor volumes on outcomes in 47 of 48 consecutive patients undergoing resection for malignant pleural mesothelioma who were treated prospectively and randomized to photodynamic therapy or no photodynamic therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9490658&#34; target=&#34;_blank&#34;&gt;Transduction of non-small cell lung cancer cells by adenoviral and retroviral vectors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These observations suggest that neither Ad nor RV vectors will suffice a priori as the optimal gene transfer vehicle, and successful gene therapy of lung cancer may require tumor-specific or patient-specific vectors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-03-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9507577&#34; target=&#34;_blank&#34;&gt;Clinical features and epidemiology of malignant pleural mesothelioma in west Glasgow 1987-1992.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Only three patients were given definitive treatment reflecting the lack of effective therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9515850&#34; target=&#34;_blank&#34;&gt;Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To examine the individual and joint effect of various pretreatment clinical characteristics on the survival of patients with mesothelioma treated by the Cancer and Leukemia Group B (CALGB). […] Between June 1984 and September 1994, 337 patients with malignant mesothelioma and no prior chemotherapy were accrued to seven phase II studies conducted by the CALGB which screened the efficacy of 10 treatment regimens or dose levels. […] Median survival time (MST) for the 10 treatment regimens ranged from 3.9 to 9.8 months (overall=7.2; 95% confidence interval [CI], 6.5 to 8.3), with 1-year survival between 14% and 50% (overall=27%; 95% CI, 23 to 33%). […] Cox survival models and exponential regression trees were used to examine the prognostic importance of pretreatment patient characteristics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9543295&#34; target=&#34;_blank&#34;&gt;Thoracoscopy–state of the art.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In spontaneous pneumothorax it allows staging, thereby facilitating treatment decisions, and in addition coagulation of eventual blebs and talc poudrage for efficient pleurodesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9544832&#34; target=&#34;_blank&#34;&gt;A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, this treatment proved ineffective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9545840&#34; target=&#34;_blank&#34;&gt;[Value of thoracoscopy and talc pleurodesis in diagnosis and palliative treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At the present time, we believe that thoracoscopy is well indicated in any suspicion of MPM not only for diagnosis but also for palliative treatment of this pleural disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9554537&#34; target=&#34;_blank&#34;&gt;Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy was repeated every 3 weeks. […] Therapy was continued until disease progression or excessive toxicity mandated discontinuation. […] There were 2 early deaths of unknown cause on Days 9 and 17 of therapy, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-04-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9563782&#34; target=&#34;_blank&#34;&gt;Hyperplastic mesothelial cells in lymph nodes: report of six cases of a benign process that can stimulate metastatic involvement by mesothelioma or carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All effusions cleared with treatment of the underlying disorder, which included lymphoproliferative processes, congestive heart failure, and inflammatory diseases (Dressler syndrome, vasculitis, and glomerulonephritis).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9569039&#34; target=&#34;_blank&#34;&gt;Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Both cell lines responded to exogenous HGF/SF treatment by a change of morphology but in different ways: BR became more elongated and bipolar, while BT formed more spread-out cell colonies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9607419&#34; target=&#34;_blank&#34;&gt;Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a fatal neoplasm that is unresponsive to standard modalities of cancer therapy. […] We conducted a phase I dose-escalation clinical trial of adenoviral (Ad)-mediated intrapleural herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) gene therapy in patients with mesothelioma as a model for treatment of a localized malignancy. […] A replication-incompetent recombinant adenoviral vector containing the HSVtk gene under control of the Rous sarcoma virus (RSV) promoter-enhancer was introduced into the pleural cavity of patients with malignant mesothelioma followed by 2 weeks of systemic therapy with GCV at a dose of 5 mg/kg twice a day. […] Further development of therapeutic trials for treatment of localized malignancy using this vector is thus warranted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9610071&#34; target=&#34;_blank&#34;&gt;Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is a tumor of the pleura for which there is no satisfactory treatment. […] Current treatment modalities include surgery, chemotherapy, and radiation therapy, although in some series none of these modalities is superior to no treatment at all. […] Because of the dismal prognosis for patients with MM, new modes of treatment are desperately needed. […] A promising area of research into the treatment of various malignancies is gene therapy. […] We are describing a Phase I clinical gene therapy trial for MM, which we are presently conducting at the Louisiana State University Medical Center of New Orleans.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9611294&#34; target=&#34;_blank&#34;&gt;[Diffuse primary malignant mesothelioma in abdominal cavity].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We call attention to the importance of precancer diagnosis, the best chance to treatment options, always based on surgical resections, radiation or chemotherapy alone or combined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9646980&#34; target=&#34;_blank&#34;&gt;CT and MR in pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MRI has a limited but important role particularly in the evaluation of focal pleural tumors such as lipomas and in determining the extent of malignant mesothelioma prior to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9656243&#34; target=&#34;_blank&#34;&gt;[Therapeutic strategy for pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment strategy for these tumors has been investigated, including various surgical and chemotherapeutic approaches. […] In spite of these efforts. no curative method for malignant mesothelioma has been established yet, although the gene therapy is expected to be the most powerful tool in the near future.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-09-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9684098&#34; target=&#34;_blank&#34;&gt;Gene therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is a fatal malignancy refractory to all forms of standard anticancer therapy. […] This article reports the results of a phase I clinical trial assessing the safety of intrapleural delivery and efficacy of intratumoral gene transfer of recombinant adenovirus (rAd) containing herpes simplex virus thymidine kinase (HSVtk) gene into the pleural space of patients with MM, followed by systematic treatment with the antiviral drug ganciclovir (GCV) for 14 days. […] AD.RSVtk/GCV gene therapy proved to be well tolerated, with evidence of significant gene transfer particularly at high vector doses and with elimination of preliminary biopsy. […] Ongoing gene therapy trials for mesothelioma at two other centers, focusing on immunostimulation and using suicide gene therapy as a tumor vaccine, are also reviewed in this article.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9689814&#34; target=&#34;_blank&#34;&gt;Systemic drug therapy of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
According to most reviews, radiotherapy has a limited role in the treatment of MPM. […] Prospective phase II trials are recommended for the identification of new active treatments while large-scale randomized phase III trials are needed to identify the best available treatment. […] This paper reviews the available literature on the systemic drug therapy of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9689815&#34; target=&#34;_blank&#34;&gt;Human malignant mesothelioma of the pleura: new perspectives for diagnosis and therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This preliminary report suggests that adenovirus-mediated p53 hyperexpression counteracts transforming properties of the large T-antigen and suggests that gene therapy may be useful in treating human malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9727622&#34; target=&#34;_blank&#34;&gt;Cytokeratin markers in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Close correlation of various individual pretreatment marker levels was observed only between TPS and CYFRA 21-1, both in MPM (r = 0.84; p &amp;lt; 0.001) and in non-small cell lung cancer (NSCLC) (r = 0.71; p &amp;lt; 0.001). […] In serial determinations of the markers during chemotherapy of MPM (n = 10), TPS and CYFRA 21-1 were shown to demonstrate more or less the same pattern of reactivity, although the changes in the TPS levels better reflected the clinical response to therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9752282&#34; target=&#34;_blank&#34;&gt;[Standards, Options, and Recommendations for the management of patients with malignant mesothelioma of the pleura. Fédération Nationale des Centres de Lutte Contre le Cancer].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The main criteria considered were incidence, risk factors, pronostic factors and efficacy of cancer treatment. […] The results are: 1) systematic assessment of (professional) exposure to asbestos is based on a standardized interrogatory, completed by specific consultation for professional disease; 2) diagnostic and clinical staging is based on multiple biopsies under thoracoscopy and thoracic scanner; 3) there is no indication for extemporaneous examination, immunocytochemistry should use cytokeratine, EMA, vimentine, ACE, Leu-M1; 4) clinical care: the recommended staging classification is the IMIG (International Mesothelioma Interest Group) classification; 5) validated, independent pronostic factors are stage of disease patient’s functional status and histologic type (i.e. epithelial lesions are of better prognosis); 6) treatment is based on symptomatic and palliative treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9762399&#34; target=&#34;_blank&#34;&gt;[Benign fibrous mesothelioma: report of 8 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
BFM is rare and localized malignant mesothelioma, whose prognosis and treatment is significantly different, must be considered as a differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9776257&#34; target=&#34;_blank&#34;&gt;SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, SV40 DNA and Tag expression in mesothelioma tumour cells, though probably not relevant for diagnostic or prognostic purposes, may be crucial for innovative gene therapy strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-12-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9800793&#34; target=&#34;_blank&#34;&gt;Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Conventional therapy for pleural mesothelioma has met with disappointing results. […] From 1991 to 1996, 40 patients with malignant pleural mesothelioma were treated with surgical resection followed by immediate intracavitary photodynamic therapy. […] Morbidity and treatment-related mortality rates for the entire series, pleurectomy, and extrapleural pneumonectomy were 45% and 7.5%, 39% and 3.6%, and 71% and 28.6%, respectively. […] Multivariate analysis identified stage, length of hospital stay, photodynamic therapy dose, and nodal status as independent prognostic indicators for survival. […] Surgical intervention and photodynamic therapy offer good survival results in patients with stage I or II pleural mesothelioma. […] For patients in stage III or IV, better treatment modalities need to be developed. […] Improvements in early detection and preoperative staging are necessary for proper patient selection for treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-12-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9817178&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Up to now, no single treatment has been proven to be effective and death usually occurs within about 12-17 months after diagnosis. […] However, certain forms may have a better prognosis when diagnosed early and treated by multimodal therapy or intrapleural immunotherapy. […] Although radiotherapy seems necessary and is efficient in preventing the malignant seeding after diagnostic procedures in patients, there has been no randomized phase III study showing the superiority of any treatment compared with another. […] However, for the early-stage disease (stage I) a logical therapeutic approach seems to be neoadjuvant intrapleural treatment using cytokines. […] For more advanced disease (stages II and III) resectability should be discussed with the thoracic surgeons and a multimodal treatment combining surgery, radiotherapy and chemotherapy should be proposed for a randomized controlled study. […] Palliative treatment is indicated for stage IV.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9827714&#34; target=&#34;_blank&#34;&gt;Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis associated with malignant pleural mesothelioma (MPM) is poor in spite of surgery, radiotherapy, photodynamic therapy, or chemotherapy. […] Several clinical studies have demonstrated objective antitumoral responses to intrapleural interleukin-2 (IL-2) administration in the treatment of malignant pleurisy. […] Patients with histologically documented MPM were evaluated for response 36 days after treatment by computed tomography scan and thoracoscopy with biopsies. […] Survival was calculated from the start of treatment to death according to the Kaplan-Meier method, and the survival of responders and nonresponders was compared using the log rank test. […] All patients received their planned treatment. […] However, determination of the schedule of IL-2 and its superiority to conventional treatment in a Phase III study has yet to be accomplished.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-12-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9828278&#34; target=&#34;_blank&#34;&gt;Treatment results of 17 patients with diffuse pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment for diffuse pleural mesothelioma is very difficult. […] From May 1960 to August 1996, 17 patients underwent treatment for pathologically confirmed malignant pleural mesothelioma at Veteran General Hospital-Taipei. […] Single or combined treatment protocols with surgery, chemotherapy, and radiotherapy had been used according to the clinical situation. […] In spite of trying multiple different treatment protocols, disease staging ( p = 0.0186) and the epithelial pathological type ( p = 0.0353) were the significant prognostic factors in our series.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9853530&#34; target=&#34;_blank&#34;&gt;The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a tumor of the pleura for which there is no satisfactory treatment. […] Current treatment modalities include surgery, chemotherapy, and radiation therapy, although in some series none of these modalities is superior to no treatment at all. […] Because of the dismal prognosis for patients with malignant mesothelioma, a new mode of treatment is desperately needed. […] A promising area of research into the treatment of various malignancies is gene therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9856666&#34; target=&#34;_blank&#34;&gt;Phase II trial of topotecan for the treatment of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The North Central Cancer Treatment Group designed a phase II trial to assess the efficacy and toxicity of topotecan in patients with unresectable malignant pleural mesothelioma. […] Nineteen men and three women, median age 66 years (range, 44-78 years), were treated with topotecan 1.5 mg/m2 intravenously over 30 minutes daily for 5 days at 3-week intervals until toxicity, progression of disease, or a patient decided to discontinue treatment. […] A total of 113 cycles of treatment were given, for a median of three cycles (range, 1-26 cycles). […] Eighteen of 21 patients (86%) experienced grade 3 or 4 neutropenia during the initial treatment cycle.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-12-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9860200&#34; target=&#34;_blank&#34;&gt;Localized fibrous tumours of the pleura: 15 new cases and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To present a series of localized fibrous tumours of the pleura (LFTP), to define the clinical and histopathological diagnostic criteria of this tumour, and to determine the optimal treatment and follow-up. […] Treatment consists of complete resection including adjacent structures if necessary.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9863397&#34; target=&#34;_blank&#34;&gt;[Modern approach to malignant pleural mesothelioma. 1) Pretherapeutic evaluation].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this review we outlined the basis of current concepts of pretreatment evaluation in patients with malignant pleural mesothelioma. […] Recent TNM classification and modern diagnostic approach such as computerized tomography and thoracoscopy, as well as standard means of diagnosis are aimed at obtaining early diagnosis and staging in order to undertake the adequate therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-01-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9869119&#34; target=&#34;_blank&#34;&gt;Environmentally-induced malignant pleural mesothelioma and HLA distribution in Turkey.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This will help in screening the population at risk, and facilitate preventive measures such as family counselling and gene therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9869758&#34; target=&#34;_blank&#34;&gt;Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;ol style=&#34;list-style-type: decimal&#34;&gt;
&lt;li&gt;Multimodality therapy including extrapleural pneumonectomy is feasible in selected patients with malignant pleural mesotheliomas, (2) pre-resectional evaluation of extrapleural nodes may select patients for radical therapy, (3) microscopic resection margins affect long-term survival, highlighting the need for further investigation of locoregional control, and (4) patients with epithelial, margin-negative, extrapleural node-negative resection had extended survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9921022&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma. II. Modern therapeutic concepts].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the second part of our review of malignant pleural mesothelioma, we reviewed current concepts of the treatment of this highly malignant disease. […] Although there are still advocates for the use of best supportive care to the treatment of these patients, the accumulated evidence favorizes the combined modality approach. […] New treatment approaches are needed to improve poor survival in patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9931667&#34; target=&#34;_blank&#34;&gt;[Treatment strategy in pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The surgical treatment comprises a radical pleuropneumonectomy with resection of the pericardium and diaphragm (P3D) or palliative pleurectomy/decortication of the tumor. […] Preliminary results of multimodal therapy concepts, including additional chemo- and/or radiotherapy, suggest an improvement in survival. […] Nevertheless, so far treatment has been focused on the palliation of clinical symptoms like pain and dyspnee.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-04-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;&lt;/li&gt;
&lt;/ol&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>Terms to cluster Treatment Abstract</title>
      <link>/mesothelioma/syntax_summary/treatment/terms/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/syntax_summary/treatment/terms/</guid>
      <description> 

&lt;script src=&#34;/mesothelioma/mesotheliomarmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 2.&lt;/strong&gt; 27 terms used to create the Treatment Category and its counts.
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Term
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Count
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All (sum)
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
3044
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
treatment
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2241
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapy
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2207
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pretreatment
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
60
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therapeutics
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
39
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Palliative Care
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatment Outcome
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medication
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Conservative Treatment
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
5
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Molecular Targeted Therapy
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
4
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
drug effects
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Molecular Therapy
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical Protocols
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Health Resorts
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Homebound Persons
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intensive Care Units
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Life Support Care
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medical Futility
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medication Adherence
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medication Therapy Management
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patient Care Planning
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patient Compliance
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patient Dropouts
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Residential Treatment
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Teletherapy
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Transitional Care
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Withholding Treatment
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
</description>
    </item>
    
  </channel>
</rss>
